Scrape source,URL,Source,Reference,DOI,PDB ID,Used SAbDab?,GenBank ID VH,GenBank ID VL,Binds to,Origin,Date added,VH Description,VL Description,VH,VL,CDRH1,CDRH2,CDRH3,CDRL1,CDRL2,CDRL3,Heavy J gene,Heavy V gene,Light J gene,Light V gene
Patent,https://patents.google.com/patent/CN112285348B/en,(3/4)  the heavy chain and light chain amino acid sequences of the antibody 2 are respectively shown as seq id no:3 and seq id no:4,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QIQLVQSGPELKKPGETVKISCKASGYTFTEYPMHWVKQAPGKGFKWMGLIYTDTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCVRGENWYYFDYWGQGTTLTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPLTFGAGTKLELK,GYTFTEYP,IYTDTGEP,VRGENWYYFDY,SSVSSSY,STS,HQYHRSPLT,IGHJ2*01 (mouse),IGHV9-1*01 (mouse),IGKJ5*01 (mouse),IGKV4-74*01 (mouse)
Patent,https://patents.google.com/patent/CN112285348B/en,(1/2)  the heavy chain and light chain amino acid sequences of the antibody 1 are respectively shown as seq id no:1 and seq id no:2,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQSGPELVKPGASVKISCKASGYTFSYSWMNWVKQRPGKGLEWIGRIYPGDGDTNYSGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARNDYDEGEYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLLTFGAGTKLELK,GYTFSYSW,IYPGDGDT,ARNDYDEGEY,QNVGTN,SAS,QQYNSYPLLT,IGHJ4*01 (mouse),IGHV1-82*01 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN111303280B/en,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPDLFDYYYGMDVWGQGTTVTVSS,EIVMTQSPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCTQATQFPYTFGQGTKVDIK,GYTLTELS,FDPEDGET,ATSTAVAGTPDLFDYYYGMDV,QSLVHSDGNTY,KIS,TQATQFPYT,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ3*01 (human),IGKV2-24*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1766/1765)  a) the light chain variable region set forth in seq id no:1765; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1766; ,,,,,,,,,, No.13 HC variable region , No.13 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELVLTQPPSASGTPGQSVTISCSGSSSNIGNNYVYWYQQLPGTAPKLLIYGNYQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTKLTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGNNY,GNY,AAWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1996/1995)  a) the light chain variable region set forth in seq id no:1995; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1996; ,,,,,,,,,, No.128 HC variable region , No.128 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSTSNIGNNFVSWYQHLPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,TSNIGNNF,DND,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1756/1755)  a) the light chain variable region set forth in seq id no:1755; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1756; ,,,,,,,,,, No.8 HC variable region , No.8 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1746/1745)  a) the light chain variable region set forth in seq id no:1745; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1746; ,,,,,,,,,, No.3 HC variable region , No.3 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLVSGRYCSGVTCYSWFDPWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTRLEIK,GFTFSSYA,ISGSGGST,AKSLVSGRYCSGVTCYSWFDP,QDISNY,DAS,QQYDNLPIT,IGHJ5*02 (human),IGHV3-23*04 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2018/2017)  a) the light chain variable region set forth in seq id no:2017; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2018; ,,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2262/2261)  a) the light chain variable region set forth in seq id no:2261; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2262; ,,,,,,,,,, No.261 HC variable region , No.261 LC variable region ,EVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYVFGTGTKVTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SSNIGNNY,DND,GTWDSSLSAYV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1742/1741)  a) the light chain variable region set forth in seq id no:1741; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1742; ,,,,,,,,,, No.1 HC variable region , No.1 LC variable region ,EVQLLESGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGDCGGDCYSFLLGEDAFDIWGQGTMVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK,GFTFGDYA,ISWNSGRI,AKGDCGGDCYSFLLGEDAFDI,QSISSY,AAS,QQSYSTPFT,IGHJ3*02 (human),IGHV3-9*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2290/2289)  a) the light chain variable region set forth in seq id no:2289; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2290; ,,,,,,,,,, No.275 HC variable region , No.275 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELVLTQPPSVSVAPGKTARITCGGNNIGSNTVNWYQQLPGTAPKLLIYSNNLRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKVTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,NIGSNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1754/1753)  a) the light chain variable region set forth in seq id no:1753; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1754; ,,,,,,,,,, No.7 HC variable region , No.7 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPPGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTELTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2164/2163)  a) the light chain variable region set forth in seq id no:2163; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2164; ,,,,,,,,,, No.212 HC variable region , No.212 LC variable region ,EVQLVQSGGGVVRPGRSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWEDSLNGYVFGTGTKVTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWEDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2314/2313)  a) the light chain variable region set forth in seq id no:2313; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2314; ,,,,,,,,,, No.287 HC variable region , No.287 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREEATTGINTNWFDPWGQGTLVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREEATTGINTNWFDP,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ5*02 (human),IGHV1-69*04 (human),IGLJ7*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1836/1835)  a) the light chain variable region set forth in seq id no:1835; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1836; ,,,,,,,,,, No.48 HC variable region , No.48 LC variable region ,QVQLQESGPGLVRPSETLSLTCSVSGGSISHYFWSWIRQSPGKGLEWIGNIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,GGSISHYF,IYYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-59*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2174/2173)  a) the light chain variable region set forth in seq id no:2173; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2174; ,,,,,,,,,, No.217 HC variable region , No.217 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNVWVFGGGTKVTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNVWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1930/1929)  a) the light chain variable region set forth in seq id no:1929; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1930; ,,,,,,,,,, No.95 HC variable region , No.95 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1852/1851)  a) the light chain variable region set forth in seq id no:1851; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1852; ,,,,,,,,,, No.56 HC variable region , No.56 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQEYGSSPGRVTFGPGTKVDIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,GAS,QEYGSSPGRVT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1966/1965)  a) the light chain variable region set forth in seq id no:1965; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1966; ,,,,,,,,,, No.113 HC variable region , No.113 LC variable region ,QITLKESGPALVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSNSNIGNNYISWYQQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,NSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1802/1801)  a) the light chain variable region set forth in seq id no:1801; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1802; ,,,,,,,,,, No.31 HC variable region , No.31 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRRAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELGLTQPPSVSGTPGQRVTISCSGSSSNIGGNYVHWYQQLPGAAPKLLIYSNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGRVFGGGTKLTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGGNY,SND,AAWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1758/1757)  a) the light chain variable region set forth in seq id no:1757; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1758; ,,,,,,,,,, No.9 HC variable region , No.9 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLNGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1768/1767)  a) a light chain variable region set forth in seq id no:1767; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1768; ,,,,,,,,,, No.14 HC variable region , No.14 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPPSVSGAPGQRVTISCSGSSSNIGGNYVHWYQQLPGAAPKLLIYSNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGRVFGGGTQLTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGGNY,SND,AAWDDSLNGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ7*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1926/1925)  a) the light chain variable region set forth in seq id no:1925; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1926; ,,,,,,,,,, No.93 HC variable region , No.93 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGVDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGRFGGGTKLTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGVDV,SSNIGNNY,DNN,GTWDSSLSAGR,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2298/2297)  a) the light chain variable region set forth in seq id no:2297; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2298; ,,,,,,,,,, No.279 HC variable region , No.279 LC variable region ,EVQLLESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGIAPYTRGAFDYWGQGTLVTVSS,ELTLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLPTFGQGTRLEIK,GYTFTSYY,INPSGGST,ARGGIAPYTRGAFDY,QDISNY,DAS,QQSYSTLPT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1898/1897)  a) the light chain variable region set forth in seq id no:1897; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1898; ,,,,,,,,,, No.79 HC variable region , No.79 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPSITFGQGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYYSTPSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2238/2237)  a) the light chain variable region set forth in seq id no:2237; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2238; ,,,,,,,,,, No.249 HC variable region , No.249 LC variable region ,VQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLSHGVVGAQDAFDIWGQGTMVTVSS,ELELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDGSSDHYVFGTGTKVTVL,GFTFSSYA,ISGSGGST,AKLSHGVVGAQDAFDI,NIGSKS,YDS,QVWDGSSDHYV,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ1*01 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2226/2225)  a) the light chain variable region set forth in seq id no:2225; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2226; ,,,,,,,,,, No.243 HC variable region , No.243 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGWVFGGGTKVTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2288/2287)  a) the light chain variable region set forth in seq id no:2287; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2288; ,,,,,,,,,, No.274 HC variable region , No.274 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLGVVFGGGTKVTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,SSNIGAGYD,GNS,QSYDSSLGVV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2258/2257)  a) the light chain variable region set forth in seq id no:2257; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2258; ,,,,,,,,,, No.259 HC variable region , No.259 LC variable region ,QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL,GFTFGDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SSNIGSNT,SNN,AAWDDSLNGVV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2260/2259)  a) the light chain variable region set forth in seq id no:2259; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2260; ,,,,,,,,,, No.260 HC variable region , No.260 LC variable region ,EVQLVESGGGLVQPGRTLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVIVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLVFGGGTELTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SSNIGSNT,TNN,AAWDDSLNGLV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2188/2187)  a) the light chain variable region set forth in seq id no:2187; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2188; ,,,,,,,,,, No.224 HC variable region , No.224 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYSMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDSSLSAWVFGGGTKLTVL,GFTFSSYS,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDSSLSAWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2248/2247)  a) the light chain variable region set forth in seq id no:2247; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2248; ,,,,,,,,,, No.254 HC variable region , No.254 LC variable region ,QVQLVQSGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPVFGGGTELTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,NIGSKS,YDS,QVWDSSSDHPV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2240/2239)  a) the light chain variable region set forth in seq id no:2239; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2240; ,,,,,,,,,, No.250 HC variable region , No.250 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREEATTGINTNWFDPWGQGTLVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREEATTGINTNWFDP,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ5*02 (human),IGHV1-69*04 (human),IGLJ7*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1838/1837)  a) the light chain variable region set forth in seq id no:1837; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1838; ,,,,,,,,,, No.49 HC variable region , No.49 LC variable region ,QVQLQESGPGLVRPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELALTQPPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,SSDVGGYNY,DVS,SSYTSSSTVV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2280/2279)  a) the light chain variable region set forth in seq id no:2279; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2280; ,,,,,,,,,, No.270 HC variable region , No.270 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGLTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPLTFGGGTKVDIK,GLTVSSNY,IYSGGST,ARDLVVYGMDV,QSVSSY,DAS,QQYGSSPLT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2166/2165)  a) the light chain variable region set forth in seq id no:2165; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2166; ,,,,,,,,,, No.213 HC variable region , No.213 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKVTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2234/2233)  a) the light chain variable region set forth in seq id no:2233; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2234; ,,,,,,,,,, No.247 HC variable region , No.247 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQSPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGWVFGGGTELTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2212/2211)  a) the light chain variable region set forth in seq id no:2211; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2212; ,,,,,,,,,, No.236 HC variable region , No.236 LC variable region ,EVQLLESRGGVVQPGRSLRLSCAASGFTFSTYSMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQPEDEADYYCGTWDSNSETWVFGGGTKLTVL,GFTFSTYS,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,GTWDSNSETWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1912/1911)  a) the light chain variable region set forth in seq id no:1911; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1912; ,,,,,,,,,, No.86 HC variable region , No.86 LC variable region ,EVQLVQSGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQRAGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYGSSPYT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2316/2315)  a) the light chain variable region set forth in seq id no:2315; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2316; ,,,,,,,,,, No.288 HC variable region , No.288 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARANLGYCTNGVCAPSGGWGQGTLVTVSS,ELMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHWVFGGGTKVTVL,GFTFSSYA,ISYDGSNK,ARANLGYCTNGVCAPSGG,SGSIASNY,EDN,QSYDSSNHWV,IGHJ1*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV6-57*03 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1880/1879)  a) the light chain variable region set forth in seq id no:1879; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1880; ,,,,,,,,,, No.70 HC variable region , No.70 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPATLSVSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSITFGQGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYGSSPSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2182/2181)  a) the light chain variable region set forth in seq id no:2181; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2182; ,,,,,,,,,, No.221 HC variable region , No.221 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSDDEADYYCATWDDSLSGWVFGGGTQLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1976/1975)  a) the light chain variable region set forth in seq id no:1975; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1976; ,,,,,,,,,, No.118 HC variable region , No.118 LC variable region ,QITLKESGPTLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSNSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDNSLSAGVFGTGTKVTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,NSNIGNNY,DNN,GTWDNSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2296/2295)  a) the light chain variable region set forth in seq id no:2295; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2296; ,,,,,,,,,, No.278 HC variable region , No.278 LC variable region ,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGIAPYTRGAFDYWGQGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCQAGQDISNYLNWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAHSFPFTFGPGTKVDIK,GYTFTSYY,INPSGGST,ARGGIAPYTRGAFDY,QDISNY,KAS,QQAHSFPFT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1744/1743)  a) the light chain variable region set forth in seq id no:1743; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1744; ,,,,,,,,,, No.2 HC variable region , No.2 LC variable region ,EVQLLESGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGDCGGDCYSFLLGEDAFDIWGQGTMVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKVGKAPKLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQPEDFATYYCQQSYSIPHTFGQGTKLEIK,GFTFGDYA,ISWNSGRI,AKGDCGGDCYSFLLGEDAFDI,QSISTY,AAS,QQSYSIPHT,IGHJ3*02 (human),IGHV3-9*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2044/2043)  a) the light chain variable region set forth in seq id no:2043; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2044; ,,,,,,,,,, No.152 HC variable region , No.152 LC variable region ,QITLKESGPSLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGRSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTQLTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*01 (human),IGLJ7*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2150/2149)  a) the light chain variable region set forth in seq id no:2149; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2150; ,,,,,,,,,, No.205 HC variable region , No.205 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGQFTISRDNSKNALYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKVTVL,GFTFSSFA,ISFDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1916/1915)  a) the light chain variable region set forth in seq id no:1915; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1916; ,,,,,,,,,, No.88 HC variable region , No.88 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSITFGQGTRLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QQYGSSPSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2176/2175)  a) the light chain variable region set forth in seq id no:2175; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2176; ,,,,,,,,,, No.218 HC variable region , No.218 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVSISCSGSTSNIGSNPVNWFQQLPGTAPKLLIYSNNQRPSGVPNRFSGSKSGTSASLAISGLQSDDEADYYCAAWDDSLNGWVFGGGTKVTVL,GFTFSSFA,ISFDGSNK,ARGDYYGSGSYYNPSPFFDY,TSNIGSNP,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2172/2171)  a) the light chain variable region set forth in seq id no:2171; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2172; ,,,,,,,,,, No.216 HC variable region , No.216 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1850/1849)  a) the light chain variable region set forth in seq id no:1849; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1850; ,,,,,,,,,, No.55 HC variable region , No.55 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSITFGQGTRLEIK,GGSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSTY,DAS,QQYGSSPSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2148/2147)  a) the light chain variable region set forth in seq id no:2147; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2148; ,,,,,,,,,, No.204 HC variable region , No.204 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSKTVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSKT,SNN,ATWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1872/1871)  a) the light chain variable region set forth in seq id no:1871; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1872; ,,,,,,,,,, No.66 HC variable region , No.66 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSNYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPLTFGGGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSNY,DAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1832/1831)  a) the light chain variable region set forth in seq id no:1831; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1832; ,,,,,,,,,, No.46 HC variable region , No.46 LC variable region ,EVQLVESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2306/2305)  a) the light chain variable region set forth in seq id no:2305; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2306; ,,,,,,,,,, No.283 HC variable region , No.283 LC variable region ,EVQLLESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRGVLDYWGQGTLVTVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKVDIK,GFTVSSNY,IYPGGST,ARDLRGVLDY,QSVSSY,DAS,QQYGSSPPYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2310/2309)  a) a light chain variable region set forth in seq id no:2309; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2310; ,,,,,,,,,, No.285 HC variable region , No.285 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREKGYSGSGSVNWFDPWGQGTLVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL,GGTFSSYA,IIPILGIA,AREKGYSGSGSVNWFDP,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ5*02 (human),IGHV1-69*04 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2200/2199)  a) the light chain variable region set forth in seq id no:2199; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2200; ,,,,,,,,,, No.230 HC variable region , No.230 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNFKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSSNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SSN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2292/2291)  a) the light chain variable region set forth in seq id no:2291; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2292; ,,,,,,,,,, No.276 HC variable region , No.276 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSASGAPGQRVTISCSGSSSNIGGSDVGWYQHLPGMAPRLLIYKSNQRPSGVPDRFSASKSGTSASLAISGLQSEDEGDYYCATWDDRLNWVFGGGTKVTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,SSNIGGSD,KSN,ATWDDRLNWV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2222/2221)  a) the light chain variable region set forth in seq id no:2221; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2222; ,,,,,,,,,, No.241 HC variable region , No.241 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGINSVNWYQQLPGTAPKLLIYSNNQRPSGVLDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKLTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGINS,SNN,AAWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2300/2299)  a) the light chain variable region set forth in seq id no:2299; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2300; ,,,,,,,,,, No.280 HC variable region , No.280 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIVYGMDVWGQGTTVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGGVFGGGTKVTVL,GITVSSNY,IYSGGST,ARDLIVYGMDV,SSNTGAGYD,SNN,AAWDDSLNGGV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2276/2275)  a) the light chain variable region set forth in seq id no:2275; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2276; ,,,,,,,,,, No.268 HC variable region , No.268 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSVSGAPGQRVTISCTGSDSNIGAGYDVHWYQQLPGTAPKLLIYNNNNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYFCQSSDSGLTGWVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,DSNIGAGYD,NNN,QSSDSGLTGWV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2230/2229)  a) the light chain variable region set forth in seq id no:2229; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2230; ,,,,,,,,,, No.245 HC variable region , No.245 LC variable region ,EVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNAWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDSLNAWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2134/2133)  a) the light chain variable region set forth in seq id no:2133; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2134; ,,,,,,,,,, No.197 HC variable region , No.197 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCEASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVRGYSGYGSTYYFDYWGQGTLVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSIFGGGTKLTVL,GGTFSSYA,IIPILGIA,ARVRGYSGYGSTYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSI,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2210/2209)  a) the light chain variable region set forth in seq id no:2209; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2210; ,,,,,,,,,, No.235 HC variable region , No.235 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKLTVL,GFTFSSYA,ISFDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1956/1955)  a) the light chain variable region set forth in seq id no:1955; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1956; ,,,,,,,,,, No.108 HC variable region , No.108 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL,GFSLSTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1882/1881)  a) the light chain variable region set forth in seq id no:1881; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1882; ,,,,,,,,,, No.71 HC variable region , No.71 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVLTQSPATLSVSPGEGATLSCRASQSVSSNLAWYQHKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVDIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSN,DAS,QQYNNWPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2146/2145)  a) the light chain variable region set forth in seq id no:2145; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2146; ,,,,,,,,,, No.203 HC variable region , No.203 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQSPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1906/1905)  a) the light chain variable region set forth in seq id no:1905; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1906; ,,,,,,,,,, No.83 HC variable region , No.83 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISGSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELQMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKLEIK,GDSISGSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSN,GAS,QQYNNWPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1834/1833)  a) the light chain variable region set forth in seq id no:1833; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1834; ,,,,,,,,,, No.47 HC variable region , No.47 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVMTQSPGTLSLSPGERATLFCRASQSVSSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFALYYCQQYGSSPLTFGGGTKLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,DAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1878/1877)  a) the light chain variable region set forth in seq id no:1877; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1878; ,,,,,,,,,, No.69 HC variable region , No.69 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPATLSVSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIHAASTRATGIPDRFSGSGSGTDFTLTISRVEPEDVAVYYCQQYGDSLSITFGQGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVRSSY,AAS,QQYGDSLSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1946/1945)  a) the light chain variable region set forth in seq id no:1945; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1946; ,,,,,,,,,, No.103 HC variable region , No.103 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGKNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGKNY,DNN,GTWDSSLSAVV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2152/2151)  a) the light chain variable region set forth in seq id no:2151; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2152; ,,,,,,,,,, No.206 HC variable region , No.206 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1870/1869)  a) the light chain variable region set forth in seq id no:1869; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1870; ,,,,,,,,,, No.65 HC variable region , No.65 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVMTQSPATLSLSPGESATLACRASQSVSSSFLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQEYGSSPGRVTFGPGTKVDIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSF,GAS,QEYGSSPGRVT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2270/2269)  a) the light chain variable region set forth in seq id no:2269; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2270; ,,,,,,,,,, No.265 HC variable region , No.265 LC variable region ,EVQLLESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVFGGGTQLTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,SSNIGAGYD,GNS,QSYDSSLSGV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ7*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2224/2223)  a) the light chain variable region set forth in seq id no:2223; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2224; ,,,,,,,,,, No.242 HC variable region , No.242 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYAESVKGRFTVSRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSKTVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKVTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSKT,SNN,ATWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2180/2179)  a) the light chain variable region set forth in seq id no:2179; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2180; ,,,,,,,,,, No.220 HC variable region , No.220 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCPASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYFADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKVTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*15 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2218/2217)  a) the light chain variable region set forth in seq id no:2217; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2218; ,,,,,,,,,, No.239 HC variable region , No.239 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,DLVLTQPPSASGTPGQRVTMSCSGSSSNIGSKTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTQLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSKT,SNN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2232/2231)  a) the light chain variable region set forth in seq id no:2231; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2232; ,,,,,,,,,, No.246 HC variable region , No.246 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGYVFGPGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1902/1901)  a) the light chain variable region set forth in seq id no:1901; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1902; ,,,,,,,,,, No.81 HC variable region , No.81 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1828/1827)  a) the light chain variable region set forth in seq id no:1827; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1828; ,,,,,,,,,, No.44 HC variable region , No.44 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGGSISRSSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLKSRVTIPVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVTTPYTFGQGTKVDIK,GGSISRSSYY,IYYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYVTTPYT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2154/2153)  a) the light chain variable region set forth in seq id no:2153; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2154; ,,,,,,,,,, No.207 HC variable region , No.207 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAIRGLRSEDEADYYCATWDDALSGWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDALSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1846/1845)  a) the light chain variable region set forth in seq id no:1845; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1846; ,,,,,,,,,, No.53 HC variable region , No.53 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELQMTQSPGTLSLSPGERATLSCRASQSISSYLAWYQQKPGQSPRLLIYGGSSRATGIPDRFSGSGSGTDFTLTISRLEPADFAVYYCQQYGSSPLTFGQGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSISSY,GGS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2228/2227)  a) the light chain variable region set forth in seq id no:2227; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2228; ,,,,,,,,,, No.244 HC variable region , No.244 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2272/2271)  a) the light chain variable region set forth in seq id no:2271; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2272; ,,,,,,,,,, No.266 HC variable region , No.266 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVRDSSSDHPVFGGGTKVTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,NIGSKS,YDS,QVRDSSSDHPV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2320/2319)  a) the light chain variable region set forth in seq id no:2319; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2320. ,,,,,,,,,, No.290 HC variable region , No.290 LC variable region ,EVQLVQSGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2142/2141)  a) the light chain variable region set forth in seq id no:2141; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2142; ,,,,,,,,,, No.201 HC variable region , No.201 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVRGYSGYGSTYYSDYWGQGTLVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSSYA,IIPILGIA,ARVRGYSGYGSTYYSDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*04 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2244/2243)  a) the light chain variable region set forth in seq id no:2243; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2244; ,,,,,,,,,, No.252 HC variable region , No.252 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKVTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SSNIGSNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2266/2265)  a) the light chain variable region set forth in seq id no:2265; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2266; ,,,,,,,,,, No.263 HC variable region , No.263 LC variable region ,EVQLVESGGGLVQPGRTLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSPNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYVFGTGTKLTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SPNIGNNY,DNN,GTWDSSLSAYV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2204/2203)  a) the light chain variable region set forth in seq id no:2203; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2204; ,,,,,,,,,, No.232 HC variable region , No.232 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYSMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKLTVL,GFTFSSYS,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNAWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2302/2301)  a) the light chain variable region set forth in seq id no:2301; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2302; ,,,,,,,,,, No.281 HC variable region , No.281 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIVYGMDVWGQGTTVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCAAWDDSLSGWVFGGGTKVTVL,GITVSSNY,IYSGGST,ARDLIVYGMDV,SSNIGAGYD,GNS,AAWDDSLSGWV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2308/2307)  a) the light chain variable region set forth in seq id no:2307; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2308; ,,,,,,,,,, No.284 HC variable region , No.284 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGHVDIPYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTQLTVL,GVTVSSNY,IYSGGST,ARGHVDIPYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ7*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2158/2157)  a) the light chain variable region set forth in seq id no:2157; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2158; ,,,,,,,,,, No.209 HC variable region , No.209 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSKAVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKVTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSKA,SNN,ATWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2282/2281)  a) the light chain variable region set forth in seq id no:2281; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2282; ,,,,,,,,,, No.271 HC variable region , No.271 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELELTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSSYAGSNNLVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,SSNIGSNT,SNN,SSYAGSNNLV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2178/2177)  a) the light chain variable region set forth in seq id no:2177; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2178; ,,,,,,,,,, No.219 HC variable region , No.219 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQFPGAAPKLLIYSNSQRPSGVPDRVSASKSGTSASLAISGLQSEDEGDYYCAGWDDSLNGWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNS,AGWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2130/2129)  a) the light chain variable region set forth in seq id no:2129; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2130; ,,,,,,,,,, No.195 HC variable region , No.195 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYNFTRYGISWVRQAPGQGLEWMGWISAYNGNTKYAQKLQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARVLGIAVAGTPIWGQGTLVTVSS,ELMLTQPHSVSGSPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSDWVFGGGTKVTVL,GYNFTRYG,ISAYNGNT,ARVLGIAVAGTPI,SGSIASNY,EDN,QSYDSSDWV,IGHJ1*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV6-57*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1998/1997)  a) the light chain variable region set forth in seq id no:1997; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1998; ,,,,,,,,,, No.129 HC variable region , No.129 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSNSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSSSKSGTSATLGITGLQTGDEADYYCGTWDNNLSAGVFGTGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,NSNIGNNY,DNN,GTWDNNLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2170/2169)  a) the light chain variable region set forth in seq id no:2169; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2170; ,,,,,,,,,, No.215 HC variable region , No.215 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQSPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,GFTFSSFA,ISFDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2156/2155)  a) the light chain variable region set forth in seq id no:2155; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2156; ,,,,,,,,,, No.208 HC variable region , No.208 LC variable region ,EVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1922/1921)  a) the light chain variable region set forth in seq id no:1921; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1922; ,,,,,,,,,, No.91 HC variable region , No.91 LC variable region ,QITLKESGPTLVKPAQTLRLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVFS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDNSLSAGVFGTGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDNSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2318/2317)  a) the light chain variable region set forth in seq id no:2317; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2318; and ,,,,,,,,,, No.289 HC variable region , No.289 LC variable region ,EVQLLESGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKNLRYFDWLLGDDAFDIWGQGTMVTVSS,ELVLTQPPSVSAAPGQKVTISCSGGSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,GFTFGDYA,ISWNSGRI,AKNLRYFDWLLGDDAFDI,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ3*02 (human),IGHV3-9*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1748/1747)  a) the light chain variable region set forth in seq id no:1747; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1748; ,,,,,,,,,, No.4 HC variable region , No.4 LC variable region ,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLVSGRYCSGVTCYSWFDPWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLPITFGQGTRLEIK,GFTFSSYA,ISGSGGST,AKSLVSGRYCSGVTCYSWFDP,QDISNY,DAS,QQYDDLPIT,IGHJ5*02 (human),IGHV3-23*04 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1752/1751)  a) the light chain variable region set forth in seq id no:1751; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1752; ,,,,,,,,,, No.6 HC variable region , No.6 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQDRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGKVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGKV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2252/2251)  a) the light chain variable region set forth in seq id no:2251; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2252; ,,,,,,,,,, No.256 HC variable region , No.256 LC variable region ,EVQLVESGGGLVQPGRTLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKVTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2132/2131)  a) the light chain variable region set forth in seq id no:2131; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2132; ,,,,,,,,,, No.196 HC variable region , No.196 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVRGYSGYGSTYYFDYWGQGTLVTVSS,ELVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTQLTVL,GGTFSSYA,IIPILGIA,ARVRGYSGYGSTYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*04 (human),IGLJ7*01 (human),IGLV1-40*02 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1884/1883)  a) the light chain variable region set forth in seq id no:1883; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1884; ,,,,,,,,,, No.72 HC variable region , No.72 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLPFGTGTKVTVL,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,SSNIGSNY,DVS,SSYTSSSTLP,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(2168/2167)  a) the light chain variable region set forth in seq id no:2167; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2168; ,,,,,,,,,, No.214 HC variable region , No.214 LC variable region ,EVQLVESGGGVVQPGRSLRLSCPASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELMLTQPHSASGTPGQRVTISCSGSSSNIGSNTVNWFQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDTLDSWVFGGGTKLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,ATWDDTLDSWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1918/1917)  a) the light chain variable region set forth in seq id no:1917; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1918; ,,,,,,,,,, No.89 HC variable region , No.89 LC variable region ,QITLKESGPTLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPRQKVTISCSGSSSNIGDNYVSWYQQFPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTQLTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGDNY,DND,GTWDSSLSAVV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102205028B1/en,(1920/1919)  a) the light chain variable region set forth in seq id no:1919; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1920; ,,,,,,,,,, No.90 HC variable region , No.90 LC variable region ,QITLKESGPTLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN113004396B/en,"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGSPSGGWYTLDYWGQGTLVTVSS,ENVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRWTFGQGTKVEIK,GFTFSSYG,IWYDGSNK,ARDGSPSGGWYTLDY,QSVSSSY,GAS,QQYGSSRWT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113004396B/en,"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113461812A/en,"(12/11) in one embodiment of the present invention, the amino acid sequences of the light and heavy chains of a whole antibody igg are shown in seq id no:11 and 12, respectively, and the nucleotide sequences encoding the light and heavy chains are shown in seq id no:13-14, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQSGAELVKPGASVKLSCKTSGYTFTRYYIYWVKQRPGQGLEWIGEINPNNGGTNFNEKFKSKATLTVDKSSNTAYMQLSSLTSEDSAVYYCTIFITTVIARDYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVEYSGTTLMQWFQQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDVAMYFCHQSREVPWTFGGGTKLEIK,GYTFTRYY,INPNNGGT,TIFITTVIARDY,ESVEYSGTTL,AAS,HQSREVPWT,IGHJ3*01 (mouse),IGHV1-53*01 (mouse),IGKJ1*01 (mouse),IGKV3-1*01 (mouse)
Patent,https://patents.google.com/patent/CN113461812A/en,"(8/7) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-00d are shown in seq id no:7 and 8, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQSGAELVKPGASVKLSCKTSGYTFTRYYIYWVKQRPGQGLEWIGEINPNNGGTNFNEKFKSKATLTVDKSSNTAYMQLSSLTSEDSAVYYCTIFITTVIARDYWGQGTL,DIVLTQSPASLAVSLGQRATISCRASESVEYSGTTLMQWFQQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDVAMYFCHQSREVPWTFGGGTKLEIK,GYTFTRYY,INPNNGGT,TIFITTVIARDY,ESVEYSGTTL,AAS,HQSREVPWT,IGHJ2*02 (mouse),IGHV1-53*01 (mouse),IGKJ1*01 (mouse),IGKV3-1*01 (mouse)
Patent,https://patents.google.com/patent/CN113834933A/en,(1/2)  the heavy chain and light chain amino acid sequences of the neutralizing antibody are respectively shown as seq id no:1 and 2.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGIIVSRNYMNWVRQAPGKGLEWVSVVYSGGSTFYADSVKGRFTISRDESQNTLYLQMNRLRAEDTAVYFCARDLGPRGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIK,GIIVSRNY,VYSGGST,ARDLGPRGMDV,QSVSSSY,GAS,QQYGSSPPWT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112898415B/en,"(4/8) the antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region has the amino acid sequence set forth in seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVGPLMVRGVIIPWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLNVVFGGGTKLTVL,GFTFSSYG,IWYDGSNK,VGPLMVRGVIIP,SSNIGAGYD,GNS,QSYDSSLNVV,IGHJ5*02 (human),IGHV3-33*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112898415B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111560070B/en,"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; the second variable region is an antibody heavy chain variable region which is represented by seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWVICSSTSCYTKYSYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLIARLFGGGTKLTVL,GGTFSSYA,IIPIFGTA,ARGGWVICSSTSCYTKYSYYGMDV,SSNIGNNY,DNN,GTWDSSLIARL,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN111560070B/en,(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111560070B/en,"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112175073A/en,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40.",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLVKPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTRDRYARYDILTGLSPAGADYFYYAMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPQYTFGQGTKLEIK,GFTFGDYA,IRSKAYGGTT,TRDRYARYDILTGLSPAGADYFYYAMDV,QSVSSY,DAS,QQRSNWPQYT,IGHJ6*01 (human),IGHV3-49*05 (human),IGKJ2*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112175073A/en,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSTSTAYMELSRLRSDNTAVYYCAREPLYCSSTSCYVASGLEDYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVVFGGGTKLTVL,GYTFTGYY,INPNSGGT,AREPLYCSSTSCYVASGLEDYYYYGMDV,SSNIGAGYD,GNS,QSYDSSLSGSVV,IGHJ6*01 (human),IGHV1-2*04 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112175073A/en,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAIHWVRQAPGKGLEWVSGITWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKHHQIAVAGDAEDYYFDYWGQGTLVTVSS,SYELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSRSDRVVFGGGTKLTAL,GFTFDDYA,ITWNSGTI,AKHHQIAVAGDAEDYYFDY,NIGSKS,DDS,QVWDSRSDRVV,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
Patent,https://patents.google.com/patent/CN112175073A/en,"(19/20) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:19, and the light chain amino acid sequence is set forth in seq id no:20",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWTWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRVTISVDTSKSQFSLKLSSVTAADTAVYYCATDYYDSSGYSYGMDVWGHGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANNFPRTFGQGTKVEIK,GGSISSYY,IYYTGST,ATDYYDSSGYSYGMDV,QGISGW,AAS,QQANNFPRT,IGHJ6*01 (human),IGHV4-59*01 (human),IGKJ1*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113388028A/en,"(17/19) the human antibody or fragment thereof of claim 3, wherein the antibody heavy chain variable region that inhibits binding of ace2 to sars-cov-2s1 by steric hindrance effect is seq id no:17 and the light chain variable region is seq id no:19.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHITGTTFSDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFATFGQGTKVEIK,GGSISSSSYY,IYYSGST,ARHITGTTFSDY,QSVSSSY,GAS,QQFAT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113388028A/en,"(9/11) the human antibody or fragment thereof of claim 3, wherein the heavy chain variable region of the antibody having the same binding site as ace2 on sars-cov-2s1 protein is selected from seq id no:9, 13 and the light chain variable region is selected from seq id no:11, 15.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSFSISWVRQAPGQGLEWMGRIIPVLGIANYAQEVQGRVTITADKSTSTAYMELSSLRSEDTAVYFCTTDRFVEPATGPFFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSNWLTFGGGTKVEIK,GGTFSSFS,IIPVLGIA,TTDRFVEPATGPFFDY,QSVSSN,GAS,QQYSNWLT,IGHJ4*01 (human),IGHV1-69*02 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(175/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:180.",,,,,,,,,, PR300928VHhuv4, PR300928VLhuv3,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCAREGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASSRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,AREGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(177/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:182",,,,,,,,,, PR300928VHhuv2, PR300928VLhuv1,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(176/182) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:182",,,,,,,,,, PR300928VHhuv3, PR300928VLhuv1,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(115/140) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:115, and the amino acid sequence of the light chain variable region is shown as seq id no:140",,,,,,,,,, Synthetic, Synthetic,QVQLKESGPGPVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGNTNYNSALMSRLSISKDNSKSQVFLKLNSLQVDDTAMYYCAYYRYDAFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMFWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYHCQHSRELPYTFGGGTKLEIK,GFSLTSYG,IWAGGNT,AYYRYDAFAY,KSVSTSGYSY,LAS,QHSRELPYT,IGHJ3*01 (mouse),IGHV2-9*02 (mouse),IGKJ2*01 (mouse),IGKV3-12*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(118/143) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:118, and the amino acid sequence of the light chain variable region is shown as seq id no:143",,,,,,,,,, Synthetic, Synthetic,EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVSRIRSKSDNYAAYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRADGYSSWFAYWGQGTLVTVSA,DVVMTQIPLSLPVSLGDQASISCRSSQSLVHNNGNTYLHWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,GFTFNTYA,IRSKSDNYAA,VRADGYSSWFAY,QSLVHNNGNTY,KVS,SQSTHVPWT,IGHJ3*01 (mouse),IGHV10-1*02 (mouse),IGKJ1*01 (mouse),IGKV1-110*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(116/141) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:116, and the amino acid sequence of the light chain variable region is shown as seq id no:141",,,,,,,,,, Synthetic, Synthetic,EVKLVESGGGLVQPGGSLKLSCAASGFTFSGYTMSWVRQTPEKSLEWVAYISNGGANTYYPDTVQGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHRDWDDAMDYWGQGTSVTVSS,QIVLTQSPAIMSASLGEEITLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSTYTFGGGTKLEIK,GFTFSGYT,ISNGGANT,ARHRDWDDAMDY,SSVSY,STS,HQWSTYT,IGHJ4*01 (mouse),IGHV5-12-2*01 (mouse),IGKJ2*01 (mouse),IGKV4-80*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(128/152) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:128, and the amino acid sequence of the light chain variable region is shown as seq id no:152",,,,,,,,,, Synthetic, Synthetic,QVQLQESGPGLMKSSGTLSLTCAVSGGSIRSSNWWSWVRQPPGKGLEWIGEIFQSGITNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARDGDYYGSGSSYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSDLAWYQQKPGQARGLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,GGSIRSSNW,IFQSGIT,ARDGDYYGSGSSYFDY,QSVSSD,GAS,QQYNNWPLT,IGHJ4*01 (human),IGHV4-4*02 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(133/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:133, and the amino acid sequence of the light chain variable region is shown as seq id no:154",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHWVRQAPGKGLEWVAVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPLTFGGGTKVEIK,GFTFSYYG,IWYDGSNR,ATDPPGLRFRFDY,QSLLHSNGYNY,LGS,MQGLQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(173/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:169",,,,,,,,,, PR300961VHhuv1, PR300961Vlhuv1,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWVNWVRQAPGQGLEWMGMIHPSDSETRLNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(172/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:167",,,,,,,,,, PR300961VHhuv2, PR300961Vlhuv3,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(176/181) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:181",,,,,,,,,, PR300928VHhuv3, PR300928VLhuv2,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(178/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:181",,,,,,,,,, PR300928VHhuv1, PR300928VLhuv2,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRVTITVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(124/148) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:124, and the amino acid sequence of the light chain variable region is shown in seq id no:148",,,,,,,,,, Synthetic, Synthetic,EVKLVESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVAYISNGGVNTYYPDTVKGRFTISRDNAKNTLYLQMNSLKSEDTAMYYCARHRDWDDAMDYWGQGTSVTVSS,QIVLTQSPAIMSASLGEEITLTCSATSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYPFGGGTKLEIK,GFTFSSYT,ISNGGVNT,ARHRDWDDAMDY,SSVSY,STS,HQWSSYP,IGHJ4*01 (mouse),IGHV5-12-2*01 (mouse),IGKJ2*01 (mouse),IGKV4-80*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(126/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:126, and the amino acid sequence of the light chain variable region is shown in seq id no:150",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGAELVRPGALVKLSCKASGFNIKDYYMHWVKQRPEQGLEWIGWIDPENGNSIYHPNFQGKASITADTSSNTAYLQLSSLTSEDAAVYYCASPYGFISWFAYWGQGTLVTVSA,QIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYMYTFGGGTKLEIK,GFNIKDYY,IDPENGNS,ASPYGFISWFAY,SSVSY,RTS,QQYHSYPYMYT,IGHJ3*01 (mouse),IGHV14-1*02 (mouse),IGKJ2*01 (mouse),IGKV4-61*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(120/145) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:120, and the amino acid sequence of the light chain variable region is shown as seq id no:145",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMLWVKQSHGKSLEWIGGINPNNGDTGYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVNVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTIRNVLSEDLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,INPNNGDT,ARDGYPYYYAMDY,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(135/155) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:135, and the amino acid sequence of the light chain variable region is shown in seq id no:155",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFNDYGMHWVRQAPGKGLEWVAVIWYDGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSDGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,GFTFNDYG,IWYDGSYT,ARDPPGLRFRFDY,QSLLHSDGYNY,LGS,MQALQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(131/155) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:131, and the amino acid sequence of the light chain variable region is shown as seq id no:155",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASRFTFSNYDMHWVRQAPGKGLEWVAVIWYDGSYKYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSDGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,RFTFSNYD,IWYDGSYK,ARDPPGLRFRFDY,QSLLHSDGYNY,LGS,MQALQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(117/142) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:117, and the amino acid sequence of the light chain variable region is shown as seq id no:142",,,,,,,,,, Synthetic, Synthetic,QVQLQQPGAELVRPGASVMLSCKASGYSFTTYWMTWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDRATLTVDKSSNTAYMQLSSPTSEDSAVYYCARGGGYDWYFDVWGAGTTVTVSS,DIVLTQSPASLVVSLGQRATISCRATESVDSYGNSFMHWYQQKPGQPPTLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEGPWTFGGGTNLEIK,GYSFTTYW,IHPSDSET,ARGGGYDWYFDV,ESVDSYGNSF,RAS,QQSNEGPWT,IGHJ1*01 (mouse),IGHV1-61*01 (mouse),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(121/146) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:121, and the amino acid sequence of the light chain variable region is shown as seq id no:146",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIYWVKQSHGKSLEWIGGINPNNGDTSYNQKFKGKATLTVDTSSSTAYMELRSLTSEDSAVYYCARDGYPYYYAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNTYPWTFGGGTKLEIK,GYTFTEYT,INPNNGDT,ARDGYPYYYAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(114/139) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:114, and the amino acid sequence of the light chain variable region is shown as seq id no:139",,,,,,,,,, Synthetic, Synthetic,QVQLQQPGAELVRPGVSVKMSCKASGYSFTSYWMNWVKQRPGQGLEWLGMIHPSDSESRLNQKFMDKATLTVDKSSSTAYMQLNSPTSEDSAVYYCARADGYEWYFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPVRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPWTFSGGTKLEIK,GYSFTSYW,IHPSDSES,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ1*01 (mouse),IGHV1-61*01 (mouse),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(129/153) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:129, and the amino acid sequence of the light chain variable region is shown as seq id no:153",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNYYGSGIYLWYFDLWGRGTLVTVSS,DIQMTQSPSTLSAFVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSTFGQGTKLEIK,GFTFSSYG,IWYDGSNK,AKNYYGSGIYLWYFDL,QSISSW,KAS,QQYNSYST,IGHJ2*01 (human),IGHV3-33*03 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(136/91) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:136, and the amino acid sequence of the light chain variable region is shown as seq id no:91",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSYQYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNFLDWYLQKPGQSPQLLIFLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGQGTRLEIK,GFTFSSYG,IWYDGSYQ,ATDPPGLRFRFDY,QSLLHSNGYNF,LGS,MQALQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(172/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:169",,,,,,,,,, PR300961VHhuv2, PR300961Vlhuv1,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(171/167) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:167",,,,,,,,,, PR300961VHhuv3, PR300961Vlhuv3,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADTYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADTYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(175/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:182",,,,,,,,,, PR300928VHhuv4, PR300928VLhuv1,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCAREGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,AREGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(171/169) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:169",,,,,,,,,, PR300961VHhuv3, PR300961Vlhuv1,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADTYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADTYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(171/168) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:168",,,,,,,,,, PR300961VHhuv3, PR300961Vlhuv2,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADTYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADTYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(113/138) in a specific embodiment of the present invention, the amino acid sequence of the heavy chain variable region is represented by seq id no:113, and the amino acid sequence of the light chain variable region is represented by seq id no:138",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEFTMHWVKQSHGKSLEWIGGLNPNNDDTTYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCTREDGNYVSFAYWGQGTLVTVSA,DIVMSQSPSSLGASVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLIISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,GYTFTEFT,LNPNNDDT,TREDGNYVSFAY,QSLLYSGNQKNY,WAS,QQYYSYPLT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(130/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:130, and the amino acid sequence of the light chain variable region is shown as seq id no:154",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHWVRQAPGKGLEWVAVIWYDGSNRFYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCATDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPLTFGGGTKVEIK,GFTFSYYG,IWYDGSNR,ATDPPGLRFRFDY,QSLLHSNGYNY,LGS,MQGLQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(176/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:176, and the amino acid sequence of the light chain variable region is shown as seq id no:180",,,,,,,,,, PR300928VHhuv3, PR300928VLhuv3,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASSRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(179/183) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:179, and the amino acid sequence of the light chain variable region is shown in seq id no:183",,,,,,,,,, PR300928VHhu, PR300928VLhu,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWFQQKPGKAPKSLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(172/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:168",,,,,,,,,, PR300961VHhuv2, PR300961Vlhuv2,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(122/147) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:122, and the amino acid sequence of the light chain variable region is shown in seq id no:147",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGDNTYNQKLKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSASSRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,INPNNGDN,ARDGYPYYYALDY,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-22*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(177/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:181",,,,,,,,,, PR300928VHhuv2, PR300928VLhuv2,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(175/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:181",,,,,,,,,, PR300928VHhuv4, PR300928VLhuv2,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNQGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCAREGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNQGDT,AREGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(127/151) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:127, and the amino acid sequence of the light chain variable region is shown as seq id no:151",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSNGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCASHSGYYYGYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKSGKAPKLLIYATSSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVEIK,GFTFSSNG,IWYDGSNK,ASHSGYYYGYYFDY,QSISSY,ATS,QQSYSTPPT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(134/157) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:134, and the amino acid sequence of the light chain variable region is shown as seq id no:157",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFNFSYYGIHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLQSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,GFNFSYYG,IWYDGSNK,ARDPPGLRFRFDY,QSLLQSNGYNY,LGS,MQALQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(174/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:174, and the amino acid sequence of the light chain variable region is shown in seq id no:150",,,,,,,,,, PR300961VHhu, Synthetic,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWVNWVRQAPGQGLEWMGMIHPSDSETRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,QIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYMYTFGGGTKLEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,SSVSY,RTS,QQYHSYPYMYT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ2*01 (mouse),IGKV4-61*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(173/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:168",,,,,,,,,, PR300961VHhuv1, PR300961Vlhuv2,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWVNWVRQAPGQGLEWMGMIHPSDSETRLNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(173/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:167",,,,,,,,,, PR300961VHhuv1, PR300961Vlhuv3,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWVNWVRQAPGQGLEWMGMIHPSDSETRLNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(119/144) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:119, and the amino acid sequence of the light chain variable region is shown as seq id no:144",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWFGGINPNNGDTSYNQKFKGKATLTVDKSSTTAYMDLRSLTSEDSAVYYCARDGYPYYFAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKGLIYSASHRYSGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNTYPWTFGGGTKLEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(178/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:182",,,,,,,,,, PR300928VHhuv1, PR300928VLhuv1,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRVTITVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(125/149) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:125, and the amino acid sequence of the light chain variable region is shown in seq id no:149",,,,,,,,,, Synthetic, Synthetic,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGDTTYNQKFKGKATLTVDKSSSTAFMELRSLTSEDSAVFFCAREDGNYVSFAYWGQGTLVSVSA,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCHQYYSYPLTFGAGTKLELK,GYTFTEYT,INPNNGDT,AREDGNYVSFAY,QSLLYSSNQKNY,WAS,HQYYSYPLT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN113480644A/en,"(177/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:180",,,,,,,,,, PR300928VHhuv2, PR300928VLhuv3,QVQLVQSGAEVKKPGASVKISCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRATLTVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASSRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(132/156) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:132, and the amino acid sequence of the light chain variable region is shown in seq id no:156",,,,,,,,,, Synthetic, Synthetic,QVQLVQAGAEVKKPGASVKVSCKASGYTFTRYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARALGWDVFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYWTFGQGTKVEIK,GYTFTRYD,MNPNSGNT,ARALGWDVFDI,QSISSW,KAS,QQYNSYWT,IGHJ3*02 (human),IGHV1-8*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(137/97) or the amino acid sequence of the heavy chain variable region is shown as seq id no:137, and the amino acid sequence of the light chain variable region is shown as seq id no:97",,,,,,,,,, Synthetic, Synthetic,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYSCARETSYSGYDWGYFDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQTPPWTFGQGTKVEIK,GFTFSSYG,IWYDGSNK,ARETSYSGYDWGYFDS,QSLLHSNGYNY,LGS,MQTLQTPPWT,IGHJ5*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(178/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:180",,,,,,,,,, PR300928VHhuv1, PR300928VLhuv3,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTMYWVRQAPGQRLEWMGGINPNNGDTSYNQKFKGRVTITVDKSATTAYMELSSLRSEDTAVYYCARDGYPYYFAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKGLIYSASSRYSGVPSRFSGSGSGTDFTLTISSVQPEDLATYFCQQYNTYPWTFGQGTKVEIK,GYTFTEYT,INPNNGDT,ARDGYPYYFAMDY,QNVDTN,SAS,QQYNTYPWT,IGHJ6*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
Patent,https://patents.google.com/patent/CN113480644A/en,"(123/139) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:123, and the amino acid sequence of the light chain variable region is shown in seq id no:139",,,,,,,,,, Synthetic, Synthetic,QVQLQQSGAELVRPGASVKLSCKASGYSFTSYWVNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARADGYEWYFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPVRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPWTFSGGTKLEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ1*01 (mouse),IGHV1-61*01 (mouse),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
Patent,https://patents.google.com/patent/CN113817050A/en,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVESGGGLVQPGGSLRLSCAASEITVSSNYMNWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDLMEVGGMDVWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQGVSNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSRSGTDFTLTISSLQPEDVATYYCQNYNSAPFAFGPGTKVEIK,EITVSSNY,IYSGGTT,ARDLMEVGGMDV,QGVSNY,AAS,QNYNSAPFA,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-27*01 (human)
Patent,https://patents.google.com/patent/CN111732654B/en,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREVSDFDWLYRSHYGMDVWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPQTFGGGTKVEIK,GGTFSSYA,IIPILGIA,AREVSDFDWLYRSHYGMDV,QSISSY,AAS,QQSYSTPQT,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113150129A/en,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-27 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,QVQLVQSGAEVKTPGASVKLSCKTSGYTFTTYYIHWVRQAPGQGLEWMGIINPSGGTTSYAQKFQGRVTMTRDTSTSTVYMELSGLRSEDTAVYYCARVRERWLQLHYWGQGTLVTVSS,QPVLTQPPSVSEAPRQRVTISCSGSSSNIGTNAVNWYQQLPGKAPKLLIYHNDLLPSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDRLNGRVFGGGTELTVL,GYTFTTYY,INPSGGTT,ARVRERWLQLHY,SSNIGTNA,HND,AAWDDRLNGRV,IGHJ4*01 (human),IGHV1-46*01 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
Patent,https://patents.google.com/patent/CN113150129A/en,"(12/16) the heavy chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16.",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCATGRSLNNWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNGVSWYQQHPGKAPKLMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSASWVFGGGTKLTVL,GYTFTSYY,INPSGGST,ATGRSLNN,SSDVGNYNG,EVN,SSYAGSASWV,IGHJ1*01 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV2-23*02 (human)
Patent,https://patents.google.com/patent/CN112521496A/en,"(4/3) the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:3, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:4",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,EVQVQQSGAELVKPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDPTNDDIKYDPKFQGKASITADTSSNVAYLQLSSLTSEDTAVFYCASRYDYVYAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIR,GFNIKDTY,IDPTNDDI,ASRYDYVYAMDY,KSVSTSGYSY,LVS,QHIR,IGHJ4*01 (mouse),IGHV14-3*02 (mouse),IGKJ5*01 (mouse),IGKV3-12*01 (mouse)
Patent,https://patents.google.com/patent/CN112521496A/en,"(2/1)  the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:1, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:2.",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,QVQLQQPGAELVRPGPSVKLSCKASGYSFTSYWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARSDGYYWYFDVWGAGTTVTVSS,IVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEAADAATYYCQQDNEDPWTFGGGTKLEIK,GYSFTSYW,IHPSDSET,ARSDGYYWYFDV,ESVDSYGNSF,LAS,QQDNEDPWT,IGHJ1*01 (mouse),IGHV1-61*01 (mouse),IGKJ1*01 (mouse),IGKV3-10*01 (mouse)
Patent,https://patents.google.com/patent/CN112521496A/en,"(6/5) the gene of the encoding monoclonal antibody, the gene sequence of the variable region of the light chain of the encoding sars-cov-2 spike rbd/2e10 is shown in seq id no:5; the gene sequence of the heavy chain variable region of coding sars-cov-2 spike rbd/2e10 is shown in seq id no:6.",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113264998A/en,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-22 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,QVQLVQSGAEVKKPGESLRISCKGSGYSFTTRWISWVRQMPGKGLEWMGRIDPSDSYSHYSPSFQGHVTISADRSITTAYLQWSSLKASDTAMYYCVSGGNWDSWGQGTLVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGSNPVNWYQQVPGKAPKLLIYYNDLLPSGVSGRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL,GYSFTTRW,IDPSDSYS,VSGGNWDS,SSNIGSNP,YND,AAWDDSLNGVV,IGHJ5*01 (human),IGHV5-10-1*01 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
Patent,https://patents.google.com/patent/CN113264998A/en,"(12/16) the heavy chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16.",,,,,,,,,, Artificial Synthesis, Artificial Synthesis,QVQLQESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADSSGRVYYYYGMDVWGQGTTVTVSS,DILMTQSPSSLSASVGDRVTITCRASQDVSNFLAWYQQKPGKAPKLLINGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAAYYCQQLIVYPLTFGGGTKLEIK,GFTFSSYA,ISYDGSNK,ARADSSGRVYYYYGMDV,QDVSNF,GAS,QQLIVYPLT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN112961222A/en,(7/6) the amino acid sequences of the variable region of the light chain and the variable region of the heavy chain of the monoclonal antibody clone4g1 are respectively shown as seq id no:6 and 7,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QLKESGETVRISCKASGYTFTDYSVHWVKQAPGKGLKWMGWINTETGEPTYADDFKGRFAFSLETSANTAYLQINNLKNEDTAIYFCTRSTATSDWGQGTTLTVSS,DILMTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKVLIYTASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQTNADPLTFGAGTKLELK,GYTFTDYS,INTETGEP,TRSTATSD,QSVDYDGDSY,TAS,QQTNADPLT,IGHJ2*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ5*01 (mouse),IGKV3-4*01 (mouse)
Patent,https://patents.google.com/patent/CN112961222A/en,(9/8) the monoclonal antibody has the amino acid sequences of the light chain variable region and the heavy chain variable region of clone 11d5 shown in seq id no:8 and seq id no:9.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),VQLQQSGAELVRPGALVKLSCKASGFNIKDYYIYWVKQRPEQGLEWIGWIDPENGYTIYDPKFQGKASITADTSSNTAYLQLSSLTSEDTAVYYCARSGSSFAYWGQGTTVTVSS,DIVMTQSTLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGAHFPRTFGGGTKLEIK,GFNIKDYY,IDPENGYT,ARSGSSFAY,QSLLDSDGKTY,LVS,WQGAHFPRT,IGHJ2*01 (mouse),IGHV14-1*02 (mouse),IGKJ1*01 (mouse),IGKV1-135*01 (mouse)
Patent,https://patents.google.com/patent/CN113861288A/en,"(1)  having the amino acid sequence of seq id no:1 is named b3a3, and the single domain antibody (heavy chain variable regio",,,,,,,,,, Artificial sequence (Artificial sequence),N/A,QVQLVESGGGLVQAGGSLRLSCAASGRIFEVTWMGWYRQAPGKEREFVASISRGGGTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAALHQTVLTSVEWEGYDYWGQGTQVTVSS,,GRIFEVTW,ISRGGGT,AALHQTVLTSVEWEGYDY,,,,IGHJ4*01 (human),IGHV3-11*05 (human),,
Patent,https://patents.google.com/patent/CN113861288A/en,(3) the nucleic acid molecule encoding the single domain antibody b3a3 is shown in seq id no:3.,,,,,,,,,, Artificial sequence (Artificial sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113861288A/en,(4) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.,,,,,,,,,, Artificial sequence (Artificial sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113861288A/en,(2) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.,,,,,,,,,, Artificial sequence (Artificial sequence),N/A,QVQLVESGGGLVQAGGSLRLSCAASGRILAVFVMGWYRQAPGKEREFVASITHGGTTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAQDLDYNVYFHPYWQLYDYWGQGTQVTVSS,,GRILAVFV,ITHGGTT,AAQDLDYNVYFHPYWQLYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/KR20220012792A/en,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018.",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(21/27) cs 2: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:21, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:27",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGSGDYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLVISEVRNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTQLTVL,GGTFSSYA,IIPIFGTA,ARGSGDYGMDV,SSDVGGYNY,EVR,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ7*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,(25/33) cs 8: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:25 and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:33.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREDVYGGNSRWFDPWGQGTLVTVSS,QAVLTQPSSVSGAPGQRVTISCTGSSSNIEAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREDVYGGNSRWFDP,SSNIEAGYD,GNS,QSYDSSLSGSV,IGHJ5*02 (human),IGHV1-69*10 (human),IGLJ7*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(23/30) cs 5: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:23, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:30",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPRSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGSGDYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLVISEVRNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTQLTVL,GGTFSSYA,IIPIFGTA,ARGSGDYGMDV,SSDVGGYNY,EVR,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*06 (human),IGLJ7*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(22/28) cs 3: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:28",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGSGDYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGLYNYVSWYQQHPGKAPKLMVSEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARGSGDYGMDV,SSDVGLYNY,EVS,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*06 (human),IGLJ1*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(22/31) cs 6: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:31",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGSGDYGMDVWGQGTTVTVSS,QAALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLVISEVRNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTQVTVL,GGTFSSYA,IIPIFGTA,ARGSGDYGMDV,SSDVGGYNY,EVR,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*06 (human),IGLJ7*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(20/26) cs 1: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:20, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:26",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRGVGRGYSYGFLPLDYWGQGTLVTVSS,DIQMTQSPLSLPATPGEPASISCRSSQSLLHSDGYSYLHWYVQKPGQSPQLLISADSNRASGVPGRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKLDIK,GGTFSSYA,IIPIFGTA,ARDRGVGRGYSYGFLPLDY,QSLLHSDGYSY,ADS,MQALQTPWT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(24/32) cs 7: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:24, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:32",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGSGDYSMDVWGQGTLVTVSS,QSALAQPASVSGSPGQSITISCTGTSSDVGGYNYVAWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTKLTVL,GGTFSSYA,IIPILGIA,ARGSGDYSMDV,SSDVGGYNY,EVS,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN113683687A/en,"(22/29) cs 4: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:29",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGSGDYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLVISEVRNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTRDTRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARGSGDYGMDV,SSDVGGYNY,EVR,SSYTTRDTRV,IGHJ6*01 (human),IGHV1-69*06 (human),IGLJ1*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/CN111518203B/en,"(4/8) the monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWRHSSGWDNWYFDLWGRGTLVTVSS,ENVLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLLGTFGPGTKVDIK,GGTFSSYA,IIPIFGTA,ARGGWRHSSGWDNWYFDL,QSISSY,AAS,QQSYSTLLGT,IGHJ2*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111518203B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113045646A/en,"(8/10) through analysis, the antibody obtained from the hybridoma cell line 8c4 has light chains and heavy chains with sequences shown as seq id no:10 and 8.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113943368A/en,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQVPGKGLEWVSGISWNSGTIDYADSVKGRFTISRDNAKNSLYLQMNNLRAEDTAFYYCTKDHLGELSSPDYWGQGTLVTVSS,QPVLTQSPSASASLGDSVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLNSDGRHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGIHVGGGTKLTVL,GFTFDDYA,ISWNSGTI,TKDHLGELSSPDY,SGHSSYA,LNSDGRH,QTWGTGIH,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
Patent,https://patents.google.com/patent/CN112625136B/en,"(29/23) in some embodiments, the polypeptide complex is a bispecific antibody complex consisting of 2 heavy chains consisting of the amino acid sequence set forth in seq id no:29, 30, or 31 and 2 light chains consisting of the amino acid sequence set forth in seq id no:23.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGAFYYGSGSYPFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GYTFTSYA,IIPILGIA,ASGAFYYGSGSYPFDY,QDISDY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112625136B/en,"(22/23) the polypeptide complex of claim 7 wherein the first epitope-binding portion comprises a heavy chain comprising the heavy chain variable region and a light chain comprising the light chain variable region, and wherein the heavy chain comprises the sequence set forth in seq id no:22 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto; and/or the light chain comprises the sequence shown as seq id no:23 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGAFYYGSGSYPFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GYTFTSYA,IIPILGIA,ASGAFYYGSGSYPFDY,QDISDY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112625136B/en,"(5) in some embodiments, the single domain antibody or vhh fragment thereof comprises or consists of the sequence: a vhh amino acid sequence as set forth in seq id no:5,6 or 7 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,EVQLVESGGGLVQPGGSLRLSCAASGFRFGSYYMSWVRQAPGKAPEWVSDINTRGETTRYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAVAASPATFEGRSDPDYWGQGTLVTVSS,,GFRFGSYY,INTRGETT,AVAASPATFEGRSDPDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113929774A/en,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGVVQPGRSLGLSCAVSGFTFSSYAMHWVRQAPGKGLEWVALISNDGTIDSYADSVKGRFTISRDNSKNTLYLRMSSLRAEDTAVYYCARDKEQLVPTFDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSPQPEDFATYYCQQSYSTPGLTFGGGTKVEIK,GFTFSSYA,ISNDGTID,ARDKEQLVPTFDY,QSISSY,AAS,QQSYSTPGLT,IGHJ4*01 (human),IGHV3-30*15 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112552399A/en,(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.,,,,,,,,,, synthetic, synthetic,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAITWVRQAPGQGLEWMGGIIPIFGTANFAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAHLGGFADPFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQKAGQAPRVLIYDAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGQGTRLEIK,GGTFSSYA,IIPIFGTA,AHLGGFADPFDY,QSVSNY,DAF,QQRSNWPPRIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112552399A/en,(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising the sequence of seq id no:8; ,,,,,,,,,, synthetic, synthetic,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQASGQGLEWMGWMNPNSANPGYAQKFQGRVTMTRNTSISTAFMELSSLRSDDTAVYYCARARVTIHYDILTGYYSNAFDIWGQGTMVAVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGADFTLTISSLQPEDFATYYCQQSYTTFMYTFGQGTMLEIK,GYTFTSYD,MNPNSANP,ARARVTIHYDILTGYYSNAFDI,QTISSY,AAS,QQSYTTFMYT,IGHJ3*02 (human),IGHV1-8*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112552399A/en,(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18,,,,,,,,,, synthetic, synthetic,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELNSLRSEDTAVYYCAGRSAYGDKGYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSNFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCQQRSNWPPQETFGQGTKVEIK,GGTFSSYA,IIPIFGTT,AGRSAYGDKGYYFDY,QSVSNF,DAS,QQRSNWPPQET,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112239500B/en,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig",,,,,,,,,, Artificial sequence, Artificial sequence,QIQLVQSGPELKKPGETVKISCKASGFTFTDYAMNWVKQAPGKGLKWMGWLNTYSGEPTYAEDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARTAILRSYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASEDLSTALAWCQQKPGQSPKLLIYWGSTRHSGVPDRFTGIRSGTDYTLTISSVQAEDLALYYCQQHWSTPLTFGAGTKLELK,GFTFTDYA,LNTYSGEP,ARTAILRSYFDY,EDLSTA,WGS,QQHWSTPLT,IGHJ2*01 (mouse),IGHV9-3-1*01 (mouse),IGKJ5*01 (mouse),IGKV6-25*01 (mouse)
Patent,https://patents.google.com/patent/CN112300274A/en,"(7/9)  vh comprises the amino acid sequence as set forth in seq id no:7, and vl comprises the amino acid sequence set forth in seq id no:9;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QLQLQESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGFGEFGFVPGASWFDPWGQGTLVTVSS,QPVLTQPPSVSATPGQTVTISCSGSSSNIGSSPVNWYQQLPGAAPKLLIYTNDKRPSGVPDRFSGSKSATSASLAISGLQSEDEADYYCAVWHDSLNTYVFGTGTELTVL,GFTFSSYA,ISYDGSNK,ARDRGFGEFGFVPGASWFDP,SSNIGSSP,TND,AVWHDSLNTYV,IGHJ5*02 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN112300274A/en,"(1/5)  vh comprises the amino acid sequence as set forth in seq id no:1, and vl comprises the amino acid sequence set forth in seq id no:5;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QLQLQESGPGLVKPSETLSLTCAVSGGSINSDNWWSWVRQTPEKGLEWIGEVYHSGITNYNPSLKSRVSISVDKSKNQFSLNLNSVTAADTAVYYCARDLGSTSSDGMDVWGQGTTVTVSS,QAGLTQPPSLSVSPGQTARITCSGNALPKQYAYWYRQRPGQAPELVMSRDVERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADNSGTFVVFGGGTQLIIL,GGSINSDNW,VYHSGIT,ARDLGSTSSDGMDV,ALPKQY,RDV,QSADNSGTFVV,IGHJ6*01 (human),IGHV4-4*02 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
Patent,https://patents.google.com/patent/CN112409488A/en,"(4/8) in a specific embodiment, the amino acid sequence of the heavy chain variable region is seq id no:4 and the amino acid sequence of the light chain variable region is seq id no:8.",,,,,,,,,, heavy chain variable region, light chain variable region,EVQLEESGAELVRPGASVKISCKAFGYTFTNHHINWMKQRPGQGLDWIGYVNPYNDYTKYSQNFKGKATLSVDRSSSTAYMELSSLTSEDSAVYYCARWRDYDRDWYFDVWGAGTTVIVSS,DIVMTQSPATLSVTPGDRVSLSCRASQSIRDYLYWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPYTFGGGTKLEIK,GYTFTNHH,VNPYNDYT,ARWRDYDRDWYFDV,QSIRDY,YAS,QNGHSFPYT,IGHJ1*01 (mouse),IGHV1-4*01 (mouse),IGKJ2*01 (mouse),IGKV5-39*01 (mouse)
Patent,https://patents.google.com/patent/CN113912709A/en,"(15/16) the variable region of the heavy chain sequence of vacw-212 is shown as seq id no:15, and the variable region of the light chain sequence is shown as seq id no:16",,,,,,,,,, VacW-212 heavy chain variable region, VacW-212 light chain variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANIKQDESEKYYVDSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARMEYPYGGIDYWGQGTLVTVSA,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNRNWVFGGGTKLTVL,GFTFSSYW,IKQDESEK,ARMEYPYGGIDY,SGSIASNY,EDN,QSYDSSNRNWV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(9/10) the variable region of the heavy chain sequence of vacw-138 is the sequence shown in seq id no:9, and the variable region of the light chain sequence is the sequence shown in seq id no:10",,,,,,,,,, VacW-138 heavy chain variable region, VacW-138 light chain variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISSSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLVAYPYGMDVWGQGTTVTVSS,AIQLTQSPFSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQVDTYQFTFGPGTKVDIK,GFTFSSYA,ISSSGGST,AKSLVAYPYGMDV,QGISSA,DAS,QQVDTYQFT,IGHJ6*01 (human),IGHV3-23*04 (human),IGKJ3*01 (human),IGKV1-13*02 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(3/4) the variable region of the heavy chain sequence of vacw-92 is the sequence shown in seq id no:3, and the variable region of the light chain sequence is the sequence shown in seq id no:4",,,,,,,,,, VacW-92 heavy chain variable region, VacW-92 light chain variable region,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWMGVINPSGGNTRYAQKFQGRVTMTRDTSTSTVYMELSSLRFEDTAVYYCARDSPSKLLWFGELHILYGMDVWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSSAYVFGTGTKVTVL,GYTFTSYY,INPSGGNT,ARDSPSKLLWFGELHILYGMDV,TGAVTSGHY,DTS,LLSYSSAYV,IGHJ6*01 (human),IGHV1-46*01 (human),IGLJ1*01 (human),IGLV7-46*01 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(7/8) the variable region of the heavy chain sequence of vacw-120 is the sequence shown in seq id no:7, and the variable region of the light chain sequence is the sequence shown in seq id no:8",,,,,,,,,, VacW-120 heavy chain variable region, VacW-120 light chain variable region,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDSPNYYDSSGLGIVAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKFLIYGNSNRPSGVPDRVSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSSYT,IIPILGIA,ARDSPNYYDSSGLGIVAFDI,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ3*02 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(11/12) the variable region of the heavy chain sequence of vacw-201 is the sequence shown in seq id no:11, and the variable region of the light chain sequence is the sequence shown in seq id no:12",,,,,,,,,, VacW-201 heavy chain variable region, VacW-201 light chain variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMEYPYGGVDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNRNWVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ARMEYPYGGVDY,SGSIASNY,EDN,QSYDSSNRNWV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(13/14) the variable region of the heavy chain sequence of vacw-209 is the sequence shown in seq id no:13, and the variable region of the light chain sequence is the sequence shown in seq id no:14",,,,,,,,,, VacW-209 heavy chain variable region, VacW-209 light chain variable region,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSIAMHWVRQAPGKGLEWVAVMSFDGSIKYYGDSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCARGVQGYYDRSGYYNLDYNYGMDVWGQGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GFTFSSIA,MSFDGSIK,ARGVQGYYDRSGYYNLDYNYGMDV,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(1/2) the variable region of the heavy chain sequence of vacw-89 is the sequence shown in seq id no:1, and the variable region of the light chain sequence is the sequence shown in seq id no:2",,,,,,,,,, VacW-89 heavy chain variable region, VacW-89 light chain variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAPHWNADYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPFTFGPGTKVDIK,GFTFSSYA,ISGSGGST,AKAPHWNADYFDY,QSISSW,DAS,QQYNSYPFT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ3*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(5/6) the variable region of the heavy chain sequence of vacw-105 is the sequence shown in seq id no:5, and the variable region of the light chain sequence is the sequence shown in seq id no:6",,,,,,,,,, VacW-105 heavy chain variable region, VacW-105 light chain variable region,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSYTISWVRQAPGQGLEWMGRILPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVTGAPVESAAWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVPISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,GGTFRSYT,ILPILGIA,ARVTGAPVESAAWFDP,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ5*02 (human),IGHV1-69*02 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113912709A/en,"(17/18) the variable region of the heavy chain sequence of vacw-215 is the sequence shown in seq id no:17, and the variable region of the light chain sequence is the sequence shown in seq id no:18.",,,,,,,,,, VacW-215 heavy chain variable region, VacW-215 light chain variable region,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSTWLRGGFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHFYVFGTGTKVTVL,GFTVSSNY,IYSGGST,ARSTWLRGGFDY,SGSIASNY,EDN,QSYDSSNHFYV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV6-57*02 (human)
Patent,https://patents.google.com/patent/CN112961238A/en,"(6) a nanobody based on the s1 subunit of the s protein of a novel coronavirus is disclosed, which comprises an sdab antibody fragment, wherein the amino acid sequence of the sdab antibody fragment is shown as seq id no:6.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISAIGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADSSLAGLRGRLYDYWGQGTQVTVSS,,GYTNSRYY,ISAIGRT,AADSSLAGLRGRLYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN112961238A/en,"(7) the nanobody of claim 1, based on the s1 subunit of the s protein of a novel coronavirus, characterized in that: the nucleotide sequence of the sdab antibody fragment is shown in seq id no:7.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112961238A/en,"(2) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISAIGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADSSLAGLRGRLYDYWGQGTQVTVSS,,GYTNSRYY,ISAIGRT,AADSSLAGLRGRLYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN112961238A/en,"(1) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111647077B/en,"(91) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH10,N/A,QLQLVESGGDLVQPGESLRLSCVASGATSDIYAIGWFRQAPGKEREGVSCISPSGGSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAASPSWHYCSGYEHEYDDWGQGTQVTVSS,,GATSDIYA,ISPSGGST,AAASPSWHYCSGYEHEYDD,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(89) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH8,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLDRYAIGWFRQAPGKEREGVSCISSGGTTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAGTQLRYGCSRQARRYDYWGQGTQVTVSS,,GFTLDRYA,ISSGGTT,AAGTQLRYGCSRQARRYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(104) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH23,N/A,QLQLVESGGDLVQPGESLRLSCVASASGRTSSTIGWFRQAPGKEREGVSCITWSGGSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAGLSPLMLTASRRYEYWGQGTQVTVSS,,ASGRTSST,ITWSGGST,AAGLSPLMLTASRRYEY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(93) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH12,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTFHYYAIGWFRQAPGKEREGVSCISSGGGRTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAALQGSLHYCSGLVGEYEYWGQGTQVTVSS,,GFTFHYYA,ISSGGGRT,AALQGSLHYCSGLVGEYEY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(107) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH26,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTFGTYRIGWFRQAPGKEREGVSCIFWSGGGASYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAARAPTTQEYDYWGQGTQVTVSS,,GRTFGTYR,IFWSGGGA,AARAPTTQEYDY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(101) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH20,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTFSSYAIGWFRQAPGKEREGVSCISSGGITSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAANRGRFTGWRSLTDYTYWGQGTQVTVSS,,GRTFSSYA,ISSGGIT,AANRGRFTGWRSLTDYTY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(103) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH22,N/A,QLQLVESGGDLVQPGESLRLSCVASGSGVSTGSIGWFRQAPGKEREGVSCYTSVGSISYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAFFVPFGDTYWGQGTQVTVSS,,GSGVSTGS,YTSVGSI,AFFVPFGDTY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(108) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH27,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTLSTYEIGWFRQAPGKEREGVSCVTPTGFGTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAGSGKGLGSLQRSPDDWGQGTQVTVSS,,GRTLSTYE,VTPTGFGT,AGSGKGLGSLQRSPDD,,,,IGHJ5*01 (human),IGHV3-48*03 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(98) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH17,N/A,QLQLVESGGDLVQPGESLRLSCVASGHTGSTYIIGWFRQAPGKEREGVSCISRSGILRSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAARDSLTGVIGNTPGEYDYWGQGTQVTVSS,,GHTGSTYI,ISRSGILR,AARDSLTGVIGNTPGEYDY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(100) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH19,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTFTRYPIGWFRQAPGKEREGVSCISGSGIITSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAVDNAPTSSLPLTPGEYDYWGQGTQVTVSS,,GRTFTRYP,ISGSGIIT,AVDNAPTSSLPLTPGEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(106) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH25,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTFSSYAIGWFRQAPGKEREGVSCLDVTGRSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAVYTPFRFAFKTDPDRQDHWGQGTQVTVSS,,GFTFSSYA,LDVTGRST,AAVYTPFRFAFKTDPDRQDH,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(102) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH21,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTFSTYAIGWFRQAPGKEREGVSCISPSRIITSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAADSSYGGRLGRRIDDYEYWGQGTQVTVSS,,GRTFSTYA,ISPSRIIT,AADSSYGGRLGRRIDDYEY,,,,IGHJ4*01 (human),IGHV3-11*05 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(87) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH6,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLGNYAIGWFRQAPGKEREGVSCISLSGDIISYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAPFPSLLYCSLCPSNPEFCRHWGQGTQVTVSS,,GFTLGNYA,ISLSGDII,AAPFPSLLYCSLCPSNPEFCRH,,,,IGHJ1*01 (human),IGHV3-11*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH3,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLDSYAIGWFRQAPGKEREGVSCITKHGGTTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAADHRALRFGCAVVPGPYDYWGQGTQVTVSS,,GFTLDSYA,ITKHGGTT,AADHRALRFGCAVVPGPYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(92) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH11,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLDYYAIGWFRQAPGKEREGVSCISPSGTSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAANPSYYYCSGYPHEYDDWGQGTQVTVSS,,GFTLDYYA,ISPSGTST,AAANPSYYYCSGYPHEYDD,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH2,N/A,QLQLVESGGDLVQPGESLRLSCVASGLSLEHYAIGWFRQAPGKEREGVSCIDSSGGSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAALQGSYYYTSLHQTEYDYWGQGTQVTVSS,,GLSLEHYA,IDSSGGST,AALQGSYYYTSLHQTEYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(95) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH14,N/A,QLQLVESGGDLVQPGESLRLSCVASGFRLGGYAIGWFRQAPGKEREGVSCISGSGIISSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAPSGSSYGSRRLPCGIDSQDYQTWGQGTQVTVSS,,GFRLGGYA,ISGSGIIS,AAPSGSSYGSRRLPCGIDSQDYQT,,,,IGHJ1*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(85) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH4,N/A,QLQLVESGGDLVQPGESLRLSCVASGLTLNNNTIGWFRQAPGKEREGVSCISPSGIVTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAVLQWNGAGLPSPLGSWGQGTQVTVSS,,GLTLNNNT,ISPSGIVT,AVLQWNGAGLPSPLGS,,,,IGHJ5*01 (human),IGHV3-11*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH1,N/A,QLQLVESGGDLVQPGESLRLSCVASGLSLEHYAIGWFRQAPGKEREGVSCISDSGATRSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCSATPGAFRTCAFRDFSHLANWGQGTQVTVSS,,GLSLEHYA,ISDSGATR,SATPGAFRTCAFRDFSHLAN,,,,IGHJ1*01 (human),IGHV3-11*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(99) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH18,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTVSSYVIGWFRQAPGKEREGVSCISRSGIITSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAAQTQVLPTEDRSYDYWGQGTQVTVSS,,GRTVSSYV,ISRSGIIT,AAAQTQVLPTEDRSYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(97) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH16,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTFDDYSIGWFRQAPGKEREGVSCFSSLDGSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAATRGSSWYWYRPSEYDYWGQGTQVTVSS,,GFTFDDYS,FSSLDGST,AATRGSSWYWYRPSEYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(88) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH7,N/A,QLQLVESGGDLVQPGESLRLSCVASGFSLDGYAIGWFRQAPGKEREGVSCIGRLGTTTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAAKRSTWFGCSTLDDYDYWGQGTQVTVSS,,GFSLDGYA,IGRLGTTT,AAKRSTWFGCSTLDDYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(96) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH15,N/A,QLQLVESGGDLVQPGESLRLSCVASFDDFAIGWIGWFRQAPGKEREGVSCSARGIVNTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAALVGLNDRSLPHEAEEYDYWGQGTQVTVSS,,FDDFAIGW,SARGIVNT,AALVGLNDRSLPHEAEEYDY,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(105) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH24,N/A,QLQLVESGGDLVQPGESLRLSCVASGRTVSMYAIGWFRQAPGKEREGVSCISRSGRSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAARDGGLHYALYVEASHYNYWGQGTQVTVSS,,GRTVSMYA,ISRSGRST,AARDGGLHYALYVEASHYNY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(90) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH9,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLDYYAIGWFRQAPGKEREGVSCISSSGTSTSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAALQGSYYYTSLHQTEYDYWGQGTQVTVSS,,GFTLDYYA,ISSSGTST,AALQGSYYYTSLHQTEYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(94) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH13,N/A,QLQLVESGGDLVQPGESLRLSCVASFKSYHIAWIGWFRQAPGKEREGVSCSLTGASITSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAARDYASSLYCSRNEAMYAYWGQGTQVTVSS,,FKSYHIAW,SLTGASIT,AARDYASSLYCSRNEAMYAY,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
Patent,https://patents.google.com/patent/CN111647077B/en,"(86) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108.",,,,,,,,,, VHH5,N/A,QLQLVESGGDLVQPGESLRLSCVASGFTLGNYEIGWFRQAPGKEREGVSCISRSGVIFSYADSVRGRFTISRENAKNAVYLEMNSLKPEDTAVYYCAARFRAGLVQSLCQSTPEFYQDWGQGTQVTVSS,,GFTLGNYE,ISRSGVIF,AARFRAGLVQSLCQSTPEFYQD,,,,IGHJ1*01 (human),IGHV3-48*03 (human),,
Patent,https://patents.google.com/patent/CN112225797B/en,"(5/4) preferably, the monoclonal antibody has the amino acid sequence of the light chain variable region shown in seq id no:4 and the amino acid sequence of the heavy chain variable region shown in seq id no:5.",,,,,,,,,, mouse (Mus musculus), mouse (Mus musculus),QVQLQQSGPDLARPGASVKLSCKASGDTFTDHYIIWVKQRTGQGLEWIGEIYPGNGHTYYNERFKGKATLTADDSSSTAYMQLSSLTSEDSAVYFCARSRYYGPFAYWGQGTLVTVSA,DIQMIQSPASLSVSVGETVTITCRASENIYSSLAWYQQKQGKSPQLLVYVATDLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPWTFGGGTKLEIK,GDTFTDHY,IYPGNGHT,ARSRYYGPFAY,ENIYSS,VAT,QHFWGTPWT,IGHJ3*01 (mouse),IGHV1-81*01 (mouse),IGKJ1*01 (mouse),IGKV12-46*01 (mouse)
Patent,https://patents.google.com/patent/CN112225797B/en,"(3/2) the gene of claim 4, wherein the gene encoding the light chain variable region has the sequence shown in seq id no:2; the gene sequence of the coding heavy chain variable region is shown in seq id no:3.",,,,,,,,,, mouse (Mus musculus), mouse (Mus musculus),,,,,,,,,,,,
Patent,https://patents.google.com/patent/KR20220003405A/en,"(55/56)  in one embodiment of the present invention, the heavy chain variable region of (d) comprises the amino acid sequence of seq id no:55, and the light chain variable region of (d) comprises the amino acid sequence of seq id no:56.",,,,,,,,,, Heavy chain variable regi on of R9 , light chain variable region of R9 ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYGMSWVRQAPGKGLEWVSYISSYYSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGGSYPYDYFDYWGQGTLVTVSS,QSVLTQPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAAPDYASYVFGGGTKLTVL,GFTFSYYG,ISSYYSYT,ARYGGSYPYDYFDY,SSNIGSNY,RNN,AAAPDYASYV,IGHJ4*01 (human),IGHV3-23*03 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220003405A/en,"(7/8)  in one embodiment of the present invention, the heavy chain variable region of (a) comprises the amino acid sequence of seq id no:7, and the light chain variable region of (a) comprises the amino acid sequence of seq id no:8.",,,,,,,,,, Heavy chain variable region of R1 , light chain variable region of R1 ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYSMSWVRQAPGKGLEWVSYISSYYYSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGYSGYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAASPAYYYYVFGGGTKLTVL,GFTFSGYS,ISSYYYST,ARYGYSGYFDY,SSNIGSNY,RNN,AASPAYYYYV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220003405A/en,"(23/24)  in one embodiment of the present invention, the heavy chain variable region of (b) comprises the amino acid sequence of seq id no:23, and the light chain variable region of (b) comprises the amino acid sequence of seq id no:24.",,,,,,,,,, Heavy c hain variable region of R3 , light chain variable region of R3 ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSYIGGGYGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGGSAYFDYWGQGTLVTVSS,QSVLTQPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAYYRYNRYVFGGGTKLTVL,GFTFSSYG,IGGGYGGT,ARYGGSAYFDY,SSNIGSNY,RNN,AAYYRYNRYV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220003405A/en,"(87/88)  in one embodiment of the present invention, the heavy chain variable region of (f) comprises the amino acid sequence of seq id no:87, and the light chain variable region of (f) comprises the amino acid sequence of seq id no:88.",,,,,,,,,, Heavy chain variable region of R17 , light chain variable region of R17 ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYSMSWVRQAPGKGLEWVSYISGHYGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSYSNFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAASGNYRSYVFGGGTKLTVL,GFTFSNYS,ISGHYGYT,ARYSYSNFDY,SSNIGSNY,RNN,AASGNYRSYV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220003405A/en,"(71/72)  in one embodiment of the present invention, the heavy chain variable region of (e) includes the amino acid sequence of seq id no:71, and the light chain variable region of (e) includes the amino acid sequence of seq id no:72.",,,,,,,,,, Heavy chain variable region of R15 , light chain variable region of R15 ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSYISGYYYSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSYDYSSFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAASANDYYVFGGGTKLTVL,GFTFSSYG,ISGYYYST,ARYSYDYSSFDY,SSNIGSNY,RNN,AASANDYYV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/CN112661841A/en,"(1/2) a monoclonal antibody 17-2, the heavy chain amino acid sequence of said monoclonal antibody 17-2 is shown in seq id no:1; the light chain amino acid sequence of the monoclonal antibody 17-2 is shown as seq id no:2.",,,,,,,,,, 17-2 heavy chain amino acid sequence (17-2 heavy chain amino acid sequence), 17-2 light chain amino acid sequence (17-2 light chain amino acid sequence),QLQLQESGPGLVKASETLSLTCTVSSGSVSSDSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTMSVDTSKNQFSLKLDSVTAADTAAYYCARGPLGLYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISGLQPEDFATYYCQESNSSPFTFGPGTKVDIK,SGSVSSDSYY,IYYSGST,ARGPLGLYYYYMDV,QSINNY,AAS,QESNSSPFT,IGHJ6*04 (human),IGHV4-61*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113667016A/en,"(11/16) in one embodiment, the antibody is 89c8, the amino acid sequence of its heavy chain is set forth in seq id no:11, and the amino acid sequence of its light chain is set forth in seq id no:16.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGGLGFGELFRKTGYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYAASTRATAIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYNKLPLTFGGGTKVDIK,GGTFSSYA,IIPILGIA,ARGGLGFGELFRKTGYYFDY,QSVSSN,AAS,QQYNKLPLT,IGHJ4*01 (human),IGHV1-69*10 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113667016A/en,"(21/22) in one embodiment, the antibody is cr3022, the heavy chain has the amino acid sequence shown in seq id no:21, and the light chain has the amino acid sequence shown in seq id no:22.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(5/16)  the heavy chain variable region as set forth in seq id no:5, and the light chain variable region as set forth in seq id no:16;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARVGRGYFDWLFRSDKPYYYGMDVWGHGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPPTFGQGTKLE,GGSFSGYY,INHSGST,ARVGRGYFDWLFRSDKPYYYGMDV,QSLLHSNGYNY,LGS,MQALQTPPT,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ2*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(2/13)  the heavy chain variable region as set forth in seq id no:2, and the light chain variable region as set forth in seq id no:13;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARVGRGYFDWLFRSDKPYYYGMDVWGHGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSQVTFGGGTKVDIK,GGSFSGYY,INHSGST,ARVGRGYFDWLFRSDKPYYYGMDV,QSVSSSY,GAS,QQYGRSQVT,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(11/22)  the heavy chain variable region shown as seq id no:11, and the light chain variable region shown as seq id no:22.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGGLGFGELFRKTGYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYAASTRATAIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYNKLPLTFGGGTKVDIK,GGTFSSYA,IIPILGIA,ARGGLGFGELFRKTGYYFDY,QSVSSN,AAS,QQYNKLPLT,IGHJ4*01 (human),IGHV1-69*10 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(4/15)  the heavy chain variable region as set forth in seq id no:4, and the light chain variable region as set forth in seq id no:15;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLLESGGGLVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRYYDILTGYLRPPSRYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVKSSYLAWYQQKPGQAPRLLIYGASSRATGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPFTFGPGTKVDIK,GFTFSSYG,ISYDGSNK,ARDLRYYDILTGYLRPPSRYYYYGMDV,QSVKSSY,GAS,QQYGTSPFT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,(8/19)  the heavy chain variable region as set forth in seq id no:8 and the light chain variable region as set forth in seq id no:19;,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSRETPGFDESIAAALGGYYYYGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLWTFGQGTKVDIK,GFTFSSYA,ISYDGSNK,ARGSRETPGFDESIAAALGGYYYYGMDV,QSVSSN,GAS,QQYNNWPLWT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(7/18)  the heavy chain variable region as set forth in seq id no:7, and the light chain variable region as set forth in seq id no:18;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRYYDILTGYLRPPSRYYYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCQASQDINYFLNWYQQKPGKAPKLLISDASNLETGVPSRFSGSGSGTDFTFTINTLQPEDIATYYCQQYDNLPFTFGPGTKVEIK,GFTFSSYG,ISYDGSNK,ARDLRYYDILTGYLRPPSRYYYYGMDV,QDINYF,DAS,QQYDNLPFT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,(9/20)  the heavy chain variable region as set forth in seq id no:9 and the light chain variable region as set forth in seq id no:20;,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGHYWSWIRQPPGKGLEWIGEIDHSGSTNYNPSLKSRVSISVDTSKNQFSLKLTSVTAADTAVYYCARVGRGYFDWLFRSDKPYYYGMDVWGHGTTVTVSS,DIRMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKSGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK,GGSFSGHY,IDHSGST,ARVGRGYFDWLFRSDKPYYYGMDV,QGISSW,AAS,QQANSFPLT,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,(3/14)  the heavy chain variable region as set forth in seq id no:3 and the light chain variable region as set forth in seq id no:14;,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNMLYLQMNSLKTEDTAVYYCTTDLPKTRYFDWLFHSDYYYYGMDVWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLWTFGQGTKVEIK,GFTFSNAW,IKSKTDGGTT,TTDLPKTRYFDWLFHSDYYYYGMDV,QSISSY,AAS,QQSYSTLWT,IGHJ6*01 (human),IGHV3-15*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(6/17)  the heavy chain variable region as set forth in seq id no:6, and the light chain variable region as set forth in seq id no:17;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDLPKTRYFDWLFHSDYYYYGMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQAISTSLAWYHQKPGKAPKLLIYDASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVE,GFTFDDYA,IKSKTDGGTT,TTDLPKTRYFDWLFHSDYYYYGMDV,QAISTS,DAS,QQSYSTPPT,IGHJ6*01 (human),IGHV3-15*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,(10/21)  the heavy chain variable region shown as seq id no:10 and the light chain variable region shown as seq id no:21; or,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVGRGYFDWLFRSDKPYYYGMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GGSFSGYY,INHSGST,ARVGRGYFDWLFRSDKPYYYGMDV,QSVLYSSNNKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN113667010A/en,"(1/12)  a heavy chain variable region as set forth in seq id no:1, and a light chain variable region as set forth in seq id no:12;",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRYYDILTGYLRPPSRYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVDIK,GFTFSSYG,ISYDGSNK,ARDLRYYDILTGYLRPPSRYYYYGMDV,QSVSSY,GAS,QQYNNWPLT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(6/16)  a heavy chain variable region consisting of the amino acid sequence of seq id no:6 and a light chain variable region consisting of the amino acid sequence of seq id no:16,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVSSISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKREYSGRVFSFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLFYATSNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK,GFTFSNYA,ISGSGSST,AKREYSGRVFSFDY,QSISNY,ATS,QQSYSTPYT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(4/14)  a heavy chain variable region consisting of the amino acid sequence of seq id no:4 and a light chain variable region consisting of the amino acid sequence of seq id no:14,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYEMSWVRQAPGKGLEWVSAISSSGGTKGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTGVGLTSTFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYATSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPYTFGQGTKVEIK,GFTFSNYE,ISSSGGTK,AKDTGVGLTSTFDI,QSISNY,ATS,QQSYSFPYT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(10/20)  or a heavy chain variable region consisting of the amino acid sequence of seq id no:10 and a light chain variable region consisting of the amino acid sequence of seq id no:20,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYEMHWVRQAPGKGLEWVSAISSSGGTKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSGYSWVSVFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYDASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK,GFTFSDYE,ISSSGGTK,AKDSGYSWVSVFDV,QSISNY,DAS,QQSYSTPWT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(7/17)  a heavy chain variable region consisting of the amino acid sequence of seq id no:7 and a light chain variable region consisting of the amino acid sequence of seq id no:17,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYEMNWVRQAPGKGLEWVSAISSSGGTKDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDIGVYYTTVFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPWTFGQGTKVEIK,GFTFSDYE,ISSSGGTK,AKDIGVYYTTVFDY,QSISNY,AAS,QQSYSSPWT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(8/18)  a heavy chain variable region consisting of the amino acid sequence of seq id no:8 and a light chain variable region consisting of the amino acid sequence of seq id no:18,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMHWVRQAPGKGLEWVSSISSSGSSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDIGLYWTSVFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK,GFTFSSYE,ISSSGSSK,AKDIGLYWTSVFDY,QSISNY,GAS,QQSYSTPWT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(2/12)  a heavy chain variable region consisting of the amino acid sequence of seq id no:2 and a light chain variable region consisting of the amino acid sequence of seq id no:12,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYEMHWVRQAPGKGLEWVSSISGSGSDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEVTGYADIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNWLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGQGTKVEIK,GFTFSDYE,ISGSGSDT,AKEVTGYADI,QSISNW,AAS,QQSYSTPFT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,"(1/11)  the method of claim 1, the antibody or antigen-binding fragment thereof a heavy chain variable region consisting of the amino acid sequence of seq id no:1 and a light chain variable region consisting of the amino acid sequence of seq id no:11",,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISSSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWHGGGWQVYTAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNWLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK,GFTFSSYA,ISSSGSST,AKWHGGGWQVYTAFDV,QSISNW,AAS,QQSYSTPLT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(9/19)  a heavy chain variable region consisting of the amino acid sequence of seq id no:9 and a light chain variable region consisting of the amino acid sequence of seq id no:19,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSRISSSGSSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKREYGGEVYAFDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPYTFGQGTKVEIK,GFTFSSYA,ISSSGSSK,AKREYGGEVYAFDH,QSISNY,AAS,QQSYSFPYT,IGHJ1*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(3/13)  a heavy chain variable region consisting of the amino acid sequence of seq id no:3 and a light chain variable region consisting of the amino acid sequence of seq id no:13,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVSAISSSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQLYAGWITYWGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPYTFGQGTKVEIK,GFTFSDYA,ISSSGSST,AKQLYAGWITYWGMDY,QSISSY,DAS,QQSYSFPYT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR102233689B1/en,(5/15)  a heavy chain variable region consisting of the amino acid sequence of seq id no:5 and a light chain variable region consisting of the amino acid sequence of seq id no:15,,,,,,,,,, VH, VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSAISSSGGSTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRAWGWVEVFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPLTFGQGTKVEIK,GFTFSSYE,ISSSGGST,AKDRAWGWVEVFDF,QSISRY,AAS,QQSYSFPLT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111647076B/en,"(8) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,EVQLLESGGGLVQPGGSLRLSCAASDFYFADYEMSWVRQAPGKGLEWIGSIYHSGSTYYNPSLKSRVTISRDNSKNTLYLQMNSLRAEDTAMYYCAREWHSGYDYWGQGTLVTVSS,,DFYFADYE,IYHSGST,AREWHSGYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111647076B/en,"(5) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,EVQLLESGGGLVQPGGSLRLSCAASDFAFSSYEMSWVRQAPGKGLEWIGEIHHSGSTYYNPSLKSLVTISRDNSKNTLYLQMNSLRAEDTAVYYCVKDFGHLGQMASWGQGTLVTVSS,,DFAFSSYE,IHHSGST,VKDFGHLGQMAS,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN114031685A/en,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5.",,,,,,,,,, Homo sapiens, Homo sapiens,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGITWNSGTIGYADSVKGRFIISRDNAKNSLHLQMNSLRVEDTALYYCAKDNSDYSGYYWELENYGMDVWGQGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDSSLSGVVFGGGTRLTVL,GFTFDDYA,ITWNSGTI,AKDNSDYSGYYWELENYGMDV,SSNIGAGYD,DNN,QSFDSSLSGVV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112625136A/en,"(29/23) in some embodiments, the polypeptide complex is a bispecific antibody complex consisting of 2 heavy chains consisting of the amino acid sequence set forth in seq id no:29, 30, or 31 and 2 light chains consisting of the amino acid sequence set forth in seq id no:23.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGAFYYGSGSYPFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GYTFTSYA,IIPILGIA,ASGAFYYGSGSYPFDY,QDISDY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112625136A/en,"(5) in some embodiments, the single domain antibody or vhh fragment thereof comprises or consists of the sequence: a vhh amino acid sequence as set forth in seq id no:5,6 or 7 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,EVQLVESGGGLVQPGGSLRLSCAASGFRFGSYYMSWVRQAPGKAPEWVSDINTRGETTRYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAVAASPATFEGRSDPDYWGQGTLVTVSS,,GFRFGSYY,INTRGETT,AVAASPATFEGRSDPDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279A/en,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279A/en,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGNIDSTRYHGWFRQAPGKGLEAVAAIKGVWPEDYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADQYEWWVPGEVGPYLYWGQGTQVTVSS,,GNIDSTRY,IKGVWPED,AADQYEWWVPGEVGPYLY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGADAFVIIGGWFRQAPGKGLEAVAAIAWTDQHEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAQDSAYIKSKGSRAYEYWGQGTQVTVSS,,GADAFVII,IAWTDQHE,AAQDSAYIKSKGSRAYEY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGGNAAERMAGWFRQAPGKGLEAVAAIYYAKFGPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAEAFVQSPYSGSHTTKYWGQGTQVTVSS,,GGNAAERM,IYYAKFGP,AAEAFVQSPYSGSHTTKY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279A/en,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGLAQSKWAYGWFRQAPGKGLEAVAAIDVATGPWYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAHHIPTKHPAFPDFRDYWGQGTQVTVSS,,GLAQSKWA,IDVATGPW,AAHHIPTKHPAFPDFRDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGRQAVVFGWFRQAPGKGLEAVAAIHVPAKNRYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAHYEFNDFVWQGYSSDYWGQGTQVTVSS,,GRQAVV,IHVPAKNR,AAHYEFNDFVWQGYSSDY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111303279A/en,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279A/en,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112513076A/en,"(70) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-7,N/A,QLQLVESGGGLVQAGDSLRLSCATSRTFSVGEVMGWFRQAPGKEREFVAGIRWGSESTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAATEKVYSAYYYYSRDRLYDYRGQGTQVTVSS,,RTFSVGEV,IRWGSEST,AAATEKVYSAYYYYSRDRLYDY,,,,IGHJ4*01 (human),IGHV3-NL1*01 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(71) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-8,N/A,QLQLVESGGGLVQAGDSLRLSCATSGFTFDDYAMGWFRQAPGKEREFVAGISSRDGRTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAANHLTYYSGSYYFPYEYHYRGQGTQVTVSS,,GFTFDDYA,ISSRDGRT,AAANHLTYYSGSYYFPYEYHY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(67) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-4,N/A,QLQLVESGGGLVQAGDSLRLSCATSGFTFDDYAMGWFRQAPGKEREFVAGIGSRDGSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAPDSVSYYGWSLNPYEYDYRGQGTQVTVSS,,GFTFDDYA,IGSRDGST,AAAPDSVSYYGWSLNPYEYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-21,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRIPSWNIMGWFRQAPGKEREFVAGIRWTSGTTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAGWRRGGVQQISTGSHDYDPRGQGTQVTVSS,,GRIPSWNI,IRWTSGTT,AGWRRGGVQQISTGSHDYDP,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(72) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-9,N/A,QLQLVESGGGLVQAGDSLRLSCATSRCTFNWDGMGWFRQAPGKEREFVAGISWSGQEPYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAAQYTGASYSILRDQVGYDYRGQGTQVTVSS,,RCTFNWDG,ISWSGQEP,AAAAQYTGASYSILRDQVGYDY,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(74) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, SP11,N/A,QLQLVESGGGLVQAGDSLRLSCATSGHTFSSYAMGWFRQAPGKEREFVAGIDWSGDEAYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAADRGLSYYYDRTQEYGIRGQGTQVTVSS,,GHTFSSYA,IDWSGDEA,AAADRGLSYYYDRTQEYGI,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-20,N/A,QLQLVESGGGLVQAGDSLRLSCATSGDTFNNYAMGWFRQAPGKEREFVAGIARSGRSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAADPAPLWFAWTSDMAKYKFRGQGTQVTVSS,,GDTFNNYA,IARSGRST,AAADPAPLWFAWTSDMAKYKF,,,,IGHJ1*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(77) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-14,N/A,QLQLVESGGGLVQAGDSLRLSCATSASGRSTHRMGWFRQAPGKEREFVAGIMPGGGFPYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAARSETGEYDNRGQGTQVTVSS,,ASGRSTHR,IMPGGGFP,AAARSETGEYDN,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-19,N/A,QLQLVESGGGLVQAGDSLRLSCATSGSIASITAMGWFRQAPGKEREFVAGSNSRGSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAYVNTLRAEMPEAYRGQGTQVTVSS,,GSIASITA,SNSRGST,AYVNTLRAEMPEAY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(65) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-2,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRTFSSYAMGWFRQAPGKEREFVAGISWTGDTTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAADRGLSYYYYRTQDYDYRGQGTQVTVSS,,GRTFSSYA,ISWTGDTT,AAADRGLSYYYYRTQDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(79) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-16,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRTFSSYTMGWFRQAPGKEREFVAGISRSGGGTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAVSRRVLLTDTPRDYDRRGQGTQVTVSS,,GRTFSSYT,ISRSGGGT,AAVSRRVLLTDTPRDYDR,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(66) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-3,N/A,QLQLVESGGGLVQAGDSLRLSCATSGFTLDYYTMGWFRQAPGKEREFVAGTSSADGSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAAPGAYYSGTYYRACHSAGMEYRGQGTQVTVSS,,GFTLDYYT,TSSADGST,AAAAPGAYYSGTYYRACHSAGMEY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(68) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-5,N/A,QLQLVESGGGLVQAGDSLRLSCATSGGTFSRSGMGWFRQAPGKEREFVAGRADVGFPYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAATSLQSGKYDYRGQGTQVTVSS,,GGTFSRSG,RADVGFP,AAATSLQSGKYDY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(69) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-6,N/A,QLQLVESGGGLVQAGDSLRLSCATSGHTFSRFGMGWFRQAPGKEREFVAGRNDGGFPYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAATSPESGRYDYRGQGTQVTVSS,,GHTFSRFG,RNDGGFP,AAATSPESGRYDY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(76) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-13,N/A,QLQLVESGGGLVQAGDSLRLSCATSGLTGSTFVMGWFRQAPGKEREFVAGIRWTYGRTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAREGYRGSAYQTSDFDYRGQGTQVTVSS,,GLTGSTFV,IRWTYGRT,AAAREGYRGSAYQTSDFDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(75) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-12,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRTLRSFAMGWFRQAPGKEREFVAGISWSGDDTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAGGHTINHDIISPDYRGQGTQVTVSS,,GRTLRSFA,ISWSGDDT,AAAGGHTINHDIISPDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(73) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-10,N/A,QLQLVESGGGLVQAGDSLRLSCATSTRTFSNYNMGWFRQAPGKEREFVAGISRAGAEIYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAAARVMGVSPAIYNYRGQGTQVTVSS,,TRTFSNYN,ISRAGAEI,AAAARVMGVSPAIYNY,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(81) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-18,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRTSSRYVMGWFRQAPGKEREFVAGITSTGFGTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAADTSLLTRRPSDSASPYDYRGQGTQVTVSS,,GRTSSRYV,ITSTGFGT,AAADTSLLTRRPSDSASPYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(64) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-1,N/A,QLQLVESGGGLVQAGDSLRLSCATSGRAVTIYHMGWFRQAPGKEREFVAGISPSRVITYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAATRGSFDRNRVNYDYRGQGTQVTVSS,,GRAVTIYH,ISPSRVIT,AATRGSFDRNRVNYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(78) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-15,N/A,QLQLVESGGGLVQAGDSLRLSCATSGFTLDYYRMGWFRQAPGKEREFVAGISSSDGSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAATGPLTYYSGRYYLGGCFDTYAMDFRGQGTQVTVSS,,GFTLDYYR,ISSSDGST,AATGPLTYYSGRYYLGGCFDTYAMDF,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112513076A/en,"(80) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84.",,,,,,,,,, VHH-17,N/A,QLQLVESGGGLVQAGDSLRLSCATSGNTLDYYAMGWFRQAPGKEREFVAGIKSSDGSTYYADSVKGRFTISRDNGKTTVYLQMNSLKPEDTAVYYCAAIGPLTYYSGRYYFPYDYDYRGQGTQVTVSS,,GNTLDYYA,IKSSDGST,AAIGPLTYYSGRYYFPYDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(50) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,EVQLVESGGGLVQPGGSLTLSCAASGFTFSSYAMAWYRQAPGKECEWVATITITGGNSNYADSVKGRFTISRDNAKNTVYLQMNSLKSEDTAVYYCNADPSCPLGQGTQVTVSS,,GFTFSSYA,ITITGGNS,NADPSCP,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(44) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVDSGGGLVQPGGSLRLSCAASGFGFNMYAMGWYRQAPGKQRELVATIARDGSTGYAISVKGRFTISRDNVKNTVDLQMNSLKPEDTAVYYCKRELGPYASWGQGTQVTVSS,,GFGFNMYA,IARDGST,KRELGPYAS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(45) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QAQLVESGGGLVQPGGSLRLSCAASGFLFKMYAMGWYRQAPGKQRELVASIANDGSTGYGDSVKGRFIISRDNVKNTVDLQMNSLKPEDTAHYYCKRELGPFSSWGQGTQVTVST,,GFLFKMYA,IANDGST,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(48) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QLVEPGGSLRLSCATSKSAFAIFAMSWYRQAPGKECEWVATITITGGNSNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCNADPGCPLGQGTQVTVSS,,KSAFAIFA,ITITGGNS,NADPGCP,,,,IGHJ5*02 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(41) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QVKLEESGGGLVQPGGSLRVSCAASGFNFNIYNMGWYRQAPGKQRELVATIAAGGSTGYADPVKGRFAISRDNVKNTVDLQMNSLKPEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFNFNIYN,IAAGGST,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(39) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QVQLVESGGGLVQPGGSLRLSCAASGFIFKMYAMGWYRQAPGLQRESVASIAQDGSASYADSVKGRFTISRDNVKNTVDLQMNSLKPEDTAHYYCKRELGPFSSWGQGTQVTVSS,,GFIFKMYA,IAQDGSA,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(43) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVESGGGLVQPGGSLRLSCAASGFNFNFYAMGWYRQAPGKQRELVATIAADGSAAYADSVKGRFTISRHNEKNTVDLQMNSLKPEDTGVYYCKRELGPFGSWGQGTQVTVSS,,GFNFNFYA,IAADGSA,KRELGPFGS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(35) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVDSGGGLVQPGGSLTLSCSASGFFFNGYNMGWYRQAPGKQRELVATISEAGTTGYADSVKGRFTISRDNVKNTVDLHMNSLKPEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFFFNGYN,ISEAGTT,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(40) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVESGGGLVQPGGSLRLSCAASGFNFNIYAMGWYRQAPGKQRELLATIAAGGSTNYADSVKGRFTISRDNIKNKVDLQMNSLKPEDTAVYYCKRELGSFSSWGQGTQVTVSS,,GFNFNIYA,IAAGGST,KRELGSFSS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(37) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QAQLVESGGGLVQPGGSLRLSCAASGFNFNMYAMGWYRQAPGKERELVATVAAGGSTGYADSVKGRFTISRDNVKMKVDLQMNSLKLEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFNFNMYA,VAAGGST,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(36) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVDSGGGLVQPGGSLRLSCAASGFAFNIYNMGWYRQAPGKQRELVATIAADGSTGYADSVKGRFTISRDNVKNKVDLQMNSLKPEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFAFNIYN,IAADGST,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(42) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QVQLVESGGGLVQPGGSLRLSCAASGFVFNMYAMGWYRQAPGKQRELVATIAKDGSTGYAISVKGRFTISRDNVKNTVDLQMNSLKPEDTAVYYCKRELGPYGSWGQGTQVTVSS,,GFVFNMYA,IAKDGST,KRELGPYGS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(49) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QVQLVESGGGLVQPGGSLTLSCSASGFFFNGYNMGWYRQAPGKQRELVATISEAGTTGYADSVKGRFTISRDNVKNTVDLHMNSLKPEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFFFNGYN,ISEAGTT,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(38) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVDSGGGMVQPGGSLRLSCAASGFNFNIYAMGWYRQAPGKQRELVATIAAGGNTGYADSVKGRFTISRDNVKNKVNLQMNNLKPEDTAVYYCKRELGPFSSWGQGTQVTVSS,,GFNFNIYA,IAAGGNT,KRELGPFSS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(47) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVDSGGGLVQPGGSLRLSCAASGFNFNFYAMGWYRQAPGKQRELVATIAAGGSTNYADSVKGRFTISRHNEKNTVDLQMNSLKPEDTGVYYCKRELGPFASWGQGTQVTVSS,,GFNFNFYA,IAAGGST,KRELGPFAS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(51) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,QVQLVESGGGSVRAGESLRLSCAASGFTFSSYAMGWYRQAPGKECEWVATITITGGNSNYADSVKGRFTISRDNAKNTVYLQMNSLQPEDTAVYYCNADPGCPLGQGTQVTVSS,,GFTFSSYA,ITITGGNS,NADPGCP,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
Patent,https://patents.google.com/patent/CN113943367A/en,"(46) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52.",,,,,,,,,, Artificial sequence,N/A,AVQLVESGGGLVQPGGSLRLSCAASGFNFNIYAMGWYRQAPGKQRELVATIAAGGSTGYADSVKGRFTISRDNVKNKVDLQMNSLKPEDTAVYYCKRELGPFASWGQGTQVTVSS,,GFNFNIYA,IAAGGST,KRELGPFAS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112010967B/en,"(1) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQAGDSLRLACAATGRTLSNYIMGWFRQAPGKEPLFVAAISRSGVITKYADSVEGRFTISRDNAKNTAYLQMTSLEPEDTAVYYCAASSSKYMATREYDYWGQGTQVTVSS,,GRTLSNYI,ISRSGVIT,AASSSKYMATREYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112010967B/en,"(3) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGRTFSSTGMGWFRQGPGKEREFVAAISGDGDTTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCASARFTWGLYSDFVNSYEYDAWGQGTPVTVSS,,GRTFSSTG,ISGDGDTT,ASARFTWGLYSDFVNSYEYDA,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112010967B/en,"(2) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGASLRLSCAASGRTFSSTGMGWFRQAPGKEREFVAAISGDGDTTYYADSVKGRFTISRDNAKNTVYLQMNSLKPWDTAVYYCASTRFTWGLYSDFVNSYEYDAWGQGTPVTVSS,,GRTFSSTG,ISGDGDTT,ASTRFTWGLYSDFVNSYEYDA,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112010967B/en,"(4) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGASLRLFCVASGRTFSSTGMGWFRQAPGKEREFVAAISGPGDTTYYVDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCASAGFTWGLYSDFVNSYEYNYWGQGTPVTVSS,,GRTFSSTG,ISGPGDTT,ASAGFTWGLYSDFVNSYEYNY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111269313B/en,"(9/10) an anti-n protein monoclonal antibody characterized by: wherein the heavy chain variable region amino acid sequence of the antibody is seq id no:9, the amino acid sequence of the light chain variable region sequence is seq id no:10.",,,,,,,,,, 2 Ambystoma laterale x Ambystoma jeffersonianum, 2 Ambystoma laterale x Ambystoma jeffersonianum,QIQLQQSGASLVRPGALVKLSCKASDSHYYSQSLHWVKQRPVQGLEWIGDIGSADNSTKYAPPFLGKAQITADTSSNTAYLQLSSLTSEDTAVYYCIRYASSGWGWGQGTTLTVSS,DIVITQSPALMADSPGEKVTITCDYSEEISMSYLAWYQQSSGISPKPWIYTTAGLAPGVPARFSGSGSGTSYSLTITSAEAEDAATYYCSSASSLPCRFGAGTKLELK,DSHYYSQS,IGSADNST,IRYASSGWG,EEISMSY,TTA,SSASSLPCR,IGHJ2*01 (mouse),IGHV14-1*02 (mouse),IGKJ5*01 (mouse),IGKV4-53*01 (mouse)
Patent,https://patents.google.com/patent/CN112979791B/en,"(4/8) the antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of the heavy chain variable region is represented by seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSFYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREWFGETWEGMDAWGQGTTVTVSS,ENVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLLTFGGGTKVEIK,GFTFSFYA,ISYDGSNK,AREWFGETWEGMDA,QSVSSY,DAS,QQRSNWPLLT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112979791B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112341541A/en,"(2/1) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-163 are shown in seq id no:1 and 2, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCEASEIIVNRNYMNWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTMYLQMNSLRAEDTAVYYCARSYGDFYVDFWGQGTLVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHGRTFGQGTKVEIK,EIIVNRNY,IYPGGST,ARSYGDFYVDF,QSVSSSY,GAS,QQHGRT,IGHJ5*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN111727199A/en,"(43/44) iv) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:43, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:44",,,,,,,,,, antibody 4 heavy chain variable region, antibody 4 light chain variable region,QVQLQESGPGLVKPSETLSLTCTVSGGSINSRSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARADREYVWGSYDGPGSPFDYWGQGTLVTVSS,ELVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYLQVPGTAPKLLIYGDHQRPSGVPDRFSGSKSGTSASLSISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL,GGSINSRSYY,IYYSGST,ARADREYVWGSYDGPGSPFDY,SSNIGNNA,GDH,AAWDDSLNGVV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
Patent,https://patents.google.com/patent/CN111727199A/en,"(39/40) ii) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:39, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:40",,,,,,,,,, antibody 2 heavy chain variable region, antibody 2 light chain variable region,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGIAKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDLPGDSRDGYNYDAFDIWGQGTMVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQLPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCATWDRSLSVELFGGGTKVTVL,GGTFSSYA,IIPIFGIA,ARDLPGDSRDGYNYDAFDI,SSNIGNNF,DND,ATWDRSLSVEL,IGHJ3*02 (human),IGHV1-69*04 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN111727199A/en,"(45/46) v) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:45, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:46",,,,,,,,,, antibody 5 heavy chain variable region, antibody 5 light chain variable region,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGIAKYAQKFQGRVTITADRSTSTAYMELSSLRSEDTAVYYCVTRSGDYSGSSGLAFDIWGQGTMVTVSS,ELVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKVEIK,GGTFSSYA,IIPIFGIA,VTRSGDYSGSSGLAFDI,QSVSSSY,GAS,QQYGSSPYT,IGHJ3*02 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN111727199A/en,"(47/48) vi) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:47, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:48.",,,,,,,,,, antibody 6 heavy chain variable region,N/A,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRLAPGKGLEWVSGISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDWSSGWSSPLDYWGQGTLVTVSS,,GFTFDDYA,ISWNSGTI,AKDWSSGWSSPLDY,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
Patent,https://patents.google.com/patent/CN111727199A/en,"(37/38) i) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:37, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:38",,,,,,,,,, antibody 1 heavy chain variable region, antibody 1 light chain variable region,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYVISWVRQAPGQGLEWVGRIIPIFGTVKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDLPGDSRDGYNYDAFDIWGQGTLVTVSL,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNAGVFGGGTELTVL,GGTFSSYV,IIPIFGTV,ARDLPGDSRDGYNYDAFDI,SSNIGNNY,DNN,GTWDSSLNAGV,IGHJ5*01 (human),IGHV1-69*06 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN111727199A/en,(41/42) iii) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:41 and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:42,,,,,,,,,, antibody 3 heavy chain variable region, antibody 3 light chain variable region,QVQLQESGPGLVKPSETLSLTCTVSGGSINSRSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARADREHVWGSYDGPGSPFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQFPGTAPKLLIYSSNQRPSGVPDRFSGSKSGTSASLAISGLQSQDEADYHCAAWDDSLNGLVFGGGTQLTVL,GGSINSRSYY,IYYSGST,ARADREHVWGSYDGPGSPFDY,SSNIGSNT,SSN,AAWDDSLNGLV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ7*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113735970A/en,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGVVQPGTSLRLSCAASGFSFSHYVMYWVRQAPGKGLDWVAIISFDGSSQYYADSVKGRFTISRDNSKDTLYLQMHSLRPEDTAVYYCAIHGGTYYYDKNILAWGQGTLVTVSS,AIRMTQSPPTLSLSPGERATLSCRASQSVTNYLVWYQQKPGQAPRLLIYDTFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVDIK,GFSFSHYV,ISFDGSSQ,AIHGGTYYYDKNILA,QSVTNY,DTF,QQRSNWPPT,IGHJ1*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN111620946B/en,"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSFWFDPWGQGTLVTVSS,QSVLTQAPSVSGAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSFWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN113671184A/en,"(27/28) the vh comprises an amino acid sequence shown as seq id no:27, and the vl comprises an amino acid sequence shown as seq id no:28.",,,,,,,,,, 12-8 VH, 12-8 VL,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGRGLEWIGYIHYSGSTNYNPSLRSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARDQGYSSGWPDAFDIWGQGTMVTISS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATDIPARFSDSGSGTDFTLTITSLEPEDFAVYYCQQRSNWPGTFGQGTKVEIK,GGSISSYY,IHYSGST,ARDQGYSSGWPDAFDI,QSVSSY,DAS,QQRSNWPGT,IGHJ3*02 (human),IGHV4-59*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN113671184A/en,"(24/25) the vh comprises an amino acid sequence shown as seq id no:24, and the vl comprises an amino acid sequence shown as seq id no:25",,,,,,,,,, 12-5 VH, 12-5 VL,EVQLVESGGGVVRPGGSLRLSCAASGFTFGDYAMSWVRQAPEKGLEWVSGINWNGGRTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARYLQHSYFDLLLPNDAFDIWGQGTMVTVSS,EIVVTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTIRRLEAEDFAVYYCQQYGSSPLTFGGGTKVEIK,GFTFGDYA,INWNGGRT,ARYLQHSYFDLLLPNDAFDI,QSVSSNY,GAS,QQYGSSPLT,IGHJ3*02 (human),IGHV3-20*04 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113671184A/en,"(21/22) the vh comprises an amino acid sequence shown as seq id no:21, and the vl comprises an amino acid sequence shown as seq id no:22",,,,,,,,,, 32-1 VH, 32-1 VL,EVQLVESGGGLVQPGGSLRLSCTASEINVSSNYMNWVRQAPGKGLEWVSVLYAGGTTYYADSVKDRFTISRDNSKNTLYLQMNNLRAEDTAFYYCAREAYAFDIWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQLLNSYPPSTFGQGTRLEIK,EINVSSNY,LYAGGTT,AREAYAFDI,QGISSY,AAS,QLLNSYPPST,IGHJ3*02 (human),IGHV3-66*01 (human),IGKJ5*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113004395B/en,"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAAYGPYYGMDVWGQGTTVTVSS,ENVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,GFTFSSYG,IWYDGSNK,ARAAYGPYYGMDV,QSVSSSY,GAS,QQYGSSPIFT,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113004395B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113583115A/en,(16/19)  a vh comprising the sequence shown as seq id no:16 and a vl comprising the sequence shown as seq id no:19;,,,,,,,,,, h3F4-2-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYWMSWVRQAPGKGLEWIGIIFTGGSTYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARTSYYDVSGWGVGRLDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQSSQSVYDNNWLGWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCAGGYSGNIFAFGQGTKLEIL,GFSLSSYW,IFTGGST,ARTSYYDVSGWGVGRLDL,QSVYDNNW,SAS,AGGYSGNIFA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113583115A/en,(15/19)  a vh comprising the sequence shown as seq id no:15 and a vl comprising the sequence shown as seq id no:19;,,,,,,,,,, h3F4-1-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYWMSWVRQAPGKGLEWVSIIFTGGSTYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARTSYYDVSGWGVGRLDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQSSQSVYDNNWLGWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCAGGYSGNIFAFGQGTKLEIL,GFSLSSYW,IFTGGST,ARTSYYDVSGWGVGRLDL,QSVYDNNW,SAS,AGGYSGNIFA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113583115A/en,(17/19) (3) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19,,,,,,,,,, h3F4-3-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYWMSWVRQAPGKGLEWVSIIFTGGSTYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTATYFCARTSYYDVSGWGVGRLDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQSSQSVYDNNWLGWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCAGGYSGNIFAFGQGTKLEIL,GFSLSSYW,IFTGGST,ARTSYYDVSGWGVGRLDL,QSVYDNNW,SAS,AGGYSGNIFA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113583115A/en,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2.",,,,,,,,,, 3F4 VH, 3F4 VL,SVKESGGRLVTPGTPLTLTCTVSGFSLSSYWMSWVRQAPGKGLEWIGIIFTGGSTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARTSYYDVSGWGVGRLDLWGQGTLVTVSS,DPMLTQTASSVSAAVGGTVTISCQSSQSVYDNNWLGWYQQKPGQPPKLLIYSASTLASGVPSRFKGSGSGTQFTLTISDLECDDAATYYCAGGYSGNIFAFGGGTELEIL,GFSLSSYW,IFTGGST,ARTSYYDVSGWGVGRLDL,QSVYDNNW,SAS,AGGYSGNIFA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ5*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113583115A/en,(18/19)  a vh comprising the sequence shown as seq id no:18 and a vl comprising the sequence shown as seq id no:19.,,,,,,,,,, h3F4-4-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,EVQLVESGGGLVQPGGSLRLSCTVSGFSLSSYWMSWVRQAPGKGLEWVSIIFTGGSTYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARTSYYDVSGWGVGRLDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQSSQSVYDNNWLGWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCAGGYSGNIFAFGQGTKLEIL,GFSLSSYW,IFTGGST,ARTSYYDVSGWGVGRLDL,QSVYDNNW,SAS,AGGYSGNIFA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN5502 heavy chain variable region amino acid sequence, RN5502 light chain variable region amino acid sequence,CQSVEESGGRLVKPDETLTLTCTVSGFSLSSYAMSWVRQAPGKGLEWIGIIAYYGDTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCAREAMTMVTLDRLDVWGQGTLVTVSS,AYDMTQTPSSVSAAVGGTVTIKCQASQNIYSNLAWYQQKPGQPPKLLIYDASDLASGVPSRFKGSGSGTEFTLTISGVQCDDAATYYCQQGYSYSNLEYAFGGGTEVVVK,GFSLSSYA,IAYYGDT,AREAMTMVTLDRLDV,QNIYSN,DAS,QQGYSYSNLEYA,IGHJ5*01 (human),IGHV4-59*01 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN8105 heavy chain variable region amino acid sequence, RN8105 light chain variable region amino acid sequence,CQSVEESGGRLVTPGTPLTLTCTVSGFSLSSYTMGWVRQAPGKGLEWIGIIISSSGSTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARVEWDTYDDYGDYIFGIWGPGTLVTVSS,DIVMTQTPASVSAAVGGTVTIKCQASEDIYSLLAWYQQKPGQPPKLLIYDASDLASGVPSRFSGSGSGTEYTLTISDLECDDAATYYCQGGYYSGSGTGGFGGGTEVVVK,GFSLSSYT,IISSSGST,ARVEWDTYDDYGDYIFGI,EDIYSL,DAS,QGGYYSGSGTGG,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN0510 heavy chain variable region amino acid sequence, RN0510 light chain variable region amino acid sequence,CQSVEESGGRLVTPGTPLTLTCTVSGFSLSSYDMTWVRQAPGKGLEWIGGIGGNSITYYASWAKGRFTISKTSTTVDLKVTSPTTEDTATYFCARDDDYGDWFAFDPWGPGTLVTVSS,AQVLTQTASPVSAAVGSTVTINCQASQSVYNNDNLAWYQQKPGQPPKLLIYKASTLASGVPSRFEGSGSGTQFTLTISGVQCDDAATYYCQGEFSCSSADCTAFGGGTEVVVK,GFSLSSYD,IGGNSIT,ARDDDYGDWFAFDP,QSVYNNDN,KAS,QGEFSCSSADCTA,IGHJ5*02 (human),IGHV3-23*01 (human),IGKJ4*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN2604 heavy chain variable region amino acid sequence, RN2604 light chain variable region amino acid sequence,CQSLEESGGRLVTPGTPLTLTCTVSGIDLNNYAMGWVRQAPGKGLEYIGIISFGGSTYYASWVNGRFTISKTSTTVDLKLTSPTAADTATYFCARFSTYDDYGDYFRAFDPWGPGTLVTVSS,ALVMTQTPSSTSEPVGGTVTIKCQASQSIGSDLSWYQQKPGQPPKLLIYYSSTLASGVPSRFSGSGSGTEFTLTISGVQCDDAATYYCLGVYGFSSDDGIAFGGGTVVVVK,GIDLNNYA,ISFGGST,ARFSTYDDYGDYFRAFDP,QSIGSD,YSS,LGVYGFSSDDGIA,IGHJ5*02 (human),IGHV3-64*04 (human),IGKJ4*01 (human),IGKV1-6*01 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN1245 heavy chain variable region amino acid sequence, RN1245 light chain variable region amino acid sequence,CQSVEESGGRLVTPGTSLTLTCTVSGFSLSSYNMQWVRQAPGKGLEYIGYIGPTGSAYYANWAKGRFTISKTSTTVDLQMTSLTTEDTATYFCAREDATDWGLDIWGPGTLVTVSS,AYDMTQTPASVEAAVGGTVTIKCQASESIGNALSWYQQKPRQRPRLLIYRASTLASGVSSRFRGSGSGTQFTLTISDLECADAATYYCQQIFSGANIDNAFGGGTEVVVK,GFSLSSYN,IGPTGSA,AREDATDWGLDI,ESIGNA,RAS,QQIFSGANIDNA,IGHJ2*01 (human),IGHV3-64*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN1279 heavy chain variable region amino acid sequence, 279 light chain variable region amino acid sequence,CQSLEESGGRLVTPGTPLTLTCTASGFSLSSYNMGWVRQAPGEGLEWIGTTSDSGITYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCGRGWLYFNLWGQGTLVTVSS,AQVLTQTASPVSAAVGGTVTIKCQSSQSVYDNNALAWYQQKPGQPPKFLIYDASDLASGVPSRFSGSGSGTEFTLTISDLECDDAATYYCAGGYSDAIVNFGGGTEVVVK,GFSLSSYN,TSDSGIT,GRGWLYFNL,QSVYDNNA,DAS,AGGYSDAIVN,IGHJ2*01 (human),IGHV3-23*01 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
Patent,https://patents.google.com/patent/CN113817052A/en,N/A,,,,,,,,,, RN1248 heavy chain variable region amino acid sequence, RN1248 light chain variable region amino acid sequence,CQQLEQSGGGAEGGLVKPGGSLELCCKASGFSLSNSYWICWVRQAPGKGLEWIGCIYPGSSGSAYYASWVNGRFTLSRDIDQSTGCLQLNSLTAADTAMYYCARGRSYDDYGDYPDYFNLWGQGTLVTVSS,AIEMTQTPFSVSAAVGGTVTINCQASESIYSNLAWYQQKPGQPPKLLIYAASYLASGVPSRFKGSGSGTEYTLTISGVQCADAATYYCQSAYYESSVVYTVFGGGTEVVVK,GFSLSNSYW,IYPGSSGSA,ARGRSYDDYGDYPDYFNL,ESIYSN,AAS,QSAYYESSVVYTV,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN111748032B/en,"(4/8) the monoclonal antibody according to claim 1, which comprises a heavy chain variable region consisting of the amino acid sequence shown in seq id no:4 and a light chain variable region consisting of the amino acid sequence shown in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELGSLRSEDTAVYYCARAGWSVSPLKYNWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVSISCSGSTSSIGRNTVSWFQQLPGTAPKLLIYRDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEAEYYCSAWHDTLNGVVFGGGTKLTVL,GGTFSNYA,IIPIFGTA,ARAGWSVSPLKYNWFDP,TSSIGRNT,RDN,SAWHDTLNGVV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/CN111748032B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113999303A/en,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8.",,,,,,,,,, VH, VL,SVEESGGRLVTPGTPLTLTCTASGFSPSSYGMSWVRQAPGKGLEWIGYINIEDYAYYAPWAKGRFTISKTSSTTVDLKVTSPTTEDTATYFCGRGGYAADIWGPGTLVTVSS,DVVMTQTASPVSAAVGGTVTISCQSSESVYTNNRLSWFQQKPGQRPKLLIYRASKLASGVPSRFSGSGSGTQFTLIISDVQCDDAATYYCAGVGSGGTDIAFGGGTKVEIK,GFSPSSYG,INIEDYA,GRGGYAADI,ESVYTNNR,RAS,AGVGSGGTDIA,IGHJ2*01 (human),IGHV3-33*02 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113999303A/en,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18.",,,,,,,,,, VH, VL,EVQLVESGGGLVKPGGSLKLSCAASGITFSDYYMYWVRQTPEKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCVRDKSMGFGAWFAYWGQGTLVTVSA,EIVLTQSPTTMAASPGEKITITCSASSSISSNYLHWYQQRPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGHSIPYTFGGGTKLEIK,GITFSDYY,ISDGGSYT,VRDKSMGFGAWFAY,SSISSNY,RTS,QQGHSIPYT,IGHJ3*01 (mouse),IGHV5-4*02 (mouse),IGKJ2*01 (mouse),IGKV4-91*01 (mouse)
Patent,https://patents.google.com/patent/CN113249337B/en,"(17/19) the amino acid sequence of the heavy chain variable region of the antibody bg1 is shown as seq id no:17, and the amino acid sequence of the light chain variable region is shown as seq id no:19",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),GPELKKPGETVKISCKASGYTFRNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNIKNEDTATYFCARSPLIRSYFDYWGQGTTLTVSS,DIVLTQSPAIMSASPGEKVTMTCSASSSVSYLHWYQQKSGTSPKRWIYDTSKLSSGVPARFSGSGSGTSFSLTISSMEVEDAATYYCQQWSSNPYTFGGGTKLEIK,GYTFRNYG,INTYTGEP,ARSPLIRSYFDY,SSVSY,DTS,QQWSSNPYT,IGHJ2*01 (mouse),IGHV9-3-1*01 (mouse),IGKJ2*01 (mouse),IGKV4-59*01 (mouse)
Patent,https://patents.google.com/patent/CN113249337B/en,"(7/9) the amino acid sequence of the heavy chain variable region of the antibody dg8 is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:9",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),GPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWMGWINTETGEPTYADDFQGRFDFSLETSASTAYLQINNLKNEATATYFCSRGGYDSDGGYYALDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTIACGTTENIYGALNWYQRKQGKSPQLLIYGAINLVDGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSPPFTFGGGTKLEIK,GYTFTDYS,INTETGEP,SRGGYDSDGGYYALDY,ENIYGA,GAI,QNVLSPPFT,IGHJ4*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ4*02 (mouse),IGKV12-89*01 (mouse)
Patent,https://patents.google.com/patent/CN113999301A/en,(7/8) seq id no:7 and seq id no:8 are the amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-sars-cov-2 (covid-,,,,,,,,,, mouse (Mus musculus), mouse (Mus musculus),EVKFEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTPYDYAYPWFWGQGTLVTVSA,EIVLTQSPTTMAASPGEKITITCSASSSISSHYLHWYQQKPGFSPKLLIYRSYSLASGFPGRFSGSGSGTSFSLSIGTMEAEDVATYYCQQGSSRITPFGGGTKLEIK,GFTFSDAW,IRNKANNHAT,TPYDYAYPWF,SSISSHY,RSY,QQGSSRITP,IGHJ3*01 (mouse),IGHV6-6*01 (mouse),IGKJ1*01 (mouse),IGKV4-91*01 (mouse)
Patent,https://patents.google.com/patent/CN111592594A/en,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8.",,,,,,,,,,Homo sapiens,Homo sapiens,QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARPQGGSSWYRDYYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,GYTFTSYA,INTNTGNP,ARPQGGSSWYRDYYYGMDV,QSISSW,KAS,QQYNSYPYT,IGHJ6*01 (human),IGHV7-4-1*02 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN111620945A/en,"(4/8) preferably, the first variable region is an antibody light chain variable region comprising seq id no:8; wherein said second variable region is an antibody heavy chain variable region comprising the amino acid sequence of seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCVRERGYSGYGAAYYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSSYA,IIPILGIA,VRERGYSGYGAAYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111620945A/en,"(9/10) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:10, and the variable region of the antibody heavy chain is seq id no:9.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111518204B/en,"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; wherein said second variable region is an antibody heavy chain variable region represented by seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTEGAMVRRVIYGMDVWGQGTTVTVSS,ENVLTQSPGTLSLSPGERATLSCRARQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,GFTFSNAW,IKSKTDGGTT,TTEGAMVRRVIYGMDV,QSVSSSY,GAS,QQYGSSPIT,IGHJ6*01 (human),IGHV3-15*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN111518204B/en,(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111518204B/en,"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112979793B/en,"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFIFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRGPTGWTFDYWGQGTLVTVSS,ENVLTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQRPGQAPRLLIYDSSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWKITFGQGTRLEIK,GFIFSSYG,IWYDGSNK,ARDLRGPTGWTFDY,QSVSNY,DSS,QHRSNWKIT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112979793B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112979790B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111793129B/en,"(11/12) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:11, and the light chain amino acid sequence is shown as seq id no:12.",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGVVQPGGSLRLSCAASGFRFDDHAMHWVRQAPGKGLEWVSVISGDGGSTYYADSVKGRFSISRDDSKNSLYLQMNSLRTEDTALYYCAKDRSYGPPDVFNYEYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNWVFGGGTKLTVL,GFRFDDHA,ISGDGGST,AKDRSYGPPDVFNYEYGMDV,SSNIGSNT,SNN,AAWDDSLNWV,IGHJ6*01 (human),IGHV3-43*02 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20210134300A/en,"(216/218) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:216 and a light chain comprising the amino acid sequence set forth in seq id no:218",,,,,,,,,, Synthetic , Synthetic ,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,GFTFSDYY,ITYSGSTI,ARDRGTTMVPFDY,QDITNY,AAS,QQYDNLPLT,IGHJ4*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR20210134300A/en,"(202/210) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:202 and an lcvr comprising the amino acid sequence set forth in seq id no:210",,,,,,,,,, Synthetic , Synthetic ,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,GFTFSDYY,ITYSGSTI,ARDRGTTMVPFDY,QDITNY,AAS,QQYDNLPLT,IGHJ4*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR20210134300A/en,"(640/646) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:640 and an lcvr comprising the amino acid sequence set forth in seq id no:646",,,,,,,,,, Synthetic , Synthetic ,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,GFTFSNYA,ISYDGSNK,ASGSDYGDYLLVY,SSDVGGYNY,DVS,NSLTSISTWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20210134300A/en,"(654/656) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:654 and a light chain comprising the amino acid sequence set forth in seq id no:656",,,,,,,,,, Synthetic , Synthetic ,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,GFTFSNYA,ISYDGSNK,ASGSDYGDYLLVY,SSDVGGYNY,DVS,NSLTSISTWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/CN113234151B/en,"(13) the trimeric nanobody of claim 3, wherein it is represented by seq id no:13.",,,,,,,,,, Artificial sequence,N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISMIGRTYDADSVKNRFTISRDNAKNTVYLQANSLKPEDTAVYTCAAGSSRSSLLRYGYAGQGTQVTVSS,,GYTNSRYY,ISMIGRT,AAGSSRSSLLRYGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN113234151B/en,"(1) the nanobody ansp-1 of claim 1, wherein the nanobody amino acid sequence is set forth in seq id no:1.",,,,,,,,,, Artificial sequence,N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISMIGRTYDADSVKNRFTISRDNAKNTVYLQANSLKPEDTAVYTCAAGSSRSSLLRYGYAGQGTQVTVSS,,GYTNSRYY,ISMIGRT,AAGSSRSSLLRYGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN113512113A/en,"(9/11)  seq id no:9 and seq id no:11; in the present invention, an antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain is designated as ""cz-d7"".",,,,,,,,,,  Homo sapiens,  Homo sapiens,QVQLVQSGAEVKTPGSSVKVSCKASGGSFSNYAISWVRQAPGQGLEWMGRIIATLGISNYAQKFQGRVTMTADKSTSTAYMELSSLRSEDTAVYYCASPITNFGVLIEVDAFHIWGQGTMVTVSS,EIVLTQSPFTLSLSPGERATLSCGASQSVSSSYLAWYQQKPGLAPRLLIYDGSSRATDIPDRFSGSGSGTDFTLTISRLEPEDFAMYYCQQYSTSPLTFGGGTKVEIK,GGSFSNYA,IIATLGIS,ASPITNFGVLIEVDAFHI,QSVSSSY,DGS,QQYSTSPLT,IGHJ3*02 (human),IGHV1-69*04 (human),IGKJ4*01 (human),IGKV3D-20*01 (human)
Patent,https://patents.google.com/patent/CN113512113A/en,"(1/3) an antibody composition comprising a first antibody and a second antibody, wherein the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the first antibody are represented by seq id no:1 and seq id no:3, respectively, and the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the second antibody are represented by:",,,,,,,,,,  Homo sapiens,  Homo sapiens,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTNSAMQWVRQARGQRLEWVGWIVVASGNANSARRFHDRVTITSDMSTSTAYLELSSLRSEDTAVYYCALNHCSNTTCLDGFDIWGQGTMVSVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVRNSLLAWYQQKPGQAPRLLIYAASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFVVYYCQQHGSSPPWTFGQGTKVEFK,GFTFTNSA,IVVASGNA,ALNHCSNTTCLDGFDI,QSVRNSL,AAS,QQHGSSPPWT,IGHJ3*02 (human),IGHV1-58*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN111732655B/en,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYAMSWVRQAPGKGLEWVSAITGSGGSTYYADSVKGRFTISRDNSKNTLYLHMNSLRAEDTAVYYCAKDDYGDYVLGAFDIWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYKFVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,GFPFSSYA,ITGSGGST,AKDDYGDYVLGAFDI,SSDVGTYKF,EGS,CSYAGSSTLV,IGHJ3*02 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
Patent,https://patents.google.com/patent/CN113557431A/en,(1/48) seq id no:48 (peptide derived from seq id no:1 with gst fusion reactive with sars-cov-2 antibody) mshhhhhhhhspmysiitpnilrleseetmvleahdaqgdvpv tvtvhdfpgkklvlssektvltpatnhmgnvtftipanrefkse kgrnkfvtvqatfgtqvvekvvlvslqsgiegrmygfqptngv gyqygfqptngvgyq,,,,,,,,,, SARS-CoV-2S1 domain derived from S protein, SARS-CoV-2 antibody-reactive SEQ ID NO: 1-derived peptides,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113698475A/en,"(3/4) the amino acid sequence of the heavy chain variable region of the monoclonal antibody a10 for resisting the porcine delta coronavirus n protein is shown as seq id no:3, the amino acid sequence of the light chain variable region is shown as seq id no:4, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),ASVRLSCTASGFNIKDYYMHWVKQRPEQGLEWIGWIDPENGDTEYAPRFLGKATMTTDTSSNTAYLQLSSLTSEDTGVYYCKVYDGYYFDFWGQGTPLTVSS,PASISCKSSQSLLNSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGIYYCWQATHFPHTFGGGTKLER,GFNIKDYY,IDPENGDT,KVYDGYYFDF,QSLLNSDGKTY,LVS,WQATHFPHT,IGHJ2*02 (mouse),IGHV14-4*02 (mouse),IGKJ1*02 (mouse),IGKV1-135*01 (mouse)
Patent,https://patents.google.com/patent/CN113698475A/en,"(1/2) the amino acid sequence of the heavy chain variable region of the monoclonal antibody e8 for resisting the porcine delta coronavirus n protein is shown as seq id no:1, the amino acid sequence of the light chain variable region is shown as seq id no:2 is shown in the specification",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),STSQSLSITCTISGFSLTSYGVHWIRQPPGKGLEWLGVIWSVGNTTYNSTLRSRLSITKDNSKSQVFLKMNSLQTDDTAIYYCARQVYGNSFAYWGQGTLVTVSA,RSASISCRSSQSLVHSNGNTYLHWHLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQGTHVMYTFGGGTKLEI,GFSLTSYG,IWSVGNT,ARQVYGNSFAY,QSLVHSNGNTY,KVS,SQGTHVMYT,IGHJ3*01 (mouse),IGHV2-6-1*01 (mouse),IGKJ2*01 (mouse),IGKV1-110*01 (mouse)
Patent,https://patents.google.com/patent/CN112076316A/en,"(11/12) the antibody composition of claim 4, wherein the amino acid sequence of the heavy chain variable region of the antibody that specifically binds to the n-terminal domain of the s protein of sars-cov-2 is set forth in seq id no:11, and the amino acid sequence of the light chain variable region is set forth in seq id no:12.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPDLFDYYYGMDVWGQGTTVTVSS,EIVMTQSPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCTQATQFPYTFGQGTKVDIK,GYTLTELS,FDPEDGET,ATSTAVAGTPDLFDYYYGMDV,QSLVHSDGNTY,KIS,TQATQFPYT,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ3*01 (human),IGKV2-24*01 (human)
Patent,https://patents.google.com/patent/CN112076316A/en,"(1/5) the antibody composition of claim 1, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody that specifically binds to the s protein receptor binding region of sars-cov-2 is set forth in seq id no:1, and the amino acid sequence of the light chain variable region is set forth in seq id no:5.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYAMSWVRQAPGKGLEWVSAITGSGGSTYYADSVKGRFTISRDNSKNTLYLHMNSLRAEDTAVYYCAKDDYGDYVLGAFDIWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYKFVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,GFPFSSYA,ITGSGGST,AKDDYGDYVLGAFDI,SSDVGTYKF,EGS,CSYAGSSTLV,IGHJ3*02 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
Patent,https://patents.google.com/patent/CN111690059A/en,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVESGGGWIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,AIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLGMYTFGQGTKLEIK,GLTVSSNY,IYSGGST,ARDLVVYGMDV,QSISSY,AAS,QQSYSTLGMYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220010410A/en,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising ",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112250763B/en,(3/4)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:3; and the variable region of the light chain of the amino acid sequence shown as seq id no:4;,,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVQSGPEVKEPGSSVKVSCKASGGTFDTAAISWVRQAPGQGPEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREHTVAPVYGFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTSLTFGGGTKVEIK,GGTFDTAA,IIPIFGTA,AREHTVAPVYGFDV,QSISSY,AAS,QQSYSTSLT,IGHJ5*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112250763B/en,(11/12)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:11; and the variable region of the light chain of the amino acid sequence shown as seq id no:12.,,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAYSSSWLLQSFYYYGMDVWGQGTTVTVSS,NIQLTQSPVSLSASVGDRVTLTCRASQGIGYSLVWYQKKPGTAPKLLIFDASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQVIHYPLTFGGGTKVEIK,GFTFSSYG,ISYDGSNK,ARAYSSSWLLQSFYYYGMDV,QGIGYS,DAS,QQVIHYPLT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
Patent,https://patents.google.com/patent/KR20210128252A/en,"(66/78)  in order to confirm the gene sequence of the scfv mutant clones obtained in example 2, the dna base sequence was analyzed using sanger sequencing. six scfv antibody variants with antibody sequences were selected through analysis. in this process, only the vh of scfv was additionally selected four vh antibody variants with increased binding affinity to the corona-19 virus-rbd region. in addition, the vh and vl amino acid sequences of six scfv variants (seq id no:66 to 77) (fig. 4) and the amino acid sequences of four vh variants (seq id no:78 to 81) (fig. 5) were identified.",,,,,,,,,, JS 1_VH, JS_VH 4,QVQLVQSGGGVVQPGSSLRLSCEASGFAIGDNALNWVRQAPGKGLEWVGYIRSNSYGGTAEYAASVKGRFTISRDESKNIAYLEMNSLRAEDTAVYYCARRAHYYGDSTYNPSWYFDLWGRGTPVTVSS,,GFAIGDNA,IRSNSYGGTA,ARRAHYYGDSTYNPSWYFDL,,,,IGHJ2*01 (human),IGHV3-49*04 (human),,
Patent,https://patents.google.com/patent/KR20210128252A/en,"(78/67)  in one embodiment, the antibody or fragment having immunological activity specific for the corona-19 virus of the present invention comprises any one selected from seq id no:78 to 81, 66, 68, 70, 72, 74 and 76 vh, and/or a vl comprising any one selected from seq id no:67, 69, 71, 73, 75 and 77.",,,,,,,,,, JS_VH 4, JS 1_VL,QVQLQESGGGVVQPGESLRLSCAASGFTFEDYAMHWVRQPPGKGLEWVSLSGDGFFTHYADSVEGRFTVSRDNSKNSLYLQMNSLRAEDTAVYYCARDSFGGHLDLWGQGTLVTVSS,EIVLTQSPSFLSASVGDRVTITCRASQDVSRRLAWYQRKPGKAPKLLIYGVSNLASGVPSRFTGSGSGTEFTLTISSLQSDDFATYYCQQGYSSPRTFGQGTKVDIK,GFTFEDYA,SGDGFFT,ARDSFGGHLDL,QDVSRR,GVS,QQGYSSPRT,IGHJ2*01 (human),IGHV3-NL1*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN111718411A/en,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLLESGGGLVQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDILGGMDVWGQGTTVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPTFGQGTKVEIK,GFTVSSNY,IYSGGST,ARDLDILGGMDV,QSVSSSY,GAS,QQYGSSPPT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN111303279B/en,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279B/en,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279B/en,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGNIDSTRYHGWFRQAPGKGLEAVAAIKGVWPEDYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADQYEWWVPGEVGPYLYWGQGTQVTVSS,,GNIDSTRY,IKGVWPED,AADQYEWWVPGEVGPYLY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279B/en,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGADAFVIIGGWFRQAPGKGLEAVAAIAWTDQHEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAQDSAYIKSKGSRAYEYWGQGTQVTVSS,,GADAFVII,IAWTDQHE,AAQDSAYIKSKGSRAYEY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279B/en,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGGNAAERMAGWFRQAPGKGLEAVAAIYYAKFGPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAEAFVQSPYSGSHTTKYWGQGTQVTVSS,,GGNAAERM,IYYAKFGP,AAEAFVQSPYSGSHTTKY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111303279B/en,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279B/en,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGLAQSKWAYGWFRQAPGKGLEAVAAIDVATGPWYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAHHIPTKHPAFPDFRDYWGQGTQVTVSS,,GLAQSKWA,IDVATGPW,AAHHIPTKHPAFPDFRDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN111303279B/en,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGLVQPGGSLRLSCAASGRQAVVFGWFRQAPGKGLEAVAAIHVPAKNRYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAHYEFNDFVWQGYSSDYWGQGTQVTVSS,,GRQAVV,IHVPAKNR,AAHYEFNDFVWQGYSSDY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111303279B/en,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111303279B/en,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111995674B/en,"(7/8) the heavy chain amino acid sequence of the human-mouse chimeric whole antibody mhc3 is shown as seq id no:7, and the light chain amino acid sequence is shown as seq id no:8.",,,,,,,,,,  Artificial sequence,  Artificial sequence,EVQLVESGGDLVKPGGSLKLSCAASGFTFNTYAMNWVRQTPGKGLEWVARIRSKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVTPYYGNYADWFTYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,GFTFNTYA,IRSKSNNYAT,VTPYYGNYADWFTY,QSLVHSNGNTY,KVS,SQSTHVPYT,IGHJ2*02 (mouse),IGHV10-1*02 (mouse),IGKJ2*01 (mouse),IGKV1-110*01 (mouse)
Patent,https://patents.google.com/patent/CN111995674B/en,"(11/12) in one embodiment of the invention, the recombinant expression vector for expressing the heavy chain of the antibody is obtained by cloning seq id no:11 (encoding gene of the heavy chain of the antibody) between enzyme cutting sites hind iii and bamh i of pcdna3.1(+) vector; cloning seq id no:12 (coding gene of antibody light chain) between enzyme cutting site hind iii and bamh i of pcdna3.1(+) vector to obtain recombinant expression vector for expressing the light chain of the antibody",,,,,,,,,,  Artificial sequence,  Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112898416A/en,"(4/8)  that specifically bind to a novel coronavirus np protein, wherein the binding protein or antibody of the novel coronavirus np protein comprises or consists of the vl sequence of seq id no:8 and the vh sequence of seq id no:4.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWVICSSTSCYTKYSYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSISNIGSAHVSWYQQVPGTAPKLLIYDNSERPSGIPARFSAFKYGTSATLDITGLQTGDEADYYCASWDISLSAGIFGGGTKLTVL,GGTFSSYA,IIPIFGTA,ARGGWVICSSTSCYTKYSYYGMDV,ISNIGSAH,DNS,ASWDISLSAGI,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112898416A/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(107/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:107 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPFGIDDAYLPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARGPFGIDDAYLPDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(49/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:49 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETSYDGYVTLADYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARETSYDGYVTLADY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(54/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:54 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPFGYSAGYLPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARGPFGYSAGYLPDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(48/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:48 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLGPTYGGYARDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARHLGPTYGGYARDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(56/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:56 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETSYDGYVTLADYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARETSYDGYVTLADY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(108/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:108 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPFGIDDAYLPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARGPFGIDDAYLPDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(55/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:55 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLGPTYGGYARDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARHLGPTYGGYARDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(46/50) in some embodiments, the fusion proteins disclosed herein include a polypeptide and an antibody or antigen-binding fragment comprising a vh set forth as seq id no:46, 47, 48, 49, or 107, a vl set forth as seq id no:50, or a biological equivalent of each",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDPSASYYLDDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARDRDPSASYYLDDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(47/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:47 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPFGYSAGYLPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARGPFGYSAGYLPDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113637083A/en,"(53/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:53 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDPSASYYLDDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARDRDPSASYYLDDY,QGISSY,AAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112390879B/en,"(7/8) the antibody or antigen-binding fragment thereof targeting sars-cov-2 according to claim 1, wherein the amino acid sequence of vh is as shown in seq id no:7; the amino acid sequence of the vl is shown as seq id no:8.",,,,,,,,,, VH amino acids, VL amino acids,EVQLVESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHVRSAYYYGSGSYRDEGNWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGTRSNIGAGHDVHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGAKSGTSASLAITGLQAEDEADYYCQSYDRTLTSYVFGTGTKVTVL,GGSISSSSYY,IYYRGST,ARHVRSAYYYGSGSYRDEGNWFDP,RSNIGAGHD,GNN,QSYDRTLTSYV,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112390879B/en,"(9/10)  the amino acid sequences of the preferred heavy and light chain variable regions are shown as seq id no:7 and 8, respectively, the nucleotide sequences of the preferred heavy and light chain variable regions are shown as seq id no:9 and 10, respectively, and the detailed description is shown in table 1 below.",,,,,,,,,, VH nucleotides, VL nucleotides,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN111333722A/en,"(32/33)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:32, and the amino acid sequence of the light chain variable region is seq id no:33.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGGGLVQPGGSLRLSCAASGFNFSSYAMHWVRQAPGKGPEWVALISSDGSVTYFTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSGWDDAFDIWGQGTMVTVSS,QSVLTQPPSMSLAPGQTATITCAGTNIGRKYVHWYQQRPGQAPVLVMSDNDDRPSGIPERFSASNSGHTATLIINRVEVDDEADYYCQVWDTTYSRPVIFGGGTKLTVL,GFNFSSYA,ISSDGSVT,ARSGWDDAFDI,NIGRKY,DND,QVWDTTYSRPVI,IGHJ3*02 (human),IGHV3-30*10 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
Patent,https://patents.google.com/patent/CN111333722A/en,"(26/27) preferably, the amino acid sequence of the heavy chain variable region of the neutralizing antibody or antigen binding fragment thereof is seq id no:26, and the amino acid sequence of the light chain variable region is seq id no:27",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVKLLESGGGLVQPGGSLRLSCTASGLNFGTSVMHWVRQVQGTGLLWVSRIDSGGTSITYADSVRGRFTVSRDNAKNTLYLQMNSLRVEDTGVYYCSTDSGSIGEFWGQGTLVTVSS,ELQMTQSPSPLSASVGDRVTITCRAGQNIRGYVNWYQHKAGEAPKLLIYHASNLQSGLPLRFSGSGSGTDFTLTITSLQPEDFAIYYCQQSHDTLTWTFGQGTKVEIK,GLNFGTSV,IDSGGTSI,STDSGSIGEF,QNIRGY,HAS,QQSHDTLTWT,IGHJ1*01 (human),IGHV3-74*03 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111333722A/en,"(28/29)  or the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:28, and the amino acid sequence of the light chain variable region of the neutralizing antibody is seq id no:29",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQESGGGLVQPGESLKLSCAASGFTFSSSAMHWVRQASGKGLEWIGRIRSKPNSYATAYAASVTGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTSVCSGGSCYQWGQGTLVTVSS,ELVMTQSPDSLAVSLGERATINCKSSRNVLYSPNNKNYLGWYQQKPGQPPKLLIYWASSRESGVPDRFSGSGSETDFTLTISSLQAEDVAVYYCHQYFSTLWTFGQGTKVEIK,GFTFSSSA,IRSKPNSYAT,TSVCSGGSCYQ,RNVLYSPNNKNY,WAS,HQYFSTLWT,IGHJ1*01 (human),IGHV3-73*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN111333722A/en,"(30/31)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:30, and the amino acid sequence of the light chain variable region is seq id no:31",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVMPGRSLRLSCRHSGFTFADYTMNWFRQVPGKGLEWIGFIRSKTYGGTAEYAASVKGRFTISRDDSKSIAYLEMNSLNTEDTGVYRCTRISGYYGAGSGGAMDVWGQGTTVTVSS,ELVLTQSPGTLSLSPGERATLSYRASQSVSSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGPGTKVDIK,GFTFADYT,IRSKTYGGTA,TRISGYYGAGSGGAMDV,QSVSSSY,DAS,QQRSNWPLT,IGHJ6*01 (human),IGHV3-49*03 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN113563475A/en,"(34/35)  the amino acid sequence of the heavy chain variable region of the monoclonal antibody h4 is shown as seq id no:34, and the amino acid sequence of the light chain variable region of the monoclonal antibody h4 is shown as seq id no:35.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARVPYCSSTSCHRDWYFDLWGRGTLVTVSS,DIQMTQSPLSLPVTPGEPASISCRSSQSLLDSDDGNTYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIK,GYTFTGYY,INPNSGGT,ARVPYCSSTSCHRDWYFDL,QSLLDSDDGNTY,TLS,MQRIEFPLT,IGHJ2*01 (human),IGHV1-2*06 (human),IGKJ4*01 (human),IGKV2-40*01 (human)
Patent,https://patents.google.com/patent/CN113563475A/en,"(1/3) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectivel",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113563475A/en,"(7/5) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113563475A/en,"(3/1) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113563475A/en,"(6/8)  further preferably, the bispecific antibody bs-mab-2 has the amino acid sequence of the light chain as shown in seq id no:8 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:6 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCAREAYGMDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPYTFGQGTKLEIK,GFIVSSNY,IYSGGST,AREAYGMDV,QGISSY,AAS,QQLNSYPPYT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113563475A/en,"(5/7) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectivel",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113563475A/en,"(32/33) preferably, the amino acid sequence of the heavy chain variable region of monoclonal antibody b38 is shown in seq id no:32, and the amino acid sequence of the light chain variable region of monoclonal antibody b38 is shown in seq id no:33",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCAREAYGMDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPYTFGQGTKLEIK,GFIVSSNY,IYSGGST,AREAYGMDV,QGISSY,AAS,QQLNSYPPYT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113563475A/en,"(2/4) preferably, the bispecific antibody bs-mab-1 has the amino acid sequence of the light chain as shown in seq id no:4 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:2 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARVPYCSSTSCHRDWYFDLWGRGTLVTVSS,DIQMTQSPLSLPVTPGEPASISCRSSQSLLDSDDGNTYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEIK,GYTFTGYY,INPNSGGT,ARVPYCSSTSCHRDWYFDL,QSLLDSDDGNTY,TLS,MQRIEFPLT,IGHJ2*01 (human),IGHV1-2*06 (human),IGKJ4*01 (human),IGKV2-40*01 (human)
Patent,https://patents.google.com/patent/CN114002427A/en,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8.",,,,,,,,,, VH, VL,SVEESGGRLVTPGTPLTLTCTASGFSPSSYGMSWVRQAPGKGLEWIGYINIEDYAYYAPWAKGRFTISKTSSTTVDLKVTSPTTEDTATYFCGRGGYAADIWGPGTLVTVSS,DVVMTQTASPVSAAVGGTVTISCQSSESVYTNNRLSWFQQKPGQRPKLLIYRASKLASGVPSRFSGSGSGTQFTLIISDVQCDDAATYYCAGVGSGGTDIAFGGGTKVEIK,GFSPSSYG,INIEDYA,GRGGYAADI,ESVYTNNR,RAS,AGVGSGGTDIA,IGHJ2*01 (human),IGHV3-33*02 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN114002427A/en,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18.",,,,,,,,,, VH, VL,EVQLVESGGGLVKPGGSLKLSCAASGITFSDYYMYWVRQTPEKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCVRDKSMGFGAWFAYWGQGTLVTVSA,EIVLTQSPTTMAASPGEKITITCSASSSISSNYLHWYQQRPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGHSIPYTFGGGTKLEIK,GITFSDYY,ISDGGSYT,VRDKSMGFGAWFAY,SSISSNY,RTS,QQGHSIPYT,IGHJ3*01 (mouse),IGHV5-4*02 (mouse),IGKJ2*01 (mouse),IGKV4-91*01 (mouse)
Patent,https://patents.google.com/patent/CN113527471A/en,(4/3) vh is seq id no:4 and vl is seq id no:3,,,,,,,,,, Homo sapiens, Homo sapiens,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDVADAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPVNTFGQGTKLEIK,GLTVSSNY,IYSGGST,ARDVADAFDI,QGISSY,AAS,QQLNSYPPVNT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113527471A/en,(8/7) vh is seq id no:8 and vl is seq id no:7.,,,,,,,,,, Homo sapiens, Homo sapiens,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSVISGSGGSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYCCAKGYYYDSSGYYFREDAFDIWGQGTLVTVSS,DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK,GFTFSSYA,ISGSGGST,AKGYYYDSSGYYFREDAFDI,QGISNY,AAS,LQHNSYPYT,IGHJ5*01 (human),IGHV3-23*01 (human),IGKJ2*01 (human),IGKV1-17*03 (human)
Patent,https://patents.google.com/patent/CN113527471A/en,"(2/1) vh is seq id no:2, vl is seq id no:1",,,,,,,,,, Homo sapiens, Homo sapiens,EVQLVESGGGLIQPGGSLRLSCAASGITVSRNYMSWVRQAPGKGLEWVSIIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYGDYYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFLFGGGTKVEIK,GITVSRNY,IYSGGST,ARGYGDYYFDY,QGISSW,AAS,QQANSFL,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113527471A/en,(6/5) vh is seq id no:6 and vl is seq id no:5,,,,,,,,,, Homo sapiens, Homo sapiens,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGSSNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAESPLGGGSGYSVSWFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSNWPPWTFGQGTKVEIK,GGTFSSYA,IIPIFGSS,AESPLGGGSGYSVSWFDP,QSVSSN,GAS,QQYSNWPPWT,IGHJ5*02 (human),IGHV1-69*15 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR20220010402A/en,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising ",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112239501B/en,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig",,,,,,,,,, Artificial sequence, Artificial sequence,DVQLVESGGGLVQPGGSRKLSCAASGVTFSTFAMHWVRQAPEKGLEWVAYLNSASNLIYYADTLKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCTRHAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSIDYDGDSFMNWFQQKPGQPPKLLIYDASNVESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSNEDPYTFGGGTKLEIK,GVTFSTFA,LNSASNLI,TRHAMDY,QSIDYDGDSF,DAS,QHSNEDPYT,IGHJ4*01 (mouse),IGHV5-17*02 (mouse),IGKJ2*01 (mouse),IGKV3-4*01 (mouse)
Patent,https://patents.google.com/patent/CN113912710A/en,"(7/8) the amino acid sequence of the heavy chain variable region is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),VKLQESGPELKKPGETVRISCKASGYTLTDYSIHWVKQAPGKGLKWMGWINTETVEPTYTDDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCASTGTEFDYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHITGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPLTFGAGTKLELK,GYTLTDYS,INTETVEP,ASTGTEFDY,QSLVHITGNTY,KVS,SQSTHVPLT,IGHJ2*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ5*01 (mouse),IGKV1-110*01 (mouse)
Patent,https://patents.google.com/patent/CN113493506A/en,"(10/12) the heavy chain coding region is seq id no:10 and the light chain coding region is seq id no:12, the above procedure was carried out to obtain an antibody solution of p2a-1a 10.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(34/36) the heavy chain coding region is seq id no:34 and the light chain coding region is the dna molecule shown in seq id no:36, the above procedure was carried out to obtain an antibody solution of p2c-1c 8.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(18/20) the heavy chain coding region is seq id no:18 and the light chain coding region is seq id no:20, the above procedure was carried out to obtain an antibody solution of p2b-2f 6.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(22/24) the heavy chain coding region is seq id no:22 and the light chain coding region is seq id no:24, the above steps are carried out to obtain an antibody solution of p2b-2g 4.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(42/44) the heavy chain coding region is seq id no:42 and the light chain coding region is seq id no:44, the above steps are carried out to obtain an antibody solution of p2c-1d 5.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(14/16) the heavy chain coding region is seq id no:14 and the light chain coding region is the dna molecule shown in seq id no:16, the above procedure was carried out to obtain an antibody solution of p2a-1b 3.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(6/8) the heavy chain coding region is seq id no:6 and the light chain coding region is seq id no:8, the above procedure was carried out to obtain an antibody solution of p2a-1a 9.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(46/48) the heavy chain coding region is seq id no:46 and the light chain coding region is seq id no:48, the above steps are carried out to obtain an antibody solution of p2c-1f 11.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(38/40) the heavy chain coding region is seq id no:38 and the light chain coding region is seq id no:40, the above steps are carried out to obtain an antibody solution which is a p2c-1c10 antibody solution.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(2/4) the heavy chain coding region is seq id no:2 and the light chain coding region is seq id no:4, the above steps are carried out to obtain an antibody solution of p2a-1a 8.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(30/32) the heavy chain coding region is seq id no:30 and the light chain coding region is seq id no:32, the above procedure was carried out to obtain an antibody solution of p2c-1a 3.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113493506A/en,"(26/28) the heavy chain coding region is seq id no:26 and the light chain coding region is the dna molecule shown in seq id no:28, the above procedure was carried out to obtain an antibody solution of p2b-2g 11.",,,,,,,,,, Artificial sequence, Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112980885A/en,(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.,,,,,,,,,, (1)..(119), (1)..(109),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAITWVRQAPGQGLEWMGGIIPIFGTANFAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAHLGGFADPFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQKAGQAPRVLIYDAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGQGTRLEIK,GGTFSSYA,IIPIFGTA,AHLGGFADPFDY,QSVSNY,DAF,QQRSNWPPRIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112980885A/en,(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising seq id no:8; ,,,,,,,,,, (1)..(129), (1)..(108),QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQASGQGLEWMGWMNPNSANPGYAQKFQGRVTMTRNTSISTAFMELSSLRSDDTAVYYCARARVTIHYDILTGYYSNAFDIWGQGTMVAVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGADFTLTISSLQPEDFATYYCQQSYTTFMYTFGQGTMLEIK,GYTFTSYD,MNPNSANP,ARARVTIHYDILTGYYSNAFDI,QTISSY,AAS,QQSYTTFMYT,IGHJ3*02 (human),IGHV1-8*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112980885A/en,(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18,,,,,,,,,, (1)..(122), (1)..(109),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELNSLRSEDTAVYYCAGRSAYGDKGYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSNFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCQQRSNWPPQETFGQGTKVEIK,GGTFSSYA,IIPIFGTT,AGRSAYGDKGYYFDY,QSVSNF,DAS,QQRSNWPPQET,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220010411A/en,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising ",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220012771A/en,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018.",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112062838B/en,"(3) a pharmaceutical composition comprising a pharmaceutically active ingredient, wherein the pharmaceutically active ingredient comprises the neutralizing single domain antibody against sars-cov-2 of the novel coronavirus of any one of claims 1 to 3 and the sars-cov-2 neutralizing antibody 4a3 having the amino acid sequence shown in seq id no:3.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIASSGYYTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDADSFDYWGQGTLVTVSS,,GFTFSSYA,IASSGYYT,AKDADSFDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN112062838B/en,"(2) preferably, the amino acid sequence of the single domain antibody is shown as seq id no:2.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVQSGGGLVQPGGSLRLSCAASDFDFYDYEMSWVRQAPGKALEWIGEIHHSGSTYYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCVKDFVGADGPFVFDYWGQGTLVTVSS,,DFDFYDYE,IHHSGST,VKDFVGADGPFVFDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN112979794B/en,"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGSGSYYWGSLDYWGQGTLVTVSS,ENVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLFTFGPGTKVDIK,GFTFSSYG,IWYDGSNK,ARDGSGSYYWGSLDY,QSVSSSY,GAS,QQYGSSPLFT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112979794B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1436/1435)  a) a light chain variable region of seq id no:1435; and b) a binding molecule comprising the heavy chain variable region of seq id no:1436; ,,,,,,,,,, No. 148 HC variable region , No. 148 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELPIHWVRRAPGKGLEWMGRFDPEDGETIYAQNFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATDLTTVTNPLNYYYYGMDVWGXGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNYVYWYQQLPRTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKLTVL,GYTLTELP,FDPEDGET,ATDLTTVTNPLNYYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGWV,IGHJ6*01 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1492/1491)  a) a light chain variable region of seq id no:1491; and b) a binding molecule comprising a heavy chain variable region of seq id no:1492; ,,,,,,,,,, No. 176 HC variable region , No. 176 LC variable region ,EVQLVQSGAEVKKPGESLKISCRGSGYSFTSHWIAWVRQMPGKGLEWMGIIYPGDSDSRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARGPNLYNWFDSWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKVTVL,GYSFTSHW,IYPGDSDS,ARGPNLYNWFDS,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1402/1401)  a) a light chain variable region of seq id no:1401; and b) a binding molecule comprising a heavy chain variable region of seq id no:1402; ,,,,,,,,,, No. 131 HC variable region , No. 131 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVMSYDGSNKYYADSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCAKPDDSSGYYPDYWGQGTLVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL,GFTFSNYG,MSYDGSNK,AKPDDSSGYYPDY,SSDVGSYNL,DVS,SSYTSSSTLV,IGHJ4*01 (human),IGHV3-30*13 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1342/1341)  a) a light chain variable region of seq id no:1341; and b) a binding molecule comprising a heavy chain variable region of seq id no:1342; ,,,,,,,,,, No. 101 HC variable region , No. 101 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFIFGTYGMHWVRQAPGKGLEWVGVISYDGFNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLGGNYYYGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDIGGYNYVSWYQQHPGKAPKLMIYAVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYFCSSYTSSSGTLNVFGTGTKVTVL,GFIFGTYG,ISYDGFNK,ARSLGGNYYYGMDV,SSDIGGYNY,AVS,SSYTSSSGTLNV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ1*01 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1208/1207)  a) a light chain variable region of seq id no:1207; and b) a binding molecule comprising a heavy chain variable region of seq id no:1208; ,,,,,,,,,, No. 34 HC variable region , No. 34 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKTSGGTFSNYPLTWVRQAPGQGLEWLGGIIPIIGATNYAQKFQGRVTITADESTSTAFMELSSLRSEDTAVYYCARGRGYSGYGAAYYFDYWGXGTLVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKVTVL,GGTFSNYP,IIPIIGAT,ARGRGYSGYGAAYYFDY,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1360/1359)  a) a light chain variable region of seq id no:1359; and b) a binding molecule comprising the heavy chain variable region of seq id no:1360; ,,,,,,,,,, No. 110 HC variable region , No. 110 LC variable region ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGSTYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARGYALNPWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKVTVL,GFTFSNYA,ISGSGGST,ARGYALNP,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ5*02 (human),IGHV3-23*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1452/1451)  a) a light chain variable region of seq id no:1451; and b) a binding molecule comprising the heavy chain variable region of seq id no:1452; ,,,,,,,,,, No. 156 HC variable region , No. 156 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIIWVRQTPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQDYWGQGTLVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQDY,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1426/1425)  a) a light chain variable region of seq id no:1425; and b) a binding molecule comprising a heavy chain variable region of seq id no:1426; ,,,,,,,,,, No. 143 HC variable region , No. 143 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSDVVFGGGTKLTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,GTWDSSLSDVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1274/1273)  a) a light chain variable region of seq id no:1273; and b) a binding molecule comprising a heavy chain variable region of seq id no:1274; ,,,,,,,,,, No. 67 HC variable region , No. 67 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSSSPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPALTFGGGTKVDIK,GFTFSSSSP,ISYDGSNK,AREIALNNYYGMDV,QSVSSSY,GAS,QQYGSSPALT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1316/1315)  a) a light chain variable region of seq id no:1315; and b) a binding molecule comprising a heavy chain variable region of seq id no:1316; ,,,,,,,,,, No. 88 HC variable region , No. 88 LC variable region ,EVQLVQSGAEVKKPGSSVRVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQEYWGQGTLVTVSP,ELTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPKYTFGXGTKVEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQEY,QSVSSY,DAS,QQRSNWPPKYT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1216/1215)  a) a light chain variable region of seq id no:1215; and b) a binding molecule comprising the heavy chain variable region of seq id no:1216; ,,,,,,,,,, No. 38 HC variable region , No. 38 LC variable region ,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVSVISGSGGSTSNADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKVYCGDDCYPVVGTPGDAFDIWGGGTMVTVSS,ELVVTQEPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTELTVL,GFTFSDYA,ISGSGGST,AKVYCGDDCYPVVGTPGDAFDI,NIGSKS,YDS,QVWDSSSDHWV,IGHJ3*02 (human),IGHV3-23*04 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1308/1307)  a) a light chain variable region of seq id no:1307; and b) a binding molecule comprising a heavy chain variable region of seq id no:1308; ,,,,,,,,,, No. 84 HC variable region , No. 84 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVEGYDSSGYYLDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWPPVLTFGXGTKVEIK,GGTFSSYA,IIPIFGTA,ARVEGYDSSGYYLDY,QSVSSY,DAS,QQRRNWPPVLT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1446/1445)  a) a light chain variable region of seq id no:1445; and b) a binding molecule comprising a heavy chain variable region of seq id no:1446; ,,,,,,,,,, No. 153 HC variable region , No. 153 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSSSPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKVDIK,GFTFSSSSP,ISYDGSNK,AREIALNNYYGMDV,QSVSSSY,GAS,QQYGSSPYT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1202/1201)  a) a light chain variable region of seq id no:1201; and b) a binding molecule comprising a heavy chain variable region of seq id no:1202; ,,,,,,,,,, No. 31 HC variable region , No. 31 LC variable region ,QVQLVQSGAEVKKPGESLKISCKGSGYSFISYWIVWVRQMPGKGLEWMGTIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGPNIYNWFDSWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLVFGTGTKLTVL,GYSFISYW,IYPGDSDT,ARGPNIYNWFDS,SSNIGSNT,SNN,AAWDDSLNGLV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1454/1453)  a) a light chain variable region of seq id no:1453; and b) a binding molecule comprising the heavy chain variable region of seq id no:1454; ,,,,,,,,,, No. 157 HC variable region , No. 157 LC variable region ,QITLKESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVGRNYLAWYQHKPGQAPRLLIYDASTRATDIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGXGTRLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVGRNY,DAS,QQYGSSPIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1150/1149)  a) a light chain variable region of seq id no:1149; and b) a binding molecule comprising a heavy chain variable region of seq id no:1150; ,,,,,,,,,, No. 5 HC variable region , No.5 LC variable region ,EVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKVTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1460/1459)  a) a light chain variable region of seq id no:1459; and b) a binding molecule comprising a heavy chain variable region of seq id no:1460; ,,,,,,,,,, No. 160 HC variable region , No. 160 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1304/1303)  a) a light chain variable region of seq id no:1303; and b) a binding molecule comprising the heavy chain variable region of seq id no:1304; ,,,,,,,,,, No. 82 HC variable region , No. 82 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1354/1353)  a) a light chain variable region of seq id no:1353; and b) a binding molecule comprising the heavy chain variable region of seq id no:1354; ,,,,,,,,,, No. 107 HC variable region , No. 107 LC variable region ,EVQLVESGAEVKKPGSSVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARPRGYSGYGSNWYFDLWGRGTLVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKVTVL,GYTFTNYG,ISAYNGNT,ARPRGYSGYGSNWYFDL,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ2*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1420/1419)  a) a light chain variable region of seq id no:1419; and b) a binding molecule comprising the heavy chain variable region of seq id no:1420; ,,,,,,,,,, No. 140 HC variable region , No. 140 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1186/1185)  a) a light chain variable region of seq id no:1185; and b) a binding molecule comprising a heavy chain variable region of seq id no:1186; ,,,,,,,,,, No. 23 HC variable region , No. 23 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGLTFSDYGMHWVRQAPGKGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDSGLYGSGWSTYQYYAMDVWGGGTTVTVSS,ELGQTQQLSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKVTVL,GLTFSDYG,ISYDGSNK,ARDSGLYGSGWSTYQYYAMDV,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1380/1379)  a) a light chain variable region of seq id no:1379; and b) a binding molecule comprising a heavy chain variable region of seq id no:1380; ,,,,,,,,,, No. 120 HC variable region , No. 120 LC variable region ,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNQRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSAWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDTSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1188/1187)  a) a light chain variable region of seq id no:1187; and b) a binding molecule comprising a heavy chain variable region of seq id no:1188; ,,,,,,,,,, No. 24 HC variable region , No. 24 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEDAETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSPAVTTAGWFDPWGQGTLVTVSS,ELELTQPSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQHHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKLTVL,GYTLTELS,FDPEDAET,ATSPAVTTAGWFDP,SSDVGGYNY,DVS,SSYTSSSTYV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1252/1251)  a) a light chain variable region of seq id no:1251; and b) a binding molecule comprising the heavy chain variable region of seq id no:1252; ,,,,,,,,,, No. 56 HC variable region , No. 56 LC variable region ,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQPPGKGLEWVSVIYPGGSTFFADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSYDFLTDYTDAFDIWGQGTMVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSAWVFGGGTKVTVL,GFTVSSNY,IYPGGST,ARSYDFLTDYTDAFDI,SSNIGNNY,DNN,QSYDSSLSAWV,IGHJ3*02 (human),IGHV3-53*03 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1310/1309)  a) a light chain variable region of seq id no:1309; and b) a binding molecule comprising the heavy chain variable region of seq id no:1310; ,,,,,,,,,, No. 85 HC variable region , No. 85 LC variable region ,EVQLVQSGGGVVQPGRSLRLSCAASGLTFSDYGMHWVRQAPGKGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDSGLYGSGWSTYQYYAMDVWGGGTTVTVSS,ELGQTQQLSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL,GLTFSDYG,ISYDGSNK,ARDSGLYGSGWSTYQYYAMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1382/1381)  a) a light chain variable region of seq id no:1381; and b) a binding molecule comprising a heavy chain variable region of seq id no:1382; ,,,,,,,,,, No. 121 HC variable region , No. 121 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGDHGMDVWGXGTTVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGRNYVSWYQQLPGTAPKLLIYDNNRRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVAFGGGTKLTVL,GYTFTSYY,INPSGGST,ARGGDHGMDV,SSNIGRNY,DNN,GTWDSSLSAVA,IGHJ6*01 (human),IGHV1-46*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1332/1331)  a) a light chain variable region of seq id no:1331; and b) a binding molecule comprising a heavy chain variable region of seq id no:1332; ,,,,,,,,,, No. 96 HC variable region , No. 96 LC variable region ,EVQLLESGGGVVQPERSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGINKYYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCARALGGNYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTWTFGQGTKVEIK,GFTFSSYA,ISYDGINK,ARALGGNYYYGMDV,QSISSY,AAS,QQSYSTWT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1272/1271)  a) a light chain variable region of seq id no:1271; and b) a binding molecule comprising a heavy chain variable region of seq id no:1272; ,,,,,,,,,, No. 66 HC variable region , No. 66 LC variable region ,EVQLVESGGGVVQPGRSLRLSCATSGFTFSSSSPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKVTVL,GFTFSSSSP,ISYDGSNK,AREIALNNYYGMDV,SSDVGGYNY,DVS,SSYTSSSTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1366/1365)  a) a light chain variable region of seq id no:1365; and b) a binding molecule comprising a heavy chain variable region of seq id no:1366; ,,,,,,,,,, No. 113 HC variable region , No. 113 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNSRRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNS,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1292/1291)  a) a light chain variable region of seq id no:1291; and b) a binding molecule comprising the heavy chain variable region of seq id no:1292; ,,,,,,,,,, No. 76 HC variable region , No. 76 LC variable region ,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYGISWMRQAPGQGLEWMGGIIPILATTKFAQKFQGRVTITADESTSTTYMELSSLRSDDTAVYYCARGWGLRLFGEFSVWFDPWGLGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTQLTVL,GGTFSSYG,IIPILATT,ARGWGLRLFGEFSVWFDP,SSNIGSNT,GNS,QSYDSSLSGVV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1314/1313)  a) a light chain variable region of seq id no:1313; and b) a binding molecule comprising a heavy chain variable region of seq id no:1314; ,,,,,,,,,, No. 87 HC variable region , No. 87 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGINKYYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCARALGGNYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGXGTRLEIK,GFTFSSYA,ISYDGINK,ARALGGNYYYGMDV,QSISSY,AAS,QQSYSTPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ5*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1312/1311)  a) a light chain variable region of seq id no:1311; and b) a binding molecule comprising a heavy chain variable region of seq id no:1312; ,,,,,,,,,, No. 86 HC variable region , No. 86 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSTFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGXGTRLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQDY,QSVSTF,DAS,QQRSNWPPRIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1422/1421)  a) a light chain variable region of seq id no:1421; and b) a binding molecule comprising the heavy chain variable region of seq id no:1422; ,,,,,,,,,, No. 141 HC variable region , No. 141 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCEAWDSSLSAVLFGGGTKVTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,EAWDSSLSAVL,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1324/1323)  a) a light chain variable region of seq id no:1323; and b) a binding molecule comprising the heavy chain variable region of seq id no:1324; ,,,,,,,,,, No. 92 HC variable region , No. 92 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFIFGTYGMHWVRQAPGKGLEWVGVISYDGFNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLGGNYYYGMDVWGQGTTVTVSS,ELVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLGGPVFGGGTKVTVL,GFIFGTYG,ISYDGFNK,ARSLGGNYYYGMDV,SSNIGAGYD,GNS,AAWDDSLGGPV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ1*01 (human),IGLV1-40*02 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1328/1327)  a) a light chain variable region of seq id no:1327; and b) a binding molecule comprising a heavy chain variable region of seq id no:1328; ,,,,,,,,,, No. 94 HC variable region , No. 94 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFIFGTYGMHWVRQAPGKGLEWVGVISYDGFNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLGGNYYYGMDVWGQGTTVTVSS,ELQMTQSPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLEIK,GFIFGTYG,ISYDGFNK,ARSLGGNYYYGMDV,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1222/1221)  a) a light chain variable region of seq id no:1221; and b) a binding molecule comprising a heavy chain variable region of seq id no:1222; ,,,,,,,,,, No. 41 HC variable region , No. 41 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRYYSSWYGPRTWFDPWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,GGSFSGYY,INHSGST,ARGRYYSSWYGPRTWFDP,SSNIGSNT,SNN,AAWDDSLNGYV,IGHJ5*02 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1428/1427)  a) a light chain variable region of seq id no:1427; and b) a binding molecule comprising the heavy chain variable region of seq id no:1428; ,,,,,,,,,, No. 144 HC variable region , No. 144 LC variable region ,EVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVVTQPSVSAAPGRKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTQLTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ7*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1510/1509)  a) a light chain variable region of seq id no:1509; and b) a binding molecule comprising a heavy chain variable region of seq id no:1510; ,,,,,,,,,, No. 185 HC variable region , No. 185 LC variable region ,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNHWIAWVRQMPGKGLEWMGIIYPYDSDTKYSPSFQGQVTISADKSVSTAYLQWSSLKASDTAMYYCARNPTVTNWFDSWGQGTLVTVSS,ELQMTQSPSVSGTPGQRVTISCSGSSSNVGSNIVNWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKVDIK,GYSFSNHW,IYPYDSDT,ARNPTVTNWFDS,SSNVGSNI,NNN,AAWDDSLNAWV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1250/1249)  a) a light chain variable region of seq id no:1249; and b) a binding molecule comprising a heavy chain variable region of seq id no:1250; ,,,,,,,,,, No. 55 HC variable region , No. 55 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFTSSAINWVRQAPGQGLEWMGGIIPIFGTVNYAQKFQGRVTITADEFTSTAYMELSSLRSEDTAIYYCARDHIVSPLYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,GGTFTSSA,IIPIFGTV,ARDHIVSPLYGMDV,QSISSY,AAS,QQSYSTPLT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1390/1389)  a) a light chain variable region of seq id no:1389; and b) a binding molecule comprising the heavy chain variable region of seq id no:1390; ,,,,,,,,,, No. 125 HC variable region , No. 125 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRYYSSWYGPRTWFDPWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSNSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,GGSFSGYY,INHSGST,ARGRYYSSWYGPRTWFDP,NSNIGSNT,SNN,AAWDDSLNGYV,IGHJ5*02 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1424/1423)  a) a light chain variable region of seq id no:1423; and b) a binding molecule comprising a heavy chain variable region of seq id no:1424; ,,,,,,,,,, No. 142 HC variable region , No. 142 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSAGVFGGGTKVTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,GTWDTSLSAGV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1190/1189)  a) a light chain variable region of seq id no:1189; and b) a binding molecule comprising the heavy chain variable region of seq id no:1190; ,,,,,,,,,, No. 25 HC variable region , No. 25 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGTNTVNWYQHLPGMAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLLFGGGTKVTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGTNT,SNN,AAWDDSLNGLL,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1198/1197)  a) a light chain variable region of seq id no:1197; and b) a binding molecule comprising a heavy chain variable region of seq id no:1198; ,,,,,,,,,, No. 29 HC variable region , No. 29 LC variable region ,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAPSDLSFIWTGYYSEYYFDYWGQGTLVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKVTVL,GFTFSSYA,ISGSGGTT,AKAPSDLSFIWTGYYSEYYFDY,SSDVGGYNY,DVS,SSYTSSSTLGV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1352/1351)  a) a light chain variable region of seq id no:1351; and b) a binding molecule comprising a heavy chain variable region of seq id no:1352; ,,,,,,,,,, No. 106 HC variable region , No. 106 LC variable region ,QITLKESGGGVVQPGRSLRLSCAGSGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTYYADSVKGRFTISRDNSENTLYLQMNSLGAEDTAVYYCAKAPSDLSFIWTGYYSEYYFDYWGQGTLVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRYVFGTGTKVTVL,GFTFSSYA,ISGSGGTT,AKAPSDLSFIWTGYYSEYYFDY,SSDVGGYNY,DVS,SSYTSSSTRYV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1168/1167)  a) a light chain variable region of seq id no:1167; and b) a binding molecule comprising a heavy chain variable region of seq id no:1168; ,,,,,,,,,, No. 14 HC variable region , No.14 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAGSGFTSSYAMNWVRQAPGKGLEWVSAISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAPSDLSFIWTGYYSEYYFDYWGXGTLVTVSS,ELALNQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAHKLMMYDVSNRPSGAYNRFSGSKSGNTASLTISALQAEDEADYYCSSYTSSSTSHVVFGGGTKVTVL,GFTSSYA,ISGSGGTT,AKAPSDLSFIWTGYYSEYYFDY,SSDVGGYNY,DVS,SSYTSSSTSHVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1398/1397)  a) a light chain variable region of seq id no:1397; and b) a binding molecule comprising a heavy chain variable region of seq id no:1398; ,,,,,,,,,, No. 129 HC variable region , No. 129 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPRGGNYRGALDIWGQGTMVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVDWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEDDYYCAAWDDSLNAPWVFGGGTKVTVL,GFTFSSYA,ISYDGSNK,ARPRGGNYRGALDI,SSNIGSNT,NNN,AAWDDSLNAPWV,IGHJ3*02 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1516/1515)  a) a light chain variable region of seq id no:1515; and b) a binding molecule comprising a heavy chain variable region of seq id no:1516; ,,,,,,,,,, No. 188 HC variable region , No. 188 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRYPGYYDILTGQIGTGERNAMDVWGXGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSDIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKVTVL,GGTFSNYA,IIPIFGTA,ARDRYPGYYDILTGQIGTGERNAMDV,SSDIGSNT,SNN,AAWDDSLNGWV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1374/1373)  a) a light chain variable region of seq id no:1373; and b) a binding molecule comprising the heavy chain variable region of seq id no:1374; ,,,,,,,,,, No. 117 HC variable region , No. 117 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRRAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVRYYDFWSGWDVMDVWGXGTTVTVSS,ELELTQPSVSGAPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,GFPLSRYA,ISGSGGST,AKVRYYDFWSGWDVMDV,SSNIGNNY,DNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1266/1265)  a) a light chain variable region of seq id no:1265; and b) a binding molecule comprising a heavy chain variable region of seq id no:1266; ,,,,,,,,,, No. 63 HC variable region , No. 63 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSSSPMHWVRQAPGKGLEWVAVISYGGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,GFTFSSSSP,ISYGGSNK,AREIALNNYYGMDV,QSVSSSY,GAS,QQYGSSPYT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1514/1513)  a) a light chain variable region of seq id no:1513; and b) a binding molecule comprising a heavy chain variable region of seq id no:1514; ,,,,,,,,,, No. 187 HC variable region , No. 187 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSTHALSWVRQAPGQGLEWMGGIIPIFGPADYAQKFQGRVTITADKSTSTAYMELSSLRSDDTAVYYCARGLSLGFCSAGSCYDYLDYWGQGTLVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL,GGTFSTHA,IIPIFGPA,ARGLSLGFCSAGSCYDYLDY,SSDVGGYNY,DVS,SSYTSSSTLV,IGHJ4*01 (human),IGHV1-69*06 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1156/1155)  a) a light chain variable region of seq id no:1155; and b) a binding molecule comprising the heavy chain variable region of seq id no:1156; ,,,,,,,,,, No. 8 HC variable region , No.8 LC variable region ,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMTWVRQAPGKGLEWVGRIKTKTDGGTTDYAAPVKGRFTISRNDSKNMLYLQMNSLKTEDTAVYYCTTHSRPDYWGXGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYAASRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYSTPYTFGQGTKLEIK,GFTFSNAW,IKTKTDGGTT,TTHSRPDY,QGISNS,AAS,QQYYSTPYT,IGHJ4*01 (human),IGHV3-15*01 (human),IGKJ2*01 (human),IGKV1-NL1*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1226/1225)  a) a light chain variable region of seq id no:1225; and b) a binding molecule comprising a heavy chain variable region of seq id no:1226; ,,,,,,,,,, No. 43 HC variable region , No. 43 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELELTQPSVSGAPGQRVTISCSGSSSNIGGNYVHWYQQLPGAAPKLLIYSNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGGNY,SND,AAWDDSLNGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1506/1505)  a) a light chain variable region of seq id no:1505; and b) a binding molecule comprising a heavy chain variable region of seq id no:1506; ,,,,,,,,,, No. 183 HC variable region , No. 183 LC variable region ,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIAWVRQMPGKGLEWMGIIYPYDSDTRKSPSFQGQVTMSADKSITTAYLQWSSLKTSDTAMYYCARQDSGTYGWIDYWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLMQGVFGGGTKVTVL,GYSFSNYW,IYPYDSDT,ARQDSGTYGWIDY,SSNIGSNT,SNN,AAWDDSLMQGV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1162/1161)  a) a light chain variable region of seq id no:1161; and b) a binding molecule comprising the heavy chain variable region of seq id no:1162; ,,,,,,,,,, No. 11 HC variable region , No.11 LC variable region ,EVQLVQSGAEVKKPGSSVRVSCKASGDTFIRYAISWVRQAPGQGPEWMGGIIPIFGKVNYAQKFQDRVTITADESTSTVNMELSSLRSEDTAVYYCAKGGSTWYGGNWFDPWGQGTLVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKVTVL,GDTFIRYA,IIPIFGKV,AKGGSTWYGGNWFDP,SSDVGGYNY,DVS,SSYTSSSTLV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1338/1337)  a) a light chain variable region of seq id no:1337; and b) a binding molecule comprising the heavy chain variable region of seq id no:1338; ,,,,,,,,,, No. 99 HC variable region , No. 99 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIIWVRQTPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQDYWGQGTLVTVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPMYTFGXGTKLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQDY,QSVSSY,DAS,QQRSNWPPMYT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ2*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1246/1245)  a) a light chain variable region of seq id no:1245; and b) a binding molecule comprising a heavy chain variable region of seq id no:1246; ,,,,,,,,,, No. 53 HC variable region , No. 53 LC variable region ,EVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQPPGKGLEWVSVIYPGGSTFFADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSYDFLTDYTDAFDIWGQGTMVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKLEIK,GFTVSSNY,IYPGGST,ARSYDFLTDYTDAFDI,QSISSY,AAS,QQSYSTPLT,IGHJ3*02 (human),IGHV3-53*03 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1176/1175)  a) a light chain variable region of seq id no:1175; and b) a binding molecule comprising the heavy chain variable region of seq id no:1176; ,,,,,,,,,, No. 18 HC variable region , No.18 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKVTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1326/1325)  a) a light chain variable region of seq id no:1325; and b) a binding molecule comprising the heavy chain variable region of seq id no:1326; ,,,,,,,,,, No. 93 HC variable region , No. 93 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVSGYDSSGYYQDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPKLTFGGGTKVEIK,GGTFSSYA,IIPIFGTA,ARVSGYDSSGYYQDY,QSVSSF,DAS,QQRSNWPPKLT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1490/1489)  a) a light chain variable region of seq id no:1489; and b) a binding molecule comprising a heavy chain variable region of seq id no:1490; ,,,,,,,,,, No. 175 HC variable region , No. 175 LC variable region ,QVQLVQSGAEVKKPGESLKISCKGSGYSFISYWIAWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISVDKSITTAYLQWSSLEASDTAMYYCARGPNLYNWFDFWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGHVVFGGGTQLTVL,GYSFISYW,IYPGDSDT,ARGPNLYNWFDF,SSNIGSNT,SNN,AAWDDSLNGHVV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1494/1493)  a) a light chain variable region of seq id no:1493; and b) a binding molecule comprising a heavy chain variable region of seq id no:1494; ,,,,,,,,,, No. 177 HC variable region , No. 177 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIQWVRQAPGQGLEWMGWINPNSGDTNYAHKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGSYYNVMYWFDPWGQGTLVTVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVDIK,GYTFTDYY,INPNSGDT,ARGGSYYNVMYWFDP,QSVSSY,DAS,QQYYSTPFT,IGHJ5*02 (human),IGHV1-2*07 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1224/1223)  a) a light chain variable region of seq id no:1223; and b) a binding molecule comprising a heavy chain variable region of seq id no:1224; ,,,,,,,,,, No. 42 HC variable region , No. 42 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNFYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYFCARQEWLRGGFDDWGQGTLVTVSS,ELMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL,GGSISSSSYY,FYYSGST,ARQEWLRGGFDD,SGSIASNY,EDN,QSYDSSNWV,IGHJ5*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV6-57*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1356/1355)  a) a light chain variable region of seq id no:1355; and b) a binding molecule comprising the heavy chain variable region of seq id no:1356; ,,,,,,,,,, No. 108 HC variable region , No. 108 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQDYWGQGTLVTVSS,ELVLTQSPGTLSLSPGERATLSCRASQSVSSFLAWYQHKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQDY,QSVSSF,DAS,QQRSNWPPALT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1160/1159)  a) a light chain variable region of seq id no:1159; and b) a binding molecule comprising the heavy chain variable region of seq id no:1160; ,,,,,,,,,, No. 10 HC variable region , No.10 LC variable region ,EVQLVQSGGGLVEPGGSLRLSCAASGFTFGNAWMSWVRQAPGKGLEWVGRIKTKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFSTPDYWGQGTLVTVSS,ELQMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQPPKLLLYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCLQYFTIPWTFGQGTKVEIK,GFTFGNAW,IKTKTDGGTT,TTFSTPDY,QSVSSN,WAS,LQYFTIPWT,IGHJ4*01 (human),IGHV3-15*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1204/1203)  a) a light chain variable region of seq id no:1203; and b) a binding molecule comprising the heavy chain variable region of seq id no:1204; ,,,,,,,,,, No. 32 HC variable region , No. 32 LC variable region ,EVQLVQSGGGLIQPGGSLRLSCAASEFIVSSNYMTWVRQAPGKGLEWVSIIYPGGSTYYADSVKGRFTISRDNSKNTLYLRMNSLRAEDTAVYYCARDLPLTGTTLDYWGQGTLVTVSS,ELVLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKLEIK,EFIVSSNY,IYPGGST,ARDLPLTGTTLDY,QSISSY,AAS,QQSYSTPLT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1440/1439)  a) a light chain variable region of seq id no:1439; and b) a binding molecule comprising a heavy chain variable region of seq id no:1440; ,,,,,,,,,, No. 150 HC variable region , No. 150 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCTASDFTFSSYAMSWVRQAPGKGLEWVSAISGSGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTKVRYYDFWSGWDVMDVWGXGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGPVFGGGTKVTVL,DFTFSSYA,ISGSGGDT,TKVRYYDFWSGWDVMDV,SSNIGSNT,SNN,AAWDDSLSGPV,IGHJ6*01 (human),IGHV3-23*04 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1392/1391)  a) a light chain variable region of seq id no:1391; and b) a binding molecule comprising a heavy chain variable region of seq id no:1392; ,,,,,,,,,, No. 126 HC variable region , No. 126 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARASGYDSSGYYSDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSTYLSWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCLQRSNWPPALTFGGGTKLEIK,GGTFSSYA,IIPIFGTA,ARASGYDSSGYYSDY,QSVSTY,DAS,LQRSNWPPALT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1232/1231)  a) a light chain variable region of seq id no:1231; and b) a binding molecule comprising a heavy chain variable region of seq id no:1232; ,,,,,,,,,, No. 46 HC variable region , No. 46 LC variable region ,QVQLVQSGAEVKKPGASVKVSCRASGYAFTRYGISWVRQAPGQGLEWMGWISAYNGNTKYAQKLQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARVLGIAVAGTPIWGQGTLVTVSP,ELVLTQPPSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKVTVL,GYAFTRYG,ISAYNGNT,ARVLGIAVAGTPI,SGSIASNY,EDN,QSYDSSNWV,IGHJ1*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV6-57*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1370/1369)  a) a light chain variable region of seq id no:1369; and b) a binding molecule comprising a heavy chain variable region of seq id no:1370; ,,,,,,,,,, No. 115 HC variable region , No. 115 LC variable region ,EVQLMQSGAEVKKPGSSVKVSCKASGGTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYWVFGGGTKVTVL,GGTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSAYWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1320/1319)  a) a light chain variable region of seq id no:1319; and b) a binding molecule comprising the heavy chain variable region of seq id no:1320; ,,,,,,,,,, No. 90 HC variable region , No. 90 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVEGYDSSGYYLDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYCQQRRNWPPRITFGXGTRLEIK,GGTFSSYA,IIPIFGTA,ARVEGYDSSGYYLDY,QSVSSY,DAS,QQRRNWPPRIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1300/1299)  a) a light chain variable region of seq id no:1299; and b) a binding molecule comprising the heavy chain variable region of seq id no:1300; ,,,,,,,,,, No. 80 HC variable region , No. 80 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYVISWVRQAPGXGLEWVGRIIPIFGTVKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDLPGDSRDGYNYDAFDIWGQGTLVTVSL,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKVTVL,GGTFSSYV,IIPIFGTV,ARDLPGDSRDGYNYDAFDI,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*01 (human),IGHV1-69*06 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1448/1447)  a) a light chain variable region of seq id no:1447; and b) a binding molecule comprising the heavy chain variable region of seq id no:1448; ,,,,,,,,,, No. 154 HC variable region , No. 154 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPELSIHWVRQAPGKGLEWMGGFDPENGETIHAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTPMIRASWFDPWGQGTLVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGNYNYVSWYQQHPDKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSGTLVFGGGTKLTVL,GYTLPELS,FDPENGET,ATSTPMIRASWFDP,SSDVGNYNY,DVS,SSYTSSGTLV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1464/1463)  a) a light chain variable region of seq id no:1463; and b) a binding molecule comprising the heavy chain variable region of seq id no:1464; ,,,,,,,,,, No. 162 HC variable region , No. 162 LC variable region ,EVQLVESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGXGTRLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QQYGSSPIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1458/1457)  a) a light chain variable region of seq id no:1457; and b) a binding molecule comprising a heavy chain variable region of seq id no:1458; ,,,,,,,,,, No. 159 HC variable region , No. 159 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVDIK,GDSISSGGYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-31*02 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1350/1349)  a) a light chain variable region of seq id no:1349; and b) a binding molecule comprising the heavy chain variable region of seq id no:1350; ,,,,,,,,,, No. 105 HC variable region , No. 105 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQEYWGQGTLVTVSS,ELTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGTPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPMYTFGXGTRLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQEY,QSVSSY,DAS,QQRSNWPPMYT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1462/1461)  a) a light chain variable region of seq id no:1461; and b) a binding molecule comprising a heavy chain variable region of seq id no:1462; ,,,,,,,,,, No. 161 HC variable region , No. 161 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELQMTQSPATLSLSPGERATLSCRASQSVNSYSAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYHTSPITFGXGTRLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVNSY,DAS,QQYHTSPIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1318/1317)  a) a light chain variable region of seq id no:1317; and b) a binding molecule comprising the heavy chain variable region of seq id no:1318; ,,,,,,,,,, No. 89 HC variable region , No. 89 LC variable region ,EVQLLESGGSVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARGGSYLYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTWTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARARGGSYLYGMDV,QSISSY,KAS,QQSYSTWT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1144/1143)  a) a light chain variable region of seq id no:1143; and b) a binding molecule comprising the heavy chain variable region of seq id no:1144; ,,,,,,,,,, No. 2 HC variable region , No.2 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIFDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEAEYYCGTWDSSLSGWVFGGGTKVTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSGWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1408/1407)  a) a light chain variable region of seq id no:1407; and b) a binding molecule comprising a heavy chain variable region of seq id no:1408; ,,,,,,,,,, No. 134 HC variable region , No. 134 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELELTQPSVSGSPGDSITISCTGTRGDIGAYDGVSWYQQLPGKAPKLIIYAVTQRPSGISDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSSWVFGGGTKLTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,RGDIGAYDG,AVT,SSYTSSSSWV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ3*02 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1348/1347)  a) a light chain variable region of seq id no:1347; and b) a binding molecule comprising a heavy chain variable region of seq id no:1348; ,,,,,,,,,, No. 104 HC variable region , No. 104 LC variable region ,EVQLVQSGGGVVQPGRSLRLSCAASGFIFGTYGMHWVRQAPGKGLEWVGVISYDGFNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLGGNYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYQDSKRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQAWDSSTVFGGGTKLTVL,GFIFGTYG,ISYDGFNK,ARSLGGNYYYGMDV,NIGSKS,QDS,QAWDSSTV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ2*01 (human),IGLV3-21*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1406/1405)  a) a light chain variable region of seq id no:1405; and b) a binding molecule comprising a heavy chain variable region of seq id no:1406; ,,,,,,,,,, No. 133 HC variable region , No. 133 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAISPAIIRVDWFDPWGQGTLVTVSS,ELELTQPSVSGSPGDSITISCTGTRGDIGAYDGVSWYQQLPGKAPKLIIYAVTQRPSGISDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSSWVFGGGTKLTVL,GYTLPELS,FDPEDGET,AISPAIIRVDWFDP,RGDIGAYDG,AVT,SSYTSSSSWV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1500/1499)  a) a light chain variable region of seq id no:1499; and b) a binding molecule comprising a heavy chain variable region of seq id no:1500; ,,,,,,,,,, No. 180 HC variable region , No. 180 LC variable region ,QVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARTYGSGSYSDFDYWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGGVFGGGTKVTVL,GYSFTSNW,IYPGDSDT,ARTYGSGSYSDFDY,SSNIGSNT,SNN,AAWDDSLNGGV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1484/1483)  a) a light chain variable region of seq id no:1483; and b) a binding molecule comprising a heavy chain variable region of seq id no:1484; ,,,,,,,,,, No. 172 HC variable region , No. 172 LC variable region ,EVQLVQSGAEVKKPGESLKISCRGSGYSFTSHWIAWVRQMPGKGLEWMGIIYPGDSDSRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARGPNLYNWFDSWGQGTLVTVSS,ELVVTQEPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPVFGGTQLTVL,GYSFTSHW,IYPGDSDS,ARGPNLYNWFDS,SSNIGSNT,SNN,AAWDDSLSGPV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ7*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1282/1281)  a) a light chain variable region of seq id no:1281; and b) a binding molecule comprising the heavy chain variable region of seq id no:1282; ,,,,,,,,,, No. 71 HC variable region , No. 71 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYAMHWVRQAPGKGLEWVAVISYDGSHKNYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAVYYCARDNCGGDCGGGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSRTWVFGGGTKLTVL,GFTFSGYA,ISYDGSHK,ARDNCGGDCGGGMDV,SSDVGGYNY,DVS,SSYTSSRTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1404/1403)  a) a light chain variable region of seq id no:1403; and b) a binding molecule comprising the heavy chain variable region of seq id no:1404; ,,,,,,,,,, No. 132 HC variable region , No. 132 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEDAETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSPAVTTAGWFDPCGQGTLVTVSS,ELKLTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSTWVFGGGTKLTVL,GYTLTELS,FDPEDAET,ATSPAVTTAGWFDP,SSDVGGYNY,DVS,SSYTTSSTWV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1262/1261)  a) a light chain variable region of seq id no:1261; and b) a binding molecule comprising the heavy chain variable region of seq id no:1262; ,,,,,,,,,, No. 61 HC variable region , No. 61 LC variable region ,EVQLLESGGALVQPGRSLRLSCAASGFTFDDYAMHWVRQGPGKGLEWVSGTTWNSGTIGYADSVKGRFIISRDNAENSLYLQMNSLRPEDTALYYCAKDIGSGDRPDAFHLWGQGTMVTVSS,ELVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDRVVFGGGTKVTVL,GFTFDDYA,TTWNSGTI,AKDIGSGDRPDAFHL,NIGSKS,DDS,QVWDSSSDRVV,IGHJ3*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-21*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1264/1263)  a) a light chain variable region of seq id no:1263; and b) a binding molecule comprising a heavy chain variable region of seq id no:1264; ,,,,,,,,,, No. 62 HC variable region , No. 62 LC variable region ,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIENNYVSWYQQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDNSLSAWVFGGGTKVTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIENNY,DNN,GTWDNSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1468/1467)  a) a light chain variable region of seq id no:1467; and b) a binding molecule comprising a heavy chain variable region of seq id no:1468; ,,,,,,,,,, No. 164 HC variable region , No. 164 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVMTQSPATLSVSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPLTFGGGTKLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,GAS,QQYGTSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1172/1171)  a) a light chain variable region of seq id no:1171; and b) a binding molecule comprising a heavy chain variable region of seq id no:1172; ,,,,,,,,,, No. 16 HC variable region , No.16 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNASLFGGGTKVTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AAWDDSLNASL,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1182/1181)  a) a light chain variable region of seq id no:1181; and b) a binding molecule comprising a heavy chain variable region of seq id no:1182; ,,,,,,,,,, No. 21 HC variable region , No. 21 LC variable region ,EVQLVQSGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQEYGSSPRRVTFGPGTKVEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QEYGSSPRRVT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1488/1487)  a) a light chain variable region of seq id no:1487; and b) a binding molecule comprising a heavy chain variable region of seq id no:1488; ,,,,,,,,,, No. 174 HC variable region , No. 174 LC variable region ,EVQLVQSGAEVKKPGESLKISCKSSGYSFISYWIAWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISVDKSITTAYLQWSSLEASDTAMYYCARGPNLYNWFDFWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGSVVFGGGTKVTVL,GYSFISYW,IYPGDSDT,ARGPNLYNWFDF,SSNIGSNT,SNN,AAWDDSLNGSVV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1158/1157)  a) a light chain variable region of seq id no:1157; and b) a binding molecule comprising the heavy chain variable region of seq id no:1158; ,,,,,,,,,, No. 9 HC variable region , No.9 LC variable region ,QVQLVQSGAEVKKPGSSVRLSCKASGGPFERKVIAWVRQAPGQGLEWVGGHAPFVRKPTYAQKFQGRVTMTADDSTSTAFMELSTLRSDDTAVYYCATKAVTTYSGFDTWGQGTLVLVSA,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTQLTVL,GGPFERKV,HAPFVRKP,ATKAVTTYSGFDT,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ5*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1418/1417)  a) a light chain variable region of seq id no:1417; and b) a binding molecule comprising a heavy chain variable region of seq id no:1418; ,,,,,,,,,, No. 139 HC variable region , No. 139 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPEVAIHWVRQAPGKGLEWMGGFDPEDGETSYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGPVLGLSKWLEFDPWGQGTLVTVSS,ELQMTQSPSVSGSPGQSITISCTGTSSDVGAYNYVSWYQHHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSSSTWVFGGGTKVDIK,GYTLPEVA,FDPEDGET,ATGPVLGLSKWLEFDP,SSDVGAYNY,DVS,NSYTSSSTWV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1362/1361)  a) a light chain variable region of seq id no:1361; and b) a binding molecule comprising the heavy chain variable region of seq id no:1362; ,,,,,,,,,, No. 111 HC variable region , No. 111 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVVTQPPSASGTPGQRVTISCSGSSSNIGSNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGSNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1278/1277)  a) a light chain variable region of seq id no:1277; and b) a binding molecule comprising a heavy chain variable region of seq id no:1278; ,,,,,,,,,, No. 69 HC variable region , No. 69 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGIFSSYAISWVRQAPGQGLEWMGGIIPMFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPTSRSTYYYYSGSYYPWGQGTLVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGGYNNVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSPWVFGGGTQLTVL,GGIFSSYA,IIPMFGTT,ARDPTSRSTYYYYSGSYYP,SSDVGGYNN,DVS,SSYTSSSPWV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1416/1415)  a) a light chain variable region of seq id no:1415; and b) a binding molecule comprising a heavy chain variable region of seq id no:1416; ,,,,,,,,,, No. 138 HC variable region , No. 138 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPEVAIHWVRQAPGKGLEWMGGFDPEDGETSYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGPVLGLSKWLEFDPWGQGTLVTVSS,ELQMTQSPSVSGSPGQSITISCTGTSTDIGRYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYAFGTGTKVDIK,GYTLPEVA,FDPEDGET,ATGPVLGLSKWLEFDP,STDIGRYNY,DVS,SSYTSSSTYA,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1294/1293)  a) a light chain variable region of seq id no:1293; and b) a binding molecule comprising a heavy chain variable region of seq id no:1294; ,,,,,,,,,, No. 77 HC variable region , No. 77 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKGLEWVAVISYDGSLKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSCSGGSCFDYWGQGTLVTVSS,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIFDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDSSLSTPNWVFGGGTKLTVL,GFTFSSYP,ISYDGSLK,ARDSSCSGGSCFDY,SSNIGNNY,DNN,GAWDSSLSTPNWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1496/1495)  a) a light chain variable region of seq id no:1495; and b) a binding molecule comprising a heavy chain variable region of seq id no:1496; ,,,,,,,,,, No. 178 HC variable region , No. 178 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIQWVRQAPGQGLEWMGWINPNSGDTNYAHKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGSYYNVMYWFDPWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYAASRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVDIK,GYTFTDYY,INPNSGDT,ARGGSYYNVMYWFDP,QGISNS,AAS,QQYYSTPFT,IGHJ5*02 (human),IGHV1-2*07 (human),IGKJ3*01 (human),IGKV1-NL1*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1170/1169)  a) a light chain variable region of seq id no:1169; and b) a binding molecule comprising the heavy chain variable region of seq id no:1170; ,,,,,,,,,, No. 15 HC variable region , No.15 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGYSISRGDYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISADTSKNQFSLKLSSVTAADTAAYYCARHGTSGYYYPNWFDPWGQGTLVTVSS,ELELTQPSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL,GYSISRGDY,IYHSGST,ARHGTSGYYYPNWFDP,SSDVGGYNY,DVS,SSYTSSSTLV,IGHJ5*02 (human),IGHV4-38-2*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1378/1377)  a) a light chain variable region of seq id no:1377; and b) a binding molecule comprising a heavy chain variable region of seq id no:1378; ,,,,,,,,,, No. 119 HC variable region , No. 119 LC variable region ,QVQLVQSGAEVKKPGASLKVSCKASGYAFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNVRPSGIPDRFSGSKSGTSATLGITRLQTGDEADYYCAAWDTSLSSWVFGGGTKLTVL,GYAFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,AAWDTSLSSWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1234/1233)  a) a light chain variable region of seq id no:1233; and b) a binding molecule comprising a heavy chain variable region of seq id no:1234; ,,,,,,,,,, No. 47 HC variable region , No. 47 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIQWVRQAPGQGLEWMGWINPNSGDTNYAHKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGSYYNVMYWFDPWGQGTLVTVSS,ELVMTQSPATLSVSPGDRATLSCRASQSVRSDIAWYQQKPGQAPRLLIYDTSTRATGIPARFSGSGSGTEFTLTVSSLQAEDVAVYYCQQYYTTPFTFGPGTKVDIK,GYTFTDYY,INPNSGDT,ARGGSYYNVMYWFDP,QSVRSD,DTS,QQYYTTPFT,IGHJ5*02 (human),IGHV1-2*07 (human),IGKJ3*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1346/1345)  a) a light chain variable region of seq id no:1345; and b) a binding molecule comprising the heavy chain variable region of seq id no:1346; ,,,,,,,,,, No. 103 HC variable region , No. 103 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAAIWHDGYNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSKAADYWGQGTLVIVSS,ELQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYRASTLQSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYKTYPLTFGGGTKVEIK,GFTFSSYG,IWHDGYNK,ARGSKAADY,QSISSW,RAS,QQYKTYPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1486/1485)  a) a light chain variable region of seq id no:1485; and b) a binding molecule comprising a heavy chain variable region of seq id no:1486; ,,,,,,,,,, No. 173 HC variable region , No. 173 LC variable region ,EVQLVQSGAEVKKPGESLKISCRGSGYSFTSHWIAWVRQMPGKGLEWMGIIYPGDSDSRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARGPNLYNWFDSWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,GYSFTSHW,IYPGDSDS,ARGPNLYNWFDS,SSNIGSNT,SNN,AAWDDSLNGPV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1280/1279)  a) a light chain variable region of seq id no:1279; and b) a binding molecule comprising a heavy chain variable region of seq id no:1280; ,,,,,,,,,, No. 70 HC variable region , No. 70 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVMSYDGSNKYYADSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCAKPDDSSGYYPDYWGQGTLVTVSS,ELALTQPSVSGSPGQSITISCTGTSTDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGSTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKVTVL,GFTFSNYG,MSYDGSNK,AKPDDSSGYYPDY,STDVGGYNY,DVS,SSYTSSSTLV,IGHJ4*01 (human),IGHV3-30*13 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1210/1209)  a) a light chain variable region of seq id no:1209; and b) a binding molecule comprising the heavy chain variable region of seq id no:1210; ,,,,,,,,,, No. 35 HC variable region , No. 35 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYAISWVRQAPGQGLEWMGGIIPIFGTGNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSLYYYDRSGYPISEDYFDYWGGGTLVTVSA,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAGDEADYYCQSYDSSLSGSWVFGGGTKLTVL,GGTFSRYA,IIPIFGTG,ARSLYYYDRSGYPISEDYFDY,SSNIGAGYD,GNS,QSYDSSLSGSWV,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1200/1199)  a) a light chain variable region of seq id no:1199; and b) a binding molecule comprising the heavy chain variable region of seq id no:1200; ,,,,,,,,,, No. 30 HC variable region , No. 30 LC variable region ,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWLGVINRSGGSTIYAQTFQGRVTMTRDTSTSTAYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,GYTFTGYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1396/1395)  a) a light chain variable region of seq id no:1395; and b) a binding molecule comprising a heavy chain variable region of seq id no:1396; ,,,,,,,,,, No. 128 HC variable region , No. 128 LC variable region ,QVQLVQSGGGLVQSGGSLRLSCAASGFPLSRYAMSWVRRAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPRGQDYGDYGFLDYWGXGTLVTVSS,ELVLTQPSVSGAPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKVTVL,GFPLSRYA,ISGSGGST,AKGPRGQDYGDYGFLDY,SSNIGNNY,DNN,AAWDDSLNGVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1228/1227)  a) a light chain variable region of seq id no:1227; and b) a binding molecule comprising a heavy chain variable region of seq id no:1228; ,,,,,,,,,, No. 44 HC variable region , No. 44 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSITFGXGTRLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QQYGSSPSIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1412/1411)  a) a light chain variable region of seq id no:1411; and b) a binding molecule comprising a heavy chain variable region of seq id no:1412; ,,,,,,,,,, No. 136 HC variable region , No. 136 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSHKNYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAVYYCARDNCGGDCGGGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDKADYYCSSYTSSSTPWVFGGGTELTVL,GFTFSSYA,ISYDGSHK,ARDNCGGDCGGGMDV,SSDVGGYNY,DVS,SSYTSSSTPWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1196/1195)  a) a light chain variable region of seq id no:1195; and b) a binding molecule comprising the heavy chain variable region of seq id no:1196; ,,,,,,,,,, No. 28 HC variable region , No. 28 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAPSDLSFIWTGYYSEYYFDYWGQGTLVTVSS,ELVLTQPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNYVVFGGGTKLTVL,GFTFSSYA,ISGSGGTT,AKAPSDLSFIWTGYYSEYYFDY,SSDVGGYNY,EVS,SSYAGSNYVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1146/1145)  a) a light chain variable region of seq id no:1145; and b) a binding molecule comprising a heavy chain variable region of seq id no:1146; ,,,,,,,,,, No. 3 HC variable region , No.3 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASDFTFSSYAMSWVRQAPGKGLEWVSAISGSGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVRYYDFWSGWDVMDVWGXGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,DFTFSSYA,ISGSGGDT,AKVRYYDFWSGWDVMDV,SSNIGSNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1322/1321)  a) a light chain variable region of seq id no:1321; and b) a binding molecule comprising a heavy chain variable region of seq id no:1322; ,,,,,,,,,, No. 91 HC variable region , No. 91 LC variable region ,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNSYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKVTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNSY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1476/1475)  a) a light chain variable region of seq id no:1475; and b) a binding molecule comprising a heavy chain variable region of seq id no:1476; ,,,,,,,,,, No. 168 HC variable region , No. 168 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISGSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHGSSPFTFGPGTKVDIK,GDSISGSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,GAS,QQHGSSPFT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1434/1433)  a) a light chain variable region of seq id no:1433; and b) a binding molecule comprising the heavy chain variable region of seq id no:1434; ,,,,,,,,,, No. 147 HC variable region , No. 147 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGGIFSSYAISWVRQAPGQGLEWMGGIIPMFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPTSRSTYYYYSGSYYPWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSGSNIGSNYVHWYQQLPGTAPKLLIYRNSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTELTVL,GGIFSSYA,IIPMFGTT,ARDPTSRSTYYYYSGSYYP,GSNIGSNY,RNS,AAWDDSLSGWV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1184/1183)  a) a light chain variable region of seq id no:1183; and b) a binding molecule comprising the heavy chain variable region of seq id no:1184; ,,,,,,,,,, No. 22 HC variable region , No. 22 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTDFTLTINGLQAEDVAVYYCQQYYQVPLTFGGGTKVEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QQYYQVPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1164/1163)  a) a light chain variable region of seq id no:1163; and b) a binding molecule comprising the heavy chain variable region of seq id no:1164; ,,,,,,,,,, No. 12 HC variable region , No.12 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSDAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREATYDSSGRPTGDYGMDVWGXGTTVTVSS,ELELTQPSVSVSPGQTARITCSGDVLAKKYARWFQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGAQVEDEADYYCYSAADNNGVFGGGTQLTVL,GFTFSSDA,ISYDGSNK,AREATYDSSGRPTGDYGMDV,VLAKKY,KDS,YSAADNNGV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV3-27*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1372/1371)  a) a light chain variable region of seq id no:1371; and b) a binding molecule comprising a heavy chain variable region of seq id no:1372; ,,,,,,,,,, No. 116 HC variable region , No. 116 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQSRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVMTQSPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLEIK,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1334/1333)  a) a light chain variable region of seq id no:1333; and b) a binding molecule comprising the heavy chain variable region of seq id no:1334; ,,,,,,,,,, No. 97 HC variable region , No. 97 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARGGSYLYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCQASQDISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTWTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARARGGSYLYGMDV,QDISSY,AAS,QQSYSTWT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1358/1357)  a) a light chain variable region of seq id no:1357; and b) a binding molecule comprising a heavy chain variable region of seq id no:1358; ,,,,,,,,,, No. 109 HC variable region , No. 109 LC variable region ,EVQLVQSGGGVVQPGRSPRLSCAASGFTFSSYAMHWVRQAPGKGLEWLALISYDGNNKYYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAVYYCARATYGSYYYGMDAWGLGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRTTQNINTYLNWYQQQPGKAPKLLIYAASRLQSGVPSRFSGTGSGTDFTLTITSVQPEDFATYYCQRSYSTPYTFGQGTKLEIK,GFTFSSYA,ISYDGNNK,ARATYGSYYYGMDA,QNINTY,AAS,QRSYSTPYT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1474/1473)  a) a light chain variable region of seq id no:1473; and b) a binding molecule comprising a heavy chain variable region of seq id no:1474; ,,,,,,,,,, No. 167 HC variable region , No. 167 LC variable region ,QVQLQESGPGLVKPSGTLSLTCTVSGDSISGSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVMTQSPATLSLSPGERATLSCRASQSVRNYLAWYQQKPGQAPRLLMYDASTRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPLTFGGGTKLEIK,GDSISGSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVRNY,DAS,QQYGRSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1298/1297)  a) a light chain variable region of seq id no:1297; and b) a binding molecule comprising a heavy chain variable region of seq id no:1298; ,,,,,,,,,, No. 79 HC variable region , No. 79 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTQYLHWVRQAPGQGLEWMGIINPYGGSTTYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSPSGYYGDYEGDAFDIWGXGTMVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSASKDAASAYLTITGLQAEDEGDYYCQSYDSRLRAVVFGGGTQLTVL,GYTFTTQY,INPYGGST,ARSPSGYYGDYEGDAFDI,SSNIGAGYD,GNS,QSYDSRLRAVV,IGHJ3*02 (human),IGHV1-46*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1330/1329)  a) a light chain variable region of seq id no:1329; and b) a binding molecule comprising the heavy chain variable region of seq id no:1330; ,,,,,,,,,, No. 95 HC variable region , No. 95 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYDGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGSNTVSWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL,DGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AAWDDSLNGVV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1414/1413)  a) a light chain variable region of seq id no:1413; and b) a binding molecule comprising the heavy chain variable region of seq id no:1414; ,,,,,,,,,, No. 137 HC variable region , No. 137 LC variable region ,QVQLVQSGGGVVQPGRFLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSHKNYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAVYYCARDNCGGDCGGGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCTGTNSDVGGYNYVSWYQHHPGKAPKLMIYDVTKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL,GFTFSSYA,ISYDGSHK,ARDNCGGDCGGGMDV,NSDVGGYNY,DVT,SSYTSSSTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1388/1387)  a) a light chain variable region of seq id no:1387; and b) a binding molecule comprising a heavy chain variable region of seq id no:1388; ,,,,,,,,,, No. 124 HC variable region , No. 124 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDGSGYYQDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGXGTRLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDGSGYYQDY,QSVSSY,DAS,QQRSNWPPRIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1276/1275)  a) a light chain variable region of seq id no:1275; and b) a binding molecule comprising a heavy chain variable region of seq id no:1276; ,,,,,,,,,, No. 68 HC variable region , No. 68 LC variable region ,QVQLVQSGAEVKKPGSSVRLSCKASGGPFERKVIAWVRQAPGQGLEWVGGHAPFVRKPTYARKFQGRVTLTADDSTSTAFMEFSSLRSDDTAVYFCATKAVTTYSGFDNWGQGTLVFVSA,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTQLTVL,GGPFERKV,HAPFVRKP,ATKAVTTYSGFDN,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ5*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1386/1385)  a) a light chain variable region of seq id no:1385; and b) a binding molecule comprising the heavy chain variable region of seq id no:1386; ,,,,,,,,,, No. 123 HC variable region , No. 123 LC variable region ,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSDAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREATYDSSGRPTGDYGMDVWGXGTTVTVSS,ELELTQPSVSVSPGQTARITCSGDVLAKKYARWFQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGAQVEDEADYYCYSAADNNGVFGGGTKLTVL,GFTFSSDA,ISYDGSNK,AREATYDSSGRPTGDYGMDV,VLAKKY,KDS,YSAADNNGV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV3-27*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1284/1283)  a) a light chain variable region of seq id no:1283; and b) a binding molecule comprising a heavy chain variable region of seq id no:1284; ,,,,,,,,,, No. 72 HC variable region , No. 72 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWMRQAPGQGLEWMGGIIPILATTKFAQKFQGRVTITADESTSTTYMELSSLRSDDTAVYYCARGWGLRLFGEFSVWFDPWGLGTLVTVSS,ELQMTQSPSVSGAPGQRVTISCSGSSSNIGSNAVNWYQQLPGTAPKLLIYSNSYRPSGVSDRFSGSKSGTSASLAITGLRPEDEADYYCQSYDSALRGPLFGGGTKVDIK,GGTFSSYG,IIPILATT,ARGWGLRLFGEFSVWFDP,SSNIGSNA,SNS,QSYDSALRGPL,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1478/1477)  a) a light chain variable region of seq id no:1477; and b) a binding molecule comprising the heavy chain variable region of seq id no:1478; ,,,,,,,,,, No. 169 HC variable region , No. 169 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGKVFGGGTELTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNY,RNN,AAWDDSLSGKV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1442/1441)  a) a light chain variable region of seq id no:1441; and b) a binding molecule comprising a heavy chain variable region of seq id no:1442; ,,,,,,,,,, No. 151 HC variable region , No. 151 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGTYYYDSSGPLNWFDPWGXGTLVTVSS,ELELTQPSVSGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKVTVL,GFTFSSYW,IKQDGSEK,ARGTYYYDSSGPLNWFDP,SSNIGAGYD,SNN,AAWDDSLNGPV,IGHJ5*02 (human),IGHV3-7*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1254/1253)  a) a light chain variable region of seq id no:1253; and b) a binding molecule comprising the heavy chain variable region of seq id no:1254; ,,,,,,,,,, No. 57 HC variable region , No. 57 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIQWVRQAPGQGLEWMGWINPNSGDTNYAHKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGSYYNVMYWFDPWGQGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPITFGXGTRLEIK,GYTFTDYY,INPNSGDT,ARGGSYYNVMYWFDP,QGISNY,DAS,QQYYSTPIT,IGHJ5*02 (human),IGHV1-2*07 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1512/1511)  a) a light chain variable region of seq id no:1511; and b) a binding molecule comprising a heavy chain variable region of seq id no:1512; ,,,,,,,,,, No. 186 HC variable region , No. 186 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPFFGTSNYAQKFQGRVTVTADESTSTAYMELSSLRSEDTAVYYCARGQFSDSSGYQHPYYDYGMDVWGGGTTVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKVTVL,GGTFSSYA,IIPFFGTS,ARGQFSDSSGYQHPYYDYGMDV,SSNIGAGYD,GNS,QSYDSSLSGPNWV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1430/1429)  a) a light chain variable region of seq id no:1429; and b) a binding molecule comprising the heavy chain variable region of seq id no:1430; ,,,,,,,,,, No. 145 HC variable region , No. 145 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFNNYVINWVRQAPGQGLEWMGGFIPVFGIADYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSGLFDWLLPRSRHRDYFDYWGXGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPTFGGGTKLEIK,GGTFNNYV,FIPVFGIA,ARSGLFDWLLPRSRHRDYFDY,QSVSSSY,GAS,QQYGSSPPT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1166/1165)  a) a light chain variable region of seq id no:1165; and b) a binding molecule comprising the heavy chain variable region of seq id no:1166; ,,,,,,,,,, No. 13 HC variable region , No.13 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AAWDDSLNGVV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1286/1285)  a) a light chain variable region of seq id no:1285; and b) a binding molecule comprising a heavy chain variable region of seq id no:1286; ,,,,,,,,,, No. 73 HC variable region , No. 73 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFGSYGISWMRQAPGQGLEWMGGIIPILATTKFAQKFQGRVTITADESTSTTYMELSSLRSDDTAVYYCARGWGLRLFGEFSVWFDPWGLGTLVTVSS,ELVLTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVVFGGGTQLTVL,GGTFGSYG,IIPILATT,ARGWGLRLFGEFSVWFDP,SSNIGAGYD,GNS,QSYDSSLSDVV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1336/1335)  a) a light chain variable region of seq id no:1335; and b) a binding molecule comprising a heavy chain variable region of seq id no:1336; ,,,,,,,,,, No. 98 HC variable region , No. 98 LC variable region ,EVQLLESGGGVVQPERSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGINKYYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCARALGGNYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSNPFTFGXGTRLEIK,GFTFSSYA,ISYDGINK,ARALGGNYYYGMDV,QSISSY,AAS,QQSYSNPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ5*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1432/1431)  a) a light chain variable region of seq id no:1431; and b) a binding molecule comprising a heavy chain variable region of seq id no:1432; ,,,,,,,,,, No. 146 HC variable region , No. 146 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGIFSSYAISWVRQAPGQGLEWMGGIIPMFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPTSRSTYYYYSGSYYPWGQGTLVTVSS,ELGQTQQLSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GGIFSSYA,IIPMFGTT,ARDPTSRSTYYYYSGSYYP,SSNIGNNY,DNN,AAWDDSLNGWV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1498/1497)  a) a light chain variable region of seq id no:1497; and b) a binding molecule comprising the heavy chain variable region of seq id no:1498; ,,,,,,,,,, No. 179 HC variable region , No. 179 LC variable region ,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARTYGSGSYSDFDYWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNSGVFGGGTKLTVL,GYSFTSNW,IYPGDSDT,ARTYGSGSYSDFDY,SSNIGSNT,SNN,AAWDDSLNSGV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1466/1465)  a) a light chain variable region of seq id no:1465; and b) a binding molecule comprising a heavy chain variable region of seq id no:1466; ,,,,,,,,,, No. 163 HC variable region , No. 163 LC variable region ,EVQLVQSGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELALTQPSVSGSPGQSITISCTGTSSNVGDYNYVSWYQQHPGKAPKLMIYDVTNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSGSTPVVFGGGTKLTVL,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,SSNVGDYNY,DVT,SSYTSGSTPVV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1504/1503)  a) a light chain variable region of seq id no:1503; and b) a binding molecule comprising the heavy chain variable region of seq id no:1504; ,,,,,,,,,, No. 182 HC variable region , No. 182 LC variable region ,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVSVISGSGGSTSNADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKVYCGDDCYPVVGTPGDAFDIWGGGTMVTVSS,ELVLTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,GFTFSDYA,ISGSGGST,AKVYCGDDCYPVVGTPGDAFDI,SSNIGAGYD,GNS,QSYDSSLSGVV,IGHJ3*02 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1240/1239)  a) a light chain variable region of seq id no:1239; and b) a binding molecule comprising a heavy chain variable region of seq id no:1240; ,,,,,,,,,, No. 50 HC variable region , No. 50 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGVTFSRYAINWVRQAPGQGLEWMGGIIPLLGTADYPQKFQGRVTITTDESTTTAYMELSSLRSEDTAVYYCARTLYYYDRSGNARTDDYFDHWAQGTLVTVSS,ELVLTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPWVFGGGTKLTVL,GVTFSRYA,IIPLLGTA,ARTLYYYDRSGNARTDDYFDH,SSNIGAGYD,GNS,QSYDSSLSGPWV,IGHJ1*01 (human),IGHV1-69*05 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1220/1219)  a) a light chain variable region of seq id no:1219; and b) a binding molecule comprising the heavy chain variable region of seq id no:1220; ,,,,,,,,,, No. 40 HC variable region , No. 40 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISGSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK,GDSISGSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYGSSPQT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1268/1267)  a) a light chain variable region of seq id no:1267; and b) a binding molecule comprising a heavy chain variable region of seq id no:1268; ,,,,,,,,,, No. 64 HC variable region , No. 64 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSSSPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELELTQPSVSGSPGQSITISCTGNRSDIGGYNSLSWYQQHPGKAPKLIIYDVNNRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCNSYTSKNTWVFGGGTKVTVL,GFTFSSSSP,ISYDGSNK,AREIALNNYYGMDV,RSDIGGYNS,DVN,NSYTSKNTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1142/1141)  a) a light chain variable region of seq id no:1141; and b) a binding molecule comprising a heavy chain variable region of seq id no:1142; ,,,,,,,,,, No. 1 HC variable region , No.1 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQSSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISSLRSEDEADYYCASWDDRLSALVFGGGTKLTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,ASWDDRLSALV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1480/1479)  a) a light chain variable region of seq id no:1479; and b) a binding molecule comprising the heavy chain variable region of seq id no:1480; ,,,,,,,,,, No. 170 HC variable region , No. 170 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVSS,ELVVTQPPSVSGAPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSGRVFGGGTKVTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,SSNIGSNT,SNN,STWDDSLSGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1290/1289)  a) a light chain variable region of seq id no:1289; and b) a binding molecule comprising a heavy chain variable region of seq id no:1290; ,,,,,,,,,, No. 75 HC variable region , No. 75 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKGLEWVAVISYDGSLKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSCSGGSCFDYWGQGTLVTVSS,ELVVTQEPSLTVSPGGTVTLTCSSSTGAVTRGHFPNWLQQKPGQTPRALIHSTSNKHSWTPARFSGSLLGDKAALTLSGVQPEDEAEYYCLLYDAGAPGWVFGGGTKVTVL,GFTFSSYP,ISYDGSLK,ARDSSCSGGSCFDY,TGAVTRGHF,STS,LLYDAGAPGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV7-43*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1302/1301)  a) a light chain variable region of seq id no:1301; and b) a binding molecule comprising a heavy chain variable region of seq id no:1302; ,,,,,,,,,, No. 81 HC variable region , No. 81 LC variable region ,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTQLTVL,GFTFSSFA,ISFDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1192/1191)  a) a light chain variable region of seq id no:1191; and b) a binding molecule comprising a heavy chain variable region of seq id no:1192; ,,,,,,,,,, No. 26 HC variable region , No. 26 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWMRQAPGQGLEWMGGIIPLFGTAKYAQRFQDRVTFIADDTSTAYMELNSLRSEDTAVYYCARGGWIYRGNWFDPWGQGTLVTVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVGKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKVTVL,GGTFSFYA,IIPLFGTA,ARGGWIYRGNWFDP,SSDVGGYNY,DVG,SSYTSSSTWV,IGHJ5*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1456/1455)  a) a light chain variable region of seq id no:1455; and b) a binding molecule comprising the heavy chain variable region of seq id no:1456; ,,,,,,,,,, No. 158 HC variable region , No. 158 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYGTSPFTFGPGTKVDIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,HQYGTSPFT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1270/1269)  a) a light chain variable region of seq id no:1269; and b) a binding molecule comprising a heavy chain variable region of seq id no:1270; ,,,,,,,,,, No. 65 HC variable region , No. 65 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSSSPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIALNNYYGMDVWGQGTTVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFTFGPGTKVEIK,GFTFSSSSP,ISYDGSNK,AREIALNNYYGMDV,QSVSSSY,GAS,QQYGSSPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1258/1257)  a) a light chain variable region of seq id no:1257; and b) a binding molecule comprising a heavy chain variable region of seq id no:1258; ,,,,,,,,,, No. 59 HC variable region , No. 59 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISGSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTPKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELQMTQSPATLSVSPGEGATLSCRASQSVSSNLAWYQHKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKLEIK,GDSISGSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSN,DAS,QQYNNWPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1296/1295)  a) a light chain variable region of seq id no:1295; and b) a binding molecule comprising the heavy chain variable region of seq id no:1296; ,,,,,,,,,, No. 78 HC variable region , No. 78 LC variable region ,QVQLVQSGAEVKKPGESLKISCKGSGYRFSSNWIAWVRQMPGKGLEWMGIIYPGDSDTRNSPSFQGQVTMSADKSISTAYLQWSSLKASDSAMYYCARLAYFHPQRNGGYEYYFDYWGQGTLVTVSP,ELVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKVTVL,GYRFSSNW,IYPGDSDT,ARLAYFHPQRNGGYEYYFDY,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1444/1443)  a) a light chain variable region of seq id no:1443; and b) a binding molecule comprising the heavy chain variable region of seq id no:1444; ,,,,,,,,,, No. 152 HC variable region , No. 152 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWMGGIIPFLGTANYAQKFQGRVTITADESTRTAYMELSSLRSEDTAMYYCATGKPYYCTGSTCYQPLGPWGQGTLVTVSS,ELQMTQSPSTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFSLSISSLEPEDFAVYYCQQGLTFGGGTKVEIK,GGTFNSYA,IIPFLGTA,ATGKPYYCTGSTCYQPLGP,QSVSSY,DAS,QQGLT,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1152/1151)  a) a light chain variable region of seq id no:1151; and b) a binding molecule comprising a heavy chain variable region of seq id no:1152; ,,,,,,,,,, No. 6 HC variable region , No.6 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDAWGKGTTVTVSS,ELVVTQPPSVSGAPGQRVTISCTGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKVTVL,GYTFTSYY,INRSGGST,ARGGRHSLDA,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1154/1153)  a) a light chain variable region of seq id no:1153; and b) a binding molecule comprising the heavy chain variable region of seq id no:1154; ,,,,,,,,,, No. 7 HC variable region , No.7 LC variable region ,EVQLVQSGAELKKPGSSVRLSCKASGGPFERKVIAWVRQAPGQGLEWVGGHAPFVRKPTYAQKFQGRVTMTADDSTATAFMELSSLGYGDTGVYYCATKAVTTYSGFDNWGQGTLVFVST,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTQLTVL,GGPFERKV,HAPFVRKP,ATKAVTTYSGFDN,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ5*01 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1520/1519)  a) a light chain variable region of seq id no:1519; and b) a binding molecule comprising the heavy chain variable region of seq id no:1520. ,,,,,,,,,, No. 190 HC variable region , No. 190 LC variable region ,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGFINPSDVTTYYAQKFQGRVTMTRDTSTSTVYMELSSLRSDDTAVYFCARSRIAPTEDFFDYWGQGSLVTVSS,ELELTQPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKVTVL,GYTFTSYY,INPSDVTT,ARSRIAPTEDFFDY,NIGSKS,YDS,QVWDSSSDHWV,IGHJ4*01 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1212/1211)  a) a light chain variable region of seq id no:1211; and b) a binding molecule comprising a heavy chain variable region of seq id no:1212; ,,,,,,,,,, No. 36 HC variable region , No. 36 LC variable region ,EVQLVESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADAAVYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTRLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVGSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1174/1173)  a) a light chain variable region of seq id no:1173; and b) a binding molecule comprising the heavy chain variable region of seq id no:1174; ,,,,,,,,,, No. 17 HC variable region , No.17 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSTSNIGSNTVNWYQQLPGTAPKLLIYTDNRRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKLTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,TSNIGSNT,TDN,AAWDDSLNGYV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1230/1229)  a) a light chain variable region of seq id no:1229; and b) a binding molecule comprising a heavy chain variable region of seq id no:1230; ,,,,,,,,,, No. 45 HC variable region , No. 45 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYDISWVRQAPGQGLEWMGGIIPILGIPNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRGYSGYGANWYFDLWGRGTLVTVSS,ELVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEAEYYCQSYDSSLSGPVFGGGTKLTVL,GGTFSSYD,IIPILGIP,ARSRGYSGYGANWYFDL,SSNIGAGYD,GNS,QSYDSSLSGPV,IGHJ2*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*02 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1260/1259)  a) a light chain variable region of seq id no:1259; and b) a binding molecule comprising a heavy chain variable region of seq id no:1260; ,,,,,,,,,, No. 60 HC variable region , No. 60 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIIWVRQTPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVTGYDSSGYYQDYWGQGTLVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKLEIK,GGTFSSYA,IIPIFGTA,ARVTGYDSSGYYQDY,QSVSSY,DAS,QQRSNWPPALT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1410/1409)  a) a light chain variable region of seq id no:1409; and b) a binding molecule comprising the heavy chain variable region of seq id no:1410; ,,,,,,,,,, No. 135 HC variable region , No. 135 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSHKNYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAVYYCARDNCGGDCGGGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCSGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTELTVL,GFTFSSYA,ISYDGSHK,ARDNCGGDCGGGMDV,SSDVGGYNY,DVS,SSYTSSSTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1206/1205)  a) a light chain variable region of seq id no:1205; and b) a binding molecule comprising the heavy chain variable region of seq id no:1206; ,,,,,,,,,, No. 33 HC variable region , No. 33 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGLTFSDYGMHWVRQAPGKGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCVRDSGLYGSGWSTYQYYAMDVWGGGTTVTVSS,ELVLTQSPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKVTVL,GLTFSDYG,ISYDGSNK,VRDSGLYGSGWSTYQYYAMDV,NIGSKS,DDS,QVWDSSSDHVV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ2*01 (human),IGLV3-21*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1340/1339)  a) a light chain variable region of seq id no:1339; and b) a binding molecule comprising a heavy chain variable region of seq id no:1340; ,,,,,,,,,, No. 100 HC variable region , No. 100 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGAPGQRVTISCTGSRSNIGINSVNWYQQLPGTAPKLLIYSNNQRPSGVLDRFSGSKSGTSASLAISELQSEDEADYYCAAWDDSLNGYVFGTGTKLTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,RSNIGINS,SNN,AAWDDSLNGYV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1450/1449)  a) a light chain variable region of seq id no:1449; and b) a binding molecule comprising the heavy chain variable region of seq id no:1450; ,,,,,,,,,, No. 155 HC variable region , No. 155 LC variable region ,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSDYWMSWVRQAPGKGLEWVGNIKEDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYSGNFWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNYVNWYQHLPGTAPKLLIYSNNQRPSGIPDRFSGSKSGTSASLAISGLQSEDEADYFCATWDDSLNGQVFGGGTKVTVL,GFTFSDYW,IKEDGSEK,ARGYSGNF,SSNIGSNY,SNN,ATWDDSLNGQV,IGHJ1*01 (human),IGHV3-7*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1242/1241)  a) a light chain variable region of seq id no:1241; and b) a binding molecule comprising a heavy chain variable region of seq id no:1242; ,,,,,,,,,, No. 51 HC variable region , No. 51 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWVGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVSSY,DAS,QQYGSSPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1518/1517)  a) a light chain variable region of seq id no:1517; and b) a binding molecule comprising a heavy chain variable region of seq id no:1518; and ,,,,,,,,,, No. 189 HC variable region , No. 189 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKTSGGTFSNYPLTWVRQAPGQGLEWLGGIIPIIGATNYAQKFQGRVTITADESTSTAFMELSSLRSEDTAVYYCARGRGYSGYGAAYYFDYWGXGTLVTVSS,ELVLTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSNYP,IIPIIGAT,ARGRGYSGYGAAYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1438/1437)  a) a light chain variable region of seq id no:1437; and b) a binding molecule comprising a heavy chain variable region of seq id no:1438; ,,,,,,,,,, No. 149 HC variable region , No. 149 LC variable region ,QVQLVQSGADVKKPGASVKVSCKASGYAFTSYGTTWVRQAPGQGLEWMGWISGYNENSTHAQKFQGRVTMTTDKSTSTAYMELRSLRSDDTAVYYCARDALRYDILTGFTGFDYWGQGTQVTVSS,ELELTQPSASGTPGQRVTISCSGSSSNVGSNYVYWYQQLPGTAPKLLIYRNSQRPSGVPARFSGSKSGTSASLVISGLRSEDEADYYCAAWDDSLSGWMFGGGTQLTVL,GYAFTSYG,ISGYNENS,ARDALRYDILTGFTGFDY,SSNVGSNY,RNS,AAWDDSLSGWM,IGHJ4*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1306/1305)  a) a light chain variable region of seq id no:1305; and b) a binding molecule comprising the heavy chain variable region of seq id no:1306; ,,,,,,,,,, No. 83 HC variable region , No. 83 LC variable region ,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGPNIYNWFDSWGQGTLVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKVTVL,GYSFTSYW,IYPGDSDT,ARGPNIYNWFDS,SSNIGSNT,NNN,AAWDDSLNGVV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1288/1287)  a) a light chain variable region of seq id no:1287; and b) a binding molecule comprising a heavy chain variable region of seq id no:1288; ,,,,,,,,,, No. 74 HC variable region , No. 74 LC variable region ,QVQLQESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSHKNYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAVYYCARDNCGGDCGGGMDVWGQGTTVTVSS,ELALTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTELTVL,GFTFSSYA,ISYDGSHK,ARDNCGGDCGGGMDV,SSDVGGYNY,DVS,SSYTSSSTWV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1238/1237)  a) a light chain variable region of seq id no:1237; and b) a binding molecule comprising a heavy chain variable region of seq id no:1238; ,,,,,,,,,, No. 49 HC variable region , No. 49 LC variable region ,EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASGVVTADWYFDLWGRGTLATVSS,ELELTQPSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSPWVFGGGTKVTVL,GFTFSSYA,ISGSGGST,ASGVVTADWYFDL,SSDVGGYNY,DVS,SSYTSSSPWV,IGHJ2*01 (human),IGHV3-23*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1248/1247)  a) a light chain variable region of seq id no:1247; and b) a binding molecule comprising a heavy chain variable region of seq id no:1248; ,,,,,,,,,, No. 54 HC variable region , No. 54 LC variable region ,EVQLLESGGGLVQPGRSLRLSCAASGFNFDDYAMHWVRQAPGKGLEWVSGISWNSGTIGYADSVKGRFIISRDNAKNSLYLQMRSLKPEDTALYYCAKEELGPYSNRWYSSSSDGMDVWGGGTTVTVSS,ELVLTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,GFNFDDYA,ISWNSGTI,AKEELGPYSNRWYSSSSDGMDV,SSNIGAGYD,GNS,QSYDSSLSGVV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1344/1343)  a) a light chain variable region of seq id no:1343; and b) a binding molecule comprising a heavy chain variable region of seq id no:1344; ,,,,,,,,,, No. 102 HC variable region , No. 102 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSNSNIGNNFVSWYQQLPGTAPKLLIYDNNVRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCAAWDTSLSSWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,NSNIGNNF,DNN,AAWDTSLSSWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1384/1383)  a) a light chain variable region of seq id no:1383; and b) a binding molecule comprising the heavy chain variable region of seq id no:1384; ,,,,,,,,,, No. 122 HC variable region , No. 122 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELELTQPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGTVFGGGTKVTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AAWDDSLNGTV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1472/1471)  a) a light chain variable region of seq id no:1471; and b) a binding molecule comprising the heavy chain variable region of seq id no:1472; ,,,,,,,,,, No. 166 HC variable region , No. 166 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISGSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAMYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK,GDSISGSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSY,DAS,QQYGSSPQT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1368/1367)  a) a light chain variable region of seq id no:1367; and b) a binding molecule comprising a heavy chain variable region of seq id no:1368; ,,,,,,,,,, No. 114 HC variable region , No. 114 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELELTQPSVSAAPGRKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSAWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,RNN,AAWDDSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1180/1179)  a) a light chain variable region of seq id no:1179; and b) a binding molecule comprising the heavy chain variable region of seq id no:1180; ,,,,,,,,,, No. 20 HC variable region , No.20 LC variable region ,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQSPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGPVFGGGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGPV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1508/1507)  a) a light chain variable region of seq id no:1507; and b) a binding molecule comprising a heavy chain variable region of seq id no:1508; ,,,,,,,,,, No. 184 HC variable region , No. 184 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNFYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYFCARQEWLRGGFDDWGQGTLVTVSS,ELMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKVTVL,GGSISSSSYY,FYYSGST,ARQEWLRGGFDD,SGSIASNY,EDN,QSYDSSNWV,IGHJ5*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV6-57*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1482/1481)  a) a light chain variable region of seq id no:1481; and b) a binding molecule comprising the heavy chain variable region of seq id no:1482; ,,,,,,,,,, No. 171 HC variable region , No. 171 LC variable region ,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQDRVTITADESTSTAYMELSSLRSEDTAVYYCARDGVVVPAVMYDTTDPYYYGMDVWGQGTTVTVPS,ELELTQPSVSGTPGQGVTISCSGLTSNIGSNFVYWYQQLPGTAPKLLIYRNNERPSGVPDRFSGSKSGTSASLAISGLRSEDEGEYFCAAWDDTLVGRVFGGGTQLTVL,GGTFSSYA,IIPIFGTA,ARDGVVVPAVMYDTTDPYYYGMDV,TSNIGSNF,RNN,AAWDDTLVGRV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ7*01 (human),IGLV1-47*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1400/1399)  a) a light chain variable region of seq id no:1399; and b) a binding molecule comprising a heavy chain variable region of seq id no:1400; ,,,,,,,,,, No. 130 HC variable region , No. 130 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGAMFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPTGWYSGYFDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPVQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPITFGXGTKVEIK,GAMFSSYA,IIPIFGTT,ARDPTGWYSGYFDY,QSVSSY,DAS,QQYGSSPPIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1376/1375)  a) a light chain variable region of seq id no:1375; and b) a binding molecule comprising the heavy chain variable region of seq id no:1376; ,,,,,,,,,, No. 118 HC variable region , No. 118 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSSIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKVTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSSIGNNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1502/1501)  a) a light chain variable region of seq id no:1501; and b) a binding molecule comprising the heavy chain variable region of seq id no:1502; ,,,,,,,,,, No. 181 HC variable region , No. 181 LC variable region ,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVSVISGSGGSTSNADSVKGRFTISRDNSKSTLYLQMNSLRTEDTAVYYCAKVYCGDDCYPVVGTPGDAFDIWGGGTMVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLRAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GFTFSDYA,ISGSGGST,AKVYCGDDCYPVVGTPGDAFDI,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ3*02 (human),IGHV3-23*04 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1194/1193)  a) a light chain variable region of seq id no:1193; and b) a binding molecule comprising a heavy chain variable region of seq id no:1194; ,,,,,,,,,, No. 27 HC variable region , No. 27 LC variable region ,QVQLVQSGAEVKKPGATVKVSCKASGYTFNNYGISWVRQAPGQGLEWMGGISSHNGNTKYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGGYYYGSGSYYNPRFAFDIWGQGTMVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVLGGGTKLTVL,GYTFNNYG,ISSHNGNT,AREGGYYYGSGSYYNPRFAFDI,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ3*02 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1148/1147)  a) a light chain variable region of seq id no:1147; and b) a binding molecule comprising a heavy chain variable region of seq id no:1148; ,,,,,,,,,, No. 4 HC variable region , No.4 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,GYTFTSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1256/1255)  a) a light chain variable region of seq id no:1255; and b) a binding molecule comprising a heavy chain variable region of seq id no:1256; ,,,,,,,,,, No. 58 HC variable region , No. 58 LC variable region ,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGRGTLVTVSS,ELALTQPSVSGSPGQSITIPCTGTSSDVGGYSHVSWYQQHPGKAPKLILYEVSDRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSSSTWVFGGGTQLTVL,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,SSDVGGYSH,EVS,NSYTSSSTWV,IGHJ2*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV2-14*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1178/1177)  a) a light chain variable region of seq id no:1177; and b) a binding molecule comprising a heavy chain variable region of seq id no:1178; ,,,,,,,,,, No. 19 HC variable region , No.19 LC variable region ,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTALYYCARGRYSSNWYEAWTPRGIGMDVWGGGTTVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAARDDSLNGAVFGGGTKVTVL,GGSFSGYY,INHSGST,ARGRYSSNWYEAWTPRGIGMDV,SSNIGSNT,SNN,AARDDSLNGAV,IGHJ6*01 (human),IGHV4-34*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1244/1243)  a) a light chain variable region of seq id no:1243; and b) a binding molecule comprising a heavy chain variable region of seq id no:1244; ,,,,,,,,,, No. 52 HC variable region , No. 52 LC variable region ,EVQLVESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLNLSSATAADTAVYYCARGSRGYYDFLTGYSTGGFDYWGQGTLVAVSS,ELVMTQSPATLSVSPGERATLSCRASQSVNSNLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKLEIK,GDSISSSSYY,IYYSGST,ARGSRGYYDFLTGYSTGGFDY,QSVNSN,DAS,QQYNNWPLT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1394/1393)  a) a light chain variable region of seq id no:1393; and b) a binding molecule comprising the heavy chain variable region of seq id no:1394; ,,,,,,,,,, No. 127 HC variable region , No. 127 LC variable region ,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYHCVRVGTYDSSGYSFDYWGQGTLVTVSS,ELTLTQSPGTLSLSPGERATLSCRASQSVSSFLAWYQQKPGQPPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPSITFGXGTRLEIK,GGTFSSYA,IIPIFGTA,VRVGTYDSSGYSFDY,QSVSSF,DAS,QQRSNWPPSIT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1364/1363)  a) a light chain variable region of seq id no:1363; and b) a binding molecule comprising the heavy chain variable region of seq id no:1364; ,,,,,,,,,, No. 112 HC variable region , No. 112 LC variable region ,QVQLVQSGAEVKKPGASVKVSCKASGYTFSSYYMHWVRQAPGQGLEWMGIINRSGGSTIYAQTFQGRVTMTRDTSTSTVYMEMSSLTSEDTAVYYCARGGRHSLDVWGKGTTVTVSS,ELVVTQPPVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYVFGTGTKLTVL,GYTFSSYY,INRSGGST,ARGGRHSLDV,SSNIGNNY,DNN,GTWDSSLSAYV,IGHJ6*04 (human),IGHV1-46*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1218/1217)  a) a light chain variable region of seq id no:1217; and b) a binding molecule comprising a heavy chain variable region of seq id no:1218; ,,,,,,,,,, No. 39 HC variable region , No. 39 LC variable region ,EVQLVESGGGVVQPGRSLRLSCAASGLTFSDYGMHWVRQAPGKGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDSGLYGSGWSTYQYYAMDVWGGGTTVTVSS,ELELTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGGEADYYCGTWDSSLSAGWVFGGGTKVTVL,GLTFSDYG,ISYDGSNK,ARDSGLYGSGWSTYQYYAMDV,SSNIGNNY,DNN,GTWDSSLSAGWV,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1214/1213)  a) a light chain variable region of seq id no:1213; and b) a binding molecule comprising a heavy chain variable region of seq id no:1214; ,,,,,,,,,, No. 37 HC variable region , No. 37 LC variable region ,EVQLVQSGAEVKKPGESLKISCRGSGYSFTSHWIAWVRQMPGKGLEWMGIIYPGDSDSRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARGPNLYNWFDSWGQGTLVTVSS,ELVLTQPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYTNNRRPSGAPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGLVFGGGTKVTVL,GYSFTSHW,IYPGDSDS,ARGPNLYNWFDS,SSNIGSNT,TNN,AAWDDSLNGLV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1470/1469)  a) a light chain variable region of seq id no:1469; and b) a binding molecule comprising a heavy chain variable region of seq id no:1470; ,,,,,,,,,, No. 165 HC variable region , No. 165 LC variable region ,EVQLLESGPGLVKPSETLSLTCTVSGDSISSSSYYWGWIRQPPGKGLEWIGNIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSRGYYDILTGYSTGGFDYWGXGTLVTVSS,ELVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLAFGGGTKLEIK,GDSISSSSYY,IFYSGST,ARGSRGYYDILTGYSTGGFDY,QSVSSSY,GAS,QQYGSSPLA,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220013344A/en,(1236/1235)  a) a light chain variable region of seq id no:1235; and b) a binding molecule comprising a heavy chain variable region of seq id no:1236; ,,,,,,,,,, No. 48 HC variable region , No. 48 LC variable region ,EVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQPPGKGLEWVSVIYPGGSTFFADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSYDFLTDYTDAFDIWGQGTMVTVSS,ELELTQPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGLWVFGGGTKLTVQ,GFTVSSNY,IYPGGST,ARSYDFLTDYTDAFDI,SSNIGAGYD,GNS,QSYDSSLSGLWV,IGHJ3*02 (human),IGHV3-53*03 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113683686A/en,"(15/21) in another preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:15, and the amino acid sequence of the light chain variable region of the antibody is shown in seq id no:21.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLQESGPSLVKPSQTLSLTCSVTGDSITNGYWNWIRKFPGNKLEYMGYISYSGSTYYSPSLKSRISITRDTSKNQHYLQLNSVTSEDTATYYCASDYHGSKYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGHRVSITCKASQDVGNDVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNRYPYTFGGGTKLEIK,GDSITNGY,ISYSGST,ASDYHGSKYYFDY,QDVGND,WAS,QQYNRYPYT,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113683686A/en,"(3/9) in another preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown as seq id no:3, and the amino acid sequence of the light chain variable region of the antibody is shown as seq id no:9.",,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),QVQLKQSGPSLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVMWRGGNTDYNAAFMSRLSITKDNSKSQVFFKMNSLQTDDTAIYYCAKNGGAHAMDFWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,GFSLTSYG,MWRGGNT,AKNGGAHAMDF,ESVDSYGNSF,LAS,QQNNEDPFT,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
Patent,https://patents.google.com/patent/CN111995674A/en,"(7/8) the heavy chain amino acid sequence of the human-mouse chimeric whole antibody mhc3 is shown as seq id no:7, and the light chain amino acid sequence is shown as seq id no:8.",,,,,,,,,,  Artificial sequence,  Artificial sequence,EVQLVESGGDLVKPGGSLKLSCAASGFTFNTYAMNWVRQTPGKGLEWVARIRSKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVTPYYGNYADWFTYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,GFTFNTYA,IRSKSNNYAT,VTPYYGNYADWFTY,QSLVHSNGNTY,KVS,SQSTHVPYT,IGHJ2*02 (mouse),IGHV10-1*02 (mouse),IGKJ2*01 (mouse),IGKV1-110*01 (mouse)
Patent,https://patents.google.com/patent/CN111995674A/en,"(11/12) in one embodiment of the invention, the recombinant expression vector for expressing the heavy chain of the antibody is obtained by cloning seq id no:11 (encoding gene of the heavy chain of the antibody) between enzyme cutting sites hind iii and bamh i of pcdna3.1(+) vector; cloning seq id no:12 (coding gene of antibody light chain) between enzyme cutting site hind iii and bamh i of pcdna3.1(+) vector to obtain recombinant expression vector for expressing the light chain of the antibody",,,,,,,,,,  Artificial sequence,  Artificial sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN114044821A/en,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5.",,,,,,,,,, Homo sapiens, Homo sapiens,EVQLVESGGALVQPGGSLRLSCAASGFTFANYAMSWVRQAPGKGLEWVSSMTGSSIDSYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCAKGELLWFGDLLHNWFDPWGRGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASQSVSTNLAWYQQKPGQAPRLLIHGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYDSWPGTFGPGTKVDIK,GFTFANYA,MTGSSIDS,AKGELLWFGDLLHNWFDP,QSVSTN,GAS,QQYDSWPGT,IGHJ2*01 (human),IGHV3-23*04 (human),IGKJ3*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN112521494B/en,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVESGGGLVQPGGSLRLSCAASEITVSSNYMNWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDLMEVGGMDVWGQGTTVTVSS,LPVLTQPPSASGTPGQRVTISCSGSSSNVENDNVNWFQQQVPGSTPKLVIYNDRLRPSGVPDRFSGSKSGTSAYLAISGLQSEDEADYYCVAWDASLQSYVFGTGTKVTVL,EITVSSNY,IYSGGTT,ARDLMEVGGMDV,SSNVENDN,NDR,VAWDASLQSYV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113999302A/en,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8.",,,,,,,,,, VH, VL,SVEESGGRLVTPGTPLTLTCTASGFSPSSYGMSWVRQAPGKGLEWIGYINIEDYAYYAPWAKGRFTISKTSSTTVDLKVTSPTTEDTATYFCGRGGYAADIWGPGTLVTVSS,DVVMTQTASPVSAAVGGTVTISCQSSESVYTNNRLSWFQQKPGQRPKLLIYRASKLASGVPSRFSGSGSGTQFTLIISDVQCDDAATYYCAGVGSGGTDIAFGGGTKVEIK,GFSPSSYG,INIEDYA,GRGGYAADI,ESVYTNNR,RAS,AGVGSGGTDIA,IGHJ2*01 (human),IGHV3-33*02 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
Patent,https://patents.google.com/patent/CN113999302A/en,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18.",,,,,,,,,, VH, VL,EVQLVESGGGLVKPGGSLKLSCAASGITFSDYYMYWVRQTPEKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCVRDKSMGFGAWFAYWGQGTLVTVSA,EIVLTQSPTTMAASPGEKITITCSASSSISSNYLHWYQQRPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGHSIPYTFGGGTKLEIK,GITFSDYY,ISDGGSYT,VRDKSMGFGAWFAY,SSISSNY,RTS,QQGHSIPYT,IGHJ3*01 (mouse),IGHV5-4*02 (mouse),IGKJ2*01 (mouse),IGKV4-91*01 (mouse)
Patent,https://patents.google.com/patent/KR20220010456A/en,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising ",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN113045647A/en,"(18/22) in some embodiments, the antibody is a fab, wherein the vl amino acid sequence of the fab is set forth in seq id no:22, and the vh amino acid sequence of the fab is set forth in seq id no:18.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGFNIYSSYMHWVRQAPGKGLEWVASISPSYSYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYSYYGMDYWGQGTLVTVS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQPPWHGLITFGQGTKVEIK,GFNIYSSY,ISPSYSYT,ARYSYYGMDY,QSVSSA,SAS,QQPPWHGLIT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111995676B/en,"(1/5) the monoclonal antibody against non-rbd region of the spinous protein of a neocoronavirus according to claim 1, wherein: the amino acid sequence of the heavy chain variable region of the monoclonal antibody is seq id no:1, the amino acid sequence of the light chain variable region of the monoclonal antibody is seq id no:5.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYITNNGANTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYATFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYNASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAAYYPTTFGQGTKVEIK,GFTFSSYA,ITNNGANT,AKSYATFDY,QSISSY,NAS,QQAAYYPTT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN112062840A/en,"(1) the nanobody based on the s protein of coronavirus of claim 1, characterized in that: the nucleotide sequence of the expression cassette sequence of the nano antibody is shown in seq id no:1.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112062840A/en,"(2) a nanobody based on the s protein of a novel coronavirus, characterized in that: the amino acid sequence of the expression cassette sequence of the nano antibody is shown in seq id no:2.",,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLQESGGGLVQAGGSLRLSCAASGRTFSSNAMGWFRQAPGKEREFVAAISSGSGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAAYRYNGRDYYDRYDYWGQGTQVTVSS,,GRTFSSNA,ISSGSGST,AAAYRYNGRDYYDRYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113173995A/en,(4/3) the sequence of the variable region vl-2 of the light chain of the scfv-2 is shown as seq id no:3; the sequence of the heavy chain variable region vh-2 of the scfv-2 is shown as seq id no:4.,,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYMHWVRQAPGQGLEWMGWINPNSGGANYAQKFQGRVTLTRDTSITTVYMELSRLRFDDTAVYYCARGSRYDWNQNNWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNYVSWYQQHPGKAPKLMIFDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSFTTSSTVVFGGGTKLTVL,GYIFTGYY,INPNSGGA,ARGSRYDWNQNNWFDP,SSDVGTYNY,DVS,SSFTTSSTVV,IGHJ5*02 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
Patent,https://patents.google.com/patent/CN113173995A/en,"(2/1) wherein the sequence of the variable region vl-1 of the light chain of the scfv-1 is shown in seq id no:1, and the sequence of the variable region vh-1 of the heavy chain of the scfv-1 is shown in seq id no:2",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGVVQPGGSLRLSCAASGFRFDDHAMHWVRQAPGKGLEWVSVISGDGGSTYYADSVKGRFSISRDDSKNSLYLQMNSLRTEDTALYYCAKDRSYGPPDVFNYEYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNWVFGGGTKLTVL,GFRFDDHA,ISGDGGST,AKDRSYGPPDVFNYEYGMDV,SSNIGSNT,SNN,AAWDDSLNWV,IGHJ6*01 (human),IGHV3-43*02 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113501872A/en,"(8/7) preferably, the amino acid sequence of the light chain variable region of the antibody sk1 is shown as seq id no:7, and the amino acid sequence of the heavy chain variable region is shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGRSLRLSCAASGFIFDDYAMHWVRQAPGKGLEWVSGISWNSGTIGYADSVKGRFIISRDNAKNSLYLQLNRLGVEDTALYYCVKDIYYRDRNLGFAFDIWGQGTMVTVSS,DIQLTQSPSSLSASIGDTVTITCRASQSIDNYLHWYQKKPGIAPKLLISATSTLENGVPSRFSGSRSGTDFTLTISSLQIEDFATYYCQQGHSVPLTFGGGTKLEVR,GFIFDDYA,ISWNSGTI,VKDIYYRDRNLGFAFDI,QSIDNY,ATS,QQGHSVPLT,IGHJ3*02 (human),IGHV3-9*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(37/39) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:37, and the amino acid sequence of the light chain is identical to that of seq id no:39 are shown as being identical.",,,,,,,,,, R157 heavy chain full length-IgG1(Artificial Sequence), R157 light chain full length(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREQGYSGSGANYYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTVSCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREQGYSGSGANYYFDY,SSNIGAGYD,GNT,QSYDSSLSDVV,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(27/25) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent.",,,,,,,,,, R157 light chain variable(Artificial Sequence), R157 heavy chain variable(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREQGYSGSGANYYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTVSCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREQGYSGSGANYYFDY,SSNIGAGYD,GNT,QSYDSSLSDVV,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(19/17) in a preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical.",,,,,,,,,, R14 light chain variable(Artificial Sequence), R14 heavy chain variable(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREIGYSSSGSNYYMDVWGKGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,GGTFSSYT,IIPILGIA,AREIGYSSSGSNYYMDV,SSNIGAGYD,GNS,QSYDSSLSGVV,IGHJ6*04 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(17/19) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical.",,,,,,,,,, R14 heavy chain variable(Artificial Sequence), R14 light chain variable(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREIGYSSSGSNYYMDVWGKGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,GGTFSSYT,IIPILGIA,AREIGYSSSGSNYYMDV,SSNIGAGYD,GNS,QSYDSSLSGVV,IGHJ6*04 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(33/35) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:33, and the amino acid sequence of the light chain is identical to that of seq id no:35 are shown as being identical.",,,,,,,,,, R44 heavy chain full length-IgG1(Artificial Sequence), R44 light chain full length(Artificial Sequence),QVQLVQSGGGLVQPGGSLRLSCAASEITVSSNYMSWVRQAPGKGLEWVSVLYSGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVYGMDVWGQGTTVTVSS,DIVLTQTPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQELSTYPVTFGQGTKVEIK,EITVSSNY,LYSGGST,AREVYGMDV,QGISSY,AAS,QELSTYPVT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(21/23) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement.",,,,,,,,,, R44 heavy chain variable(Artificial Sequence), R44 light chain variable(Artificial Sequence),QVQLVQSGGGLVQPGGSLRLSCAASEITVSSNYMSWVRQAPGKGLEWVSVLYSGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVYGMDVWGQGTTVTVSS,DIVLTQTPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQELSTYPVTFGQGTKVEIK,EITVSSNY,LYSGGST,AREVYGMDV,QGISSY,AAS,QELSTYPVT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(29/31) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:29, and the amino acid sequence of the light chain is identical to that of seq id no:31 are shown as being identical.",,,,,,,,,, R14 heavy chain full length-IgG1(Artificial Sequence), R14 light chain full length(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREIGYSSSGSNYYMDVWGKGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,GGTFSSYT,IIPILGIA,AREIGYSSSGSNYYMDV,SSNIGAGYD,GNS,QSYDSSLSGVV,IGHJ6*04 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(25/27) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent.",,,,,,,,,, R157 heavy chain variable(Artificial Sequence), R157 light chain variable(Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREQGYSGSGANYYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTVSCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVVFGGGTQLTVL,GGTFSSYA,IIPILGIA,AREQGYSGSGANYYFDY,SSNIGAGYD,GNT,QSYDSSLSDVV,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113956352A/en,"(23/21) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement.",,,,,,,,,, R44 light chain variable(Artificial Sequence), R44 heavy chain variable(Artificial Sequence),QVQLVQSGGGLVQPGGSLRLSCAASEITVSSNYMSWVRQAPGKGLEWVSVLYSGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVYGMDVWGQGTTVTVSS,DIVLTQTPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQELSTYPVTFGQGTKVEIK,EITVSSNY,LYSGGST,AREVYGMDV,QGISSY,AAS,QELSTYPVT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113683692A/en,"(15/16) the heavy chain variable region of b is shown as seq id no:15, and the light chain variable region is shown as seq id no:16.",,,,,,,,,, artificial sequence, artificial sequence,QVQLQQPEAELMKPGASVKISCKATGYTFTSYAIEWVKQRPGKGLEWIGVISTGNGSNDKFKGKATMTVTSSNTAYMQLARLTSEDSAVYYCARGGIHYFGFYAYFAYWGQGTLVTVSA,DIVLSQSPASLAVSLGEKVTMSCSITCKASQDVGTAWYQQKPGQSPKLLIYIYSTRESQTGVPDRFTGSGSGTDFTLTISSVEASDYAVYCQQYYSYPPTFGGGTKLEIK,GYTFTSYA,ISTGN,ARGGIHYFGFYAYFAY,QDVG,IYSTR,QQYYSYPPT,IGHJ3*01 (mouse),IGHV1-55*01 (mouse),IGKJ1*02 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN113683692A/en,"(13/14) in some embodiments, the heavy chain variable region of a is as set forth in seq id no:13 and the light chain variable region is as set forth in seq id no:14.",,,,,,,,,, artificial sequence, artificial sequence,QVQLQQPGPELVKPGASVKISCKAGSGYTFTDYWMHWVKQRPGHGLEWIGWIQTETGDPTYFKGRFAFTLETSATAYMQLSNLKNEDTATYYCARGSDYGYAMDYWGQGTLVTVSA,DIVMTQSPSSLAVSVGQRATISCKTSASLLYSSNQKNYLAVAWYQQKPGQSPKLLWYWESTQHTGVPDRFTGSGSGTDFTLTISTVQSEDYADYFCQQYSSYPLTFGAGTKLELK,SGYTFTDYW,IQTETGDP,ARGSDYGYAMDY,ASLLYSSNQKNYLA,WES,QQYSSYPLT,IGHJ3*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ5*01 (mouse),IGKV8-24*01 (mouse)
Patent,https://patents.google.com/patent/CN112940087A/en,(27/28) the sequencing results were as follows: the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody are respectively shown in seq id no:27 and seq id no:28,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVKLQESGGGLVKPGGSLKLSCAASGFTFSNYSMSWVRQTPEKRLEWVATISNGGGYIYYLDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCGRPRPEKEFISTSTAMDHWGQGTTVT,DIVMSQSPSSLAVSVEVTMSCKSSQSLLYSSYQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIK,GFTFSNYS,ISNGGGYI,GRPRPEKEFISTSTAMDH,QSLLYSSYQKNY,WAS,QQYYSYPFT,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ4*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN111518202B/en,"(4/8) the monoclonal antibody of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGSGSYYWGSLDYWGQGTLVTVSS,ENVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPWTFGQGTKVEIK,GFTFSSYG,IWYDGSNK,ARDGSGSYYWGSLDY,QSVSSY,GAS,QQRSNWPWT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN111518202B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113583114A/en,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2.",,,,,,,,,, amino acid sequence of 3C11 heavy chain variable region (VH), 3C11 light chain variable region (VL) amino acid sequence,EVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLVASYRYGMDVWGQGTTVTVSS,DIQMTQSPVSLSASIGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDNLPVTFGGGTKVEIK,GFTVSRNY,IYSGGST,ARGLVASYRYGMDV,QDITNY,DAS,HQYDNLPVT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/CN113583114A/en,"(9/10) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:9 and a vl comprising the sequence shown as seq id no:10.",,,,,,,,,, amino acid sequence of heavy chain variable region (VH) of 5C6, 5C6 light chain variable region (VL) amino acid sequence,EVQLVESGGGVVQPGRSLRLSCAASGFTFRTYAMHWVRQAPGKGLEWVAVMWNDGSNKYYADSVKGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCAREGVAAAGSSSDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLYSFGQGTKLEIK,GFTFRTYA,MWNDGSNK,AREGVAAAGSSSDAFDI,QSISNF,AAS,QQSYSTLYS,IGHJ3*02 (human),IGHV3-30*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113583114A/en,"(17/18) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18.",,,,,,,,,, 6G9 amino acid sequence of heavy chain variable region (VH), 6G9 light chain variable region (VL) amino acid sequence,QVQLVQSGAEVKKLGASVKVSCKASGYSFTDYYIHWVRQAPGQGLEWMGWINPISGGTNYAQKFQGRVTMTRDTSITTVYMELSRLRSDDTAVYYCARDLPPYNWNGPLRSQRFDCWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLPFTFGPGTKVDIK,GYSFTDYY,INPISGGT,ARDLPPYNWNGPLRSQRFDC,QDISNY,DAS,QHYDNLPFT,IGHJ5*01 (human),IGHV1-2*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/CN112979792B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112538111A/en,"(2/1) a new coronavirus single-chain antibody sequentially comprises a light chain variable region and a heavy chain variable region from an n section to a c end, wherein the amino acid sequence of the light chain variable region is shown as seq id no:1, and the amino acid sequence of the heavy chain variable region is shown as seq id no:2.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWMGWINTETGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARGSDYYAMDYWGQGTSVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPPTFGGGTKLEIK,GYTFTDYS,INTETGEP,ARGSDYYAMDY,QSLLYSSNQKNY,WAS,QQYYSYPPT,IGHJ4*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ1*02 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN113527472A/en,"(10/9) antibody or fragment thereof specific for the sars-cov-2s protein according to claim 6 or 7, wherein the heavy chain variable region of the antibody or fragment thereof is identical to the heavy chain variable region of seq id no:10 has a sequence homology of 70% or more; the light chain variable region is identical to seq id no:9 has a sequence homology of 70% or more.",,,,,,,,,, MW07-HL, MW07-VL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDASEKYYLDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLGILWFGDYPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSTPRTFGQGTKVEIK,GFTFSSYW,IKQDASEK,ARDLGILWFGDYP,QGISNS,AAS,QQFYSTPRT,IGHJ5*02 (human),IGHV3-7*01 (human),IGKJ1*01 (human),IGKV1-NL1*01 (human)
Patent,https://patents.google.com/patent/CN112409479A/en,"(2/1) the amino acid sequences of the variable regions of the light chain and the heavy chain of antibody ncov-121 are shown as seq id no:1 and 2, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVQSGGGLVQPGRSLTLSCGASGFTFEDYAMHWVRQAPGKGLEWVSGIDWNSGVIGYADSVKGRFIISRDNAKNSLYLHMRSLTAEDTALYYCAKDVYSESGSGSYYDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQWVFGGGTKLTVL,GFTFEDYA,IDWNSGVI,AKDVYSESGSGSYYDY,SGSIASNY,EDN,QSYDSSNQWV,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ3*02 (human),IGLV6-57*01 (human)
Patent,https://patents.google.com/patent/KR101828794B1/en,"(7/8)  in one embodiment of the invention, the antibody comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8.",,,,,,,,,, Heavy chain variable region, Light chain variable region,SSSSSSSSSSSSSKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPIDAVAFDIWGQGTMVTVSS,ELVLTQPPSASGTPGQRVNISCSGSSSNVGSNAVTWYQQVPGTAPKLLIYNNSKRPSGVPDRFSGSKSGTSASLAISGLQSEEEADYYCAAWDDSLNGPVFGGGTKVTVL,,SSSSSSS,ARAPIDAVAFDI,SSNVGSNA,NNS,AAWDDSLNGPV,IGHJ3*02 (human),IGHV3-11*03 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN111690058B/en,(3/4)  a heavy chain variable region comprising the sequence of seq id no:3 and a light chain variable region comprising the sequence of seq id no:4.,,,,,,,,,, antibody P17-A11 VH sequence, antibody P17-A11 VL sequence,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111690058B/en,(1/2) (a) a heavy chain variable region comprising the sequence of seq id no:1 and a light chain variable region comprising the sequence of seq id no:2,,,,,,,,,, antibody P16-A3 VH sequence, antibody P16-A3 VL sequence,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAYSSSWLLQSFYYYGMDVWGQGTTVTVSS,NIQLTQSPVSLSASVGDRVTLTCRASQGIGYSLVWYQKKPGTAPKLLIFDASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQVIHYPLTFGGGTKVEIK,GFTFSSYG,ISYDGSNK,ARAYSSSWLLQSFYYYGMDV,QGIGYS,DAS,QQVIHYPLT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
Patent,https://patents.google.com/patent/CN111690058B/en,"(19/20)  the heavy chain sequence of seq id no:19, and the light chain sequence of seq id no:20.",,,,,,,,,, antibody P17-A11 HC, antibody P17-A11 LC,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN111690058B/en,"(17/18) (a) the heavy chain sequence of seq id no:17, and the light chain sequence of seq id no:18",,,,,,,,,, antibody P16-A3 HC, antibody P16-A3 LC,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAYSSSWLLQSFYYYGMDVWGQGTTVTVSS,NIQLTQSPVSLSASVGDRVTLTCRASQGIGYSLVWYQKKPGTAPKLLIFDASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQVIHYPLTFGGGTKVEIK,GFTFSSYG,ISYDGSNK,ARAYSSSWLLQSFYYYGMDV,QGIGYS,DAS,QQVIHYPLT,IGHJ6*01 (human),IGHV3-30*03 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(126/125)  a) the light chain variable region set forth in seq id no:125; and b) an antibody comprising the heavy chain variable region set forth in seq id no:126; ,,,,,,,,,, No. 9 HC variable region, No. 9 LC variable region,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSNSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSSSKSGTSATLGITGLQTGDEADYYCGTWDNNLSAGVFGTGTKVTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,NSNIGNNY,DNN,GTWDNNLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(120/119)  a) the light chain variable region set forth in seq id no:119; and b) an antibody comprising the heavy chain variable region set forth in seq id no:120; ,,,,,,,,,, No. 6 HC variable region, No. 6 LC variable region,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(128/127)  a) the light chain variable region set forth in seq id no:127; and b) an antibody comprising the heavy chain variable region set forth in seq id no:128; ,,,,,,,,,, No. 10 HC variable region, No. 10 LC variable region,EVQLVESGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNVWVFGGGTKVTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNVWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(110/109)  a) the light chain variable region set forth in seq id no:109; and b) an antibody comprising the heavy chain variable region set forth in seq id no:110; ,,,,,,,,,, No. 1 HC variable region, No. 1 LC variable region,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLVSGRYCSGVTCYSWFDPWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTRLEIK,GFTFSSYA,ISGSGGST,AKSLVSGRYCSGVTCYSWFDP,QDISNY,DAS,QQYDNLPIT,IGHJ5*02 (human),IGHV3-23*04 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(114/113)  a) the light chain variable region set forth in seq id no:113; and b) an antibody comprising the heavy chain variable region set forth in seq id no:114; ,,,,,,,,,, No. 3 HC variable region, No. 3 LC variable region,QITLKESGPTLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPRQKVTISCSGSSSNIGDNYVSWYQQFPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTQLTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGDNY,DND,GTWDSSLSAVV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(118/117)  a) the light chain variable region set forth in seq id no:117; and b) an antibody comprising the heavy chain variable region set forth in seq id no:118; ,,,,,,,,,, No. 5 HC variable region, No. 5 LC variable region,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGVDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGRFGGGTKLTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGVDV,SSNIGNNY,DNN,GTWDSSLSAGR,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(116/115)  a) the light chain variable region set forth in seq id no:115; and b) an antibody comprising the heavy chain variable region set forth in seq id no:116; ,,,,,,,,,, No. 4 HC variable region, No. 4 LC variable region,QITLKESGPTLVKPSQTLTLTCTFSGFSLTTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLTTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(136/135)  a) the light chain variable region set forth in seq id no:135; and b) an antibody comprising the heavy chain variable region set forth in seq id no:136; ,,,,,,,,,, No. 14 HC variable region, No. 14 LC variable region,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELVLTQPPSASGTPGQRVTISCSGSSSNIGSKAVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKVTVL,GFTFSSFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSKA,SNN,ATWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(132/131)  a) the light chain variable region set forth in seq id no:131; and b) an antibody comprising the heavy chain variable region set forth in seq id no:132; ,,,,,,,,,, No. 12 HC variable region, No. 12 LC variable region,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVRGYSGYGSTYYSDYWGQGTLVTVSS,ELELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSSYA,IIPILGIA,ARVRGYSGYGSTYYSDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*04 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(138/137)  a) the light chain variable region set forth in seq id no:137; and b) an antibody comprising the heavy chain variable region set forth in seq id no:138; ,,,,,,,,,, No. 15 HC variable region, No. 15 LC variable region,QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKVTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(142/141)  a) the light chain variable region set forth in seq id no:141; and b) an antibody comprising the heavy chain variable region set forth in seq id no:142; and ,,,,,,,,,, No. 17 HC variable region, No. 17 LC variable region,EVQLVESGGGLVQPGRTLRLSCAASGFTFDDYAMHWVRQPPGKGLEWVSGIDWNSGLIGYADAVKGRFTLSRDNAKNSIFLQMNSLRAEDTALYYCVKDMGSTGGYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSPNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYVFGTGTKLTVL,GFTFDDYA,IDWNSGLI,VKDMGSTGGYYGMDV,SPNIGNNY,DNN,GTWDSSLSAYV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(112/111)  a) the light chain variable region set forth in seq id no:111; and b) an antibody comprising the heavy chain variable region set forth in seq id no:112; ,,,,,,,,,, No. 2 HC variable region, No. 2 LC variable region,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLVSGRYCSGVTCYSWFDPWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDDLPITFGQGTRLEIK,GFTFSSYA,ISGSGGST,AKSLVSGRYCSGVTCYSWFDP,QDISNY,DAS,QQYDDLPIT,IGHJ5*02 (human),IGHV3-23*04 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(122/121)  a) the light chain variable region set forth in seq id no:121; and b) an antibody comprising the heavy chain variable region set forth in seq id no:122; ,,,,,,,,,, No. 7 HC variable region, No. 7 LC variable region,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELELTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL,GFSLSTSGMG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(130/129)  a) the light chain variable region set forth in seq id no:129; and b) an antibody comprising a heavy chain variable region set forth in seq id no:130; ,,,,,,,,,, No. 11 HC variable region, No. 11 LC variable region,QVQLVQSGAEVKKPGSSVKVSCEASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVRGYSGYGSTYYFDYWGQGTLVTVSS,ELVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSIFGGGTKLTVL,GGTFSSYA,IIPILGIA,ARVRGYSGYGSTYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSI,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(134/133)  a) the light chain variable region set forth in seq id no:133; and b) an antibody comprising the heavy chain variable region set forth in seq id no:134; ,,,,,,,,,, No. 13 HC variable region, No. 13 LC variable region,EVQLVQSGGGVVQPGRSLRLSCAASGFTFSRFAMHWVRQAPGKGLEWVAVVSYDGSNNYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,ELELTQPPSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GFTFSRFA,VSYDGSNN,ARGDYYGSGSYYNPSPFFDY,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(124/123)  a) the light chain variable region set forth in seq id no:123; and b) an antibody comprising the heavy chain variable region set forth in seq id no:124; ,,,,,,,,,, No. 8 HC variable region, No. 8 LC variable region,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYYTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSTSNIGNNFVSWYQHLPGTAPKLLIYDNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,TSNIGNNF,DND,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(144/143)  a) the light chain variable region set forth in seq id no:143; and b) an antibody comprising a heavy chain variable region set forth in seq id no:144. ,,,,,,,,,, No. 18 HC variable region, No. 18 LC variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,ELVLTQPPSVSVAPGKTARITCGGNNIGSNTVNWYQQLPGTAPKLLIYSNNLRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKVTVL,GFTVSSNY,IYSGGST,ARDLVVYGMDV,NIGSNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/KR102229225B1/en,(140/139)  a) the light chain variable region set forth in seq id no:139; and b) an antibody comprising a heavy chain variable region set forth in seq id no:140; ,,,,,,,,,, No. 16 HC variable region, No. 16 LC variable region,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDYYGSGSYYNPSPFFDYWGQGTLVTVSS,DLVLTQPPSASGTPGQRVTMSCSGSSSNIGSKTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTQLTVL,GFTFSNFA,ISYDGSNK,ARGDYYGSGSYYNPSPFFDY,SSNIGSKT,SNN,AAWDDSLSGWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113429476A/en,"(6/2) the coronavirus-binding bifunctional fusion protein of claim 1, which has the amino acid sequence of seq id no:6 and the amino acid sequence of the heavy chain shown in seq id no:2, or a light chain amino acid sequence set forth in seq id no.",,,,,,,,,, Artificial sequence (Artificial sequence), Artificial sequence (Artificial sequence),EVQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN112979793A/en,"(4/8) preferably, the antibody comprises the heavy chain variable region shown in seq id no:4 and the light chain variable region shown in seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLLESGGGVVQPGRSLRLSCAASGFIFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLRGPTGWTFDYWGQGTLVTVSS,ENVLTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQRPGQAPRLLIYDSSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWKITFGQGTRLEIK,GFIFSSYG,IWYDGSNK,ARDLRGPTGWTFDY,QSVSNY,DSS,QHRSNWKIT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN112979793A/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(27/28) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:27 and the light chain variable region shown in seq id no:28.",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVASMAQDGSDKYYVDSVKGRFTISRDNAKNSLYLHMNSLRAEDTAVYSCAIHGGNLAFEYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTISCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,GFTFSSYW,MAQDGSDK,AIHGGNLAFEY,QSISSW,KAS,QQYNSYPWT,IGHJ4*01 (human),IGHV3-7*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(65/66) preferably, the monoclonal antibody comprises the heavy chain variable region shown as seq id no:65 and the light chain variable region shown as seq id no:66",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIKPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCASRHEGYGSGSYYIDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIYSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYNSYFWTFGQGTKVEIK,GYTFTGYY,IKPNSGGT,ASRHEGYGSGSYYIDY,QSIYSW,KAS,QQYNSYFWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(7/8) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:7 and the light chain variable region shown in seq id no:8",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGWISAYNGNTNSAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCVRDRGNWFDPWGQGTLVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTSYYPSWYQQTPGQAPRTLIYSTNTRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGSGTRVFGGGTKLTVL,GYTFTSYA,ISAYNGNT,VRDRGNWFDP,SGSVSTSYY,STN,VLYMGSGTRV,IGHJ5*02 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV8-61*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(56/57) preferably, the monoclonal antibody c10897p3s comprises the heavy chain variable region of seq id no:56 and the light chain variable region of seq id no:57",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLLESGGGFIQPGGSLRLSCAASGFTFSIYAMTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGGLGRGYDILTGTFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPSITFGQGTRLEIK,GFTFSIYA,ISGSGGST,GGLGRGYDILTGTFDY,QSVSSN,GAS,QQYNNWPPSIT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(85/86) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:85 and the light chain variable region shown in seq id no:86.",,,,,,,,,, Artificial sequence, Artificial sequence,QVQFVQSGAEVKKPGASVKVSCKASGFTFTDATMYWVRQAPGQRLEWVGWINAGSGNTEFPQKFRGRVTVTRDTSASVLYMELSSLTSEDTAVYYCAGGVHTDGVRWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGTYNYVSWYQHHPGQAPKLMIYEVSKRPSGVPDRFSGSKSGHTASLTVSGLQADDEADYYCTSHAGFNNFVVFGGGTKLTVL,GFTFTDAT,INAGSGNT,AGGVHTDGVR,SSDVGTYNY,EVS,TSHAGFNNFVV,IGHJ1*01 (human),IGHV1-3*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(75/76) preferably, the monoclonal antibody c10543o1s comprises the heavy chain variable region of seq id no:75 and the light chain variable region of seq id no:76",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSINTAYMELSSLRSEDTAVYYCATREGPDLRWLQEDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVHNNGNTYLCWFQQRPGQSPRRLIYNVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHWPLTFGGGTKLEIK,GYTFTSYD,MNPNSGNT,ATREGPDLRWLQEDAFDI,QSLVHNNGNTY,NVS,LQATHWPLT,IGHJ3*02 (human),IGHV1-8*01 (human),IGKJ4*01 (human),IGKV2-30*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(46/47) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:46 and the light chain variable region shown in seq id no:47",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLQESGPGLVKPSETLSLTCTVSGGSISNYFWSWIRQPAGKGLEWIGRIYTTGSTDYNPSLKSRVSASVDTSKNQFSLKVRSVTAADTAMYYCARESRTYDGSGYYIDSWGQGALVTVSS,DIVMTQSPDSLAVSLGERATLNCESSHTLLYSLNNKSSLAWYQQKPGQPPKVLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSVPRTFGQGTKVEIK,GGSISNYF,IYTTGST,ARESRTYDGSGYYIDS,HTLLYSLNNKSS,WAS,QQYYSVPRT,IGHJ5*01 (human),IGHV4-4*07 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(37/38) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:37 and the light chain variable region shown in seq id no:38",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVESGGGEVQPGTSLRLSCVTSGFTFAHYGMHWVRQAPGKGLEWVAVTWSDGIRRYYGDSVRGRFTISKDTSKNTLYLQMNSLRVEDTAVYYCARDHSIGLFYMDVWGKGTTVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLNSDSVSTNYYPSWHQQTPGQAPRTLIYNTNIRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGSGIWVFGGGTRLTVL,GFTFAHYG,TWSDGIRR,ARDHSIGLFYMDV,SDSVSTNYY,NTN,VLYMGSGIWV,IGHJ6*04 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV8-61*01 (human)
Patent,https://patents.google.com/patent/CN112940110A/en,"(17/18) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18",,,,,,,,,, Artificial sequence, Artificial sequence,EVQLVESGGGLVQPGGSLRLSCVASGFTFSSHGMHWVRQATGKGLEWVSAIGAAGDPYYPGSVKGRFTISRDNAKNSLYLQMNSLRAGDTAVYYCARSVAGGLFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQCPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQQYYSSPYTFGQGTKLEIK,GFTFSSHG,IGAAGDP,ARSVAGGLFDY,QSVLYSSNNKNY,WAS,QQYYSSPYT,IGHJ4*01 (human),IGHV3-13*05 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN111647079B/en,"(4/3) the amino acid sequence of the light chain of the neutralizing antibody of the anti-novel coronavirus n protein is shown as seq id no:3, the amino acid sequence of the heavy chain is shown as seq id no:4, respectively",,,,,,,,,,  Homo sapiens,  Homo sapiens,QVQLLEQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGTIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWSSSAGGYYGMDVWGQGTTVTVSS,EIELTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPTTFGQGTRLEIK,GGTFSSYA,TIPIFGTA,ARGGWSSSAGGYYGMDV,QSLLHSNGYNY,LGS,MQALQTPTT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN111647079B/en,"(2/1) the neutralizing antibody for resisting the novel coronavirus n protein consists of a light chain and a heavy chain, wherein the amino acid sequence of a variable region of the light chain is shown as seq id no:1, the amino acid sequence of the heavy chain variable region is shown as seq id no:2, respectively.",,,,,,,,,,  Homo sapiens,  Homo sapiens,QVQLLEQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGTIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWSSSAGGYYGMDVWGQGTTVTVSS,EIELTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPTTFGQGTRLEIK,GGTFSSYA,TIPIFGTA,ARGGWSSSAGGYYGMDV,QSLLHSNGYNY,LGS,MQALQTPTT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
Patent,https://patents.google.com/patent/CN113402602A/en,"(34/44) still further, the amino acid sequence of vh of the antibody is selected from one of seq id no:2-seq id number 4, seq id no:14; and/or the amino acid sequence of the vl of the antibody is selected from one of seq id no:32-seq id no:34 and seq id no:44.",,,,,,,,,, VL(Artificial Sequence), VL(Artificial Sequence),,AIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,,,,QSISSY,AAS,QQSYSTPRT,,,IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113402602A/en,"(218/228) further, the amino acid sequence of the scfv single-chain antibody is one of seq id no:216-seq id no:218 and seq id no:228. more specifically, the scfv single-chain antibodies are hts0422, hts0433, hts0446 and hts0483 in table 1 below, and the sequences of their heavy chains, light chains and their variable regions are also shown in table 1.",,,,,,,,,, VH_VL(Artificial Sequence), VH_VL(Artificial Sequence),QVQLVQSGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKEDAGYYYDSSGYYYPKAHWYFDLWGRGTLVTVSS,,GFTFDDYA,ISWNSGSI,AKEDAGYYYDSSGYYYPKAHWYFDL,,,,IGHJ2*01 (human),IGHV3-9*01 (human),,
Patent,https://patents.google.com/patent/CN113444169B/en,(33/34)  a heavy chain with an amino acid sequence shown as seq id no:33 and a light chain with an amino acid sequence shown as seq id no:34.,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRAGWVRGAFDIWGQGTMVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNLWVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,TRAGWVRGAFDI,SGSIASNY,EDN,QSYDSSNLWV,IGHJ3*02 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
Patent,https://patents.google.com/patent/CN113444169B/en,(22/23) (i) a heavy chain having an amino acid sequence shown in seq id no:22 and a light chain having an amino acid sequence shown in seq id no:23,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARVLPMYGDYLDY,QSISRY,AAS,QQSYSTPPEYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113444169B/en,(7/8)  a heavy chain variable region having an amino acid sequence shown in seq id no:7 and a light chain variable region having an amino acid sequence shown in seq id no:8;,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARVLPMYGDYLDY,QSISRY,AAS,QQSYSTPPEYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113444169B/en,(31/32)  heavy chain variable region whose amino acid sequence is shown as seq id no:31 and light chain variable region whose amino acid sequence is shown as seq id no:32.,,,,,,,,,, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRAGWVRGAFDIWGQGTMVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNLWVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,TRAGWVRGAFDI,SGSIASNY,EDN,QSYDSSNLWV,IGHJ3*02 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
Patent,https://patents.google.com/patent/CN113583116A/en,(17/19)  a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19.,,,,,,,,,, h36H6-10/h36H6-12 VH, h36H6-12 VL,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTMHWVKQSPGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSASTAYMELSSLRSEDTAVYYCAREGDYYVSSYGYWGQGTLVTVSS,DIVMSQSPDSLAVSLGERATISCKSSQSLLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDLAVYYCQQYYSFPLTFGQGTKLEIK,GYTFTEYT,INPNNGDT,AREGDYYVSSYGY,QSLLYSSNQKNY,WAS,QQYYSFPLT,IGHJ3*01 (mouse),IGHV1-18*01 (mouse),IGKJ2*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN113583116A/en,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2.",,,,,,,,,, 36H6 VH, 36H6 VL,EVQLQQSGPELVNPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVFYCAREGDYYVSSYGYWGQGTTLTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSFPLTFGAGTKLELK,GYTFTEYT,INPNNGDT,AREGDYYVSSYGY,QSLLYSSNQKNY,WAS,QQYYSFPLT,IGHJ2*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN113583116A/en,"(3/4) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:3 and a vl comprising the sequence shown as seq id no:4.",,,,,,,,,, 2B4 VH, 2B4 VL,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWMNWVKQRPEQGLEWIGRIDPYDSETHYNQKFKDKAILTVDKSSTTAYMQLSSLTSEDSAVYYCARWGTVEWFFDYWGQGTTLTVSQ,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNSYNQENYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPFTFGSGTKLEIK,GYTFTSYW,IDPYDSET,ARWGTVEWFFDY,QSLLNSYNQENY,FAS,QQHYSTPFT,IGHJ2*01 (mouse),IGHV1-52*01 (mouse),IGKJ4*01 (mouse),IGKV8-24*01 (mouse)
Patent,https://patents.google.com/patent/CN113583116A/en,(17/18) (1) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18,,,,,,,,,, h36H6-10/h36H6-12 VH, h36H6-10 VL,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTMHWVKQSPGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSASTAYMELSSLRSEDTAVYYCAREGDYYVSSYGYWGQGTLVTVSS,DIVMSQSPDSLAVSLGERVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFPLTFGQGTKLEIK,GYTFTEYT,INPNNGDT,AREGDYYVSSYGY,QSLLYSSNQKNY,WAS,QQYYSFPLT,IGHJ3*01 (mouse),IGHV1-18*01 (mouse),IGKJ2*01 (human),IGKV4-1*01 (human)
Patent,https://patents.google.com/patent/CN112979790A/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(9/10) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:9, and the light chain amino acid sequence is set forth in seq id no:10",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGRGLEWVSLLYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLITYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPLTFGGGTKVEIK,GITVSSNY,LYSGGST,ARDLITYGMDV,QGISSY,AAS,QQLNSYPPLT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(49/50) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:49, and the light chain amino acid sequence is shown as seq id no:50",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARGEIQPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGSPGQSVTISCTGTSSDFGGYNSVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNFDVFGTGTKVTVL,GFTVSSNY,IYSGGST,ARGEIQPYYYYGMDV,SSDFGGYNS,EVS,SSYAGSNNFDV,IGHJ6*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV2-8*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLLVATIRDFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,GLTVSSNY,IYSGGST,ARLLVATIRDFDY,QSVSSN,GAS,QQYNNWPPWT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(69/70) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:69, and the light chain amino acid sequence is shown as seq id no:70.",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGALIQPGGSLRLSCAASGLTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYGDYENYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHLWTFGQGTKVEIK,GLTVSSNY,IYSGGST,ARGYGDYENYFDY,QGISSY,AAS,QHLWT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(59/60) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:59, and the light chain amino acid sequence is shown as seq id no:60",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLFQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLECVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGMLHGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLPGLTFGGGTKVEIK,GLTVSSNY,IYSGGST,ARDRGMLHGMDV,QDISNY,DAS,QHYDNLPGLT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(19/20) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:19, and the light chain amino acid sequence is shown as seq id no:20",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIDYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDLIDYGMDV,QGISSY,AAS,QQLNSYPPYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN112159469A/en,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30",,,,,,,,,, Artificial Sequence, Artificial Sequence,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSAFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSSAGGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,GLTVSSNY,IYSGGSA,ARDLSSAGGMDV,QSVSSSY,GAS,QQYGSSPGT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/KR20220012826A/en,"(2018/2017) the method according to any one of claims 1 to 6, the binding molecule is light chain variable region of the polypeptide sequence of seq id no:2017; and seq id no:2018 heavy chain variable region of the polypeptide sequence a binding molecule comprising a.",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN113956353A/en,"(15/16) 3. the dna sequence of the heavy chain variable region and the light chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein of claim 2, wherein the dna sequence of the heavy chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein is shown as seq id no:15 or seq id no:16",,,,,,,,,, Artificial Sequence, Artificial Sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113956353A/en,(16/19)  the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19. the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16,,,,,,,,,, Artificial Sequence, Artificial Sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113956353A/en,(16/20) the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 6e8 is shown in seq id no:20.,,,,,,,,,, Artificial Sequence, Artificial Sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN113956353A/en,"(15/19) specifically, the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:15; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19",,,,,,,,,, Artificial Sequence, Artificial Sequence,,,,,,,,,,,,
Patent,https://patents.google.com/patent/CN112430265A/en,"(2/1) the amino acid sequences of the variable regions of the light and heavy chains of antibody ncov-61 are shown in seq id no:1 and 2, respectively.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCEASEIIVNRNYMNWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTMYLQMNSLRAEDTAVYYCARSYGDFYVDFWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,EIIVNRNY,IYPGGST,ARSYGDFYVDF,SSNIGNNY,DNN,GTWDSSLSAWV,IGHJ5*01 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112125973B/en,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10.",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGRTYYNPSLKSRLTISVDTSKNQFSLKLSSMTAADTAVYYCARVQGNQTLRYFDWSAPLVTFWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSSNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPMFGGGTKLTVL,GGSISSGGYY,IYYSGRT,ARVQGNQTLRYFDWSAPLVTFWFDP,SSNIGSNT,SSN,AAWDDSLNGPM,IGHJ5*02 (human),IGHV4-31*02 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
Patent,https://patents.google.com/patent/CN113563464A/en,"(9/11)  seq id no:9 and seq id no:11, the antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain in one embodiment of the present invention is named ""wjq-c11"".",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYEMNWVRQAPGKGLEWVSYIHNSGNPVYYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAIYYCARALRYSTSWYDYWGQGTLVTVSS,EIVLTQSPVSLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLFIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,GFAFSTYE,IHNSGNPV,ARALRYSTSWYDY,QSVSSY,DAS,QQRSNWPRT,IGHJ4*01 (human),IGHV3-48*03 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
Patent,https://patents.google.com/patent/CN113563464A/en,"(5/7)  seq id no:5 and seq id no:7; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is named ""wjq-g10"", or",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLVQPGESLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYAGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDMAIYYCARDLSYYGMDVWGQGTTVTVSS,DIQLTQFPFSLSASVGDRVTITCRASQGISTYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQLLNSYPVHFGQGTKLEIK,GLTVSSNY,IYAGGST,ARDLSYYGMDV,QGISTY,AAS,QLLNSYPVH,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN113563464A/en,"(1/3)  seq id no:1 and seq id no:3; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is designated as ""sw-c11"", or",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLIQPGGSLRLSCAASEFIVSRNYMSWVRQAPGTGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMDSLRVEDTAVYYCARDYGDFYFDYWGQGTLVTVSS,EIVMTQSPVSLSVSPGERATLSCRASQGVASNLAWYQQKAGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISTLQSEDSAVYYCQQYNDRPRTFGQGTKLEIK,EFIVSRNY,IYPGGST,ARDYGDFYFDY,QGVASN,GAS,QQYNDRPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-15*01 (human)
Patent,https://patents.google.com/patent/CN113563463A/en,(6)  a neutralizing nanobody shown in seq id no:6 or a functionally active variant thereof.,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYTYSYIYAGWFRQAPGQEREAVSAIAGENYSYYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAWPTQDGYAAWGQGTQVTVSS,,GGSEYTYSYIY,IAGENYS,AAWPTQDGYAA,,,,IGHJ1*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113563463A/en,(4)  a neutralizing nanobody or a functionally active variant thereof represented by seq id no:4;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYSTWRHYVGWFRQAPGQEREAVSAIASLDSSVAYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAIETVHGHMIWGQGTQVTVSS,,GGSEYSTWRHY,IASLDSSV,AAIETVHGHMI,,,,IGHJ3*02 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113563463A/en,(1)  a neutralizing nanobody shown in seq id no:1 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYATFRHYIGWFRQAPGQEREAVSAIAAANGEHSYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAIVDGWIWGQGTQVTVSS,,GGSEYATFRHY,IAAANGEH,AAIVDGWI,,,,IGHJ3*02 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113563463A/en,(3)  a neutralizing nanobody shown in seq id no:3 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYDFSWSYIGWFRQAPGQEREAVSAIADHWTQDDYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAMSIGWPELFWGQGTQVTVSS,,GGSEYDFSWSY,IADHWTQD,AAMSIGWPELF,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN113563463A/en,(2)  a neutralizing nanobody shown in seq id no:2 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYRYSDWTSGWFRQAPGQEREAVSAIAGYDNTPNYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAWYIKMNSDMHVQREWEWGQGTQVTVSS,,GGSEYRYSDWT,IAGYDNTP,AAWYIKMNSDMHVQREWE,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/CN113563463A/en,(5)  a neutralizing nanobody shown in seq id no:5 or a functionally active variant thereof;,,,,,,,,,, Artificial Sequence (Artificial Sequence),N/A,QVQLVESGGGSVQPGGSLRLSCTASGGSEYATFGHYAGWFRQAPGQEREAVSAIAGAGDRRAYADSVKGRFTISRDNSKNTVTLQMNNLRAEDTAIYYCAAIDTEYGQNIWGQGTQVTVSS,,GGSEYATFGHY,IAGAGDRR,AAIDTEYGQNI,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
Patent,https://patents.google.com/patent/KR20220012800A/en,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018.",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(27/29)  vh comprises the amino acid sequence as set forth in seq id no:27, and vl comprises the amino acid sequence set forth in seq id no:29;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVDIK,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,QSVSSSY,GAS,QQYGSSPGT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(31/33)  vh comprises the amino acid sequence as set forth in seq id no:31, and vl comprises the amino acid sequence set forth in seq id no:33;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPRFGPGTKVEIK,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,QGISSY,AAS,QQLNSYPR,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(23/25)  vh comprises the amino acid sequence as set forth in seq id no:23, and vl comprises the amino acid sequence set forth in seq id no:25;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTLVTVSS,EIVMTQSPGTLSLSPGERVTLSCRTSQSVSRFFSWYQQKPGQAPRLLIHTASTRATDIPDRFSASGSGTDFTLTISRLEPEDSAMYYCQHYGASPYTFGQGTKVDIK,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,QSVSRF,TAS,QHYGASPYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(15/17)  vh comprises the amino acid sequence as set forth in seq id no:15, and vl comprises the amino acid sequence set forth in seq id no:17;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTLVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,QSVSSSY,GAS,QQYGSSPWT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(19/21)  vh comprises the amino acid sequence as set forth in seq id no:19, and vl comprises the amino acid sequence set forth in seq id no:21;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTMVTVSS,EIVMTQSPSVLPLFPGESGSLSCRASQNVGDFLAWYQHKPGQAPKLLIYGATNRPTGIPDRFSGTGSGTDFTLTISRMEPEDFAVYFCQQYGTSPPITFGPGTKVDIK,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,QNVGDF,GAT,QQYGTSPPIT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN112574299A/en,"(35/37)  vh comprises the amino acid sequence as set forth in seq id no:35, and vl comprises the amino acid sequence set forth in seq id no:37;",,,,,,,,,, Artificial Sequence, Artificial Sequence,QVQLVQSGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGRGLEWVSLIYPGGSTYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARDLSEKGGMDVWGQGTTVTVSS,QAVLTQPPSVSVAPGKTARITCGGNHIGSKSVNWYQQKSGQAPVLVIYSDSDRPSGIPARFSGSNSGDTATLTISRVEAGDEADYYCQVWDNRSDHWVFGGGTQLTVL,GVTVSSNY,IYPGGST,ARDLSEKGGMDV,HIGSKS,SDS,QVWDNRSDHWV,IGHJ6*01 (human),IGHV3-53*01 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
Patent,https://patents.google.com/patent/CN113512114A/en,"(27/28) (b) a heavy chain variable region (vh) comprising seq id no:27 or a variant thereof; and/or, a light chain variable region (vl) comprising seq id no:28 or a variant thereof;",,,,,,,,,, BD836 VH, BD836 VL,QVQLVQSGPEVKKPGTSVRVSCKASGFTFSTSAVQWVRQARGQRLEWIGWIAVGSGKTDYLQKFQERVTMTRDESTNTAYMQLSSLRSEDTAVYYCAAPHCSGGTCYDGFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSGYFAWYQQRPGRAPRLLIYGASSRATAIPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYGTSPWTFGQGTKVEIK,GFTFSTSA,IAVGSGKT,AAPHCSGGTCYDGFDI,QSVRSGY,GAS,QQYGTSPWT,IGHJ5*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113512114A/en,"(7/8) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:7and a vl comprising the sequence shown as seq id no:8",,,,,,,,,, BD812 VH, BD812 VL,EVQLVQSGAEVKKPGESLKISCQFSEYKLISFWIAWVRQRPGKGLEWMGIIYPDDSDTKYSPSSQGQVTISADKSIRTAYLQWSSLMASDTAMYYCTSGSYYGTLDFWGQGTLVTVSS,DIEITQSPSSLSASVGDRVTISCRASQDIRTYVAWYQQRPGKVPRLLIYAASTLQSGVPSRFSGRGSGTDFTLTISSLQPEDVATYYCQQYNSAPLTFGGGAKVEIK,EYKLISFW,IYPDDSDT,TSGSYYGTLDF,QDIRTY,AAS,QQYNSAPLT,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
Patent,https://patents.google.com/patent/CN113150135A/en,"(7/8) preferably, the neutralizing antibody c14646p3s comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8",,,,,,,,,, Artificial sequence, Artificial sequence,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPIFGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARTPLHMATEEGYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQTPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPFTFGPGTKVDIK,GGTFSSYT,IIPIFGIA,ARTPLHMATEEGYFDY,QGISSW,AAS,QQANSFPFT,IGHJ4*01 (human),IGHV1-69*02 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
Patent,https://patents.google.com/patent/CN113150135A/en,"(17/18) preferably, the neutralizing antibody c2767p3s comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18",,,,,,,,,, Artificial sequence, Artificial sequence,QLQLQESGPGLVKPSETLSLTCIVSGGSISSSSYYWGWIRQPPGKGLEWIGSFFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDSSGSYHLDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYVFGTGTKVTVL,GGSISSSSYY,FFYSGST,ARDSSGSYHLDY,SSNIGAGYD,GNS,QSYDSSLSVLYV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113004397B/en,"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWRSSGYHDYSYYGMDVWGQGTTVTVSS,ENVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRGVTFGPGTKVDIK,GGTFSSYA,IIPIFGTA,ARGGWRSSGYHDYSYYGMDV,QSVSSSY,GAS,QQYGSSPRGVT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
Patent,https://patents.google.com/patent/CN113004397B/en,"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN113980135A/en,"(8/26) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:8, and the light chain variable region comprises the amino acid sequence shown as seq id no:26",,,,,,,,,, A48 VH, A48 VH,EVKLMESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSKINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGINVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNIYPLTFGAGTKLELK,GFDFSRYW,INPDSSKI,ARPDYYGSRYVGAMDY,QNVGIN,SAS,QQYNIYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(14/32) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:14 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:32",,,,,,,,,, A82 VH, A82 VH,QVQLQQSGPDLVKPGASVKISCKASGYSFTDHYMHWVKQSHGKSLEWIGRISPNNGITIYNQKFKDKALLTVDQSSSTAYMELRSLTSEDSAVYYCLIYYDNDSFTYWGQGTLVTVSS,DILMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGAGTKLELK,GYSFTDHY,ISPNNGIT,LIYYDNDSFTY,QDVGTA,WAS,QQYSSYPLT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(10/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:10 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18",,,,,,,,,, A57 VH, A5A57 VH,EVQLQQSGPDLVTPGASVKMSCKASGYSFTDHYIHWGKQSHGESLEWIGRVSPNNGGTNYNQKFKGKAIFTVDKSSSTAYMELRGLTSEDSAVYYCWIYFDYDGRAGFTYWGQGTLVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGSGTKLEIK,GYSFTDHY,VSPNNGGT,WIYFDYDGRAGFTY,QDVGTA,WAS,QQYSSYPLT,IGHJ3*01 (mouse),IGHV1-34*01 (mouse),IGKJ4*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(3/31) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:31",,,,,,,,,, A8A50A81 VH, A81 VH,EVKVIESGGGLVQPGGSLQLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTISYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARRGITTWAMDYWGQGTSVTVSS,DIVMTQSHKFMSTSIGDRVSITCKASQDVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGGTKLEIK,GFDFSRYW,INPDSSTI,ARRGITTWAMDY,QDVGTN,SAS,QQYNSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(9/28) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:9 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:28",,,,,,,,,, A55 VH, A55 VH,EVQLVESGGGLVQPGGSLKVSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTISYTPSLKDEFIISRDNAKNTLYLQMSKVRSEDTAHYYCARRGLLLLTMDYWGQGTSVTVSS,DIQMNQSPSSLSASLGDTITITCHASQNINVWLSWYQQKPGNIPKLLIYKASKLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPLAFGGGTKLEIK,GFDFSRYW,INPDSSTI,ARRGLLLLTMDY,QNINVW,KAS,QQGQSYPLA,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ4*01 (human),IGKV1-33*01 (human)
Patent,https://patents.google.com/patent/CN113980135A/en,"(12/20) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:12 and the light chain variable region comprises the amino acid sequence shown as seq id no:20",,,,,,,,,, A74 VH, A9A74 VH,EVQLQQSGPDLVTPGASVKMSCKASGYSFTDHYIHWGKQSHGKSLEWIGRVSPNNGGTNYNQKFKGKAILTVDKSSSTAYMELRGLTSEDSAVYYCWIYYDYDGRAGFTYWGRGTLVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGAGTKLELK,GYSFTDHY,VSPNNGGT,WIYYDYDGRAGFTY,QDVGTA,WAS,QQYSSYPLT,IGHJ3*01 (mouse),IGHV1-34*01 (mouse),IGKJ5*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(15/33) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:15 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:33",,,,,,,,,, A96 VH, A96 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSKINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPWTFGGGTKLEIK,GFDFSRYW,INPDSSKI,GRPDYYGSRYVGAMDY,QNVGTN,SAS,QQYNSYPWT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(11/29) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:11 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:29",,,,,,,,,, A58 VH, A58 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSKINYTPSLKDKFIISRDNAKKTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKLMSTSVGDRVSVTCKASQNVGTYVAWYQQKPGQSPKVLIYSAAYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGAGTKLELK,GFDFSRYW,INPDSSKI,ARPDYYGSRYVGAMDY,QNVGTY,SAA,QQYNSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(3/27) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:27",,,,,,,,,, A8A50A81 VH, A50 VH,EVKVIESGGGLVQPGGSLQLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTISYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARRGITTWAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVDTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELK,GFDFSRYW,INPDSSTI,ARRGITTWAMDY,QNVDTA,SAS,QQYSSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-13*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(2/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:2 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18",,,,,,,,,, A5, A5A57 VH,EVQLQQSGPDLVTPGASVKMSCKASGYSFTDHYIHWGKQSHGENLEWIGRVSPNNGGTNYNQKFKGKAIFTVDKSSSTAYMELRGLTSEDSAVYYCWIYYDYDGRAGFAYWGQGTQVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGSGTKLEIK,GYSFTDHY,VSPNNGGT,WIYYDYDGRAGFAY,QDVGTA,WAS,QQYSSYPLT,IGHJ3*01 (mouse),IGHV1-34*01 (mouse),IGKJ4*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(1/23) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:23",,,,,,,,,, A3A20A21 VH, A21 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGESNPDSSKINYTPSLKDKFIISRDNAKKTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGSGTKLEIK,GFDFSRYW,SNPDSSKI,ARPDYYGSRYVGAMDY,QNVGTN,SAS,QQYNSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ4*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(7/25) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:7 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:25",,,,,,,,,, A45 VH, A45 vh,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARYYGYQDYYAMDYWGQGTSVTVSS,DIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQSYSYPLTFGAGTKLELK,GFDFSRYW,INPDSSTI,ARYYGYQDYYAMDY,ENVGTY,GAS,GQSYSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-20*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(96/97) more preferably, the first binding epitope comprises a heavy chain having the sequence shown in seq id no:96 and a light chain having the sequence shown in seq id no:97.",,,,,,,,,, HC, LC,QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGAFYYGSGSYPFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GYTFTSYA,IIPILGIA,ASGAFYYGSGSYPFDY,QDISDY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113980135A/en,"(1/17) the anti-drug antibody of claim 4, wherein the heavy chain variable region comprises the amino acid sequence set forth in seq id no:1 and the light chain variable region comprises the amino acid sequence set forth in seq id no:17;",,,,,,,,,, A3A20A21 VH, A3 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGESNPDSSKINYTPSLKDKFIISRDNAKKTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGGTKLEIK,GFDFSRYW,SNPDSSKI,ARPDYYGSRYVGAMDY,QNVGTN,SAS,QQYNSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(1/22) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:22",,,,,,,,,, A3A20A21 VH, A20 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGESNPDSSKINYTPSLKDKFIISRDNAKKTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSTSYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPLTFGAGTKLELK,GFDFSRYW,SNPDSSKI,ARPDYYGSRYVGAMDY,QNVGTN,STS,QQYNNYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(13/30) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:13 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:30",,,,,,,,,, A77 VH, A77 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEIHPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGPNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNRYPLTFGAGTKLELK,GFDFSRYW,IHPDSSTI,ARPDYYGSRYVGAMDY,QNVGPN,SAS,QQYNRYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(16/34) alternatively, the heavy chain variable region comprises the amino acid sequence shown as seq id no:16 and the light chain variable region comprises the amino acid sequence shown as seq id no:34.",,,,,,,,,, A105 VH, A105 VH,EVKLMESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGESNPDSSKINYTPSLKDKFIISRDNAKKTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DILMTQSQKFMSTSVGDRVSVTCKASQNVDSNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNTYPLTFGAGTKLELK,GFDFSRYW,SNPDSSKI,ARPDYYGSRYVGAMDY,QNVDSN,SAS,QQYNTYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(6/24) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:6 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:24",,,,,,,,,, A24 VH, A24 VH,EVKLMESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGEGLEWIGEINPDSSTISYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARRGLLLLTMDYWGQGTSVTVSS,DIVMTQSPKSLSMSVGERVTLSCKASENVDTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATYFTLTISSVQAEDLADYHCGQTYSYPFTFGSGTKLEIK,GFDFSRYW,INPDSSTI,ARRGLLLLTMDY,ENVDTY,GAS,GQTYSYPFT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ4*01 (mouse),IGKV6-20*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(4/20) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:4 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:20",,,,,,,,,, A9 VH, A9A74 VH,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMNWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCAKRGLLRFAMDYWGQGTSVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGAGTKLELK,GFDFSRYW,INPDSSTI,AKRGLLRFAMDY,QDVGTA,WAS,QQYSSYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN113980135A/en,"(94/95)  preferably, the first binding epitope comprises the heavy chain variable region of seq id no:94 and the light chain variable region of seq id no:95",,,,,,,,,, VH, VL,QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGAFYYGSGSYPFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GYTFTSYA,IIPILGIA,ASGAFYYGSGSYPFDY,QDISDY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113980135A/en,"(5/21) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:5 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:21",,,,,,,,,, A14 VH, A14 VH,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSKINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPDYYGSRYVGAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTFVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNTYPLTFGAGTKLELK,GFDFSRYW,INPDSSKI,ARPDYYGSRYVGAMDY,QNVGTF,SAS,QQYNTYPLT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ5*01 (mouse),IGKV6-15*01 (mouse)
Patent,https://patents.google.com/patent/CN112898416B/en,"(4/8) the binding protein of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGWVICSSTSCYTKYSYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSISNIGSAHVSWYQQVPGTAPKLLIYDNSERPSGIPARFSAFKYGTSATLDITGLQTGDEADYYCASWDISLSAGIFGGGTKLTVL,GGTFSSYA,IIPIFGTA,ARGGWVICSSTSCYTKYSYYGMDV,ISNIGSAH,DNS,ASWDISLSAGI,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN112898416B/en,(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLVQSGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGNIYYSGSTDYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCAREQFSGGDYEGFDFWGQGTLVTVSS,QSVLTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GGSISSYY,IYYSGST,AREQFSGGDYEGFDF,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ5*01 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
Patent,https://patents.google.com/patent/CN111825762A/en,(13) f1 nanobody: has the sequence shown in seq id no:13,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGGGLVQAGGSLRLSCAASGSTFSSNAMWFRQAPGKEREFVAAINWGSSSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAYLSSSRSGDYDYWGQGTQVTVSS,,GSTFSSN,INWGSSST,AAYLSSSRSGDYDY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(6) e7 nanobody: has the sequence shown in seq id no:6,,,,,,,,,, human (Homo sapiens),N/A,DVQLQASGGGLVQPGGSLRLSCAASRFTFSTYWMYWVRQAPGKGLEWVSGFNIGGGSTYYADSVKGRFTIFGDNAKNTLYLQMNNLKPEDTAVYYCAPLLASAFVLMYGSRHLYWGKGTQVTVSS,,RFTFSTYW,FNIGGGST,APLLASAFVLMYGSRHLY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(19) h6 nanobody: has the sequence shown in seq id no:19.,,,,,,,,,, human (Homo sapiens),N/A,QVQLLESGPGLVKPSQTLSLTCTVSGGSITTDVAYWSWLRQPPGKGLEWMGAIASSGSTYNSPFFGSRTFISRDTSKSQFTLQLSSVTPEDTAVYYCAAIAVRDPHYVGVGGYWGKGTQVTVSS,,GGSITTDVAY,IASSGST,AAIAVRDPHYVGVGGY,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(12) a1 nanobody: has the sequence shown in seq id no:12,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGGGLVQAGGSLRLSCAASGSTSSSYAMGWFRQAPGKEREFVAAISSGGSRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAALASSGYSRDYGAYDYWGQGTQVTVSS,,GSTSSSYA,ISSGGSRT,AALASSGYSRDYGAYDY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(15) c7 nanobody: has the sequence shown in seq id no:15,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISAIGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADSSLAGLRGRLYDYWGQGTQVTVSS,,GYTNSRYY,ISAIGRT,AADSSLAGLRGRLYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(14) g3 nanobody: has the sequence shown in seq id no:14,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISAIGRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASDRLSGLRSYGYWGQGTQVTVSS,,GYTNSRYY,ISAIGRT,AASDRLSGLRSYGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(4) e3 nanobody: has the sequence shown in seq id no:4,,,,,,,,,, human (Homo sapiens),N/A,QVQLQASGGGWVQPGGSLRLSCAASGFTFSSYAMTWVRQALGKGLEWVSDINYGGHTSYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCAAVAMLPFLTAVTPRPGYWGKGTQVTVSS,,GFTFSSYA,INYGGHT,AAVAMLPFLTAVTPRPGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(1) b4 nanobody: has the sequence shown in seq id no:1,,,,,,,,,, human (Homo sapiens),N/A,QVQLQASGGGLVQTGGSLRLSCASSGRAFTLNEVGWYRQAPGKQRELVATITRGGDINYADSVKDRFTITRDNARNTLYLQMTNLKSEDTAVYYCAPRNGSPSVFEILLVSVYWGKGTQVTVSS,,GRAFTLNE,ITRGGDI,APRNGSPSVFEILLVSVY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(2) b6 nanobody: has the sequence shown in seq id no:2,,,,,,,,,, human (Homo sapiens),N/A,DVQLQASGGGLVQGGGSLRVSCTYSGRTFSRNIMGWFRQSPGKTREFVAAIGWSRVTTLYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCASGAVPAHQIGFRSTTLYWGKGTQVTVSS,,GRTFSRNI,IGWSRVTT,ASGAVPAHQIGFRSTTLY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(10) g2 nanobody: has the sequence shown in seq id no:10,,,,,,,,,, human (Homo sapiens),N/A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSADMSWVRQAPGKGPEWVSVIESSGSTYYAESVKGRFTISRDNAKNTVYLQMNNLKPEDTAVYYCAYVVPYAIAAGAPDQIGYWGKGTQVTVSS,,GFTFSSAD,IESSGST,AYVVPYAIAAGAPDQIGY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(16) d4 nanobody: has the sequence shown in seq id no:16,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGGGLVQAGGSLRLSCAASGSTFSSYAMGWFRQAPGKEREFVAAISWGGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASYGYLDLDLPAYDYWGQGTQVTVSS,,GSTFSSYA,ISWGGGST,AASYGYLDLDLPAYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(3) b9 nanobody: has the sequence shown in seq id no:3,,,,,,,,,, human (Homo sapiens),N/A,QVQLQASGGGLVQAGGSLRLSCAASGVIFSLNYMGWYRQAAGKGRELVATINRSGGASYGDSVKGRFTISRDNAKNTVDLQMNSLKPEDTAVYYCANVIGTVNAYGAASKPAYWGKGTQVTVSS,,GVIFSLNY,INRSGGA,ANVIGTVNAYGAASKPAY,,,,IGHJ4*01 (human),IGHV3-23*02 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,"(9) f8 nanobody: has the sequence shown in seq id no:9, and (",,,,,,,,,, human (Homo sapiens),N/A,QVQLQASGGGLVQAGGSLRLSCASTGSIFSGDVDGVGWFRRAPGKERELLARIRDGGTTYYADSVKGRFTISGDDAMNTVYLQMNSLKPEDTAVYYCAFGHTHMVRPGSTVMIMYWDKGTQVTVSS,,GSIFSGDVDG,IRDGGTT,AFGHTHMVRPGSTVMIMY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(7) f4 nanobody: has the sequence shown in seq id no:7,,,,,,,,,, human (Homo sapiens),N/A,QVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMSWVRQAPGKGLEWVSAIHSGGDNTNYAESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCAPGPGFTTMDRSQARIAYWGKGTQVTVSS,,GFTFSAYA,IHSGGDNT,APGPGFTTMDRSQARIAY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(11) g5 nanobody: has the sequence shown in seq id no:11,,,,,,,,,, human (Homo sapiens),N/A,QVQLAESGGGLVQPGGSLRLSCAASGFALSSNWMYWVRQAPGKGLEWVTLIRPTNGNKDYVDSVKGRFTISRDDAKNTLYLQMNSLKSEDTAVYYCAPRVRLKVRFQDRVMVTYWGKGTQVTVSS,,GFALSSNW,IRPTNGNK,APRVRLKVRFQDRVMVTY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(18) h4 nanobody: has the sequence shown in seq id no:18,,,,,,,,,, human (Homo sapiens),N/A,QVQLQESGPGLVKSSQTVSLTCSDSGGSITTTHYYWSWIRQPPGKGLEWIGYIAYIGDTFYNSSLKSRTAISWDTSKNQFTLHLNSVTPEDTAVYYCADRNRVRGYDPCLHGYWGKGTQVTVSS,,GGSITTTHYY,IAYIGDT,ADRNRVRGYDPCLHGY,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(17) h3 nanobody: has the sequence shown in seq id no:17,,,,,,,,,, human (Homo sapiens),N/A,QVQLVESGGGLVQPGGSLRLSCAASGFTFNSYDFTWVRQAPGKGLEWVSAITANGGSTFYAGSVKGRFTVSRDNAKNVVSLQMSSLTLEDTAVYYCARTSEARYRGYPRFRVMFYWGKGTQVTVSS,,GFTFNSYD,ITANGGST,ARTSEARYRGYPRFRVMFY,,,,IGHJ6*04 (human),IGHV3-64*04 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(8) f5 nanobody: has the sequence shown in seq id no:8,,,,,,,,,, human (Homo sapiens),N/A,QVQLVESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSSIYSYISNSYYADSVKGRFTGSTDNAKNTLYLQMNSLKSEDTAVYYCAHRFQTRVRTTNPIESEYWGKGTQVTVSS,,GFTFDDYG,IYSYISNS,AHRFQTRVRTTNPIESEY,,,,IGHJ4*01 (human),IGHV3-NL1*01 (human),,
Patent,https://patents.google.com/patent/CN111825762A/en,(5) e6 nanobody: has the sequence shown in seq id no:5,,,,,,,,,, human (Homo sapiens),N/A,DVQLVESGGGLVQPGGSLPLSCAASGFIFDNYAMSWVRQAPGKGLEWVSKLHTGVLNTYYANSVKGRFTISTDNAKNTLYLQMNSLQSEDTAVYYCAFGPAPKPQNVLTTALPYWGKGTQVTVSS,,GFIFDNYA,LHTGVLNT,AFGPAPKPQNVLTTALPY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
Patent,https://patents.google.com/patent/CN113797333A/en,"(7/8)  preferably, antibody cb6 has the amino acid sequence shown in seq id no:7 for the heavy chain variable region and seq id no:8 for the light chain variable region",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARVLPMYGDYLDY,QSISRY,AAS,QQSYSTPPEYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113797333A/en,"(9/10)  preferably, antibody cb6 has the heavy chain amino acid sequence shown as seq id no:9 and the light chain amino acid sequence shown as seq id no:10.",,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARVLPMYGDYLDY,QSISRY,AAS,QQSYSTPPEYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
Patent,https://patents.google.com/patent/CN113234151A/en,"(13)  further, the trimeric nanobody is shown in seq id no:13.",,,,,,,,,, Artificial sequence,N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISMIGRTYDADSVKNRFTISRDNAKNTVYLQANSLKPEDTAVYTCAAGSSRSSLLRYGYAGQGTQVTVSS,,GYTNSRYY,ISMIGRT,AAGSSRSSLLRYGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN113234151A/en,"(1) the nanobody of claim 1, wherein the nanobody has an amino acid sequence shown in seq id no:1.",,,,,,,,,, Artificial sequence,N/A,QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEREFVAAISMIGRTYDADSVKNRFTISRDNAKNTVYLQANSLKPEDTAVYTCAAGSSRSSLLRYGYAGQGTQVTVSS,,GYTNSRYY,ISMIGRT,AAGSSRSSLLRYGY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
Patent,https://patents.google.com/patent/CN111420048A/en,"(3/1) the invention also provides a light chain variable region amino acid sequence of the antihuman basigin humanized antibody as shown in seq id no:1, and a heavy chain amino acid sequence as shown in seq id no:3",,,,,,,,,, heavy chain variable region (VH) amino acid sequence of humanized antibody against BASIGIN, anti-BASIGIN humanized antibody light chain variable region (V L) amino acid sequence,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMNWVRQAPGKGLEWVSEIRLKSNNYATHYAESVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYDYEYWGQGTLVTVSA,DIQMTQSPSTLSASVGDRVTLSCKASENVGTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCGQSYSYPFTFGSGTKLEIK,GFTFSNFW,IRLKSNNYAT,TSYDYEY,ENVGTY,GAS,GQSYSYPFT,IGHJ4*01 (human),IGHV3-15*07 (human),IGKJ4*01 (mouse),IGKV6-20*01 (mouse)
Patent,https://patents.google.com/patent/KR20220012810A/en,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018.",,,,,,,,,, No.139 HC variable region , No.139 LC variable region ,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGGGTTVTVSS,ELVLTQPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPYNDDTNYIQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDDYDYAGAYWGQGTLVTVSA,DIVMSQSPSSLAVSVGEKVTVSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,GYTFTEYT,INPYNDDT,ARDDYDYAGAY,QSLLYSSNQKNY,WAS,QQYYSYPLT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAELVKPGASVKMSCKASGYTFISYSMHWVKQTPGQGLEWIGAIYPGNGDTSYTQKFKGKATLTADKSSTTAYMQLSSLTSEDSAVYYCARDHGNYVLDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPWTFGGGTKLEIK,GYTFISYS,IYPGNGDT,ARDHGNYVLDY,QDVGTA,WAS,QQYSSYPWT,IGHJ2*01 (mouse),IGHV1-12*01 (mouse),IGKJ1*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYDVGAMDYWGQGTSVTVSS,,GYTFTEYT,INPNNGDT,ARDGYDVGAMDY,,,,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),,
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYDVGAMDYWGQGTSVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTIRSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,GYTFTEYT,INPNNGDT,ARDGYDVGAMDY,QSLLYSSNQKNY,WAS,QQYYSYPLT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAELVKPGASVKMSCKASGYTFTSYSMHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARDYHYDGYYVTLDYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGGGTKLEIK,GYTFTSYS,IYPGNGDT,ARDYHYDGYYVTLDY,QEISGY,AAS,LQYASYPWT,IGHJ2*01 (mouse),IGHV1-12*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGTELVKPGASVKMSCKASGYTFTSYSIHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARDYHYDGYYVTLDYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGGGTKLEIK,GYTFTSYS,IYPGNGDT,ARDYHYDGYYVTLDY,QEISGY,AAS,LQYASYPWT,IGHJ2*01 (mouse),IGHV1-12*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVMLVESGGDLVKPGGSLKLSCAASGFTFSGYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARHDGNYVDYAMDYWGQGTSVTVSS,QLVLTQSPAIMSASLGEEITLTCSASSSVSYMHWYQQKSGTSPKLLIYTTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSCWTFGGGTKLEIK,GFTFSGYA,ISSGGSYT,ARHDGNYVDYAMDY,SSVSY,TTS,HQWSCWT,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ1*01 (mouse),IGKV4-80*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGDTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYCCAREDYGSSYAYWGQGTLVTVSA,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYNSNQKKYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAIYYCQQYYSYPLTFGAGTKLELK,GYTFTEYT,INPNNGDT,AREDYGSSYAY,QSLLYNSNQKKY,WAS,QQYYSYPLT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAELVKPGASVKMSCKASGYTFTSYSMHWVKQTPGQGLEWIGAIYPGNGDTSYTQKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYYCARDYHYDGYYVTLDYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGGGTKLEIK,GYTFTSYS,IYPGNGDT,ARDYHYDGYYVTLDY,QEISGY,AAS,LQYASYPWT,IGHJ2*01 (mouse),IGHV1-12*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVQLQQSGPELVKPGASVKISCKASGYSFTGYFMNWVKQSHGKSLEWIGRINPYNGDTFYNQKFKGKATLTVDKSSSTAHMELLSLTSEDSAVYYCGRGYLDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIFSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQEHYSNPYTFGGGTKLEIK,GYSFTGYF,INPYNGDT,GRGYLDY,QDVSTA,SAS,QEHYSNPYT,IGHJ2*01 (mouse),IGHV1-37*01 (mouse),IGKJ2*01 (mouse),IGKV6-17*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),EVMLVESGGGLVKPGGSLKLSCAASGFMFSRYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTMSRDNAKNTLYLQMSSLRSEDTAMYNCARHDGNYVDYAMDYWGQGTSVTVSS,QIVLTQSPAIMSASLGEEITLTCSASSSVSHMHWYQQKSGTSPKLLIYSTFNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSWTFGGGTKLEIK,GFMFSRYA,ISSGGSYT,ARHDGNYVDYAMDY,SSVSH,STF,HQWSSWT,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ1*01 (mouse),IGKV4-80*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGGNTDYNAAFISRLSISKDNSKSQVFFKMNSLQANDTAIYYCARNRYGSAMDYWGQGTSVTVSS,DVVLTQTPLSLPVNIGDQASISCKSTKRLLNSDGFTFLDWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSHYLPLTFGAGTKLELK,GFSLTSYG,IWSGGNT,ARNRYGSAMDY,KRLLNSDGFTF,LVS,FQSHYLPLT,IGHJ4*01 (mouse),IGHV2-2*02 (mouse),IGKJ5*01 (mouse),IGKV1-99*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAELVKPGASVKLSCKASGYTFISYWMHWVKQRPGQGLEWIGEIDPSDSYTNSNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARSELWAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSHGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEIR,GYTFISYW,IDPSDSYT,ARSELWAMDY,KSLLHSHGITY,QMS,AQNLELPWT,IGHJ4*01 (mouse),IGHV1-69*02 (mouse),IGKJ1*01 (mouse),IGKV2-109*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAEFVMPGASVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGAIDTSDTYTRYNQKFKDKATLTVDESSSTAYMQLSSLTSEDSAVYYCARFLYYYGNPTFDYWGQGTTLTVSS,DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGAGTKLELK,GYTFTDYW,IDTSDTYT,ARFLYYYGNPTFDY,KSISKY,SGS,QQHNEYPLT,IGHJ2*01 (mouse),IGHV1-69*01 (mouse),IGKJ5*01 (mouse),IGKV16-104*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLKESGPGLVAPSQSLSITCTVSGFSLSDYSISWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKHPLYYGSNSDGYYAMDYWGQGTSVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGIVVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIK,GFSLSDYS,IWGGGST,AKHPLYYGSNSDGYYAMDY,QDVGIV,WAS,QQYSSYPLT,IGHJ4*01 (mouse),IGHV2-6-5*01 (mouse),IGKJ1*01 (mouse),IGKV6-23*01 (mouse)
Patent,https://patents.google.com/patent/CN111978395A/en,N/A,,,,,,,,,, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),QVQLQQPGAELVRPGASVKLSCKASGYTFISYWIHWVKQRPGQGLEWIGEIDPSDSYSNYNQNFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARSELWAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSHGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEI,GYTFISYW,IDPSDSYS,ARSELWAMDY,KSLLHSHGITY,QMS,AQNLELPWT,IGHJ4*01 (mouse),IGHV1-69*02 (mouse),IGKJ1*01 (mouse),IGKV2-109*01 (mouse)
Patent,https://patents.google.com/patent/CN113735969A/en,"(1/5) in a preferred embodiment, the heavy chain variable region of the monoclonal antibody has the amino acid sequence shown in seq id no:1, and the light chain variable region has the amino acid sequence shown in seq id no:5.",,,,,,,,,,  Homo sapiens,  Homo sapiens,EVQLVESGGGLVQPGGTLRLSCVASGFSFSNYWMSWVRQAPGKGLEWVANIKQDGSETHYVDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYFCVKDRTDWELIRGYFGHWGQGTQITVSS,DIVMTQTPSSLSLSPGDRATLSCRASENIINYLAWYQQRPGQSPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRIIWPPYTFGQGTKVDIK,GFSFSNYW,IKQDGSET,VKDRTDWELIRGYFGH,ENIINY,DAS,QQRIIWPPYT,IGHJ1*01 (human),IGHV3-7*01 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
PDB,,,,,7P77,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVKNFEMEWYRKAPGKEREWVAAIQSGGVETYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCFVYVGRSYIGQGTQVTVS,,GFPVKNFE,IQSGGVET,FVYVGRSY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7P77,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALITVNGHTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAAWGYAWPLHQDDYWYWGQGTQVTVS,,GSISSITY,LITVNGHT,AAAAWGYAWPLHQDDYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7P78,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVKNFEMEWYRKAPGKEREWVAAIQSGGVETYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCFVYVGRSYIGQGTQVTVS,,GFPVKNFE,IQSGGVET,FVYVGRSY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7P78,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALITVNGHTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAAWGYAWPLHQDDYWYWGQGTQVTVS,,GSISSITY,LITVNGHT,AAAAWGYAWPLHQDDYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7P79,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVKNFEMEWYRKAPGKEREWVAAIQSGGVETYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCFVYVGRSYIGQGTQVTVS,,GFPVKNFE,IQSGGVET,FVYVGRSY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7P7A,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALITVNGHTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAAWGYAWPLHQDDYWYWGQGTQVTVS,,GSISSITY,LITVNGHT,AAAAWGYAWPLHQDDYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7RNJ,True,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSQYMHWVRQAPGQGLEWIGIINPSGVHTSYAQKFQGRVTLTRDTSTSTLYMELSSLRSEDTAVYYCARGSPKGAFDYWGQGTLVTVSS,EIVMMQSPGTLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPRFTFGPGTKVEIK,GYTFTSQY,INPSGVHT,ARGSPKGAFDY,QSVRSNY,GAS,QQYGSSPPRFT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7SJS,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYVMTWARQAPGKGLEWVSAISGTGYTYYADSVKGRFTVSRDNSKNTLFLQMSSLRAEDTAVYYCAITMAPVVWGQGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKRYAYWYQQKSGQAPILVIYEDKKRPSGIPERLSGSKSGTVATLTISGAQVEDEADYYCYSTDSSGNHAVFGGGTQLTVL,GFTFSSYV,ISGTGYT,AITMAPVV,ALPKRY,EDK,YSTDSSGNHAV,IGHJ6*01 (human),IGHV3-23*01 (human),IGLJ7*01 (human),IGLV3-10*01 (human)
PDB,,,,,7JW0,True,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIEMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,QSIGSY,AAS,QQSYVSPTYT,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7M7W,True,,,,,,,,QVRLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTVYLQWSSLKASDTAMYYCARQWSHYTYDYYYWGQGTLVTISS,QSVLTQPASVSGSPGQSITISCTGISSDVGGYNSVSWYQQHPGKAPKLMIYDVTNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPPYVFGTGTKVSVL,GYSFTSYW,IYPGDSDT,ARQWSHYTYDYYY,SSDVGGYNS,DVT,SSYTSSSTPPYV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7M7W,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRIILMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGDDDAFDIWGQGTLVTVYS,QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLTVL,GGIFNTYT,IILMSGMA,ARGFNGNYYGWGDDDAFDI,NSNIGAGYD,GNS,QSYDSSLSGPNWV,IGHJ5*01 (human),IGHV1-69*02 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,6WPT,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,6XC2,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDVYGLDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPKFTFGPGTKVEIK,GLTVSSNY,IYSGGST,ARDLDVYGLDV,QGISSY,AAS,QQLNSYPPKFT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,6XC4,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKSTLYLQMNSLRVEDTAVYYCARDFGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDFGDFYFDY,QSVSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,6XCM,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGWELPYDYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSNNFVVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARGEGWELPYDY,SSDVGGYKY,EVS,SSYEGSNNFVV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,6XDG,True,,,,,,,,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,GFTFSDYY,ITYSGSTI,ARDRGTTMVPFDY,QDITNY,AAS,QQYDNLPLT,IGHJ4*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,6XDG,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,GFTFSNYA,ISYDGSNK,ASGSDYGDYLLVY,SSDVGGYNY,DVS,NSLTSISTWV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
PDB,,,,,6XKP,True,,,,,,,,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARARGSSGWYRIGTRWGNWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSNVVFGGGTMLTVL,GFTFSDYY,ISSSGSTI,ARARGSSGWYRIGTRWGNWFDP,SSDVGGYNY,EVS,SSYTSSSNVV,IGHJ5*02 (human),IGHV3-11*01 (human),IGLJ2*01 (human),IGLV2-14*01 (human)
PDB,,,,,6XKQ,True,,,,,,,,QVQLVQSEAEVKEPGASVEVSCKASGYNFTNFAISWVRQAPGQGLEWMGWISGYNGDTNSAQKFLGRVTMTTDTSTTTAYMELRSLRSDDTAVYYCAGSDNYGFPYNGMDVWGQGTTVTVFN,QSALTQPPSASGSPGQSVTISCTGTSSDLGAYHFVTWYQHYPGKAPKVMIYGVRKRPSGVPDRFSGSKSGNTASLTVSGLQDEDEADYYCSSYAGNNDFVFGGGTKLTVL,GYNFTNFA,ISGYNGDT,AGSDNYGFPYNGMDV,SSDLGAYHF,GVR,SSYAGNNDFV,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,6YOR,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7A5R,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7AKD,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCSVSGGSISSHYWSWIRQPPGKGLEWIGYIYYSGSTNHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVLLWFGEPIFEIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIYGASTRAPGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEI,GGSISSHY,IYYSGST,ARGVLLWFGEPIFEI,QSVSSS,GAS,QQYNNWPLT,IGHJ3*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
PDB,,,,,7B3O,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVADAFDIWGQGTMVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPFTFGPGTKVDIK,GLTVSSNY,IYSGGST,ARDVADAFDI,QGISSY,AAS,QQLNSYPPFT,IGHJ3*02 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7BWJ,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAVVGIVVVPAAGRRAFDIWGQGTMVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL,GYSISSGYY,IYHSGST,ARAVVGIVVVPAAGRRAFDI,SSDVGGYNY,EVS,SSYAGSNNLV,IGHJ3*02 (human),IGHV4-38-2*02 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,7BYR,True,,,,,,,,QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARPQGGSSWYRDYYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,GYTFTSYA,INTNTGNP,ARPQGGSSWYRDYYYGMDV,QSISSW,KAS,QQYNSYPYT,IGHJ6*01 (human),IGHV7-4-1*02 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
PDB,,,,,7C01,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARVLPMYGDYLDY,QSISRY,AAS,QQSYSTPPEYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CAC,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7CDI,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK,GITVSSNY,IYSGGST,ARDLVVYGMDV,QSVSSSY,GAS,QQYGSSPT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7CDJ,True,,,,,,,,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDFSHQQLVPSWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,GFTFSDYY,ISSSGSTI,ARDFSHQQLVPS,QGISSY,AAS,QQLNSYPLT,IGHJ5*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CH4,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGIIVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARDLGPYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSDLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSDLYTFGQGTKLEIK,GIIVSSNY,IYSGGST,ARDLGPYGMDV,QGISSD,AAS,QQLNSDLYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CH5,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLNLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGVSSFLAWYQQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,EFIVSRNY,IYSGGST,ARDYGDYYFDY,QGVSSF,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7CHB,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTDYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCARDLGEAGGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,GITVSSNY,IYSGGST,ARDLGEAGGMDV,QGISSY,AAS,QQLNSYPPA,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CHH,True,,,,,,,,EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK,GFAFTTYA,ISDGGGSA,AKTRGRGLYDYVWGSKDY,QSLLHSNGYNY,LGS,MQALQTPGT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
PDB,,,,,7CHO,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCARALQVGATSDYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDYYCQSCDSSLSVVVFGGGTKLTVL,GFIVSSNY,IYSGGST,ARALQVGATSDYFDY,SSNIGAGYD,GNS,QSCDSSLSVVV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7CHP,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSFIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLQEHGMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHLNSYPPGYTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDLQEHGMDV,QGISSY,AAS,QHLNSYPPGYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CHS,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLHLNSYRTFGLGTKVEIK,GFTVSSNY,IYSGGST,ARDRDYYGMDV,QGISSY,AAS,LHLNSYRT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CJF,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLQELGSLDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQEANSFPYTFGQGTKLEIK,GFIVSSNY,IYSGGST,ARDLQELGSLDY,QGISSW,AAS,QEANSFPYT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-12*01 (human)
PDB,,,,,7EAM,True,,,,,,,,EVQLQQSGAELVRPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDPGDGDTEYDPSFQGKATITADTSSNTAYLELSSLTSEDTAVYYCTRFYDYVNYGMDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWSTPPWTFGGGTKLEVK,GFNIKDTY,IDPGDGDT,TRFYDYVNYGMDY,GNIHNY,NAK,QHFWSTPPWT,IGHJ4*01 (mouse),IGHV14-1*01 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,7EAN,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCTTSGFNIIDTYMHWVKQRPEEGLEWIGGIDPVNGNSEYDPKFQDKATITADTSSNTAYLHLSRLTSEDTAVYYCASAHYYGSSSSFPYWGQGTDLVTVSA,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTHVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGVGTDFTLTITNVQSEDLAEYFCQQYNSYFTFGSGTKLEIK,GFNIIDTY,IDPVNGNS,ASAHYYGSSSSFPY,QNVGTH,SAS,QQYNSYFT,IGHJ3*01 (mouse),IGHV14-3*02 (mouse),IGKJ4*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,7JX3,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTGSETYYYDSSGPFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQVFGGGTKLTVL,GFTFSNAW,IKSKTDGGTT,TTGSETYYYDSSGPFDY,SGSIASNY,EDN,QSYDSSNQV,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
PDB,,,,,7JX3,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7JX3,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIEMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,QSIGSY,AAS,QQSYVSPTYT,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7K43,True,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTVSS,EIVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKVEIK,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K8M,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,GFIVSSNY,IYSGGST,ARDYGDYYFDY,QSVSSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K8V,True,,,,,,,,QVQLQQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYMQWSSLKASDTAMYYCARSFRDDPRIAVAGPADAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISYWLAWYQQKPGKAPKLLIYQASSLESGVPSRFSGSESGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,GYSFTSYW,IYPGDSDT,ARSFRDDPRIAVAGPADAFDI,QSISYW,QAS,QQYNSYPYT,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
PDB,,,,,7K8W,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKLQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARANHETTMDTYYYYYYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYKYVSWYQRHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTSVVFGGGTQLTVL,GYTFTSYY,INPSGGST,ARANHETTMDTYYYYYYMDV,SSDVGGYKY,DVS,SSYTSSSTSVV,IGHJ6*04 (human),IGHV1-46*04 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7K8X,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWISPVSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAPLFPTGVLAGDYYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,GYTFTGYY,ISPVSGGT,ARAPLFPTGVLAGDYYYYGMDV,SSDVGSYNL,EGS,CSYAGSSTLV,IGHJ6*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,7LRS,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPNCSNVVCYDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYSASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGTSPWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,AAPNCSNVVCYDGFDI,QSVSSSY,SAS,QQYGTSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7M42,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNRGSIGYADSVKGRFTISRDNAKNSLYLQMSSLRAEDTALYYCAKDGERWDSVVVPSARNGMDVWGQGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSYVFGTGTKVTVL,GFTFDDYA,ISWNRGSI,AKDGERWDSVVVPSARNGMDV,SSNIGAGYD,GNS,QSYDSSLSGSYV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,7M42,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYMHWVRQAPGQGLEWMGWINPNSGGANYAQKFQGRVTLTRDTSITTVYMELSRLRFDDTAVYYCARGSRYDWNQNNWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNYVSWYQQHPGKAPKLMIFDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSFTTSSTVVFGGGTKLTVL,GYIFTGYY,INPNSGGA,ARGSRYDWNQNNWFDP,SSDVGTYNY,DVS,SSFTTSSTVV,IGHJ5*02 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7M6D,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7M6D,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGITVVRNYMTWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTMYLQMNSLRAEDTAIYYCARDLEVVGAMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPMYTFGQGTKLEIK,GITVVRNY,IYSGGTT,ARDLEVVGAMDV,QSVPSSY,GAS,QQYGSPMYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7M6F,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCSVSGFTVSSNYMNWVRQAPGKGLEWVSVIYPGGSTFYPDSVKGRFTISRDDSKNTLYLQMNSLRPEDTAAYYCASSRPPIGQLVPGLDLDWFDPWGQGTLVIVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYYVHWYQQHPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSGWVFGGGTKLTVL,GFTVSSNY,IYPGGST,ASSRPPIGQLVPGLDLDWFDP,SSNIGAGYY,GNS,QSYDSRLSGWV,IGHJ5*02 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,7M6G,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGWVSAYNGNTNYAQKLQGRVTMTTDTSTNTAYMELRSLRSDDTAIYYCAIPYSSVTFDCWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSGTFLAWYQQKPGQAPRLLISGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRPTFGQGTKLEIK,GYTFTSYA,VSAYNGNT,AIPYSSVTFDC,QSVSGTF,GAS,QQYGSSRPT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7M6H,True,,,,,,,,QVQLVQSGAEVKKAGASVKVSCKASGYTFTSYDINWVRQASGQGLEWMGWMNPISGNTGYAQKFQGRVTMTRNTSITTAYMELSSLRSEDTAVYFCARGGRYCSSTTCYSGVGMDVWGQGTTVTVPS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYHQLPGTAPKFLIYGNSNRPSGVPDRFSGSKSGTSASLAITRLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GYTFTSYD,MNPISGNT,ARGGRYCSSTTCYSGVGMDV,SSNIGAGYD,GNS,QSYDSSLSGWV,IGHJ6*01 (human),IGHV1-8*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,7MKL,True,,,,,,,,QVQLKESGPGLVAPSQSLSITCTVSGFSLTRYGVHWVRQPPGKGLEWLGVIWADGSTYYNSALMSRLSISKDNSKSQVFLNMNSLQTDDTAKYYCARDGRGYDDYWGQGTTLT,QIVLTQSPAIMSASPGEKVTMTCSASSTVSFIYWYQQKPGSSPRLLIYDTSNPASGVPVRFSGSGCGTSYYLTISRMEAEDAATYYCQQWNTYPLTFGAGTKLEL,GFSLTRYG,IWADGST,ARDGRGYDDY,STVSF,DTS,QQWNTYPLT,IGHJ2*01 (mouse),IGHV2-9*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
PDB,,,,,7MLZ,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSGGSCFDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGFPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIR,GFTFTSSA,IVVGSGNT,AAPYCSGGSCFDGFDI,QSVSSSY,GAS,QQYGNSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N4I,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFISYWIAWVRQMPGKGLEWMGIIYPGDSDTTYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARLLYYSDSSPLDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTPRTFGPGTKVDIK,GYSFISYW,IYPGDSDT,ARLLYYSDSSPLDS,QSISTY,AAS,QQSHSTPRT,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7N4J,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCSVSGDSISSSDYSWGWIRQPPGKGLEWIGTIYYIKNTYYNPSLRSRVTLSVDTSKNLFSLKLSSVTAADTAVYYCARERPPFDVVVVPAARPYNWFDPWGLGTLVIVSS,QSVLMQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDSSLSGSKVFGGGTKLTVL,GDSISSSDYS,IYYIKNT,ARERPPFDVVVVPAARPYNWFDP,SSNIGAGYD,GNN,QSYDSSLSGSKV,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7N4L,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLSLQMNSLRPEDTAVYYCAKDSPYYYDSSGYYPGYFQDWGQGSLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQTISDYLNWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPRTFGQGTKVEIK,GFTFSSYG,ISYDGSNK,AKDSPYYYDSSGYYPGYFQD,QTISDY,AAS,QQSYITPRT,IGHJ1*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7N4M,True,,,,,,,,QVQLQESGPRLVKPSETLSLTCTVSGGSISGSNYFWGWIRQPPGKGLEWIGTIYYGGSTYYNPSLKSRVTISVDTSENQFSLKLSSVTAADTAVYYCANLAWLRGYFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSVSLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL,GGSISGSNYF,IYYGGST,ANLAWLRGYFDY,SGSIASNY,EDN,QSYDSSNWV,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV6-57*03 (human)
PDB,,,,,7R6W,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7R6W,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAYKGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARPDYQVLGYDFWIGYYGMDVWGQGTTVIVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSEVVFGGGTKLTVL,GYTFTNYG,ISAYKGNT,ARPDYQVLGYDFWIGYYGMDV,SSNIGAGYD,GNT,QSYDSSLSGSEVV,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7R7N,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGPFSSSAISWVRQAPGQGLEWMGGIIPMVGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSRYCSGGSCYSVWFDPWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEMK,GGPFSSSA,IIPMVGTA,ARDSRYCSGGSCYSVWFDP,QSISSY,AAS,QQSYSTPRT,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7SN2,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGTNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLAYRDYVWRYFDLWGRGTLVTVSG,EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKFGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQCRSNWPPGITFGQGTRLEIK,GFTFSSYG,IWYDGTNT,ARDLAYRDYVWRYFDL,QSVSTY,DAS,QCRSNWPPGIT,IGHJ2*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
PDB,,,,,1HZH,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQDRVTFTADTSANTAYMELRSLRSADTAVYYCARVGPYSWDDSPQDNYYMDVWGKGTTVIVSS,EIVLTQSPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK,GYRFSNFV,INPYNGNK,ARVGPYSWDDSPQDNYYMDV,HSIRSRR,GVS,QVYGASSYT,IGHJ6*04 (human),IGHV1-3*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,6WS6,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KMG,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GGTFSNYA,IIPILGIA,ARGYYEARHYYYYYAMDV,QSISSY,AAS,QQSYSTPRT,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7L7E,True,,,,,,,,EVQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK,GFTFMSSA,IVIGSGNT,AAPYCSSISCNDGFDI,QSVSSSY,GAS,QHYGSSRGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7L7E,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIK,GFTFRDVW,IKSKIDGGTT,TTAGSYYYDTVGPGLPEGKFDY,QSVLYSSNNKNY,WAS,QQYYSTLT,IGHJ4*01 (human),IGHV3-15*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,7LD1,True,,,,,,,,QVQLVQSGAEVKKPGASVQVSCQASANTFTNHYIHWVRQAPGQGLEWMGIIYPTGGNTIYAQGFQGRVTMTRDTSLNTIYLELSSLRSEDTAVYYCARDVRVDDSWSGYDLLSGGTYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSVLYSSNNENYLAWYQQKPGQPPKLLIYWASTRESGIPDRFSGSGSGTDFTLTISRLQAEDVAVYYCQQYYSLPRTFGQGTKVEIK,ANTFTNHY,IYPTGGNT,ARDVRVDDSWSGYDLLSGGTYFDY,QSVLYSSNNENY,WAS,QQYYSLPRT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7MMO,True,,,,,,,,QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL,GFSLSISGVG,IYWDDDK,AHHSISTIFDH,SSDVGDYNY,EVS,SSYTTSSAV,IGHJ1*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*01 (human)
PDB,,,,,7RAL,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRIILMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGDDDAFDIWGQGTLVTVYS,QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLTVL,GGIFNTYT,IILMSGMA,ARGFNGNYYGWGDDDAFDI,NSNIGAGYD,GNS,QSYDSSLSGPNWV,IGHJ5*01 (human),IGHV1-69*02 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,7BEI,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSIIYSGGTTYYADSVKGRFTISRDSSMNTLYLQMNSLRAEDTAVYYCARDLMVYGIDVWGQGTTVTVSS,EIVMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLDSYPPGYTFGQGTKVDIK,GVTVSSNY,IYSGGTT,ARDLMVYGIDV,QGISSY,AAS,QQLDSYPPGYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CWL,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,2QQN,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK,GFTFSSYA,ISPAGGYT,ARGELPYYRMSKVMDV,QYFSSY,GAS,QQYLGSPPT,IGHJ6*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CAK,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7B18,True,,,,,,,,QVQLVETGGGFVQPGGSLRLSCAASGVTLDYYAIGWFRQAPGKEREGVSCIGSSDGRTYYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCALTVGTYYSGNYHYTCSDDMDYWGKGTQVTVSS,,GVTLDYYA,IGSSDGRT,ALTVGTYYSGNYHYTCSDDMDY,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
PDB,,,,,7B18,True,,,,,,,,QVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMGWARQVPGKGLEWVSYIYSDGSTEYQDSVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCATEGSLGGWGRDFGSWGQGTQVTVSS,,GFTFSSYA,IYSDGST,ATEGSLGGWGRDFGS,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7KKK,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGIIFGRNAMGWYRQAPGKERELVAGITRRGSITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPASPAPGDYWGQGTQVTVSS,,GIIFGRNA,ITRRGSIT,AADPASPAPGDY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7KSG,True,,,,,,,,QVQLVETGGGFVQPGGSLRLSCAASGVTLDYYAIGWFRQAPGKEREGVSCIGSSDGRTYYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCALTVGTYYSGNYHYTCSDDMDYWGKGTQVTVSS,,GVTLDYYA,IGSSDGRT,ALTVGTYYSGNYHYTCSDDMDY,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
PDB,,,,,7THE,False,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGRVTITADKSTSTAYLELSSLRSEDTAVYYCARYMVTRDQYYYDMDVWGQGTTVTVS,,GGTFSSYA,IIPMFGIA,ARYMVTRDQYYYDMDV,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
PDB,,,,,7THE,False,,,,,,,,,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSPPPTFGQGTKLEI,,,,QSISNY,AAS,QQSYSPPPT,,,IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,6YLA,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7CAN,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVEVWRMEWYRQAPGKEREGVAAIESYGHGTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVYDDGQLAYHYDYWGQGTQVTVSA,,GFPVEVWR,IESYGHGT,NVYDDGQLAYHYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7K9Z,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGGIIPMFGTTNYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDRGDTIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNGFPLTFGPGTKVDIK,GYTFTSYG,IIPMFGTT,ARDRGDTIDY,QGISNN,AAS,QQGNGFPLT,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,7K9Z,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGGTFSTYGISWVRQAPGQGLEWMGWISPNSGGTDLAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASDPRDDIAGGYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGQGTKLEIK,GGTFSTYG,ISPNSGGT,ASDPRDDIAGGY,QSVLYSSNNKNY,WAS,QQYYSTPPT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
PDB,,,,,7C2L,True,,,,,,,,EVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPDLFDYYYGMDVWGQGTTVTVSS,EIVMTQSPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCTQATQFPYTFGQGTKVDIK,GYTLTELS,FDPEDGET,ATSTAVAGTPDLFDYYYGMDV,QSLVHSDGNTY,KIS,TQATQFPYT,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ3*01 (human),IGKV2-24*01 (human)
PDB,,,,,3IGA,True,,,,,,,,QVQLQQPGAELVKPGASVKLSCKASGYTFTSDWIHWVKQRPGHGLEWIGEIIPSYGRANYNEKIQKKATLTADKSSSTAFMQLSSLTSEDSAVYYCARERGDGYFAVWGAGTTVTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTDIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIANYYCQQSNRWPFTFGSGTKLEIK,GYTFTSDW,IIPSYGRA,ARERGDGYFAV,QSIGTD,YAS,QQSNRWPFT,IGHJ1*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,6W41,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7L0N,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIQMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,QSIGSY,AAS,QQSYVSPTYT,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7L0N,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7TN0,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,,,,QTVSSTS,GAS,QQHDTSLT,,,IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7TN0,False,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,,,,IGHJ5*01 (human),IGHV1-18*01 (human),,
PDB,,,,,7TN0,False,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,,,,IGHJ5*01 (human),IGHV1-18*01 (human),,
PDB,,,,,7TN0,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,,,,QTVSSTS,GAS,QQHDTSLT,,,IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7TN0,False,,,,,,,,,DIQMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,,,,QSIGSY,AAS,QQSYVSPTYT,,,IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7TN0,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
PDB,,,,,7TN0,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
PDB,,,,,7TN0,False,,,,,,,,,DIQMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,,,,QSIGSY,AAS,QQSYVSPTYT,,,IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,6XCN,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGWELPYDYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSNNFVVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARGEGWELPYDY,SSDVGGYKY,EVS,SSYEGSNNFVV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,7NX8,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7NX8,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,2DD8,True,,,,,,,,QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGGITPILGIANYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARDTVMGGMDVWGQGTTVTVSS,YELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVFGTGTKVTVL,GGTFSSYT,ITPILGIA,ARDTVMGGMDV,NIGSKS,DDS,QVWDSSSDYV,IGHJ6*01 (human),IGHV1-69*16 (human),IGLJ1*01 (human),IGLV3-21*03 (human)
PDB,,,,,2GHW,True,,,,,,,,EVQLVQSGGGVVQPGKSLRLSCAASGFAFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRSYYLDYWGQGTLVTVSS,TTLTQSPATLSLSPGERATLSCRASQSVRSNLAWYQQKPGQAPRPLIYDASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSNWPPTFGQGTKVEVK,GFAFSSYA,ISYDGSNK,ARDRSYYLDY,QSVRSN,DAS,QQRSNWPPT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,3BGF,True,,,,,,,,EVQLEESGTVLARPGASVKMSCKASGYTFTTYRMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKDKAKLTAVTSTSSAYMELSSLTNEDSAVYFCTREGIPQLLRTLDYWGQGTSVTVSS,DILMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQEKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYVSYPWTFGGGTKLEIK,GYTFTTYR,IYPGNSDT,TREGIPQLLRTLDY,QEISGY,AAS,LQYVSYPWT,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
PDB,,,,,6WAQ,True,,,,,,,,QVQLQESGGGLVQAGGSLRLSCAASGRTFSEYAMGWFRQAPGKEREFVATISWSGGSTYYTDSVKGRFTISRDNAKNTVYLQMNSLKPDDTAVYYCAAAGLGTVVSEWDYDYDYWGQGTQVTVSS,,GRTFSEYA,ISWSGGST,AAAGLGTVVSEWDYDYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,7BNV,True,,,,,,,,QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARHPSPYYYGSGSYSGGFDYWGQGTLVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDNWPLMHTFGQGTKLEIK,GYSFTSYW,IYPGDSDT,ARHPSPYYYGSGSYSGGFDY,QSVSSSY,GAS,QQYDNWPLMHT,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV3-15*01 (human)
PDB,,,,,7C8V,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYSWNMWWYRQAPGKEREWVAAIESHGDSTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCYVWVGHTYYGQGTQVTVSA,,GFPVYSWN,IESHGDST,YVWVGHTY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7D2Z,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVWQGEMAWYRQAPGKEREWVAAISSMGYKTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVMVGFWYAGQGTQVTVSA,,GFPVWQGE,ISSMGYKT,AVMVGFWY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7DET,True,,,,,,,,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,GYSFTSYW,IHPSDSET,ARADGYEWYFDV,ESVDSYGNSF,RAS,QQSNEDPWT,IGHJ2*01 (human),IGHV1-46*01 (human),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
PDB,,,,,7DEU,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGDNTYNQKLKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSASSRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,INPNNGDN,ARDGYPYYYALDY,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-22*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,7E5R,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7E5R,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTV,SVLTQAPSVSGAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7E5R,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7E8M,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS,EIVLTQSPGTLSISPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK,GITVSSNY,IYSGGST,ARDLVVYGMDV,QSVSSSY,GAS,QQYGSSPT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7JMO,True,,,,,,,,QVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLERAGGMDVWGQGTMVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLYTFGQGTKVDIK,GFTVSSNY,IYSGGST,ARDLERAGGMDV,QSVSSSY,GAS,QQYGSLYT,IGHJ6*01 (human),IGHV3-53*02 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7JVB,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAVSGAGAHRVGWFRRAPGKEREFVAAIGASGGMTNYLDSVKGRFTISRDNAKNTIYLQMNSLKPQDTAVYYCAARDIETAEYIYWGQGTQVTVSS,,GAGAHR,IGASGGMT,AARDIETAEYIY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7KGJ,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYRDRMAWYRQAPGKEREWVAAIYSAGQQTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDVGHHYEYYDYWGQGTQVTVSA,,GFPVYRDR,IYSAGQQT,NVKDVGHHYEYYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KN3,True,,,,,,,,QVQLVQSGGGLIQPGGSLRLSCAASGFTVSLSHMNWVRQAPGKGLEWVSITYGDGNSDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREYYYGMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSLPLTFGGGTKLEIK,GFTVSLSH,TYGDGNS,AREYYYGMDV,QSVLYSSNNKNY,WAS,QQYYSLPLT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,7LOP,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7LOP,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREVMVRGALPPYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPVTFGGGTKVEIK,GYTFTGYY,INPNSGGT,AREVMVRGALPPYGMDV,QSVSSY,DAS,QQRSNWPPVT,IGHJ6*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,7MF1,True,,,,,,,,QVQLVQSGAEVKKPGSSVRVSCKASGGTFSTYPISWVRQAPGQGLEWMGGIIPIFGTAKSAQKFQGRVTITADEFTSTAYMEMSSLRSEDTAMYYCAREGRRYGSGWYISTGYFDYWGQGTLVTVSS,QLVLTQPASVSGSPGQSIIVSCTGTSSDVGGYKFVSWYQQHPGKAPRVMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQADDEADYYCSSYTNSSTVVFGGGTKVTVL,GGTFSTYP,IIPIFGTA,AREGRRYGSGWYISTGYFDY,SSDVGGYKF,DVS,SSYTNSSTVV,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7MFU,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVQAREMEWYRQAPGKEREWVAAIKSTGTYTAYAYSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCYVYVGSSYIGQGTQVTVSA,,GFPVQARE,IKSTGTYT,YVYVGSSY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7MFU,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALITVNGHTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAAWGYAWPLHQDDYWYWGQGTQVTVSA,,GSISSITY,LITVNGHT,AAAAWGYAWPLHQDDYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7MJI,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWIGRMYNNGRTSYNPSLKSLVTISRDNSKNTLYLQMNSLRAEDTATYYCARDNLGYRPSENLYGMDVWGQGTTVTVSS,,GFTFDDYA,MYNNGRT,ARDNLGYRPSENLYGMDV,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7MJL,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGYGDYYFDYWGQGTLVTVSS,DVVMTQSPATLSLSPGEKATLSCRASQSVSSYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSPLTFGGGTKVEIK,GFTVSSNY,IYSGGST,ARGYGDYYFDY,QSVSSY,WAS,QQYGSSPLT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
PDB,,,,,7MZH,True,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSYYDYWGQGTLVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGHNAVHWYQQLPGKAPKLLIYYDDLLPAGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDILNGPVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARSYYDY,SSNIGHNA,YDD,AAWDDILNGPV,IGHJ4*01 (human),IGHV1-2*06 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
PDB,,,,,7MZJ,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGWGAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQSVSISCSGTYSNIGSNPVNWYQQVPGTAPKLLIYANDQRPSGVPDRFSGSKSATSAFLAIGGLQSEDDADYYCSTWDDSLPGPLFGGGTKLTVL,GFTFSRFA,ISGSGGST,AKVGWGAFDI,YSNIGSNP,AND,STWDDSLPGPL,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,7MZJ,True,,,,,,,,VVQLVESGGGLVKPGGSLRLSCAASGFTFSYAWMSWVRQAPGKGLEWVGRIKRKSDGGTTDYAAPVKGRFTISRDDSKNTLYLQMSSLKTEDTAVYYCTTDLCRSTSCEHDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTVTCRASQSIRSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPAITFGQGTRVQIK,GFTFSYAW,IKRKSDGGTT,TTDLCRSTSCEHDAFDI,QSIRSY,AAS,QQSYTTPAIT,IGHJ3*02 (human),IGHV3-15*01 (human),IGKJ5*01 (human),IGKV1-39*01 (human)
PDB,,,,,7MZM,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGPEWVSYISGGSSFTNYADSVQGRFTIYRDNAKNSMFLRMNSLRAEDTAVYYCARSPPTGDSSDWYDSPAYNNYYMDVWGKGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPTVTFGQGTRLEIK,GFTFSDYY,ISGGSSFT,ARSPPTGDSSDWYDSPAYNNYYMDV,QSVSSSY,GAS,QQYGTSPTVT,IGHJ6*04 (human),IGHV3-11*05 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N3I,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYSSGGTDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,GFTVSSNY,IYSGGST,ARDLYSSGGTDI,QSVSSSY,GAS,QQYGSSPGT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NEG,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGLTVNRNYMSWIRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAIYYCARDFYEGSFDIWGQGTMVTVSS,AIQLTQSPSFLSASIGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFASYYCQQLNSYPAPVFGPGTKVDIK,GLTVNRNY,IYSGGST,ARDFYEGSFDI,QGISSY,AAS,QQLNSYPAPV,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7NX6,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7NX6,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NX9,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NX9,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7NXA,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NXA,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7PRY,True,,,,,,,,EVQLVESGPGLVKPSETLSLTCTVSGGSISSSSHYWGWIRQPPGKGLEWIGSIYYSESAYYNPSLKSRVTMSIDTSKNQFSLKLNSVTAADTAVYYCARVTEPRWTSCYFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRTSQSVTSYLAWYQQRPGQAPRLLIYDASDRATGIPARFSGSGSGTDFTLTISNLEPEDFAVYYCQLRSNWPPITFGQGTRLETK,GGSISSSSHY,IYYSESA,ARVTEPRWTSCYFDY,QSVTSY,DAS,QLRSNWPPIT,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
PDB,,,,,7PRY,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVLSYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGSYAYYYYMDVWGKGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGGGSGTDFTFTITSLQPEDIATYYCQQYDNLPLTFGGGTKVDIK,GFTFSTYA,LSYDGSNK,AKGGSYAYYYYMDV,QDISNY,DAS,QQYDNLPLT,IGHJ6*04 (human),IGHV3-30-3*02 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7PRZ,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGIHWVRQAPGKGLEWVAVISYDGSHKYYADSVKGRFTISRDNSKNTLYLQMNSLKTEDTAVYYCAKDSSAAIPYYYYGMDVWGQGTTVTVSS,AIQMTQSPDSLAVSLGERATINCKSSQSILYNSNNKTYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPLIFGPGTKVDIK,GFTFSNYG,ISYDGSHK,AKDSSAAIPYYYYGMDV,QSILYNSNNKTY,WAS,QQYYSIPLI,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ3*01 (human),IGKV4-1*01 (human)
PDB,,,,,7PS0,True,,,,,,,,QVQLVQSGPGLVKPSQTLSLTCSVSDGSISSSDYYWSWIRQPPGKGLEWIGYIYYTGSTYYNPSLKSRVSISVDRSKNQFSLKLSSVTAADTAVYYCARLVVPSPKGSWFDPWGQGTLVTVSS,SYELTQPASVSGSPGQSITISCTGTSIDVGNYNLASWYQQHPGKAPKLIIYEGSRRPSGVSNRFSGAKSGNTASLTISGLQAEDEADYYCCSYVGSSTYVFGSGTKVTVL,DGSISSSDYY,IYYTGST,ARLVVPSPKGSWFDP,SIDVGNYNL,EGS,CSYVGSSTYV,IGHJ5*02 (human),IGHV4-30-4*01 (human),IGLJ1*01 (human),IGLV2-23*01 (human)
PDB,,,,,7PS1,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGLTVRSNYMNWVRQAPGKGLEWVSLIYSGGSTFYADSVKGRFTISRHDSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSSSLAWYQQKHGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISGLEPEDFAVYYCQQYGSSPLFGGGTKVEIK,GLTVRSNY,IYSGGST,ARDLVVYGMDV,QSVSSSS,GTS,QQYGSSPL,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7PS2,True,,,,,,,,QVQLVQSGAEVKKPGESLRISCKGSGHNSPSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLQASDTAIYYCARHVVALTHLYPDYWGQGTLVTVSS,DIQMTQSPATLSVSPGERATLSCRASQSVSSTLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWSTWTFGQGTKVDIK,GHNSPSYW,IDPSDSYT,ARHVVALTHLYPDY,QSVSST,GAS,QQYNNWSTWT,IGHJ4*01 (human),IGHV5-10-1*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,7PS2,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHRVRQAPGKGLEWVALISYEESNRYYGDSVRGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCAKDQGPATVMVTAIRGAMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYFGSPSITFGQGTRLEIK,GFTFSNYG,ISYEESNR,AKDQGPATVMVTAIRGAMDV,QSVLYSSNNKNY,WAS,QQYFGSPSIT,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ5*01 (human),IGKV4-1*01 (human)
PDB,,,,,7PS4,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGDSGTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDSAMYYCARSRVGATGGYYDYYMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNLGGNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGTGTKVTVL,GYSFTNYW,IYPGDSGT,ARSRVGATGGYYDYYMDV,SSNLGGNT,SNN,AAWDDSLNGPV,IGHJ6*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
PDB,,,,,7PS5,True,,,,,,,,QVQLVESGPEMKKPGTSVKVSCKASGFTFITSAVQWVRQARGQRLEWMGWIAVGSGNTNYAQKFQDRVTINRDMSTSTAYMELSSLRSEDTAVYYCAAPHCNRTSCHDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRNYLAWYQQKPGQVPRLLIYGASSRATGIPDRFRGSGSGTDFTLTINRLESEDFAVYYCQQYGSSLFTFGPGTKVDIK,GFTFITSA,IAVGSGNT,AAPHCNRTSCHDGFDI,QSVSRNY,GAS,QQYGSSLFT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7PS6,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVFGGSITSSNHYWVWIRQPPGKGLEWIGSMYYSGSTAYNPSLTNRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQIGPKRPSQVADWFDPWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,GGSITSSNHY,MYYSGST,ARQIGPKRPSQVADWFDP,QGISSY,AAS,QQLNSYPLT,IGHJ5*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7PS6,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISPYNGNTHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGELLGWFDPWGQGTLVTVSS,QSVVTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYAGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,GYTFTSYG,ISPYNGNT,ARDGELLGWFDP,SSDVGSYNL,AGS,CSYAGSSTWV,IGHJ5*02 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV2-23*01 (human)
PDB,,,,,7PS7,True,,,,,,,,QVQLVESGPGQVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVFYCARHAAPSPGDNWFDPWGQGTLVTVSS,QSVLTQPPSVSVSPGQTARITCSGDALSTQNGNWYQQKPGQAPVMVICKDSERPSGIPERFSGSRSGTTVTLTISGVQAEDEADYHCQSADNRAHVVFGGGTKLTVL,GGSISSSSYY,IYYSGSA,ARHAAPSPGDNWFDP,ALSTQN,KDS,QSADNRAHVV,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
PDB,,,,,7Q0G,True,,,,,,,,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVSS,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,GFTVSSNY,IYSGGST,ARDHVRPGMNI,QDISNY,DAS,QQYDNLPVT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7Q0G,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSVISWVRQAPGQGLEWMGGIIPLFGSANYAQKFQGRVTITADESTSTAYMEMTSLRSEDTAVYYCAKVSQWALILFWGQGTLVTVSS,AIRMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPSWTFGQGTKVEIK,GGTFSSSV,IIPLFGSA,AKVSQWALILF,QSVSSSY,GAS,QQYGTSPSWT,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7Q0H,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVFGGSITSSNHYWVWIRQPPGKGLEWIGSMYYSGSTAYNPSLTNRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQIGPKRPSQVADWFDPWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,GGSITSSNHY,MYYSGST,ARQIGPKRPSQVADWFDP,QGISSY,AAS,QQLNSYPLT,IGHJ5*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7Q0H,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASRGTFNTYVFTWVRQAPGQGLEWMGGIIPFFGTADYAQKFQGRVTITADDSTSTAYMELSSLRSEDTAVYYCSRLSQWDLLPMWGQGTLVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQSFTSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGTGSGTDFTLTISRLEPEDFAVYYCQQYGTSPRMYTFGQGTKVDIK,RGTFNTYV,IIPFFGTA,SRLSQWDLLPM,QSFTSSY,GAS,QQYGTSPRMYT,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7QNW,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSRYYWGWIRQPPGKGLEWIGTFYYSGITYYNPSLKSRVTIFVDTSKNQFSLKLSSVTAADTAVYYCARPRPPDYYDNSGALLFDIWGQGTMVTVSS,AIRMTQSPSTLSASVGDRVTIACRASQSISAWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTINSLQPDDFATYYCQQYISSSPWTFGQGTKVEIK,GDSISSSRYY,FYYSGIT,ARPRPPDYYDNSGALLFDI,QSISAW,KAS,QQYISSSPWT,IGHJ3*02 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
PDB,,,,,7QNW,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7RKS,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCASGYTGYDYFVRGDYYGLDVWGQGTTVTVSS,QPVLTQSPSASASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLNTDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGILVFGGGTKLTVL,GFTFSNYA,ISYDGSNK,ASGYTGYDYFVRGDYYGLDV,SGHSSYA,LNTDGSH,QTWGTGILV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
PDB,,,,,7S4S,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFIVSRNYMIWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLEVAGAIDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGATSRATGTPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYGSSPGYTFGQGTKLEIK,GFIVSRNY,IYSGGST,ARDLEVAGAIDY,QSISSSY,GAT,QQYGSSPGYT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7VNB,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASDFSFYDYEMSWVRQAPGKALEWIGSMYHSGRTYINPSLKSLVTISRDNSKNTLYLQMNSLRAEDTAMYYCVSNWASGSTGDYWGQGTLVTVSS,,DFSFYDYE,MYHSGRT,VSNWASGSTGDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7W9F,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWIGGINPNIGDTSYNQNFKGKATLTVDRSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDHWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSTSYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFGGGTKLEIK,GYTFTEYT,INPNIGDT,ARDGYPYYYALDH,QNVGTN,STS,QQYNSYPYT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ2*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,6NB6,True,,,,,,,,QAQLVESGGALVQPGRSLRLSCAASGFTFRNYAMHWVRQAPATGLQWLAVITSDGRNKFYADSVKGRFTISREDSKNTLYLQMDSLRGEDTAVYYCVTQRDNSRDYFPHYFHDMDVWGQGTTVAVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGDTYLNWFQQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGSHWPPTFGQGTKVEIK,GFTFRNYA,ITSDGRNK,VTQRDNSRDYFPHYFHDMDV,QSLVYSDGDTY,QVS,MQGSHWPPT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
PDB,,,,,7K8Z,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,GFTFSSYA,IPFDGRNK,ASSSGYLFHSDY,QSISNW,EAS,QQYNSYPWT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
PDB,,,,,7K90,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNRLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,GFTVSNNY,IYSGGST,AREGEVEGYNDFWSGYSRDRYYFDY,SSDVGGYNY,DVS,SSYTSSSTRV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,1IGM,True,,,,,,,,EVHLLESGGNLVQPGGSLRLSCAASGFTFNIFVMSWVRQAPGKGLEWVSGVFGSGGNTDYADAVKGRFTITRDNSKNTLYLQMNSLRAEDTAIYYCAKHRVSYVLTGFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLAWYQQKPGKAPELRIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYQNLPLTFGPGTKVDIK,GFTFNIFV,VFGSGGNT,AKHRVSYVLTGFDS,QDISNY,DAS,QQYQNLPLT,IGHJ5*01 (human),IGHV3-23*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,4F57,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCVASGFSFSDFGMNWVRQAPGKGLEWVAFVPFDRRINYYAESVRGRFTISRDDSKNTVFLQMDSLRPEDTAIYYCAKHRSQWNFWPREGGLDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYRQHPGEAPKAIIFDVTNRPSGISNRFSGSKFGNTASLTISGLQAEDEADYYCAAYTVASTLLFGGGTKVTVL,GFSFSDFG,VPFDRRIN,AKHRSQWNFWPREGGLDH,SSDVGGYNY,DVT,AAYTVASTLL,IGHJ1*01 (human),IGHV3-30*02 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,5JMO,True,,,,,,,,QVQLQESGGGLVQPGGSLTLSCAASGFTFSSYSMYWVRQAPGKGLEWVSSINRVGSNTDYADSVKGRFTISRDNAKNTLYLQMNSLKSEDTALYYCAVGMYAAPPWRGQGTQVTVSS,,GFTFSSYS,INRVGSNT,AVGMYAAPPW,,,,IGHJ5*02 (human),IGHV3-74*01 (human),,
PDB,,,,,6W7Y,True,,,,,,,,EVQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,6ZDH,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,6ZHD,True,,,,,,,,QVQLVESGGGLMQAGGSLRLSCAVSGRTFSTAAMGWFRQAPGKEREFVAAIRWSGGSAYYADSVKGRFTISRDKAKNTVYLQMNSLKYEDTAVYYCAQTHYVSYLLSDYATWPYDYWGQGTQVTVSS,,GRTFSTAA,IRWSGGSA,AQTHYVSYLLSDYATWPYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7BZ5,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCAREAYGMDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPYTFGQGTKLEIK,GFIVSSNY,IYSGGST,AREAYGMDV,QGISSY,AAS,QQLNSYPPYT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CAH,True,,,,,,,,VQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7CAI,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,1F11,True,,,,,,,,EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMKWVKQSHGKSLEWIGDINPNNGGTGYNQKFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCANDYGSTYGFAYWGQGTLVTVSA,DMVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLKSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIK,GYTFTDYY,INPNNGGT,ANDYGSTYGFAY,QSVDYDGDSY,VAS,QQSNEDPFT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ4*01 (mouse),IGKV3-4*01 (mouse)
PDB,,,,,1V7M,True,,,,,,,,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKVNNHAIHYAESVKGRFTVSRDDSKSSVYLQMNSLRAEDTGIYYCSGWSFLYWGQGTLVTVSA,QVVLTQSPGIMSASPGEKVTITCSASSSVSYMYWFQQKPGTSPKLWIYSTSNLASGVPARFRGSGSGTSYSLTISRMEAEDAATYYCQQRSGYPRTFGGGTKLEIK,GFTFSDAW,IRSKVNNHAI,SGWSFLY,SSVSY,STS,QQRSGYPRT,IGHJ3*01 (mouse),IGHV6-6*01 (mouse),IGKJ1*01 (mouse),IGKV4-57*01 (mouse)
PDB,,,,,1V7N,True,,,,,,,,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKVNNHAIHYAESVKGRFTVSRDDSKSSVYLQMNSLRAEDTGIYYCSGWSFLYWGQGTLVTVSA,QVVLTQSPGIMSASPGEKVTITCSASSSVSYMYWFQQKPGTSPKLWIYSTSNLASGVPARFRGSGSGTSYSLTISRMEAEDAATYYCQQRSGYPRTFGGGTKLEIK,GFTFSDAW,IRSKVNNHAI,SGWSFLY,SSVSY,STS,QQRSGYPRT,IGHJ3*01 (mouse),IGHV6-6*01 (mouse),IGKJ1*01 (mouse),IGKV4-57*01 (mouse)
PDB,,,,,7LQV,True,,,,,,,,QVQLVQSGAEVKKAGSSVKVSCKASGGTFSSHTITWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCASLQTVDTAIEKYYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,GGTFSSHT,IIPILGIA,ASLQTVDTAIEKYYGMDV,KLGDKY,QDN,QAWDSSTAV,IGHJ6*01 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,6WPS,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,6XEY,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYTQMFQGRVTMTRDTSISTAYMEVSRLRSDDTAVYYCARDRSWAVVYYYMDVWGKGTTVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARDRSWAVVYYYMDV,SSDVGGYNY,EVS,SSYAGSNNLV,IGHJ6*04 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,6YZ5,True,,,,,,,,QVQLVESGGGLMQAGGSLRLSCAVSGRTFSTAAMGWFRQAPGKEREFVAAIRWSGGSAYYADSVKGRFTISRDKAKNTVYLQMNSLKYEDTAVYYCARTENVRSLLSDYATWPYDYWGQGTQVTVSS,,GRTFSTAA,IRWSGGSA,ARTENVRSLLSDYATWPYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6ZER,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7JMP,True,,,,,,,,QVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYTGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAHVDTAMVESGAFDIWGQGTRVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVTKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,GFTVSSNY,IYTGGTT,ARAHVDTAMVESGAFDI,SSDVGSYNL,EVT,CSYAGSSTWV,IGHJ3*02 (human),IGHV3-53*02 (human),IGLJ3*02 (human),IGLV2-23*02 (human)
PDB,,,,,7JMW,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,GYTFTSYY,INSSGGST,ARPPRNYYDRSGYYQRAEYFQH,QDISNY,DAS,QQYDNPPLT,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7JV2,True,,,,,,,,EVQLVESGGDSVQPGGSLRLSCAAAGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCALSSGYSGYAGNYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGARPEDEAEYYCLLSYSGARGVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ALSSGYSGYAGNY,TGAVTSGHY,DTS,LLSYSGARGV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV7-46*01 (human)
PDB,,,,,7JVC,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARVWWLRGSFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHVVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ARVWWLRGSFDY,SGSIASNY,EDN,QSYDSSNHVV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
PDB,,,,,7K8S,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGRPSDIVVVVAFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSIYG,ISYDGSNK,AKEGRPSDIVVVVAFDY,QSISSY,AAS,QQSYSTPRT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7K8U,True,,,,,,,,QVQLQQWGAGLLKPSETLSLSCAVYGGSLSGYYWSWIRQPPGKGLEWIGEINHFGSTGYNPSLKSRVTISVDTSKSQFSVKLSSVTAADTAVYYCARKPLLYSNLSPGAFDIWGQGTMVTVSS,EIVLTQSPGTVSLSPGERATLSCWASQSVSASYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTTPRTFGGGTKVEIK,GGSLSGYY,INHFGST,ARKPLLYSNLSPGAFDI,QSVSASY,GAS,QQYGTTPRT,IGHJ3*02 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KFV,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGATYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLISYPGTFGQGTKLEIK,GFTVSSNY,IYSGGAT,ARGDVSGYRYGLDY,QGISSY,AAS,QQLISYPGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7LAA,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGVTFSSYWMSWVRQAPGKGLEWVANIRQDGSEKYSVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARARRADNSGYYGFHFDCWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSDSKSGTSASLAITRLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,GVTFSSYW,IRQDGSEK,ARARRADNSGYYGFHFDC,SSNIGAGYD,GNN,QSYDSSLSGWV,IGHJ5*01 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,7LCN,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPELSMHWVRQAPGKGLEWMGGFHPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGSPFGVVTDWFDPWGRGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNPYVFGTGTKVTVL,GYTLPELS,FHPEDGET,ATGSPFGVVTDWFDP,SSDVGGYNY,EVS,SSYAGSNNPYV,IGHJ2*01 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-8*01 (human)
PDB,,,,,7LRT,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPNCSNVVCYDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYSASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGTSPWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,AAPNCSNVVCYDGFDI,QSVSSSY,SAS,QQYGTSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7MY2,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGLTFSKYAMGWFRQAPGKERKFVATISWSGDSAFYADSVKGRFTISRDNARNTVYLQMNSLKPEDTAVYYCAADRGMGYGDFMDYWGQGTSVTASS,,GLTFSKYA,ISWSGDSA,AADRGMGYGDFMDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7MY3,True,,,,,,,,QVKLEESGGGSVQAGGSLRLICTAPGLTHNNCGLDWYRRAPGKEREFVSSISADGTTSYADSVKGRFTISKDKVEDTVYLQMNSLKPEDTAIYSCKTAFPYFGNSCVLDYWGQGTSVTVSS,,GLTHNNCG,ISADGTT,KTAFPYFGNSCVLDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7RA8,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRIILMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGDDDAFDIWGQGTLVTVYS,QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLTVL,GGIFNTYT,IILMSGMA,ARGFNGNYYGWGDDDAFDI,NSNIGAGYD,GNS,QSYDSSLSGPNWV,IGHJ5*01 (human),IGHV1-69*02 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,5W9P,True,,,,,,,,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,5C6T,True,,,,,,,,QLQLQESGPGLVKPSETLSLTCTVSGASIDRSTYYWGWIRQPPGKGLEWIANIYYNGRAVYSPSLKSRVTISVDTSKNQFSLKVRSLTAADTAVYYCATRWNYFFDFDYWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIETNYVSWYQQFPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEAEYYCGTWDDNSWVFGGGTKLTVL,GASIDRSTYY,IYYNGRA,ATRWNYFFDFDY,SSNIETNY,RNN,GTWDDNSWV,IGHJ2*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
PDB,,,,,6OZC,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,7L09,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,5H2B,True,,,,,,,,QVKLQESGAELVKPGASVKLSCKASGYTFTNYWMHWVKLRPGQGFEWIGEINPSNGGSNYNEKFKRKATLTVDKSSSTAYMQLSSLTSEDSAVFYCSIWDSYFDYWGQGTTLTVSS,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,GYTFTNYW,INPSNGGS,SIWDSYFDY,ENVVTY,GAS,GQGYSYPYT,IGHJ2*01 (mouse),IGHV1-53*01 (mouse),IGKJ2*01 (mouse),IGKV6-20*01 (mouse)
PDB,,,,,7DCC,True,,,,,,,,EVQLQESGPSLVKPSQTLSLTCSVTGDSITNGYWNWIRKFPGNKLEYMGYISYSGSTYYSPSLKSRISITRDTSKNQHYLQLNSVTSEDTATYYCASDYHGSKYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGHRVSITCKASQDVGNDVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNRYPYTFGGGTKLEIK,GDSITNGY,ISYSGST,ASDYHGSKYYFDY,QDVGND,WAS,QQYNRYPYT,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
PDB,,,,,7DK4,True,,,,,,,,QVQLKQSGPSLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVMWRGGNTDYNAAFMSRLSITKDNSKSQVFFKMNSLQTDDTAIYYCAKNGGAHAMDFWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,GFSLTSYG,MWRGGNT,AKNGGAHAMDF,ESVDSYGNSF,LAS,QQNNEDPFT,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,7W9E,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWIGGINPNIGDTSYNQNFKGKATLTVDRSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDHWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSTSYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFGGGTKLEIK,GYTFTEYT,INPNIGDT,ARDGYPYYYALDH,QNVGTN,STS,QQYNSYPYT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ2*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,7E3L,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFSSSAVQWVRQARGQHLEWIGWIVVGSGNTNYAQKFQERVTLTRDMSTRTAYMELSSLRSEDTAVYYCAAPNCNSTTCHDGFDIWGQGTVVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLESEDFAVYYCQQYDNSPWTFGQGTKVEIK,GFTFSSSA,IVVGSGNT,AAPNCNSTTCHDGFDI,QSVRSSY,GAS,QQYDNSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K45,True,,,,,,,,QVQLVQSGPEVKKPGTSVRVSCKASGFTFTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQKFHERVTITRDMSTSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS,DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,ASPYCSGGSCSDGFDI,QSVSSSY,GAS,QQYVGLTGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K4N,True,,,,,,,,QVQLVQSGPEVKKPGTSVRVSCKASGFTFTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQKFHERVTITRDMSTSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS,DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,ASPYCSGGSCSDGFDI,QSVSSSY,GAS,QQYVGLTGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7L7D,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK,GFTFMSSA,IVIGSGNT,AAPYCSSISCNDGFDI,QSVSSSY,GAS,QHYGSSRGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7PHG,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTDYAQQFQERVTITRDMSTSTAYMELSSLGSEDTAVYYCAAPNCSGGSCYDGFDLWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRGSQSVRSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,AAPNCSGGSCYDGFDL,QSVRSSY,GAS,QQYGSSPWT,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7L57,True,,,,,,,,VQLVQSGAEVKKPGASVRVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISDGTNYAQKFQGWVTMTRDTSISTVYMELSRLRSDDTAVYYCARGGSRCSGGNCYGWAYDAFDIWGQGTMITV,SALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADCYCSSYTSSSTFVFGTGTKVTVL,GYTFTGYY,INPISDGT,ARGGSRCSGGNCYGWAYDAFDI,SSDVGGYNF,DVS,SSYTSSSTFV,IGHJ3*02 (human),IGHV1-2*04 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7RW2,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVINPSGGSTSYAEKFRGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDREPHSDSSGYWDSLKYYYYYALDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPELLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNTYPFTFGPGTKVDIK,GYTFTSYY,INPSGGST,ARDREPHSDSSGYWDSLKYYYYYALDV,QGISSY,AAS,QQLNTYPFT,IGHJ6*01 (human),IGHV1-46*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7L2C,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLIELSMHWVRQAPGKGLEWMGGFDPEDVETIYAQQFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGWAYKSTWYFGYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSRMGFGGGTKLTVL,GYTLIELS,FDPEDVET,ATGWAYKSTWYFGY,SSDVGGYNY,EVS,SSYAGSRMG,IGHJ4*01 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,6Z2M,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,6Z2M,True,,,,,,,,QVQLVESGGGLMQAGGSLRLSCAVSGRTFSTAAMGWFRQAPGKEREFVAAIRWSGGSAYYADSVKGRFTISRDKAKNTVYLQMNSLKYEDTAVYYCARTENVRSLLSDYATWPYDYWGQGTQVTVSS,,GRTFSTAA,IRWSGGSA,ARTENVRSLLSDYATWPYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,5FYL,True,,,,,,,,QLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,GYRFNFYH,ISPYSGDK,AKGLLRDGSSTWLPYL,NSVCCSHKS,EDN,CSYTHNSGCV,IGHJ2*01 (human),IGHV1-18*01 (human),IGLJ1*01 (human),IGLV2-14*02 (human)
PDB,,,,,5FYL,True,,,,,,,,QVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSS,FVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVL,GTLVRDNY,VHDSGDT,ATTKHGRRIYGVVAFKEWFTYFYMDV,SLGSRS,NNN,HIWDSRRPTNWV,IGHJ6*04 (human),IGHV4-59*02 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,7CZP,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKKQFSLKLSSVTAADTAVYYCARLERDWPLDAFDIWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKFMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSNNTFAFGGGTKLTVL,GGSISSYY,IYYSGST,ARLERDWPLDAFDI,SSDVGGYNY,DVS,SSYTSNNTFA,IGHJ3*02 (human),IGHV4-59*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7D6I,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRAGWVRGAFDIWGQGTMVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNLWVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,TRAGWVRGAFDI,SGSIASNY,EDN,QSYDSSNLWV,IGHJ3*02 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
PDB,,,,,7KQB,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLITMVRGEDYWGQGTLVTVSS,DIQLTQSPSSLSASVGHRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNLPRTFGGGTKLEVL,GFTFSSYE,ISYDGSNK,ARLITMVRGEDY,QSISSY,AAS,QQSYNLPRT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7RKV,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCASGYTGYDYFVRGDYYGLDVWGQGTTVTVSS,QPVLTQSPSASASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLNTDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGILVFGGGTKLTVL,GFTFSNYA,ISYDGSNK,ASGYTGYDYFVRGDYYGLDV,SGHSSYA,LNTDGSH,QTWGTGILV,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
PDB,,,,,7BEH,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYTQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYSCARDMAFSMVRGSFDYWGQGTLVTVSS,QAVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNHWVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARDMAFSMVRGSFDY,SSDVGGYNY,EVS,SSYAGSNHWV,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-8*01 (human)
PDB,,,,,7BEK,True,,,,,,,,EVQLLESGGDLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMHSLRAEDTAVYYCARDLGSGDMDVWGKGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIQAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYRYTFGQGTKVEIK,GVTVSSNY,IYPGGST,ARDLGSGDMDV,QGISSY,AAS,QQLNSYRYT,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
PDB,,,,,7BEL,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVLSYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGSYAYYYYMDVWGKGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGGGSGTDFTFTITSLQPEDIATYYCQQYDNLPLTFGGGTKVDIK,GFTFSTYA,LSYDGSNK,AKGGSYAYYYYMDV,QDISNY,DAS,QQYDNLPLT,IGHJ6*04 (human),IGHV3-30-3*02 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7BEL,True,,,,,,,,QLQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYNWTWIRQPAGKGLEWIGRIYNSGSTNYNPSLKSRVTISVDTSKNQLSLKVRSVTAADTAVYYCARHCSGGTCYPKYYYGMDVWGQGTTVTVSS,QSALTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQFPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGVQSEDEADYYCAAWDDSLNVVVFGGGTKLTVL,GGSISSGSYN,IYNSGST,ARHCSGGTCYPKYYYGMDV,SSNIGNNA,YDD,AAWDDSLNVVV,IGHJ6*01 (human),IGHV4-61*02 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
PDB,,,,,1TQB,True,,,,,,,,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNLVKQAPGKGFEWMGWINTFTGEPTYADDFKGRFVFSLDTSASTAYLQINNLKNEDTATYFFTRGTDYWGQGTTLTVSS,DVVMSQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSRLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGIYFCWQGSHFPQTFGGGTKLEIK,GYTFTNYG,INTFTGEP,TRGTDY,QSLLDSDGKTY,LVS,WQGSHFPQT,IGHJ2*01 (mouse),IGHV9-3-1*01 (mouse),IGKJ1*01 (mouse),IGKV1-135*01 (mouse)
PDB,,,,,4YXH,True,,,,,,,,QVQLQQSGTELVMPGASVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGSIDPSDSYTSHNEKFKGKATLTVDESSSTAYMQLSSLTSEDSAVYFCSRSGYGYYAMEYWGQGTSVTVSS,DIVLTQSPAILSVSPGERVSFSCRASQNIGTSIHWYQQRTNESPRLIIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSNTWPYTFGGGTKLELK,GYTFTDYW,IDPSDSYT,SRSGYGYYAMEY,QNIGTS,YAS,QQSNTWPYT,IGHJ4*01 (mouse),IGHV1-69*01 (mouse),IGKJ2*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,5JW4,True,,,,,,,,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYNAVWNWIRQSPSRGLEWLGRTYYRSGWYNDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARSGHITVFGVNVDAFDMWGQGTMVTVSS,MTQSPSSLSASVGDRVTITCRTSQSLSSYTHWYQQKPGKAPKLLIYAASSRGSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIK,GDSVSSYNAV,TYYRSGWYN,ARSGHITVFGVNVDAFDM,QSLSSY,AAS,QQSRT,IGHJ3*01 (human),IGHV6-1*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5JW4,True,,,,,,,,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYNAVWNWIRQSPSRGLEWLGRTYYRSGWYNDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARSGHITVFGVNVDAFDMWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLSSYTHWYQQKPGKAPKLLIYAASSRGSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIK,GDSVSSYNAV,TYYRSGWYN,ARSGHITVFGVNVDAFDM,QSLSSY,AAS,QQSRT,IGHJ3*01 (human),IGHV6-1*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5X2O,True,,,,,,,,EVQLQQSGPELVKPGASMKISCKASGYSFTGYSMNWVKQSHGKNLEWIGLINPYNGDTTYKQKFKGKATLTVDRSSSTAYMELLRLTSEDSAVYYCARSGRGAPTTTTAWFTYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPILLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDFATYYCQQTNEDPRTFGGGTKLEIK,GYSFTGYS,INPYNGDT,ARSGRGAPTTTTAWFTY,ESVDSYGNSF,RAS,QQTNEDPRT,IGHJ3*01 (mouse),IGHV1-37*01 (mouse),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
PDB,,,,,7CM4,True,,,,,,,,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,GFSLSTSGVG,IDWDDNK,ARIPGFLRYRNRYYYYGMDV,SSNIGNNY,DNN,GTWDSSLSAGV,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7R6X,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIQMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,GFTFSSYD,IGTAGDT,ARGDSSGYYYYFDY,QSIGSY,AAS,QQSYVSPTYT,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7R6X,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7R6X,True,,,,,,,,QVQLVQSGPEVKKPGTSVRVSCKASGFTFTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQKFHERVTITRDMSTSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS,DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,ASPYCSGGSCSDGFDI,QSVSSSY,GAS,QQYVGLTGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7VNE,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASDSSFYDYEMSWVRQAPGKAQEWIGSMYPSGRTYINPSLKSLVTISRDNSKNTLYLQLNSLRAEDTAMYYCVSNWASGSTGDYWGQGTLVTVSS,,DSSFYDYE,MYPSGRT,VSNWASGSTGDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7MJH,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWIGRMYNNGRTSYNPSLKSLVTISRDNSKNTLYLQMNSLRAEDTATYYCARDNLGYRPSENLYGMDVWGQGTTVTVSS,,GFTFDDYA,MYNNGRT,ARDNLGYRPSENLYGMDV,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7MJJ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGYGDYYFDYWGQGTLVTVSS,DVVMTQSPATLSLSPGEKATLSCRASQSVSSYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSPLTFGGGTKVEIK,GFTVSSNY,IYSGGST,ARGYGDYYFDY,QSVSSY,WAS,QQYGSSPLT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
PDB,,,,,6RCO,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFATTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARDKHSWSYAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGLRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIHSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GGTFSNYA,IIPIFATT,ARDKHSWSYAFDI,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ3*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
PDB,,,,,7N8I,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDF,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7NTC,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYSMNWVRQAPGKGLEWVSSISSNSNYIYYADSMKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASNRSPYDSSNYYFDYWGQGTRVTISS,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHHDSLPLTFGGGTKVEIK,GFSFSSYS,ISSNSNYI,ASNRSPYDSSNYYFDY,QDISNY,DAS,QHHDSLPLT,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,2FB4,True,,,,,,,,EVQLVQSGGGVVQPGRSLRLSCSSSGFIFSSYAMYWVRQAPGKGLEWVAIIWDDGSDQHYADSVKGRFTISRNDSKNTLFLQMDSLRPEDTGVYFCARDGGHGFCSSASCFGPDYWGQGTPVTVSS,QSVLTQPPSASGTPGQRVTISCSGTSSNIGSSTVNWYQQLPGMAPKLLIYRDAMRPSGVPDRFSGSKSGASASLAIGGLQSEDETDYYCAAWDVSLNAYVFGTGTKVTVL,GFIFSSYA,IWDDGSDQ,ARDGGHGFCSSASCFGPDY,SSNIGSST,RDA,AAWDVSLNAYV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
PDB,,,,,6DB7,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCEASGYTFAKFAIHWVRQAPRQGLEWMGWINGDDGKTEYSQKFQDRVTMTRDTSASTVYMELSSLRSEDTALYYCARAMYPDTVTGNDNPAPPPFEGDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKEYAYWYQQKSGQAPVLVIYEDTRRPSGIPERFSGSSSGTMATLTVSGAHVDDEADYYCYSRDTSANQWVFGGGTKLTVL,GYTFAKFA,INGDDGKT,ARAMYPDTVTGNDNPAPPPFEGDY,ALPKEY,EDT,YSRDTSANQWV,IGHJ4*01 (human),IGHV1-3*01 (human),IGLJ3*02 (human),IGLV3-10*01 (human)
PDB,,,,,7CWS,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTV,SVLTQAPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7CWS,True,,,,,,,,VQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7L2D,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLIELSMHWVRQAPGKGLEWMGGFDPEDAETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGIAVIGPPPSTYYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVL,GYTLIELS,FDPEDAET,ATGIAVIGPPPSTYYYYGMDV,SSDVGGYNY,DVS,SSYTSSSTYV,IGHJ6*01 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7L2E,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSGYNYGYSWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSADALAKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSTDNSGTYPNWVFGGGTKLTVL,GFTFSSYG,ISYDGSNK,AKDSGYNYGYSWFDP,ALAKQY,KDS,QSTDNSGTYPNWV,IGHJ5*02 (human),IGHV3-30*18 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
PDB,,,,,7L2F,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGLTFSSYVMHWVRQAPGKGLDWVGVIWYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRDYYDFWSGYDYYYGLDVWGQGTTVTVSS,EIVLTQSPGILSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSGALTFGGGTKVEIK,GLTFSSYV,IWYDGSKK,ARDPRDYYDFWSGYDYYYGLDV,QSVSSSY,GAS,QQYGSSGALT,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LAB,True,,,,,,,,EVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATSSGPSRLCGGGSCYHSFDYWGQGTLVTVSS,LTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTWTFGQGTKVEIK,GYTFTDYY,VDPEDGET,ATSSGPSRLCGGGSCYHSFDY,QSVSSSY,GAS,QQYGSSPTWT,IGHJ4*01 (human),IGHV1-69-2*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LXX,True,,,,,,,,EVQLVESGGGLVNPGGSLRLSCAASGFTFSDYTIHWVRQAPGKGLEWVSSISSSSNYIYYADSVKGRFTISRDNAKNSLSLQMNSLRAEDTAVYYCARDGNAYKWLLAENVRFDYWGQGTLVTVSS,VTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSDRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPNWVFGGGTKLT,GFTFSDYT,ISSSSNYI,ARDGNAYKWLLAENVRFDY,SSDVGGYNY,DVS,SSYTSSSTPNWV,IGHJ4*01 (human),IGHV3-21*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
PDB,,,,,7LY3,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARAVAGEWYFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALAKHYAYWYRQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSIGSSWVFGGGTKLTVL,GFTFSSYG,IWYDGSNR,ARAVAGEWYFDY,ALAKHY,KDS,QSADSIGSSWV,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
PDB,,,,,7M8J,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGPAVRRGSWFDPWGQGTLVTVSS,VVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAHWVFGGGTKLTVL,GYTLTELS,FDPEDGET,ATGPAVRRGSWFDP,SSNIGNNY,DNN,GTWDSSLSAHWV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
PDB,,,,,7LXY,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LXY,True,,,,,,,,VQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYFCARAFPDSSSWSGFTIDYWGQGTLVTV,YELTQPPSVSTARITCGGNNIERKSVHWCQQKPGQAPALVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSGSDQVIFGGGTKLT,GFTFSNYG,IWYDGSNK,ARAFPDSSSWSGFTIDY,NIERKS,DDS,QVWDSGSDQVI,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
PDB,,,,,5GGU,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,GFTFSSYG,IWYDGSNK,ARDPRGATLYYYYYGMDV,QSINSY,AAS,QQYYSTPFT,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7THT,False,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGRVTITADKSTSTAYLELSSLRSEDTAVYYCARYMVTRDQYYYDMDVWGQGTTVTVS,,GGTFSSYA,IIPMFGIA,ARYMVTRDQYYYDMDV,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
PDB,,,,,7THT,False,,,,,,,,,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSPPPTFGQGTKLEI,,,,QSISNY,AAS,QQSYSPPPT,,,IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,7THT,False,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGRVTITADKSTSTAYLELSSLRSEDTAVYYCARYMVTRDQYYYDMDVWGQGTTVTVS,,GGTFSSYA,IIPMFGIA,ARYMVTRDQYYYDMDV,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
PDB,,,,,7THT,False,,,,,,,,,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSPPPTFGQGTKLEI,,,,QSISNY,AAS,QQSYSPPPT,,,IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,7THT,False,,,,,,,,,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSPPPTFGQGTKLEI,,,,QSISNY,AAS,QQSYSPPPT,,,IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,7THT,False,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGRVTITADKSTSTAYLELSSLRSEDTAVYYCARYMVTRDQYYYDMDVWGQGTTVTVS,,GGTFSSYA,IIPMFGIA,ARYMVTRDQYYYDMDV,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
PDB,,,,,7TOW,False,,,,,,,,QVQLVQSGGGVVQPGRSLRLSCAASGFNFGDFGMHWVRQAPGKGLEWVAVISYEGRNKNHADSVRGRFTISRDNSRNMLYLQMNSLRRGDTAVYYCAKENRDRNYDSWSASYSDYYYGMDVWGQGTTVTVSS,,GFNFGDFG,ISYEGRNK,AKENRDRNYDSWSASYSDYYYGMDV,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
PDB,,,,,7TOW,False,,,,,,,,,DIVMTQSPSFLSASVGDRVTITCRASQGIDRYLAWYQQKPGSAPKLLIYAASTLQSGVPSRFSGSGSETDFTLTISSLQPDDFATYYCQQLSTYPTITFGQGTRLEIK,,,,QGIDRY,AAS,QQLSTYPTIT,,,IGKJ5*01 (human),IGKV1-9*01 (human)
PDB,,,,,7TOW,False,,,,,,,,QVQLVQSGGGVVQPGRSLRLSCAASGFNFGDFGMHWVRQAPGKGLEWVAVISYEGRNKNHADSVRGRFTISRDNSRNMLYLQMNSLRRGDTAVYYCAKENRDRNYDSWSASYSDYYYGMDVWGQGTTVTVSS,,GFNFGDFG,ISYEGRNK,AKENRDRNYDSWSASYSDYYYGMDV,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
PDB,,,,,7TOW,False,,,,,,,,,DIVMTQSPSFLSASVGDRVTITCRASQGIDRYLAWYQQKPGSAPKLLIYAASTLQSGVPSRFSGSGSETDFTLTISSLQPDDFATYYCQQLSTYPTITFGQGTRLEIK,,,,QGIDRY,AAS,QQLSTYPTIT,,,IGKJ5*01 (human),IGKV1-9*01 (human)
PDB,,,,,4CAD,True,,,,,,,,QVQLKQSGAELMKPGASVKISCKATGYKFSSYWIEWVKQRPGHGLEWIGEIFPGSGNTNYNEKFKGKATLTADTSSNTAYMQLSSLTSEDSAVYYCARRGAFYSYGSSYYAMDFWGQGTSVTVSS,DIQLTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGNYYCQHFWSTPWTFGGGTKLELK,GYKFSSYW,IFPGSGNT,ARRGAFYSYGSSYYAMDF,GNIHNY,NAK,QHFWSTPWT,IGHJ4*01 (mouse),IGHV1-9*01 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,7K8O,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGRPSDIVVVVAFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSIYG,ISYDGSNK,AKEGRPSDIVVVVAFDY,QSISSY,AAS,QQSYSTPRT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7S0B,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSLISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLWGSGFFAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDAGTPLTFGQGTKVEIK,GFTFSSYA,ISGSGGST,ARDLWGSGFFAFDV,QDISNY,DAS,QQDAGTPLT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7S0C,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVSAIWGSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRDLAAFTKTAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHDALPWTFGQGTKVEIK,GFTFSSYA,IWGSGSNT,ARGRDLAAFTKTAFDV,QDISNY,DAS,QQHDALPWT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-33*01 (human)
PDB,,,,,7S0D,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSYISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRWASGWLAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQAYAYPLTFGQGTKVEIK,GFTFSSYA,ISGSGGGT,ARDRWASGWLAFDV,QDISNY,DAS,QQAYAYPLT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7S0E,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMHWVRQAPGKGLEWVSAISGSGGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDHAYDWGFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQWADWPLTFGQGTKVEIK,GFTFSSYY,ISGSGGYT,ARDRDHAYDWGFDV,QDISNY,DAS,QQWADWPLT,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,6P91,True,,,,,,,,EVQLVQSGGGLVRPGGSLRLSCAAAGFTFKSYSMNWVRQAPGRGLEWVSSITSGGSKTYYADVVKGRFTVSRDNAKQSLYLQMNSLRAEDTAIYFCARSLHSTSQPSYMDVWGRKITVIVSS,DIVLTQSPGTLSLSPGERATLSCRASQSVISYYVAWYQHKGGQAPRLLIYGASSRATGVPDRFSGSGSGTDFTLTISSLEPEDFALYYCQYYGSSPLWAFGQGTKVEIK,GFTFKSYS,ITSGGSKT,ARSLHSTSQPSYMDV,QSVISYY,GAS,QYYGSSPLWA,IGHJ6*01 (human),IGHV3-21*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,6QD7,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCEASGFPLRDYAMSWVRQAPGRGLQWVSTIGGNDNAANYADSVKGRFTVSRDNSKSTIYLQMNSLRAEDTALYFCAKSVRLSRPSPFDLWGQGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQHQPGQAPRLLIYEASNRATGIPARFSGSGSGTEFTLTISSLEPEDVAVYYCQQRASWPLTFGGGTKVEIK,GFPLRDYA,IGGNDNAA,AKSVRLSRPSPFDL,QSVSTY,EAS,QQRASWPLT,IGHJ2*01 (human),IGHV3-23*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,6ULC,True,,,,,,,,QEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVL,GFTFHKYG,ISDDGMR,AREAGGPIWHDDVKYYDFNDGYYNYHYMDV,SSDVGGFDS,DVS,SSLTDRSHRI,IGHJ6*04 (human),IGHV3-30*03 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,4XAK,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTASYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVGYCSSTSCNRGAFDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,GGTFSSYA,IIPIFGTA,ARVGYCSSTSCNRGAFDI,QGIRND,AAS,QQLNSYPLT,IGHJ3*02 (human),IGHV1-69*06 (human),IGKJ4*01 (human),IGKV1-17*01 (human)
PDB,,,,,6Z43,True,,,,,,,,QVQLVESGGGLMQAGGSLRLSCAVSGRTFSTAAMGWFRQAPGKEREFVAAIRWSGGSAYYADSVKGRFTISRDKAKNTVYLQMNSLKYEDTAVYYCARTENVRSLLSDYATWPYDYWGQGTQVTVSS,,GRTFSTAA,IRWSGGSA,ARTENVRSLLSDYATWPYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7EJ4,True,,,,,,,,EVQLEESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQSPEKRLEWVAEISSGGTYTNYPDTATGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCANFGNYEEIAYWGQGTLVTVSA,QIVLTQSPAIMSVSLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPYTFGGGTKLEIK,GFTFSSYT,ISSGGTYT,ANFGNYEEIAY,SSVSSSY,STS,HQYHRSPYT,IGHJ3*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ2*01 (mouse),IGKV4-74*01 (mouse)
PDB,,,,,7KLH,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSHTYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSHTYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7MKM,True,,,,,,,,QVQLKESGPGLVAPSQSLSITCTVSGFSLTRYGVHWVRQPPGKGLEWLGVIWADGSTYYNSALMSRLSISKDNSKSQVFLNMNSLQTDDTAKYYCARDGRGYDDYWGQGTTLT,QIVLTQSPAIMSASPGEKVTMTCSASSTVSFIYWYQQKPGSSPRLLIYDTSNPASGVPVRFSGSGCGTSYYLTISRMEAEDAATYYCQQWNTYPLTFGAGTKLEL,GFSLTRYG,IWADGST,ARDGRGYDDY,STVSF,DTS,QQWNTYPLT,IGHJ2*01 (mouse),IGHV2-9*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
PDB,,,,,7TAT,True,,,,,,,,QVQLVESGGVVVQPGGSLRLSCAASGFTFHDHTMHWVRQAPGKGLEWVSLITWNGGTIHYSDSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKDLGRGGWYLPSDAWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSANIGSNTVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLKGVFGGGTKLTVL,GFTFHDHT,ITWNGGTI,AKDLGRGGWYLPSDA,SANIGSNT,SNN,AAWDDSLKGV,IGHJ5*01 (human),IGHV3-43*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,7VYT,False,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASRSGSGWFGALDYWGQGTLVTVS,,GYTFTSYY,INPSGGST,ASRSGSGWFGALDY,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
PDB,,,,,7VYT,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGGTFGQGTKVEIK,,,,QSVSSSY,GAS,QQYGSSPGGT,,,IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7VYT,False,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASRSGSGWFGALDYWGQGTLVTVS,,GYTFTSYY,INPSGGST,ASRSGSGWFGALDY,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
PDB,,,,,7VYT,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGGTFGQGTKVEIK,,,,QSVSSSY,GAS,QQYGSSPGGT,,,IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7BEP,True,,,,,,,,EVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYIRSSGHTIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARGGVLRFLEWPLNAFDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNNALGTFGQGTKVEIK,GFTFSDYY,IRSSGHTI,ARGGVLRFLEWPLNAFDI,QGISNY,AAS,QKYNNALGT,IGHJ3*02 (human),IGHV3-11*01 (human),IGKJ1*01 (human),IGKV1-27*01 (human)
PDB,,,,,7BEP,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KMH,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPYGGNSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTRLEIK,GLTVSSNY,IYSGGST,ARSPYGGNS,QDISNY,DAS,QQYDNLPIT,IGHJ5*01 (human),IGHV3-53*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
PDB,,,,,4ZS6,True,,,,,,,,EVQLLETGGGLVKPGGSLRLSCAASGFSLSDYYMNWIRQAPGKGLEWVAYISSSSGYTNYGDSVKGRFTISRDHAKNSLYLQMNSLRVEDTAVYYCVRDRDDFWSGYYKHWGLGTLVTVSS,IRMTQSPSFLSASVGDRVTITCRASQDINSFLAWYQQRPGKAPKLLIYGASNLETGVPSRFSGGGSGTDFTLTISSLQPEDIATYYCQQYDKLPTFGQGTRLEIK,GFSLSDYY,ISSSSGYT,VRDRDDFWSGYYKH,QDINSF,GAS,QQYDKLPT,IGHJ1*01 (human),IGHV3-11*03 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
PDB,,,,,7COE,True,,,,,,,,QVQLVQSGAEVKRPGSSVKVSCKTSGGTFNNNAINWVRQAPGQGLEWMGGIIPFFGIAKYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLPRESSYGSGSYYTHYYAMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCGASQSVSSSYLAWYQQKPGLAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,GGTFNNNA,IIPFFGIA,ARDLPRESSYGSGSYYTHYYAMDV,QSVSSSY,DAS,QQYGSSPLT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3D-20*01 (human)
PDB,,,,,7DEO,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHWVRQAPGKGLEWVAVIWYDGSNRFYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCATDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPLTFGGGTKVEIK,GFTFSYYG,IWYDGSNR,ATDPPGLRFRFDY,QSLLHSNGYNY,LGS,MQGLQTPLT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
PDB,,,,,7ORA,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGEGATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSGATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPYT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7ORA,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVLSYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGSYAYYYYMDVWGKGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGGGSGTDFTFTITSLQPEDIATYYCQQYDNLPLTFGGGTKVDIK,GFTFSTYA,LSYDGSNK,AKGGSYAYYYYMDV,QDISNY,DAS,QQYDNLPLT,IGHJ6*04 (human),IGHV3-30-3*02 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7ORB,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYPLHWVRQAPGKGPEWVAVISQDGGNKYYVDSVKGRFTISRDNSKNTLYLQMNNLRAEDTALYYCARDVVVVVAARNHYYNGMDVWGQGTTVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPFTFGPGTKVEIK,GFTFNNYP,ISQDGGNK,ARDVVVVVAARNHYYNGMDV,QGISSW,AVS,QQAKSFPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,7ORB,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGEGATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSGATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPYT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7F7E,False,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIVGSGGSTYYADSVKGRFIISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLIYGHYDILTGAYYFDYWGQGTLVTVSS,,GFTFSSYA,IVGSGGST,AKSLIYGHYDILTGAYYFDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,7F7E,False,,,,,,,,,AQMTQSPSSVSASVGDRVTIPCRASQGIGNWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPFGQGTRLEIK,,,,QGIGNW,AAS,QQANSFPP,,,IGKJ5*01 (human),IGKV1-12*01 (human)
PDB,,,,,6F0D,True,,,,,,,,QVQLVQSGGGLVQAGGSLRLSCAFSGRTFSMYTMGWFRQAPGKEREFVAANRGRGLSPDIADSVNGRFTISRDNAKNTLYLQMDSLKPEDTAVYYCAADLQYGSSWPQRSSAEYDYWGQGTTVTVSS,,GRTFSMYT,NRGRGLSP,AADLQYGSSWPQRSSAEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6YM0,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,6ZCZ,True,,,,,,,,QVQLVESGGGLMQAGGSLRLSCAVSGRTFSTAAMGWFRQAPGKEREFVAAIRWSGGSAYYADSVKGRFTISRDKAKNTVYLQMNSLKYEDTAVYYCAQTHYVSYLLSDYATWPYDYWGQGTQVTVSS,,GRTFSTAA,IRWSGGSA,AQTHYVSYLLSDYATWPYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6ZCZ,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7JN5,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVVS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7RKU,True,,,,,,,,QVQLQESGPGLVKPSETLSVTCTVSGGSISSSRYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHAAAYYDRSGYYFIEYFQHWGQGTLVTVSS,DIQMTQSPSTLSASVGDSVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYRYTFGQGTKLEIK,GGSISSSRYY,IYYSGST,ARHAAAYYDRSGYYFIEYFQH,QSISSW,KAS,QQYNNYRYT,IGHJ1*01 (human),IGHV4-39*01 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
PDB,,,,,7L3N,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GGTFSNYA,IIPILGIA,ARGYYEARHYYYYYAMDV,QSISSY,AAS,QQSYSTPRT,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5CMA,True,,,,,,,,QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK,GYTFTNYD,IFPGDGST,ARQTTATWFAY,QSISDY,YAS,QNGHSFPLT,IGHJ3*01 (mouse),IGHV1-85*01 (mouse),IGKJ5*01 (mouse),IGKV5-39*01 (mouse)
PDB,,,,,6NB8,True,,,,,,,,QAQLVESGGALVQPGRSLRLSCAASGFTFRNYAMHWVRQAPATGLQWLAVITSDGRNKFYADSVKGRFTISREDSKNTLYLQMDSLRGEDTAVYYCVTQRDNSRDYFPHYFHDMDVWGQGTTVAVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGDTYLNWFQQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGSHWPPTFGQGTKVEIK,GFTFRNYA,ITSDGRNK,VTQRDNSRDYFPHYFHDMDV,QSLVYSDGDTY,QVS,MQGSHWPPT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
PDB,,,,,7VYR,False,,,,,,,,VQLQQSGAEVKKPGSSVKVSCKASGGTFGNWSISWVRQAPGQGLEWMGGIDPSRGEATYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARETEQGGMDVWGQGTTVTVSS,,GGTFGNWS,IDPSRGEA,ARETEQGGMDV,,,,IGHJ6*01 (human),IGHV1-69*05 (human),,
PDB,,,,,7VYR,False,,,,,,,,,SYELTQPPSVSVAPGKTARITCGGNNIGRKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVYDLFSDYVFGTGTKVEIK,,,,NIGRKS,DDS,QVYDLFSDYV,,,IGLJ1*01 (human),IGLV3-21*03 (human)
PDB,,,,,7VYR,False,,,,,,,,VQLQQSGAEVKKPGSSVKVSCKASGGTFGNWSISWVRQAPGQGLEWMGGIDPSRGEATYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARETEQGGMDVWGQGTTVTVSS,,GGTFGNWS,IDPSRGEA,ARETEQGGMDV,,,,IGHJ6*01 (human),IGHV1-69*05 (human),,
PDB,,,,,7VYR,False,,,,,,,,,SYELTQPPSVSVAPGKTARITCGGNNIGRKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVYDLFSDYVFGTGTKVEIK,,,,NIGRKS,DDS,QVYDLFSDYV,,,IGLJ1*01 (human),IGLV3-21*03 (human)
PDB,,,,,2X7L,True,,,,,,,,QEQLVESGGRLVTPGTALTLTCKVSGFSLSGFWLNWVRQAPGKGLEWVGAIYRGSGSEWYASWAKGRFTISDTSTTVTLKLTSPTTEDTATYFCAADTTDNGYFTIWGPGTLVTVSS,VMTQTPSSVSEPVGGTVTIKCQASQSISSWLSWYQQKPGQPPKLLIYDASNLASGVPSRFMGSGSGTEYTLTISGVQREDAATYYCLGGYPAASYRTAFGGGTELEI,GFSLSGFW,IYRGSGSE,AADTTDNGYFTI,QSISSW,DAS,LGGYPAASYRTA,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ5*01 (human),IGKV1-12*01 (human)
PDB,,,,,7E9O,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7E9O,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9O,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9O,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7E9O,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9O,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7E9Q,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9Q,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7E9Q,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7E9Q,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9Q,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPFT,,,IGKJ3*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E9Q,False,,,,,,,,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLGADPEYGMDVWGQGTTVTVSS,,GFTFDDYA,VSWNSGTI,AKAVEMVRGLGADPEYGMDV,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
PDB,,,,,7K8Y,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWISPVSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAPLFPTGVLAGDYYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,GYTFTGYY,ISPVSGGT,ARAPLFPTGVLAGDYYYYGMDV,SSDVGSYNL,EGS,CSYAGSSTLV,IGHJ6*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,7KS9,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARIYGDYAWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSRSGTDFTFTISSLQPEDIATYYCHQYDNLPLTFGGGTKVEIK,GFTVSSNY,IYSGGST,ARIYGDYA,QDISNY,DAS,HQYDNLPLT,IGHJ1*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7L5B,True,,,,,,,,QVQLVQSGAEVKKPGASVRVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISDGTNYAQKFQGWVTMTRDTSISTVYMELSRLRSDDTAVYYCARGGSRCSGGNCYGWAYDAFDIWGQGTMITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADCYCSSYTSSSTFVFGTGTKVTVL,GYTFTGYY,INPISDGT,ARGGSRCSGGNCYGWAYDAFDI,SSDVGGYNF,DVS,SSYTSSSTFV,IGHJ3*02 (human),IGHV1-2*04 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7LSS,True,,,,,,,,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHHKIERIFDYWGQGTLVTVSS,SALAQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSTVFGGGTKLTVL,GFSLSTSGVG,IYWDDDK,AHHKIERIFDY,SSDVGAYNY,DVS,SSYTTSSTV,IGHJ4*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,5LHN,True,,,,,,,,VQLQESGGGLVQPGGSLRLSCAASGFTLGYYAIGWFRRAPGKEREGVSCISSSGGSTNYADSVKGRFTISRDNAKNTVDLQMNSLKPEDTAIYYCAAEWVPPGYGATVQALCNNAGYGMEYWGKGTQVTVSS,,GFTLGYYA,ISSSGGST,AAEWVPPGYGATVQALCNNAGYGMEY,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
PDB,,,,,7NLL,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NLL,False,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7NS6,False,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSFITSSDGSTYYVDSVKGRFTISRDNAKNTVYLQMNSLTPEDTAIYYCAVGPSFSYTGSTYYRSELPWDYDYWGQGTQVTVSS,,GFTLDDYA,ITSSDGST,AVGPSFSYTGSTYYRSELPWDYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,4FAB,True,,,,,,,,EVKLDETGGGLVQPGRPMKLSCVASGFTFSDYWMNWVRQSPEKGLEWVAQIRNKPYNYETYYSDSVKGRFTISRDDSKSSVYLQMNNLRVEDMGIYYCTGSYYGMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSQGNTYLRWYLQKPGQSPKVLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,GFTFSDYW,IRNKPYNYET,TGSYYGMDY,QSLVHSQGNTY,KVS,SQSTHVPWT,IGHJ4*01 (mouse),IGHV6-7*02 (mouse),IGKJ1*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,4UT6,True,,,,,,,,EVQLVESGGGLVQPGGSLKLSCAASGFTFSSHWMHWVRQAPGKGLVWVSRTNSDGSSTSYADSVKGRFMISRDNSKNTVYLHMNGLRAEDTAVYFCARDGVRYYYDSTGYYPDNFFQYGLDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGISSDVETYNLVSWYEQHPGKAPKLIIYEASKRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCCSYAGGKSLVFGGGTRLTVL,GFTFSSHW,TNSDGSST,ARDGVRYYYDSTGYYPDNFFQYGLDV,SSDVETYNL,EAS,CSYAGGKSLV,IGHJ6*01 (human),IGHV3-74*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,6DDV,True,,,,,,,,QGQMQQSGAELVKPGASVKLSCKTSGFTFSDNYISWLKQKPGQSLEWIAWIYAGTGGSSYNQKFRDKAQLTVDTSSRTAYMQLSSLTTEDSAIYYCARHDYYGTSGAWFAYWGRGTLVTVSA,DVLMTQTPLSLPVSLGDQASISCRSSQHIVHSNENTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,GFTFSDNY,IYAGTGGS,ARHDYYGTSGAWFAY,QHIVHSNENTY,KVS,FQGSHVPWT,IGHJ3*01 (mouse),IGHV1-84*01 (mouse),IGKJ1*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,7ND5,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSIIYSGGTTYYADSVKGRFTISRDSSMNTLYLQMNSLRAEDTAVYYCARDLMVYGIDVWGQGTTVTVSS,EIVMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLDSYPPGYTFGQGTKVDIK,GVTVSSNY,IYSGGTT,ARDLMVYGIDV,QGISSY,AAS,QQLDSYPPGYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7PQY,False,,,,,,,,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVSS,,GFTVSSNY,IYSGGST,ARDHVRPGMNI,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
PDB,,,,,7PQY,False,,,,,,,,,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,,,,QDISNY,DAS,QQYDNLPVT,,,IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7PQY,False,,,,,,,,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVSS,,GFTVSSNY,IYSGGST,ARDHVRPGMNI,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
PDB,,,,,7PQY,False,,,,,,,,,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,,,,QDISNY,DAS,QQYDNLPVT,,,IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7PQZ,False,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPDILTGYYNYYYYGMDVWGQGTMVTVSS,,GFTFSSYG,IWYDGSNK,AKGPDILTGYYNYYYYGMDV,,,,IGHJ6*01 (human),IGHV3-33*03 (human),,
PDB,,,,,7PQZ,False,,,,,,,,,SVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVVFGGGTKLTVL,,,,SSNIGAGYD,GNS,QSYDSSLSGFYVV,,,IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7PQZ,False,,,,,,,,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVSS,,GFTVSSNY,IYSGGST,ARDHVRPGMNI,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
PDB,,,,,7PQZ,False,,,,,,,,,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,,,,QDISNY,DAS,QQYDNLPVT,,,IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7PR0,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPITWTFGQGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPITWT,,,IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,7PR0,False,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPGGITAAGTSVLFGYYGMDVWGQGTTVTVSS,,GFTFSSYS,ISSSSSTI,ASPGGITAAGTSVLFGYYGMDV,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
PDB,,,,,7PR0,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPITWTFGQGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPITWT,,,IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,7PR0,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPGGITAAGTSVLFGYYGMDVWGQGTTVTVSS,,GFTFSSYS,ISSSSSTI,ASPGGITAAGTSVLFGYYGMDV,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
PDB,,,,,7PR0,False,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPGGITAAGTSVLFGYYGMDVWGQGTTVTVSS,,GFTFSSYS,ISSSSSTI,ASPGGITAAGTSVLFGYYGMDV,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
PDB,,,,,7PR0,False,,,,,,,,,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPITWTFGQGTKVDIK,,,,QSLLHSNGYNY,LGS,MQALQTPITWT,,,IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,7Q0A,False,,,,,,,,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVS,,GFTVSSNY,IYSGGST,ARDHVRPGMNI,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
PDB,,,,,7Q0A,False,,,,,,,,,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,,,,QDISNY,DAS,QQYDNLPVT,,,IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,2VIR,True,,,,,,,,QVQLKESGPGLVAPSQSLSITCTVSGFLLISNGVHWVRQPPGKGLEWLGVIWAGGNTNYNSALMSRVSISKDNSKSQVFLKMKSLQTDDTAMYYCARDFYDYDVFYYAMDYWGQGTSVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,GFLLISNG,IWAGGNT,ARDFYDYDVFYYAMDY,TGAVTTSNY,GTN,ALWYSNHWV,IGHJ4*01 (mouse),IGHV2-9*02 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,6ZXN,True,,,,,,,,QVQLVETGGGLVQPGGSLRLSCAASGFTFSSVYMNWVRQAPGKGPEWVSRISPNSGNIGYTDSVKGRFTISRDNAKNTLYLQMNNLKPEDTALYYCAIGLNLSSSSVRGQGTQVTVSS,,GFTFSSVY,ISPNSGNI,AIGLNLSSSSV,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
PDB,,,,,1FIG,True,,,,,,,,DVQLQQSGPELEKPGASVKISCKASGFSLPGHNINWIVQRNGKSLEWIGNIDPYYGGTNFNPKFKGKATLTVDKSSSTLYMHLTSLQSEDSAVYYCARRRDGNYGFTYWGQGTLVTVSA,NVLTQSPAIMSASPGEKVTMACRASSSVSSTYLHWYQQKSGASPKLLIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELK,GFSLPGHN,IDPYYGGT,ARRRDGNYGFTY,SSVSSTY,STS,QQYSGYPLT,IGHJ3*01 (mouse),IGHV1-20*02 (mouse),IGKJ5*01 (mouse),IGKV4-57-1*01 (mouse)
PDB,,,,,4C58,True,,,,,,,,QVQLQESGGGSVQAGGSLRLSCGASEYTSRMGWFRQAPGAEREGVACIHRQSNLSYYSDSVRGRFTISQDNAKTTAFLLMSSLKPEDTAIYYCATTTDCAAFVERATAITAGQGTQVTVSS,,EYTSR,IHRQSNLS,ATTTDCAAFVERATAIT,,,,IGHJ1*01 (human),IGHV3-30*02 (human),,
PDB,,,,,7DK5,True,,,,,,,,QVQLKQSGPSLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVMWRGGNTDYNAAFMSRLSITKDNSKSQVFFKMNSLQTDDTAIYYCAKNGGAHAMDFWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,GFSLTSYG,MWRGGNT,AKNGGAHAMDF,ESVDSYGNSF,LAS,QQNNEDPFT,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,7JV4,True,,,,,,,,EVQLVESGGDSVQPGGSLRLSCAAAGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCALSSGYSGYAGNYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGARPEDEAEYYCLLSYSGARGVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ALSSGYSGYAGNY,TGAVTSGHY,DTS,LLSYSGARGV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV7-46*01 (human)
PDB,,,,,5F72,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFAISASSIHWVRQAPGKCLEWVASIDPETGETLYAKSVAGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARAYAGDGVYYADVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYSFPSTFGCGTKVEIK,GFAISASS,IDPETGET,ARAYAGDGVYYADV,QSVSSA,SAS,QQSYSFPST,IGHJ5*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7K3Q,True,,,,,,,,QVQLVQSGPEVKKPGTSVRVSCKASGFTFTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQKFHERVTITRDMSTSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS,DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,ASPYCSGGSCSDGFDI,QSVSSSY,GAS,QQYVGLTGWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7E7Y,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSAVYSGGSTYYADSVKGRFTISRHNSKNTLYLQMKSLRPEDTAIYYCARLINHYYDSSGDGGAFDIWGQGTMVTVSS,LTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQRPGKAPKLILYEVTKRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,GVTVSSNY,VYSGGST,ARLINHYYDSSGDGGAFDI,SSDVGSYNL,EVT,CSYAGSSTWV,IGHJ3*02 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV2-23*02 (human)
PDB,,,,,5MES,True,,,,,,,,QVTLKESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQVGATWAFDIWGQGTLVTVS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKLTVL,GFTFSSYS,ISSSSSYI,ARQVGATWAFDI,SSNIGSNT,SNN,AAWDDSLNAWV,IGHJ5*01 (human),IGHV3-21*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
PDB,,,,,5VAG,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPSFWAAEYFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GGTFSSYA,IIPIFGTA,ARDPSFWAAEYFQH,QSISSY,AAS,QQSYSTPRT,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6UDA,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDVGTEGSLLHFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWWTFGQGTKVEIK,GYTFTSYY,INPSGGST,ARDVGTEGSLLHFDY,QSVSSN,GAS,QQYNNWWT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,7CZW,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERCYYGSGRAPRCVWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKLTVL,GDSVSSGSYY,IYYSGST,ARERCYYGSGRAPRCVWFDP,SSDVGGYNY,DVS,SSYTSSSTLVV,IGHJ5*02 (human),IGHV4-61*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7E3K,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFSGSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQRFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSTSCRDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPWTFGQGTKVEIK,GFTFSGSA,IVVGSGNT,AAPYCSSTSCRDGFDI,QSVRSSY,GAS,QQYGRSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K8T,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGRPSDIVVVVAFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSIYG,ISYDGSNK,AKEGRPSDIVVVVAFDY,QSISSY,AAS,QQSYSTPRT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7SC1,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMRWVRQAPGKGLEWVSLIYAGGSTFYADSVKGRFIISRHNSKNILYLQMNSLRAEDTAVYFCARDLYVFGMDVWGQGTAVTVSA,,GLTVSSNY,IYAGGST,ARDLYVFGMDV,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7SC1,False,,,,,,,,,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTVFTLTISSLQPEDFATYYCQQLNSDSSTFGQGTKLEIK,,,,QGISSY,AAS,QQLNSDSST,,,IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7SC1,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMRWVRQAPGKGLEWVSLIYAGGSTFYADSVKGRFIISRHNSKNILYLQMNSLRAEDTAVYFCARDLYVFGMDVWGQGTAVTVSA,,GLTVSSNY,IYAGGST,ARDLYVFGMDV,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7SC1,False,,,,,,,,,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTVFTLTISSLQPEDFATYYCQQLNSDSSTFGQGTKLEIK,,,,QGISSY,AAS,QQLNSDSST,,,IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7SC1,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMRWVRQAPGKGLEWVSLIYAGGSTFYADSVKGRFIISRHNSKNILYLQMNSLRAEDTAVYFCARDLYVFGMDVWGQGTAVTVSA,,GLTVSSNY,IYAGGST,ARDLYVFGMDV,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7SC1,False,,,,,,,,,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTVFTLTISSLQPEDFATYYCQQLNSDSSTFGQGTKLEIK,,,,QGISSY,AAS,QQLNSDSST,,,IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7M53,True,,,,,,,,EVQLQQSGPVLVKPGASVRMSCKASGYTITDYYLNWVKQSHGKSLEWLGVLNPYSGGSLYSQTFKGKATLTVDRSSSTAYLELNSLTSEDSAVYYCARQLGRGNGLDYWGQGTSVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLHSSDQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCHQYLSSYTFGGGTKLEIK,GYTITDYY,LNPYSGGS,ARQLGRGNGLDY,QSVLHSSDQKNY,WAS,HQYLSSYT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ2*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,7NAB,True,,,,,,,,EVQLVESGAEVKKPGESLKISCKGSGYTFTRYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGHVTISADKSISTAYLQWNSLKASDTAMYYCARLPQYCSNGVCQRWFDPWGQGTLVTVSS,EIVLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSFPYTFGQGTNLEIK,GYTFTRYW,IYPGDSDT,ARLPQYCSNGVCQRWFDP,QGISSW,AAS,QQGNSFPYT,IGHJ5*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-12*01 (human)
PDB,,,,,7SOB,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,VLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGT,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7SOB,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFA,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,3DSF,True,,,,,,,,EVQLVESGGGLVQPKGSLKISCAASGFTFNIYAMNWVRQAPGKGLEWVARIRSQSNNYTTYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRQMGDYWGQGTTLTVSS,IQMTQSPASLSVSVGETVTITCRASENIYSFLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQFSLKINSLQSEDFGTYYCQHFWGTPFTFGSGTKLEIK,GFTFNIYA,IRSQSNNYTT,VRQMGDY,ENIYSF,AAT,QHFWGTPFT,IGHJ2*01 (mouse),IGHV10-1*02 (mouse),IGKJ4*01 (mouse),IGKV12-46*01 (mouse)
PDB,,,,,7WCR,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WCR,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WCZ,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WCZ,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD0,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WD0,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD0,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WD0,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD7,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WD7,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD7,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WD7,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD7,False,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGQSLEWIGGINPNIDDTTYNQNFKDKATLTVDKSSSTAYMEFRSLTFDDSAVYYCARDDKASFAFWGQGTLVTVSA,,GYTFTEYT,INPNIDDT,ARDDKASFAF,,,,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),,
PDB,,,,,7WD7,False,,,,,,,,,DIVMSQSPSSLAVSDGERVTLTCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELR,,,,QSLLYSTNQKNY,WAS,QQYYSYPLT,,,IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,7WD8,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WD8,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7WD9,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WD9,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7WD9,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WD9,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7WD9,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WD9,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7WDF,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WDF,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7WDF,False,,,,,,,,QVQLQQPGAELVRPGASVKLSCKASGYSFTRFWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSTTAYMQLSSPTSEDSAVYYCARKDYDYDAWFAYWGQGTLVTVSA,,GYSFTRFW,IHPSDSET,ARKDYDYDAWFAY,,,,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),,
PDB,,,,,7WDF,False,,,,,,,,,DIVLTQSPASLAVSLGQRATISCRASKSVSASVYSYMHWYQQKPGQPPKLLIYLASSLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCHHSRELPPAFGGGTKLEIK,,,,KSVSASVYSY,LAS,HHSRELPPA,,,IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,7CHF,True,,,,,,,,EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK,GFAFTTYA,ISDGGGSA,AKTRGRGLYDYVWGSKDY,QSLLHSNGYNY,LGS,MQALQTPGT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
PDB,,,,,7CHF,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGIIVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARDLGPYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSDLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSDLYTFGQGTKLEIK,GIIVSSNY,IYSGGST,ARDLGPYGMDV,QGISSD,AAS,QQLNSDLYT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,1MOE,True,,,,,,,,EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAYLQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWYQQKPGQPPKLLIYRASNLESGIPVRFSGTGSRTDFTLIIDPVEADDVATYYCQQTNEDPYTFGGGTKLEIK,GFNIKDTY,IDPANGNS,APFGYYVSDYAMAY,ESVDIFGVGF,RAS,QQTNEDPYT,IGHJ4*01 (mouse),IGHV14-3*02 (mouse),IGKJ2*01 (mouse),IGKV3-5*01 (mouse)
PDB,,,,,6XC7,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKSTLYLQMNSLRVEDTAVYYCARDFGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDFGDFYFDY,QSVSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,6XC7,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,6XE1,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGVIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDVSGGMDVWGQGTTVTVSS,QIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKLEIK,GVIVSSNY,IYSGGST,ARDLDVSGGMDV,QSVSSSY,GAS,QQYGSSPQT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7MM0,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSGGSCFDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGFPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIR,GFTFTSSA,IVVGSGNT,AAPYCSGGSCFDGFDI,QSVSSSY,GAS,QQYGNSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,1IGT,True,,,,,,,,EVKLQESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWVAYISNGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARHGGYYAMDYWGQGTTVTVSS,DIVLTQSPSSLSASLGDTITITCHASQNINVWLSWYQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPLTFGGGTKLEIK,GFTFSDYY,ISNGGGST,ARHGGYYAMDY,QNINVW,KAS,QQGQSYPLT,IGHJ4*01 (mouse),IGHV5-12*02 (mouse),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,1MCO,True,,,,,,,,VLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKLSSVTAADTAVYYCARVPLVVNPWGQGTLVTVSS,SALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVL,GDSINTILYY,IYYSGST,ARVPLVVNP,SSDVGGYNY,EVN,SSYEGSDNFV,IGHJ5*02 (human),IGHV4-59*01 (human),IGLJ1*01 (human),IGLV2-8*01 (human)
PDB,,,,,6DF2,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGYTFTENTVHWVRQAPGKGLEWIGGINPYYGGSIFSPKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRAGAYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSSSYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSRRTSYRTFGQGTKVEIK,GYTFTENT,INPYYGGS,ARRAGAYYFDY,SSVSSSY,STS,QQYSRRTSYRT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7JXE,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAYKGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARPDYQVLGYDFWIGYYGMDVWGQGTTVIVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSEVVFGGGTKLTVL,GYTFTNYG,ISAYKGNT,ARPDYQVLGYDFWIGYYGMDV,SSNIGAGYD,GNT,QSYDSSLSGSEVV,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7K8R,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,GFTFSSYA,IPFDGRNK,ASSSGYLFHSDY,QSISNW,EAS,QQYNSYPWT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
PDB,,,,,7A29,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVESENMHWYRQAPGKEREWVAAIYSTGGWTLYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVQVGYWYEGQGTQVTVS,,GFPVESEN,IYSTGGWT,AVQVGYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KN5,True,,,,,,,,QVQLVETGGGFVQPGGSLRLSCAASGVTLDYYAIGWFRQAPGKEREGVSCIGSSDGRTYYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCALTVGTYYSGNYHYTCSDDMDYWGKGTQVTVSS,,GVTLDYYA,IGSSDGRT,ALTVGTYYSGNYHYTCSDDMDY,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
PDB,,,,,7KN5,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREGVSCISSSGGSTHFADSVKGRFTISRDNAKNTVYLQMNSLIPEDTAVYYCAAQSGSYYWCGSDWHEYEYWGQGTQVTVSS,,GFTLDYYA,ISSSGGST,AAQSGSYYWCGSDWHEYEY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,5FUC,True,,,,,,,,DVQFVESGGGSVHAGGSLRLNCATSGYIYSTYCMGWFRQAPGKEREGVAHIYTNSGRTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAIYYCAARPSIRCASFSATEYKDWGQGTQVTVSS,,GYIYSTYC,IYTNSGRT,AARPSIRCASFSATEYKD,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
PDB,,,,,4B50,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGSISSVDVMSWYRQAPGKQRELVAFITDRGRTNYKVSVKGRFTISRDNSKNMVYLQMNSLKPEDTADYLCRAESRTSWSSPSPLDVWGRGTQVTVSS,,GSISSVDV,ITDRGRT,RAESRTSWSSPSPLDV,,,,IGHJ2*01 (human),IGHV3-66*01 (human),,
PDB,,,,,6XC3,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDVYGLDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPKFTFGPGTKVEIK,GLTVSSNY,IYSGGST,ARDLDVYGLDV,QGISSY,AAS,QQLNSYPPKFT,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,6XC3,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,6ZDG,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,6ZFO,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7A5S,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVAS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7BEO,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFGVYYCQQYGSSPWTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7BEO,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYPLHWVRQAPGKGPEWVAVISQDGGNKYYVDSVKGRFTISRDNSKNTLYLQMNNLRAEDTALYYCARDVVVVVAARNHYYNGMDVWGQGTTVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPFTFGPGTKVEIK,GFTFNNYP,ISQDGGNK,ARDVVVVVAARNHYYNGMDV,QGISSW,AVS,QQAKSFPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,7CWM,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CWO,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CWT,True,,,,,,,,VKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVS,IVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,GFTFTNYG,ISSGGSYT,ARFRYGGGGTVDY,ESVDNYGISF,AAS,QQSKEVPRI,IGHJ3*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,7CWT,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTV,SVLTQAPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7CWU,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTV,SVLTQAPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7CWU,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CYH,True,,,,,,,,VKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVSS,IVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,GFTFTNYG,ISSGGSYT,ARFRYGGGGTVDY,ESVDNYGISF,AAS,QQSKEVPRI,IGHJ4*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,7CYP,True,,,,,,,,VKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVSS,IVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,GFTFTNYG,ISSGGSYT,ARFRYGGGGTVDY,ESVDNYGISF,AAS,QQSKEVPRI,IGHJ4*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,7DCX,True,,,,,,,,EVQLQESGPSLVKPSQTLSLTCSVTGDSITNGYWNWIRKFPGNKLEYMGYISYSGSTYYSPSLKSRISITRDTSKNQHYLQLNSVTSEDTATYYCASDYHGSKYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGHRVSITCKASQDVGNDVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNRYPYTFGGGTKLEIK,GDSITNGY,ISYSGST,ASDYHGSKYYFDY,QDVGND,WAS,QQYNRYPYT,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
PDB,,,,,7DD2,True,,,,,,,,EVQLQESGPSLVKPSQTLSLTCSVTGDSITNGYWNWIRKFPGNKLEYMGYISYSGSTYYSPSLKSRISITRDTSKNQHYLQLNSVTSEDTATYYCASDYHGSKYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGHRVSITCKASQDVGNDVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNRYPYTFGGGTKLEIK,GDSITNGY,ISYSGST,ASDYHGSKYYFDY,QDVGND,WAS,QQYNRYPYT,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
PDB,,,,,7DK6,True,,,,,,,,QVQLKQSGPSLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVMWRGGNTDYNAAFMSRLSITKDNSKSQVFFKMNSLQTDDTAIYYCAKNGGAHAMDFWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,GFSLTSYG,MWRGGNT,AKNGGAHAMDF,ESVDSYGNSF,LAS,QQNNEDPFT,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,7E5S,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTV,SVLTQAPSVSGAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7E5S,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7E5S,True,,,,,,,,EVKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVSS,EIVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,GFTFTNYG,ISSGGSYT,ARFRYGGGGTVDY,ESVDNYGISF,AAS,QQSKEVPRI,IGHJ4*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,7E5S,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7KLW,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYRDRMAWYRQAPGKEREWVAAIYSAGQQTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDVGHHYEYYDYWGQGTQVTVS,,GFPVYRDR,IYSAGQQT,NVKDVGHHYEYYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KLW,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALITVNGHTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAAWGYAWPLHQDDYWYWGQGTQVTVS,,GSISSITY,LITVNGHT,AAAAWGYAWPLHQDDYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KMK,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSHTYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSHTYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7KML,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSHTYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSHTYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7KN6,True,,,,,,,,QVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMGWARQVPGKGLEWVSYIYSDGSTEYQDSVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCATEGSLGGWGRDFGSWGQGTQVTVSS,,GFTFSSYA,IYSDGST,ATEGSLGGWGRDFGS,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7KN6,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKSTLYLQMNSLRVEDTAVYYCARDFGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDFGDFYFDY,QSVSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KXJ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSHTYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSHTYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7L06,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,7LM8,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,GYTFTSYY,INSSGGST,ARPPRNYYDRSGYYQRAEYFQH,QDISNY,DAS,QQYDNPPLT,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7LM8,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCQGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGESDTRYSSSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARIRGVYSSGWIGGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRQWTFGQGTKVEIK,GYSFTSYW,IYPGESDT,ARIRGVYSSGWIGGDY,QSISSY,AAS,QQSYSTPRQWT,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7LXZ,True,,,,,,,,EVQLVESGGGLVNPGGSLRLSCAASGFTFSDYTIHWVRQAPGKGLEWVSSISSSSNYIYYADSVKGRFTISRDNAKNSLSLQMNSLRAEDTAVYYCARDGNAYKWLLAENVRFDYWGQGTLVTVSS,VTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSDRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPNWVFGGGTKLT,GFTFSDYT,ISSSSNYI,ARDGNAYKWLLAENVRFDY,SSDVGGYNY,DVS,SSYTSSSTPNWV,IGHJ4*01 (human),IGHV3-21*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
PDB,,,,,7LXZ,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LY0,True,,,,,,,,VQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARAVAGEWYFDYWGQGTLVTVS,YELTQPPSVSVSPGQTARITCSGDALAKHYAYWYRQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSIGSSWVFGGGTKLTV,GFTFSSYG,IWYDGSNR,ARAVAGEWYFDY,ALAKHY,KDS,QSADSIGSSWV,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
PDB,,,,,7LY2,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LY2,True,,,,,,,,VQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARAVAGEWYFDYWGQGTLVTVS,YELTQPPSVSVSPGQTARITCSGDALAKHYAYWYRQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSIGSSWVFGGGTKLTV,GFTFSSYG,IWYDGSNR,ARAVAGEWYFDY,ALAKHY,KDS,QSADSIGSSWV,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
PDB,,,,,7MDW,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAVSGLGAHRVGWFRRAPGKEREFVAAIGANGGNTNYLDSVKGRFTISRDNAKNTIYLQMNSLKPQDTAVYYCAARDIETAEYTYWGQGTQVTVSS,,GLGAHR,IGANGGNT,AARDIETAEYTY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7MDW,True,,,,,,,,VQLVESGGGLVQAGGSLRLSCAVSGRTFSTYGMAWFRQAPGKERDFVATITRSGETTLYADSVKGRFTISRDNAKNTVYLQMNSLKIEDTAVYYCAVRRDSSWGYSRDLFEYDYWGQGTQVTVS,,GRTFSTYG,ITRSGETT,AVRRDSSWGYSRDLFEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7MJK,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGYGDYYFDYWGQGTLVTVSS,DVVMTQSPATLSLSPGEKATLSCRASQSVSSYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSPLTFGGGTKVEIK,GFTVSSNY,IYSGGST,ARGYGDYYFDY,QSVSSY,WAS,QQYGSSPLT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
PDB,,,,,7N0G,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYRDRMAWYRQAPGKEREWVAAIYSAGQQTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDVGHHYEYYDYWGQGTQVTVSA,,GFPVYRDR,IYSAGQQT,NVKDVGHHYEYYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7N0H,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYRDRMAWYRQAPGKEREWVAAIYSAGQQTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDVGHHYEYYDYWGQGTQVTVSA,,GFPVYRDR,IYSAGQQT,NVKDVGHHYEYYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7N8H,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N8H,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDF,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7N9B,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAVSGLGAHRVGWFRRAPGKEREFVAAIGANGGNTNYLDSVKGRFTISRDNAKNTIYLQMNSLKPQDTAVYYCAARDIETAEYTYWGQGTQVTVSS,,GLGAHR,IGANGGNT,AARDIETAEYTY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7NDA,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFGVYYCQQYGSSPWTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NX7,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7NX7,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NXB,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NXB,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASAFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGKLWVYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLALTFGGGTKVEIK,AFTFSSYD,ISYDGSNK,AKDGGKLWVYYFDY,QSISSY,AAS,QQSYSTLALT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7R8L,True,,,,,,,,VQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVMYAGGSTFYADSVKGRFTISRDDSKNTLFLQMNSLRAEDTAIYYCARDLYSSGGTDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSIGSSYLAWYQQKPGLAPRLLIYGASRRATGIPDKFSGSGSGADFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,GITVSSNY,MYAGGST,ARDLYSSGGTDI,QSIGSSY,GAS,QQYGSSPGT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7R8L,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSVLYSSINKNY,WAS,QQYYSTPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
PDB,,,,,7SO9,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7SO9,True,,,,,,,,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,GYTFTGYY,INPISSGT,ARAAPFYDFWSGYSYFDY,QSVSSSY,GAS,QQYGSSAWT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7SOA,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7SOC,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,IVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVE,GYPFTSYG,ISTYNGNT,ARDYTRGAWFGESLIGGFDN,QTVSSTS,GAS,QQHDTSLT,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7SOD,True,,,,,,,,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK,GFTFNSYG,IRYDGGNK,ANLKDSRYSGSYYDY,QDIRFY,DAS,QQYDNLPFT,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7VNC,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASDFSFYDYEMSWVRQAPGKALEWIGSMYHSGRTYINPSLKSLVTISRDNSKNTLYLQMNSLRAEDTAMYYCVSNWASGSTGDYWGQGTLVTVSS,,DFSFYDYE,MYHSGRT,VSNWASGSTGDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7VND,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASDFSFYDYEMSWVRQAPGKALEWIGSMYHSGRTYINPSLKSLVTISRDNSKNTLYLQMNSLRAEDTAMYYCVSNWASGSTGDYWGQGTLVTVSS,,DFSFYDYE,MYHSGRT,VSNWASGSTGDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,5BVJ,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,GFTFSVYG,IWYDGDNQ,ARDLRTGPFDY,QSIGSS,YAS,HQSSSLPFT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ3*01 (human),IGKV6-21*01 (human)
PDB,,,,,7EO2,True,,,,,,,,VQLVESGGGLVQPGGSRKLSCSASGFAFSSFGMHWVRQAPEKGLEWVAYISSGSGTIYYADTVKGRFTISRDDPKNTLFLQMTSLRSEDTAMYYCVRSIYYYGSSPFDFWGQGTTLTVS,DIVMTQATSSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLTISRLEAEDVGVYYCMQHLEYPLTFGAGTKLE,GFAFSSFG,ISSGSGTI,VRSIYYYGSSPFDF,KSLLHSNGNTY,RMS,MQHLEYPLT,IGHJ2*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV2-137*01 (mouse)
PDB,,,,,5U15,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARGGWISLYYDSSGYPNFDY,SSDVGSYNL,EVS,CSYAGSSTVI,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*02 (human)
PDB,,,,,7JV6,True,,,,,,,,EVQLVESGGDSVQPGGSLRLSCAAAGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCALSSGYSGYAGNYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGARPEDEAEYYCLLSYSGARGVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ALSSGYSGYAGNY,TGAVTSGHY,DTS,LLSYSGARGV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV7-46*01 (human)
PDB,,,,,7BEN,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYPLHWVRQAPGKGPEWVAVISQDGGNKYYVDSVKGRFTISRDNSKNTLYLQMNNLRAEDTALYYCARDVVVVVAARNHYYNGMDVWGQGTTVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPFTFGPGTKVEIK,GFTFNNYP,ISQDGGNK,ARDVVVVVAARNHYYNGMDV,QGISSW,AVS,QQAKSFPFT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,7BEN,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGEGATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSGATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPYT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7JVA,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARVWWLRGSFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHVVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ARVWWLRGSFDY,SGSIASNY,EDN,QSYDSSNHVV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
PDB,,,,,7RR0,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFSSSAVQWVRQARGQRLEWIGWIVVGSGNANYAPRFQERVTITRDMSTNTAYMELSSLRSEDTAVYYCAAPNCSRTLCYDGFNMWGQGTMVTV,EIVLTQSPGSLSLSPGERATLSCRASQSVRSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSETDFTLTISRLEPEDFAVYYCQQYDSSPWTFGQGTKVEI,GFTFSSSA,IVVGSGNA,AAPNCSRTLCYDGFNM,QSVRSSY,GAS,QQYDSSPWT,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,5IML,True,,,,,,,,VQLVESGGGLVQAGGSLRLSCAASGRTFSSYGMGWFRQAPGKEREFVAAIRWNGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGRWDKYGSSFQDEYDYWGQGTQVTVSS,,GRTFSSYG,IRWNGGST,AAGRWDKYGSSFQDEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6JJP,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVATISGGGSYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPDSSGVAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASITCKASQDVETVVAWYLQKPGQSPRLLIYWASTRHTGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQYSRYPWTFGQGTKLEIK,GFTFSSYD,ISGGGSYT,ASPDSSGVAY,QDVETV,WAS,QQYSRYPWT,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,2D03,True,,,,,,,,EVQLLEESGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARNRGYSYAMDSWGQGTSVTVSS,LVMTQSPLSLPVSLGDQASISCRSSQSLVHSSGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISRVEAEDLGVYYCFQSSHVPLTFGAGTKLELK,GFSLTSYG,IWSGGST,ARNRGYSYAMDS,QSLVHSSGNTY,KVS,FQSSHVPLT,IGHJ4*01 (mouse),IGHV2-2*01 (mouse),IGKJ5*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,7NEH,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGLTVNRNYMSWIRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAIYYCARDFYEGSFDIWGQGTMVTVSS,AIQLTQSPSFLSASIGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFASYYCQQLNSYPAPVFGPGTKVDIK,GLTVNRNY,IYSGGST,ARDFYEGSFDI,QGISSY,AAS,QQLNSYPAPV,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,6HUO,True,,,,,,,,SLRVSCAASGRTFTTYIMAWFRQAPGKEREFLAAMDQGRIQYYGDSVRGRFTISRDYAKNSVDLQLDGLRPEDTAVYYCAAGAGFWGLRTASSYHYWGQGTQVTVSS,,GRTFTTYI,MDQGRIQ,AAGAGFWGLRTASSYHY,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
PDB,,,,,7CWN,True,,,,,,,,QQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHATLMNNKDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,GFTFSSYA,ISYDGSNK,ARHATLMNNKDI,QSISSY,AAS,QQSYSTPRT,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CWN,True,,,,,,,,VQLVQSGAEVKKPGATVKISCKVSGYSFSNYYIHWVKQAPGKSLEWIGYIDPFNGGTSDNLKFKGAATLTADTSTDTAYMELSSLRSEDTAVYYCARSEYDPYYVMDYWGQGTTVTVSS,IVLTQSPFQSVSPKEKVTITCRASQSISSNLHWYQQKPDQSPKLLIKYASQSISGIPSRFSGSGSGTDFTLTINSLEAEDFGIYFCQQTNFWPYIFGQGTKLEIL,GYSFSNYY,IDPFNGGT,ARSEYDPYYVMDY,QSISSN,YAS,QQTNFWPYI,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
PDB,,,,,7DD8,True,,,,,,,,EVQLQESGPSLVKPSQTLSLTCSVTGDSITNGYWNWIRKFPGNKLEYMGYISYSGSTYYSPSLKSRISITRDTSKNQHYLQLNSVTSEDTATYYCASDYHGSKYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGHRVSITCKASQDVGNDVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNRYPYTFGGGTKLEIK,GDSITNGY,ISYSGST,ASDYHGSKYYFDY,QDVGND,WAS,QQYNRYPYT,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
PDB,,,,,7DK7,True,,,,,,,,QVQLKQSGPSLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVMWRGGNTDYNAAFMSRLSITKDNSKSQVFFKMNSLQTDDTAIYYCAKNGGAHAMDFWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,GFSLTSYG,MWRGGNT,AKNGGAHAMDF,ESVDSYGNSF,LAS,QQNNEDPFT,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,7DZX,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINQDGSEKYYVDSVKGRFTISRDNAKNSLYLQVNSLRAEDTAVYYCARDWDYDILTGSWFGAFDIWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK,GFTFSSYW,INQDGSEK,ARDWDYDILTGSWFGAFDI,QGIRND,AAS,LQHNSYPLT,IGHJ3*02 (human),IGHV3-7*01 (human),IGKJ4*01 (human),IGKV1-17*01 (human)
PDB,,,,,7L02,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,7ND3,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAVSGFTVSRNYMSWVRQAPGKGLEWVSLIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLFHRSGYHDYWGQGTLVTVSS,VIWMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQKPGKAPKLLIFDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPAFGGGTKVDIK,GFTVSRNY,IYSGGST,ARDLFHRSGYHDY,QDINNY,DAS,QQYDNLPA,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7ND6,True,,,,,,,,EVQLLESGGDLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMHSLRAEDTAVYYCARDLGSGDMDVWGKGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIQAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYRYTFGQGTKVEIK,GVTVSSNY,IYPGGST,ARDLGSGDMDV,QGISSY,AAS,QQLNSYRYT,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
PDB,,,,,7ND7,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYTQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYSCARDMAFSMVRGSFDYWGQGTLVTVSS,QAVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNHWVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARDMAFSMVRGSFDY,SSDVGGYNY,EVS,SSYAGSNHWV,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-8*01 (human)
PDB,,,,,7ND8,True,,,,,,,,EVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYIRSSGHTIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARGGVLRFLEWPLNAFDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNNALGTFGQGTKVEIK,GFTFSDYY,IRSSGHTI,ARGGVLRFLEWPLNAFDI,QGISNY,AAS,QKYNNALGT,IGHJ3*02 (human),IGHV3-11*01 (human),IGKJ1*01 (human),IGKV1-27*01 (human)
PDB,,,,,7ND9,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFGVYYCQQYGSSPWTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVSSSY,GAS,QQYGSSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NDB,True,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASRRGTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,GFTFTTSA,IVVGSGNT,AAPHCNSTSCYDAFDI,QSVRSSY,GAS,QQYGSSPWT,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7NDD,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVALISYDGGNRYYADSVKGRFTISRDNSKNTLYLQMNRLRAEDTAMYYCAKDRDDGWDWYYFMDVWGKGTTVTVSS,DIQLTQSPGTLSLSPGERATLSCRASQSISGNYLAWYQHKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSYTFGQGTKVEIK,GFTFSSYG,ISYDGGNR,AKDRDDGWDWYYFMDV,QSISGNY,GAS,QQYGSSYT,IGHJ6*04 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,1C12,True,,,,,,,,QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYISYSGSTSYSPSLKSRISLTRDTSKNQFFLQLNSVTTEDTATYYCVTSLTWLLRRKRSYWGQGTTVTVSS,DIELTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFKGLIYHGTNLEDGVPSRFSGSGSGADYSLTISSLESEDFADYYCVQYVQFPFTFGSGTKLEIK,GYSITSDYA,ISYSGST,VTSLTWLLRRKRSY,QGISSN,HGT,VQYVQFPFT,IGHJ2*01 (mouse),IGHV3-2*02 (mouse),IGKJ4*01 (mouse),IGKV14-100*01 (mouse)
PDB,,,,,7A25,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVESENMHWYRQAPGKEREWVAAIYSTGGWTLYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVQVGYWYEGQGTQVTVS,,GFPVESEN,IYSTGGWT,AVQVGYWY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7B14,True,,,,,,,,QVQLVETGGGFVQPGGSLRLSCAASGVTLDYYAIGWFRQAPGKEREGVSCIGSSDGRTYYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCALTVGTYYSGNYHYTCSDDMDYWGKGTQVTVSS,,GVTLDYYA,IGSSDGRT,ALTVGTYYSGNYHYTCSDDMDY,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
PDB,,,,,7C8W,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVEVWRMEWYRQAPGKEREGVAAIESYGHGTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDDGQLAYHYDYWGQGTQVTVSA,,GFPVEVWR,IESYGHGT,NVKDDGQLAYHYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7KGK,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVAYKTMWWYRQAPGKEREWVAAIESYGIKWTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCIVWVGAQYHGQGTQVTVSA,,GFPVAYKT,IESYGIKWT,IVWVGAQY,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KKL,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGYIFGRNAMGWYRQAPGKERELVAGITRRGSITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPASPAYGDYWGQGTQVTVSS,,GYIFGRNA,ITRRGSIT,AADPASPAYGDY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7KM5,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTFKNADMNWYRQVPGQGLEWVTSIYSDGRTVYADSVKGRFTVSRDNPKSTVSLQMNSLKPEDTGVYYCMAGSKSGHELDHWGQGTQVTVSS,,GFTFKNAD,IYSDGRT,MAGSKSGHELDH,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7KN7,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKSTLYLQMNSLRVEDTAVYYCARDFGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,GFTVSSNY,IYSGGST,ARDFGDFYFDY,QSVSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KN7,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREGVSCISSSGDSTHYVDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAQSGSYYWCGSDWHEYDYRGQGTQVTVSS,,GFTLDYYA,ISSSGDST,AAQSGSYYWCGSDWHEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7LDJ,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAVSGFTLDYYAIGWFRQAPGKEREGVSCISSSGGNTKYADSVKGRFTASRDNAKNTFYLQMNSLKPEDTAVYYCAAIAATYYSGSYYFQCPHDGMDYWGKGTQVTVSS,,GFTLDYYA,ISSSGGNT,AAIAATYYSGSYYFQCPHDGMDY,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
PDB,,,,,7LX5,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAVSGFTLDYYAIGWFRQAPGKEREGVSCISSSGGNTKYADSVKGRFTASRDNAKNTFYLQMNSLKPEDTAVYYCAAIAATYYSGSYYFQCPHDGMDYWGKGTQVTVSS,,GFTLDYYA,ISSSGGNT,AAIAATYYSGSYYFQCPHDGMDY,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
PDB,,,,,7LX5,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGFTFRRYLMGWARQVPGKGLEWVSGIYSDGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKDRMDGSTWPERDFGSWGQGTQVTVSS,,GFTFRRYL,IYSDGST,AKDRMDGSTWPERDFGS,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7OAN,True,,,,,,,,QVQLVESGGGSVQAGGSLTLSCVASGVTLGRHAIGWFRQAPGKERERVSCIRTFDGITSYVESTKGRFTISSNNAMNTVYLQMNSLKPEDTAVYFCALGVTAACSDNPYFWGQGTQVTVSS,,GVTLGRHA,IRTFDGIT,ALGVTAACSDNPYF,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
PDB,,,,,6BE2,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYIHYSRSTNSNPALKSRVTISSDTSKNQLSLRLSSVTAADTAVYYCARDTYYYDSGDYEDAFDIWGQGTMVTVSS,QLVLTQSPSASASLGASVKLTCTLSSGHSNYAIAWHQQQPGKGPRYLMKVNRDGSHIRGDGIPDRFSGSTSGAERYLTISSLQSEDEADYYCQTWGAGIRVFGGGTKLTVL,GGSISGYY,IHYSRST,ARDTYYYDSGDYEDAFDI,SGHSNYA,VNRDGSH,QTWGAGIRV,IGHJ3*02 (human),IGHV4-59*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
PDB,,,,,7N5H,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSSNYYWSWIRQPPGKGLEWIGYMYYSGSTKYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREVYYYDRSGYYASDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK,GGSVSSSNYY,MYYSGST,AREVYYYDRSGYYASDGFDI,QSVSSSY,GAS,QQYGSSPQT,IGHJ3*02 (human),IGHV4-59*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,1JGV,True,,,,,,,,EVKLVESRGGLVKPGGSLQLSCAASGFTFSGYAMSWFRLTPEKRLEWVASIYNGFRIHYLDSVKGRFTISSDYARNILYLQMSTLRSEDTAMYYCSRGDAYSRYFDVWGAGTTVTVSA,EVVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,GFTFSGYA,IYNGFRI,SRGDAYSRYFDV,QSLVHSNGNTY,KVS,SQSTHVPPLT,IGHJ1*01 (mouse),IGHV5-6-5*01 (mouse),IGKJ5*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,3U1S,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGNSFSNHDVHWVRQATGQGLEWMGWMSHEGDKTGLAQKFQGRVTITRDSGASTVYMELRGLTADDTAIYYCLTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDVWGHGTAVTVSS,EVVITQSPLFLPVTPGEAASLSCKCSHSLQHSTGANYLAWYLQRPGQTPRLLIHLATHRASGVPDRFSGSGSGTDFTLKISRVESDDVGTYYCMQGLHSPWTFGQGTKVEIK,GNSFSNHD,MSHEGDKT,LTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDV,HSLQHSTGANY,LAT,MQGLHSPWT,IGHJ6*01 (human),IGHV1-8*03 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,5CEX,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCSVSGASISDHYWSWIRQSPGKGLEWIGYVYDSGDTNYNPSLKSRVNLSLDTSKNQVSLSLTAVTAADSAIYYCARTQHGRRIYGIVAFREWFTYFYMDVWGQGTPVTVSS,SYVLTQPSQLSVAPGETARISCGGRSLGSRAVQWYQQKPGQAPVLVIYNNQDRPSGIPERFSGSPDSNFGTTATLTISRVEAGDEADYYCHMWDSRSAINWVFGGGTKLTVL,GASISDHY,VYDSGDT,ARTQHGRRIYGIVAFREWFTYFYMDV,SLGSRA,NNQ,HMWDSRSAINWV,IGHJ6*01 (human),IGHV4-59*11 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,6B9Z,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQSPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAIYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPILLSASVGDRVTITCRASQDVNTAVAWYQQRTNGSPRLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDEADYYCQQHYTTPPTFGAGTKVEIK,GFNIKDTY,IYPTNGYT,SRWGGDGFYAMDY,QDVNTA,SAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,4BFB,True,,,,,,,,VQLQESGGGLVQPGGSLRLSCAASGFTFSSAIMTWVRQAPGKGREWVSTIGSDGSITTYADSVKGRFTISRDNARNTLYLQMNSLKPEDTAVYYCTSAGRRGPGTQVTVSS,,GFTFSSAI,IGSDGSIT,TSAGR,,,,IGHJ2*01 (human),IGHV3-74*03 (human),,
PDB,,,,,7CZX,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYISYSGSTNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAVYYCASNGQYYDILTGQPPDYWYFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK,GGSISSYY,ISYSGST,ASNGQYYDILTGQPPDYWYFDL,QSVLYSSNNKNY,WAS,QQYYSTPLT,IGHJ2*01 (human),IGHV4-59*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,7KZB,True,,,,,,,,QMQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIYSALNWYQQKPGKAPKLLIYAASALQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTDIHPYTFGQGTKVEIK,GYGFITYW,IYPGDSET,AGGSGISTPMDV,QSIYSA,AAS,QQTDIHPYT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7KZB,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNKANSYTTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARGISPFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYIYDSLNWYQQKPGKAPKLLIYDSSYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSWDTPVTFGQGTKVEIK,GFTFSDHY,TRNKANSYTT,ARGISPFYFDY,QYIYDS,DSS,QQSWDTPVT,IGHJ4*01 (human),IGHV3-72*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5E7B,True,,,,,,,,VQLVESGGGSVQAGGSLRLSCTASGFTFDDSDMGWYHQAPGNECELVSAIFSDGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAMYYCAAATTTVASPPVRHVCNGYWGQGTQVTVSS,,GFTFDDSD,IFSDGST,AAATTTVASPPVRHVCNGY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,5DK3,True,,,,,,,,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,GYTFTNYY,INPSNGGT,ARRDYRFDMGFDY,KGVSTSGYSY,LAS,QHSRDLPLT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,5W9K,True,,,,,,,,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,3CFC,True,,,,,,,,EVKLVESGGGLVKPGGSLKLSCTASGITFSRYIMSWVRQIPEKRLEWVASISSGGITYYPDSVKGRFTISRDNVRNILYLQMSSLRSEDTALYYCARGQGRPYWGQGTLVTVSS,DIVMTQAAFSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIK,GITFSRYI,ISSGGIT,ARGQGRPY,KSLLHSNGITY,QMS,AQNLELPPT,IGHJ3*01 (mouse),IGHV5-6-5*01 (mouse),IGKJ1*02 (mouse),IGKV2-109*01 (mouse)
PDB,,,,,7CZY,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARYIVVVPAAKGFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK,GYTFTSYD,MNPNSGNT,ARYIVVVPAAKGFDP,QSVLYSSNNKNY,WAS,QQYYSTPLT,IGHJ5*02 (human),IGHV1-8*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,7D0B,True,,,,,,,,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHSLFLTVGYSSSWSPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPHTFGQGTKLEIK,GFSLSTSGVG,IYWDDDK,AHSLFLTVGYSSSWSPFDY,QSVLYSSNNKNY,WAS,QQYYSTPHT,IGHJ4*01 (human),IGHV2-5*02 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
PDB,,,,,7L56,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSITTAYMELRRLRSDDTAVYYCARGLGVGCSGGNCYLDYYYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCSSYTSSSTWVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARGLGVGCSGGNCYLDYYYMDV,SSDVGGYNY,DVS,SSYTSSSTWV,IGHJ6*04 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
PDB,,,,,3NAB,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARELYQGYMDTFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGLYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNTLSYTFGQGTKVEIK,GYSFTNYW,IDPSDSYT,ARELYQGYMDTFDS,QSIGLY,AAS,QQGNTLSYT,IGHJ5*01 (human),IGHV5-10-1*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,4F37,True,,,,,,,,QVTLKESGPGILQPSQTLSLTCSFSGFSLRTSRVGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLESRLTISKDTSRNQVFLKITSVDTADTATYYCARRGFYGRKYEVNHFDYWGQGTTLTVSS,DIVMTQTPLSLPVSLGDQASISCRSSQTILHSNGNTYLEWYLQKPGQSPNLLIYKVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSRVPLTFGAGTKLELK,GFSLRTSRVG,IYWDDDK,ARRGFYGRKYEVNHFDY,QTILHSNGNTY,KVS,FQGSRVPLT,IGHJ2*01 (mouse),IGHV8-12*01 (mouse),IGKJ5*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,4F15,True,,,,,,,,VKLQESGAVVQPGGSLRLSCAASGFTGSDYDMSWIRQAPGKGLEWVSGILGGSERSYYRDSVKGRSTISRDNSRKTLYLEMNSLRAEDTAVYYCARHSWGAYVQYGMDGWGQGTTVTVSS,DIQMTQSPASLAVSPGQRATITCRASESVSNYGINFINWFQQKPGQPPKLLIYTASNKGTGVPARFSGSGSGTDFTLTINPVEAEDTANYFCQQTKEVPYGTFGGTKLEIK,GFTGSDYD,ILGGSERS,ARHSWGAYVQYGMDG,ESVSNYGINF,TAS,QQTKEVPYGT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*02 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,6XCA,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGWELPYDYWGQGTLVTVSS,QSALTQPPSGSGSPGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSNNFVVFGGGTKLTVL,GFTVSSNY,IYSGGST,ARGEGWELPYDY,SSDVGGYKY,EVS,SSYEGSNNFVV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,2BOB,True,,,,,,,,QVQLQQPGAELVKPGASVKLSCKASGYTFTSDWIHWVKQRPGHGLEWIGEIIPSYGRANYNEKIQKKATLTADKSSSTAFMQLSSLTSEDSAVYYCARERGDGYFAVWGAGTTVTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTDIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIANYYCQQSNRWPFTFGSGTKLEIK,GYTFTSDW,IIPSYGRA,ARERGDGYFAV,QSIGTD,YAS,QQSNRWPFT,IGHJ1*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,7KN4,True,,,,,,,,QVTLRESGPGLVKPSETLSLTCAVSGGSLSSVNYYWSWIRQHPGKGLEWIGYIYYSGSTNYNPSLKSRVTMSLDTSKNQFSLKLSSVTAADTAVYYCATPGAIMGALHIWGQGTLVTVSS,QAVLTQPSSASSTPGQRVIISCSGSSSNIGSNTVSWYQQVPGAAPKLLIYFDYRRPSGVPDRFSGTRSGTSASLGISGLQSEDEADYYCAAWDDSLSAWVFGRGTKLTVL,GGSLSSVNYY,IYYSGST,ATPGAIMGALHI,SSNIGSNT,FDY,AAWDDSLSAWV,IGHJ1*01 (human),IGHV4-61*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
PDB,,,,,5I8H,True,,,,,,,,LVQSGAEVKKPGASVKVSCRAFGYTFTGNALHWVRQAPGQGLEWLGWINPHSGDTTTSQKFQGRVYMTRDKSINTAFLDVTRLTSDDTGIYYCARDKYYGNEAVGMDVWGQGTSVTVSS,DIQLTQSPSFLSASVGDKVTITCRASQGVRNELAWYQQKPGKAPNLLIYYASTLQSGVPSRFSATGSGTHFTLTVSSLQPEDFATYFCQHMSSYPLTFGGGTKVEIK,GYTFTGNA,INPHSGDT,ARDKYYGNEAVGMDV,QGVRNE,YAS,QHMSSYPLT,IGHJ6*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,5I8H,True,,,,,,,,QVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSS,FVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVL,GTLVRDNY,VHDSGDT,ATTKHGRRIYGVVAFKEWFTYFYMDV,SLGSRS,NNN,HIWDSRRPTNWV,IGHJ6*04 (human),IGHV4-59*02 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,5T3Z,True,,,,,,,,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,GDSMNNYY,ISDRESA,ATARRGQRIYGVVSFGEFFYYYSMDV,ALGSRA,NNQ,HMWDSRSGFSWS,IGHJ6*04 (human),IGHV4-4*08 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,5T3Z,True,,,,,,,,EVQLVESGAQVKKPGASVTVSCTASGYKFTGYHMHWVRQAPGRGLEWMGWINPFRGAVKYPQNFRGRVSMTRDTSMEIFYMELSRLTSDDTAVYYCAREMFDSSADWSPWRGMVAWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCAGSSRDVGGFDLVSWYQQHPGKAPKLIIYEVNKRPSGISSRFSASKSGNTASLTISGLQEEDEAHYYCYSYADGVAFGGGTKLTVL,GYKFTGYH,INPFRGAV,AREMFDSSADWSPWRGMVA,SRDVGGFDL,EVN,YSYADGVA,IGHJ1*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*02 (human)
PDB,,,,,5V8L,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGNSFSNHDVHWVRQATGQGLEWMGWMSHEGDKTGLAQKFQGRVTITRDSGASTVYMELRGLTADDTAIYYCLTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDVWGHGTAVTVSS,EVVITQSPLFLPVTPGEAASLSCKCSHSLQHSTGANYLAWYLQRPGQTPRLLIHLATHRASGVPDRFSGSGSGTDFTLKISRVESDDVGTYYCMQGLHSPWTFGQGTKVEIK,GNSFSNHD,MSHEGDKT,LTGSKHRLRDYFLYNEYGPNYEEWGDYLATLDV,HSLQHSTGANY,LAT,MQGLHSPWT,IGHJ6*01 (human),IGHV1-8*03 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,5V8L,True,,,,,,,,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTYSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,GYNIRDYF,INPKTGQP,ARQRSDYWDFDV,NGY,DGS,QVYEF,IGHJ3*01 (human),IGHV1-2*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,5VIG,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFKNYAMAWVRQAPGKGLEWVSLLYNSEESTYYADSVKGRFTISRDNSKNTLFLQMNRLRVEDTAVYFCVRDRSNGWSSINLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTMTCRASQTISGWLAWYQQKPGKAPKLLIYQASRLESGIPSRFSGSGSGTEFTLTISSLQPDDVATYYCQQYSTFWTFGLGTKVEIK,GFTFKNYA,LYNSEEST,VRDRSNGWSSINL,QTISGW,QAS,QQYSTFWT,IGHJ2*01 (human),IGHV3-23*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
PDB,,,,,5VN3,True,,,,,,,,QVQLLESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVTS,LELTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYDNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,6OKP,True,,,,,,,,QVQLQESGPGLVKPSETLSVTCRVSGGSLDLYYWSWIRQPPGKGLQWIGFVYFDGSYGDYDPSLRSRVTISADMSKNQISLRLKSVTPADTAVYYCARLGPGGIFDRWTGHYGDKWLDPWGQGTLVTVSS,QIDLTQSPRTLSLSAGERATLLCRASQSVSNVALAWYQHKPGQAPRLLLHEASTRATGIPDRFIGSGSGRDFTLTITSLEPEDFAVYYCQLSGRRLGQGTKVEIK,GGSLDLYY,VYFDGSYG,ARLGPGGIFDRWTGHYGDKWLDP,QSVSNVA,EAS,QLSGRR,IGHJ5*02 (human),IGHV4-4*08 (human),IGKJ1*01 (human),IGKV3-11*02 (human)
PDB,,,,,6OKP,True,,,,,,,,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,GDSMNNYY,ISDRESA,ATARRGQRIYGVVSFGEFFYYYSMDV,ALGSRA,NNQ,HMWDSRSGFSWS,IGHJ6*04 (human),IGHV4-4*08 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,6UTA,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRGPRGVGELFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,GFTFSSYA,ISGSGGST,AKDRGPRGVGELFDY,QSISSW,KAS,QQYNSYPWT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
PDB,,,,,6VPX,True,,,,,,,,VQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAAISGDAWHVVYSNSVQGRFLVSRDNVKNTLYLEMNSLKIEDTAVYRCARMFQESGPPRLDRWSGRNYYYYSGMDVWGQGTTVTVSS,IVMTQTPLSLSVTPGQPASISCKSSESLRQSNGKTSLYWYRQKPGQSPQLLVFEVSNRFSGVSDRFVGSGSGTDFTLRISRVEAEDVGFYYCMQSKDFPLTFGGGTKVD,DFPFSKYP,ISGDAWHV,ARMFQESGPPRLDRWSGRNYYYYSGMDV,ESLRQSNGKTS,EVS,MQSKDFPLT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV2D-29*02 (human)
PDB,,,,,6VPX,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTV,YELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,GFDFDNAW,ITGPGEGWSV,ARTGKYYDFWSGYPPGEEYFQD,SLRSHY,GKN,SSRDKSGSRLSV,IGHJ2*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV3-19*01 (human)
PDB,,,,,7LO6,True,,,,,,,,EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYDNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,5GGS,True,,,,,,,,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,GYTFTNYY,INPSNGGT,ARRDYRFDMGFDY,KGVSTSGYSY,LAS,QHSRDLPLT,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,5WT9,True,,,,,,,,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,GITFSNSG,IWYDGSKR,ATNDDY,QSVSSY,DAS,QQSSNWPRT,IGHJ4*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,5IVO,True,,,,,,,,QVQLVESGGGLVQPGGSLTLSCTASGFTLDHYDIGWFRQAPGKEREGVSCINNSDDDTYYADSVKGRFTIFMNNAKDTVYLQMNSLKPEDTAIYYCAEARGCKRGRYEYDFWGQGTQVTVSS,,GFTLDHYD,INNSDDDT,AEARGCKRGRYEYDF,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
PDB,,,,,4CC8,False,,,,,,,,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWCQGTVVVVSS,,GYNFRDYS,IKPLWGAV,VRRGSCDYCGDFPWQY,,,,IGHJ1*01 (human),IGHV1-2*02 (human),,
PDB,,,,,4CC8,False,,,,,,,,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWCQGTVVVVSS,,GYNFRDYS,IKPLWGAV,VRRGSCDYCGDFPWQY,,,,IGHJ1*01 (human),IGHV1-2*02 (human),,
PDB,,,,,4CC8,False,,,,,,,,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWCQGTVVVVSS,,GYNFRDYS,IKPLWGAV,VRRGSCDYCGDFPWQY,,,,IGHJ1*01 (human),IGHV1-2*02 (human),,
PDB,,,,,4CC8,False,,,,,,,,,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,,,,QGGNA,DTS,QQFEF,,,IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,4CC8,False,,,,,,,,,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,,,,QGGNA,DTS,QQFEF,,,IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,4CC8,False,,,,,,,,,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,,,,QGGNA,DTS,QQFEF,,,IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,7D4G,True,,,,,,,,EVQLLEQSGAEVKKPGASVRVSCKVSGYTLPEVAMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATTTPFSSSYWFDPWGQGTLVTVSS,QSVLTQAPSVSGAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL,GYTLPEVA,FDPEDGET,ATTTPFSSSYWFDP,SSNIGNNY,DNN,GTWDSSLSAVV,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,7DX4,True,,,,,,,,LLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIIGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERGYSGYGAAYYFDYWGQGTLVTVSS,SVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GGTFSSYA,IIPIIGIA,ARERGYSGYGAAYYFDY,SSNIGAGYD,GNS,QSYDSSLSGSV,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7EJ5,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIYWVKQSLGKSLEWIGGNNPNNDDTTYKQFFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDFWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKSSQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDHFTGSGSGTDFTLTISNVQSADLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,NNPNNDDT,ARDGYPYYYALDF,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,7F62,True,,,,,,,,EVQLEESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQSPEKRLEWVAEISSGGTYTNYPDTATGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCANFGNYEEIAYWGQGTLVTVSA,QIVLTQSPAIMSVSLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPYTFGGGTKLEIK,GFTFSSYT,ISSGGTYT,ANFGNYEEIAY,SSVSSSY,STS,HQYHRSPYT,IGHJ3*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ2*01 (mouse),IGKV4-74*01 (mouse)
PDB,,,,,7F63,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIYWVKQSLGKSLEWIGGNNPNNDDTTYKQFFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDFWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKSSQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDHFTGSGSGTDFTLTISNVQSADLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,NNPNNDDT,ARDGYPYYYALDF,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,2G75,True,,,,,,,,QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGGITPILGIANYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARDTVMGGMDVWGQGTTVTVSS,YELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVFGTGTKVTVL,GGTFSSYT,ITPILGIA,ARDTVMGGMDV,NIGSKS,DDS,QVWDSSSDYV,IGHJ6*01 (human),IGHV1-69*16 (human),IGLJ1*01 (human),IGLV3-21*03 (human)
PDB,,,,,7CYV,True,,,,,,,,QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADISTSTAYMALSSLRSEDTAVYYCAKVEVNIGMDDYYYYYGMDVWGQGTTVTVSS,SYVLTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYVVFGGGTKLTVL,GGTFSSYA,IIPILGIA,AKVEVNIGMDDYYYYYGMDV,ALPKQY,KDS,QSADSSGTYVV,IGHJ6*01 (human),IGHV1-69*04 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
PDB,,,,,5C6W,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREPDYYDSSGYYPIDAFDIWGQGTTVTVSS,QSALTQPASVSASPGQSITISCTGTSSDVGAYDWVSWYQQHPGKAPKLLIFDVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCASATLLDTYVFGTGTKVTVL,GGTFSSYA,IIPIFGTA,AREPDYYDSSGYYPIDAFDI,SSDVGAYDW,DVN,ASATLLDTYV,IGHJ3*02 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7E7E,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFIDYYMNWVRQAPGKGLEWVGFIRNKANDYTTEYSTSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHMYDDGFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVRYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQWSYNPLTFGQGTKLEIK,GFTFIDYY,IRNKANDYTT,ARHMYDDGFDF,SSVRY,DTS,QQWSYNPLT,IGHJ5*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,7B17,True,,,,,,,,VQLVETGGGFVQPGGSLRLSCAASGVTLDYYAIGWFRQAPGKEREGVSCIGSSDGRTYYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCALTVGTYYSGNYHYTCSDDMDYWGKGTQVTVSS,,GVTLDYYA,IGSSDGRT,ALTVGTYYSGNYHYTCSDDMDY,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
PDB,,,,,4C57,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCSASGFKFNDSYMSWVRRVPGKGLEWVAGIWEDSSAAHYRDSVKGRFTISRDNAKNMLYLQMSSLKSDDTGLYYCVRRGYSGDYRPINNPSSQGTQVTVSS,,GFKFNDSY,IWEDSSAA,VRRGYSGDYRPINNP,,,,IGHJ5*02 (human),IGHV3-11*03 (human),,
PDB,,,,,1GIG,True,,,,,,,,QVQLKESGPGLVAPSQSLSITCTVSGFLLISNGVHWVRQPPGKGLEWLGVIWAGGNTNYNSALMSRVSISKDNSKSQVFLKMKSLQTDDTAMYYCARDFYDYDVFYYAMDYWGQGTSVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,GFLLISNG,IWAGGNT,ARDFYDYDVFYYAMDY,TGAVTTSNY,GTN,ALWYSNHWV,IGHJ4*01 (mouse),IGHV2-9*02 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,1K4C,True,,,,,,,,QVQLQQPGAELVKPGASVKLSCKASGYTFTSDWIHWVKQRPGHGLEWIGEIIPSYGRANYNEKIQKKATLTADKSSSTAFMQLSSLTSEDSAVYYCARERGDGYFAVWGAGTTVTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTDIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIANYYCQQSNRWPFTFGSGTKLEIK,GYTFTSDW,IIPSYGRA,ARERGDGYFAV,QSIGTD,YAS,QQSNRWPFT,IGHJ1*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,6DG2,True,,,,,,,,QVQLQQPGTELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPRNGRTDFSEKFKSKATLTVDTSSSTAFIQLSSLTSEDSAVYYCARWGYYGSSDYWGQGTALTVSS,DIVVTQSHKFMSTSVGDRVSITCKASQDVSVAVAWYQQKTGQSPKLLIYSASYRITGVPDRFTGSGSGTDFTFTISSVQAEDMAVYYCQQHYSTPPWTFGGGTKLEIK,GYTFTSYW,INPRNGRT,ARWGYYGSSDY,QDVSVA,SAS,QQHYSTPPWT,IGHJ2*02 (mouse),IGHV1-53*01 (mouse),IGKJ1*01 (mouse),IGKV6-17*01 (mouse)
PDB,,,,,7K9H,True,,,,,,,,QVQLKQSGPGLVAPSQSLSITCTVSGFSLINYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARKDYYGRYYGMDYWGQGTSVTVS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHWVFGGGTKLTVL,GFSLINYA,IWTGGGT,ARKDYYGRYYGMDY,TGAVTTSNY,GTN,ALWYNNHWV,IGHJ4*01 (mouse),IGHV2-9-1*01 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,7K9I,True,,,,,,,,QVQLKQSGPGLVAPSQSLSITCTVSGFSLINYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARKDYYGRYYGMDYWGQGTSVTVS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHWVFGGGTKLTVL,GFSLINYA,IWTGGGT,ARKDYYGRYYGMDY,TGAVTTSNY,GTN,ALWYNNHWV,IGHJ4*01 (mouse),IGHV2-9-1*01 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,7K9J,True,,,,,,,,EVQLQQSGAELVKPGASVKMSCKASGYTFTSYWITWVKQRPGQGLEWIGDIYPGSGSTKYNEKFRSEATLTVDTSSTTAYMQLSSLTSEDSAVYYCARWDFYGSRTFDYWGQGTTLTVSS,DIVLTQSPAILSVSPGERVSFSCRASQNIGTIIHWYQQRTNGSPRLLIKYASESVSGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSSSWPLTFGAGTKLEL,GYTFTSYW,IYPGSGST,ARWDFYGSRTFDY,QNIGTI,YAS,QQSSSWPLT,IGHJ2*01 (mouse),IGHV1-55*01 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,7K9K,True,,,,,,,,EVQLQQSGAELVKPGASVKMSCKASGYTFTSYWITWVKQRPGQGLEWIGDIYPGSGSTKYNEKFRSEATLTVDTSSTTAYMQLSSLTSEDSAVYYCARWDFYGSRTFDYWGQGTTLTVSS,DIVLTQSPAILSVSPGERVSFSCRASQNIGTIIHWYQQRTNGSPRLLIKYASESVSGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSSSWPLTFGAGTKLEL,GYTFTSYW,IYPGSGST,ARWDFYGSRTFDY,QNIGTI,YAS,QQSSSWPLT,IGHJ2*01 (mouse),IGHV1-55*01 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,7FG2,True,,,,,,,,EVQLVESGGGQVETGGSLRLSCQASGSTFSDYVMAWFRQRPGKEREFVATISRNGGTTTYGSSVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCYAVGGDGDSWGQGTQVTVSS,,GSTFSDYV,ISRNGGTT,YAVGGDGDS,,,,IGHJ5*01 (human),IGHV3-23*02 (human),,
PDB,,,,,7FG3,True,,,,,,,,EVQLVESGGGQVETGGSLRLSCQASGSTFSDYVMAWFRQRPGKEREFVATISRNGGTTTYGSSVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCYAVGGDGDSWGQGTQVTVSS,,GSTFSDYV,ISRNGGTT,YAVGGDGDS,,,,IGHJ5*01 (human),IGHV3-23*02 (human),,
PDB,,,,,1BAF,True,,,,,,,,DVQLQESGPGLVKPSQSQSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYMSYSGSTRYNPSLRSRISITRDTSKNQFFLQLKSVTTEDTATYFCARGWPLAYWGQGTQVSVS,QIVLTQSPAIMSASPGEKVTMTCSASSSVYYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSYPPITFGVGTKLELK,GYSITSDYA,MSYSGST,ARGWPLAY,SSVYY,DTS,QQWSSYPPIT,IGHJ3*01 (mouse),IGHV3-2*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
PDB,,,,,7CHE,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTDYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCARDLGEAGGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,GITVSSNY,IYSGGST,ARDLGEAGGMDV,QGISSY,AAS,QQLNSYPPA,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CHE,True,,,,,,,,EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK,GFAFTTYA,ISDGGGSA,AKTRGRGLYDYVWGSKDY,QSLLHSNGYNY,LGS,MQALQTPGT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
PDB,,,,,7E3O,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVALISYDGSNKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLGLRFLEWPISSYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIFSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLKGVFGGGTKLTVL,GFTFSSYA,ISYDGSN,ARGLGLRFLEWPISSY,SSNIGSNT,SNN,AAWDDSLKGV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,7D8B,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSSAISGFSISSTSIDWVRQAPGKGLEWVARISPSSGSTSYADSVKGRFTISADTSKNTVYLQMNSLRAEDTAVYYTGRVAKALNSRSPSFVVNTYSSIGFDYRGQGTLVTVSS,,GFSISSTS,ISPSSGST,GRVAKALNSRSPSFVVNTYSSIGFDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7EY5,True,,,,,,,,ELQLVQSGAEVKKPGESLKISCKYSGNISPNFWIGWVRQMAGKGLEWMGIIYPDDSDSRYSPSFQGQVIISADKSITTALLHWSSLKVSDTAKYYCVYGSGSPSNWFHPWGQGTLVTVSS,EVVMTQSPATLSVSPGERATLSCRASQSVRYNLAWYQQKPGQAPRLLIYDASTRATGIPGRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDNWPPWTFGQGTKVEIK,GNISPNFW,IYPDDSDS,VYGSGSPSNWFHP,QSVRYN,DAS,QQYDNWPPWT,IGHJ5*02 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,7EY5,True,,,,,,,,EVQLVESGGGFVKPGGSLRLSCAASGFKFSDAWMNWVRQAPGKGLEWVGRIKSKADGQTTDYAAPVKGRFSISRDDSKNTLFLQIHNLESDDTAVYYCTTGALVESRYFDWFTGYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQGIYNYLAWYQQKPGKVPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYKSAPLTFGGGTKVEIK,GFKFSDAW,IKSKADGQTT,TTGALVESRYFDWFTGYYFDY,QGIYNY,GAS,QKYKSAPLT,IGHJ4*01 (human),IGHV3-15*07 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
PDB,,,,,7EZV,True,,,,,,,,QVQLVQSGPEVKKPGTSVRVSCKASGFTFSTSAVQWVRQARGQRLEWIGWIAVGSGKTDYLQKFQERVTMTRDESTNTAYMQLSSLRSEDTAVYYCAAPHCSGGTCYDGFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSGYFAWYQQRPGRAPRLLIYGASSRATAIPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYGTSPWTFGQGTKVEIK,GFTFSTSA,IAVGSGKT,AAPHCSGGTCYDGFDI,QSVRSGY,GAS,QQYGTSPWT,IGHJ5*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7EZV,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCQFSEYKLISFWIAWVRQRPGKGLEWMGIIYPDDSDTKYSPSSQGQVTISADKSIRTAYLQWSSLMASDTAMYYCTSGSYYGTLDFWGQGTLVTVSS,DIEITQSPSSLSASVGDRVTISCRASQDIRTYVAWYQQRPGKVPRLLIYAASTLQSGVPSRFSGRGSGTDFTLTISSLQPEDVATYYCQQYNSAPLTFGGGAKVEIK,EYKLISFW,IYPDDSDT,TSGSYYGTLDF,QDIRTY,AAS,QQYNSAPLT,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
PDB,,,,,7LQW,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGNIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGVGYRGVIPLNWFDPWGQGTVVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSDLAWYQHKPGQAPRLLIYGASTRATGIPVRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPFTFGGGTKVEIK,GGTFSSYA,NIPIFGTA,ARGVGYRGVIPLNWFDP,QSVSSD,GAS,QQYNNWPPFT,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
PDB,,,,,1DEE,True,,,,,,,,QVQLVESGGGVVQPGKSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVALISYDESNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVKFYDPTAPNDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,GFTFSGYG,ISYDESNK,AKVKFYDPTAPNDY,QSISSY,AAS,QQSYSAPRT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,1IGC,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTGMYYCARWGNYPYYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGNSYPYTFGGGTKLEIK,GFTFSSFG,ISSGSSTL,ARWGNYPYYAMDY,ENVVTY,GAS,GQGNSYPYT,IGHJ4*01 (mouse),IGHV5-17*02 (mouse),IGKJ2*01 (mouse),IGKV6-20*01 (mouse)
PDB,,,,,6I6J,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVKRWSMTWYRQAPGKEREWVAAIRSAGHWTHYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDEGDFSYWYDYWGQGTQVTVSA,,GFPVKRWS,IRSAGHWT,NVKDEGDFSYWYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7R9D,True,,,,,,,,QVQLVEYGGGSVQAGGYLRLSCVASGSISLSSGMGWYRQAPGKERELVASISGGSSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASEQLTSGHAYWGQGTQVTVSS,,GSISLSSG,ISGGSST,AASEQLTSGHAY,,,,IGHJ4*01 (human),IGHV3-NL1*01 (human),,
PDB,,,,,7R9D,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCAASGFTFSNFGMHWVRQAPEMGLEWVAYISSGSTTIYYGDTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARRPLYDGDYGYPMDYWGQGTSVTVSS,NIMLTQSPSSLAVSAGERVTMSCKSTQSILYNSNQKTYLAWYQQKPGQSPKLLIYWASTRASGVPDRFTGSGSGTDFTLTINSVQPEDLAVYYCHQYLSAWTFGGGTKLEIK,GFTFSNFG,ISSGSTTI,ARRPLYDGDYGYPMDY,QSILYNSNQKTY,WAS,HQYLSAWT,IGHJ4*01 (mouse),IGHV5-17*02 (mouse),IGKJ1*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,7RXC,True,,,,,,,,DVQLVESGGGLVQPGKSLRLSCAASGFTFSNFGMHWVRQAPEMGLEWVAYISSGSTTKYYGDTVKGRFTISRDNPKNTLYLQMNSLRSEDTAMYYCARRPLYDGDYGYPMDYWGQGTSVTVSS,NIMLTQSPSSLAVSAGERVTMSCKSTQSILYNSNQKTYLAWYQQKPGQSPKLLIYWASTRASGVPDRFTGSGSGTDFTLTINSVQPEDLAVYYCHQYLSAWTFGGGTKLEIK,GFTFSNFG,ISSGSTTK,ARRPLYDGDYGYPMDY,QSILYNSNQKTY,WAS,HQYLSAWT,IGHJ4*01 (mouse),IGHV5-17*02 (mouse),IGKJ1*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,7RXC,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVKRWSMTWYRQAPGKEREWVAAIRSAGHWTHYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDEGDFSYWYDYWGQGTQVTVSS,,GFPVKRWS,IRSAGHWT,NVKDEGDFSYWYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7RXD,True,,,,,,,,DVQLVESGGGLVQPGKSLRLSCAASGFTFSNFGMHWVRQAPEMGLEWVAYISSGSTTKYYGDTVKGRFTISRDNPKNTLYLQMNSLRSEDTAMYYCARRPLYDGDYGYPMDYWGQGTSVTVSS,NIMLTQSPSSLAVSAGERVTMSCKSTQSILYNSNQKTYLAWYQQKPGQSPKLLIYWASTRASGVPDRFTGSGSGTDFTLTINSVQPEDLAVYYCHQYLSAWTFGGGTKLEIK,GFTFSNFG,ISSGSTTK,ARRPLYDGDYGYPMDY,QSILYNSNQKTY,WAS,HQYLSAWT,IGHJ4*01 (mouse),IGHV5-17*02 (mouse),IGKJ1*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,7RXD,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYRDRMAWYRQAPGKEREWVAAIYSAGQQTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDVGHHYEYYDYWGQGTQVTVSS,,GFPVYRDR,IYSAGQQT,NVKDVGHHYEYYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,4XNQ,True,,,,,,,,QVQLQESGPGLVKPSGTVSLTCAVSGGSISSSYWWSWVRQPPGKGLEWIGEIYHSGNTNYNPSLKSRVTISVDKSKNLFSLKLSSVTAADTAVYYCARVALFDILTGGWFDPWGQGTLVTVSS,YELTQPPSVSVSPGQTVNITCSGDTLGDKYVCWYQQKPGQSPVLVIYQDTKRPSGIPERFSGSNSGDTATLTVSGTQAMDEADYYCQAWDSSSFVFGTGTKVTVL,GGSISSSYW,IYHSGNT,ARVALFDILTGGWFDP,TLGDKY,QDT,QAWDSSSFV,IGHJ5*02 (human),IGHV4-4*02 (human),IGLJ1*01 (human),IGLV3-1*01 (human)
PDB,,,,,3N9G,True,,,,,,,,EVQLVQSGAEVRKPGASTKVSCKASGYTFTHYYMHWVRQAPGQGLEWMGIINPSGGSTTYAQKLQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDWGSNYVWGSYPKYWGQGTLVTVSS,QSVLTQPSSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,GYTFTHYY,INPSGGST,ARDWGSNYVWGSYPKY,SSNIGSNT,GNN,AAWDDSLNGPV,IGHJ4*01 (human),IGHV1-46*04 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,5HHV,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIHGVTRNWGQGTLVTVSS,FMLTQPHSVSESPGKTVTISCTRSSGSLANYYVQWYQQRPGSSPTIVIFANNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDPYSVVFGGGTKLTVL,GFTFSSYA,ISGSGGST,ARDLIHGVTRN,SGSLANYY,ANN,QTYDPYSVV,IGHJ1*01 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
PDB,,,,,5IES,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIK,GYTFTGYY,INPNSGGT,AKISGSYSFDY,QSVLYSSNNKNY,WAS,QQYYS,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,5WL2,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHGNYYYYSGMDVWGQGTTVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQLPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGAVFGGGTQLTVL,GGTFSSYA,IIPIFGTA,ARHGNYYYYSGMDV,SSNIGNNA,YDD,AAWDDSLNGAV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ7*01 (human),IGLV1-36*01 (human)
PDB,,,,,6A67,True,,,,,,,,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGTYYWSWIRHHPGKGLEWIGYIYHSGSAYYNPSLESRVTMSVDTSKNQFSLKLSSVTAADTAIYYCARAENLLSPYLAEGFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSTSNIGSNAVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGSWVFGGGTKLTVL,GGSISSGTYY,IYHSGSA,ARAENLLSPYLAEGFDP,TSNIGSNA,SNN,AAWDDSLSGSWV,IGHJ5*02 (human),IGHV4-31*02 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
PDB,,,,,6MHR,True,,,,,,,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,GGSFSGYY,INHGGYV,ARDYGPGNYDWYFDL,QSVSSY,DAS,QQRSNWPPALT,IGHJ2*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,6PE7,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,GFTFSDYG,ISSGRGNI,ARSWGYFDV,QSLLNRGNQKNY,WAS,QNDYTYPLT,IGHJ6*01 (human),IGHV3-21*01 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
PDB,,,,,6PHB,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGDSMSSYYWSWIRQPAGKGLEWIGRISTSGSTNYNPSLKSRVTMSVDTSNNHFSMRLNSVTAADTAVYYCACSGSYSFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLRIFTFGPGTKVDIK,GDSMSSYY,ISTSGST,ACSGSYSFFDY,QDISNF,DAS,QQYDNLRIFT,IGHJ4*01 (human),IGHV4-4*07 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7JXC,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTGSETYYYDSSGPFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQVFGGGTKLTVL,GFTFSNAW,IKSKTDGGTT,TTGSETYYYDSSGPFDY,SGSIASNY,EDN,QSYDSSNQV,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
PDB,,,,,7MZF,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDRGDYLFDYWGQGTLVTVSS,DIQMTQPPSPLFASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSETEFTLTISSLQPDDFATYYCQQYNSYFPTFGQGTKVEIK,EFIVSRNY,IYSGGTT,ARDRGDYLFDY,QSISSW,KAS,QQYNSYFPT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
PDB,,,,,7MZG,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVFYPGGSTYNADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAVYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQESYSTPGLFTFGPGTKVDIK,GLTVSSNY,FYPGGST,ARDAVYYGMDV,QSISSY,AAS,QESYSTPGLFT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7MZI,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGWGAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQSVSISCSGTYSNIGSNPVNWYQQVPGTAPKLLIYANDQRPSGVPDRFSGSKSATSAFLAIGGLQSEDDADYYCSTWDDSLPGPLFGGGTKLTVL,GFTFSRFA,ISGSGGST,AKVGWGAFDI,YSNIGSNP,AND,STWDDSLPGPL,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,7MZK,True,,,,,,,,LVQLVQSGAEVKKPGASVKISCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGGTSYAQKFQGRVTMTRDTSTSTVYMELTSLRSDDTAVYYCAKDRVTIFWGNGMDVWGQGTTVTVSS,DIVMTQSPVSLAVSLGERATIKCKSSQSVLYSSNNKNYLGWYQQKPGQPLRLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYSTTPLTFGGGTKVEIK,GYTFTSYY,INPSGGGT,AKDRVTIFWGNGMDV,QSVLYSSNNKNY,WAS,HQYSTTPLT,IGHJ6*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,7MZK,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGWGAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQSVSISCSGTYSNIGSNPVNWYQQVPGTAPKLLIYANDQRPSGVPDRFSGSKSATSAFLAIGGLQSEDDADYYCSTWDDSLPGPLFGGGTKLTVL,GFTFSRFA,ISGSGGST,AKVGWGAFDI,YSNIGSNP,AND,STWDDSLPGPL,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
PDB,,,,,7MZL,True,,,,,,,,QVQLQQWGAGLLKPSETLSLTCVVYGETLSGYYWTWIRQSPGKGLEWIGEISLRGTANYNPSLKSRVTLSVEASKNQFSLKMTSVTAADTAVYYCVGGVVLDNVVWFDPWGQGIPVTVSL,ESVLTQSPVSLSLSPGERATLSCRASQSVGTYLAWYQHRPGQAPRLLIYNASKRATGIPARFSGSGSGTDFTLTISSLEPEDLAVYFCQQRSNWLTFGGGTKVEIK,GETLSGYY,ISLRGTA,VGGVVLDNVVWFDP,QSVGTY,NAS,QQRSNWLT,IGHJ5*02 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,7MZN,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCVASGLTVSSNYMNWVRQTPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARVGGYCSSANCVSDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIRNYLNWYQQKPGKAPKIMIYDASILETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTQLEIK,GLTVSSNY,IYSGGST,ARVGGYCSSANCVSDV,QDIRNY,DAS,QQYDNLPIT,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
PDB,,,,,5MHE,True,,,,,,,,EVKLEESGGGLVKLGGSLKLSCAASGFTFSSYYMSWVRQTPEKRLELVAAINSNGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALYYCARGDYYGSSLYYYAMDYWGQGTSVTVSS,DIVLNQSPAIMSASPGEKVTMTCNSSSSVSYMHWYQHKPGSSPRLLIYDTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPLTFGAGTKLEIT,GFTFSSYY,INSNGGST,ARGDYYGSSLYYYAMDY,SSVSY,DTS,QQRSSYPLT,IGHJ4*01 (mouse),IGHV5-6-2*01 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
PDB,,,,,7P40,True,,,,,,,,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAVQWVRQARGQRLEWIGWIVVGSGNTDYAQQFQERVTITRDMSTSTAYMELSSLGSEDTAVYYCAAPNCSGGSCYDGFDLWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRGSQSVRSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,GFTFTSSA,IVVGSGNT,AAPNCSGGSCYDGFDL,QSVRSSY,GAS,QQYGSSPWT,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7S5P,False,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGTAMAYGMDVWGQGTTVTVSS,,GFTVSSNY,IYSGGST,ARGTAMAYGMDV,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7S5P,False,,,,,,,,,YELTQPPSVSVAPGQTARITCGGNNIGGQSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,,,,NIGGQS,DDS,QVWDSSSDHVV,,,IGLJ2*01 (human),IGLV3-21*02 (human)
PDB,,,,,7S5Q,False,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGITFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSGGTCHDGFDIWGQGTMVTVSS,,GITFTSSA,IVVGSGNT,AAPYCSGGTCHDGFDI,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
PDB,,,,,7S5Q,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,,,,QSVSSSY,GAS,QQYGSSPWT,,,IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7S5Q,False,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,,GYTFTSYY,INSSGGST,ARPPRNYYDRSGYYQRAEYFQH,,,,IGHJ1*01 (human),IGHV1-46*01 (human),,
PDB,,,,,7S5Q,False,,,,,,,,,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,,,,QDISNY,DAS,QQYDNPPLT,,,IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7S5R,False,,,,,,,,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAMQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSTNCYDAFDIWGQGTMVTVSS,,GFTFTSSA,IVVGSGNT,AAPYCSSTNCYDAFDI,,,,IGHJ3*02 (human),IGHV1-58*02 (human),,
PDB,,,,,7S5R,False,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,,,,QSVSSSY,GAS,QQYGSSPWT,,,IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7S5R,False,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,,GYTFTSYY,INSSGGST,ARPPRNYYDRSGYYQRAEYFQH,,,,IGHJ1*01 (human),IGHV1-46*01 (human),,
PDB,,,,,7S5R,False,,,,,,,,,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,,,,QDISNY,DAS,QQYDNPPLT,,,IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,5SX4,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,GGSVSSGDYY,IYYSGNT,VRDRVTGAFDI,QDISNY,DAS,QHFDHLPLA,IGHJ3*02 (human),IGHV4-61*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,1WEJ,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEKGLEWIGRIDPASGNTKYDPKFQDKATITADTSSNTAYLQLSSLTSEDTAVYYCAGYDYGNFDYWGQGTTLTVSS,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWSTPWTFGGGTKLEIK,GFNIKDTY,IDPASGNT,AGYDYGNFDY,GNIHNY,NAK,QHFWSTPWT,IGHJ2*01 (mouse),IGHV14-3*02 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,5K8A,True,,,,,,,,EVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,GFSLSTAGMS,IWWDDKK,ARDMIFNFYFDV,SRVGY,DTS,FQGSGYPFT,IGHJ6*01 (human),IGHV2-70*01 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
PDB,,,,,6KTR,True,,,,,,,,EVQLLETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDNWQELLFDYWGQGTLVTVSS,QAGLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQTEDEADYYCSSWTRSSGLVFGGGTQLTVL,GFTFSSYA,ISGSGGST,AKDNWQELLFDY,SSDVGGYNY,DVS,SSWTRSSGLV,IGHJ4*01 (human),IGHV3-23*01 (human),IGLJ7*01 (human),IGLV2-14*03 (human)
PDB,,,,,6PZE,True,,,,,,,,QVQLVESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDPGLEWELSVLSNWFDPWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSAYVFATGTKVTVL,GGSISSSSYY,IYYSGST,ARDPGLEWELSVLSNWFDP,SSNIGNNY,DNN,GTWDTSLSAYV,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
PDB,,,,,6Z3P,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLHSSSWFYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGPGTKVDIK,GYSFTSYW,IYPGDSDT,ARLHSSSWFYGMDV,QSISSY,AAS,QQSYSTPRT,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7LS9,True,,,,,,,,EVHLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNKANSYTTEYAASVKGRFTISRDDAKNSLYLQMNSLKTEDTAVYYCARVHRWAYCINGVCFGAYSDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSTFGQGTKLEIK,GFTFSDHY,TRNKANSYTT,ARVHRWAYCINGVCFGAYSDY,QSVSSSY,GAS,QQYGSSPST,IGHJ4*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,7V26,True,,,,,,,,QVTLRESGPTLVKPKQTLTLTCTFSGFSLSTPGGGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSSLTITKDTSKNQVVLTMTNMDPVDTATYYCARLTAADTIFDCWGQGTLVTVSS,QSALTQPASVSGSPGLSITISCTATSSDVGAYNYVSWYQQHPGQAPKLMIYDVSKRPSGVSNRFSGSKSANTASLTISGLQAEDEADYYCSSYTTTSVVFGGGTKLTVL,GFSLSTPGGG,IYWDDDK,ARLTAADTIFDC,SSDVGAYNY,DVS,SSYTTTSVV,IGHJ5*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
PDB,,,,,7V2A,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRHMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISVDTSISTAYLQWSSLKASDTAMYYCTRHQYGYNYGYFYYYIDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNPVSWYRQVPGTAPKLLIYDNNKRPSGIPDRFSGSKSGASATLGITGLQTGDEADYYCGTWHTSLSSGVFGGGTKLTVL,GYSFSNYW,IYPGDSDT,TRHQYGYNYGYFYYYIDV,SSNIGNNP,DNN,GTWHTSLSSGV,IGHJ6*04 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
PDB,,,,,5JRP,True,,,,,,,,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSVYYSGGASYNPSLKSRATISVDTSKNQFSLNLDSVSAADTAIYYCASIYGSGTFYYYFYMDVWGKGSTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQVISNYLNWYQQKPGKAPKLLIYDTSNLKTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYENLQFTFGPGTKVDIK,GGSISSSSYY,VYYSGGA,ASIYGSGTFYYYFYMDV,QVISNY,DTS,QQYENLQFT,IGHJ6*04 (human),IGHV4-39*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,1FOR,True,,,,,,,,QLQQSGAELVRPGSSVKISCKASGYAFSSFWVNWVKQRPGQGLEWIGQIYPGDGDNKYNGKFKGKATLTADKSSTTAYMQLYSLTSEDSAVYFCARSGNYPYAMDYWGQGTSVTVSS,QIVLTQSPAIMSAFPGEKVTITCSATSSVNYMHWFQQKPGTSPKLWIYSSSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPITFGSGTKLEIK,GYAFSSFW,IYPGDGDN,ARSGNYPYAMDY,SSVNY,SSS,QQRSSYPIT,IGHJ4*01 (mouse),IGHV1-80*01 (mouse),IGKJ4*01 (mouse),IGKV4-57*01 (mouse)
PDB,,,,,7MFV,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVAYKTMWWYRQAPGKEREWVAAIESYGIKWTRYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCIVWVGAQYHGQGTQVTVSA,,GFPVAYKT,IESYGIKWT,IVWVGAQY,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
PDB,,,,,1IGY,True,,,,,,,,VKLQESGAELARPGASVKMSCKASGYTFTTYTIHWIKQRPGQGLEWIGYINPSSVYTNYNQRFKDKATLTRDRSSNTANIHLSSLTSDDSAVYYCVREGEVPYWGQGTTVTVSS,KSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,GYTFTTYT,INPSSVYT,VREGEVPY,ENVVTY,GAS,GQGYSYPYT,IGHJ2*01 (mouse),IGHV1-4*01 (mouse),IGKJ2*01 (mouse),IGKV6-20*01 (mouse)
PDB,,,,,7EH5,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIYWVKQSLGKSLEWIGGNNPNNDDTTYKQFFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDFWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKSSQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDHFTGSGSGTDFTLTISNVQSADLAEYFCQQYNNYPWTFGGGTKLEIK,GYTFTEYT,NNPNNDDT,ARDGYPYYYALDF,QNVGTN,SAS,QQYNNYPWT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
PDB,,,,,7EH5,True,,,,,,,,EVQLEESGPGLVQPSQSLSITCTVSDFSLTTYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQTNDTAIYYCARMGDGYYVGAMDYWGQGTSVTVSS,DIQLTQSPAILSVSPGERVSFSCRASQSIGTSIHWYQQRTNGSPRHLIKYASESISGIPSRFSGSGSGTDFTLTINGVESEDIADYYCQQGHNWPLTFGAGTKLELK,DFSLTTYG,IWSGGST,ARMGDGYYVGAMDY,QSIGTS,YAS,QQGHNWPLT,IGHJ4*01 (mouse),IGHV2-2*02 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,7CZR,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETLAFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,GFTVSSNY,IYPGGST,ARETLAFDY,QGISSY,AAS,QQLNSYPPA,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7CZS,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETLAFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,GFTVSSNY,IYPGGST,ARETLAFDY,QGISSY,AAS,QQLNSYPPA,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7D0D,True,,,,,,,,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHSLFLTVGYSSSWSPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPHTFGQGTKLEIK,GFSLSTSGVG,IYWDDDK,AHSLFLTVGYSSSWSPFDY,QSVLYSSNNKNY,WAS,QQYYSTPHT,IGHJ4*01 (human),IGHV2-5*02 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
PDB,,,,,5VLP,True,,,,,,,,QVQLKQSGAELVRPGASVKLSCKASGYIFTDYYINWLKKRPGQGLEWIARIYPGSGHTYYNENFKDKATLTAEKSSSNVYMQLSSLTSEDSAVYFCARENFYGSSYVDWYFDVWGTGTTVTVSS,DIVMTQSQKFMSTSGGDRVSITCKTSQNVGTAVAWFQQKPGQSPKLLIYSASNRYTGVSDRFTGSGSGTEFIFTISYAQSEDLADYFCHQYSSYPLTFGAGTKLELK,GYIFTDYY,IYPGSGHT,ARENFYGSSYVDWYFDV,QNVGTA,SAS,HQYSSYPLT,IGHJ1*03 (mouse),IGHV1-76*01 (mouse),IGKJ5*01 (mouse),IGKV6-13*01 (mouse)
PDB,,,,,1KIQ,True,,,,,,,,QVQLQESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYNSALKSRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDFRLDYWGQGTTLTVSS,DIVLTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYYTTTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWSTPRTFGGGTKLEIK,GFSLTGYG,IWGDGNT,ARERDFRLDY,GNIHNY,YTT,QHFWSTPRT,IGHJ2*01 (mouse),IGHV2-6-7*01 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,5XJM,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCAASGFTFSGFGMHWVRQAPEKGLEWVAYISSGSSLIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYFCATSLYYGTPWFAYWGQGTLVTVSA,DIVLTQSPAIMSASPGEKVTMTCSASSSVTYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATFYCQQWSSYPLTFGAGTKLELK,GFTFSGFG,ISSGSSLI,ATSLYYGTPWFAY,SSVTY,DTS,QQWSSYPLT,IGHJ3*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
PDB,,,,,4B41,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASRSIISNNAMGWYRQAPGKQRELVARISSGGRTTYADSVKGRFTISRDNAKTTVYLQMNSLKPEDTAVYYCNAASLVRGPLDHWGQGTQVTVSS,,RSIISNNA,ISSGGRT,NAASLVRGPLDH,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
PDB,,,,,3K1K,True,,,,,,,,QVQLVESGGALVQPGGSLRLSCAASGFPVNRYSMRWYRQAPGKEREWVAGMSSAGDRSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYYCNVNVGFEYWGQGTQVTVSS,,GFPVNRYS,MSSAGDRS,NVNVGFEY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,5M13,True,,,,,,,,QVQLVESGGGSVQAGGSLRLSCVASGDIKYISYLGWFRQAPGKEREGVAALYTSTGRTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAEWGSQSPLTQWFYRYWGQGTQVTVSA,,GDIKYISY,LYTSTGRT,AAAEWGSQSPLTQWFYRY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7JWB,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFRIYSYYSYIGWVRRAPGKGEELVARIYPSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWDFASPYYPGSSGLDYWGQGTLVTVSS,,GFRIYSYYSY,IYPSSGYT,ARWDFASPYYPGSSGLDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7EYA,True,,,,,,,,VQLVESGGGLVKPGGSLRLSCAASGFTFSNYDMNWVRQAPGKGLEWVSSISSSSTYTHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRAYRLGELSSLWGDDAFDIWGQGTMVTVSS,VWMTQSPSLLSASTGDRVTVSCRMSQDISSYLAWYQQKPGKAPELLIYAAFTLQSGVPSRFSGSGSGTEFTLTISSLQSEDFATYYCQQYYSFPHTFGQGTKLERR,GFTFSNYD,ISSSSTYT,ARDRAYRLGELSSLWGDDAFDI,QDISSY,AAF,QQYYSFPHT,IGHJ3*02 (human),IGHV3-21*01 (human),IGKJ2*01 (human),IGKV1D-8*01 (human)
PDB,,,,,5KVG,True,,,,,,,,EAQLQQSGTGLARPGASVKLSCKASGYTFTSYGISWVTQRAGQGLEWIGVIYPRSGNTYYNEKFRGKATLTADKSSSSAYMELRGLTAEDSAVYFCARENYGSVYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQFSSYPYTFGGGTKLEIK,GYTFTSYG,IYPRSGNT,ARENYGSVY,QNVGTA,SAS,QQFSSYPYT,IGHJ2*01 (mouse),IGHV1-81*01 (mouse),IGKJ2*01 (mouse),IGKV6-13*01 (mouse)
PDB,,,,,15C8,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQKPEQGLEWIAQIDPANGNTKYDPKFQGKATITADTSSNTAYLHLSSLTSEDSAVYYCAADPPYYGHGDYWGQGTTLTVSS,DIVLTQSPAIMSASLGERVTMTCTASSSVSSSNLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPYTFGGGTKLEIK,GFNIKDTY,IDPANGNT,AADPPYYGHGDY,SSVSSSN,STS,HQYHRSPYT,IGHJ2*01 (mouse),IGHV14-3*02 (mouse),IGKJ2*01 (mouse),IGKV4-74*01 (mouse)
PDB,,,,,7LXW,True,,,,,,,,VQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYFCARAFPDSSSWSGFTIDYWGQGTLVTV,YELTQPPSVSTARITCGGNNIERKSVHWCQQKPGQAPALVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSGSDQVIFGGGTKLT,GFTFSNYG,IWYDGSNK,ARAFPDSSSWSGFTIDY,NIERKS,DDS,QVWDSGSDQVI,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
PDB,,,,,7M55,True,,,,,,,,EVQLQQSGPVLVKPGASVRMSCKASGYTITDYYLNWVKQSHGKSLEWLGVLNPYSGGSLYSQTFKGKATLTVDRSSSTAYLELNSLTSEDSAVYYCARQLGRGNGLDYWGQGTSVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLHSSDQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCHQYLSSYTFGGGTKLEIK,GYTITDYY,LNPYSGGS,ARQLGRGNGLDY,QSVLHSSDQKNY,WAS,HQYLSSYT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ2*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,1KTR,True,,,,,,,,QVQLQQSGPEDVKPGASVKISCKASGYTFTDYYMNWVKQSPGKGLEWIGDINPNNGGTSYNQKFKGRATLTVDKSSSTAYMELRSLTSEDSSVYYCESQSGAYWGQGTTVTVSA,DILMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK,GYTFTDYY,INPNNGGT,ESQSGAY,QSIVHSNGNTY,KVS,FQGSHVPFT,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ4*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,6UM5,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVSG,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARGGWISLYYDSSGYPNFDY,SSDVGSYNL,EVS,CSYAGSSTVI,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*02 (human)
PDB,,,,,7ME7,True,,,,,,,,VQLVESGGGLVQAGGSLRLSCAVSGRTFSTYGMAWFRQAPGKERDFVATITRSGETTLYADSVKGRFTISRDNAKNTVYLQMNSLKIEDTAVYYCAVRRDSSWGYSRDLFEYDYWGQGTQVTVS,,GRTFSTYG,ITRSGETT,AVRRDSSWGYSRDLFEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7ME7,True,,,,,,,,HVQLVESGGGLVQAGGSLRLSCAASGSIFSSNAMSWYRQAPGKQRELVASITSGGNADYADSVKGRFTISRDKNTVYPEMSSLKPADTAVYYCHAVGQEASAYAPRAYWGQGTQVTVSS,,GSIFSSNA,ITSGGNA,HAVGQEASAYAPRAY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,7MEJ,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAVSGLGAHRVGWFRRAPGKEREFVAAIGANGGNTNYLDSVKGRFTISRDNAKNTIYLQMNSLKPQDTAVYYCAARDIETAEYTYWGQGTQVTVSS,,GLGAHR,IGANGGNT,AARDIETAEYTY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7MEJ,True,,,,,,,,VQLVESGGGLVQAGGSLTLTCAASGRTFSSETMDMGWFRQAPGKEREFVAADSWNDGSTYYADSVKGRFTISRDSAKNTLYLQMNSLKPEDTAVYYCAAETYSIYEKDDSWGYWGQGTQVTVS,,GRTFSSETMD,DSWNDGST,AAETYSIYEKDDSWGY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7N9C,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYSMGWFRQAQGKEREFVATINGNGRDTYYTNSVKGRFTISRDDATNTVYLQMNSLKPEDTAIYYCAADKDVYYGYTSFPNEYEYWGQGTQVTVSS,,GRTFSSYS,INGNGRDT,AADKDVYYGYTSFPNEYEY,,,,IGHJ4*01 (mouse),IGHV5-6-3*01 (mouse),,
PDB,,,,,7N9E,True,,,,,,,,DVQLVESGGGLVQAGGSLRLSCAASGFTFSNYVMYWGRQAPGKGREWVSGIDSDGSDTAYASSVKGRFTISRDNAKNTLYLQMNNLKPEDTALYYCVKSKDPYGSPWTRSEFDDYWGQGTQVTVSS,,GFTFSNYV,IDSDGSDT,VKSKDPYGSPWTRSEFDDY,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
PDB,,,,,7N9T,True,,,,,,,,HVQLVESGGGLVQAGGSLRLSCAASGSIFSSNAMSWYRQAPGKQRELVASITSGGNADYADSVKGRFTISRDKNTVYPEMSSLKPADTAVYYCHAVGQEASAYAPRAYWGQGTQVTVSS,,GSIFSSNA,ITSGGNA,HAVGQEASAYAPRAY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,5MVZ,True,,,,,,,,EVQLVESGAEVKKPGESLKISCKGSGYTFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARFVSLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLWTFGQGTKVEIK,GYTFTSYW,IYPGDSDT,ARFVSLDAFDI,QSVSSY,DAS,QQRSNWLWT,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,6QX4,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSDINSSGTTYYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCATEGKYGRTWYGQLEYHYWGQGTQVTVSS,,GFTFSSYP,INSSGTT,ATEGKYGRTWYGQLEYHY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6QX4,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGSIFRINDMGWYRQAPGKQRELVAAITSGGSTNYADSVKGRFTISRDNAKKMVYLQMNSLKPEDTAVYYCHADFSTGWAPYDYWGQGTQVTVSS,,GSIFRIND,ITSGGST,HADFSTGWAPYDY,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
PDB,,,,,4QF1,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSPRGELPFDYWGQGTLVTVSS,YELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKLTVL,GFTFDDYA,ISWNSGSI,AKDSPRGELPFDY,ALPKKY,EDS,YSTDSSGNHRV,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-10*01 (human)
PDB,,,,,6B0S,True,,,,,,,,EVQLQESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSITSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPGIAAADNHWFDPWGQGTLVTVSS,AYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVVVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL,GFTFSSYS,ITSSSSYI,ARDPGIAAADNHWFDP,KLGDKY,QDT,QAWDSSTVV,IGHJ5*02 (human),IGHV3-21*01 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,6GHG,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK,GFTFSSYA,ISGSGGST,AKGSGFDY,QSVSSSY,GAS,QQYGSSPLT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N62,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGRFTISRDNSKNTLYLHMNSLRAEDTAVYYCAKDQDDGYYYYYYMDVWGKGTTVTVSG,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRFLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLFGGGTKVEIK,GFTFSSFG,ISFDGSNK,AKDQDDGYYYYYYMDV,QSVSSSY,GAS,QQYGSSPL,IGHJ6*04 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N64,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGRPLDRGRSWYDEIQQGDDFDIWGQGTMVTVSS,DIQMTQSPVSLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPGTFGQGTKVEIK,GFTFDDYA,ISWNSGI,AKGRPLDRGRSWYDEIQQGDDFDI,QSISSW,DAS,QQYNSYPGT,IGHJ3*02 (human),IGHV3-9*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
PDB,,,,,6MEG,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSHGISWVRQAPGQGLEWMGWISVYNGYTNYAQNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARASQIRGVDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQFPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPWVFGGGTQVTVL,GYIFTSHG,ISVYNGYT,ARASQIRGVDY,SSNIGSNY,GNN,AAWDDSLSGPWV,IGHJ4*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV1-47*01 (human)
PDB,,,,,7N3E,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGVAVDWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSALYVFGTGTKVTVL,GYSFTSYW,IYPGDSDT,ARGVAVDWYFDL,SSNIGAGYD,GNS,QSYDSSLSALYV,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,7N3F,True,,,,,,,,EVQLVQSGAEVKKPGESLNISCKASGYSFTIYWIAWVRQLPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWRSLKASDSAVYYCARGVAVDWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCAGSSSNIGAGFDVYWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSSGSVLSDLYVFGTGTKVTVL,GYSFTIYW,IYPGDSDT,ARGVAVDWYFDL,SSNIGAGFD,GNN,QSSGSVLSDLYV,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,7N3G,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYSSGGTDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,GFTVSSNY,IYSGGST,ARDLYSSGGTDI,QSVSSSY,GAS,QQYGSSPGT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7N3H,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVMYAGGSTFYADSVKGRFTISRDDSKNTLFLQMNSLRAEDTAIYYCARDLYSSGGTDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSIGSSYLAWYQQKPGLAPRLLIYGASRRATGIPDKFSGSGSGADFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,GITVSSNY,MYAGGST,ARDLYSSGGTDI,QSIGSSY,GAS,QQYGSSPGT,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7R8M,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGVAVDWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSALYVFGTGTKVTVL,GYSFTSYW,IYPGDSDT,ARGVAVDWYFDL,SSNIGAGYD,GNS,QSYDSSLSALYV,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,7R8N,True,,,,,,,,EVQLVESGGGLIQAGGSLRLSCAASGFGVRNNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTVFLQMNSLRAEDTAVYYCAREGDVEGFSDLWSGYSRDRYYFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITFSCTGTSSDVGGYNYVSWYQQYPGKAPKLLIYDVTNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSFTSSNTRVFGTGTKVTVL,GFGVRNNY,IYSGGTT,AREGDVEGFSDLWSGYSRDRYYFDY,SSDVGGYNY,DVT,SSFTSSNTRV,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,7R8O,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARREAYGPRDYYYYYGMDVWGQGTTVTVSS,QSALTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIPDRFSVLGSGLNRYLTIKNIQEEDESDYHCGADQGSGSNFVGVFGGGTKLTVG,GGTFSSYA,IIPIFGTA,ARREAYGPRDYYYYYGMDV,SGYSNYK,VGTGGIVG,GADQGSGSNFVGV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
PDB,,,,,7FAB,True,,,,,,,,VQLEQSGPGLVRPSQTLSLTCTVSGTSFDDYYWTWVRQPPGRGLEWIGYVFYTGTTLLDPSLRGRVTMLVNTSKNQFSLRLSSVTAADTAVYYCARNLIAGGIDVWGQGSLVTVSS,SVLTQPPSVSGAPGQRVTISCTGSSSNIGAGHNVKWYQQLPGTAPKLLIFHNNARFSVSKSGTSATLAITGLQAEDEADYYCQSYDRSLRVFGGGTKLTVL,GTSFDDYY,VFYTGTT,ARNLIAGGIDV,SSNIGAGHN,HN,QSYDRSLRV,IGHJ5*01 (human),IGHV4-30-4*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7KLG,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYRYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSYRYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7KXK,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFDLGGYSMHWVRQAPGKGLEWVAGIYASGGATAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYYYGGFGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASDLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSHTYPITFGQGTKVEIK,GFDLGGYS,IYASGGAT,ARSYYYGGFGMDY,QSVSSA,SAS,QQSHTYPIT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6DID,True,,,,,,,,QLVESGGGLVQPGASLTLTCTASGFSFSSDYYMCWVRQAPGKGLEWIACIWTANSISYYARWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGSGDGQSLWGPGTLVTVSS,DIVMTQTPASVEAAVGGTVAIKCQASQSIRSYLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTQFTLTISGVECDDAATYYCQRNYDSYSGAYYPNGFGGGTEVVVK,GFSFSSDYY,IWTANSIS,ARGGSGDGQSL,QSIRSY,EAS,QRNYDSYSGAYYPNG,IGHJ2*01 (human),IGHV3-33*02 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,6P65,True,,,,,,,,SLEESGGDLVKPGASLTLTCTASGFSFGWNDYMSWVRQAPGKGLEWIGCIYAGSTRSTYYANWAKGRLTISKTSSTAVTLQMTSLTAADTATYFCARGAVTYDGLGGAYLKHFNLWGPGTLVTVSS,AIKMTQTPSSVSAAVGGTVTVNCRASEDIESYLAWYQQKPGQPPKLLIYDTSKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCLYGYISSDRIDFGFGGGTELVVK,GFSFGWNDY,IYAGSTRST,ARGAVTYDGLGGAYLKHFNL,EDIESY,DTS,LYGYISSDRIDFG,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-8*01 (human)
PDB,,,,,6PEH,True,,,,,,,,SLEESGGDLVKPGASLTLTCTASGFSFGWNDYMSWVRQAPGKGLEWIGCIYAGSTRSTYYANWAKGRLTISKTSSTAVTLQMTSLTAADTATYFCARGAVTYDGLGGAYLKHFNLWGPGTLVTVSS,AIKMTQTPSSVSAAVGGTVTVNCRASEDIESYLAWYQQKPGQPPKLLIYDTSKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCLYGYISSDRIDFGFGGGTELVVK,GFSFGWNDY,IYAGSTRST,ARGAVTYDGLGGAYLKHFNL,EDIESY,DTS,LYGYISSDRIDFG,IGHJ2*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-8*01 (human)
PDB,,,,,7DK0,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGSSNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAESPLGGGSGYSVSWFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSNWPPWTFGQGTKVEIK,GGTFSSYA,IIPIFGSS,AESPLGGGSGYSVSWFDP,QSVSSN,GAS,QQYSNWPPWT,IGHJ5*02 (human),IGHV1-69*15 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,7DPM,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSVISGSGGSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYCCAKGYYYDSSGYYFREDAFDIWGQGTLVTVSS,DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK,GFTFSSYA,ISGSGGST,AKGYYYDSSGYYFREDAFDI,QGISNY,AAS,LQHNSYPYT,IGHJ5*01 (human),IGHV3-23*01 (human),IGKJ2*01 (human),IGKV1-17*03 (human)
PDB,,,,,7OLZ,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGRTFSNDALGWFRQAPRKEREFVAAINWNSGTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAASDYGLPREDFLYDYWGQGTQVTVSS,,GRTFSNDA,INWNSGT,AAASDYGLPREDFLYDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,7OLZ,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGITLDYYAIGWFRQAPGKEREGVSRIRSSDGSTNYADSVKGRFTMSRDNAKNTVYLQMNSLKPEDTAVYYCAYGPLTKYGSSWYWPYEYDYWGQGTQVTVSS,,GITLDYYA,IRSSDGST,AYGPLTKYGSSWYWPYEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7ON5,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGITLDYYAIGWFRQAPGKEREGVSRIRSSDGSTNYADSVKGRFTMSRDNAKNTVYLQMNSLKPEDTAVYYCAYGPLTKYGSSWYWPYEYDYWGQGTQVTVSS,,GITLDYYA,IRSSDGST,AYGPLTKYGSSWYWPYEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7E39,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYGMHWVRQAPGKGLEWVAVIWFDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETVSYGMDVWGQGTTVTVSS,NIQMTQSPSAMSASVGDRVTITCRARQGISNYLAWFQQKPGKVPKHLIYAASSLLSGVPSRFSGSGSETEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK,GFIFSSYG,IWFDGSNK,ARETVSYGMDV,QGISNY,AAS,LQHNSYPYT,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ2*01 (human),IGKV1D-17*01 (human)
PDB,,,,,7E3B,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRGYSSGWTDGFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNIPFTFGLGTKVDIK,GGSISSYY,IYYSGST,ARDRGYSSGWTDGFDI,QDITNY,DAS,QQYDNIPFT,IGHJ3*02 (human),IGHV4-59*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
PDB,,,,,7E3C,True,,,,,,,,EVLLVESGGGLVQPGGSLRLSCAASGLTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRCTISRHNSKNTLYLQMNSLRAEDTAVYYCARDLDYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPLTFGGGSRVEIK,GLTVSSNY,IYSGGST,ARDLDYYGMDV,QGISNY,AAS,QQLNSYPPLT,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
PDB,,,,,7KMI,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVAGTYDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPGGTFGPGTKVDIK,GFTVSSNY,IYPGGST,AREVAGTYDY,QGISSW,AAS,QQANSFPGGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,7L58,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARVPYCSSTSCHRDWYFDLWGRGTLVT,DIQMTQSPLSLPVTPGEPASISCRSSQSLLDSDDGNTYLDWYLQKPGQSPQLLIYTLSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRIEFPLTFGGGTKVEI,GYTFTGYY,INPNSGGT,ARVPYCSSTSCHRDWYFDL,QSLLDSDDGNTY,TLS,MQRIEFPLT,IGHJ2*01 (human),IGHV1-2*06 (human),IGKJ4*01 (human),IGKV2-40*01 (human)
PDB,,,,,2XTJ,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNSHAISWVRQAPGQGLEWMGGINPILGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHYEIQIGRYGMNVYYLMYRFASWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRSALNWYQQKPGKAPKLLIYNGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQFDGDPTFGQGTKVEIK,GGTFNSHA,INPILGIA,ARHYEIQIGRYGMNVYYLMYRFAS,QGIRSA,NGS,QQFDGDPT,IGHJ5*01 (human),IGHV1-69*10 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,4LRN,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGTTGWGWLGKPIGAFAYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSTFGQGTKVEIK,GGTFSSYA,IIPIFGTA,AREGTTGWGWLGKPIGAFAY,QSVSSSY,GAS,QQYGSSPST,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,5I1E,True,,,,,,,,EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK,GFTVSSNY,IYSGGST,ARYDGIYGELDF,QSISSY,AAS,QQSYSTPLT,IGHJ5*01 (human),IGHV3-53*02 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,6U3Z,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCAVSGASISSNYWSWIRQPPGKGLEWIGRIYDPTDSTDYNPSLESRATISKDTSKNHFSLTLSSVTAADTAVYFCARGLWSGYFFWFDVWGPGVLVTVSS,DIQMTQSPSSLSASVGDSVTVTCRASQGIDKELSWYQQKPGKAPTLLIYAASSLQTGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCLQDYATPYSFGQGTKVEIK,GASISSNY,IYDPTDST,ARGLWSGYFFWFDV,QGIDKE,AAS,LQDYATPYS,IGHJ2*01 (human),IGHV4-4*08 (human),IGKJ1*01 (human),IGKV1-6*01 (human)
PDB,,,,,7NDC,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVALISYDGGNRYYADSVKGRFTISRDNSKNTLYLQMNRLRAEDTAMYYCAKDRDDGWDWYYFMDVWGKGTTVTVSS,DIQLTQSPGTLSLSPGERATLSCRASQSISGNYLAWYQHKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSYTFGQGTKVEIK,GFTFSSYG,ISYDGGNR,AKDRDDGWDWYYFMDV,QSISGNY,GAS,QQYGSSYT,IGHJ6*04 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7OR9,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYIFIRYGISWVRQAPGQGLEWMGWISANNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGGILTGYLDYFDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRLTITCRASQSIASYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYHCQQSYSTLGITFGPGTKVDIK,GYIFIRYG,ISANNGYT,ARDGGILTGYLDYFDH,QSIASY,AAS,QQSYSTLGIT,IGHJ1*01 (human),IGHV1-18*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,7OR9,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LJR,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYAINWVRQAPGQGLEWMGRIIPIFGIANYAQKFQGKVTITADKSTSTAYMELSSLRSEDTAVYYCARADYYYDSSGYFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQTPRLLIYGASSRATGIPARFSGSGSGTNFTLTISRLEPEDFAVYYCQQYSSSRTFGQGTKVEIK,GGTFSRYA,IIPIFGIA,ARADYYYDSSGYFFDY,QSVSSSY,GAS,QQYSSSRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,4HC1,True,,,,,,,,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKNRVSITRDTSKNHFFLKLSSVTTEDTATYYCARASDSDGFAYWGQGTLVTVSA,DILMTQSPSSMSVSLGDTVSFTCHASQGIGRNIGWLQQKPGKSFKGLIYHGTNLKDGVPSRFSGSGSGADYSLTISRIESEDFADYYCIQYVQFPYTFGGGTKLEIK,GYSITSGYY,ISYDGSN,ARASDSDGFAY,QGIGRN,HGT,IQYVQFPYT,IGHJ3*01 (mouse),IGHV3-6*01 (mouse),IGKJ2*01 (mouse),IGKV14-100*01 (mouse)
PDB,,,,,4L5F,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKASGYSFIGYYIHWVKQSPEKSLEWIGEINPRTGDTTYNQKFKAKATLTVDKSSSTAYMQLTSLTSEDSAVYYCTKRINWALDYWGQGTTLTVSS,TTVTQSPASLSVATGEKVTIRCITSTDIDDDMNWYQQKPGERPKLLISEGNTLRPGVPSRFSSSGYGTDFVFTIENTLSEDVADYFCLQSDNLPLTFGSGTKLEIK,GYSFIGYY,INPRTGDT,TKRINWALDY,TDIDDD,EGN,LQSDNLPLT,IGHJ2*01 (mouse),IGHV1-42*01 (mouse),IGKJ4*01 (mouse),IGKV17-127*01 (mouse)
PDB,,,,,4G6A,True,,,,,,,,VQLLEQSGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNLSLRSRISITRDTSKNQYYLQLNSVTTEDTATYYCALITTTTYAMDYWGQGTTVTVSS,LTLTQSPASLAVSLGQRATISCRASESVDGYGNSFLHWFQQKPGQPPKLLIYLASNLNSGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNVDPWTFGGGTKLEIK,GDSITSGY,ISYSGST,ALITTTTYAMDY,ESVDGYGNSF,LAS,QQNNVDPWT,IGHJ4*01 (mouse),IGHV3-8*02 (mouse),IGKJ1*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,5FGC,True,,,,,,,,EVQLVESGGGLAQPGESLRLSCAASGFNFYTYAMTWVRQAPGKGLEWVSASSSTDGTTYYADSVKGRFTISRDNSKNILYLQMNSLKAEDTATYYCARAVVFTDSSAYYYSKYFDYWSQGTLVTVSS,YELTQPPSVSVSPGQAATITCSGDKLGDKYVSWYQQRPGQSPLLVVYQDNKRPSGIPERISGSNSGNTATLTIRGTRAMDEADYYCQAWDSSTDVVFGGGTKLTVL,GFNFYTYA,SSSTDGTT,ARAVVFTDSSAYYYSKYFDY,KLGDKY,QDN,QAWDSSTDVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,5NPH,True,,,,,,,,EVQLQQSGPELVKPGASLKISCKTSGYTFTDFTFHWVKLSHGPSLEWIGTIKPSNGDTAYNQKFKGKATLSVDKSASTAHIEFRSLTSEDSAVYFCARFGGSYPYAMDYWGQGTSVIVSS,DIVLTQSPATLSVTPGDRVSLSCRASQGIYNYVHWFQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVESEDFGMYFCQQTNKWPLTFGAGTKLELK,GYTFTDFT,IKPSNGDT,ARFGGSYPYAMDY,QGIYNY,YAS,QQTNKWPLT,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV5-45*01 (mouse)
PDB,,,,,1OB1,True,,,,,,,,ELQLVQSGPQLKKPGETVRISCKASGYTFTTAGIQWVQRLPGKDLKWIGWINTHSGVPQYADDFKGRFAFSLETSASTAFLQIINLKNEDTATYFCARNYYRFDGGMDFWGQGTSVTVSS,DIVMTQTPAIMSAFLGERVTMTCTATSSLSSSYLHWYQQKPGSSPKLWIYTTSNLASGVPSRFSGSGSGTSYSLTISSMEAEDAATYYCHQFHHSPYTFGGGTKLEIK,GYTFTTAG,INTHSGVP,ARNYYRFDGGMDF,SSLSSSY,TTS,HQFHHSPYT,IGHJ4*01 (mouse),IGHV9-4*02 (mouse),IGKJ2*01 (mouse),IGKV4-74*01 (mouse)
PDB,,,,,2FD6,True,,,,,,,,VKLQQSGPEVVKPGASVKISCKASGYSFTNFYIHWVKQRPGQGLEWIGWIFHGSDNTEYNEKFKDKATLTADTSSSTAYMQLSSLTSEDSAVYFCARWGPHWYFDVWGQGTTVTVSS,DIVLTQSPDITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIFEISKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPFTFGGGTKLEIK,GYSFTNFY,IFHGSDNT,ARWGPHWYFDV,SSVSY,EIS,QQWNYPFT,IGHJ1*01 (mouse),IGHV1-66*01 (mouse),IGKJ4*02 (mouse),IGKV4-86*01 (mouse)
PDB,,,,,2J5L,True,,,,,,,,EVQLVESGGGLVKPGGSLKLSCAASGFIFSDYYMYWVRQTPEKRLEWVATISDGNSYTYYVDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAIYYCARDGPTDSSGYGGFGYWGQGTLVTVS,SVLSQSPAILSASPGEKVTMTCRARSSVSYMHWYQQKSGSSPKPWIHATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSHPPTFGSGTKLEIK,GFIFSDYY,ISDGNSYT,ARDGPTDSSGYGGFGY,SSVSY,ATS,QQWSSHPPT,IGHJ3*01 (mouse),IGHV5-4*02 (mouse),IGKJ4*01 (mouse),IGKV4-72*01 (mouse)
PDB,,,,,5F7L,True,,,,,,,,VQLQESGGGLVQPGGSLRLSCAASGSIYSLIAMGWYRQAPGKEHELVATISSGSTTYYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAMYYCAAYSDRLTDCSNCEADYWGQGTQVTVS,,GSIYSLIA,ISSGSTT,AAYSDRLTDCSNCEADY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
PDB,,,,,7M3I,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNEFSLKLSSVTAADTAVYYCASSQRPDGNLYYFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKTVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,GGSISSYY,VYYSGST,ASSQRPDGNLYYFDY,NIGSKT,DDS,QVWDSSSDHYV,IGHJ4*01 (human),IGHV4-59*01 (human),IGLJ1*01 (human),IGLV3-21*02 (human)
PDB,,,,,6FG1,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDEAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,GFNIKDTY,IDPANGYT,AREGYYGNYGVYAMDY,QDINKY,YTS,LQYDNLWT,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ1*01 (mouse),IGKV19-93*01 (mouse)
PDB,,,,,6FG1,True,,,,,,,,QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYTMHWVRQAPGQRLEWMGWINAGHGTTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARPTSEGVAGPSRYYWYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGGGTKVEIK,GYTFTSYT,INAGHGTT,ARPTSEGVAGPSRYYWYFDL,QSVSSN,GAS,QQYNNWPPLT,IGHJ2*01 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
PDB,,,,,7NP1,True,,,,,,,,EVQLVQSGGGLVKPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGGSIVGVTSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSETEFTLTISSLHPDDFATYYCQQSYSTLPYTFGQGTKVEIK,GITVSSNY,IYSGGST,ARGEGGSIVGVTSDY,QSISRY,AAS,QQSYSTLPYT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6ION,True,,,,,,,,QVTLKESGPGILQPSQTLSLTCSFSGFSLNSFGTGVGWIRQPSGKGLEWLAHIWWNDYKYYNAALESRLTISKDTSNNQVFLKIASVDTADTATYYCARLRLRYFDYWGQGTTLTVSS,DILMTQSPAILSVSPGEGVSFSCWANQNIGTSIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSNSWPIFTFGSGTKLEIK,GFSLNSFGTG,IWWNDYK,ARLRLRYFDY,QNIGTS,YAS,QQSNSWPIFT,IGHJ2*01 (mouse),IGHV8-8*01 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,7CHC,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLNLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGVSSFLAWYQQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,EFIVSRNY,IYSGGST,ARDYGDYYFDY,QGVSSF,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7CHC,True,,,,,,,,EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK,GFAFTTYA,ISDGGGSA,AKTRGRGLYDYVWGSKDY,QSLLHSNGYNY,LGS,MQALQTPGT,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
PDB,,,,,7KFW,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTVFLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPGTFGQGTKLEIK,GFTVSSNY,IYSGGTT,ARGDVSGYRYGLDY,QGISSY,AAS,QQLNSYPGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7KFX,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAVSGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSAFVGDRVTITCRASEGISSYLAWYQQKPGNAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPGTFGQGTKLEIK,GFTVSNNY,IYSGGTT,ARGDVSGYRYGLDY,EGISSY,AAS,QQLNSYPGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7KFY,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLENGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPGTFGQGTKLEIK,GFTVSSNY,IYSGGTT,ARGDVSGYRYGLDY,QGISSY,AAS,QQLNSYPGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
PDB,,,,,7LK9,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGTGLFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,GFTVSSNY,IYSGGST,ARDLGTGLFDY,QSVSSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7LKA,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGTGLFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLDSYPPGTFGPGTKVDIK,GFTVSSNY,IYSGGST,ARDLGTGLFDY,QGISSY,AAS,QQLDSYPPGT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,5CD3,True,,,,,,,,QVQLVESGTQFRRPGASVRLSCEASGYTFISSFIHWIRQGPGQGLEWMGWMNPRHGAVNYPRRFQGKVTMTRDTSIDTAYMELRDLRSDDTAMYFCVTSRTKDYDWDFVWGQGTLVVVSS,DIQMTQSPVTLSASIGDRVTITCRASQRIDNWVAWYQQKPGRAPKLLIYKASILETGVPSRFSGSGSGTEFTLSINSLQPDDVATYYCQQFEEFGRGTKIDIK,GYTFISSF,MNPRHGAV,VTSRTKDYDWDFV,QRIDNW,KAS,QQFEE,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ3*01 (human),IGKV1-5*03 (human)
PDB,,,,,4DN3,True,,,,,,,,QVELVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,GGTFSSYG,IIPIFGTA,ARYDGIYGELDF,QSVSDAY,DAS,HQYIQLHSFT,IGHJ5*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,5CZX,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRTYAMHWVRQAPGQGLEWMGGIVPYHGITDYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDDYSTYAFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIASYLAWYQQKPGKAPKLLIYDASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYKTPYTFGQGTKVEIK,GGTFRTYA,IVPYHGIT,ARDDYSTYAFAY,QSIASY,DAS,QQAYKTPYT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5X8M,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,GFTFSRYW,IKQDGSEK,AREGGWFGELAFDY,QRVSSSY,DAS,QQYGSLPWT,IGHJ4*01 (human),IGHV3-7*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7DZY,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANINQDGGEKYYVDSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPYDLYGDYGGTFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQSEDFALYYCQQYNNWWRTFGQGTKVEIN,GFTFSSYW,INQDGGEK,ARDPYDLYGDYGGTFDY,QSVSSN,GAS,QQYNNWWRT,IGHJ4*01 (human),IGHV3-7*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,7K8P,True,,,,,,,,QVQLQQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYMQWSSLKASDTAMYYCARSFRDDPRIAVAGPADAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISYWLAWYQQKPGKAPKLLIYQASSLESGVPSRFSGSESGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,GYSFTSYW,IYPGDSDT,ARSFRDDPRIAVAGPADAFDI,QSISYW,QAS,QQYNSYPYT,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
PDB,,,,,4JHW,True,,,,,,,,QVQLVQSGAEVKKPGSSVMVSCQASGGPLRNYIINWLRQAPGQGPEWMGGIIPVLGTVHYAPKFQGRVTITADESTDTAYIHLISLRSEDTAMYYCATETALVVSTTYLPHYFDNWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK,GGPLRNYI,IIPVLGTV,ATETALVVSTTYLPHYFDN,QDIVNY,VAS,QQYDNLPLT,IGHJ5*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,6RCU,True,,,,,,,,QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISGYDGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGPQVGDFDWQVYYYYGMDVWGQGTTVTVSS,AIRMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPNLLISKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNSYLYTFGQGTKVEIR,GYTFTSYG,ISGYDGNT,ARDGPQVGDFDWQVYYYYGMDV,QSINTW,KAS,QQYNSYLYT,IGHJ6*01 (human),IGHV1-18*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
PDB,,,,,6RCU,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFATTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARDKHSWSYAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGLRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIHSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,GGTFSNYA,IIPIFATT,ARDKHSWSYAFDI,SSNIGSNT,SNN,AAWDDSLNGWV,IGHJ3*02 (human),IGHV1-69*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
PDB,,,,,5B71,True,,,,,,,,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,GFTVHSSYY,IFTGSGAE,ASDAGYDYPTHAMHY,QGISSS,GAS,QNTKVGSSYGNT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
PDB,,,,,12E8,True,,,,,,,,EVQLQQSGAEVVRSGASVKLSCTASGFNIKDYYIHWVKQRPEKGLEWIGWIDPEIGDTEYVPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCNAGHDYDRGRFPYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLMIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELK,GFNIKDYY,IDPEIGDT,NAGHDYDRGRFPY,QNVGTA,SAS,QQYSSYPLT,IGHJ3*01 (mouse),IGHV14-4*02 (mouse),IGKJ5*01 (mouse),IGKV6-13*01 (mouse)
PDB,,,,,5W9I,True,,,,,,,,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,5NST,False,,,,,,,,,IRMTQSPSSLSASPGDKVSITCRASQHINDSLAWFQQRPGKAPKLLIYGASNLHSGVPSRFSGTGSGTDFTLTITGLQSEDFATYFCQQCNCFPPDFGQGTRLEIK,,,,QHINDS,GAS,QQCNCFPPD,,,IGKJ5*01 (human),IGKV1-16*01 (human)
PDB,,,,,5NST,False,,,,,,,,,,,,,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
PDB,,,,,5NST,False,,,,,,,,,AIRMTQSPSSLSASPGDKVSITCRASQHINDSLAWFQQRPGKAPKLLIYGASNLHSGVPSRFSGTGSGTDFTLTITGLQSEDFATYFCQQCNCFPPDFGQGTRLEIK,,,,QHINDS,GAS,QQCNCFPPD,,,IGKJ5*01 (human),IGKV1-8*01 (human)
PDB,,,,,5NST,False,,,,,,,,,,,,,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
PDB,,,,,6P9H,True,,,,,,,,QVQLVQSGAEVKRPGSSVRVSCKDSGDSFRRYVINWVRQAPGQGLEWMGGIIPIFDKAKSVQKFQDRLTITADESTSTSYMELSSLTSEDTAVYYCARKEDGRRDDVFDIWGQGTLVTVSS,EIVMTQSPATLSVSLGERATLSCRASHSVGSSLAWYQQKPGLAPRLLIYGVSTRATGIPARFSGSGSATEFTLTISSLQSEDLAAYHCQQYDNWPFTFGQGTKLEIK,GDSFRRYV,IIPIFDKA,ARKEDGRRDDVFDI,HSVGSS,GVS,QQYDNWPFT,IGHJ5*01 (human),IGHV1-69*01 (human),IGKJ2*01 (human),IGKV3-15*01 (human)
PDB,,,,,1MRC,True,,,,,,,,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKGKATLTVDTSSSTAYMQLSSLTSEDSAVYYCANLRGYFDYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPRTFGGGTKLEIK,GYTFTSYW,IDPSDSYT,ANLRGYFDY,QSLVHSNGNTY,KVS,SQSTHVPRT,IGHJ2*01 (mouse),IGHV1-50*01 (mouse),IGKJ1*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,5IIE,True,,,,,,,,QVTLKEFGPALVKPTQPLTLTCSFSGFSLRSSDTAVVWIRQPPGKALEWLAAIYWDDVEHINPSLKSRLSISKDSPNSLVVLTMANMDPVDTATYYCGRVRFVSGGYYTDRIDSWGPGLLVTVSS,QSVLTQPPSVSGAPGQRVTISCAGTKSNIGDCSVSWYQQLPGATPRLLIYQNNNRPSGVSDRFSGSKSGTSASLAITGLQTEDEADYFCLSYDTSFSGWRFGGGTRLTVL,GFSLRSSDTA,IYWDDVE,GRVRFVSGGYYTDRIDS,KSNIGDCS,QNN,LSYDTSFSGWR,IGHJ5*01 (human),IGHV2-5*08 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
PDB,,,,,5VN8,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQDRVTFTADTSANTAYMELRSLRSADTAVYYCARVGPYSWDDSPQDNYYMDVWGKGTTVIVSS,EIVLTQSPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK,GYRFSNFV,INPYNGNK,ARVGPYSWDDSPQDNYYMDV,HSIRSRR,GVS,QVYGASSYT,IGHJ6*04 (human),IGHV1-3*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,6N35,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,6UM6,True,,,,,,,,QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGWMNPQTGRTNTARNFQGRVTMTRDTSIGTAYMELRSLTSDDTAIYYCTTGGWISLYYDSSYYPNFDHWGQGTLLTVSG,QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCCSFGGSATVVCGGGTKVTVL,GYTFTDFY,MNPQTGRT,TTGGWISLYYDSSYYPNFDH,KYDVGSHDL,EVN,CSFGGSATVV,IGHJ1*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*02 (human)
PDB,,,,,6VTU,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCAVSGVSINDGYDWTWIRQTPGKGLEWIGYVFGRSGNFNLNPSLRNRGIISKDTCKNQFSLNLNSATAADTAVYFCARGMEGLFAAYNSLDVWGRGLLVTVSG,QAALTQPPSVSGSPGQSVIISCTGTSSDIGQYNSVSWYQQHPDKAPKLVIYGVTSRPSGVSDRFSGSKYGDTASLTISGLQAEDEADYYCSSHADENMALFGGGTRLTVL,GVSINDGYD,VFGRSGNF,ARGMEGLFAAYNSLDV,SSDIGQYNS,GVT,SSHADENMAL,IGHJ2*01 (human),IGHV4-4*08 (human),IGLJ7*01 (human),IGLV2-11*01 (human)
PDB,,,,,6XRJ,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCAVSGVSINDGYDWTWIRQTPGKGLEWIGYVFGRSGNFNLNPSLRNRGIISKDTCKNQFSLNLNSATAADTAVYFCARGMEGLFAAYNSLDVWGRGLLVTVSS,ALTQPPSVSGSPGQSVIISCTGTSSDIGQYNSVSWYQQHPDKAPKLVIYGVTSRPSGVSDRFSGSKYGDTASLTISGLQAEDEADYYCSSHADENMALFGGGTRLTVL,GVSINDGYD,VFGRSGNF,ARGMEGLFAAYNSLDV,SSDIGQYNS,GVT,SSHADENMAL,IGHJ2*01 (human),IGHV4-4*08 (human),IGLJ7*01 (human),IGLV2-11*01 (human)
PDB,,,,,7L6M,True,,,,,,,,QDLLLQSGAEVREPGASVTVSCQASNYTFPDYYIHWVRLVPGQGLEWLGEMKPKVGVTNVSKKIRDRLFMTADTSTDTAYMVLSALTPGDTAIYYCTRLEPDFLSGWAHWGKGVLVTVSP,EIVMTQTPLSLSVTPGEPASLSCRSSASLLHGNGNTYLHWYLRKAGQSPQLLIFGGSKRVPGISDRFIGSGAGTNFTLKISSVEADDVGFYYCAQGVAFPWTFGQGTKVEIK,NYTFPDYY,MKPKVGVT,TRLEPDFLSGWAH,ASLLHGNGNTY,GGS,AQGVAFPWT,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,7LU9,True,,,,,,,,QVTLMESGPALVKVTQTLAVTCTFSGFSIRDSGKGVAWIRQPPGGALEWLTSIYWDDTKYHDTSLKPRLTIFRDTSQTQVILILTNMAPLDTATYYCGRINNGGGWKDHIDFWGPGLLVTVSS,ALTQPPSVSKSLEQSVTISCTGTTTGNSVSWYQCHSGTAPRLLIYDVNKRPSGVSDRFSGSKSHNTASLTIFGLQAEDEADYYCGSYGSGGSLLFGGGTRLTVL,GFSIRDSGKG,IYWDDTK,GRINNGGGWKDHIDF,TTGNS,DVN,GSYGSGGSLL,IGHJ2*01 (human),IGHV2-70*01 (human),IGLJ2*01 (human),IGLV2-11*01 (human)
PDB,,,,,7LUA,True,,,,,,,,QDLLLQSGAEVREPGASVTVSCQASNYTFPDYYIHWVRLVPGQGLEWLGEMKPKVGVTNVSKKIRDRLFMTADTSTDTAYMVLSALTPGDTAIYYCTRLEPDFLSGWAHWGKGVLVTVSP,EIVMTQTPLSLSVTPGEPASLSCRSSASLLHGNGNTYLHWYLRKAGQSPQLLIFGGSKRVPGISDRFIGSGAGTNFTLKISSVEADDVGFYYCAQGVAFPWTFGQGTKVEIK,NYTFPDYY,MKPKVGVT,TRLEPDFLSGWAH,ASLLHGNGNTY,GGS,AQGVAFPWT,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,1RZF,True,,,,,,,,EVQLVQSGAEVNKPGSSVKVSCQASGATLNSHAFSWVRQAPGQGLEWMAGIIPIFGSSHYAQKFRGRVTISADESTRTVYLHLRGLRSDDTAVYYCASNSIAGVAAAGDYADYDGGYYYDMDVWGQGTTVTVSS,QSILTQPPSVSAAPGQKVTISCSGSSSNIGNNDVSWYQQFPGTVPKLVIYENNERPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGSKVTVL,GATLNSHA,IIPIFGSS,ASNSIAGVAAAGDYADYDGGYYYDMDV,SSNIGNND,ENN,GTWDSSLSAVV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-51*02 (human)
PDB,,,,,1RZI,True,,,,,,,,QVQLLQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPVFGSANYAQKFQGRVTITADEATSTTYMELSSLRSEDTAVYFCAKGGEDGDYLSDPFYYNHGMDVWGQGTTVTVAS,DIQMTQSPSLSASVGDRVTITCRASQSISSYLNWYQQKPGKVPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTSHTFGQGTKLEIK,GGTFSSYA,IIPVFGSA,AKGGEDGDYLSDPFYYNHGMDV,QSISSY,AAS,QQSYSTSHT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,3LH2,True,,,,,,,,QVQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGAGWLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVK,GGSFSTYA,VIPLLTIT,AREGTTGAGWLGKPIGAFAH,QSVGNNK,GAS,QQYGQSLST,IGHJ1*01 (human),IGHV1-69*10 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,3LHP,True,,,,,,,,QVQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGAGWLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVK,GGSFSTYA,VIPLLTIT,AREGTTGAGWLGKPIGAFAH,QSVGNNK,GAS,QQYGQSLST,IGHJ1*01 (human),IGHV1-69*10 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,4JDT,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKYCTARDYYNWDFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQV,GYTFTGYY,INPNSGGT,ARGKYCTARDYYNWDFQH,QSGS,SGS,QQYEF,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,4M8Q,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGTTGWGWLGKPIGAFAYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSTFGQGTKVEIK,GGTFSSYA,IIPIFGTA,AREGTTGWGWLGKPIGAFAY,QSVSSSY,GAS,QQYGSSPST,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,5ANM,True,,,,,,,,EVQLVQSGAEVKKPGATVKISCKVYGYIFTDYNIYWVRQAPGKGLEWMGLIDPDNGETFYAEKFQGRATMTADTSSDRAYMELSSLRFEDTAVYYCATVMGKWIKGGYDYWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNFNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSPTLTSPFGTGTKLTVL,GYIFTDYN,IDPDNGET,ATVMGKWIKGGYDY,SSNIGAGYD,DNF,QSYDSPTLTSP,IGHJ2*01 (human),IGHV1-69-2*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,7M6E,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARTQWGYNYGSHFFYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSDHVYWYQQLPGTAPKLFIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLSGYVFGTGTKVTVL,GYSFTSYW,IYPGDSDT,ARTQWGYNYGSHFFYMDV,SSNIGSDH,RNN,AAWDASLSGYV,IGHJ6*04 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
PDB,,,,,7M6I,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIISMFGIANNAQKFQGRLTITADTSTSTAYMELSSLRSEDTAVYYCARGPYYYDSGGYYLDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSGYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPRTFGQGTRLEIK,GGTFSSYA,IISMFGIA,ARGPYYYDSGGYYLDY,QSVGSGY,GAS,QQYAGSPRT,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,5W9J,True,,,,,,,,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,5GGV,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,GFTFSSYG,IWYDGSNK,ARDPRGATLYYYYYGMDV,QSINSY,AAS,QQYYSTPFT,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,5TRU,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,GFTFSSYT,ISYDGNNK,ARTGWLGPFDY,QSVGSSY,GAF,QQYGSSPWT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,6PPG,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,GFTFDDYA,INWSSGGI,ARDIGGFGEFYWNFGL,QSVRSY,DAS,QQRSNWPPAT,IGHJ2*01 (human),IGHV3-9*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,7M51,True,,,,,,,,EVQLQQSGPVLVKPGASVRMSCKASGYTITDYYLNWVKQSHGKSLEWLGVLNPYSGGSLYSQTFKGKATLTVDRSSSTAYLELNSLTSEDSAVYYCARQLGRGNGLDYWGQGTSVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLHSSDQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCHQYLSSYTFGGGTKLEIK,GYTITDYY,LNPYSGGS,ARQLGRGNGLDY,QSVLHSSDQKNY,WAS,HQYLSSYT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ2*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,7M52,True,,,,,,,,EVQLQQSGPVLVKPGASVRMSCKASGYTITDYYLNWVKQSHGKSLEWLGVLNPYSGGSLYSQTFKGKATLTVDRSSSTAYLELNSLTSEDSAVYYCARQLGRGNGLDYWGQGTSVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLHSSDQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCHQYLSSYTFGGGTKLEIK,GYTITDYY,LNPYSGGS,ARQLGRGNGLDY,QSVLHSSDQKNY,WAS,HQYLSSYT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ2*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,6TCN,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,GYSITSGYS,ITYDGST,ARGSHYFGHWHFAV,QSVDYDGDSY,AAS,QQSHEDPYT,IGHJ1*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7CR5,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYIMHWVRQAPGKGLEWVAVISYDGSNEAYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTGVYYCARETGDYSSSWYDSWGRGTLVTVSS,QLVLTQSPSASASLGASVKLTCTLSSGHSNYAIAWHQQQPEKGPRYLMKVNSDGSHTKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGIQVFGGGTKLTVL,GFTFSSYI,ISYDGSNE,ARETGDYSSSWYDS,SGHSNYA,VNSDGSH,QTWGTGIQV,IGHJ2*01 (human),IGHV3-30*15 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
PDB,,,,,7KQE,True,,,,,,,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARRWWLRGAFDIWGQGTTVTVSS,NFMLTQPHSVSASPGKTVTIPCTGSSGNIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDNNIQVFGGGTKLTVL,GGSFSGYY,INHSGST,ARRWWLRGAFDI,SGNIASNY,EDN,QSYDNNIQV,IGHJ3*02 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
PDB,,,,,7M71,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLITMVRGEDYWGQGTLVTVSS,DIQLTQSPSSLSASVGHRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNLPRTFGGGTKLEVL,GFTFSSYE,ISYDGSNK,ARLITMVRGEDY,QSISSY,AAS,QQSYNLPRT,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,7M7B,True,,,,,,,,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARRWWLRGAFDIWGQGTTVTVSS,NFMLTQPHSVSASPGKTVTIPCTGSSGNIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDNNIQVFGGGTKLTVL,GGSFSGYY,INHSGST,ARRWWLRGAFDI,SGNIASNY,EDN,QSYDNNIQV,IGHJ3*02 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
PDB,,,,,6IEB,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSDYGDLIFDYWGQGTLVTVSS,LPVLTQPPSVSVSPGQTASITCSGDKLGDKYVCWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQACDSSTVFGGGTKLTVL,GGSISTYY,IYYSGST,ARSDYGDLIFDY,KLGDKY,QDS,QACDSSTV,IGHJ4*01 (human),IGHV4-59*01 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,7AKJ,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCSVSGGSISSHYWSWIRQPPGKGLEWIGYIYYSGSTNHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVLLWFGEPIFEIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIYGASTRAPGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEI,GGSISSHY,IYYSGST,ARGVLLWFGEPIFEI,QSVSSS,GAS,QQYNNWPLT,IGHJ3*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
PDB,,,,,1CE1,True,,,,,,,,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,GFTFTDFY,IRDKAKGYTT,AREGHTAAPFDY,QNIDKY,NTN,LQHISRPRT,IGHJ4*01 (human),IGHV4-30-4*01 (human),IGKJ1*01 (human),IGKV1-33*01 (human)
PDB,,,,,7JMX,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,GYTFTSYY,INSSGGST,ARPPRNYYDRSGYYQRAEYFQH,QDISNY,DAS,QQYDNPPLT,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,6APC,True,,,,,,,,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGYCSGGSCHFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVFGTGTKVTVL,GFTFSSYS,ISSSSSYI,ARLGYCSGGSCHFDY,SSNIGAGYD,GNS,QSYDSSLSGFYV,IGHJ4*01 (human),IGHV3-21*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
PDB,,,,,4RGM,True,,,,,,,,QIQLVQSGPELKKPGETVRISCKASGYIFTIAGIQWVQKMPGRGLRWIGWINTHSGVPEYAEEFKGRFAFSLETSARTAYLQISNLKDEDTATYFCARIYYGNNGGVMDYWGQGTSVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISDYLTWLQQKPDGTIKRLIYVASSLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYANYPWTFGGGTKLEIR,GYIFTIAG,INTHSGVP,ARIYYGNNGGVMDY,QEISDY,VAS,LQYANYPWT,IGHJ4*01 (mouse),IGHV9-4*02 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
PDB,,,,,4RGN,True,,,,,,,,EVNLIESGGDLVKPGGSLKLSCATSGFTFSAYGLSWVRQTPERRLEWVASISGGGSVYYPDSVKGRFTISRDTAGDILFLQMNSLRSEDSAIYYCVRDLYGDYVGRYAYWGQGTLVIVS,DIVMTQSPATLSVTPGDRVSLSCRASQSIGDYLHWYQQKSHESPRLLINYASQSISGIPSRFSGSGSGSDFTLIINSVEPEDVGVYYCQNGHSFPYTFGGGTKLEIR,GFTFSAYG,ISGGGSV,VRDLYGDYVGRYAY,QSIGDY,YAS,QNGHSFPYT,IGHJ3*01 (mouse),IGHV5-6-5*01 (mouse),IGKJ2*01 (mouse),IGKV5-39*01 (mouse)
PDB,,,,,4RGN,True,,,,,,,,QVQLQQSGAELVKPGASVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEIDPSDSYINYNQIFEGKATLTVDKSSTTAYLQLSSLTSEDSAVYYCARTAGLLAPMDYWGQGTSVTVSS,DIVMTQSPSSLTVTAGEKVTMTCKSSQSLFNSGNQKNFLTWYQQIPGQPPKLLIYWASTRDSGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYTYPLTFGVGTKLELK,GYTFTSHW,IDPSDSYI,ARTAGLLAPMDY,QSLFNSGNQKNF,WAS,QNDYTYPLT,IGHJ4*01 (mouse),IGHV1-69*02 (mouse),IGKJ5*01 (mouse),IGKV8-19*01 (mouse)
PDB,,,,,6WGJ,True,,,,,,,,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,GFTFRDYA,ISGSGGNT,AKDRLSITIRPRYYGLDV,QSLLYSIGYNY,LGS,MQALQTPYT,IGHJ6*01 (human),IGHV3-23*04 (human),IGKJ2*01 (human),IGKV2-28*01 (human)
PDB,,,,,3CSY,True,,,,,,,,EVQLLESGGGLVKPGGSLRLSCAASGFTLINYRMNWVRQAPGKGLEWVSSISSSSSYIHYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAVYYCVREGPRATGYSMADVFDIWGQGTMVTVSS,ELVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKSYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSAPLTFGGGTKVEIK,GFTLINYR,ISSSSSYI,VREGPRATGYSMADVFDI,QSVLYSSNNKSY,WAS,QQYYSAPLT,IGHJ3*02 (human),IGHV3-21*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,5FHC,True,,,,,,,,QVQLQESGPGLVKPSDTLSLTCTVSGGSLSSFYWSWIRQPPGKGLEWIGYIYYSGSPNYSPSLESRVTMSVDTTRNQISLKLDSVTAADTAVYYCVRASRSYYWGSYRPTAFDSWGQGTLVTVSS,YELTQPLSVSVSPGQTAIFTCSGDNLGDKYVCWFQQRPGQSPMLLIYQDNKRPSGIPERFSGSNSGNTATLTISGTQSTDEADYYCQTWDSTVVFGGGTKLTVL,GGSLSSFY,IYYSGSP,VRASRSYYWGSYRPTAFDS,NLGDKY,QDN,QTWDSTVV,IGHJ5*01 (human),IGHV4-59*07 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,5FHC,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTYYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS,DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK,GFALRMYD,VGPSGDT,VRSDRGVAGLFDS,QAFDNY,AAS,QNYNSAPLT,IGHJ5*01 (human),IGHV3-13*01 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
PDB,,,,,6DZN,True,,,,,,,,QVQLVQSGVTLVQPGGSLRVSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGLGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHRVWAAGYHFDYWGQGALVTVSS,DIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGEAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSSPIFGGGTKVEIK,GFTFSSYA,ISGLGGST,AKDHRVWAAGYHFDY,QSISSW,DAS,QQYYSSPI,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-5*01 (human)
PDB,,,,,6EAY,True,,,,,,,,QVQLQEWGEGLVKPSETLSLTCAVYGGSISGYYHWNWIRLPPGKGLEWIGNIDGNSASTNYNPSLKTRVTISKDTSKNQISLKVRSLTAADTAVYYCARDPGFTIFGVVITSWSGLDSWGQGAVVTVSS,DIQMTQSPSSLSASVGDTVTITCRASQSISNNLAWYQQRPRRAPQLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQAEDFAAYYCQQHNTLPLTFGGGTKVEIK,GGSISGYYH,IDGNSAST,ARDPGFTIFGVVITSWSGLDS,QSISNN,AAS,QQHNTLPLT,IGHJ5*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
PDB,,,,,5VOC,True,,,,,,,,VELVESGGGVVQPGRSLRLSCAASGFTFSSDGMHWVRQSPGRGLEWVAFISSDGSTPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCAKDWALFRWLRTFDHWGQGTLVTVSS,ETVMTQSPATLSVSPGGRATLSCRASQSVGINLAWYQQKPGQAPRLLIYGASTRASGFPARFSGSGSGTEFTLTITSLQSEDFAVYYCQQYNDWPPWTFGQGTKVEIK,GFTFSSDG,ISSDGSTP,AKDWALFRWLRTFDH,QSVGIN,GAS,QQYNDWPPWT,IGHJ1*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
PDB,,,,,6Z1Z,True,,,,,,,,EVQLVESGGGLVQAGGSLRLSCAASGRTFSDYVMGWFRQAPGKERTFVARIGWSGDLTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAIYYCAADERWGTGGKFDYWGQGTQVTVSS,,GRTFSDYV,IGWSGDLT,AADERWGTGGKFDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,7E23,True,,,,,,,,EVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEVNHSGSTNYNPSLKSRVTISVDTSKNQLSLKLNSVTAADTAVYYCARGNTMVRGVIIPFEYWDKGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,GGSFSGYY,VNHSGST,ARGNTMVRGVIIPFEY,QSVSSY,DAS,QQRSNWPLT,IGHJ4*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
PDB,,,,,5TP3,True,,,,,,,,VQLQESGGGLVQPGGSLRLSCAASGFTLDYYYIGWFRQAPGKEREAVSCISGSSGSTYYPDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATIRSSSWGGCVHYGMDYWGKGTQVTVSS,,GFTLDYYY,ISGSSGST,ATIRSSSWGGCVHYGMDY,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
PDB,,,,,7LM9,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCQGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGESDTRYSSSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARIRGVYSSGWIGGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRQWTFGQGTKVEIK,GYSFTSYW,IYPGESDT,ARIRGVYSSGWIGGDY,QSISSY,AAS,QQSYSTPRQWT,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,4C83,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCAASGFTFRRFGMHWVRQSPEKGLEWVAYIGGGSSTIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCTRDETGSWFAYWGQGTLVTVS,QIVLSQSPAIMSASPGEKVTMTCSASSSVRYMHWYQQKSGTSPKRWIYDTSKLASGVPTRFSGSGSGTSYSLPISSMEAEDGASYYCQQWNGYPPLTFGGGTKLEMK,GFTFRRFG,IGGGSSTI,TRDETGSWFAY,SSVRY,DTS,QQWNGYPPLT,IGHJ3*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV4-59*01 (mouse)
PDB,,,,,5BV7,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKFYEDSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCAREGAAVRSFYYSYYGMDVWGQGTTVTVSS,YELTQPPSVSVSPGQTASITCSGDKLGNKFTSWYQRKPGQSPVLVIYQDTKRPSGIPERFSGSTSGNTATLTISGTQAMDEADYYCQAWDSSTAWVFGGGTKLEVL,GFTFSSYG,IWYDGSNK,AREGAAVRSFYYSYYGMDV,KLGNKF,QDT,QAWDSSTAWV,IGHJ6*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-1*01 (human)
PDB,,,,,5BV7,True,,,,,,,,QVQLQESGPGLVKPSQTLSLTCTVSGASISSGGYNWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGYCSSTSCSRVMDVWGQGTTVTVSS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDNIGNHQVFGGGTKLTVL,GASISSGGYN,IYYSGST,ARERGYCSSTSCSRVMDV,SLRSYY,GKN,NSRDNIGNHQV,IGHJ6*01 (human),IGHV4-31*02 (human),IGLJ2*01 (human),IGLV3-19*01 (human)
PDB,,,,,5ITB,True,,,,,,,,VESGGGLIQPGGSLRLSCAVSGFTVSSKYMTWVRQAPGKGLEWVSVIYGGGSTYYADSVVGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASRLGVRATTGDLDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSWWTFGQGTKVDIK,GFTVSSKY,IYGGGST,ASRLGVRATTGDLDY,QSISSW,DAS,QQYNTYSWWT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
PDB,,,,,6IEK,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDREDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIDPIRYNWNYGDYWGQGTLVTVSS,LPVLTQPPSSSASPGESARLTCTLPSDISVSSYNIYWYQQKPGSPPRFLLYYYSDSDKGQGSGVPSRFSGSKDASDNTGILLISGLQSEDEADYYCMIWPSNAWVFGGGTKLTVL,GYTLTELS,FDREDGET,AIDPIRYNWNYGDY,SDISVSSYN,YYSDSDK,MIWPSNAWV,IGHJ4*01 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV5-37*01 (human)
PDB,,,,,4FQQ,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTQQGKRIYGVVSFGDYYYYYYMDVWGKGTTVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPWVFGGGTKLTVL,GGSISSYY,IYYSGST,ARTQQGKRIYGVVSFGDYYYYYYMDV,NIGSKS,DDS,QVWDSSSDHPWV,IGHJ6*04 (human),IGHV4-59*01 (human),IGLJ3*02 (human),IGLV3-21*02 (human)
PDB,,,,,4HK0,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGLEPRSVDYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,GYTFTGYY,INPNSGGT,ARGGLEPRSVDYYYYGMDV,NIGSKS,DDS,QVWDSSSDHVV,IGHJ6*01 (human),IGHV1-2*04 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
PDB,,,,,1IGA,True,,,,,,,,LEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSSLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIK,GYSFTSYG,ISAGTGNT,ARDPYGGGKSEFDY,QGISSA,DAS,QQFNSYPLT,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
PDB,,,,,7BEJ,True,,,,,,,,EVQLLESGGDLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMHSLRAEDTAVYYCARDLGSGDMDVWGKGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIQAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYRYTFGQGTKVEIK,GVTVSSNY,IYPGGST,ARDLGSGDMDV,QGISSY,AAS,QQLNSYRYT,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
PDB,,,,,7BEM,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGLTVNRNYMSWIRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAIYYCARDFYEGSFDIWGQGTMVTVSS,AIQLTQSPSFLSASIGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFASYYCQQLNSYPAPVFGPGTKVDIK,GLTVNRNY,IYSGGST,ARDFYEGSFDI,QGISSY,AAS,QQLNSYPAPV,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
PDB,,,,,7ND4,True,,,,,,,,QLQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYNWTWIRQPAGKGLEWIGRIYNSGSTNYNPSLKSRVTISVDTSKNQLSLKVRSVTAADTAVYYCARHCSGGTCYPKYYYGMDVWGQGTTVTVSS,QSALTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQFPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGVQSEDEADYYCAAWDDSLNVVVFGGGTKLTVL,GGSISSGSYN,IYNSGST,ARHCSGGTCYPKYYYGMDV,SSNIGNNA,YDD,AAWDDSLNVVV,IGHJ6*01 (human),IGHV4-61*02 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
PDB,,,,,5VK2,True,,,,,,,,EVQLVQSGGGLVKAGGSLRLSCAASGFTFSTYSMNWIRQAPGKGLEWVASISSRSGSHINYVDSVKGRFTISRDNARDLLYLQMNSLRVDDSALYYCARDRRSGTSPLPLDVWGQGTTVTVFS,QSALTQPASVSGSPGQSITISCTGTGSDIGGYNFVSWYQQYPGKAPKLIIYEVRIRASGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYSIHSPWVFGGGTKLTVL,GFTFSTYS,ISSRSGSHI,ARDRRSGTSPLPLDV,GSDIGGYNF,EVR,NSYSIHSPWV,IGHJ6*01 (human),IGHV3-21*01 (human),IGLJ3*02 (human),IGLV2-14*01 (human)
PDB,,,,,6VO1,True,,,,,,,,QVQLQESGPAVVQPSETLSLTCAVSGGSISGGYGWTWIRQAPGKALEWIGNIYGHSGSTNYKSSLKRRLTISTDTSKNQFSLKLTSVTAADTAVYYCARWSTADFDYWGQGVLVTVSS,DIVMTQSPSSLSASVGDTVTITCRASQDITNDLAWYQQKPGKAPKALIYYASNLESGVPSRFSGSGAGTDFTLTISSLQPEDFALYYCQQHNNYPLTFGPGTKVDIK,GGSISGGYG,IYGHSGST,ARWSTADFDY,QDITND,YAS,QQHNNYPLT,IGHJ4*01 (human),IGHV4-30-4*07 (human),IGKJ3*01 (human),IGKV1-16*01 (human)
PDB,,,,,1TJG,True,,,,,,,,ITLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWLAIIYSDDDKRYSPSLNTRLTITKDTSKNQVVLVMTRVSPVDTATYFCAHRRGPTTLFGVPIARGPVNAMDVWGQGITVTISS,LQLTQSPSSLSASVGDRITITCRASQGVTSALAWYRQKPGSPPQLLIYDASSLESGVPSRFSGSGSGTEFTLTISTLRPEDFATYYCQQLHFYPHTFGGGTRVDVR,GFSLSDFGVG,IYSDDDK,AHRRGPTTLFGVPIARGPVNAMDV,QGVTSA,DAS,QQLHFYPHT,IGHJ6*01 (human),IGHV2-5*02 (human),IGKJ3*01 (human),IGKV1-13*02 (human)
PDB,,,,,7D30,True,,,,,,,,VQLVESGGGLVQAGGSLRLSCAASGFPVWQGEMAWYRQAPGKEREWVAAISSMGYKTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVMVGFWYAGQGTQVTVS,,GFPVWQGE,ISSMGYKT,AVMVGFWY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,3IFN,True,,,,,,,,QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMSVGWIRQPSGKGLEWLAHIWWDDDKYYNPSLKSRLTISKDTSRNQVFLKITSVDTADTATYYCARRTTTADYFAYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQSSHVPLTFGAGTKLELK,GFSLSTSGMS,IWWDDDK,ARRTTTADYFAY,QSIVHSNGNTY,KVS,FQSSHVPLT,IGHJ2*01 (mouse),IGHV8-12*01 (mouse),IGKJ5*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,7JXD,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARVWWLRGSFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHVVFGGGTKLTVL,GFTFSSYW,IKQDGSEK,ARVWWLRGSFDY,SGSIASNY,EDN,QSYDSSNHVV,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
PDB,,,,,4F33,True,,,,,,,,EVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK,GYSFTGYT,ITPYNGAS,ARGGYDGRGFDY,SSVSY,DTS,QQWSKHPLT,IGHJ1*01 (mouse),IGHV1-37*01 (mouse),IGKJ4*01 (mouse),IGKV4-59*01 (mouse)
PDB,,,,,6QTL,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCTASGRTGTIYSMAWFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKPEDTAVYYCTATRAYSVGYDYWGQGTQVTVSS,,GRTGTIYS,VGWSSGIT,TATRAYSVGYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6QTL,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCTASGRTGTIYSMAWFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKPEDTAVYYCTATRAYSVGYDYWGQGTQVTVS,,GRTGTIYS,VGWSSGIT,TATRAYSVGYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6CWD,True,,,,,,,,QEQLVESGGRLVPPGGSLTLTCTVSGIDLSSNAISWVRQAPGKGLEYIGIIYGGSIPYYSRWAKGRFTISKTSTTVALKMSTLTASDTATYFCARGKSDGDGYAAYRLDPWGLGTLVTISS,ELVLTQTPSSVSAAVGGTVTINCQASQSISSRLGWYQQKPGQPPKLLIYGASTLTSVGPSRFKGSGSGTEFTLTISGVQRDDAATYYCLGSDTSTDTAFGGGTEVVVK,GIDLSSNA,IYGGSIP,ARGKSDGDGYAAYRLDP,QSISSR,GAS,LGSDTSTDTA,IGHJ5*02 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,5IFA,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIK,GYTFTGYY,INPNSGGT,AKISGSYSFDY,QSVLYSSNNKNY,WAS,QQYYS,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,6NB7,True,,,,,,,,QAQLVESGGALVQPGRSLRLSCAASGFTFRNYAMHWVRQAPATGLQWLAVITSDGRNKFYADSVKGRFTISREDSKNTLYLQMDSLRGEDTAVYYCVTQRDNSRDYFPHYFHDMDVWGQGTTVAVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGDTYLNWFQQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGSHWPPTFGQGTKVEIK,GFTFRNYA,ITSDGRNK,VTQRDNSRDYFPHYFHDMDV,QSLVYSDGDTY,QVS,MQGSHWPPT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
PDB,,,,,5W9H,True,,,,,,,,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,1AQK,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFTFNNYAIHWVRQAPGKGLEWVAFISYDGSKNYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAIYYCARVLFQQLVLYAPFDIWGQGTMVTVSS,NVLTQPPSVSGAPGQRVTISCTGSNSNIGAGFTVHWYQHLPGTAPKLLIFANTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSARFGGGTRLTVL,GFTFNNYA,ISYDGSKN,ARVLFQQLVLYAPFDI,NSNIGAGFT,ANT,QSYDSSLSAR,IGHJ3*02 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV1-40*01 (human)
PDB,,,,,1CT8,True,,,,,,,,QVKLLESGAVLVKPGASVKLSCKTSGFTFSSSYINWLKQKPGQSLEWIAWIYAGSGGTVYNQHFTDKARLTVDTSSSTAYMQFSSLTTEDSAIYYCARYRYDEGFAYWGQGTLVTVSA,LVMTQTPATLSVTPGDSVSLSCRASQSVSNKLHWYQQKSHESPRLLIKFASQSIPGIPSRFSGSGSGSDFTLSINSVETEDFGIYFCHQTHGRPLTFGAGTKLELK,GFTFSSSY,IYAGSGGT,ARYRYDEGFAY,QSVSNK,FAS,HQTHGRPLT,IGHJ3*01 (mouse),IGHV1-55*01 (mouse),IGKJ5*01 (mouse),IGKV5-43*01 (mouse)
PDB,,,,,1HIN,True,,,,,,,,EVQLVESGGDLVKPGGSLKLSCAASGFSFSSYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCARRERYDENGFAYWGQGTLVTVS,DIVMTQSPSSLTVTAGEKVTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSNPLTFGGGTKLELK,GFSFSSYG,ISNGGGYT,ARRERYDENGFAY,QSLFNSGKQKNY,WAS,QNDYSNPLT,IGHJ3*01 (mouse),IGHV5-6*01 (mouse),IGKJ5*01 (mouse),IGKV8-19*01 (mouse)
PDB,,,,,1IC5,True,,,,,,,,VQLQESGPSLVKPSQTLSLTCSVTGDSITSDYWSWIRKFPGNRLEYMGYVSYSGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWAGDYWGQGTLVTVS,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,GDSITSDY,VSYSGST,ANWAGDY,QSIGNN,YAS,QQSNSWPYT,IGHJ3*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV5-43*01 (mouse)
PDB,,,,,1IC7,True,,,,,,,,VQLQESGPSLVKPSQTLSLTCSVTGDSITSAYWSWIRKFPGNRLEYMGYVSYSGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWAGDYWGQGTLVTVS,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,GDSITSAY,VSYSGST,ANWAGDY,QSIGNN,YAS,QQSNSWPYT,IGHJ3*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV5-43*01 (mouse)
PDB,,,,,1KEM,True,,,,,,,,EVKLVESGGGLGQPGGSLRLSCATSGFTFTDYYFNWARQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQGILYLQMNTLRAEDSATYYCARWGSYAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRFSQSIVHSNGNTYLEWYLQKSGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK,GFTFTDYY,IRNKAKGYTT,ARWGSYAMDY,QSIVHSNGNTY,KVS,FQGSHVPRT,IGHJ4*01 (mouse),IGHV7-3*02 (mouse),IGKJ1*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,1MCF,True,,,,,,,,,SALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVL,,,,SSDVGGYNY,EVN,SSYEGSDNFV,,,IGLJ1*01 (human),IGLV2-8*01 (human)
PDB,,,,,1NCA,True,,,,,,,,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTNTGEPTYGEEFKGRFAFSLETSASTANLQINNLKNEDTATFFCARGEDNFGSLSDYWGQGTTVTVSS,DIVMTQSPKFMSTSVGDRVTITCKASQDVSTAVVWYQQKPGQSPKLLIYWASTRHIGVPDRFAGSGSGTDYTLTISSVQAEDLALYYCQQHYSPPWTFGGGTKLEIK,GYTFTNYG,INTNTGEP,ARGEDNFGSLSDY,QDVSTA,WAS,QQHYSPPWT,IGHJ2*01 (mouse),IGHV9-3*02 (mouse),IGKJ1*01 (mouse),IGKV6-25*01 (mouse)
PDB,,,,,1NGX,True,,,,,,,,QVQLLESGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCTRRDSDYWGAGTTVTVSS,LVMTQTPKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGGGTKVEIK,GYTFTSYW,IDPNSGGT,TRRDSDY,QNVGTA,SAS,QQYSSYPLT,IGHJ1*01 (mouse),IGHV1-72*01 (mouse),IGKJ1*01 (mouse),IGKV6-13*01 (mouse)
PDB,,,,,1NSN,True,,,,,,,,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYITYSGTTSYNPSLKSRISISRDTSKNQFFMQLNSVTTEDTGTFYCTRGNGDWGQGTTLTVSS,DIVLTQSPSSLAVSLGQRATISCRASQSVSTSSFRYMHWYQQKPGQPPRLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK,GYSITSDYA,ITYSGTT,TRGNGD,QSVSTSSFRY,YAS,QHSWEIPYT,IGHJ2*01 (mouse),IGHV3-2*02 (mouse),IGKJ2*01 (mouse),IGKV3-7*01 (mouse)
PDB,,,,,2A1W,True,,,,,,,,DVKLVESGGGLVKPGGSLRLSCAASGFTFRNYGMSWVRQTPEKRLEWVAAISGNSLYTSYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYFCARHDDYYGKSPYFFDVWGAGTTVTASS,DVLMTQSPLSLPVSLGDQASISCRCSQSIVKSNGHTYLEWYLQKPGRSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDLGVYYCFQGSHIPWTFGGGTKLESK,GFTFRNYG,ISGNSLYT,ARHDDYYGKSPYFFDV,QSIVKSNGHTY,KVS,FQGSHIPWT,IGHJ1*01 (mouse),IGHV5-9-2*01 (mouse),IGKJ1*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,2ARJ,True,,,,,,,,QVQLKESGPGLVQPSQTLSLTCTVSGFSLTSNSVHWVRQPPGKGLEWMGGIWGDGDTDYNSALKSRLSISRDTSKNQVFLKMNSLQTDDTAIYFCTPLIGSWYFDFWGPGTMVTASS,DIVMTQSPSSLAVSAGERVTLNCKASQNVRNNIAWYQQKPGQSPKLLIYYASYRYTGVPDRFTGDGFGTDFTLAINSVQADDAAFYYCQRIYNSPYTFGAGTKLEL,GFSLTSNS,IWGDGDT,TPLIGSWYFDF,QNVRNN,YAS,QRIYNSPYT,IGHJ1*01 (mouse),IGHV2-6-4*01 (mouse),IGKJ5*01 (mouse),IGKV6-32*02 (mouse)
PDB,,,,,2DQH,True,,,,,,,,VQLQESGPSLVKPSQTLSLTCSVTGDSITSDYWSWIRKFPGNRLEYMGYVSYSGSTAYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWDGDYWGQGTLVTVS,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,GDSITSDY,VSYSGST,ANWDGDY,QSIGNN,YAS,QQSNSWPYT,IGHJ3*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV5-43*01 (mouse)
PDB,,,,,2FJH,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIK,GFTINASW,IYPYSGYT,ARWGHSTSPWAMDY,QVIRRS,AAS,QQSNTSPLT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
PDB,,,,,2GKI,True,,,,,,,,EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGAYKRGYAMDYWGQGTSVTVSS,DLVMSQSPSSLAVSAGEKVTMSCKSSQSLFNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYYHMYTFGSGTKLEIK,GYTFTSYV,INPYNDGT,ARGAYKRGYAMDY,QSLFNSRTRKNY,WAS,KQSYYHMYT,IGHJ4*01 (mouse),IGHV1S45*01 (mouse),IGKJ2*03 (mouse),IGKV8-21*01 (mouse)
PDB,,,,,2H2P,True,,,,,,,,VRLLESGGGLVQPGGSLKLSCAASGFDYSRYWMSWVRQAPGKGLKWIGEINPVSSTINYTPSLKDKFIISRDNAKDTLYLQISKVRSEDTALYYCARLYYGYGYWYFDVWGAGTTVTVSS,DIVLTQSPAIMSAAPGDKVTMTCSASSSVSYIHWYQQKSGTSPKRWIYDTSKLTSGVPVRFSGSGSGTSYSLTINTMEAEDAATYYCQQWSSHPQTFGGGTKLEI,GFDYSRYW,INPVSSTI,ARLYYGYGYWYFDV,SSVSY,DTS,QQWSSHPQT,IGHJ1*01 (mouse),IGHV4-1*02 (mouse),IGKJ1*02 (mouse),IGKV4-59*01 (mouse)
PDB,,,,,2IH1,True,,,,,,,,QVQLQQPGAELVKPGASVKLSCKASGYTFTSDWIHWVKQRPGHGLEWIGEIIPSYGRANYNEKIQKKATLTADKSSSTAFMQLSSLTSEDSAVYYCARERGDGYFAVWGAGTTVTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTDIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIANYYCQQSNRWPFTFGSGTKLEIK,GYTFTSDW,IIPSYGRA,ARERGDGYFAV,QSIGTD,YAS,QQSNRWPFT,IGHJ1*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,2VDO,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSS,DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIK,GFNIKDTY,IDPANGYT,VRPLYDYYAMDY,QGISSN,YGT,VQYAQLPYT,IGHJ4*01 (mouse),IGHV14-3*02 (mouse),IGKJ2*01 (mouse),IGKV14-100*01 (mouse)
PDB,,,,,2WUB,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTINGTYIHWVRQAPGKGLEWVGGIYPAGGATYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAKWAWPAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNRAPATFGQGTKVEIK,GFTINGTY,IYPAGGAT,AKWAWPAFDY,QDVSTA,SAS,QQSNRAPAT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-12*01 (human)
PDB,,,,,2WUC,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTINGTYIHWVRQAPGKGLEWVGGIYPAGGATYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAKWAWPAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNRAPATFGQGTKVEIK,GFTINGTY,IYPAGGAT,AKWAWPAFDY,QDVSTA,SAS,QQSNRAPAT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-12*01 (human)
PDB,,,,,3ET9,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKDSGYAFSSSWMNWVKQRPGQGPEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSVDSAVYFCARSGLLRYAMDYWGQGTSVTVSS,DIVLIQSTSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGTVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISNLEQEDIGTYFCQQGNTLPWTFGGGTKLEIR,GYAFSSSW,IYPGDGDT,ARSGLLRYAMDY,QDIRNY,YTS,QQGNTLPWT,IGHJ4*01 (mouse),IGHV1-82*01 (mouse),IGKJ1*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,3GHB,True,,,,,,,,EVQLVESGGGLVKPGGSLRLTCVASGFTFSDVWLNWVRQAPGKGLEWVGRIKSRTDGGTTDYAASVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYSCTTDGFIMIRGVSEDYYYYYMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVLWYQQFPGTAPKLLIYGNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYFCATWDSGLSADWVFGGGTKLTVL,GFTFSDVW,IKSRTDGGTT,TTDGFIMIRGVSEDYYYYYMDV,SSNIGNNY,GNN,ATWDSGLSADWV,IGHJ6*04 (human),IGHV3-15*07 (human),IGLJ3*02 (human),IGLV1-51*01 (human)
PDB,,,,,3GNM,True,,,,,,,,VQFLESGAELAKPGASVKMSCKASGYTFTTYWMHWVKQRPGQGLEWIGFISPNTDYTEYNQKFRDKATLTADKSSTTAYMQLSSLTSEDSAVYYCARSFIGYNFDFWGQGTTLTVSS,EVLMTQTPLSLPVNLGDQASISCRSSQTIVYSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEADDLGVYYCFQGSHVPFTFGSGTKLEIK,GYTFTTYW,ISPNTDYT,ARSFIGYNFDF,QTIVYSNGNTY,KVS,FQGSHVPFT,IGHJ2*01 (mouse),IGHV1-4*01 (mouse),IGKJ4*01 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,3JBD,True,,,,,,,,QVQLQESGGGSAQTGGSLRLSCAASGFTFSHGYMAWFRQAPEKEREWVACVRTSGVSAYYADSVLGRFTISQDNAKSTLYLQMNNLKPEDTAMYYCAATSISCSSGYMFWGQGTQVTVSS,,GFTFSHGY,VRTSGVSA,AATSISCSSGYMF,,,,IGHJ1*01 (human),IGHV3-30*02 (human),,
PDB,,,,,3OKN,True,,,,,,,,EVKLVESGGGLVQPGGSLRLACATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQSSLYLQMNTLRAEDSATYYCARDHDGYYERFAYWGQGTLVTVS,DIVMTQSPSSLAVSAGEKVTMNCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFALTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,GFTFTDYY,IRNKAKGYTT,ARDHDGYYERFAY,QSLLNSRTRKNY,WAS,KQSYNLRT,IGHJ3*01 (mouse),IGHV7-3*02 (mouse),IGKJ1*01 (mouse),IGKV8-21*01 (mouse)
PDB,,,,,3OKO,True,,,,,,,,EVKLVESGGGLVQPGGSLRLACATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQSSLYLQMNTLRAEDSATYYCARDHDGYYERFAYWGQGTLVTVS,DIVMTQSPSSLAVSAGEKVTMNCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFALTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,GFTFTDYY,IRNKAKGYTT,ARDHDGYYERFAY,QSLLNSRTRKNY,WAS,KQSYNLRT,IGHJ3*01 (mouse),IGHV7-3*02 (mouse),IGKJ1*01 (mouse),IGKV8-21*01 (mouse)
PDB,,,,,3QPQ,True,,,,,,,,EVQLQQPGAELVQPGTSVRLSCKASGYIFTTYWIHWVKQRPGQGLEWIGEINPNNGRINYNEKFKTKATLTVDKSSSTAYMQLSSLTSEDSAVYYCTRVGVMITTFPYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSESGTQYSLKINSLQPEDFGSYYCQHFWSTPFTFGSGTKLELK,GYIFTTYW,INPNNGRI,TRVGVMITTFPY,GNIHNY,NAK,QHFWSTPFT,IGHJ3*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,4CAU,True,,,,,,,,EVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSKTYYGDSVKGRFTISKDNSKKMVNLQMDSLGVEDTAFYYCARGIAGGWAFWGIDLWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQNVYSYLGWYQHKPGRSPRLLIFGVTSRATGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSAYTFGQGTKVEIK,GFSFSSYG,IWYDGSKT,ARGIAGGWAFWGIDL,QNVYSY,GVT,QQYAGSAYT,IGHJ2*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,4H0I,True,,,,,,,,EIQLQQSGPELVKPGASVKISCKASGYSFTDYIMLWVKQSHGKSLEWIGNINPYYGSTSYNLKFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARKNYYGSSLDYWGQGTTLTVSS,DVVMTQTPFSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,GYSFTDYI,INPYYGST,ARKNYYGSSLDY,QSLVHSNGNTY,KVS,SQSTHVPYT,IGHJ2*01 (mouse),IGHV1-39*01 (mouse),IGKJ2*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,4HIH,True,,,,,,,,INLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVVSSDGRTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCAKEGGDNKFSFDYWGQGTLVTVSS,QLTQSPATLSLSPGERATLSCRASQSVTNYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRDNWPPDATFGQGTKVEIK,GFTFSRYG,VSSDGRTT,AKEGGDNKFSFDY,QSVTNY,GAS,QQRDNWPPDAT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,4HIJ,True,,,,,,,,INLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVVSSDGRTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCAKEGGDNKFSFDYWGQGTLVTVSS,QLTQSPATLSLSPGERATLSCRASQSVTNYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRDNWPPDATFGQGTKVEIK,GFTFSRYG,VSSDGRTT,AKEGGDNKFSFDY,QSVTNY,GAS,QQRDNWPPDAT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,4HPO,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIVWVRQMPGKGLEWMGIIYPGDFDTKYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLGGRYYHDSSGYYYLDYWGQGTLVTVSS,MLTQPHSVSESPGKTVTISCTRSSGSVASDYVQWYQQRPGSAPTTVVYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDNSSWVFGGGTKLTVL,GYRFTSYW,IYPGDFDT,ARLGGRYYHDSSGYYYLDY,SGSVASDY,EDN,QSYDNSSWV,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ3*02 (human),IGLV6-57*03 (human)
PDB,,,,,4JQI,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKGLEWVASISSYYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRQFWYSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYKYVPVTFGQGTKVEIK,GFNVYSSS,ISSYYGYT,ARSRQFWYSGLDY,QSVSSA,SAS,QQYKYVPVT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,4K3H,True,,,,,,,,,QAVVTQEPSVTVSPGGTVILTCGSSTGAVTSGHYANWFQQKPGQAPRALIFETDKKYSWTPGRFSGSLLGAKAALTISDAQPEDEAEYYCSLSDVDGYLFGGGTQLTVL,,,,TGAVTSGHY,ETD,SLSDVDGYL,,,IGLJ7*01 (human),IGLV7-46*01 (human)
PDB,,,,,4M1C,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNVSSYSIHWVRQAPGKGLEWVASISSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDRVMYYWSFSKYGYPYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSTSSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSPSFLITFGQGTKVEIK,GFNVSSYS,ISSYYGST,ARDRVMYYWSFSKYGYPYGMDY,QSVSSA,STS,QQSSPSFLIT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,4MHJ,True,,,,,,,,EVHLQQSGPELVKPGASVKMSCKTSGYTFTEYTIHWMKQSHGKSLEWIGGIFPNNGDTTYNQKFKVRATLTVGRSSSTAYMDLRSLTSEDSAVYYCVRNYGSSYGYFDVWGAGTTVTVSS,DIVLTQSPGSLTVSLGQRATISCRASESVDNFGKSFMHWYQQKPGQSPKLLIYRASNREFGIPARFNGSGSGTDFALTINPVEADDVATYFCQQSNEDPRTFGGGTKLEIK,GYTFTEYT,IFPNNGDT,VRNYGSSYGYFDV,ESVDNFGKSF,RAS,QQSNEDPRT,IGHJ1*01 (mouse),IGHV1-22*01 (mouse),IGKJ1*01 (mouse),IGKV3-5*01 (mouse)
PDB,,,,,4RWY,True,,,,,,,,QLVQSGGGLKKPGTSVTISCLASEYTFNEFVIHWIRQAPGQGPLWLGLIKRSGRLMTAYNFQDRLSLRRDRSTGTVFMELRGLRPDDTAVYYCARDGLGEVAPDYRYGIDVWGQGSTVIVTS,EIVLTQSPATLSLSPGERATLSCRASQGLNFVVWYQQKRGQAPRLLIHAPSGRAPGVPDRFSARGSGTEFSLVISSVEPDDFAIYYCQEYSSTPYNFGPGTRVDRK,EYTFNEFV,IKRSGRL,ARDGLGEVAPDYRYGIDV,QGLNF,APS,QEYSSTPYN,IGHJ6*01 (human),IGHV1-46*02 (human),IGKJ3*01 (human),IGKV3-11*01 (human)
PDB,,,,,4TSB,True,,,,,,,,QVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGRGDSFVYWGKGTLVTVSS,QSVLAQPPSVSGAPGQRVSISCTGRSSNIGAGYDVHWYQQLPGKAPKLLIYGNTNRPSGVPVRFSGSMSGTSASLAITGLQAEDEADYYCQSYDRSLSGSVFGGGTKLTVL,GFTVSSNY,IYSGGST,AREGRGDSFVY,SSNIGAGYD,GNT,QSYDRSLSGSV,IGHJ4*01 (human),IGHV3-66*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,4WGW,True,,,,,,,,QVQLQESGGGLVQAGGSLRLSCAASRSIFSIDTANWYRQPPGMQRELVATITRDGNANYADSVKGRFTISRDRARNTVYLQMNSLKPEDTGVYYCNAAIRTTVRTSAQEYWGQGTQVTVSS,,RSIFSIDT,ITRDGNA,NAAIRTTVRTSAQEY,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
PDB,,,,,4XCC,True,,,,,,,,QVQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGWGWLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVK,GGSFSTYA,VIPLLTIT,AREGTTGWGWLGKPIGAFAH,QSVGNNK,GAS,QQYGQSLST,IGHJ1*01 (human),IGHV1-69*10 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,4XMP,True,,,,,,,,EVQLVQSGTQMKEPGASVTISCVTSGYEFVEILINWVRQVPGRGLEWMGWMNPRGGGVNYARQFQGKVTMTRDVYRDTAYLTLSGLTSGDTAKYFCVRGRSCCGGRRHCNGADCFNWDFQHWGQGTLVIVS,IGVTQSPAILSVSLGERVTLSCKTSQAITPRHLVWHRQKGGQAPSLVMTGTSERASGIPDRFIGSGSGTDFTLTITRLEAEDFAVYYCQCLEAFGQGTKLEIK,GYEFVEIL,MNPRGGGV,VRGRSCCGGRRHCNGADCFNWDFQH,QAITPRH,GTS,QCLEA,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,4YHK,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIK,GYTFTDYY,TNPRNGGT,TIGTSGYDYFDY,QSIVHSDGNIY,KVS,FQASHVPYT,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ2*01 (human),IGKV2-29*02 (human)
PDB,,,,,5BJZ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNLSSSSIHWVRQAPGKGLEWVASIYSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREYHSYWSYSWWPRVGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQASLTALLTFGQGTKVEIK,GFNLSSSS,IYSYYGST,AREYHSYWSYSWWPRVGLDY,QSVSSA,SAS,QQASLTALLT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
PDB,,,,,5CBA,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREPDYYDSSGYYPIDAFDIWGQGTTVTVSS,QSALTQPASVSASPGQSITISCTGTSSDVGAYDWVSWYQQHPGKAPKLLIFDVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSYTRRDTYVFGTGTKVTVL,GGTFSSYA,IIPIFGTA,AREPDYYDSSGYYPIDAFDI,SSDVGAYDW,DVN,SSYTRRDTYV,IGHJ3*02 (human),IGHV1-69*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
PDB,,,,,5CIL,True,,,,,,,,VQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGDGDLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVK,GGSFSTYA,VIPLLTIT,AREGTTGDGDLGKPIGAFAH,QSVGNNK,GAS,QQYGQSLST,IGHJ1*01 (human),IGHV1-69*10 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,5CJO,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNVSSYSIHWVRQAPGKGLEWVASISSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDRVMYYWSFSKYGYPYGMDYWGQGTLVTV,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSTSSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSPSFLITFGQGTKVEIK,GFNVSSYS,ISSYYGST,ARDRVMYYWSFSKYGYPYGMDY,QSVSSA,STS,QQSSPSFLIT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5CUS,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYYMQWVRQAPGKGLEWVSYIGSSGGVTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGLGDAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGLNYVSWYQQLPGTAPKLLISRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSPPGEAFGGGTKLTVL,GFTFSYYY,IGSSGGVT,ARVGLGDAFDI,LSNIGLNY,RNN,AAWDDSPPGEA,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-47*01 (human)
PDB,,,,,5EII,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNISYSSIHWVRQAPGKGLEWVASISSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRGQASWDYWWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSDDPITFGQGTKVEIK,GFNISYSS,ISSYYGST,ARSRGQASWDYWWAMDY,QSVSSA,SAS,QQSSDDPIT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,5F3H,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLNPEDFATYYCQQHYSTPWTFGGGTKVEIK,GFTFSSYA,ISSGGSYT,AKQDYAMNY,QDVSTA,SAS,QQHYSTPWT,IGHJ4*01 (human),IGHV3-23*03 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,5FXC,True,,,,,,,,QVQLQESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTGVGQFAYWGQGTTVTVSS,VVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,GFTFSNYW,IRLKSNNYAT,TGVGQFAY,TGAVTTSNY,GTN,ALWYSNHWV,IGHJ2*01 (mouse),IGHV6-6*02 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,5HVF,True,,,,,,,,VQLQESGGGLVQAGGSLRLSCAASGSIFSPNAMGWYRQAPGKERELVAARTNVGSTYADSVKGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCNAWGQDGWLGQYDYWGQGTQVTVSS,,GSIFSPNA,RTNVGS,NAWGQDGWLGQYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,5JMR,True,,,,,,,,QVQLQESGGGLVQPGGSLTLSCAASGFTFSSYSMYWVRQAPGKGLEWVSSINRVGSNTDYADSVKGRFTISRDNAKNTLYLQMNSLKSEDTALYYCAVGMYAAPPWRGQGTQVTVSS,,GFTFSSYS,INRVGSNT,AVGMYAAPPW,,,,IGHJ5*02 (human),IGHV3-74*01 (human),,
PDB,,,,,5KTZ,True,,,,,,,,QVQLQESGGGSVQAGGSLTLSCAASGYAVSRYSMGWFRQAPGKENEGVAAIDSSGVGTTYADSVKGRFTISRDNAKDTVYLRMNSLKPEDTAIYYCASGFGLSLSRYTYAYWGQGTQVTVSS,,GYAVSRYS,IDSSGVGT,ASGFGLSLSRYTYAY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,5KVF,True,,,,,,,,EVQLQQPGAELVKPGASVKLSCKASGYTFTSSWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKNKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARYYYDYDGMDYWGQGTSVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYTYPYTFGGGTKLEIN,GYTFTSSW,IHPNSGST,ARYYYDYDGMDY,QSLLYSSNQKNY,WAS,QQYYTYPYT,IGHJ4*01 (mouse),IGHV1-64*01 (mouse),IGKJ1*02 (mouse),IGKV8-30*01 (mouse)
PDB,,,,,5KW9,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCRTSGDTFNTHAISWVRQAPGQGLEWMGGIIPIFATTNYANKFQGTVTISADESTSTAYLEVRSLRSEDTAVYYCASNRANRADDYDYYFDYWGQGTLVTVSS,EIVMSQSPDSLAVSLGERATINCKSSQSVLYKSDKKNYLAWYQQKSGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPRTFGQGTKVDIK,GDTFNTHA,IIPIFATT,ASNRANRADDYDYYFDY,QSVLYKSDKKNY,WAS,QQYYSIPRT,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV4-1*01 (human)
PDB,,,,,5MO3,True,,,,,,,,EVQLQQSGPELVKPGTSVKMPCKASGYIFTDYVISWVKQRTGQGLEWIGEIFPRSGSTYYNEKFKGKATLTADKSSNTAYMQLSSVTSEDSAVYFCARDYYGTSFAMDYWGQGTSVTVSS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSFYLRTFGGGTKLDIK,GYIFTDYV,IFPRSGST,ARDYYGTSFAMDY,QSLLNSRTRKNY,WAS,KQSFYLRT,IGHJ4*01 (mouse),IGHV1-75*01 (mouse),IGKJ1*01 (mouse),IGKV8-21*01 (mouse)
PDB,,,,,5OCK,True,,,,,,,,EVQLEESGPGLVRPSETLSLSCTVSGFPMSESYFWGWIRQSPGKGLEWLGSVIHTGTTYYRPSLESRLTIAMDPSKNQVSLSLTSVTVADSAMYYCVRIRGGSSNWLDPWGPGIVVTASS,ESVWTQPPSVSAAPGQKVTISCSGDDSILRSAFVSWYQQVPGSAPKLVIFDDRQRPSGIPARFSGSNSGTTATLDIAGLQRGDEADYYCAAWNGRLSAFVFGSGTKLEIK,GFPMSESYF,VIHTGTT,VRIRGGSSNWLDP,DSILRSAF,DDR,AAWNGRLSAFV,IGHJ5*02 (human),IGHV4-38-2*02 (human),IGLJ6*01 (human),IGLV1-51*01 (human)
PDB,,,,,5T3S,True,,,,,,,,QLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,GYRFNFYH,ISPYSGDK,AKGLLRDGSSTWLPYL,NSVCCSHKS,EDN,CSYTHNSGCV,IGHJ2*01 (human),IGHV1-18*01 (human),IGLJ1*01 (human),IGLV2-14*02 (human)
PDB,,,,,5T3S,True,,,,,,,,QVQLQESGPGLVRPSETLSVTCIVSGGSISNYYWTWIRQSPGKGLEWIGYISDRETTTYNPSLNSRAVISRDTSKNQLSLQLRSVTTADTAIYFCATARRGQRIYGVVSFGEFFYYYYMDVWGKGTAVTVSS,PLSVALGETARISCGRQALGSRAVQWYQHKPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTTATLTISGVEVGDEADYYCHMWDSRSGFSWSFGGATRLTVL,GGSISNYY,ISDRETT,ATARRGQRIYGVVSFGEFFYYYYMDV,ALGSRA,NNQ,HMWDSRSGFSWS,IGHJ6*04 (human),IGHV4-4*08 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,5TLJ,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSDYYGDYGFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDYAGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,GYAFSSSW,IYPGDGDT,ARSDYYGDYGFAY,QSVDYAGDSY,AAS,QQSNEDPYT,IGHJ3*01 (mouse),IGHV1-82*01 (mouse),IGKJ2*01 (mouse),IGKV3-4*01 (mouse)
PDB,,,,,5TLJ,True,,,,,,,,EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVAYISSGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCSRHRGNPFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPWTFGGGTKLEIK,GFTFSSYT,ISSGGGNT,SRHRGNPFDY,KSVSTSGYSF,LAS,QHSRELPWT,IGHJ2*01 (mouse),IGHV5-6-5*01 (mouse),IGKJ1*01 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,5UD9,True,,,,,,,,QVQLRESGPGLVKPSETLSLSCTVSQDSRPSDHSWTWVRQSPGKALEWIGDIHYNGATTYNPSLRSRVRIELDQSIPRFSLKMTSMTAADTGMYYCARNAIRIYGVVALGEWFHYGMDVWGQGTAVTVSS,SSELTQPPSVSVSPGQTARITCSGAPLTSRFTYWYRQKPGQAPVLIISRSSQRSSGWSGRFSASWSGTTVTLTIRGVQADDEADYYCQSSDTSDSYKMFGGGTKLTVL,QDSRPSDHS,IHYNGAT,ARNAIRIYGVVALGEWFHYGMDV,PLTSRF,RSS,QSSDTSDSYKM,IGHJ6*01 (human),IGHV4-59*11 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
PDB,,,,,5W3E,True,,,,,,,,VQLAESGPALVAPSQALSITCTVAGFSLTAYGVAWVRQPPGAGLEWLGAIWAAGATDYNAALKSRASIAKDNSKSQVFLAMASLATADTAAYYCAREWDAYGDYWGQGTTVTVS,DIVLTQSPAALSAAAGATVAATCRASGNIHNALAWYQQKAGKSPQLLVYAAAALAAGVPSRFSGSGSGTAYALAINSLAADDFGAYYCQHFWSTPYTFGGGTKLEIK,GFSLTAYG,IWAAGAT,AREWDAYGDY,GNIHNA,AAA,QHFWSTPYT,IGHJ2*01 (mouse),IGHV2-6-7*01 (mouse),IGKJ2*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,5WAW,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAVSGFTFSDNGMAWVRQAPGKGLEWVSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRVSQSLLHSNGYTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQTRHVPYTFGGGTKVEIK,GFTFSDNG,ISNLAYSI,VSGTWFAY,QSLLHSNGYTY,KVS,SQTRHVPYT,IGHJ4*01 (human),IGHV3-48*01 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
PDB,,,,,6ANA,True,,,,,,,,QVQLQQSGAELSKPGASVKMSCKASGYTFTSYWLHWIKQRPGQGLEWIGYINPRNDYTEYNQNFKDKATLTADKSSSTAYMELSSLTSEDSAVYYCARRDITTFYWGQGTTLTVSS,DIQLTQSPSSLAVSAGDNVTMSCKSSQSVLYSANHKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVQVEDLAIYYCHQYLSSWTFGGGTKLEIK,GYTFTSYW,INPRNDYT,ARRDITTFY,QSVLYSANHKNY,WAS,HQYLSSWT,IGHJ2*01 (mouse),IGHV1-4*01 (mouse),IGKJ1*01 (mouse),IGKV8-27*01 (mouse)
PDB,,,,,6B5L,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQDRVTITRDTSTTTAYMELSSLRSEDTAVYYCALLTVLTPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPNLLIYWASTRQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,GYTFTSYA,IKAGNGNT,ALLTVLTPDDAFDI,QSVLYSSNNKNY,WAS,HQYYSSPLT,IGHJ3*02 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,6CWK,True,,,,,,,,QVQLAESGGGLVQAGGSLKLSCAASGRDFSMYMLAWFRQAPGKEREFVAAIMCSGGGGGTYYADSMQGRFTISRDNAKKTVALQMNSLKPEDTAVYYCAASTTYCSATTYSSDRLYDFWGQGTQVTVSS,,GRDFSMYM,IMCSGGGGGT,AASTTYCSATTYSSDRLYDF,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
PDB,,,,,6DB9,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFYISYSSIHWVRQAPGKGLEWVASISPYSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQGYRRRSGRGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYSFPSTFGQGTKVEIK,GFYISYSS,ISPYSGST,ARQGYRRRSGRGFDY,QSVSSA,SAS,QQSYSFPST,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6FLA,True,,,,,,,,QVQLQQSGAEVARPGASVKLSCKASGYTFTSYWLQWVKQRPGQGLEWIGAIWPGDDDTRYAQKFQGKATMTADKSSSTAYIQLSNLASEDSAVYYCARKGGFAMDYWGQGTSVTVSS,NIVMTQSPTSLAVSLGQRATISCRASESVDSFGKSFMHFYQQKPGQPPKLLIHLASNLESGVPARFTGRGSRTDFTLTIDPVEADDAATYYCQQNNEVPFTFGSGTKLEVK,GYTFTSYW,IWPGDDDT,ARKGGFAMDY,ESVDSFGKSF,LAS,QQNNEVPFT,IGHJ4*01 (mouse),IGHV1-87*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,6GJQ,True,,,,,,,,QVQLQESGGGLEQPGGSLRLSCATSGVIFGINAMGWYRQAPGKQRELVATFTSGGSTNYADFVEGRFTISRDNAKNTVYLQMNGLRPEDTAVYYCHATVVVSRYGLTYDYWGQGTQVTVSS,,GVIFGINA,FTSGGST,HATVVVSRYGLTYDY,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
PDB,,,,,6H02,True,,,,,,,,QVQLVESGGGLVQAGASLRLSCAVSGRTGSIYTMGWFRQAPGKEREVVARTTWTPGSTKYADSVKGRVAISRDIAKNTLYLQMNNLKPEDTAVYYCAACAYGTCYYGDRAYEYWGQGTQVTVSS,,GRTGSIYT,TTWTPGST,AACAYGTCYYGDRAYEY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6IBB,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCEASGYTLANYAIGWFRQAPGKEREGVSCISSGGSTVYSESVKDRFTISRDNAKKIVYLQMNSLQPEDTAVYYCAADPFGERLCIDPNTFAGYLETWGQGTQVTVSS,,GYTLANYA,ISSGGST,AADPFGERLCIDPNTFAGYLET,,,,IGHJ1*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6II4,True,,,,,,,,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYAIHWVRQAPGKGLEWVALISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNGHGSGGEVGSNWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEYNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSANRVFGGGTKLTVL,GFTFSSYA,ISYDGSNK,NGHGSGGEVGSNWFDP,SGSIASNY,EYN,QSYDSANRV,IGHJ5*02 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
PDB,,,,,6JHT,True,,,,,,,,EVKLVESGGGLVKPGGSLKLSCAASAFTITTYGMSWVRQTPEKRLEWVATITAGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSGDTAMYYCARKVTSVAEYYFDYWGQGTTLTVSS,DIVLTQSPAIMSASPGEKVTMTCSATSGLSYIHWYQQKSGTSPKRWIYDTSKLAFGAPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWDVNPYTFGGGTKLEIK,AFTITTYG,ITAGGSYT,ARKVTSVAEYYFDY,SGLSY,DTS,QQWDVNPYT,IGHJ2*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ2*01 (mouse),IGKV4-59*01 (mouse)
PDB,,,,,6KPG,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCSASGFAFSSFGMHWVRQAPEKGLEWVAYISSGSGTIYYADTVKGRFTISRDDPKNTLFLQMTSLRSEDTAMYYCVRSIYYYGSSPFDFWGQGTTLTVSS,DIVMTQATSSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLTISRLSAEDVGVYYCMQHLEYPLTFGAGTKLELK,GFAFSSFG,ISSGSGTI,VRSIYYYGSSPFDF,KSLLHSNGNTY,RMS,MQHLEYPLT,IGHJ2*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV2-137*01 (mouse)
PDB,,,,,6KSN,True,,,,,,,,QVQLEESGGGSVQAGGSLRLSCAASGYMYSTYSTYCMGWFRQAPGKEREGVAFIKRGDHSTYYTDSVKGRFTISQDSAKNTVSLQMNNLKPEDTAIYYCAADFAHSFLLSVHSGAGQYSYWGQGTQVTVSS,,GYMYSTYSTYC,IKRGDHST,AADFAHSFLLSVHSGAGQYSY,,,,IGHJ4*01 (human),IGHV3-NL1*01 (human),,
PDB,,,,,6MED,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTLNSYEITWVRQAPGQGLEWMGGITPIFETTYAQKFQGRVTITADESTSTTYMELSSLRPEDTAVYYCARDGVRYCGGGRCYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQNINNYLNWYQQKPGKAPKVLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTVRTFGQGTKVEIK,GGTLNSYE,ITPIFET,ARDGVRYCGGGRCYNWFDP,QNINNY,AAS,QQSHSTVRT,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6MTJ,True,,,,,,,,QGQLVQSGATTTKPGSSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVNMTTDTEVPVTSFTSTGAAYMEIRNLTSDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,GYRFNFYH,ISPYSGDK,AKGLLRDGSSTWLPYL,NSVCCSHKS,EDN,CSYTHNSGCV,IGHJ4*01 (human),IGHV1-18*01 (human),IGLJ1*01 (human),IGLV2-14*02 (human)
PDB,,,,,6MTJ,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYWSWIRQSPGKGLEWIGYISDSESTNYNPSLKSRVIISVDTSKNQLSLKLNSVTAADSAIYYCARAQQGKRIYGMVSFGEFFYYYYMDVWGKGTTVTVSS,SVALGETASISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,GGSISNYY,ISDSEST,ARAQQGKRIYGMVSFGEFFYYYYMDV,ALGSRA,NNQ,HMWDSRSGFSWS,IGHJ6*04 (human),IGHV4-4*08 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,6O3B,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYYSMHWVRQAPGKGLEWVASIYSSYSYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSSPGADYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWAYGPFTFGQGTKVEIK,GFNIYYYS,IYSSYSYT,ARSSPGADYGLDY,QSVSSA,SAS,QQWAYGPFT,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6ORQ,True,,,,,,,,EVQLQESGGDLVKPGGSLKLSCAASGFTFSRYGMSWVRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHGITTVGVAMDYWGQGTYSHVSS,DIVMTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGAGTKLELK,GFTFSRYG,ISSGGSYT,ARHGITTVGVAMDY,QSVDYDGDSY,AAS,QQSNEDPYT,IGHJ4*01 (mouse),IGHV5-6*01 (mouse),IGKJ5*01 (mouse),IGKV3-4*01 (mouse)
PDB,,,,,6PIS,True,,,,,,,,QLQLQESGPGLVKPSQSLSLACSVTGFSLSTGGYQWTWIRQFPGKKLEWMGYISYAGGITYNPSLKSRISITRDTSKNQFFLQLNTVTTEDTATHYCARVQYSGYGNAYFDVWGQGIQVTVSS,DIQLTQLPSFLSVSPGDKVTITCKASQNINQYLHWYQQKPEEAPKLLIYGASNLQTGIPSRFSGSGYGTDFSLTINSLDSEDVGTYFCQQGYTPRTFGPGTKLEIK,GFSLSTGGYQ,ISYAGGI,ARVQYSGYGNAYFDV,QNINQY,GAS,QQGYTPRT,IGHJ1*01 (mouse),IGHV3-2*02 (mouse),IGKJ2*01 (human),IGKV1-39*01 (human)
PDB,,,,,6QFA,True,,,,,,,,SLRLSCAASGHTFNYPIMGWFRQAPGKEREFVGAISWSGGSTSYADSVKDRFTISRDNAKNTVYLEMNNLKPEDTAVYYCAAKGRYSGGLYYPTNYDYWGQGTQVTVSS,,GHTFNYPI,ISWSGGST,AAKGRYSGGLYYPTNYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,6S2I,False,,,,,,,,QVQLQQSGAELAKPGASMKMSCRASGYSFTSYWIHWLKQRPDQGLEWIGYIDPATAYTESNQKFKDKAILTADRSSNTAFMYLNSLTSEDSAVYYCARESPRLRRGIYYYAMDYWGQGTTVTVSS,,GYSFTSYW,IDPATAYT,ARESPRLRRGIYYYAMDY,,,,IGHJ4*01 (mouse),IGHV1-4*01 (mouse),,
PDB,,,,,6S2I,False,,,,,,,,,DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGAGTKLEL,,,,QDISNY,YTS,QQGNTLPPT,,,IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,6S2I,False,,,,,,,,QVQLQQSGAELAKPGASMKMSCRASGYSFTSYWIHWLKQRPDQGLEWIGYIDPATAYTESNQKFKDKAILTADRSSNTAFMYLNSLTSEDSAVYYCARESPRLRRGIYYYAMDYWGQGTTVTVSS,,GYSFTSYW,IDPATAYT,ARESPRLRRGIYYYAMDY,,,,IGHJ4*01 (mouse),IGHV1-4*01 (mouse),,
PDB,,,,,6S2I,False,,,,,,,,,DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGAGTKLELK,,,,QDISNY,YTS,QQGNTLPPT,,,IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,6S2I,False,,,,,,,,QVQLQQSGAELAKPGASMKMSCRASGYSFTSYWIHWLKQRPDQGLEWIGYIDPATAYTESNQKFKDKAILTADRSSNTAFMYLNSLTSEDSAVYYCARESPRIYYYAMDYWGQGTTVTVSS,,GYSFTSYW,IDPATAYT,ARESPRIYYYAMDY,,,,IGHJ4*01 (mouse),IGHV1-4*01 (mouse),,
PDB,,,,,6S2I,False,,,,,,,,,DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGAGTKLELK,,,,QDISNY,YTS,QQGNTLPPT,,,IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,6S2I,False,,,,,,,,QVQLQQSGAELAKPGASMKMSCRASGYSFTSYWIHWLKQRPDQGLEWIGYIDPATAYTESNQKFKDKAILTADRSSNTAFMYLNSLTSEDSAVYYCARESPRLYYYAMDYWGQGTTVTVSS,,GYSFTSYW,IDPATAYT,ARESPRLYYYAMDY,,,,IGHJ4*01 (mouse),IGHV1-4*01 (mouse),,
PDB,,,,,6S2I,False,,,,,,,,,DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGAGTKLELK,,,,QDISNY,YTS,QQGNTLPPT,,,IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,6TCO,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,GYSITSGYS,ITYDGST,ARGSHYFGHWHFAV,QSVDYDGDSY,AAS,QQSHEDPYT,IGHJ1*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6TNP,True,,,,,,,,QVQLQQSDAELVKPGSSVKISCKASGYTFTDHAIHWVKQKPEQGLEWIGHFSPGNTDIKYNDKFKGKATLTVDRSSSTAYMQLNSLTSEDSAVYFCKTSTFFFDYWGQGTTLTVSS,ELVMTQSPSSLTVTAGEKVTMICKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLELK,GYTFTDHA,FSPGNTDI,KTSTFFFDY,QSLLNSGDQKNY,WAS,QNDYSYPLT,IGHJ2*01 (mouse),IGHV1S53*01 (mouse),IGKJ5*01 (mouse),IGKV8-19*01 (mouse)
PDB,,,,,6TXZ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISVSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKANWGFFDYWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYADSVVFGGGTKVTVL,GFTFSSYA,ISVSGGST,AKANWGFFDY,SSDVGGYNY,DVS,SSYADSVV,IGHJ4*01 (human),IGHV3-23*04 (human),IGLJ2*01 (human),IGLV2-11*01 (human)
PDB,,,,,6UR5,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTAYYLHWVRQAPGQGFEWMAWINPNTGDTNYAQKFQGRVTLSRDTSITTAYMELTRLRSDDTAVYYCAKDLTLMYVFDSGWARGAHDYYGMDVWGQGTTVAVSG,PSALTQPASVSGSPGQSVTISCTGTNSDVGTFDLVSWYQQYPGKAPKLIIYEGSRRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSVVFGGGTKLTVL,GYTFTAYY,INPNTGDT,AKDLTLMYVFDSGWARGAHDYYGMDV,NSDVGTFDL,EGS,SSYAGSVV,IGHJ6*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-14*02 (human)
PDB,,,,,6UUP,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASRRSSRSWAMHWVRQAPGKGLEWVAVISYDGRLKYYADSVKGRFTISRDNAEYLVYLQMNSLRAEDTAVYYCAAEEGDGGFFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQQLPGTAPKLLIYRNNERPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDGSLSGRGVFGTGTKLTVL,RRSSRSWA,ISYDGRLK,AAEEGDGGFFDY,SSNIGSNY,RNN,AAWDGSLSGRGV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
PDB,,,,,6VRH,True,,,,,,,,EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGNINPNNGGTSYNQKFKGKATLTVDKSSTTAYMELRSLTSEDSAVYYCTRSPVRPYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSIPRTFGGGTKLEIK,GYTFTDYY,INPNNGGT,TRSPVRPYYFDY,QDVSTA,SAS,QQHYSIPRT,IGHJ2*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-17*01 (mouse)
PDB,,,,,6VRP,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFSLSTSGIGVTWVRQAPGKGLEWLATIWWDDDNRYADSVKGRFTISADTSKNTAYLQMNSLTAEDTAVYYCAQSAITSVTDSAMDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSKFPWTFGQGTKVEIK,GFSLSTSGIG,IWWDDDN,AQSAITSVTDSAMDH,QDISSY,YTS,QQYSKFPWT,IGHJ1*01 (human),IGHV3-30*02 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6WIK,True,,,,,,,,EVQLQQSGAELVRPGALVKLSCKASGFNIKDYYMHWVKERPEQGLEWIGWIDPENGNTIYDPKFQGKASITADTSSNTAYLQLSSLTSEDTAVYYCARKRGYYGPYFDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQKKPGQSPKLLIYSASNRYSGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYGSYPLTFGSGTKLEIK,GFNIKDYY,IDPENGNT,ARKRGYYGPYFDY,QNVGTA,SAS,QQYGSYPLT,IGHJ2*01 (mouse),IGHV14-1*02 (mouse),IGKJ4*01 (mouse),IGKV6-13*01 (mouse)
PDB,,,,,6XBM,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCSASGFAFSSFGMHWVRQAPEKGLEWVAYISSGSGTIYYADTVKGRFTISRDDPKNTLFLQMTSLRSEDTAMYYCVRSIYYYGSSPFDFWGQGTTLTVSS,DIVMTQATSSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLTISRLEAEDVGVYYCMQHLEYPLTFGAGTKLELK,GFAFSSFG,ISSGSGTI,VRSIYYYGSSPFDF,KSLLHSNGNTY,RMS,MQHLEYPLT,IGHJ2*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV2-137*01 (mouse)
PDB,,,,,6XSK,True,,,,,,,,QVQLQESGPGLVKPSEILSLTCAVSGGSFSSYCWGWIRQPPGKGLEWIGSICGSGGSNYLNPSLKSRVTLSVDTSKNQFSLILNSVTAADTAVYYCAREGITIFGVVIPRVLDSWGQGAVVTVSS,DIQMTQSPSSLSASVGDTVTITCRASQSISSWLAWYQQKPGKAPNLLIYRASTLQSGVPSRFSGSGSGTDFTLTISSLQSEDFATYFCQQSTSSPFTFGPGTKLDIK,GGSFSSYC,ICGSGGSN,AREGITIFGVVIPRVLDS,QSISSW,RAS,QQSTSSPFT,IGHJ5*01 (human),IGHV4-38-2*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
PDB,,,,,6XUX,True,,,,,,,,ESGEMLFTVKKSLRLSCAASGRTFSTAAMGWFRQAPGKERDFVAGIYWTVGSTYYADSAKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAARRRGFTLAPTRANEYDYWGQGTQVTVSS,,GRTFSTAA,IYWTVGST,AARRRGFTLAPTRANEYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,7E6U,True,,,,,,,,QVQLQESGGGSVQAGGSLRLSCAASGFPISTYDMGWFRQAPGKEREGVVGITDSFSIKYEDSVKGRFTISRDNAKNALYLQMNSLKPEDTGMYYCAAGDARWSLLLRAEQYNYWGQGTQVTVSS,,GFPISTYD,ITDSFSI,AAGDARWSLLLRAEQYNY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,7JHG,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGRTISRYAMSWFRQAPGKEREFVAVARRSGDGAFYADSVQGRFTVSRDDAKNTVYLQMNSLKPEDTAVYYCAIDSDTFYSGSYDYWGQGTQVTVSS,,GRTISRYA,ARRSGDGA,AIDSDTFYSGSYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,7JHG,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYYSIHWVRQAPGKGLEWVASIYPYSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYYPYFISYYSKMEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSGPITFGQGTKVEIK,GFNIYYYS,IYPYSGST,ARYYPYFISYYSKMEAMDY,QSVSSA,SAS,QQSSSGPIT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,7JIE,True,,,,,,,,QVQLVQSGPEVKKPGSSVKVSCKASGGTVSSYAISWVRQAPGQGLEWMGGIIPIFDTTNYAQKFQGRVTITADESTGTSDMELSSLRSEDTAVYYCARDRVPSYSPSRRFSTKGAMWGKYGMDVWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISKVEAEDVGVYYCMQALQTPRTFGQGTKVEIK,GGTVSSYA,IIPIFDTT,ARDRVPSYSPSRRFSTKGAMWGKYGMDV,QSLLHSNGYNY,LGS,MQALQTPRT,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
PDB,,,,,7JKT,True,,,,,,,,QVQLVQSGPEVRAPGASVTVSCKTSGYSFTDFFIHWVRQAPGQGLEWMGWLNPIFGAVNYAHKYQGRITLTRDTSMKTAYMQLTNLRSDDTAVFYCVRKRVYDEYDWDWAYWGQGTLVTVSA,EIVLTQSPGILSLSPGERATLSCRTSQDVGSNSLAWYQEKPGQAPRLLVYGASNRATGVPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYEYFGRGTKVQVD,GYSFTDFF,LNPIFGAV,VRKRVYDEYDWDWAY,QDVGSNS,GAS,QQYEY,IGHJ4*01 (human),IGHV1-2*07 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7JTR,True,,,,,,,,QVQLQQPGSELVRPGASVKLSCKASGYTFTNSWMHWVKQRPGQGLEWIGNIFPGNGNTNYDENFKSKATLTVDTSSNTAYMQLSSLTSEDSAVYYCTRGLFAYWGQGTLVTVSA,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLINNNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHFTAPYTFGGGTKLEIK,GYTFTNSW,IFPGNGNT,TRGLFAY,QSLLINNNQKNY,FAS,QQHFTAPYT,IGHJ3*01 (mouse),IGHV1-53*01 (mouse),IGKJ2*01 (mouse),IGKV8-24*01 (mouse)
PDB,,,,,7K3A,True,,,,,,,,QVQLVQSGAEVKKPGASVTVSCQVSGYTLTSYGLSWVRQAPGQGLEWVGWINTYDGQTKYVKKFQGRVTMTTHTGTNTAYMEMKSLRSDDTAVYYCARVEGVRGVMGFHYYPMDVWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYAVHWYQQLPGTAPKLLISGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GYTLTSYG,INTYDGQT,ARVEGVRGVMGFHYYPMDV,SSNIGAGYA,GNS,QSYDSSLSGSV,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,7KQG,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYPMHWVRQAPGKGLEWVSTISWNGAGLAYADSVKGRFTVSRDNAKRVLYLQMSSLRPEDTALYYCAKDRVDTTSWDYYFHKSMDVWGQGTSVTVSG,DIQMTQSPSSLSASVGDRVTITCQASQGIGNYLSWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTHFTFIIIRLQPEDIATYYCQQYDNLPLTFGGGTKVEIT,GFTFDDYP,ISWNGAGL,AKDRVDTTSWDYYFHKSMDV,QGIGNY,DAS,QQYDNLPLT,IGHJ6*01 (human),IGHV3-9*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
PDB,,,,,7KQH,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYPMHWVRQVPGKGLEWVSSINWNGGSTDHADSVKGRFTISRDNARNSLYLEMNSLKSEDTALYYCAKDLRASSSMDYYYYSGMDVWGQGTMVTVSG,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKVLIYDASNLQTGVPSRFSGSGSGTDFIFTISSLKPEDVATYYCQQYENVPITFGQGTRLDIK,GFTFDDYP,INWNGGST,AKDLRASSSMDYYYYSGMDV,QGINNY,DAS,QQYENVPIT,IGHJ6*01 (human),IGHV3-9*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
PDB,,,,,7LLL,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGFTFSNYKMNWVRQAPGKGLEWVSDISQSGASISYTGSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCARCPAPFTRDCFDVTSTTYAYRGQGTQVTVSS,,GFTFSNYK,ISQSGASI,ARCPAPFTRDCFDVTSTTYAY,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
PDB,,,,,7P5W,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGFPVYQAWMWWYRQAPGKEREWVAAIESEGQYTWYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVKDTGHTTNQYDYWGQGTQVTVSA,,GFPVYQAW,IESEGQYT,NVKDTGHTTNQYDY,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
PDB,,,,,7RLZ,True,,,,,,,,NSQLQQSGPELVKPGASVKISCKASGYSFTGYYMHWVKQSHVKSLEWIGRIDPYDGATSYNQNFKDKASLTVDKSSTTGFMELHSLTSEDSAVYYCAREGHWDGDWYFDVWGAGTTVTVSS,DIVMTQTPLSLSVTIGQPASISCKSSQSLLHSNGKTYLNWLQQRPGQAPKILMYLVSKLDPGIPDRFSGSGSETDFTLKISRVEAEDLGVYYCLQGTYYPFTFGSGTKLEIK,GYSFTGYY,IDPYDGAT,AREGHWDGDWYFDV,QSLLHSNGKTY,LVS,LQGTYYPFT,IGHJ1*01 (mouse),IGHV1-37*01 (mouse),IGKJ4*01 (mouse),IGKV1-132*01 (mouse)
PDB,,,,,7RTB,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGFTFSNYKMNWVRQAPGKGLEWVSDISQSGASISYTGSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCARCPAPFTRDCFDVTSTTYAYRGQGTQVTVSS,,GFTFSNYK,ISQSGASI,ARCPAPFTRDCFDVTSTTYAY,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
PDB,,,,,6OBC,True,,,,,,,,QVQLAETGGGLVQPGGARTLSCAASESISSFYFMGWYRQAPGKPRELVAEISNYGRTDYGDSLKGRFTISRDNAANTVNLQMNNLAPEDTALYYCNARKWERSVLEDYWGQGTQVTVSS,,ESISSFYF,ISNYGRT,NARKWERSVLEDY,,,,IGHJ4*01 (human),IGHV3-23*02 (human),,
PDB,,,,,1P2C,True,,,,,,,,EVQLQESGAELMKPGASVKISCKATGYTFTTYWIEWIKQRPGHSLEWIGEILPGSDSTYYNEKVKGKVTFTADASSNTAYMQLSSLTSEDSAVYYCARGDGFYVYWGQGTTLTVSS,DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIK,GYTFTTYW,ILPGSDST,ARGDGFYVY,QSISNN,YTS,QQSGSWPRT,IGHJ2*01 (mouse),IGHV1-9*01 (mouse),IGKJ1*01 (mouse),IGKV5-43*01 (mouse)
PDB,,,,,43CA,True,,,,,,,,QVQLVESGPGLVAPSQSLSITCTVSGISLSRYNVHWVRQSPGKGLEWLGMIWGGGSIEYNPALKSRLSISKDNSKSQIFLKMNSLQTDDSAMYYCVSYGYGGDRFSYWGQGTLVTVS,DVVMTQTPSSLAMSVGQKVTMSCKSSQSLLNISNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDQADYFCQQHYRAPRTFGGGTKLEIK,GISLSRYN,IWGGGSI,VSYGYGGDRFSY,QSLLNISNQKNY,FAS,QQHYRAPRT,IGHJ3*01 (mouse),IGHV2-6-4*01 (mouse),IGKJ1*01 (mouse),IGKV8-24*01 (mouse)
PDB,,,,,4F2M,True,,,,,,,,QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGQGLEWIGRIYPGDGETNYSEKFKGKATLTADKSSSTAYMHLSSLTSVDSAVYFCARGGYRYDPYYAMDYWGQGTSVTVSS,DILLTQSPAILSVSPGERVSLSCRASQSIGTSIHWYQQRTNGSPRPLIKYASESISGIPSRFSGSGSGTDFTLNINSVESEDIADYFCQQTDSWPTTFGAGTKLELK,GYAFSSSW,IYPGDGET,ARGGYRYDPYYAMDY,QSIGTS,YAS,QQTDSWPTT,IGHJ4*01 (mouse),IGHV1-82*01 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,4OII,True,,,,,,,,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKLRPGQGFEWIGDINPNNGGPSYNEKFKRKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTIDDGYRFGYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSASGSGTQYSLKINSLQPEDFGSYYCQHFWSTPRTFGGGTKLEIK,GYTFTSYW,INPNNGGP,TIDDGYRFGY,GNIHNY,NAK,QHFWSTPRT,IGHJ3*01 (mouse),IGHV1-53*01 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,4UT9,True,,,,,,,,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAIYYCARDKVDDYGDYWFPTLWYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGFNYVSWFQQHPGKAPKLMLYDVTSRPSGVSSRFSGSKSGNTASLTISGLQAEDEADYYCSSHTSRGTWVFGGGTKLTVL,GYTFTSYA,INAGNGNT,ARDKVDDYGDYWFPTLWYFDY,SSDVGGFNY,DVT,SSHTSRGTWV,IGHJ4*01 (human),IGHV1-3*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
PDB,,,,,4UTA,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCSASGFTFSTYSMHWVRQAPGKGLEYVSAITGEGDSAFYADSVKGRFTISRDNSKNTLYFEMNSLRPEDTAVYYCVGGYSNFYYYYTMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISTFLAWYQHKPGQAPRLLIYDASTRATGVPARFSGSRSGTDFTLTISTLEPEDFAVYYCQQRYNWPPYTFGQGTKVEIK,GFTFSTYS,ITGEGDSA,VGGYSNFYYYYTMDV,QSISTF,DAS,QQRYNWPPYT,IGHJ6*01 (human),IGHV3-64*03 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,4UTB,True,,,,,,,,EVQLVESGGGLVRPGGSLRLSCAASGFSYSNHWMHWVRQAPGKGLVWVSRINSDGSTRNYADFVKGRFTISRDNAENTLYLEMNSLTADDTAVYYCVRDGVRFYYDSTGYYPDSFFKYGMDVWGQGTTVTVSS,QSVLTQPVSVSGSPGQSITISCTGTSSNADTYNLVSWYQQRPGKAPKLMIYEGTKRPSGVSNRFSASKSATAASLTISGLQPEDEADYYCCSYATSRTLVFGGGTKLTVV,GFSYSNHW,INSDGSTR,VRDGVRFYYDSTGYYPDSFFKYGMDV,SSNADTYNL,EGT,CSYATSRTLV,IGHJ6*01 (human),IGHV3-74*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,6C08,True,,,,,,,,QIQLVQSGPKLSKPGGTDKISSKASGYSFTDYVMNWVKAGPGKGLEWNGSINTSNGYTTYISAFKGRGSFSVDSSASTAAQQLSVLKAAATAVYFNARNFRGNGAMDYWGQGTSVTVSS,DILMTQSPSSLSVVVGFYVTITSQASNNITTYSSFIFWYQQKPGQAPKLLIYDSSTLESGIPGRFSGSGSGRDFSLTIGPNQPADGATYEDLQYNGEVRTFGGGTKLEIK,GYSFTDYV,INTSNGYT,ARNFRGNGAMDY,NNITTYSSF,DSS,LQYNGEVRT,IGHJ4*01 (mouse),IGHV9-2-1*01 (mouse),IGKJ4*01 (human),IGKV1-5*01 (human)
PDB,,,,,3OGO,True,,,,,,,,QVQLVESGGALVQPGGSLRLSCAASGFPVNRYSMRWYRQAPGKEREWVAGMSSAGDRSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYYCNVNVGFEYWGQGTQVTVSS,,GFPVNRYS,MSSAGDRS,NVNVGFEY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,5IMK,True,,,,,,,,VQLVESGGGLVQAGGSLRLSCAASGRTFSSYGMGWFRQAPGKEREFVAAIRWNGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGRWDKYGSSFQDEYDYWGQGTQVTVSS,,GRTFSSYG,IRWNGGST,AAGRWDKYGSSFQDEYDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,5N4J,True,,,,,,,,MQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLHWVRQAPGQGLEWMGWVSTNNGHTNYAQKVQGRVTMTTDTSTSTAYMELRSLRSDDTAIYYCARGVDLDYWGQGTLLTVSS,QSALTQPPSVSGSPGQSVTISCTGTSSDVGSYNRVSWFQQPPGTAPKLIIYEVSNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSLYISSSTWVFGGGTKLTVL,GYTFTNYG,VSTNNGHT,ARGVDLDY,SSDVGSYNR,EVS,SLYISSSTWV,IGHJ4*01 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV2-18*01 (human)
PDB,,,,,3ULV,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWVGWVRQMPGKGLEWMGFIDPSDSYTNYAPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARELYQGYMDTFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGLYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNTLSYTFGQGTKVEIK,GYSFTNYW,IDPSDSYT,ARELYQGYMDTFDS,QSIGLY,AAS,QQGNTLSYT,IGHJ5*01 (human),IGHV5-10-1*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,3ULV,True,,,,,,,,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGIIQKRSKWYNNYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYSYPFYSIDYWGQGTLVTVSS,QSVLTQPPSVSVAPGQTARISCSGDNIGSYYVHWYQQKPGQAPVLVIYEDSERPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDDPNFQVFGGGTKLTVL,GDSVSSNSAA,IQKRSKWYN,ARYSYPFYSIDY,NIGSYY,EDS,SSYDDPNFQV,IGHJ4*01 (human),IGHV6-1*01 (human),IGLJ2*01 (human),IGLV3-21*01 (human)
PDB,,,,,3ULV,True,,,,,,,,QVQLQQPGAELVQPGTSVRLSCKASGYIFTTYWIHWVKQRPGQGLEWIGEINPNNGRINYNEKFKTKATLTVDKSSSTAYMQLSSLTSEDSAVYYCTRVGVMITTFPYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSESGTQYSLKINSLQPEDFGSYYCQHFWSTPFTFGSGTKLELK,GYIFTTYW,INPNNGRI,TRVGVMITTFPY,GNIHNY,NAK,QHFWSTPFT,IGHJ3*01 (mouse),IGHV1-53*01 (mouse),IGKJ4*01 (mouse),IGKV12-41*01 (mouse)
PDB,,,,,2Q20,True,,,,,,,,,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPYTFGQGTKLEIK,,,,QDISNY,DAS,QQYDNLPYT,,,IGKJ2*01 (human),IGKV1-33*01 (human)
PDB,,,,,4IMK,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,GYTFTGYY,INPNSGGT,ARSPNPYYYDSSGYYYPGAFDI,NIGSKS,DDS,QVWDSSSDHYV,IGHJ3*02 (human),IGHV1-2*02 (human),IGLJ1*01 (human),IGLV3-21*02 (human)
PDB,,,,,1DQD,True,,,,,,,,EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRLSITRDTSRNQYYLQLKSVTPEDTATYYCASPPGYYGSGPYAMDYWGQGTSVTVSS,DIVLSQSPAIMSASPGEKVTITCSASSSVSYMHWFQQKPGTSPKLCIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSTYPPTFGSGTKLEIK,GDSITSGY,ISYSGST,ASPPGYYGSGPYAMDY,SSVSY,TTS,QQRSTYPPT,IGHJ4*01 (mouse),IGHV3-8*02 (mouse),IGKJ4*01 (mouse),IGKV4-57*01 (mouse)
PDB,,,,,1FPT,True,,,,,,,,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIQWIKQRPGQGLEWIGVINPGSGGTDYNANFKGKATLTADKSSSIVYMQLSSLTSDDSAVYFCARDFYDYDVGFDYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCSSSQSLVHSNGKTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTYFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,GYAFTNYL,INPGSGGT,ARDFYDYDVGFDY,QSLVHSNGKTY,KVS,SQSTHVPYT,IGHJ2*01 (mouse),IGHV1-54*01 (mouse),IGKJ2*01 (mouse),IGKV1-110*01 (mouse)
PDB,,,,,1RUL,True,,,,,,,,VQLQQSGPGLVKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYINYSGFTSHNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCAGLLWYDGGAGSWGQGTLVTVS,DVVMTQSPKTISVTIGQPASISCKSSQRLLNSNGKTFLNWLLQRPGQSPKRLIYLGTKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIK,GYSITSDFA,INYSGFT,AGLLWYDGGAGS,QRLLNSNGKTF,LGT,WQGTHFPYT,IGHJ3*01 (mouse),IGHV3-2*02 (mouse),IGKJ2*01 (mouse),IGKV1-133*01 (mouse)
PDB,,,,,2BJM,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNGGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARMWYYGTYYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGNKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,GYTFTSYW,IDPNGGGT,ARMWYYGTYYFDY,TGAVTTSNY,GTN,ALWYSNHLV,IGHJ2*01 (mouse),IGHV1-72*01 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,2ESG,True,,,,,,,,LEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSSLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIK,GYSFTSYG,ISAGTGNT,ARDPYGGGKSEFDY,QGISSA,DAS,QQFNSYPLT,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
PDB,,,,,3EFD,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNLSYSSMHWVRQAPGKGLEWVAYISPSYGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSWEAYWRWSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSYSLLTFGQGTKVEIK,GFNLSYSS,ISPSYGYT,ARSWEAYWRWSAMDY,QSVSSA,SAS,QQYSYSLLT,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,3HZM,True,,,,,,,,EVKLVESGGGLVQSGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLAFIRNKAKGYTTEYSSSVKGRFTISRDNSQSFLYLQMNTLRAEDSATYYCARDINPGSDGYYDALDYWGQGTSVTVS,DIVMTQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLRTFGGGTKLELK,GFTFTDYY,IRNKAKGYTT,ARDINPGSDGYYDALDY,QSLLNSRTRKNY,WAS,KQSYNLRT,IGHJ4*01 (mouse),IGHV7-3*02 (mouse),IGKJ5*01 (mouse),IGKV8-21*01 (mouse)
PDB,,,,,3R06,True,,,,,,,,EVQLVESGGGLVQPGKSLKLSCEASGFTFSGYGMHWVRQAPGRGLESVAYITSSSINIKYADAVKGRFTVSRDNAKNLLFLQMNILKSEDTAMYYCARFDWDKNYWGQGTMVTVSS,DIQMTQSPSSLPASLGDRVTINCQASQDISNYLNWYQQKPGKAPKLLIYYTNKLADGVPSRFSGSGSGRDSSFTISSLESEDIGSYYCQQYYNYPWTFGPGTKLEIK,GFTFSGYG,ITSSSINI,ARFDWDKNY,QDISNY,YTN,QQYYNYPWT,IGHJ4*01 (mouse),IGHV5-17*01 (mouse),IGKJ1*01 (human),IGKV1-33*01 (human)
PDB,,,,,4IDJ,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKTSGGTFNNVAINWVRQAPGQGLEWMGGIIPGLDTPNYAQKFQGRVTITADKSTTSTYLELSSLRSDDTAVYYCAREMEVSGRWRPTEAFEIWGQGTMVTVSS,TTLTQSPGTLSLSPGERATLSCRASQTISNNFVAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISSLEPEDFAVYYCQQYGSSPYTFGQGTKVDIK,GGTFNNVA,IIPGLDTP,AREMEVSGRWRPTEAFEI,QTISNNF,GAS,QQYGSSPYT,IGHJ3*02 (human),IGHV1-69*06 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,4KHT,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYAFSWVRQAPGQGLEWMGSIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYFDTYNNYGFANWGQGTLVTVSS,IELTQPPSVSVVPGQTARISCSGDNIPYEYASWYQQKPGQAPVLVIYGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCASWDSMTVDGVFGGGTKLTVL,GGTFNSYA,IIPIFGTT,ARYFDTYNNYGFAN,NIPYEY,GDN,ASWDSMTVDGV,IGHJ1*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,4M6M,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,GYSFSNYW,IDPSNSYT,ARWYYKPFDV,SSNIGSGYD,GNS,ASWTDGLSLVV,IGHJ5*01 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,4W70,True,,,,,,,,EVQLVESGGGLVQAGDSLRLSATASGRTFSRAVMGWFRQAPGKEREFVAAISAAPGTAYYAFYADSVRGRFSISADSAKNTVYLQMNSLKPEDTAVYYVAADLKMQVAAYMNQRSVDYWGQGTQVTVSS,,GRTFSRAV,ISAAPGTAYYA,AADLKMQVAAYMNQRSVDY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,4WCY,True,,,,,,,,EVQLQQSGAELVKPGASVKLSCTPSGFNIKDTYIHWVKQRPEQGLEWIGMINPANGNSNYDPKFQDKATITADTSSNTAYLQLSSLTSEDTAVYYCAEITTDFDVWGAGTTVTVSS,NIVLTQSPPSLAVSLGQRATISCRASESVDSYGNSFLHWYQQKSGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPLEADDAATYYCQQNNEAPFTFGSGTKLEIK,GFNIKDTY,INPANGNS,AEITTDFDV,ESVDSYGNSF,LAS,QQNNEAPFT,IGHJ1*01 (mouse),IGHV14-3*02 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,5KAN,True,,,,,,,,QVQLAQSENELKKPGASVKVSCKTSGYTFTRFGMSWVRQAPGQGLEWMGWISGYTGDTKYARSFQGRLTLTTDTSTGTAYMELRSLRSDDTAIYYCVRNRVQMEVSPATQSTWYMDLWGRGTLVSVSS,DIQMTQVPVSLSAFVGDRVSITCRASQDISRWLAWYQQKPGRAPKLLIYAASSLQGGVPSRFRGSGSGTEFTLTISGLQPEDFATYYCQQGST,GYTFTRFG,ISGYTGDT,VRNRVQMEVSPATQSTWYMDL,QDISRW,AAS,QQGST,IGHJ2*01 (human),IGHV1-18*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
PDB,,,,,5YUP,True,,,,,,,,EVKLVESGGGLVQPGGSRKLSCAASGFTFSDYGMAWVRQAPGKGPEWIAFISNLSRIYYADTVTGRFTISRENDKNTLFLEMSSLRSEDSAIYYCTRDDGYYRVDYWGQGATLTVSS,DIVMTQSHKFLSTSVGNRVSITCKASQDVGIGLVSWYQQKPGQSPKLLIHWASTRHTGVPDRFTGSGSGTDFTLTINNVQSEDLATYFCQQFSNYPLTFGSGTRLEIK,GFTFSDYG,ISNLSRI,TRDDGYYRVDY,QDVGIGL,WAS,QQFSNYPLT,IGHJ2*01 (mouse),IGHV5-15*02 (mouse),IGKJ4*01 (mouse),IGKV6-23*01 (mouse)
PDB,,,,,6BHZ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTY,IYPTNGYT,SRWGGDGFYAMDY,QDVNTA,SAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6CSF,True,,,,,,,,EVKLEESGGGLVQPGGSMKLSCAASGFTSSDFAMDWVRQSPEAGLEWVAEIAASERHYAESVKGRFTISRDDSKSSVYLQMNSLRAEDSGLYYCTRTAGACGQWGTGTTVTVSS,DIAMTQSPASLSASVGETVTITCRTSENIASALAWYQQKQGKSPQLLVMNAKTLAAGVPSRFSGSGSGTAFSLKINSLQPEDFGSYSCQHAAGWLLTFGGGTKLEIK,GFTSSDFA,IAASER,TRTAGACGQ,ENIASA,NAK,QHAAGWLLT,IGHJ1*03 (mouse),IGHV6-6*01 (mouse),IGKJ1*01 (mouse),IGKV12-44*01 (mouse)
PDB,,,,,6NN3,True,,,,,,,,QVQLQESGPGLVRPSQTLSLSCTVSGASISSGGYYWSWIRQHPGKGLEWIGHIYYSGTVYYNPSLRSRVSISIDNQLSLKVASVTAADTAVYYCARVRVDSVRGAGDNGFDPWGHGTLVTV,AAALTQPLSVSVSPGQTAIFTCSGDNLGDKYVYWFQQRPGQSPALLIYQDNKRPSGIPERFSGSNSGNTATLTISGTQSTDEADYYCQTWDSTVVFGGGTKL,GASISSGGYY,IYYSGTV,ARVRVDSVRGAGDNGFDP,NLGDKY,QDN,QTWDSTVV,IGHJ5*02 (human),IGHV4-31*02 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
PDB,,,,,6QKD,True,,,,,,,,QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS,,GGTFATSP,ISPSGGDR,AVRRRFDGTSYYTGDYDS,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
PDB,,,,,6QKD,True,,,,,,,,,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK,,,,QSVSSSY,DAS,QQYSYSPVT,,,IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,6TCQ,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISRLRPEDFATYYCQQSHEDPYTFGQGTKVEIK,GYSITSGYS,ITYDGST,ARGSHYFGHWHFAV,QSVDYDGDSY,AAS,QQSHEDPYT,IGHJ1*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,6UYM,True,,,,,,,,EVQLLEQSGAEVKKPGSSVKVSCETSGGTFDNYALNWVRQAPGQGLEWIGGVVPLFGTTRNAQKFQGRVTISDDKSTGTGHMELRSLRSEDTAVYYCVRSVTPRYCGGGFCYGEFDYWGQGTLVTVSS,EIELTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTVSRLEPEDSAVYFCQQYYRSPLTFGGGTKVEIK,GGTFDNYA,VVPLFGTT,VRSVTPRYCGGGFCYGEFDY,QSVSSN,GAS,QQYYRSPLT,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
PDB,,,,,6WJL,False,,,,,,,,EVQLVETGGGVVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESGYDYVFDYWGQGTLVAVSS,,GFTFSDYY,ISSSGSTI,ARESGYDYVFDY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,6WJL,False,,,,,,,,EVQLVETGGGVVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESGYDYVFDYWGQGTLVAVSS,,GFTFSDYY,ISSSGSTI,ARESGYDYVFDY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,6WJL,False,,,,,,,,,DIQMTQSPSTLSAFVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPITFGQGTRLEIK,,,,QSISSW,AAS,QQLNSYPIT,,,IGKJ5*01 (human),IGKV1-9*01 (human)
PDB,,,,,6WJL,False,,,,,,,,,DIQMTQSPSTLSAFVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPITFGQGTRLEIK,,,,QSISSW,AAS,QQLNSYPIT,,,IGKJ5*01 (human),IGKV1-9*01 (human)
PDB,,,,,7OMN,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFDIAYYSIGWVRRAPGKGEELVARIYPSSSSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWHYDYADWPGGYGMDYWGQGTLVTVSS,,GFDIAYYS,IYPSSSST,ARWHYDYADWPGGYGMDY,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
PDB,,,,,7Q9G,True,,,,,,,,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,GLTVSSNY,IYSGGST,ARGEGSPGNWFDP,QSVPSSY,GAS,QHYDTSPR,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
PDB,,,,,7KKJ,True,,,,,,,,QVQLVESGGGLVQAGGSLRLSCAASGYIFGRNAMGWYRQAPGKERELVAGITRRGSITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPASPAYGDYWGQGTQVTVSS,,GYIFGRNA,ITRRGSIT,AADPASPAYGDY,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
PDB,,,,,1FVC,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTY,IYPTNGYT,SRWGGDGFYAMDY,QDVNTA,SAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,3P9W,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIGWVRRAPGKGEELVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCYYHYYGWHPGYGLSYSSGQGTLVTVSS,,GFNIKDTY,IYPTNGYT,YYHYYGWHPGYGLSYS,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
PDB,,,,,4G80,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNVYYSSIHWVRQAPGKGLEWVAYISPSSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARKQYSYWRDSYWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHQYNSLIFGQGTKVEIK,GFNVYYSS,ISPSSGST,ARKQYSYWRDSYWAMDY,QSVSSA,SAS,QQHQYNSLI,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,4FQH,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKSSGGTSNNYAISWVRQAPGQGLDWMGGISPIFGSTAYAQKFQGRVTISADIFSNTAYMELNSLTSEDTAVYFCARHGNYYYYSGMDVWGQGTTVTVSS,QSALTQPPAVSGTPGQRVTISCSGSDSNIGRRSVNWYQQFPGTAPKLLIYSNDQRPSVVPDRFSGSKSGTSASLAISGLQSEDEAEYYCAAWDDSLKGAVFGGGTQLTVL,GGTSNNYA,ISPIFGST,ARHGNYYYYSGMDV,DSNIGRRS,SND,AAWDDSLKGAV,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ7*01 (human),IGLV1-44*01 (human)
PDB,,,,,7K8N,True,,,,,,,,QVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,GFIVSSNY,IYSGGST,ARDYGDYYFDY,QSVSSSY,GAS,QQYGSSPRT,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
PDB,,,,,7K8Q,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWISPVSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAPLFPTGVLAGDYYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,GYTFTGYY,ISPVSGGT,ARAPLFPTGVLAGDYYYYGMDV,SSDVGSYNL,EGS,CSYAGSSTLV,IGHJ6*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,3RIF,True,,,,,,,,EVQLQQSGPELVRPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGGTSYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARDGDYYRYGRYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTINFANWVQEKPDHLFTGLIGGINNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,GYSFTGYT,INPYNGGT,ARDGDYYRYGRYFDY,TGAVTTINF,GIN,ALWYSNHWV,IGHJ2*01 (mouse),IGHV1-26*01 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
PDB,,,,,1G9M,True,,,,,,,,QVQLLESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYRNNGFLKHWGQGTLVTVTS,LELTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYRNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,2B4C,True,,,,,,,,EVQLLEQSGAEVKKPGSSVQVSCKASGGTFSMYGFNWVRQAPGHGLEWMGGIIPIFGTSNYAQKFRGRVTFTADQATSTAYMELTNLRSDDTAVYYCARDFGPDWEDGDSYDGSGRGFFDFWGQGTLVTVSS,ELVLTQSPGTLSLSAGERATLSCRASQSVSSGSLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTIGRLEPEDLAVYYCQQYGTSPYTFGQGTKLEIK,GGTFSMYG,IIPIFGTS,ARDFGPDWEDGDSYDGSGRGFFDF,QSVSSGS,GAS,QQYGTSPYT,IGHJ5*01 (human),IGHV1-69*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,2NY7,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQDRVTFTADTSANTAYMELRSLRSADTAVYYCARVGPYSWDDSPQDNYYMDVWGKGTTVIVSS,EIVLTQSPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK,GYRFSNFV,INPYNGNK,ARVGPYSWDDSPQDNYYMDV,HSIRSRR,GVS,QVYGASSYT,IGHJ6*04 (human),IGHV1-3*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
PDB,,,,,3TYG,True,,,,,,,,QPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSVTAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVL,GDSTAACNSF,LSHCASYWNRGWT,ARFGGEVLRYTDWPKPAWVDL,SNNF,DVN,GSLVGNWDVI,IGHJ2*01 (human),IGHV4-38-2*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
PDB,,,,,3EAK,True,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGGSEYSYSTFSLGWFRQAPGQGLEAVAAIASMGGLTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAVRGYFMRLPSSHNFRYWGQGTLVTVSS,,GGSEYSYSTFS,IASMGGLT,AAVRGYFMRLPSSHNFRY,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
PDB,,,,,1HIL,True,,,,,,,,EVQLVESGGDLVKPGGSLKLSCAASGFSFSSYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCARRERYDENGFAYWGQGTLVTVS,DIVMTQSPSSLTVTAGEKVTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSNPLTFGGGTKLELK,GFSFSSYG,ISNGGGYT,ARRERYDENGFAY,QSLFNSGKQKNY,WAS,QNDYSNPLT,IGHJ3*01 (mouse),IGHV5-6*01 (mouse),IGKJ5*01 (mouse),IGKV8-19*01 (mouse)
PDB,,,,,6MAR,True,,,,,,,,RVQLVESGGGVVQPGKSVRLSCVVSDFPFSKYPMYWVRQAPGKGLEWVAAISGDAWHVVYSNSVQGRFLVSRDNVKNTLYLEMNSLKIEDTAVYRCARMFQESGPPRLDRWSGRNYYYYSGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSESLRQSNGKTSLYWYRQKPGQSPQLLVFEVSNRFSGVSDRFVGSGSGTDFTLRISRVEAEDVGFYYCMQSKDFPLTFGGGTKVDLK,DFPFSKYP,ISGDAWHV,ARMFQESGPPRLDRWSGRNYYYYSGMDV,ESLRQSNGKTS,EVS,MQSKDFPLT,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV2D-29*02 (human)
PDB,,,,,3BN9,True,,,,,,,,QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARPYLTYPQRRGPQNVSPFDNWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHGNLPYTFGDGTKVEIK,GFTFSSYA,ISGSGGST,ARPYLTYPQRRGPQNVSPFDN,QGISSY,AAS,QQHGNLPYT,IGHJ3*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
PDB,,,,,4RQS,True,,,,,,,,EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYDNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,6A78,True,,,,,,,,EVQLVESGGGVVQPGGSLKLSCAASGFTFSTYDMSWVRQTPDKRLELVATINSNGGSTYYPDSVKGRFTSSRDNAKNILYLQMSSLKSEDTAMYYCAREALLRPPYYALDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCGASENIYGALTWYQRKQGKSPQLLIYGAINLADDKSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPFTFGSGTKLEIK,GFTFSTYD,INSNGGST,AREALLRPPYYALDY,ENIYGA,GAI,QNVLSTPFT,IGHJ4*01 (mouse),IGHV5-6-3*01 (mouse),IGKJ4*01 (mouse),IGKV12-89*01 (mouse)
PDB,,,,,6NJN,True,,,,,,,,EVKLLESGGGLVQPGGSLKLSCAASGFDFSEYWMSWVRQAPGKGLEWIGEINPDSSSIDYTPSLKDKIIISRDNAKKTLYLQLSKVRSEDTALYYCARPRGNYVVMDYWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGSSFVHWYQQKPGQPPKLLIFLASKLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQTNEDPYTFGGGTKLEIK,GFDFSEYW,INPDSSSI,ARPRGNYVVMDY,ESVDSYGSSF,LAS,QQTNEDPYT,IGHJ4*01 (mouse),IGHV4-1*02 (mouse),IGKJ2*01 (mouse),IGKV3-10*01 (mouse)
PDB,,,,,6NJN,True,,,,,,,,QAQLKESGPGLVAPSQSLSITCTVSGFSLTNYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSRVSISKDNSKSQVFLKMNSLQTDDTVMYYCAREDYDYDWHFDVWGAGTTVTVSS,EIQMTQTTSSLSASLGDRVTISCRASQDISNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGIDYSLTINNLEQEDFATYFCQQGNTLPLTFGAGTKLELK,GFSLTNYG,IWAGGST,AREDYDYDWHFDV,QDISNY,YTS,QQGNTLPLT,IGHJ1*01 (mouse),IGHV2-9*02 (mouse),IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,6ORN,True,,,,,,,,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,GDSMNNYY,ISDRESA,ATARRGQRIYGVVSFGEFFYYYSMDV,ALGSRA,NNQ,HMWDSRSGFSWS,IGHJ6*04 (human),IGHV4-4*08 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,6DDE,True,,,,,,,,DVQLVESGGGLVQPGGSRKLSCSASGFAFSSFGMHWVRQAPEKGLEWVAYISSGSGTIYYADTVKGRFTISRDDPKNTLFLQMTSLRSEDTAMYYCVRSIYYYGSSPFDFWGQGTTLTVSS,DIVMTQATSSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLTISRLEAEDVGVYYCMQHLEYPLTFGAGTKLELK,GFAFSSFG,ISSGSGTI,VRSIYYYGSSPFDF,KSLLHSNGNTY,RMS,MQHLEYPLT,IGHJ2*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV2-137*01 (mouse)
PDB,,,,,6N2X,True,,,,,,,,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTVVTVSP,DVVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,NFRISAHT,ISTSSTYR,ARKGSDRLSDNDPFDA,QSIETW,KAS,QHYAGYSAT,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
PDB,,,,,1R70,True,,,,,,,,LEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSSLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIK,GYSFTSYG,ISAGTGNT,ARDPYGGGKSEFDY,QGISSA,DAS,QQFNSYPLT,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
PDB,,,,,2QTJ,True,,,,,,,,LEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSSLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIK,GYSFTSYG,ISAGTGNT,ARDPYGGGKSEFDY,QGISSA,DAS,QQFNSYPLT,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ4*01 (human),IGKV1-13*02 (human)
PDB,,,,,6NB3,True,,,,,,,,EVQLLESGGGLVKPGGSLRLSCEASGLTFSNVWMSWVRQAPGKGLEWVGRIKRKSEGATTDYGAPVKGRFTLSRDDSKNTVYLQMNSLKIDDTAVYYCSTLTRGGDVWSSSYYFDYWGQGALVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYDLVSWYQQHPGKSPKLMIYADIKRPSGVSHRFSGSKSGNTASLTISGLQSADEADYYCCLYAGSSTSVIFGGGTKVT,GLTFSNVW,IKRKSEGATT,STLTRGGDVWSSSYYFDY,SSDVGTYDL,ADI,CLYAGSSTSVI,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,6NB4,True,,,,,,,,EVQLLESGGGLVKPGGSLRLSCEASGLTFSNVWMSWVRQAPGKGLEWVGRIKRKSEGATTDYGAPVKGRFTLSRDDSKNTVYLQMNSLKIDDTAVYYCSTLTRGGDVWSSSYYFDYWGQGALVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYDLVSWYQQHPGKSPKLMIYADIKRPSGVSHRFSGSKSGNTASLTISGLQSADEADYYCCLYAGSSTSVIFGGGTKVT,GLTFSNVW,IKRKSEGATT,STLTRGGDVWSSSYYFDY,SSDVGTYDL,ADI,CLYAGSSTSVI,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,4KMT,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDGIYGELDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEVK,GYSFTSYW,IYPGDSDT,ARYDGIYGELDF,QSISSY,AAS,QQSYSTPLT,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
PDB,,,,,5I1D,True,,,,,,,,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIK,GFTFSSYA,ISGSGGST,AKYDGIYGELDF,QSVLYSSNNKNY,WAS,QQYYSTPLT,IGHJ5*01 (human),IGHV3-23*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,4TSA,True,,,,,,,,VQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGPGDSIDYWGKGTLVTVSS,QSVLTQPPSVSGAPGQRVSISCTGRSSNIGAGYDVHWYQQLPGKAPKLLIYGNTNRPSGVPVRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,GFTVSSNY,IYSGGST,AREGPGDSIDY,SSNIGAGYD,GNT,QSYDSSLSGSV,IGHJ4*01 (human),IGHV3-66*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
PDB,,,,,4ZD3,True,,,,,,,,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARPHYYDSLDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQRPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYSPGYTFGQGTKVEIK,GYSFTSYW,IYPGDSDT,ARPHYYDSLDAFDI,QSISSW,KAS,QHYNSYSPGYT,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
PDB,,,,,4PFE,True,,,,,,,,QVQLVESGGALVQPGGSLRLSCAASGFPVNRYSMRWYRQAPGKEREWVAGMSSAGDRSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYYCNVNVGFEYWGQGTQVTVS,,GFPVNRYS,MSSAGDRS,NVNVGFEY,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
PDB,,,,,5XS7,True,,,,,,,,EVQLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTPEKRLELVAHISSGGGYIYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRQKGLYYGFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQRPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYTTPHTFGGGTKLEIK,GFAFSTYD,ISSGGGYI,TRQKGLYYGFDY,QDVNTA,SAS,QQHYTTPHT,IGHJ2*01 (mouse),IGHV5-12-1*01 (mouse),IGKJ1*01 (mouse),IGKV6-17*01 (mouse)
PDB,,,,,7KBT,True,,,,,,,,QVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNERFKGKASFTADSSSNTAYMQLSSLTSEDSAVYYCTRTSYYFGSSYDFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSSVPKRFSGSRSGSDYSLTISSLDSEDFAVYYCLQYASYPYTFGGGTKVEIK,GYTFSSYW,ILPGSGST,TRTSYYFGSSYDFDV,QEISGY,AAS,LQYASYPYT,IGHJ1*01 (mouse),IGHV1-9*01 (mouse),IGKJ2*01 (mouse),IGKV9-124*01 (mouse)
PDB,,,,,5F1O,True,,,,,,,,DVQLQESGGGLVQAGHSLRLSCVGSGSRFDNYAMGWFRQAPGKEREFVAAISWSSGTTRYLDTVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCAARYQPRYYDSGDMDGYEYDNWGQGTQVTVSS,,GSRFDNYA,ISWSSGTT,AARYQPRYYDSGDMDGYEYDN,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
PDB,,,,,6WAR,True,,,,,,,,QVQLQESGGGSVQAGGSLRLSCVASGSIFSINAMDWYRQAPGKQRELVAGITSGGSTNYGDFVKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAAEVGGWGPPRPDYWGHGTQVTVSS,,GSIFSINA,ITSGGST,AAEVGGWGPPRPDY,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
PDB,,,,,3WBD,True,,,,,,,,QIQLQQSGPELVRPGASVKISCKASGYTFTDYYIHWVKQRPGEGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAYMQLSSLTSEDSAVYFCARGGKFAMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLYWYLQKPGQSPKPLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGTHVPYTFGGGTRLEIK,GYTFTDYY,IYPGSGNT,ARGGKFAMDY,QSLVHSNGNTY,RVS,FQGTHVPYT,IGHJ4*01 (mouse),IGHV1-84*01 (mouse),IGKJ2*01 (mouse),IGKV1-110*02 (mouse)
PDB,,,,,5VZR,True,,,,,,,,EVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,GYTFTDYA,FSTYYGNT,ARKSYYVDYVDAMDY,ESVDNYGISF,ATS,QQSKEVPRT,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,6PXG,True,,,,,,,,QVQLQQSGGELVKPGASVKLSCKTSGFTFSSSYISWLKQKPGQSLEWIAWIYAGTGGTEYNQKFTGKAQVTVDTSSSTAYMQFSSLTTEDSAIYYCARGGSSFAMDYWGQGTSVTVSS,QLVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIHTASNQGSGVPARFSGSGSGTDFSLNIHPVEDDDTAMYFCQQSEEVPLTFGAGTKLEIK,GFTFSSSY,IYAGTGGT,ARGGSSFAMDY,ESVDNYGISF,TAS,QQSEEVPLT,IGHJ4*01 (mouse),IGHV1-66*01 (mouse),IGKJ5*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,6PXH,True,,,,,,,,QVQLQQSGGELVKPGASVKLSCKTSGFTFSSSYISWLKQKPGQSLEWIAWIYAGTGGTEYNQKFTGKAQVTVDTSSSTAYMQFSSLTTEDSAIYYCARGGSSFAMDYWGQGTSVTVSS,QLVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIHTASNQGSGVPARFSGSGSGTDFSLNIHPVEDDDTAMYFCQQSEEVPLTFGAGTKLEIK,GFTFSSSY,IYAGTGGT,ARGGSSFAMDY,ESVDNYGISF,TAS,QQSEEVPLT,IGHJ4*01 (mouse),IGHV1-66*01 (mouse),IGKJ5*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,6PZ8,True,,,,,,,,QVQLQQSGGELVKPGASVKLSCKTSGFTFSSSYISWLKQKPGQSLEWIAWIYAGTGGTEYNQKFTGKAQVTVDTSSSTAYMQFSSLTTEDSAIYYCARGGSSFAMDYWGQGTSVTVSS,QLVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIHTASNQGSGVPARFSGSGSGTDFSLNIHPVEDDDTAMYFCQQSEEVPLTFGAGTKLEIK,GFTFSSSY,IYAGTGGT,ARGGSSFAMDY,ESVDNYGISF,TAS,QQSEEVPLT,IGHJ4*01 (mouse),IGHV1-66*01 (mouse),IGKJ5*01 (mouse),IGKV3-2*01 (mouse)
PDB,,,,,6J11,True,,,,,,,,EVQLVESGAEVVKPGASVKMSCKASGYPFTSYNIHWIKQTPGQGLEWIGAIYPGNGDTSYTQKFKVKATLTSDKSSSTAYMQLSSLTSEDSAVYFCARYGNYPSYAMDYWGQGTSVTVSS,DIVMTQSPASLTVSLGQRATISCRASKSVSASGYNYLHWYQQRPGQPPKLLIYLAFNLESGVPARFNGSGSGTDFTLNIHPVEEEDAATYYCQHSRDLPFTFGSGTKLEIK,GYPFTSYN,IYPGNGDT,ARYGNYPSYAMDY,KSVSASGYNY,LAF,QHSRDLPFT,IGHJ4*01 (mouse),IGHV1-12*01 (mouse),IGKJ4*01 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,3F12,True,,,,,,,,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGKCAGGSCYSGLLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPWTFGQGTKVEIK,GFTFSSYG,ISYDGSNK,AKDGKCAGGSCYSGLLDY,QSVSSY,DAS,QQRSNWPPWT,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
PDB,,,,,6NB5,True,,,,,,,,EVQLLESGGGLVKPGGSLRLSCEASGLTFSNVWMSWVRQAPGKGLEWVGRIKRKSEGATTDYGAPVKGRFTLSRDDSKNTVYLQMNSLKIDDTAVYYCSTLTRGGDVWSSSYYFDYWGQGALVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYDLVSWYQQHPGKSPKLMIYADIKRPSGVSHRFSGSKSGNTASLTISGLQSADEADYYCCLYAGSSTSVIFGGGTKVTGQ,GLTFSNVW,IKRKSEGATT,STLTRGGDVWSSSYYFDY,SSDVGTYDL,ADI,CLYAGSSTSVI,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
PDB,,,,,5GMQ,True,,,,,,,,RLEESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCASKQGDYYDRTSYAFDIWGQGTMVTVSS,DVELTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,GGTFSSYA,IIPILGIA,ASKQGDYYDRTSYAFDI,QSVSSSY,GAS,QQYGSSPIT,IGHJ3*02 (human),IGHV1-69*04 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,5ZXV,True,,,,,,,,GVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVALISYDISTDYYADSVKGRFTISRDNSKNTIYLQMNNLRTEDTALYYCAGNDYWGQGTLVTVSS,SVLTQSPSASGTPGQRVTISCSGSSSNIGNNYVYWYQQLPGTAPKLLIYWNDQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGAVFGGGTQLTVL,GFTFSNYA,ISYDISTD,AGNDY,SSNIGNNY,WND,AAWDDSLSGAV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV1-47*01 (human)
PDB,,,,,6C6Y,True,,,,,,,,QVQLQESGPGLVKPSETLSLTCAVSGDSISSNYWSWIRQPPGKGLEWIGRFSGSGGSTDFNPSLKSRVTISTDTSKNQFSLNLRSVTAADTAVYYCAKTYSGTFDYWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLSWYQQKPGKAPKPLIYYASSLETGVPSRFSGSRSGTDYTLTISSLQLEDFATYYCQQYNNSPYSFGQGTKVEIK,GDSISSNY,FSGSGGST,AKTYSGTFDY,QDINNY,YAS,QQYNNSPYS,IGHJ4*01 (human),IGHV4-4*08 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
PDB,,,,,6C6Z,True,,,,,,,,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSIYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGGHQGYCSGGSCYDFDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPAFGGGTKLEIK,GGTFSIYA,IIPIFGTA,AREGGHQGYCSGGSCYDFDY,QSLLHSNGYNY,LGS,MQALQTPA,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
PDB,,,,,5YY5,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVALISYDISTDYYADSVKGRFTISRDNSKNTIYLQMNNLRTEDTALYYCTNTYYWGQGTLVTVS,QPVLTQSPSASGTPGQRVTISCSGSSSNIGNNYVYWYQQLPGTAPKLLIYWNDQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGAVFGGGTQLTVL,GFTFSNYA,ISYDISTD,TNTYY,SSNIGNNY,WND,AAWDDSLSGAV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV1-47*01 (human)
PDB,,,,,5YY5,True,,,,,,,,GVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVALISYDISTDYYADSVKGRFTISRDNSKNTIYLQMNNLRTEDTALYYCTNTYYWGQGTLVT,LTQSPSASGTPGQRVTISCSGSSSNIGNNYVYWYQQLPGTAPKLLIYWNDQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGAVFGGGTQLT,GFTFSNYA,ISYDISTD,TNTYY,SSNIGNNY,WND,AAWDDSLSGAV,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*02 (human),IGLV1-47*01 (human)
PDB,,,,,5MHS,True,,,,,,,,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYAIHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNFKSQVFFKMNSLQSNDTAIYYCARKEELYGYDGYLFFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMQWYQQKPGQPPKLLIYLASNLESGVPVRFSGSGSGTDFTLNIHPVEEEDAAIYYCQHSRELPPTFGAGTKLELK,GFSLTNYA,IWSGGST,ARKEELYGYDGYLFFDV,KSVSTSGYSY,LAS,QHSRELPPT,IGHJ1*01 (mouse),IGHV2-2*03 (mouse),IGKJ5*01 (mouse),IGKV3-12*01 (mouse)
PDB,,,,,5UGY,True,,,,,,,,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYHINWVRQAPGQGLEWMGWIHPNSGDTNYAQKFQGWVTMTRDTAISTAYMEVNGLKSDDTAVYYCARGGLEPRSVDYYYYGMDVWGQGTTVTVSS,SVLTQPPSVSVAPGQTARITCGGNDIGRKSVHWNQQKPGQAPVLVVCYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVIFGGGTKLTVL,GYTFTDYH,IHPNSGDT,ARGGLEPRSVDYYYYGMDV,DIGRKS,YDS,QVWDSSSDHVI,IGHJ6*01 (human),IGHV1-2*04 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
PDB,,,,,5DO2,True,,,,,,,,DVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRDGNDYDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPRTFGGGTKLEIK,GFTFSSYT,ISSGGSYT,TRDGNDYDY,QDISNY,YTS,QQGNTLPRT,IGHJ2*01 (mouse),IGHV5-6-4*01 (mouse),IGKJ1*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,4ZPT,True,,,,,,,,EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGTYTYYPDSVKGRFTISRDNAENTLYLQMSSLRSEDTAMYYCVRDGNSMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTIICRASQDINNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGSDYSLTISNLEQEDIATYFCQQANTLPPTFGAGTKLELR,GFTFSSYA,ISSGGTYT,VRDGNSMDY,QDINNY,YTS,QQANTLPPT,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,4TVP,True,,,,,,,,QVHLQESGPGLVKPSETLSLTCNVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSS,FVSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVL,GTLVRDNY,VHDSGDT,ATTKHGRRIYGVVAFKEWFTYFYMDV,SLGSRS,NNN,HIWDSRRPTNWV,IGHJ6*04 (human),IGHV4-59*02 (human),IGLJ3*02 (human),IGLV3-21*01 (human)
PDB,,,,,4TVP,True,,,,,,,,QLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,GYRFNFYH,ISPYSGDK,AKGLLRDGSSTWLPYL,NSVCCSHKS,EDN,CSYTHNSGCV,IGHJ2*01 (human),IGHV1-18*01 (human),IGLJ1*01 (human),IGLV2-14*02 (human)
PDB,,,,,3SE9,True,,,,,,,,QVQLVQSGSGVKKPGASVRVSCWTSEDIFERTELIHWVRQAPGQGLEWIGWVKTVTGAVNFGSPDFRQRVSLTRDRDLFTAHMDIRGLTQGDTATYFCARQKFYTGGQGWYFDLWGRGTLIVVSS,EIVLTQSPGTLSLSPGETASLSCTAASYGHMTWYQKKPGQPPKLLIFATSKRASGIPDRFSGSQFGKQYTLTITRMEPEDFARYYCQQLEFFGQGTRLEIR,EDIFERTEL,VKTVTGAV,ARQKFYTGGQGWYFDL,SYGH,ATS,QQLEF,IGHJ2*01 (human),IGHV1-2*02 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,4ZPV,True,,,,,,,,EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGTYTYYPDSVKGRFTISRDNAENTLYLQMSSLRSEDTAMYYCVRDGNSMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTIICRASQDINNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGSDYSLTISNLEQEDIATYFCQQANTLPPTFGAGTKLELR,GFTFSSYA,ISSGGTYT,VRDGNSMDY,QDINNY,YTS,QQANTLPPT,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
PDB,,,,,4KRO,True,,,,,,,,QVQLQESGGGLVQPGGSLRLSCAASGRTFSSYAMGWFRQAPGKQREFVAAIRWSGGYTYYTDSVKGRFTISRDNAKTTVYLQMNSLKPEDTAVYYCAATYLSSDYSRYALPQRPLDYDYWGQGTQVTVSS,,GRTFSSYA,IRWSGGYT,AATYLSSDYSRYALPQRPLDYDY,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
PDB,,,,,4KRO,True,,,,,,,,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVS,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,GFSLTNYG,IWSGGNT,ARALTYYDYEFAY,QSIGTN,YAS,QQNNNWPTT,IGHJ3*01 (mouse),IGHV2-2*03 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,1AIF,True,,,,,,,,EVKLQESGGGLVQPGGSMKLSCVASGFTFNNYWMSWVRQSPEKGLEWVAEIRLNSDNFATHYAESVKGKFIISRDDSKSRLYLQMNSLRAEDTGIYYCVLRPLFYYAVDYWGQGTSVTVSS,DIQLTQSPAFMAASPGEKVTITCSVSSSISSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWNSYPYTFGGGTKLEIK,GFTFNNYW,IRLNSDNFAT,VLRPLFYYAVDY,SSISSSN,GTS,QQWNSYPYT,IGHJ4*01 (mouse),IGHV6-3*02 (mouse),IGKJ2*01 (mouse),IGKV4-53*01 (mouse)
PDB,,,,,1RZ8,True,,,,,,,,EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYDNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,2NY0,True,,,,,,,,EVQLVESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,GDTFIRYS,IITILDVA,AGVYEGEADEGEYDNNGFLKH,ESVSSD,GAS,QQYNNWPPRYT,IGHJ1*01 (human),IGHV1-69*02 (human),IGKJ5*01 (human),IGKV3-15*01 (human)
PDB,,,,,1E6J,True,,,,,,,,EVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYSNYNQKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCSRPVVRLGYNFDYWGQGSTLTVSS,EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPFTFGSGTKLEIK,GYTFTSYT,INPSSGYS,SRPVVRLGYNFDY,SSVSY,EIS,QQWNYPFT,IGHJ2*01 (mouse),IGHV1-4*01 (mouse),IGKJ4*01 (mouse),IGKV4-86*01 (mouse)
PDB,,,,,1IQD,True,,,,,,,,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELPVHWVRQAPGKGLEWVGSFDPESGESIYAREFQGSVTMTADTSTNIAYMELSSLRSDDTAVYYCAVPDPDAFDIWGQGTMVTVSS,IALTQSPGTLSLSPGERATLSCRASQSFSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQKYGTSAITFGQGTRLEIK,GYTLTELP,FDPESGES,AVPDPDAFDI,QSFSSSY,GAS,QKYGTSAIT,IGHJ3*02 (human),IGHV1-24*01 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
PDB,,,,,1N8Z,True,,,,,,,,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTY,IYPTNGYT,SRWGGDGFYAMDY,QDVNTA,SAS,QQHYTTPPT,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
PDB,,,,,1KEG,True,,,,,,,,EVQLQQSGTVLARPGASVKMSCKASGYSFTSFWMHWVKQRPGQGLEWIGTIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMEVSSLTNEDSAVYYCTRRSGYKYYALDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSLVPTFGGGTKLEIK,GYSFTSFW,IYPGNSDT,TRRSGYKYYALDY,QSIVHSNGNTY,KVS,FQGSLVPT,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),IGKJ1*02 (mouse),IGKV1-117*01 (mouse)
PDB,,,,,5VH3,True,,,,,,,,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,GFIFSNHW,IRSKSINSAT,SRNYYGSTYDY,QFVGSS,YAS,QQSHSWPFT,IGHJ2*01 (mouse),IGHV6-6*02 (mouse),IGKJ4*01 (mouse),IGKV5-48*01 (mouse)
PDB,,,,,1DFB,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSGISWDSSSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWYQQKPGKVPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSFGPGTKVDIK,GFTFNDYA,ISWDSSSI,VKGRDYYDSGGYFTVAFDI,QSISRW,KAS,QQYNSYS,IGHJ3*02 (human),IGHV3-9*03 (human),IGKJ3*01 (human),IGKV1-5*03 (human)
PDB,,,,,1DZB,True,,,,,,,,QVKLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARWDWYFDVWGQGTTVTVSS,DIELTQSPSSMYTSLGERVTITCKASQDINSYLRWFQQKPGKSPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTTTYYCLQHGESPYTFGGGTKLEIK,GFNIKDTY,IDPANGNT,ARWDWYFDV,QDINSY,YAT,LQHGESPYT,IGHJ1*01 (mouse),IGHV14-3*02 (mouse),IGKJ2*01 (mouse),IGKV14-126*01 (mouse)
PDB,,,,,1RZG,True,,,,,,,,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFNIAHYAQRFQGRVSITADESTSTAYMELSSLRSEDTAVFYCASPYPNDYNDYAPEEGMSWYFDLWGRGTLVTVS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWYQQKPGRAPKLLMYKASSLKSGVPSRFSGSGSGTEFTLTISSLQSDDFATYYCQQHDSSPYTFGQGTKLEIK,GGTFSNYA,IIPIFNIA,ASPYPNDYNDYAPEEGMSWYFDL,QSISNW,KAS,QQHDSSPYT,IGHJ2*01 (human),IGHV1-69*01 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
PDB,,,,,1W72,True,,,,,,,,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRGFHYYYYGMDIWGQGTTVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSRSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNMATLTISRVEAGDEADYYCQVWDSRTDHWVFGGGTDLTVL,GFTFDDYA,ISWNSGSI,ARGRGFHYYYYGMDI,NIGSRS,DDS,QVWDSRTDHWV,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ3*02 (human),IGLV3-21*02 (human)
PDB,,,,,1ZA6,True,,,,,,,,QVQLVQSGAEVVKPGASVKISCKASGYTFTDHAIHWVKQNPGQRLEWIGYFSPGNDDFKYNERFKGKATLTADTSASTAYVELSSLRSEDTAVYFCTRSLNMAYWGQGTLVTVSS,DIVMSQSPDSLAVSLGERVTLNCKSSQSLLYSGNQKNYLAWYQQKPGQSPKLLIYWASARESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYPLTFGAGTKLELK,GYTFTDHA,FSPGNDDF,TRSLNMAY,QSLLYSGNQKNY,WAS,QQYYSYPLT,IGHJ3*01 (mouse),IGHV1S53*01 (mouse),IGKJ4*01 (human),IGKV4-1*01 (human)
PDB,,,,,4JAN,True,,,,,,,,QVQLQESGPGVVKSSETLSLTCTVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGETNYSPSLKGRVSISVDTSEDQFSLRLRSVTAADTAVYFCASLPRGQLVNAYFRNWGRGSLVSVT,YELTQPPSVSVSPGQTATITCSGASTNVCWYQVKPGQSPEVVIFENYKRPSGIPDRFSGSKSGSTATLTIRGTQAIDEADYYCQVWDSFSTFVFGSGTQVTVL,GGSMGGTY,IFHTGET,ASLPRGQLVNAYFRN,STNV,ENY,QVWDSFSTFV,IGHJ2*01 (human),IGHV4-61*08 (human),IGLJ6*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jeong,B.S. et al.; Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants; MAbs 14 (1), 2021601 (2022); 2022.",10.1080/19420862.2021.2021601,,,7VYR_A,7VYR_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, D27 heavy chain","Chain B, D27 light chain",qvqlqqsgaevkkpgssvkvsckasggtfgnwsiswvrqapgqglewmggidpsrgeatyaqkfqgrvtittdeststaymelsslrsedtavyycareteqggmdvwgqgttvtvss,syeltqppsvsvapgktaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvydlfsdyvfgtgtkveik,ggtfgnws,idpsrgea,areteqggmdv,nigrks,dds,qvydlfsdyv,IGHJ6*01 (human),IGHV1-69*05 (human),IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.",10.1101/2022.01.25.477784,,,7THT_d,7THT_b,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain d, DH1042 heavy chain","Chain b, DH1042 light chain",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaylelsslrsedtavyycarymvtrdqyyydmdvwgqgttvtvs,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppptfgqgtklei,ggtfssya,iipmfgia,arymvtrdqyyydmdv,qsisny,aas,qqsyspppt,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.",10.1101/2022.01.25.477784,,,7TOW_A,7TOW_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain A, DH1058 Fab heavy chain","Chain B, DH1058 Fab Light chain",qvqlvqsgggvvqpgrslrlscaasgfnfgdfgmhwvrqapgkglewvavisyegrnknhadsvrgrftisrdnsrnmlylqmnslrrgdtavyycakenrdrnydswsasysdyyygmdvwgqgttvtvss,divmtqspsflsasvgdrvtitcrasqgidrylawyqqkpgsapklliyaastlqsgvpsrfsgsgsetdftltisslqpddfatyycqqlstyptitfgqgtrleik,gfnfgdfg,isyegrnk,akenrdrnydswsasysdyyygmdv,qgidry,aas,qqlstyptit,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,,,7TN0_M,7TN0_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, S304 Fab heavy chain","Chain N, S304 Fab light chain",evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvss,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdik,gftfssyd,igtagdt,argdssgyyyyfdy,qsigsy,aas,qqsyvsptyt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,,,7TN0_C,7TN0_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, S309 heavy chain","Chain D, S309 light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,,,7TM0_N,7TM0_O,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, S309 Fab Heavy Chain","Chain O, S309 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,ivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkve,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,,,7TM0_I,7TM0_H,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, S2L20 Fab heavy chain","Chain H, S2L20 Fab light chain",evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdfk,gftfnsyg,irydggnk,anlkdsrysgsyydy,qdirfy,das,qqydnlpft,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,,,7TLY_A,7TLY_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, S309 Fab heavy chain","Chain B, S309 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,F. et al.; Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants; Emerg Microbes Infect 11 (1), 548-551 (2022); 2022.",10.1080/22221751.2022.2032374,,,7F7E_C,7F7E_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, Heavy chain of A5-10 Fab","Chain L, Light chain of A5-10 Fab",evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaivgsggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycaksliyghydiltgayyfdywgqgtlvtvss,aqmtqspssvsasvgdrvtipcrasqgignwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfppfgqgtrleik,gftfssya,ivgsggst,aksliyghydiltgayyfdy,qgignw,aas,qqansfpp,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zhou,P. et al.; A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection; Sci Transl Med, eabi9215 (2022) In press; 2022.",10.1126/scitranslmed.abi9215,,,7SJS_H,7SJS_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, CC40.8 Fab heavy chain","Chain L, CC40.8 Fab light chain",evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvss,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvl,gftfssyv,isgtgyt,aitmapvv,alpkry,edk,ystdssgnhav,IGHJ6*01 (human),IGHV3-23*01 (human),IGLJ7*01 (human),IGLV3-10*01 (human)
GenBank,,,"Shan,S. et al.; A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants; Front Immunol 12, 766821 (2021); 2021.",10.3389/fimmu.2021.766821,,,7FAF_g,7FAF_f,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain g, P36-5D2 heavy chain","Chain f, P36-5D2 light chain",qvqlvqsgaevkkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycaggggrrlqfdyfdywgqgtlvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyngypwtfgqgtkveik,gytfttya,inagngnt,aggggrrlqfdyfdy,qsissw,das,qqyngypwt,IGHJ4*01 (human),IGHV1-3*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,7LQ7_H,7LQ7_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, CV503 heavy chain","Chain L, CV503 light chain",qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,ggtfg,iipilgta,ardgdsgsyyetlgfdy,ssdvggyny,evn,ssyagsnnlv,IGHJ4*01 (human),IGHV1-69*08 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,7LQ7_y,7LQ7_z,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain y, COVA1-16 heavy chain","Chain z, COVA1-16 light chain",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,gytftsyy,inssggst,arpprnyydrsgyyqraeyfqh,qdisny,das,qqydnpplt,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EZV_M,7EZV_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, 836H","Chain N, 836L",qvqlvqsgpevkkpgtsvrvsckasgftfstsavqwvrqargqrlewigwiavgsgktdylqkfqervtmtrdestntaymqlsslrsedtavyycaaphcsggtcydgfdiwgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvrsgyfawyqqrpgraprlliygassrataipdrfsgsgsgtdftltinrlepedfavyycqqygtspwtfgqgtkveik,gftfstsa,iavgsgkt,aaphcsggtcydgfdi,qsvrsgy,gas,qqygtspwt,IGHJ5*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EYA_H,7EYA_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-804H","Chain L, BD-804L",vqlvesggglvkpggslrlscaasgftfsnydmnwvrqapgkglewvssisssstythyadsvkgrftisrdnaknslylqmnslraedtavyycardrayrlgelsslwgddafdiwgqgtmvtvss,vwmtqspsllsastgdrvtvscrmsqdissylawyqqkpgkapelliyaaftlqsgvpsrfsgsgsgteftltisslqsedfatyycqqyysfphtfgqgtklerr,gftfsnyd,isssstyt,ardrayrlgelsslwgddafdi,qdissy,aaf,qqyysfpht,IGHJ3*02 (human),IGHV3-21*01 (human),IGKJ2*01 (human),IGKV1D-8*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EY5_H,7EY5_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-771H","Chain L, BD-771L",evqlvesgggfvkpggslrlscaasgfkfsdawmnwvrqapgkglewvgrikskadgqttdyaapvkgrfsisrddskntlflqihnlesddtavyycttgalvesryfdwftgyyfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrtsqgiynylawyqqkpgkvpklliygastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkyksapltfgggtkveik,gfkfsdaw,ikskadgqtt,ttgalvesryfdwftgyyfdy,qgiyny,gas,qkyksaplt,IGHJ4*01 (human),IGHV3-15*07 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EY5_B,7EY5_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, BD-821H","Chain C, BD-821L",elqlvqsgaevkkpgeslkisckysgnispnfwigwvrqmagkglewmgiiypddsdsryspsfqgqviisadksittallhwsslkvsdtakyycvygsgspsnwfhpwgqgtlvtvss,evvmtqspatlsvspgeratlscrasqsvrynlawyqqkpgqaprlliydastratgipgrfsgsgsgteftltisslqsedfavyycqqydnwppwtfgqgtkveik,gnispnfw,iypddsds,vygsgspsnwfhp,qsvryn,das,qqydnwppwt,IGHJ5*02 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EY4_H,7EY4_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-667 H","Chain L, BD-667 L",qvqlvesggglvkpggslrlscaasgfrfsdyymnwirqapgkglewisyigsggfatyygdsvkgrftvsrddaenslylqmnslraedtavyycargvtsysdnsgnyrtddafdiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvsrnlawyqqrpgqaprlliygastratgvaarftgsgfgteftltisglqsedfavyycqeynnwppwtfgqgtkveik,gfrfsdyy,igsggfat,argvtsysdnsgnyrtddafdi,qsvsrn,gas,qeynnwppwt,IGHJ3*02 (human),IGHV3-11*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EY0_H,7EY0_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-813H","Chain L, BD-813L",qvqlvesggglvqpggslrlscaasefivsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyfcarflptydyfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrtsqsistylhwyqqkpgkapklliyaasslhsgvpsrfsgsgsgthfvltinglqpedfatyycqhtdttpltffgggtkveik,efivsany,iysggst,arflptydyfdy,qsisty,aas,qhtdttpltf,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EY0_A,7EY0_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, BD-744H","Chain B, BD-744L",evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgaswnsgtigyadsvkgrfiiirdnaknslylqmnslrsedtasyycakdfsrdgdafdiwgqgtmvtvss,yvlpqppsvsvapgktaritcggnniehksvhwyqqkprqapvvvmyydsdrpsgiperfsgsnsgntatliisrveagdeaeyycqvwdrssdqpvfgggtkltvl,gftfddya,aswnsgti,akdfsrdgdafdi,niehks,yds,qvwdrssdqpv,IGHJ3*02 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity 54 (10), 2385-2398 (2021); 2021.",10.1016/j.immuni.2021.08.025,,,7E5O_H,7E5O_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, NT-193 Heavy chain","Chain L, NT-193 Light chain",evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvss,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleik,ggsfsgyy,inhsgst,argwdldyyygmdv,qgigny,aas,lqhgflpwt,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ1*01 (human),IGKV1-17*03 (human)
GenBank,,,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,,,7F63_H,7F63_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, RBD-chAb45, Heavy chain","Chain L, RBD-chAb45, Light chain",evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvss,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleik,gytfteyt,nnpnnddt,ardgypyyyaldf,qnvgtn,sas,qqynnypwt,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ1*01 (mouse),IGKV6-15*01 (mouse)
GenBank,,,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,,,7F62_H,7F62_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, RBD-chAb-25, Heavy chain","Chain L, RBD-chAb-25, Light chain",evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsa,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleik,gftfssyt,issggtyt,anfgnyeeiay,ssvsssy,sts,hqyhrspyt,IGHJ3*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ2*01 (mouse),IGKV4-74*01 (mouse)
GenBank,,,"Zhu,L. et al.; Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2; Natl Sci Rev 8 (3), nwaa297 (2020); 2021.",10.1093/nsr/nwaa297,,,7CYP_I,7CYP_H,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, Heavy chain of HB27","Chain H, Light chain of HB27",vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveil,gftftnyg,issggsyt,arfryggggtvdy,esvdnygisf,aas,qqskevpri,IGHJ4*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,,,7DX4_H,7DX4_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Heavy chain of FC08 Fab","Chain L, Light chain of FC08 Fab",llqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipiigianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysgygaayyfdywgqgtlvtvss,svltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,ggtfssya,iipiigia,arergysgygaayyfdy,ssnigagyd,gns,qsydsslsgsv,IGHJ4*01 (human),IGHV1-69*10 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,,,7D4G_N,7D4G_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, Heavy chain of FC05 Fab","Chain G, Light chain of FC05 Fab",evqlleqsgaevkkpgasvrvsckvsgytlpevamhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatttpfsssywfdpwgqgtlvtvss,qsvltqapsvsgapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,gytlpeva,fdpedget,atttpfsssywfdp,ssnignny,dnn,gtwdsslsavv,IGHJ5*02 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,,,7JMP_H,7JMP_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVA2-39 heavy chain","Chain L, COVA2-39 light chain",qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvss,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,gftvssny,iytggtt,arahvdtamvesgafdi,ssdvgsynl,evt,csyagsstwv,IGHJ3*02 (human),IGHV3-53*02 (human),IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,,,7JMO_H,7JMO_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVA2-04 heavy chain","Chain L, COVA2-04 light chain",qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvss,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdik,gftvssny,iysggst,ardleraggmdv,qsvsssy,gas,qqygslyt,IGHJ6*01 (human),IGHV3-53*02 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.",N/A,,,7TP4_H,7TP4_L,SARS-CoV,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain H, K398.22 heavy chain","Chain L, K398.22 light chain",evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvss,qaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvl,gftfssne,isesgftt,trvsifgqfivatyfdy,ssdiggyny,avs,csyagtvl,IGHJ4*01 (human),IGHV3-48*03 (human),IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.",N/A,,,7TP3_H,7TP3_L,SARS-CoV,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain H, K288.2 heavy chain","Chain L, K288.2 light chain",evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvss,divmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveik,gftfssye,isesgatt,trpqsvtvfgvaatsyeafdf,qsvssy,gss,qqytnwplt,IGHJ5*01 (human),IGHV3-48*03 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,,,7Q0A_Y,7Q0A_Z,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain Y, FI3A fab heavy chain","Chain Z, FI3A fab Light chain",evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvs,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,gftvssny,iysggst,ardhvrpgmni,qdisny,das,qqydnlpvt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,,,7PR0_G,7PR0_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain G, FD-5D Fab heavy chain","Chain F, FD-5D Fab light chain",evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaspggitaagtsvlfgyygmdvwgqgttvtvss,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitwtfgqgtkvdik,gftfssys,isssssti,aspggitaagtsvlfgyygmdv,qsllhsngyny,lgs,mqalqtpitwt,IGHJ6*01 (human),IGHV3-48*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,,,7PQZ_A,7PQZ_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain A, FD-11A Fab heavy chain","Chain B, FD-11A Fab light chain",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfyvvfgggtkltvl,gftfssyg,iwydgsnk,akgpdiltgyynyyyygmdv,ssnigagyd,gns,qsydsslsgfyvv,IGHJ6*01 (human),IGHV3-33*03 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,,,7PQZ_H,7PQZ_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvss,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,gftvssny,iysggst,ardhvrpgmni,qdisny,das,qqydnlpvt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Park,Y.J. et al.; Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry; Science 375 (6579), 449-454 (2022); 2022.",10.1126/science.abm8143,,,7TAT_F,7TAT_G,not determined,Homo sapiens (human),2022-03-15,"Chain F, S2K146 Fab heavy chain","Chain G, S2K146 Fab light chain",qvqlvesggvvvqpggslrlscaasgftfhdhtmhwvrqapgkglewvslitwnggtihysdsvkgrftisrdnsknslylqmnslrtedtalyycakdlgrggwylpsdawgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgssanigsntvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,gftfhdht,itwnggti,akdlgrggwylpsda,sanigsnt,snn,aawddslkgv,IGHJ5*01 (human),IGHV3-43*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,,,7LM9_H,7LM9_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CV38-142 Fab heavy chain","Chain L, CV38-142 Fab light chain",evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveik,gysftsyw,iypgesdt,arirgvyssgwiggdy,qsissy,aas,qqsystprqwt,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,,,7LM8_H,7LM8_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, COVA1-16 Fab heavy chain","Chain L, COVA1-16 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,gytftsyy,inssggst,arpprnyydrsgyyqraeyfqh,qdisny,das,qqydnpplt,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Liu,H. et al.; Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity; bioRxiv (2020); 2020.",10.1101/2020.08.02.233536,,,7JMX_H,7JMX_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, COVA1-16 heavy chain","Chain L, COVA1-16 light chain",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,gytftsyy,inssggst,arpprnyydrsgyyqraeyfqh,qdisny,das,qqydnpplt,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Burnett,D.L. et al.; Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability; Immunity 54 (12), 2908-2921 (2021); 2022.",10.1016/j.immuni.2021.10.019,,,7MSQ_H,7MSQ_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, AB-3467 Fab Heavy Chain","Chain L, AB-3467 Fab Light Chain",qvqlqesgpglvkpsetlsltctvsggsissyhwnwirqppgkglewigyiyysgntnynpslksrvsistdtsknqfslklssvtaadtavyycvremrrgysgydywdlyafdiwgqgtmvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphtfgqgtkleik,ggsissyh,iyysgnt,vremrrgysgydywdlyafdi,qgissy,aas,qqlnsypht,IGHJ3*02 (human),IGHV4-59*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q0I_A,7Q0I_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Beta-43 heavy chain","Chain B, Beta-43 Fab light chain",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnnfyadsvkgrftisrdnfkntlylqmnslraedtavyycarsycsggfcfgyyygldvwgqgttvtvss,syeltqppsvsvapgktatitcggnnigtksvhwyqqkpgqapvlviyynsdrpsgiperfsgsnsgntvtltisrveagdeadyycqvwdsgsdhyvfgtgtkvtvv,gftfssyg,iwydgsnn,arsycsggfcfgyyygldv,nigtks,yns,qvwdsgsdhyv,IGHJ6*01 (human),IGHV3-33*01 (human),IGLJ1*01 (human),IGLV3-21*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q0H_A,7Q0H_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Beta-50 Fab heavy chain","Chain B, Beta-50 Fab light chain",evqlvqsgaevkkpgssvkvsckasrgtfntyvftwvrqapgqglewmggiipffgtadyaqkfqgrvtitaddststaymelsslrsedtavyycsrlsqwdllpmwgqgtlvtvss,divmtqspgtlslspgeratlscrasqsftssylawyqqkpgqaprlliygassratgipdrfsgtgsgtdftltisrlepedfavyycqqygtsprmytfgqgtkvdik,rgtfntyv,iipffgta,srlsqwdllpm,qsftssy,gas,qqygtsprmyt,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q0H_H,7Q0H_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Beta-54 Fab heavy chain","Chain L, Beta-54 Fab light chain",qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,ggsitssnhy,myysgst,arqigpkrpsqvadwfdp,qgissy,aas,qqlnsyplt,IGHJ5*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q0G_A,7Q0G_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Beta-49 Fab heavy chain","Chain B, Beta-49 Fab light chain",evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvss,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveik,ggtfsssv,iiplfgsa,akvsqwalilf,qsvsssy,gas,qqygtspswt,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q0G_H,7Q0G_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvss,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,gftvssny,iysggst,ardhvrpgmni,qdisny,das,qqydnlpvt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q9P_J,7Q9P_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Beta-06 heavy chain","Chain K, Beta-06 light chain",evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvss,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletk,ggsisssshy,iyysesa,arvteprwtscyfdy,qsvtsy,das,qlrsnwppit,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q9M_E,7Q9M_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, Beta-53 fab heavy chain","Chain F, Beta-53 fab light chain",qvqlvqsgaevkkpgeslrisckgsghnspsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslqasdtaiyycarhvvalthlypdywgqgtlvtvss,diqmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwstwtfgqgtkvdik,ghnspsyw,idpsdsyt,arhvvalthlypdy,qsvsst,gas,qqynnwstwt,IGHJ4*01 (human),IGHV5-10-1*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q9K_D,7Q9K_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, Beta-32 heavy chain","Chain E, Beta-32 light chain",evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittgymelsslrsddtalyycarvgahdyydssdnwfdpwgqgtlvtvfs,diqmtqspssvsasvgdrltitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkveik,gytftgyy,inpnsggt,arvgahdyydssdnwfdp,qgissw,aas,qqansfpwt,IGHJ5*02 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q9J_J,7Q9J_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Beta-26 heavy chain","Chain K, Beta-26 light chain",qvqlqqsgpglvkpsetlsltctvsgasisnyywswirqppgkglewvgyiyytgstnhnpslksrvtisldtsknqfslrlssvtaadtavyycaraycsggscfdtfdiwgqgtmvtvss,syeltqppsvsvapgqtaritcggnnigsksvhwfqqkpgqapvlvvyddsdrpsgiperfsgsnsgntasltisrveagdeadyycqvwdsasdsgvfgtgtkltvp,gasisnyy,iyytgst,araycsggscfdtfdi,nigsks,dds,qvwdsasdsgv,IGHJ3*02 (human),IGHV4-59*01 (human),IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7Q9G_E,7Q9G_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, COVOX-222 heavy chain","Chain F, COVOX-222 light chain",evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,gltvssny,iysggst,argegspgnwfdp,qsvpssy,gas,qhydtspr,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS7_H,7PS7_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Beta-40 heavy chain","Chain B, Beta-40 Fab light chain",qvqlvesgpgqvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgsayynpslksrvtisvdtsknqfslklnsvtaadtavfycarhaapspgdnwfdpwgqgtlvtvss,qsvltqppsvsvspgqtaritcsgdalstqngnwyqqkpgqapvmvickdserpsgiperfsgsrsgttvtltisgvqaedeadyhcqsadnrahvvfgggtkltvl,ggsissssyy,iyysgsa,arhaapspgdnwfdp,alstqn,kds,qsadnrahvv,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS6_C,7PS6_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, Beta-44 Fab heavy chain","Chain D, Beta-44 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwispyngnthyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvss,qsvvtqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyagskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,gytftsyg,ispyngnt,ardgellgwfdp,ssdvgsynl,ags,csyagsstwv,IGHJ5*02 (human),IGHV1-18*01 (human),IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS5_H,7PS5_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Beta-47 Fab heavy chain","Chain L, Beta-47 Fab light chain",qvqlvesgpemkkpgtsvkvsckasgftfitsavqwvrqargqrlewmgwiavgsgntnyaqkfqdrvtinrdmststaymelsslrsedtavyycaaphcnrtschdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsrnylawyqqkpgqvprlliygassratgipdrfrgsgsgtdftltinrlesedfavyycqqygsslftfgpgtkvdik,gftfitsa,iavgsgnt,aaphcnrtschdgfdi,qsvsrny,gas,qqygsslft,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS4_B,7PS4_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Beta-38 Fab heavy chain","Chain C, Beta-38 Fab light chain",evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsgtryspsfqgqvtisadksirtaylqwsslkasdsamyycarsrvgatggyydyymdvwgqgttvtvss,qsvltqppsasgtpgqrvtiscsgsssnlggntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgtgtkvtvl,gysftnyw,iypgdsgt,arsrvgatggyydyymdv,ssnlggnt,snn,aawddslngpv,IGHJ6*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS2_A,7PS2_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Beta-29 Fab heavy chain","Chain B, Beta-29 Fab light chain",evqlvesgggvvqpgrslrlscaasgftfsnygmhrvrqapgkglewvalisyeesnryygdsvrgrftisrdnskntlylqmnslrpedtavyycakdqgpatvmvtairgamdvwgqgttvtvss,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyfgspsitfgqgtrleik,gftfsnyg,isyeesnr,akdqgpatvmvtairgamdv,qsvlyssnnkny,was,qqyfgspsit,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ5*01 (human),IGKV4-1*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS1_A,7PS1_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Beta-27 Fab heavy chain","Chain B, Beta-27 Fab light chain",evqllesggglvqpggslrlscaasgltvrsnymnwvrqapgkglewvsliysggstfyadsvkgrftisrhdskntlylqmnslraedtavyycardlvvygmdvwgqgttvtvss,diqmtqspgtlslspgeratlscrasqsvsssslawyqqkhgqaprlliygtssratgipdrfsgsgsgtdftltisglepedfavyycqqygssplfgggtkveik,gltvrsny,iysggst,ardlvvygmdv,qsvssss,gts,qqygsspl,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PS0_B,7PS0_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Beta-24 heavy chain","Chain C, Beta-24 light chain",qvqlvqsgpglvkpsqtlsltcsvsdgsisssdyywswirqppgkglewigyiyytgstyynpslksrvsisvdrsknqfslklssvtaadtavyycarlvvpspkgswfdpwgqgtlvtvss,syeltqpasvsgspgqsitisctgtsidvgnynlaswyqqhpgkapkliiyegsrrpsgvsnrfsgaksgntasltisglqaedeadyyccsyvgsstyvfgsgtkvtvl,dgsisssdyy,iyytgst,arlvvpspkgswfdp,sidvgnynl,egs,csyvgsstyv,IGHJ5*02 (human),IGHV4-30-4*01 (human),IGLJ1*01 (human),IGLV2-23*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PRZ_H,7PRZ_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Beta-22 Fab heavy chain","Chain L, Beta-22 Fab light chain",evqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslktedtavyycakdssaaipyyyygmdvwgqgttvtvss,aiqmtqspdslavslgeratinckssqsilynsnnktylawyqqkpgqppkllifwastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiplifgpgtkvdik,gftfsnyg,isydgshk,akdssaaipyyyygmdv,qsilynsnnkty,was,qqyysipli,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PRY_C,7PRY_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, Beta-6 Fab heavy chain","Chain D, Beta-6 Fab light chain",evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvss,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletk,ggsisssshy,iyysesa,arvteprwtscyfdy,qsvtsy,das,qlrsnwppit,IGHJ4*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,,,7PRY_F,7PRY_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain F, COVOX-45 Fab heavy chain","Chain G, COVOX-45 Fab light chain",qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdik,gftfstya,lsydgsnk,akggsyayyyymdv,qdisny,das,qqydnlplt,IGHJ6*04 (human),IGHV3-30-3*02 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Afonine,P.V. et al.; Real-space refinement in PHENIX for cryo-EM and crystallography; Acta Crystallogr., Sect. D: Biol. Crystallogr. 74, 531 (2018); 2021.",N/A,,,7Q6E_J,7Q6E_K,not determined,Homo sapiens (human),2022-03-15,"Chain J, Beta-49 heavy chain","Chain K, Beta-49 light chain",evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvss,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveik,ggtfsssv,iiplfgsa,akvsqwalilf,qsvsssy,gas,qqygtspswt,IGHJ1*01 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhou,P. et al.; A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes; bioRxiv (2021); 2021.",10.1101/2021.03.30.437769,,,7NAB_A,7NAB_B,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain A, CV3-25 Fab Heavy Chain","Chain B, CV3-25 Fab Light Chain",evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvss,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleik,gytftryw,iypgdsdt,arlpqycsngvcqrwfdp,qgissw,aas,qqgnsfpyt,IGHJ5*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-12*01 (human)
GenBank,,,"Westendorf,K. et al.; LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants; bioRxiv (2022); 2021.",10.1101/2021.04.30.442182,,,7MMO_D,7MMO_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, LY-CoV1404 Fab heavy chain","Chain E, LY-CoV1404 Fab light chain",xitlkesgptlvkptqtltltctfsgfslsisgvgvgwlrqppgkalewlaliywdddkryspslksrltiskdtsknqvvlkmtnidpvdtatyycahhsistifdhwgqgtlvtvss,qsaltqpasvsgspgqsitisctatssdvgdynyvswyqqhpgkapklmifevsdrpsgisnrfsgsksgntasltisglqaedeadyycssyttssavfgggtkltvl,gfslsisgvg,iywdddk,ahhsistifdh,ssdvgdyny,evs,ssyttssav,IGHJ1*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,,,7N4M_H,7N4M_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, WRAIR-2151 antibody Fab heavy chain","Chain L, WRAIR-2151 antibody Fab light chain",qvqlqesgprlvkpsetlsltctvsggsisgsnyfwgwirqppgkglewigtiyyggstyynpslksrvtisvdtsenqfslklssvtaadtavyycanlawlrgyfdywgqgtlvtvss,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsvsltisglktedeadyycqsydssnwvfgggtkltvl,ggsisgsnyf,iyyggst,anlawlrgyfdy,sgsiasny,edn,qsydssnwv,IGHJ4*01 (human),IGHV4-39*01 (human),IGLJ3*02 (human),IGLV6-57*03 (human)
GenBank,,,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,,,7N4L_H,7N4L_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, WRAIR-2125 antibody Fab heavy chain","Chain L, WRAIR-2125 antibody Fab light chain",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrpedtavyycakdspyyydssgyypgyfqdwgqgslvtvss,diqmtqspsslsasigdrvtitcrasqtisdylnwyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitprtfgqgtkveik,gftfssyg,isydgsnk,akdspyyydssgyypgyfqd,qtisdy,aas,qqsyitprt,IGHJ1*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,,,7N4J_H,7N4J_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, WRAIR-2173 antibody Fab heavy chain","Chain L, WRAIR-2173 antibody Fab light chain",qvqlqesgpglvkpsetlsltcsvsgdsisssdyswgwirqppgkglewigtiyyikntyynpslrsrvtlsvdtsknlfslklssvtaadtavyycarerppfdvvvvpaarpynwfdpwglgtlvivss,qsvlmqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgskvfgggtkltvl,gdsisssdys,iyyiknt,arerppfdvvvvpaarpynwfdp,ssnigagyd,gnn,qsydsslsgskv,IGHJ5*02 (human),IGHV4-39*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,,,7N4I_H,7N4I_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, WRAIR-2057 Antibody Fab Heavy Chain","Chain L, WRAIR-2057 Antibody Fab Light Chain",evqlvqsgaevkkpgeslkisckgsgysfisywiawvrqmpgkglewmgiiypgdsdttyspsfqgqvtisadksistaylqwsslkasdtaiyycarllyysdsspldswgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqshstprtfgpgtkvdik,gysfisyw,iypgdsdt,arllyysdssplds,qsisty,aas,qqshstprt,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,,,7CHS_H,7CHS_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, antibody P22A-1D1 heavy chain","Chain L, antibody P22A-1D1 light chain",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveik,gftvssny,iysggst,ardrdyygmdv,qgissy,aas,lhlnsyrt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,,,7CHP_H,7CHP_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, antibody P5A-3C8 heavy chain","Chain L, antibody P5A-3C8 light chain",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvss,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleik,gftvssny,iysggst,ardlqehgmdv,qgissy,aas,qhlnsyppgyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,,,7CHO_B,7CHO_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain B, antibody P5A-1D2 heavy chain","Chain C, antibody P5A-1D2 light chain",evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvl,gfivssny,iysggst,aralqvgatsdyfdy,ssnigagyd,gns,qscdsslsvvv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"VanBlargan,L. et al.; A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope; bioRxiv (2021); 2021.",10.1101/2021.04.26.441501,,,7MKL_H,7MKL_L,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain H, SARS2-38 Fv heavy chain","Chain L, SARS2-38 Fv light chain",qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttlt,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklel,gfsltryg,iwadgst,ardgrgyddy,stvsf,dts,qqwntyplt,IGHJ2*01 (mouse),IGHV2-9*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
GenBank,,,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,,,7CDJ_H,7CDJ_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, antibody P2C-1A3 heavy chain","Chain L, antibody P2C-1A3 light chain",qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,gftfsdyy,isssgsti,ardfshqqlvps,qgissy,aas,qqlnsyplt,IGHJ5*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,,,7CDI_H,7CDI_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, antibody P2C-1F11 heavy chain","Chain L, antibody P2C-1F11 light chain",evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleik,gitvssny,iysggst,ardlvvygmdv,qsvsssy,gas,qqygsspt,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,,,6ZDG_F,6ZDG_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain F, EY6A heavy chain","Chain G, EY6A light chain",evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveik,aftfssyd,isydgsnk,akdggklwvyyfdy,qsissy,aas,qqsystlalt,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wang,P. et al.; A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses; bioRxiv (2021); 2021.",10.1101/2021.10.13.464307,,,7N5H_J,7N5H_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, 2-36 Fab heavy chain","Chain K, 2-36 Fab light chain",qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,ggsvsssnyy,myysgst,arevyyydrsgyyasdgfdi,qsvsssy,gas,qqygsspqt,IGHJ3*02 (human),IGHV4-59*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,,,7EAM_C,7EAM_D,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain C, the heavy chain of Fab fragment of antibody 7D6","Chain D, the light chain of Fab fragment of antibody 7D6",evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvss,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevk,gfnikdty,idpgdgdt,trfydyvdygmdy,gnihny,nak,qhfwstppwt,IGHJ4*01 (mouse),IGHV14-1*01 (mouse),IGKJ1*01 (mouse),IGKV12-41*01 (mouse)
GenBank,,,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,,,7EAN_H,7EAN_L,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain H, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6","Chain L, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6",evqlqqsgaelvkpgasvklscttsgfniidtymhwvkqrpeeglewiggidpvngnseydpkfqdkatitadtssntaylhlsrltsedtavyycasahyygssssfpywgqgtdlvtvsa,divmtqsqkfmstsvgdrvsvtckasqnvgthvawyqqkpgqspkaliysasyrysgvpdrftgsgvgtdftltitnvqsedlaeyfcqqynsyftfgsgtkleik,gfniidty,idpvngns,asahyygssssfpy,qnvgth,sas,qqynsyft,IGHJ3*01 (mouse),IGHV14-3*02 (mouse),IGKJ4*01 (mouse),IGKV6-15*01 (mouse)
GenBank,,,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.",10.1007/s13238-021-00871-6,,,7V2A_I,7V2A_H,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain I, The heavy chain of XG014","Chain H, The light chain of XG014 Fab",evqlvqsgaevkkpgeslkisckgsgysfsnywigwvrhmpgkglewmgiiypgdsdtryspsfqgqvtisvdtsistaylqwsslkasdtamyyctrhqygynygyfyyyidvwgkgttvtvss,qsvltqppsvsaapgqkvtiscsgsssnignnpvswyrqvpgtapklliydnnkrpsgipdrfsgsksgasatlgitglqtgdeadyycgtwhtslssgvfgggtkltvl,gysfsnyw,iypgdsdt,trhqygynygyfyyyidv,ssnignnp,dnn,gtwhtslssgv,IGHJ6*04 (human),IGHV5-51*01 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.",10.1007/s13238-021-00871-6,,,7V26_e,7V26_f,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain e, XG005 Heavy chain","Chain f, XG005 Light Chain",qvtlresgptlvkpkqtltltctfsgfslstpgggvgwirqppgkalewlaliywdddkryspslkssltitkdtsknqvvltmtnmdpvdtatyycarltaadtifdcwgqgtlvtvss,qsaltqpasvsgspglsitisctatssdvgaynyvswyqqhpgqapklmiydvskrpsgvsnrfsgsksantasltisglqaedeadyycssytttsvvfgggtkltvl,gfslstpggg,iywdddk,arltaadtifdc,ssdvgayny,dvs,ssytttsvv,IGHJ5*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.",10.1016/j.celrep.2021.109814,,,7P40_I,7P40_H,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, Variable Heavy Chain P5C3 (VH)","Chain H, Variable Light Chain P5C3 (VL)",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,gftftssa,ivvgsgnt,aapncsggscydgfdl,qsvrssy,gas,qqygsspwt,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shi,R. et al.; A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2; Unpublished; 2021.",N/A,,,7D6I_B,7D6I_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Heavy chain of GH12-Fab","Chain C, Light chain of GH12-Fab",evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyyctragwvrgafdiwgqgtmvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvl,gftfssyw,ikqdgsek,tragwvrgafdi,sgsiasny,edn,qsydssnlwv,IGHJ3*02 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,,,7S0E_H,7S0E_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, N-612-004 Fab heavy chain","Chain L, N-612-004 Light Chain",evqlvesggglvqpggslrlscaasgftfssyymhwvrqapgkglewvsaisgsggytyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdhaydwgfdvwgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqwadwpltfgqgtkveik,gftfssyy,isgsggyt,ardrdhaydwgfdv,qdisny,das,qqwadwplt,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,,,7S0D_O,7S0D_P,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain O, N-612-014 Fab Heavy Chain","Chain P, N-612-014 Light Chain",evqlvesggglvqpggslrlscaasgftfssyamtwvrqapgkglewvsyisgsgggtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrwasgwlafdvwgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqayaypltfgqgtkveik,gftfssya,isgsgggt,ardrwasgwlafdv,qdisny,das,qqayayplt,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,,,7S0C_M,7S0C_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, N-612-017 Fab Heavy Chain","Chain N, N-612-017 Light Chain",evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaiwgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycargrdlaaftktafdvwgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdalpwtfgqgtkveik,gftfssya,iwgsgsnt,argrdlaaftktafdv,qdisny,das,qqhdalpwt,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,,,7S0B_C,7S0B_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, N-612-056 Fab Heavy Chain","Chain D, N-612-056 Light Chain",evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvslisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlwgsgffafdvwgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqdagtpltfgqgtkveik,gftfssya,isgsggst,ardlwgsgffafdv,qdisny,das,qqdagtplt,IGHJ5*01 (human),IGHV3-23*04 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,,,7K9K_H,7K9K_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Chain H, 2H04 heavy chain","Chain L, 2H04 light chain",evqlqqsgaelvkpgasvkmsckasgytftsywitwvkqrpgqglewigdiypgsgstkynekfrseatltvdtssttaymqlssltsedsavyycarwdfygsrtfdywgqgttltvss,divltqspailsvspgervsfscrasqnigtiihwyqqrtngsprllikyasesvsgipsrfsgsgsgtdftlsinsvesediadyycqqssswpltfgagtklel,gytftsyw,iypgsgst,arwdfygsrtfdy,qnigti,yas,qqssswplt,IGHJ2*01 (mouse),IGHV1-55*01 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
GenBank,,,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,,,7K9I_H,7K9I_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Chain H, 2B04 heavy chain","Chain L, 2B04 light chain",qvqlkqsgpglvapsqslsitctvsgfslinyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarkdyygryygmdywgqgtsvtvs,qavvtqesalttspgetvtltcrsstgavttsnyanwvqekpdhlftgliggtnnrapgvparfsgsligdkaaltitgaqtedeaiyfcalwynnhwvfgggtkltvl,gfslinya,iwtgggt,arkdyygryygmdy,tgavttsny,gtn,alwynnhwv,IGHJ4*01 (mouse),IGHV2-9-1*01 (mouse),IGLJ1*01 (mouse),IGLV1*01 (mouse)
GenBank,,,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,,,7RKV_G,7RKV_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain G, C118 Fab Heavy Chain","Chain L, C118 Fab Light Chain",qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvss,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvl,gftfsnya,isydgsnk,asgytgydyfvrgdyygldv,sghssya,lntdgsh,qtwgtgilv,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,,,7RKU_J,7RKU_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, C022 Antibody Fab Heavy Chain","Chain L, C022 Antibody Fab Light Chain",qvqlqesgpglvkpsetlsvtctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaayydrsgyyfieyfqhwgqgtlvtvss,diqmtqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynnyrytfgqgtkleik,ggsisssryy,iyysgst,arhaaayydrsgyyfieyfqh,qsissw,kas,qqynnyryt,IGHJ1*01 (human),IGHV4-39*01 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,,,7RKS_I,7RKS_M,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, C118 Antibody Fab Heavy Chain","Chain M, C118 Antibody Fab Light Chain",qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvss,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvl,gftfsnya,isydgsnk,asgytgydyfvrgdyygldv,sghssya,lntdgsh,qtwgtgilv,IGHJ6*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Chen,S.D. et al.; Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617; Unpublished; 2021.",N/A,,,7E3O_H,7E3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, nCoV617 Heigh Chain","Chain L, nCoV617 Light Chain",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyadsvkgrftisrdnskntlylqmnslraedtavyycarglglrflewpissywgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkllifsnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,gftfssya,isydgsn,arglglrflewpissy,ssnigsnt,snn,aawddslkgv,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,,,7E3L_D,7E3L_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, 58G6 heavy chain","Chain E, 58G6 light chain",qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnyaqkfqervtltrdmstrtaymelsslrsedtavyycaapncnsttchdgfdiwgqgtvvtvss,eivltqspgtlslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfavyycqqydnspwtfgqgtkveik,gftfsssa,ivvgsgnt,aapncnsttchdgfdi,qsvrssy,gas,qqydnspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,,,7E3K_H,7E3K_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, 13G9 heavy chain","Chain L, 13G9 light chain",qmqlvqsgpevkkpgtsvkvsckasgftfsgsavqwvrqargqrlewigwivvgsgntnyaqrfqervtitrdmststaymelsslrsedtavyycaapycsstscrdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveik,gftfsgsa,ivvgsgnt,aapycsstscrdgfdi,qsvrssy,gas,qqygrspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Cerutti,G. et al.; Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain; bioRxiv (2021); 2021.",10.1101/2021.06.29.450397,,,7RW2_I,7RW2_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain I, 5-7 heavy chain","Chain K, 5-7 light chain",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvss,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdik,gytftsyy,inpsggst,ardrephsdssgywdslkyyyyyaldv,qgissy,aas,qqlntypft,IGHJ6*01 (human),IGHV1-46*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,,,7E3C_B,7E3C_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Heavy chain of Ab1","Chain C, Light chain of Ab1",evllvesggglvqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyadsvkgrctisrhnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppltfgggsrveik,gltvssny,iysggst,ardldyygmdv,qgisny,aas,qqlnsypplt,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,,,7E3B_B,7E3B_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Heavy Chain of Ab5","Chain C, Light Chain of Ab5",qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwtdgfdiwgqgtmvtvss,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnipftfglgtkvdik,ggsissyy,iyysgst,ardrgyssgwtdgfdi,qditny,das,qqydnipft,IGHJ3*02 (human),IGHV4-59*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,,,7E39_C,7E39_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, Heavy Chain of Ab4","Chain B, Light Chain of Ab4",qvqlvesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaretvsygmdvwgqgttvtvss,niqmtqspsamsasvgdrvtitcrarqgisnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgseteftltisslqpedfatyyclqhnsypytfgqgtkleik,gfifssyg,iwfdgsnk,aretvsygmdv,qgisny,aas,lqhnsypyt,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ2*01 (human),IGKV1D-17*01 (human)
GenBank,,,"Tortorici,M.A. et al.; Broad sarbecovirus neutralization by a human monoclonal antibody; Nature 597 (7874), 103-108 (2021); 2021.",10.1038/s41586-021-03817-4,,,7RAL_H,7RAL_L,not determined,Homo sapiens (human),2022-03-15,"Chain H, S2X259 Fab heavy chain","Chain L, S2X259 Fab light chain",qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,ggifntyt,iilmsgma,argfngnyygwgdddafdi,nsnigagyd,gns,qsydsslsgpnwv,IGHJ5*01 (human),IGHV1-69*02 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7R8O_O,7R8O_P,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain O, C548 Fab Heavy Chain","Chain P, C548 Fab Light Chain",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarreaygprdyyyyygmdvwgqgttvtvss,qsaltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadqgsgsnfvgvfgggtkltvg,ggtfssya,iipifgta,arreaygprdyyyyygmdv,sgysnyk,vgtggivg,gadqgsgsnfvgv,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7R8N_O,7R8N_P,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain O, C051 Fab Heavy Chain","Chain P, C051 Fab Light Chain",evqlvesgggliqaggslrlscaasgfgvrnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycaregdvegfsdlwsgysrdryyfdywgqgtlvtvss,qsvltqpasvsgspgqsitfsctgtssdvggynyvswyqqypgkapklliydvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssftssntrvfgtgtkvtvl,gfgvrnny,iysggtt,aregdvegfsdlwsgysrdryyfdy,ssdvggyny,dvt,ssftssntrv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7R8M_H,7R8M_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,gysftsyw,iypgdsdt,argvavdwyfdl,ssnigagyd,gns,qsydsslsalyv,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7R8L_C,7R8L_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, CR3022 Fab heavy chain","Chain D, CR3022 Fab light chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7R8L_H,7R8L_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",vqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveik,gitvssny,myaggst,ardlyssggtdi,qsigssy,gas,qqygsspgt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7N3I_H,7N3I_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C098 Fab heavy chain","Chain L, C098 Fab light chain",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlyssggtdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,gftvssny,iysggst,ardlyssggtdi,qsvsssy,gas,qqygsspgt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7N3E_H,7N3E_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,gysftsyw,iypgdsdt,argvavdwyfdl,ssnigagyd,gns,qsydsslsalyv,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7N3H_H,7N3H_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveik,gitvssny,myaggst,ardlyssggtdi,qsigssy,gas,qqygsspgt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,,,7N3F_H,7N3F_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C080 Fab Heavy Chain","Chain L, C080 Fab Light Chain",evqlvqsgaevkkpgeslnisckasgysftiywiawvrqlpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwrslkasdsavyycargvavdwyfdlwgrgtlvtvss,qsvltqppsvsgapgqrvtiscagsssnigagfdvywyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssgsvlsdlyvfgtgtkvtvl,gysftiyw,iypgdsdt,argvavdwyfdl,ssnigagfd,gnn,qssgsvlsdlyv,IGHJ2*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,,,7MM0_H,7MM0_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, B1-182.1 Fab heavy chain","Chain L, B1-182.1 Fab light chain",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,gftftssa,ivvgsgnt,aapycsggscfdgfdi,qsvsssy,gas,qqygnspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,,,7LRT_D,7LRT_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, antibody A23-58.1 heavy chain","Chain E, antibody A23-58.1 light chain",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,gftftssa,ivvgsgnt,aapncsnvvcydgfdi,qsvsssy,sas,qqygtspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,,,7M42_D,7M42_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, REGN10985 antibody Fab fragment heavy chain","Chain C, REGN10985 antibody Fab fragment light chain",evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,ssnigagyd,gns,qsydsslsgsyv,IGHJ6*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,,,7M42_B,7M42_A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, REGN10989 antibody Fab fragment heavy chain","Chain A, REGN10989 antibody Fab fragment light chain",qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,ssdvgtyny,dvs,ssfttsstvv,IGHJ5*02 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,,,7R7N_H,7R7N_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, S2D106 FAB heavy chain","Chain L, S2D106 FAB light chain",evqlvqsgaevkkpgssvkvsckasggpfsssaiswvrqapgqglewmggiipmvgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardsrycsggscysvwfdpwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvemk,ggpfsssa,iipmvgta,ardsrycsggscysvwfdp,qsissy,aas,qqsystprt,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,,,7R6X_C,7R6X_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain C, Monoclonal antibody S2E12 Fab heavy chain","Chain D, Monoclonal antibody S2E12 Fab light chain",qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,gftftssa,ivvgsgnt,aspycsggscsdgfdi,qsvsssy,gas,qqyvgltgwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,,,7R6X_A,7R6X_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain A, Monoclonal antibody S309 Fab heavy chain","Chain B, Monoclonal antibody S309 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,,,7R6X_H,7R6X_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, Monoclonal antibody S304 Fab heavy chain","Chain L, Monoclonal antibody S304 Fab light chain",evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvss,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdik,gftfssyd,igtagdt,argdssgyyyyfdy,qsigsy,aas,qqsyvsptyt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,,,7R6W_H,7R6W_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, Heavy Chain of Fab domain of monoclonal antibody S2X35","Chain L, Light Chain of Fab domain of monoclonal antibody S2X35",qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvl,gytftnyg,isaykgnt,arpdyqvlgydfwigyygmdv,ssnigagyd,gnt,qsydsslsgsevv,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,,,7N8I_H,7N8I_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, S2L20 Fab Heavy Chain Variable Region","Chain L, S2L20 Fab Light Chain Variable Region",evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvs,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdf,gftfnsyg,irydggnk,anlkdsrysgsyydy,qdirfy,das,qqydnlpft,IGHJ4*01 (human),IGHV3-30*02 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,,,7N8H_M,7N8H_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, S2M11 Fab Heavy Chain variable region","Chain L, S2M11 Fab Light Chain variable region",vqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtv,ivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkv,gytftgyy,inpissgt,araapfydfwsgysyfdy,qsvsssy,gas,qqygssawt,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,,,7ORB_E,7ORB_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, COVOX-75 Fab heavy chain","Chain F, COVOX-75 Fab light chain",qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvss,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveik,gftfnnyp,isqdggnk,ardvvvvvaarnhyyngmdv,qgissw,avs,qqaksfpft,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,,,7ORB_C,7ORB_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, COVOX-253 Fab heavy chain","Chain D, COVOX-253 Fab light chain",qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvss,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,gftfttsa,ivvgsgnt,aaphcnstscydafdi,qsvsssy,gas,qqygsspyt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,,,7OR9_H,7OR9_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, COVOX-278 Fab heavy chain","Chain L, COVOX-278 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgyifirygiswvrqapgqglewmgwisanngytnyaqklqgrvtmttdtststaymelrslrsddtavyycardggiltgyldyfdhwgqgtlvtvss,diqmtqspsslsasvgdrltitcrasqsiasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystlgitfgpgtkvdik,gyifiryg,isanngyt,ardggiltgyldyfdh,qsiasy,aas,qqsystlgit,IGHJ1*01 (human),IGHV1-18*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,,,7OR9_A,7OR9_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, COVOX-222 Fab heavy chain","Chain B, COVOX-222 Fab light chain",evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,gltvssny,iysggst,argegspgnwfdp,qsvpssy,gas,qhydtspr,IGHJ5*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Pan,Y.B. et al.; Screening of potent and broadly neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries; Unpublished; 2021.",N/A,,,7E5Y_C,7E5Y_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, 2B11 Fab Heavy chain","Chain B, 2B11 Fab Light chain",evqlvesggglvqpggslrlscaaseitvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnsentlylqmnslraedtavyycardlmevggmdvwgqgttvtvss,lpvltqppsasgtpgqrvtiscsgsssnvendnvnwfqqqvpgstpklviyndrlrpsgvpdrfsgsksgtsaylaisglqsedeadyycvawdaslqsyvfgtgtkvtvl,eitvssny,iysggtt,ardlmevggmdv,ssnvendn,ndr,vawdaslqsyv,IGHJ6*01 (human),IGHV3-66*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E8F_C,7E8F_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain C, 368-2 H","Chain B, 368-2 L",evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvss,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleik,gfafttya,isdgggsa,aktrgrglydyvwgskdy,qsllhsngyly,lgs,mqalqtpgt,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E8F_H,7E8F_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, N9 H","Chain L, N9 L",evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvss,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvl,eftfssys,isssgsqi,atnggahsstwsfygmdv,klgdky,qds,qawdsntgv,IGHJ6*01 (human),IGHV3-21*01 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E88_J,7E88_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain J, BD-515 Fab Heavy Chain","Chain K, BD-515 Fab Light Chain",evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleik,efivsrny,iysggst,ardrglvsdy,qdinky,das,hqydnlprt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E86_A,7E86_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain A, BD-508 Fab Heavy Chain","Chain B, BD-508 Fab Light Chain",evqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlflqmnslraedtavyycardaqnygmdvwgqgttvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllifaasslqtgapsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,gfivssny,iysggst,ardaqnygmdv,qsissy,aas,qqsystppyt,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E7Y_C,7E7Y_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain C, BD-623 Fab H","Chain D, BD-623 Fab L",evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsavysggstyyadsvkgrftisrhnskntlylqmkslrpedtaiyycarlinhyydssgdggafdiwgqgtmvtvss,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvl,gvtvssny,vysggst,arlinhyydssgdggafdi,ssdvgsynl,evt,csyagsstwv,IGHJ3*02 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E7X_M,7E7X_N,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain M, N11 Fab heavy chain","Chain N, N11 Fab Light chain",qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,gytlieis,fdpeaget,atgpaiaaaetnwfdl,ssdvgsyny,dvt,ssytssstwv,IGHJ2*01 (human),IGHV1-24*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Wang,X. et al.; Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27; Unpublished; 2021.",N/A,,,7CYH_E,7CYH_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain E, Heavy chain of HB27","Chain D, Light chain of HB27",vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveil,gftftnyg,issggsyt,arfryggggtvdy,esvdnygisf,aas,qqskevpri,IGHJ4*01 (mouse),IGHV5-9-4*01 (mouse),IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Sauer,M.M. et al.; Structural basis for broad coronavirus neutralization; Nat Struct Mol Biol 28 (6), 478-486 (2021); 2021.",10.1038/s41594-021-00596-4,,,7M55_H,7M55_L,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Chain H, B6 antigen binding fragment (Fab) heavy chain","Chain L, B6 antigen binding fragment (Fab) light chain",evqlqqsgpvlvkpgasvrmsckasgytitdyylnwvkqshgkslewlgvlnpysggslysqtfkgkatltvdrssstaylelnsltsedsavyycarqlgrgngldywgqgtsvtvss,nimmtqspsslavsagekvtmsckssqsvlhssdqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvqaedlavyfchqylssytfgggtkleik,gytitdyy,lnpysggs,arqlgrgngldy,qsvlhssdqkny,was,hqylssyt,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ2*01 (mouse),IGKV8-27*01 (mouse)
GenBank,,,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,,,7M7B_H,7M7B_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Antibody Fab 3D11 heavy chain","Chain L, Antibody Fab 3D11 light chain",qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvss,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvl,ggsfsgyy,inhsgst,arrwwlrgafdi,sgniasny,edn,qsydnniqv,IGHJ3*02 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,,,7M71_H,7M71_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Antibody 5A6 Fab heavy chain","Chain L, Antibody 5A6 Fab light chain",qvqlqesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycarlitmvrgedywgqgtlvtvss,diqltqspsslsasvghrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynlprtfgggtklevl,gftfssye,isydgsnk,arlitmvrgedy,qsissy,aas,qqsynlprt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Goddard,T.D. et al.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis; Protein Sci 27 (1), 14-25 (2018); 2021.",10.1002/pro.3235,,,7KQE_I,7KQE_N,not determined,Homo sapiens (human),2022-03-15,"Chain I, Fab 3D11 heavy chain","Chain N, Fab 3D11 light chain",qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvss,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvl,ggsfsgyy,inhsgst,arrwwlrgafdi,sgniasny,edn,qsydnniqv,IGHJ3*02 (human),IGHV4-34*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv 7 (23) (2021); 2021.",10.1126/sciadv.abf5632,,,7AKD_H,7AKD_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, 47D11 neutralizing antibody heavy chain","Chain L, 47D11 neutralizing antibody light chain",qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkvei,ggsisshy,iyysgst,argvllwfgepifei,qsvsss,gas,qqynnwplt,IGHJ3*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects; Cell Rep 36 (2), 109353 (2021); 2021.",10.1016/j.celrep.2021.109353,,,7M3I_H,7M3I_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CV2-75 Fab Heavy chain","Chain L, CV2-75 Fab Light chain",xvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,ggsissyy,vyysgst,assqrpdgnlyyfdy,nigskt,dds,qvwdsssdhyv,IGHJ4*01 (human),IGHV4-59*01 (human),IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Zhou,X. et al.; Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2; Cell Rep 35 (6), 109109 (2021); 2021.",10.1016/j.celrep.2021.109109,,,7MF1_H,7MF1_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, 47D1 Fab heavy chain","Chain L, 47D1 Fab light chain",qvqlvqsgaevkkpgssvrvsckasggtfstypiswvrqapgqglewmggiipifgtaksaqkfqgrvtitadeftstaymemsslrsedtamyycaregrrygsgwyistgyfdywgqgtlvtvss,qlvltqpasvsgspgqsiivsctgtssdvggykfvswyqqhpgkaprvmiydvsnrpsgvsnrfsgsksgntasltisglqaddeadyycssytnsstvvfgggtkvtvl,ggtfstyp,iipifgta,aregrrygsgwyistgyfdy,ssdvggykf,dvs,ssytnsstvv,IGHJ4*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,,,7M7W_E,7M7W_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, Monoclonal antibody S2H97 Fab heavy chain","Chain F, Monoclonal antibody S2H97 Fab light chain",qvrlvqsgaevkksgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistvylqwsslkasdtamyycarqwshytydyyywgqgtlvtiss,qsvltqpasvsgspgqsitisctgissdvggynsvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstppyvfgtgtkvsvl,gysftsyw,iypgdsdt,arqwshytydyyy,ssdvggyns,dvt,ssytssstppyv,IGHJ4*01 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,,,7M7W_H,7M7W_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Monoclonal antibody S2X259 Fab heavy chain","Chain L, Monoclonal antibody S2X259 Fab light chain",qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,ggifntyt,iilmsgma,argfngnyygwgdddafdi,nsnigagyd,gns,qsydsslsgpnwv,IGHJ5*01 (human),IGHV1-69*02 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6I_M,7M6I_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, BG1-24 Fab Heavy Chain","Chain N, BG1-24 Fab Light Chain",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriismfgiannaqkfqgrltitadtststaymelsslrsedtavyycargpyyydsggyyldywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvgsgylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagsprtfgqgtrleik,ggtfssya,iismfgia,argpyyydsggyyldy,qsvgsgy,gas,qqyagsprt,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6H_E,7M6H_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, BG7-20 Fab Heavy Chain","Chain G, BG7-20 Fab Light Chain",qvqlvqsgaevkkagasvkvsckasgytftsydinwvrqasgqglewmgwmnpisgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyfcarggrycssttcysgvgmdvwgqgttvtvps,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyhqlpgtapkfliygnsnrpsgvpdrfsgsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvl,gytftsyd,mnpisgnt,arggrycssttcysgvgmdv,ssnigagyd,gns,qsydsslsgwv,IGHJ6*01 (human),IGHV1-8*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6G_R,7M6G_S,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain R, BG7-15 Fab Heavy Chain","Chain S, BG7-15 Fab Light Chain",qvqlvqsgaevkkpgasvkvsckasgytftsyaiswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtstntaymelrslrsddtaiyycaipyssvtfdcwgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsgtflawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrptfgqgtkleik,gytftsya,vsayngnt,aipyssvtfdc,qsvsgtf,gas,qqygssrpt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6F_H,7M6F_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BG1-22 Fab Heavy Chain","Chain L, BG1-22 Fab Light Chain",evqlvesggglvqpggslrlscsvsgftvssnymnwvrqapgkglewvsviypggstfypdsvkgrftisrddskntlylqmnslrpedtaayycassrppigqlvpgldldwfdpwgqgtlvivss,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqhpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgwvfgggtkltvl,gftvssny,iypggst,assrppigqlvpgldldwfdp,ssnigagyy,gns,qsydsrlsgwv,IGHJ5*02 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6E_H,7M6E_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BG10-19 Fab Heavy Chain","Chain L, BG10-19 Fab Light Chain",evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartqwgynygshffymdvwgkgttvtvss,qsvltqppsasgtpgqrvtiscsgsssnigsdhvywyqqlpgtapklfiyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgyvfgtgtkvtvl,gysftsyw,iypgdsdt,artqwgynygshffymdv,ssnigsdh,rnn,aawdaslsgyv,IGHJ6*04 (human),IGHV5-51*01 (human),IGLJ1*01 (human),IGLV1-47*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6D_H,7M6D_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BG4-25 Fab Heavy Chain","Chain L, BG4-25 Fab Light Chain",evqlvesgggliqpggslrlscaasgitvvrnymtwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntmylqmnslraedtaiyycardlevvgamdvwgqgttvtvss,eivltqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygspmytfgqgtkleik,gitvvrny,iysggtt,ardlevvgamdv,qsvpssy,gas,qqygspmyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,,,7M6D_A,7M6D_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, CR3022 Fab Heavy Chain","Chain B, CR3022 Fab Light Chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,,,7L57_H,7L57_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab 2-15 variable domain heavy chain","Chain L, Fab 2-15 variable domain light chain",vqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitv,saltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,gytftgyy,inpisdgt,arggsrcsggncygwaydafdi,ssdvggynf,dvs,ssytssstfv,IGHJ3*02 (human),IGHV1-2*04 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,,,7L58_H,7L58_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab H4 variable domain heavy chain","Chain L, Fab H4 variable domain light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvpycsstschrdwyfdlwgrgtlvt,diqmtqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpltfgggtkvei,gytftgyy,inpnsggt,arvpycsstschrdwyfdl,qslldsddgnty,tls,mqriefplt,IGHJ2*01 (human),IGHV1-2*06 (human),IGKJ4*01 (human),IGKV2-40*01 (human)
GenBank,,,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,,,7L56_J,7L56_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Fab 2-43 variable domain heavy chain","Chain L, Fab 2-43 variable domain light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,gytftgyy,inpnsggt,arglgvgcsggncyldyyymdv,ssdvggyny,dvs,ssytssstwv,IGHJ6*04 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,,,7LQW_H,7LQW_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, 2-17 Heavy Chain","Chain L, 2-17 Light Chain",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvss,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,ggtfssya,nipifgta,argvgyrgviplnwfdp,qsvssd,gas,qqynnwppft,IGHJ5*02 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,,,7L2F_I,7L2F_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain I, 5-24 heavy chain","Chain K, 5-24 light chain",qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvss,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveik,gltfssyv,iwydgskk,ardprdyydfwsgydyyygldv,qsvsssy,gas,qqygssgalt,IGHJ6*01 (human),IGHV3-33*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,,,7L2E_I,7L2E_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain I, 4-18 heavy chain","Chain K, 4-18 light chain",qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvss,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvl,gftfssyg,isydgsnk,akdsgynygyswfdp,alakqy,kds,qstdnsgtypnwv,IGHJ5*02 (human),IGHV3-30*18 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,,,7L2D_H,7L2D_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, 1-87 heavy chain","Chain L, 1-87 light chain",qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,gytliels,fdpedaet,atgiavigpppstyyyygmdv,ssdvggyny,dvs,ssytssstyv,IGHJ6*01 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,,,7L2C_C,7L2C_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain C, 2-51 heavy chain","Chain D, 2-51 light chain",qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvl,gytliels,fdpedvet,atgwaykstwyfgy,ssdvggyny,evs,ssyagsrmg,IGHJ4*01 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Cerutti,G. et al.; Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite; Cell Host Microbe (2021); 2021.",N/A,,,7LQV_Y,7LQV_Z,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain Y, 4-8 Heavy Chain","Chain Z, 4-8 Light chain",qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,ggtfssht,iipilgia,aslqtvdtaiekyygmdv,klgdky,qdn,qawdsstav,IGHJ6*01 (human),IGHV1-69*02 (human),IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,,,7LSS_H,7LSS_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab 2-7 variable heavy chain","Chain L, Fab 2-7 variable light chain",qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,salaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,gfslstsgvg,iywdddk,ahhkierifdy,ssdvgayny,dvs,ssyttsstv,IGHJ4*01 (human),IGHV2-5*02 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,,,7LS9_E,7LS9_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, 1-57 Fab heavy chain","Chain G, 1-57 Fab light chain",evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleik,gftfsdhy,trnkansytt,arvhrwaycingvcfgaysdy,qsvsssy,gas,qqygsspst,IGHJ4*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,,,7LAA_H,7LAA_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, DH1041 heavy chain","Chain L, DH1041 light chain",evqlvesggglvqpggslrlscaasgvtfssywmswvrqapgkglewvanirqdgsekysvdsvkgrftisrdnaknslylqmnslraedtavyycararradnsgyygfhfdcwgqgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsdsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvl,gvtfssyw,irqdgsek,ararradnsgyygfhfdc,ssnigagyd,gnn,qsydsslsgwv,IGHJ5*01 (human),IGHV3-7*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,,,7LAB_H,7LAB_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, DH1052 heavy chain","Chain L, DH1052 light chain",evqlvesgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycatssgpsrlcgggscyhsfdywgqgtlvtvss,ltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptwtfgqgtkveik,gytftdyy,vdpedget,atssgpsrlcgggscyhsfdy,qsvsssy,gas,qqygssptwt,IGHJ4*01 (human),IGHV1-69-2*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,,,7LD1_H,7LD1_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, DH1047 heavy chain","Chain L, DH1047 light chain",qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvss,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveik,antftnhy,iyptggnt,ardvrvddswsgydllsggtyfdy,qsvlyssnneny,was,qqyyslprt,IGHJ4*01 (human),IGHV1-46*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,,,7LCN_M,7LCN_S,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, DH1050.1 heavy chain","Chain S, DH1050.1 light chain",qvqlvqsgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfhpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgspfgvvtdwfdpwgrgtlvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnpyvfgtgtkvtvl,gytlpels,fhpedget,atgspfgvvtdwfdp,ssdvggyny,evs,ssyagsnnpyv,IGHJ2*01 (human),IGHV1-24*01 (human),IGLJ1*01 (human),IGLV2-8*01 (human)
GenBank,,,"Yuan,M. et al.; Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants; Science 373 (6556), 818-823 (2021); 2021.",10.1126/science.abh1139,,,7LOP_H,7LOP_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CV05-163 Fab heavy chain","Chain L, CV05-163 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarevmvrgalppygmdvwgqgttvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvtfgggtkveik,gytftgyy,inpnsggt,arevmvrgalppygmdv,qsvssy,das,qqrsnwppvt,IGHJ6*01 (human),IGHV1-2*02 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jiang,W. et al.; Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV; MAbs 13 (1), 1953683 (2021); 2021.",10.1080/19420862.2021.1953683,,,7DPM_J,7DPM_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, heavy chain of MW06","Chain K, light chain of MW06",evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggstyyadsvrgrftisrdnskntlylqmnslraedtavyccakgyyydssgyyfredafdiwgqgtlvtvss,diqmtqspsamsasvgdrvtitcrasqgisnylawfqqkpgkvpkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,gftfssya,isgsggst,akgyyydssgyyfredafdi,qgisny,aas,lqhnsypyt,IGHJ5*01 (human),IGHV3-23*01 (human),IGKJ2*01 (human),IGKV1-17*03 (human)
GenBank,,,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,,,7KML_J,7KML_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Fab 15033-7 heavy chain","Chain N, Fab 15033-7 light chain",evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqshtypitfgqgtkveik,gfdlggys,iyasggat,arsyyyggfgmdy,qsvssa,sas,qqshtypit,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,,,7KZB_A,7KZB_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, Fab heavy chain of CR3022-B6 antibody","Chain B, Fab light chain of CR3022-B6 antibody",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,diqmtqspsslsasvgdrvtitcrasqsiysalnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtdihpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsiysa,aas,qqtdihpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,,,7KZB_H,7KZB_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab heavy chain of CR3014-C8 antibody","Chain L, Fab light chain of CR3014-C8 antibody",evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqyiydslnwyqqkpgkapklliydssylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqswdtpvtfgqgtkveik,gftfsdhy,trnkansytt,argispfyfdy,qyiyds,dss,qqswdtpvt,IGHJ4*01 (human),IGHV3-72*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,,,7KMI_A,7KMI_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, LY-CoV481 Fab heavy chain","Chain B, LY-CoV481 Fab light chain",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarevagtydywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpggtfgpgtkvdik,gftvssny,iypggst,arevagtydy,qgissw,aas,qqansfpggt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,,,7KMH_A,7KMH_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, LY-CoV488 Fab heavy chain","Chain B, LY-CoV488 Fab light chain",evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarspyggnswgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,gltvssny,iysggst,arspyggns,qdisny,das,qqydnlpit,IGHJ5*01 (human),IGHV3-53*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,,,7KMG_D,7KMG_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvss,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveik,ggtfsnya,iipilgia,argyyearhyyyyyamdv,qsissy,aas,qqsystprt,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Acharya,P. et al.; A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies; bioRxiv (2020); 2020.",10.1101/2020.06.30.178897,,,7L09_M,7L09_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain M, 2G12 heavy chain","Chain L, 2G12 light chain",evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvsp,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveik,nfrisaht,istsstyr,arkgsdrlsdndpfda,qsietw,kas,qhyagysat,IGHJ2*01 (human),IGHV3-21*01 (human),IGKJ5*01 (human),IGKV1-5*03 (human)
GenBank,,,"Bertoglio,F. et al.; A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; Biorxiv (2020); 2020.",N/A,,,7B3O_H,7B3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, Heavy Chain of Fab Fragment","Chain L, Light Chain of Fab Fragment",qvqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrddskntlylqmnslraedtavyycardvadafdiwgqgtmvtvss,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppftfgpgtkvdik,gltvssny,iysggst,ardvadafdi,qgissy,aas,qqlnsyppft,IGHJ3*02 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,,,7KFX_H,7KFX_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, heavy chain of human antibody C1A-C2 Fab","Chain L, light chain of human antibody C1A-C2 Fab",evqlvesgggliqpggslrlscavsgftvsnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsg,diqltqspsslsafvgdrvtitcrasegissylawyqqkpgnapklliyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleik,gftvsnny,iysggtt,argdvsgyrygldy,egissy,aas,qqlnsypgt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,,,7KFW_H,7KFW_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, heavy chain of antibody C1A-B3 Fab","Chain L, light chain of antibody C1A-B3 Fab",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycargdvsgyrygldywgqgtlvtvsg,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleik,gftvssny,iysggtt,argdvsgyrygldy,qgissy,aas,qqlnsypgt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,,,7KFY_H,7KFY_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, heavy chain of human antibody C1A-F10 Fab","Chain L, light chain of human antibody C1A-F10 Fab",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsg,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlengvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleik,gftvssny,iysggtt,argdvsgyrygldy,qgissy,aas,qqlnsypgt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Guo,Y. et al.; A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes; Nat Commun 12 (1), 2623 (2021); 2020.",10.1038/s41467-021-22926-2,,,7CJF_A,7CJF_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain A, antibody heavy chain","Chain B, antibody light chain",evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlqelgsldywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqeansfpytfgqgtkleik,gfivssny,iysggst,ardlqelgsldy,qgissw,aas,qeansfpyt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-12*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JVC_F,7JVC_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain F, S2A4 Fab heavy chain","Chain G, S2A4 Fab light chain",evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,gftfssyw,ikqdgsek,arvwwlrgsfdy,sgsiasny,edn,qsydssnhvv,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JV6_F,7JV6_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain F, S2H13 Fab heavy chain","Chain G, S2H13 Fab light chain",evqlvesggdsvqpggslrlscaaagftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycalssgysgyagnywgqgtlvtvss,qavvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgarpedeaeyycllsysgargvfgggtkltvl,gftfssyw,ikqdgsek,alssgysgyagny,tgavtsghy,dts,llsysgargv,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JX3_H,7JX3_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, Heavy chain of Fab domain of monoclonal antibody S304","Chain L, Light chain of Fab domain of monoclonal antibody S304",evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvss,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdik,gftfssyd,igtagdt,argdssgyyyyfdy,qsigsy,aas,qqsyvsptyt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JX3_C,7JX3_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain C, Heavy chain of Fab domain of monoclonal antibody S2H14","Chain D, Light chain of Fab domain of monoclonal antibody S2H14",evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvss,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvl,gftfsnaw,iksktdggtt,ttgsetyyydssgpfdy,sgsiasny,edn,qsydssnqv,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JX3_A,7JX3_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain A, Heavy chain of Fab domain of monoclonal antibody S309","Chain B, Light chain of Fab domain of monoclonal antibody S309",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JW0_G,7JW0_F,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain G, S304 Fab heavy chain","Chain F, S304 Fab light chain",vqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvss,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdik,gftfssyd,igtagdt,argdssgyyyyfdy,qsigsy,aas,qqsyvsptyt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,,,7JVA_H,7JVA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, S2A4 Fab heavy chain","Chain L, S2A4 Fab light chain",evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,gftfssyw,ikqdgsek,arvwwlrgsfdy,sgsiasny,edn,qsydssnhvv,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,,,7JXE_H,7JXE_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, S2X35 antigen-binding (Fab) fragment","Chain L, S2X35 antigen-binding (Fab) fragment",qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvl,gytftnyg,isaykgnt,arpdyqvlgydfwigyygmdv,ssnigagyd,gnt,qsydsslsgsevv,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,,,7JXC_H,7JXC_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, S2H14 antigen-binding (Fab) fragment","Chain L, S2H14 antigen-binding (Fab) fragment",evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvss,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvl,gftfsnaw,iksktdggtt,ttgsetyyydssgpfdy,sgsiasny,edn,qsydssnqv,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV6-57*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,,,7K8X_E,7K8X_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, C121 Fab Heavy chain","Chain G, C121 Fab Light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispvsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaraplfptgvlagdyyyygmdvwgqgttvtvss,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,gytftgyy,ispvsggt,araplfptgvlagdyyyygmdv,ssdvgsynl,egs,csyagsstlv,IGHJ6*01 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K90_O,7K90_P,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain O, C144 Fab Heavy Chain","Chain P, C144 Fab Light Chain",evqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvl,gftvsnny,iysggst,aregevegyndfwsgysrdryyfdy,ssdvggyny,dvs,ssytssstrv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8Z_M,7K8Z_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, C135 Fab Heavy Chain","Chain N, C135 Fab Light Chain",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvss,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,gftfssya,ipfdgrnk,asssgylfhsdy,qsisnw,eas,qqynsypwt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8W_N,7K8W_S,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, C119 Fab Heavy Chain","Chain S, C119 Fab Light Chain",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqklqgrvtmtrdtststvymelsslrsedtavyycaranhettmdtyyyyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqrhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsvvfgggtqltvl,gytftsyy,inpsggst,aranhettmdtyyyyyymdv,ssdvggyky,dvs,ssytssstsvv,IGHJ6*04 (human),IGHV1-46*04 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8V_M,7K8V_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, C110 Fab Heavy Chain","Chain N, C110 Fab Light Chain",qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvss,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleik,gysftsyw,iypgdsdt,arsfrddpriavagpadafdi,qsisyw,qas,qqynsypyt,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8U_H,7K8U_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C104 Fab Heavy Chain","Chain L, C104 Fab Light Chain",qvqlqqwgagllkpsetlslscavyggslsgyywswirqppgkglewigeinhfgstgynpslksrvtisvdtsksqfsvklssvtaadtavyycarkpllysnlspgafdiwgqgtmvtvss,eivltqspgtvslspgeratlscwasqsvsasylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygttprtfgggtkveik,ggslsgyy,inhfgst,arkpllysnlspgafdi,qsvsasy,gas,qqygttprt,IGHJ3*02 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8T_O,7K8T_P,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain O, C002 Fab Heavy Chain","Chain P, C002 Fab Light Chain",evqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegrpsdivvvvafdywgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,gftfsiyg,isydgsnk,akegrpsdivvvvafdy,qsissy,aas,qqsystprt,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,,,7K8M_A,7K8M_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,gfivssny,iysggst,ardygdyyfdy,qsvsssy,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,,,7K8R_H,7K8R_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C135 Fab Heavy Chain","Chain L, C135 Fab Light Chain",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvss,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,gftfssya,ipfdgrnk,asssgylfhsdy,qsisnw,eas,qqynsypwt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8P_H,7K8P_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, C110 Fab Heavy Chain","Chain L, C110 Fab Light Chain",qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvss,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleik,gysftsyw,iypgdsdt,arsfrddpriavagpadafdi,qsisyw,qas,qqynsypyt,IGHJ3*02 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV1-5*01 (human)
GenBank,,,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,,,7K8N_A,7K8N_B,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,gfivssny,iysggst,ardygdyyfdy,qsvsssy,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,,,7K4N_F,7K4N_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain F, S2E12 neutralizing antibody Fab fragment (heavy chain)","Chain G, S2E12 neutralizing antibody Fab fragment (light chain)",qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,gftftssa,ivvgsgnt,aspycsggscsdgfdi,qsvsssy,gas,qqyvgltgwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,,,7K43_F,7K43_G,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain F, S2M11 Fab fragment (heavy chain)","Chain G, S2M11 Fab fragment (light chain)",evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtvss,eivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkveik,gytftgyy,inpissgt,araapfydfwsgysyfdy,qsvsssy,gas,qqygssawt,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science (2020) In press; 2020.",10.1126/science.abe3354,,,7K3Q_H,7K3Q_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab fragment of S2E12 monoclonal antibody, heavy chain","Chain L, Fab fragment of S2E12 monoclonal antibody, light chain",qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,gftftssa,ivvgsgnt,aspycsggscsdgfdi,qsvsssy,gas,qqyvgltgwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,,,6XC7_C,6XC7_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, CC12.3 heavy chain","Chain D, CC12.3 light chain",qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,gftvssny,iysggst,ardfgdfyfdy,qsvssy,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,,,6XC2_X,6XC2_Y,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain X, CC12.1 heavy chain","Chain Y, CC12.1 light chain",evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveik,gltvssny,iysggst,ardldvygldv,qgissy,aas,qqlnsyppkft,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Wang,N. et al.; Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD; Cell Rep 28 (13), 3395-3405 (2019); 2019.",10.1016/j.celrep.2019.08.052,,,6PXH_H,6PXH_L,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain H, G2 heavy chain","Chain L, G2 light chain",qvqlqqsggelvkpgasvklscktsgftfsssyiswlkqkpgqslewiawiyagtggteynqkftgkaqvtvdtssstaymqfsslttedsaiyycarggssfamdywgqgtsvtvss,qlvltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllihtasnqgsgvparfsgsgsgtdfslnihpvedddtamyfcqqseevpltfgagtkleik,gftfsssy,iyagtggt,arggssfamdy,esvdnygisf,tas,qqseevplt,IGHJ4*01 (mouse),IGHV1-66*01 (mouse),IGKJ5*01 (mouse),IGKV3-2*01 (mouse)
GenBank,,,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,,,5W9O_H,5W9O_I,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain H, G4 VH","Chain I, G4 VL",qvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvss,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleik,gytftdya,fstyygnt,arksyyvdyvdamdy,esvdnygisf,ats,qqskevprt,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
GenBank,,,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,,,5VZR_A,5VZR_B,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain A, G4 antibody heavy chain","Chain B, G4 antibody light chain",xvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvss,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleik,gytftdya,fstyygnt,arksyyvdyvdamdy,esvdnygisf,ats,qqskevprt,IGHJ4*01 (mouse),IGHV1-19*01 (mouse),IGKJ1*01 (mouse),IGKV3-2*01 (mouse)
GenBank,,,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,,,7WDF_F,7WDF_G,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"Chain F, Heavy chain of S3H3 Fab","Chain G, Light chain of S3H3 Fab",qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsa,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleik,gysftrfw,ihpsdset,arkdydydawfay,ksvsasvysy,las,hhsrelppa,IGHJ3*01 (mouse),IGHV1-61*01 (mouse),IGKJ1*02 (mouse),IGKV3-12*01 (mouse)
GenBank,,,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,,,7WD7_e,7WD7_f,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"Chain e, Heavy chain of S5D2 Fab","Chain f, Light chain of S5D2 Fab",evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgqslewigginpniddttynqnfkdkatltvdkssstaymefrsltfddsavyycarddkasfafwgqgtlvtvsa,divmsqspsslavsdgervtltckssqsllystnqknylawyqqkpgqspklliywassresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypltfgagtklelr,gytfteyt,inpniddt,arddkasfaf,qsllystnqkny,was,qqyysyplt,IGHJ3*01 (mouse),IGHV1-26*01 (mouse),IGKJ5*01 (mouse),IGKV8-30*01 (mouse)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe 30 (1), 69-82 (2022); 2022.",10.1016/j.chom.2021.12.010,,,7SC1_P,7SC1_Q,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain P, R40-1G8 Fab heavy chain","Chain Q, R40-1G8 Fab light chain",evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsa,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleik,gltvssny,iyaggst,ardlyvfgmdv,qgissy,aas,qqlnsdsst,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,,,7QNY_H,7QNY_L,not determined,Homo sapiens (human),2022-03-15,"Chain H, COVOX-158 heavy chain","Chain L, COVOX-158 light chain",evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvss,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveik,gvtvssny,iypggst,ardlgsgdmdv,qgissy,aas,qqlnsyryt,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,,,7QNY_A,7QNY_B,not determined,Homo sapiens (human),2022-03-15,"Chain A, COVOX-58 heavy chain","Chain B, COVOX-58 light chain",qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqppgkglewvsgvswnsgtigyadsvkgrfiisrdnaknslylqmnslkaedtalyycarevggtfgvlisreggldywgqgtlvtvss,syeltqppsvsvapgqtaritcggntigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrvvfgggtkltvl,gftfddya,vswnsgti,arevggtfgvlisreggldy,tigsks,dds,qvwdsssdrvv,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,,,7QNX_A,7QNX_B,not determined,Homo sapiens (human),2022-03-15,"Chain A, Beta-55 heavy chain","Chain B, Beta-55 light chain",qvqlqesgpglvkpsetlsltctvsgdsisssryywgwirqppgkglewigtfyysgityynpslksrvtifvdtsknqfslklssvtaadtavyycarprppdyydnsgallfdiwgqgtmvtvss,airmtqspstlsasvgdrvtiacrasqsisawlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpddfatyycqqyissspwtfgqgtkveik,gdsisssryy,fyysgit,arprppdyydnsgallfdi,qsisaw,kas,qqyissspwt,IGHJ3*02 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,,,7QNX_H,7QNX_L,not determined,Homo sapiens (human),2022-03-15,"Chain H, EY6A heavy chain","Chain L, EY6A light chain",evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveik,aftfssyd,isydgsnk,akdggklwvyyfdy,qsissy,aas,qqsystlalt,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain; Science 375 (6578), eabl6251 (2022); 2021.",10.1126/science.abl6251,,,7SN3_H,7SN3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, neutralizing antibody C1C-A3 heavy chain variable region","Chain L, neutralizing antibody C1C-A3 light chain variable region",qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvsg,eivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleik,gftfssyg,iwydgtnt,ardlayrdyvwryfdl,qsvsty,das,qcrsnwppgit,IGHJ2*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,,,7MJK_H,7MJK_I,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain H, Fab ab1 Heavy Chain","Chain I, Fab ab1 Light Chain",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvss,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveik,gftvssny,iysggst,argygdyyfdy,qsvssy,was,qqygssplt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
GenBank,,,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2; Commun Biol 4 (1), 500 (2021); 2021.",10.1038/s42003-021-02029-w,,,7E23_B,7E23_C,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, CA521 Heavy Chain","Chain C, CA521 Light Chain",evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,ggsfsgyy,vnhsgst,argntmvrgviipfey,qsvssy,das,qqrsnwplt,IGHJ4*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Rosa,A. et al.; SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity; Sci Adv (2021) In press; 2021.",10.1126/sciadv.abg7607,,,7NTC_H,7NTC_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, P008_056 Fab Heavy chain","Chain L, P008_056 Fab Light chain",evqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtiss,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveik,gfsfssys,issnsnyi,asnrspydssnyyfdy,qdisny,das,qhhdslplt,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,,,7LY3_F,7LY3_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain F, S2M28 Fab Heavy Chain","Chain E, S2M28 Fab Light Chain",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltvl,gftfssyg,iwydgsnr,aravagewyfdy,alakhy,kds,qsadsigsswv,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,,,7LY2_N,7LY2_O,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, S2M28 Fab Heavy Chain variable region","Chain O, S2M28 Fab Light Chain variable region",vqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvs,yeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltv,gftfssyg,iwydgsnr,aravagewyfdy,alakhy,kds,qsadsigsswv,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,,,7LXZ_N,7LXZ_O,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, S2L28 Fab Heavy Chain variable region","Chain O, S2L28 Fab Light Chain variable region",evqlvesggglvnpggslrlscaasgftfsdytihwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslslqmnslraedtavyycardgnaykwllaenvrfdywgqgtlvtvss,vtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsdrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpnwvfgggtklt,gftfsdyt,issssnyi,ardgnaykwllaenvrfdy,ssdvggyny,dvs,ssytssstpnwv,IGHJ4*01 (human),IGHV3-21*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,,,7LXY_N,7LXY_O,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain N, S2X333 Fab Heavy Chain variable region","Chain O, S2X333 Fab Light Chain variable region",vqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnsknslylqmnslraedtavyfcarafpdssswsgftidywgqgtlvtv,yeltqppsvstaritcggnnierksvhwcqqkpgqapalvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdqvifgggtklt,gftfsnyg,iwydgsnk,arafpdssswsgftidy,nierks,dds,qvwdsgsdqvi,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,,,7LJR_S,7LJR_T,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain S, Fab DH1043 heavy chain","Chain T, Fab DH1043 light chain",qvqlvqsgaevkkpgssvkvsckasggtfsryainwvrqapgqglewmgriipifgianyaqkfqgkvtitadkststaymelsslrsedtavyycaradyyydssgyffdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqtprlliygassratgiparfsgsgsgtnftltisrlepedfavyycqqysssrtfgqgtkveik,ggtfsrya,iipifgia,aradyyydssgyffdy,qsvsssy,gas,qqysssrt,IGHJ4*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,,,6ZH9_HHH,6ZH9_LLL,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain HHH, CR3022 heavy","Chain LLL, CR3022 Light chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvas,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7D0D_G,7D0D_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain G, Heavy chain of P5A-3C12","Chain F, Light chain of P5A-3C12",qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslfltvgyssswspfdywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystphtfgqgtkleik,gfslstsgvg,iywdddk,ahslfltvgyssswspfdy,qsvlyssnnkny,was,qqyystpht,IGHJ4*01 (human),IGHV2-5*02 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7D0C_G,7D0C_F,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain G, Heavy chain of P5A-3A1","Chain F, Light chain of P5A-3A1",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdfyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,gftvssny,iysggst,ardygdfyfdy,qsvsssy,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Supasa,P. et al.; Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera; Cell 184 (8), 2201-2211 (2021); 2021.",10.1016/j.cell.2021.02.033,,,7NEH_H,7NEH_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, COVOX-269 Fab heavy chain","Chain L, COVOX-269 fab light chain",qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvss,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdik,gltvnrny,iysggst,ardfyegsfdi,qgissy,aas,qqlnsypapv,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7NDD_H,7NDD_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-159 Fab heavy chain","Chain L, COVOX-159 Fab light chain",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnryyadsvkgrftisrdnskntlylqmnrlraedtamyycakdrddgwdwyyfmdvwgkgttvtvss,diqltqspgtlslspgeratlscrasqsisgnylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkveik,gftfssyg,isydggnr,akdrddgwdwyyfmdv,qsisgny,gas,qqygssyt,IGHJ6*04 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7NDB_H,7NDB_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-253H165L Fab heavy chain","Chain L, COVOX-253H165L Fab light chain",qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvss,divmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygasrrgtgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,gftfttsa,ivvgsgnt,aaphcnstscydafdi,qsvrssy,gas,qqygsspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7NDA_H,7NDA_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-253H55L Fab heavy chain","Chain L, COVOX-253H55L Fab light chain",qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvss,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveik,gftfttsa,ivvgsgnt,aaphcnstscydafdi,qsvsssy,gas,qqygsspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND8_H,7ND8_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-384 Fab heavy chain","Chain L, COVOX-384 Fab light chain",evqlvesggglvkpgeslrlscaasgftfsdyymtwirqapgkglewvsyirssghtiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarggvlrflewplnafdiwgqgtmvtvss,diqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynnalgtfgqgtkveik,gftfsdyy,irssghti,arggvlrflewplnafdi,qgisny,aas,qkynnalgt,IGHJ3*02 (human),IGHV3-11*01 (human),IGKJ1*01 (human),IGKV1-27*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND7_J,7ND7_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain J, COVOX-316 Fab heavy chain","Chain K, COVOX-316 Fab light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvss,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvl,gytftgyy,inpnsggt,ardmafsmvrgsfdy,ssdvggyny,evs,ssyagsnhwv,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-8*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND6_H,7ND6_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-158 Fab heavy chain","Chain L, COVOX-158 Fab light chain",evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvss,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveik,gvtvssny,iypggst,ardlgsgdmdv,qgissy,aas,qqlnsyryt,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND5_H,7ND5_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-150 Fab heavy chain","Chain L, COVOX-150 Fab light chain",qvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvss,eivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdik,gvtvssny,iysggtt,ardlmvygidv,qgissy,aas,qqldsyppgyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND4_F,7ND4_G,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain F, COVOX-88 Fab heavy chain","Chain G, COVOX-88 Fab light chain",qlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvss,qsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvl,ggsissgsyn,iynsgst,arhcsggtcypkyyygmdv,ssnignna,ydd,aawddslnvvv,IGHJ6*01 (human),IGHV4-61*02 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7ND3_H,7ND3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-40 heavy chain","Chain L, COVOX-40 light chain",qvqlvesggglvqpggslrlscavsgftvsrnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfhrsgyhdywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkllifdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpafgggtkvdik,gftvsrny,iysggst,ardlfhrsgyhdy,qdinny,das,qqydnlpa,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEP_G,7BEP_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain G, S309 heavy chain","Chain I, S309 light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEO_E,7BEO_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain E, COVOX-75 heavy chain","Chain F, COVOX-75 light chain",qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvss,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveik,gftfnnyp,isqdggnk,ardvvvvvaarnhyyngmdv,qgissw,avs,qqaksfpft,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEO_C,7BEO_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain C, COVOX-253H55L heavy chain","Chain D, COVOX-253H55L light chain",qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvss,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveik,gftfttsa,ivvgsgnt,aaphcnstscydafdi,qsvsssy,gas,qqygsspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEN_G,7BEN_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain G, COVOX-75 heavy chain","Chain I, COVOX-75 light chain",qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvss,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveik,gftfnnyp,isqdggnk,ardvvvvvaarnhyyngmdv,qgissw,avs,qqaksfpft,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEN_D,7BEN_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain D, COVOX-253 heavy chain","Chain F, COVOX-253 light chain",qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvss,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,gftfttsa,ivvgsgnt,aaphcnstscydafdi,qsvsssy,gas,qqygsspyt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEM_H,7BEM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-269 Vh domain","Chain L, COVOX-269 Vl domain",qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvss,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdik,gltvnrny,iysggst,ardfyegsfdi,qgissy,aas,qqlnsypapv,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEL_C,7BEL_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain C, COVOX-45 heavy chain","Chain D, COVOX-45 light chain",qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdik,gftfstya,lsydgsnk,akggsyayyyymdv,qdisny,das,qqydnlplt,IGHJ6*04 (human),IGHV3-30-3*02 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,,,7BEH_H,7BEH_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, COVOX-316 heavy chain","Chain L, COVOX-316 light chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvss,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvl,gytftgyy,inpnsggt,ardmafsmvrgsfdy,ssdvggyny,evs,ssyagsnhwv,IGHJ4*01 (human),IGHV1-2*02 (human),IGLJ3*02 (human),IGLV2-8*01 (human)
GenBank,,,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2021.",10.1126/science.abc5881,,,7CAC_E,7CAC_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",evqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvss,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,gysfsnyy,idpfnggt,arseydpyyvmdy,qsissn,yas,qqtnfwpyi,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
GenBank,,,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2020.",10.1126/science.abc5881,,,7CAH_E,7CAH_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvss,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,gysfsnyy,idpfnggt,arseydpyyvmdy,qsissn,yas,qqtnfwpyi,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
GenBank,,,"Thomson,E.C. et al.; Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity; Cell 184 (5), 1171-1187 (2021); 2021.",10.1016/j.cell.2021.01.037,,,7L0N_M,7L0N_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain M, Monoclonal antibody S304 Fab heavy chain","Chain N, Monoclonal antibody S304 Fab light chain",evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvss,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdik,gftfssyd,igtagdt,argdssgyyyyfdy,qsigsy,aas,qqsyvsptyt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Biorxiv (2021); 2021.",N/A,,,7L5B_H,7L5B_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, 2-15 Heavy chain","Chain L, 2-15 Light Chain",qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvss,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,gytftgyy,inpisdgt,arggsrcsggncygwaydafdi,ssdvggynf,dvs,ssytssstfv,IGHJ3*02 (human),IGHV1-2*04 (human),IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Banach,B.B. et al.; Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses; bioRxiv (2021); 2021.",10.1101/2020.12.31.424987,,,7KS9_H,7KS9_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, 910-30 Fab heavy chain","Chain L, 910-30 Fab light chain",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycariygdyawgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsrsgtdftftisslqpediatyychqydnlpltfgggtkveik,gftvssny,iysggst,ariygdya,qdisny,das,hqydnlplt,IGHJ1*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jones,B.E. et al.; LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection; bioRxiv (2020); 2021.",10.1101/2020.09.30.318972,,,7L3N_D,7L3N_E,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvss,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveik,ggtfsnya,iipilgia,argyyearhyyyyyamdv,qsissy,aas,qqsystprt,IGHJ6*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res 31 (1), 25-36 (2021); 2021.",10.1038/s41422-020-00444-y,,,7CWL_I,7CWL_K,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain I, Fab P17 heavy chain","Chain K, Fab P17 light chain",qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,gftfssya,isydgsnk,arhatlmnnkdi,qsissy,aas,qqsystprt,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,,,7CWN_O,7CWN_M,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain O, heavy chain of H014 Fab","Chain M, light chain of H014 Fab",vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvss,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,gysfsnyy,idpfnggt,arseydpyyvmdy,qsissn,yas,qqtnfwpyi,IGHJ6*01 (human),IGHV1-69-2*01 (human),IGKJ2*01 (human),IGKV6-21*02 (human)
GenBank,,,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,,,7CWN_G,7CWN_F,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain G, heavy chain of P17 Fab","Chain F, light chain of P17 Fab",qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,gftfssya,isydgsnk,arhatlmnnkdi,qsissy,aas,qqsystprt,IGHJ5*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7KN7_H,7KN7_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CC12.3 Fab heavy chain","Chain L, CC12.3 Fab light chain",qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,gftvssny,iysggst,ardfgdfyfdy,qsvssy,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kim,Y.G. et al.; to be publish; Unpublished; 2021.",N/A,,,7CM4_H,7CM4_L,not determined,Homo sapiens (human),2022-03-15,"Chain H, IgG heavy chain","Chain L, IgG light chain",qitlkesgptlvkptqtltltcsfsgfslstsgvgvgwirqppgkalewlalidwddnkyhttslktrltiskdtsknqvvltmtnmdpvdtatyycaripgflryrnryyyygmdvwgqgttvtvss,elvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggteltvl,gfslstsgvg,idwddnk,aripgflryrnryyyygmdv,ssnignny,dnn,gtwdsslsagv,IGHJ6*01 (human),IGHV2-70*12 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,,,7DK7_c,7DK7_d,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain c, The heavy chain fragment of 2H2 Fab","Chain d, The light chain fragment of 2H2 Fab",qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvss,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleik,gfsltsyg,mwrggnt,aknggahamdf,esvdsygnsf,las,qqnnedpft,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
GenBank,,,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,,,7DD8_A,7DD8_B,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain A, The heavy chain of 3C1 fab","Chain B, The light chain of 3C1 chain",evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvss,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleik,gdsitngy,isysgst,asdyhgskyyfdy,qdvgnd,was,qqynrypyt,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
GenBank,,,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,,,7DCX_E,7DCX_H,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Chain E, The heavy chain of 3C1 fab that binds with the up RBD","Chain H, The light chain of 3C1 fab",evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvss,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleik,gdsitngy,isysgst,asdyhgskyyfdy,qdvgnd,was,qqynrypyt,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
GenBank,,,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",N/A,,,6XKQ_H,6XKQ_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CV07-250 Heavy Chain","Chain L, CV07-250 Light Chain",qvqlvqseaevkepgasvevsckasgynftnfaiswvrqapgqglewmgwisgyngdtnsaqkflgrvtmttdtstttaymelrslrsddtavyycagsdnygfpyngmdvwgqgttvtvfn,qsaltqppsasgspgqsvtisctgtssdlgayhfvtwyqhypgkapkvmiygvrkrpsgvpdrfsgsksgntasltvsglqdedeadyycssyagnndfvfgggtkltvl,gynftnfa,isgyngdt,agsdnygfpyngmdv,ssdlgayhf,gvr,ssyagnndfv,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",N/A,,,6XKP_M,6XKP_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, CV07-270 Heavy Chain","Chain N, CV07-270 Light Chain",qvqlvesggglvkpggslrlscaasgftfsdyymtwirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarargssgwyrigtrwgnwfdpwgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssnvvfgggtmltvl,gftfsdyy,isssgsti,arargssgwyrigtrwgnwfdp,ssdvggyny,evs,ssytsssnvv,IGHJ5*02 (human),IGHV3-11*01 (human),IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.035,,,7CHH_J,7CHH_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, BD-368-2 Fab heavy chain","Chain K, BD-368-2 Fab light chain",evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvss,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleik,gfafttya,isdgggsa,aktrgrglydyvwgskdy,qsllhsngyny,lgs,mqalqtpgt,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
GenBank,,,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,,,7CHF_H,7CHF_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-604 Fab heavy chain","Chain L, BD-604 Fab light chain",evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleik,giivssny,iysggst,ardlgpygmdv,qgissd,aas,qqlnsdlyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,,,7CHE_H,7CHE_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-236 Fab heavy chain","Chain L, BD-236 Fab light chain",evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstdyadsvkgrftisrdkskntlylqmnslraedtavyycardlgeaggmdvwgqgttvtvss,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppafgggtkveik,gitvssny,iysggst,ardlgeaggmdv,qgissy,aas,qqlnsyppa,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,,,7CHC_H,7CH5_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-629 Fab H","Chain L, BD-629 Fab L",evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveik,efivsrny,iysggst,ardygdyyfdy,qgvssf,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,L. et al.; Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike; bioRxiv (2020); 2020.",10.1101/2020.06.17.153486,,,6XEY_J,6XEY_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain J, 2-4 Heavy Chain","Chain L, 2-4 Light Chain",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,gytftgyy,inpnsggt,ardrswavvyyymdv,ssdvggyny,evs,ssyagsnnlv,IGHJ6*04 (human),IGHV1-2*02 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Chi,X. et al.; A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2; Science 369 (6504), 650-655 (2020); 2020.",10.1126/science.abc6952,,,7C2L_J,7C2L_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain J, heavy chain of 4A8","Chain N, light chain of 4A8",evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvss,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfpytfgqgtkvdik,gytltels,fdpedget,atstavagtpdlfdyyygmdv,qslvhsdgnty,kis,tqatqfpyt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ3*01 (human),IGKV2-24*01 (human)
GenBank,,,"Hurlburt,N.K. et al.; Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation; bioRxiv (2020); 2020.",10.1101/2020.06.12.148692,,,6XE1_H,6XE1_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CV30 Fab Heavy chain","Chain L, CV30 Fab Kappa chain",xvqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvss,xivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,gvivssny,iysggst,ardldvsggmdv,qsvsssy,gas,qqygsspqt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,,,6XCN_H,6XCN_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, C105 Fab Heavy Chain","Chain L, C105 Fab Light Chain",qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvss,qsaltqppsasgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvl,gftvssny,iysggst,argegwelpydy,ssdvggyky,evs,ssyegsnnfvv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,,,6XCA_H,6XCA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, C105 Heavy Chain","Chain L, C105 Light Chain",qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvss,qsaltqppsgsgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvl,gftvssny,iysggst,argegwelpydy,ssdvggyky,evs,ssyegsnnfvv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,,,6XDG_C,6XDG_A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, REGN10987 antibody Fab fragment heavy chain","Chain A, REGN10987 antibody Fab fragment light chain",qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,gftfsnya,isydgsnk,asgsdygdyllvy,ssdvggyny,dvs,nsltsistwv,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,,,6XDG_B,6XDG_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, REGN10933 antibody Fab fragment heavy chain","Chain D, REGN10933 antibody Fab fragment light chain",qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,gftfsdyy,itysgsti,ardrgttmvpfdy,qditny,aas,qqydnlplt,IGHJ4*01 (human),IGHV3-11*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Cao,Y. et al.; Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells; Cell 182 (1), 73-84 (2020); 2020.",10.1016/j.cell.2020.05.025,,,7BYR_H,7BYR_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Ab23-Fab-Heavy Chain","Chain L, Ab23-Fab-Light Chain",qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpqggsswyrdyyygmdvwgqgttvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,gytftsya,intntgnp,arpqggsswyrdyyygmdv,qsissw,kas,qqynsypyt,IGHJ6*01 (human),IGHV7-4-1*02 (human),IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Ju,B. et al.; Human neutralizing antibodies elicited by SARS-CoV-2 infection; Nature 584 (7819), 115-119 (2020); 2020.",10.1038/s41586-020-2380-z,,,7BWJ_H,7BWJ_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, antibody heavy chain","Chain L, antibody light chain",qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,gysissgyy,iyhsgst,aravvgivvvpaagrrafdi,ssdvggyny,evs,ssyagsnnlv,IGHJ3*02 (human),IGHV4-38-2*02 (human),IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Shi,R. et al.; A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2; Nature 584 (7819), 120-124 (2020); 2020.",10.1038/s41586-020-2381-y,,,7C01_C,7C01_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, CB6 heavy chain","Chain D, CB6 light chain",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvss,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleik,gftvssny,iysggst,arvlpmygdyldy,qsisry,aas,qqsystppeyt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,,,6WPT_D,6WPT_E,not determined,Homo sapiens (human),2022-03-15,"Chain D, S309 neutralizing antibody heavy chain","Chain E, S309 neutralizing antibody light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,,,6WS6_E,6WS6_F,not determined,Homo sapiens (human),2022-03-15,"Chain E, S309 antigen-binding (Fab) fragment, heavy chain","Chain F, S309 antigen-binding (Fab) fragment, light chain",qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,gypftsyg,istyngnt,ardytrgawfgesliggfdn,qtvssts,gas,qqhdtslt,IGHJ5*01 (human),IGHV1-18*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wu,Y. et al.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2; Science 368 (6496), 1274-1278 (2020); 2020.",10.1126/science.abc2241,,,7BZ5_H,7BZ5_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Heavy chain of B38","Chain L, Light chain of B38",evqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycareaygmdvwgqgttvtvss,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppytfgqgtkleik,gfivssny,iysggst,areaygmdv,qgissy,aas,qqlnsyppyt,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Yuan,M. et al.; A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV; Science 368 (6491), 630-633 (2020); 2020.",10.1126/science.abb7269,,,6W41_H,6W41_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, CR3022 Fab heavy chain","Chain L, CR3022 Fab light chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zhou,H. et al.; Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein; Nat Commun 10 (1), 3068 (2019); 2019.",10.1038/s41467-019-10897-4,,,6J11_F,6J11_G,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain F, VH of 7D10","Chain G, VL of 7D10",evqlvesgaevvkpgasvkmsckasgypftsynihwikqtpgqglewigaiypgngdtsytqkfkvkatltsdkssstaymqlssltsedsavyfcarygnypsyamdywgqgtsvtvss,divmtqspasltvslgqratiscrasksvsasgynylhwyqqrpgqppklliylafnlesgvparfngsgsgtdftlnihpveeedaatyycqhsrdlpftfgsgtkleik,gypftsyn,iypgngdt,arygnypsyamdy,ksvsasgyny,laf,qhsrdlpft,IGHJ4*01 (mouse),IGHV1-12*01 (mouse),IGKJ4*01 (mouse),IGKV3-12*01 (mouse)
GenBank,,,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,,,6NB4_H,6NB4_L,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain H, LCA60 heavy chain","Chain L, LCA60 light chain",evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvt,gltfsnvw,ikrksegatt,stltrggdvwsssyyfdy,ssdvgtydl,adi,clyagsstsvi,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,,,6NB7_H,6NB7_L,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain H, S230 heavy chain","Chain L, S230 light chain",qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,gftfrnya,itsdgrnk,vtqrdnsrdyfphyfhdmdv,qslvysdgdty,qvs,mqgshwppt,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,,,6NB8_H,6NB8_L,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain H, S230 antigen-binding (Fab) fragment, heavy chain","Chain L, S230 antigen-binding (Fab) fragment, light chain",qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,gftfrnya,itsdgrnk,vtqrdnsrdyfphyfhdmdv,qslvysdgdty,qvs,mqgshwppt,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,,,6NB5_I,6NB5_M,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain I, LCA60 antigen-binding (Fab) fragment, heavy chain","Chain M, LCA60 antigen-binding (Fab) fragment, light chain",evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvtgq,gltfsnvw,ikrksegatt,stltrggdvwsssyyfdy,ssdvgtydl,adi,clyagsstsvi,IGHJ4*01 (human),IGHV3-15*01 (human),IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J. Virol. 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,,,6C6Z_H,6C6Z_L,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain H, Antibody CDC2-C2 heavy chain","Chain L, Antibody CDC2-C2 light chain",qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaregghqgycsggscydfdywgqgtlvtvss,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpafgggtkleik,ggtfsiya,iipifgta,aregghqgycsggscydfdy,qsllhsngyny,lgs,mqalqtpa,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,,,6C6Y_H,6C6Y_L,SARS-CoV,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvss,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveik,gdsissny,fsgsggst,aktysgtfdy,qdinny,yas,qqynnspys,IGHJ4*01 (human),IGHV4-4*08 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,,,6C6X_H,6C6X_L,SARS-CoV,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvss,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveik,gdsissny,fsgsggst,aktysgtfdy,qdinny,yas,qqynnspys,IGHJ4*01 (human),IGHV4-4*08 (human),IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Chen,Z. et al.; Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset; J. Infect. Dis. 215 (12), 1807-1815 (2017); 2017.",10.1093/infdis/jix209,,,5GMQ_B,5GMQ_C,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain B, MCA1 heavy chain","Chain C, MCA1 light chain",atrleesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaskqgdyydrtsyafdiwgqgtmvtvss,dveltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleik,ggtfssya,iipilgia,askqgdyydrtsyafdi,qsvsssy,gas,qqygsspit,IGHJ3*02 (human),IGHV1-69*04 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,Y. et al.; A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein; Cell Res. 25 (11), 1237-1249 (2015); 2015.",10.1038/cr.2015.113,,,5DO2_C,5DO2_D,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain C, 4C2 heavy chain","Chain D, 4C2 light chain",dvklvesggglvkpggslklscaasgftfssytmswvrqtpekrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyyctrdgndydywgqgttltvss,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlprtfgggtkleik,gftfssyt,issggsyt,trdgndydy,qdisny,yts,qqgntlprt,IGHJ2*01 (mouse),IGHV5-6-4*01 (mouse),IGKJ1*01 (mouse),IGKV10-96*01 (mouse)
GenBank,,,"Du,Y. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Nat Commun 12 (1), 5000 (2021); 2021.",10.1038/s41467-021-25331-x,,,7E7E_C,7E7E_D,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, h11B11-Fab","Chain D, h11B11-Fab",evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleik,gftfidyy,irnkandytt,arhmyddgfdf,ssvry,dts,qqwsynplt,IGHJ5*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,,,7W9F_A,7W9F_B,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain A, The heavy chain of 8D3","Chain B, The light chain of 8D3",evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvss,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleik,gytfteyt,inpnigdt,ardgypyyyaldh,qnvgtn,sts,qqynsypyt,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ2*01 (mouse),IGKV6-15*01 (mouse)
GenBank,,,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,,,7KN4_M,7KN4_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, S-E6 Fab heavy chain","Chain N, S-E6 Fab light chain",qvtlresgpglvkpsetlsltcavsggslssvnyywswirqhpgkglewigyiyysgstnynpslksrvtmsldtsknqfslklssvtaadtavyycatpgaimgalhiwgqgtlvtvss,qavltqpssasstpgqrviiscsgsssnigsntvswyqqvpgaapklliyfdyrrpsgvpdrfsgtrsgtsaslgisglqsedeadyycaawddslsawvfgrgtkltvl,ggslssvnyy,iyysgst,atpgaimgalhi,ssnigsnt,fdy,aawddslsawv,IGHJ1*01 (human),IGHV4-61*01 (human),IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,,,7KN3_M,7KN3_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain M, S-B8 Fab heavy chain","Chain N, S-B8 Fab light chain",qvqlvqsgggliqpggslrlscaasgftvslshmnwvrqapgkglewvsitygdgnsdyadsvkgrftisrdnskntlylqmnslraedtavyycareyyygmdvwgqgttvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkleik,gftvslsh,tygdgns,areyyygmdv,qsvlyssnnkny,was,qqyyslplt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.",10.1038/s41594-021-00652-z,,,7EH5_E,7EH5_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain E, RBD-chAb15, heavy chain","Chain Q, RBD-chAb15, light chain",evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvss,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelk,dfslttyg,iwsggst,armgdgyyvgamdy,qsigts,yas,qqghnwplt,IGHJ4*01 (mouse),IGHV2-2*02 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
GenBank,,,"Pak,J.E. et al.; Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain; J. Mol. Biol. 388 (4), 815-823 (2009); 2008.",10.1016/j.jmb.2009.03.042,,,3BGF_B,3BGF_C,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Chain B, F26G19 Fab","Chain C, F26G19 Fab",evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,gytfttyr,iypgnsdt,tregipqllrtldy,qeisgy,aas,lqyvsypwt,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
GenBank,,,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",N/A,,,7LU9_q,7LU9_r,not determined,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain q, DH851.3 heavy chain","Chain r, DH851.3 light chain",qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvss,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvl,gfsirdsgkg,iywddtk,grinngggwkdhidf,ttgns,dvn,gsygsggsll,IGHJ2*01 (human),IGHV2-70*01 (human),IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",N/A,,,7LU9_p,7LU9_o,not determined,Macaca mulatta (Rhesus monkey),2022-03-15,"Chain p, DH851.3 heavy chain","Chain o, DH851.3 light chain",qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvss,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvl,gfsirdsgkg,iywddtk,grinngggwkdhidf,ttgns,dvn,gsygsggsll,IGHJ2*01 (human),IGHV2-70*01 (human),IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",N/A,,,7LUA_i,7LUA_j,not determined,Homo sapiens (human),2022-03-15,"Chain i, DH898.1 heavy chain","Chain j, DH898.1 light chain",qdlllqsgaevrepgasvtvscqasnytfpdyyihwvrlvpgqglewlgemkpkvgvtnvskkirdrlfmtadtstdtaymvlsaltpgdtaiyyctrlepdflsgwahwgkgvlvtvsp,eivmtqtplslsvtpgepaslscrssasllhgngntylhwylrkagqspqllifggskrvpgisdrfigsgagtnftlkissveaddvgfyycaqgvafpwtfgqgtkveik,nytfpdyy,mkpkvgvt,trlepdflsgwah,asllhgngnty,ggs,aqgvafpwt,IGHJ1*01 (human),IGHV1-2*02 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2020.",N/A,,,6XRJ_H,6XRJ_L,not determined,Homo sapiens (human),2022-03-15,"Chain H, DH717.1 heavy chain Fab fragment","Chain L, DH717.1 light chain Fab fragment",qvqlqesgpglvkpsetlsltcavsgvsindgydwtwirqtpgkglewigyvfgrsgnfnlnpslrnrgiiskdtcknqfslnlnsataadtavyfcargmeglfaaynsldvwgrgllvtvss,altqppsvsgspgqsviisctgtssdigqynsvswyqqhpdkapklviygvtsrpsgvsdrfsgskygdtasltisglqaedeadyycsshadenmalfgggtrltvl,gvsindgyd,vfgrsgnf,argmeglfaaynsldv,ssdigqyns,gvt,sshadenmal,IGHJ2*01 (human),IGHV4-4*08 (human),IGLJ7*01 (human),IGLV2-11*01 (human)
GenBank,,,"Wu,N.C. et al.; A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody; PLoS Pathog 16 (12), e1009089 (2020); 2020.",10.1371/journal.ppat.1009089,,,7JN5_H,7JN5_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, CR3022 heavy chain","Chain L, CR3022 light chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvvs,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.",N/A,,,QXP08760,QXP08759,SARS-CoV-2,synthetic construct,2022-03-15,"humanized ACE2-targeting immunoglobulin heavy chain, partial [synthetic construct]","humanized ACE2-targeting immunoglobulin light chain, partial [synthetic construct]",evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleik,gftfidyy,irnkandytt,arhmyddgfdf,ssvry,dts,qqwsynplt,IGHJ5*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Isaikina,P. et al.; Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist; Sci Adv 7 (25) (2021); 2021.",10.1126/sciadv.abg8685,,,7O7F_H,7O7F_F,not determined,Mus musculus (house mouse),2022-03-15,"Chain H, Fab antibody fragment heavy chain","Chain F, Fab antibody fragment light chain",dvqlvesggglvqpggsrklscsasgfafssfgmhwvrqapekglewvayissgsgtiyyadtvkgrftisrddpkntlflqmtslrsedtamyycvrsiyyygsspfdfwgqgttltvss,divmtqatssvpvtpgesvsiscrssksllhsngntylywflqrpgqspqlliyrmsnlasgvpdrfsgsgsgtaftltisrleaedvgvyycmqhleypltfgagtklelk,gfafssfg,issgsgti,vrsiyyygsspfdf,ksllhsngnty,rms,mqhleyplt,IGHJ2*01 (mouse),IGHV5-17*02 (mouse),IGKJ5*01 (mouse),IGKV2-137*01 (mouse)
GenBank,,,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.",N/A,,,QVL61760,QVL61759,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,ggsfsgyy,vnhsgst,argntmvrgviipfey,qsvssy,das,qqrsnwplt,IGHJ4*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,,,6XGC_I,6XGC_J,not determined,Macaca fascicularis (crab-eating macaque),2022-03-15,"Chain I, 1C4 Fab heavy chain","Chain J, 1C4 Fab light chain",evqlvesggglakpggslrlscaasgftfstyamhwvrqapgkglewisginsgggstwytasvkgrftisrdnskstlslqmnslrtedtavyycakdggnaifglvitnygldswgqgavvtvss,qsvltqppsasgapgqsvtiscsgsssnfgsnhvywyqqlsgkapklliynnnrrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwdsslnnvlfgggtrltvl,gftfstya,insgggst,akdggnaifglvitnyglds,ssnfgsnh,nnn,svwdsslnnvl,IGHJ5*01 (human),IGHV3-23*03 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Wang,L. et al.; Evaluation of candidate vaccine approaches for MERS-CoV; Nat Commun 6, 7712 (2015); 2015.",10.1038/ncomms8712,,,4ZPV_A,4ZPV_B,MERS-CoV,Mus musculus (house mouse),2022-03-15,"Chain A, D12 Fab Heavy chain","Chain B, D12 Fab light chain",evklvesggglvkpggslklscaasgftfssyamswvrqtpekrlewvatissggtytyypdsvkgrftisrdnaentlylqmsslrsedtamyycvrdgnsmdywgqgtsvtvss,diqmtqttsslsaslgdrvtiicrasqdinnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgsdysltisnleqediatyfcqqantlpptfgagtklelr,gftfssya,issggtyt,vrdgnsmdy,qdinny,yts,qqantlppt,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ5*01 (mouse),IGKV10-96*01 (mouse)
GenBank,,,"Ying,T. et al.; Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody; Nat Commun 6, 8223 (2015); 2015.",10.1038/ncomms9223,,,4XAK_D,4XAK_E,MERS-CoV,Homo sapiens (human),2022-03-15,"Chain D, Heavy chain of neutralizing antibody m336","Chain E, Light chain of neutralizing antibody m336",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtasyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstscnrgafdiwgqgtmvtvss,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveik,ggtfssya,iipifgta,arvgycsstscnrgafdi,qgirnd,aas,qqlnsyplt,IGHJ3*02 (human),IGHV1-69*06 (human),IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Reguera,J. et al.; Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies; PLoS Pathog. 8 (8), E1002859 (2012); 2012.",10.1371/journal.ppat.1002859,,,4F2M_C,4F2M_D,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Chain C, monoclonal antibody 1AF10, heavy chain","Chain D, monoclonal antibody 1AF10, light chain",qvqlqqsgpelvkpgasvkisckasgyafssswmnwvkqrpgqglewigriypgdgetnysekfkgkatltadkssstaymhlssltsvdsavyfcarggyrydpyyamdywgqgtsvtvss,dilltqspailsvspgervslscrasqsigtsihwyqqrtngsprplikyasesisgipsrfsgsgsgtdftlninsvesediadyfcqqtdswpttfgagtklelk,gyafsssw,iypgdget,arggyrydpyyamdy,qsigts,yas,qqtdswptt,IGHJ4*01 (mouse),IGHV1-82*01 (mouse),IGKJ5*01 (mouse),IGKV5-48*01 (mouse)
GenBank,,,"Li,W. et al.; Phage display library derived human Fab against SARS-CoV-2 spike protein receptor binding domain; Unpublished; 2020.",N/A,,,QOQ45101,QOQ45102,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"anti-SARS-CoV-2 S/RBD immunoglobulin heavy chain, partial [synthetic construct]","anti-SARS-CoV-2 S/RBD immunoglobulin light chain, partial [synthetic construct]",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvss,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveik,gftvssny,iysggst,argygdyyfdy,qsvssy,was,qqygssplt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ4*01 (human),IGKV3D-7*01 (human)
GenBank,,,"Castilla,J. et al.; Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies; J. Virol. 71 (7), 5251-5258 (1997); 1997.",N/A,,,AAC53258,AAC53259,SARS-CoV,Mus musculus (house mouse),2022-03-15,"monoclonal antibody gamma one chain variable region, partial [Mus musculus]","monoclonal antibody kappa chain variable region, partial [Mus musculus]",evqlqqsgaelvrsgasvklsctasgfnikdyymhwvkqrpeqglewigwidpengyteyapkfqgkatvtadtssntaylqlssltsedtavyycnafyyrydafdywgqgttltvss,divmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliysasyrytgvpvrftgsgsgtdftftissvqaedlavyycqqhystpytfgggtkleik,gfnikdyy,idpengyt,nafyyrydafdy,qdvsta,sas,qqhystpyt,IGHJ2*01 (mouse),IGHV14-4*02 (mouse),IGKJ2*01 (mouse),IGKV6-17*01 (mouse)
GenBank,,,"ter Meulen,J. et al.; Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants; PLoS Med. 3 (7), E237 (2006); 2006.",10.1371/journal.pmed.0030237,,,ABA54613,ABA54614,SARS-CoV,Homo sapiens (human),2022-03-15,"anti-SARS-CoV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV immunoglobulin light chain variable region, partial [Homo sapiens]",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtv,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AAS19425,AAS19432,SARS-CoV,Homo sapiens (human),2022-03-15,"anti-SARS S protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS S protein immunoglobulin light chain variable region, partial [Homo sapiens]",evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,ttltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,gfafssya,isydgsnk,ardrsyyldy,qsvrsn,das,qqrsnwppt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Flamar,A.L. et al.; Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells; AIDS 27 (13), 2041-2051 (2013); 2015.",10.1097/QAD.0b013e3283624305,,,AJD85779,AJD85780,not determined,synthetic construct,2022-03-15,anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],evqlvesggglvqpggslklscatsgftfsdyymywvrqapgkglewvayinsgggstyypdtvkgrftisrdnakntlylqmnslraedtavyycarrglpfhamdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcsasqgisnylnwyqqkpgkavklliyytsilhsgvpsrfsgsgsgtdytltisslqpedfatyycqqfnklpptfgggtkleik,gftfsdyy,insgggst,arrglpfhamdy,qgisny,yts,qqfnklppt,IGHJ4*01 (mouse),IGHV5-12*02 (mouse),IGKJ4*01 (human),IGKV1-16*01 (human)
GenBank,,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,,,7EZV_H,7EZV_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, H","Chain L, 812L",evqlvqsgaevkkpgeslkiscqfseyklisfwiawvrqrpgkglewmgiiypddsdtkyspssqgqvtisadksirtaylqwsslmasdtamyyctsgsyygtldfwgqgtlvtvss,dieitqspsslsasvgdrvtiscrasqdirtyvawyqqrpgkvprlliyaastlqsgvpsrfsgrgsgtdftltisslqpedvatyycqqynsapltfgggakveik,eyklisfw,iypddsdt,tsgsyygtldf,qdirty,aas,qqynsaplt,IGHJ5*01 (human),IGHV5-51*01 (human),IGKJ4*01 (human),IGKV1-27*01 (human)
GenBank,,,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,,,7NP1_K,7NP1_O,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain K, Immunoglobulin gamma-1 heavy chain","Chain O, Immunoblobulin light chain",evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveik,gitvssny,iysggst,argeggsivgvtsdy,qsisry,aas,qqsystlpyt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,,,7BNV_H,7BNV_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Heavy Chain","Chain L, Light Chain",qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpspyyygsgsysggfdywgqgtlvtvss,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqydnwplmhtfgqgtkleik,gysftsyw,iypgdsdt,arhpspyyygsgsysggfdy,qsvsssy,gas,qqydnwplmht,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.",10.1016/j.celrep.2021.109814,,,7PHG_H,7PHG_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Heavy ChaIn variable","Chain L, Light ChaIn",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,gftftssa,ivvgsgnt,aapncsggscydgfdl,qsvrssy,gas,qqygsspwt,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7RR0_B,7RR0_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain B, PDI 222 Fab Heavy Chain","Chain C, PDI 222 Fab Light Chain",qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgnanyaprfqervtitrdmstntaymelsslrsedtavyycaapncsrtlcydgfnmwgqgtmvtv,eivltqspgslslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyycqqydsspwtfgqgtkvei,gftfsssa,ivvgsgna,aapncsrtlcydgfnm,qsvrssy,gas,qqydsspwt,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZN_H,7MZN_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 231 heavy chain","Chain L, PDI 231 light chain",evqlvesgggliqpggslrlscvasgltvssnymnwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycarvggycssancvsdvwgkgttvtvss,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapkimiydasiletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtqleik,gltvssny,iysggst,arvggycssancvsdv,qdirny,das,qqydnlpit,IGHJ6*04 (human),IGHV3-53*01 (human),IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZM_H,7MZM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 215 heavy chain","Chain L, PDI 215 light chain",evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkgpewvsyisggssftnyadsvqgrftiyrdnaknsmflrmnslraedtavyycarspptgdssdwydspaynnyymdvwgkgttvtvss,eivltqspvtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsptvtfgqgtrleik,gftfsdyy,isggssft,arspptgdssdwydspaynnyymdv,qsvsssy,gas,qqygtsptvt,IGHJ6*04 (human),IGHV3-11*05 (human),IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZL_H,7MZL_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 210 heavy chain","Chain L, PDI 210 light chain",qvqlqqwgagllkpsetlsltcvvygetlsgyywtwirqspgkglewigeislrgtanynpslksrvtlsveasknqfslkmtsvtaadtavyycvggvvldnvvwfdpwgqgipvtvsl,esvltqspvslslspgeratlscrasqsvgtylawyqhrpgqaprlliynaskratgiparfsgsgsgtdftltisslepedlavyfcqqrsnwltfgggtkveik,getlsgyy,islrgta,vggvvldnvvwfdp,qsvgty,nas,qqrsnwlt,IGHJ5*02 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZK_H,7MZK_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 96 heavy chain","Chain L, PDI 96 light chain",lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvss,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveik,gytftsyy,inpsgggt,akdrvtifwgngmdv,qsvlyssnnkny,was,hqysttplt,IGHJ6*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZK_F,7MZK_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain F, WCSL 129 heavy chain","Chain D, WCSL 129 light chain",evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvss,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvl,gftfsrfa,isgsggst,akvgwgafdi,ysnigsnp,and,stwddslpgpl,IGHJ3*02 (human),IGHV3-23*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZJ_N,7MZJ_M,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain N, PDI 93 heavy chain","Chain M, PDI 93 light chain",vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvss,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqik,gftfsyaw,ikrksdggtt,ttdlcrstscehdafdi,qsirsy,aas,qqsyttpait,IGHJ3*02 (human),IGHV3-15*01 (human),IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZH_B,7MZH_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain B, WCSL 119 heavy chain","Chain C, WCSL 119 light chain",evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvss,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvl,gytftgyy,inpnsggt,arsyydy,ssnighna,ydd,aawddilngpv,IGHJ4*01 (human),IGHV1-2*06 (human),IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZG_H,7MZG_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 42 heavy chain","Chain L, PDI 42 light chain",evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsvfypggstynadsvkgrftisrdnskntlylqmnslraedtavyycardavyygmdvwgqgttvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqesystpglftfgpgtkvdik,gltvssny,fypggst,ardavyygmdv,qsissy,aas,qesystpglft,IGHJ6*01 (human),IGHV3-66*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,,,7MZF_H,7MZF_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, PDI 37 heavy chain","Chain L, PDI 37 light chain",evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggttyyadsvkgrftisrdsskntlylqmnslraedtavyycardrgdylfdywgqgtlvtvss,diqmtqppsplfasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgseteftltisslqpddfatyycqqynsyfptfgqgtkveik,efivsrny,iysggtt,ardrgdylfdy,qsissw,kas,qqynsyfpt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E8F_D,7E8F_E,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain D, H","Chain E, L",evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleik,giivssny,iysggst,ardlgpygmdv,qgissd,aas,qqlnsdlyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,,,7E8C_O,7E8C_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain O, H","Chain Q, L",evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleik,giivssny,iysggst,ardlgpygmdv,qgissd,aas,qqlnsdlyt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,,,7DZY_O,7DZY_P,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain O, Fab Heavy chain of enhancing antibody 2490","Chain P, Fab light chain of enhancing antibody 2490",evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvss,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkvein,gftfssyw,inqdggek,ardpydlygdyggtfdy,qsvssn,gas,qqynnwwrt,IGHJ4*01 (human),IGHV3-7*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,,,7DZX_H,7DZX_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain H, Fab Heavy chain of enhancing antibody","Chain L, Fab light chain of enhancing antibody",evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycardwdydiltgswfgafdiwgqgttvtvss,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,gftfssyw,inqdgsek,ardwdydiltgswfgafdi,qgirnd,aas,lqhnsyplt,IGHJ3*02 (human),IGHV3-7*01 (human),IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,,,7KLG_I,7KLG_M,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, Fab 15033 heavy chain","Chain M, Fab 15033 light chain",evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveik,gfdlggys,iyasggat,arsyyyggfgmdy,qsvssa,sas,qqsyrypit,IGHJ4*01 (human),IGHV3-23*04 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,,,7KFV_H,7KFV_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Heavy chain of antibody C1A-B12 Fab","Chain L, light chain of antibody C1A-B3 Fab",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsg,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleik,gftvssny,iysggat,argdvsgyrygldy,qgissy,aas,qqlisypgt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",N/A,,,7K9Z_B,7K9Z_A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain B, Fab Heavy Chain","Chain A, Fab Light Chain",qvqlvqsgaevkkpgasvkvsckasggtfstygiswvrqapgqglewmgwispnsggtdlaqkfqgrvtmtrdtststvymelsslrsedtavyycasdprddiaggywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,ggtfstyg,ispnsggt,asdprddiaggy,qsvlyssnnkny,was,qqyystppt,IGHJ4*01 (human),IGHV1-2*02 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",N/A,,,7K9Z_H,7K9Z_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Fab Heavy Chain","Chain L, Fab Light Chain",qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdik,gytftsyg,iipmfgtt,ardrgdtidy,qgisnn,aas,qqgngfplt,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,,,5ZXV_C,5ZXV_D,MERS-CoV,Homo sapiens (human),2022-03-15,"Chain C, heavy chain","Chain D, light chain",gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvss,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,gftfsnya,isydistd,agndy,ssnignny,wnd,aawddslsgav,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV1-47*01 (human)
GenBank,,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,,,5YY5_C,5YY5_D,MERS-CoV,Homo sapiens (human),2022-03-15,"Chain C, Heavy chain","Chain D, Light chain",gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvt,ltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqlt,gftfsnya,isydistd,tntyy,ssnignny,wnd,aawddslsgav,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*02 (human),IGLV1-47*01 (human)
GenBank,,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,,,5YY5_H,5YY5_L,MERS-CoV,Homo sapiens (human),2022-03-15,"Chain H, Heavy chain","Chain L, Light chain",evqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvtvs,qpvltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,gftfsnya,isydistd,tntyy,ssnignny,wnd,aawddslsgav,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ7*01 (human),IGLV1-47*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7D03_H,7D03_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Immunoglobulin heavy variable 4-61,chain H of FabP5A-2G7,Epididymis luminal protein 214","Chain L, IGL c2312_light_IGLV2-14_IGLJ2,IGL@ protein",qvqlqesgpglvkpsetlsltctvsgdsvssgsyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarercyygsgraprcvwfdpwgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,gdsvssgsyy,iyysgst,arercyygsgraprcvwfdp,ssdvggyny,dvs,ssytssstlvv,IGHJ5*02 (human),IGHV4-61*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7D00_J,7D00_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,chain H of FabP5A-1B8,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveik,gftvssny,iypggst,aretlafdy,qgissy,aas,qqlnsyppa,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZZ_J,7CZZ_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214","Chain N, IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant",qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycaryivvvpaakgfdpwgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,gytftsyd,mnpnsgnt,aryivvvpaakgfdp,qsvlyssnnkny,was,qqyystplt,IGHJ5*02 (human),IGHV1-8*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZX_J,7CZX_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Immunoglobulin heavy variable 4-59,chain H of P5A-1B9,IGH@ protein","Chain N, IG c168_light_IGKV4-1_IGKJ4,Uncharacterized protein",qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyisysgstnynpslksrvtisldtsknqfslklssvtaadtavyycasngqyydiltgqppdywyfdlwgrgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,ggsissyy,isysgst,asngqyydiltgqppdywyfdl,qsvlyssnnkny,was,qqyystplt,IGHJ2*01 (human),IGHV4-59*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZV_J,7CZV_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Immunoglobulin heavy variable 3-30-3,chain H of P5A-1B6_3B,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleik,gftfssya,isydgsnk,ardgqaitmvqgvigppfdy,qdisny,das,qqydnlpyt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZU_H,7CZU_K,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, Immunoglobulin heavy variable 3-30-3,Immunoglobulin heavy variable 3-30-3,Chain H of P5A-1B6_2B,Immunoglobulin gamma-1 heavy chain,Immunoglobulin gamma-1 heavy chain","Chain K, Immunoglobulin kappa variable 1-33,Immunoglobulin kappa variable 1-33,Uncharacterized protein",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleik,gftfssya,isydgsnk,ardgqaitmvqgvigppfdy,qdisny,das,qqydnlpyt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZT_I,7CZT_M,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain I, Immunoglobulin heavy variable 3-33,chainH of P5A-2G9,Immunoglobulin gamma-1 heavy chain","Chain M, IG c689_light_IGLV5-37_IGLJ3,IGL@ protein",qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarwfhtggyfdywgqgtlvtvss,qpvltqppsssaspgesarltctlpsdinvssyniywyqqkpgsppryllyyysdsdkgqgsgvpsrfsgskdasantgillisglqsedeadyycmiwpsnalyvfgtgtkvtvl,gftfssyg,iwydgsnk,arwfhtggyfdy,sdinvssyn,yysdsdk,miwpsnalyv,IGHJ4*01 (human),IGHV3-33*01 (human),IGLJ1*01 (human),IGLV5-37*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZS_J,7CZS_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveik,gftvssny,iypggst,aretlafdy,qgissy,aas,qqlnsyppa,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZR_J,7CZR_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvss,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveik,gftvssny,iypggst,aretlafdy,qgissy,aas,qqlnsyppa,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZQ_J,7CZQ_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,Chain H of P2B-1A10,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaregpksitgtafdiwgqgtivtvss,diqmtqspsslsasvgdrvtitcqasqdisnyfnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpmytfgqgtkleik,gftvssny,iysggst,aregpksitgtafdi,qdisny,das,qqydnlpmyt,IGHJ3*02 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,,,7CZP_J,7CZP_N,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain J, Immunoglobulin heavy variable 4-59,Chain H of P2B-1A1,Anti-RhD monoclonal T125 gamma1 heavy chain","Chain N, IG c181_light_IGLV2-14_IGLJ3,IGL@ protein",qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtskkqfslklssvtaadtavyycarlerdwpldafdiwgqgtmvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkfmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsnntfafgggtkltvl,ggsissyy,iyysgst,arlerdwpldafdi,ssdvggyny,dvs,ssytsnntfa,IGHJ3*02 (human),IGHV4-59*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,,,7CH5_H,7CHC_L,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain H, BD-629 Fab H","Chain L, IGK@ protein",evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveik,efivsrny,iysggst,ardygdyyfdy,qgvssf,gas,qqygssprt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.",10.1016/j.chom.2020.06.010,,,6YOR_B,6YOR_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain B, IgG H chain","Chain C, IgG L chain",qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvas,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,gygfityw,iypgdset,aggsgistpmdv,qsvlyssinkny,was,qqyystpyt,IGHJ6*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,,,7W9E_D,7W9E_E,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain D, Anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain","Chain E, The light chain of 8D3 fab",evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvss,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleik,gytfteyt,inpnigdt,ardgypyyyaldh,qnvgtn,sts,qqynsypyt,IGHJ4*01 (mouse),IGHV1-26*01 (mouse),IGKJ2*01 (mouse),IGKV6-15*01 (mouse)
GenBank,,,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,,,2DD8_H,2DD8_L,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain H, IGG Heavy Chain","Chain L, IGG Light Chain",qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,ggtfssyt,itpilgia,ardtvmggmdv,nigsks,dds,qvwdsssdyv,IGHJ6*01 (human),IGHV1-69*16 (human),IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,,,6WZT_G,6WZT_F,not determined,Macaca fascicularis (crab-eating macaque),2022-03-15,"Chain G, Cyno antibody heavy chain","Chain F, Cyno antibody light chain",qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvss,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveik,ggtfsayy,isggsgst,vrkywgdyyanwfdv,qsissw,kas,qqysgrppt,IGHJ2*01 (human),IGHV4-38-2*01 (human),IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,MZ517191,MZ517250,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 53181-1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 5317-10 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,gytftnyv,isayngst,ardpasyydfwsgyvdyyyygmdv,qsllfgngyty,lgs,mqalqtpwt,IGHJ6*01 (human),IGHV1-18*01 (human),IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,OM001674,OM001699,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 5885-1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 5885-13 immunoglobulin light chain variable region mRNA, partial cds",qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,ggsisstnyy,ifytgst,arytsyydrsgfrrveyfqh,klgdky,hdt,qawgsstav,IGHJ1*01 (human),IGHV4-39*01 (human),IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,OM457661,OM457822,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CS1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CS99 anti-SARS-CoV-2 immunoglobulin kappa chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,gfpfstyg,isydgsnk,akdfqyvaathspyyyygmdv,qsvsssy,gas,qqygssplt,IGHJ6*01 (human),IGHV3-30*18 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927186,MZ927185,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone A10 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A10 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgygdyrglygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasrdinkylawyqqkpgkapklliygessraagvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpnigdt,ardgygdyrglygmdv,rdinky,ges,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927188,MZ927187,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone A11 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A11 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysygylsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpytgdt,ardgysygylsgmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927190,MZ927189,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone A12 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A12 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgwgsllngiavagldywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpytgdt,ardgwgsllngiavagldy,qdignh,ass,hqyatypwt,IGHJ4*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927192,MZ927191,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone B2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B2 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaysgsypyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasegisnylawyqqkpgkapklliygtsdrasgipsrfsgsgsgtdftltisslqpedfanyycqqysafpwtfgggtkveik,gysftdhs,inpytgdt,ardaysgsypyyyygmdv,egisny,gts,qqysafpwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927194,MZ927193,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone B3 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B3 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdsyyydssgsglgggfdywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gytspat,ispykgdt,akdsyyydssgsglgggfdy,qdignh,ass,hqyatypwt,IGHJ4*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927196,MZ927195,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone B7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B7 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdgwgsllngiavagldywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpnigdt,akdgwgsllngiavagldy,qdignh,ass,hqyatypwt,IGHJ4*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927198,MZ927197,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone B11 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B11 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaypyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpytgdt,ardaypyyygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927200,MZ927199,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone C1 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C1 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmggistqrgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyygsgtyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqsigsflawyqqkpgkapklliygesnratgvpsrfsgsgsgtdftltisslqpedfanyycqqynrypwafgggtkveik,gysftdhs,istqrgdt,ardgyygsgtyyyygmdv,qsigsf,ges,qqynrypwa,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927202,MZ927201,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone C2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C2 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckasgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaysssyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasediskylawyqqkpgkapklliygasnlhtgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gytspat,ispykgdt,ardaysssyyygmdv,edisky,gas,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927204,MZ927203,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone C4 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C4 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgydygsvgrdyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpytgdt,ardgysgydygsvgrdyyyygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927206,MZ927205,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone C7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C7 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftnyaihwvrqapgkglewmggitpynadtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardggnwaapysmdvwgngtlvtvss,diqmtqspssvsasvgdrvtitcrashgissylawyqqkpgkapklliydatiratgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftnya,itpynadt,ardggnwaapysmdv,hgissy,dat,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927208,MZ927207,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone D2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone D2 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardarlldywgqgaqvtvss,diqmtqspssvsasvgdrvtitcrasrsignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysftdhs,inpytgdt,ardarlldy,rsignh,ass,hqyatypwt,IGHJ4*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927210,MZ927209,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone D3 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone D3 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgysfadyaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgydfwsgsygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyycqqyseypwtfgggtkveik,gysfadya,inpnigdt,ardgydfwsgsygmdv,qdignh,ass,qqyseypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927212,MZ927211,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone F1 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F1 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgypftsyaihwvrqapgkglewmggitpynadtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyssgyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gypftsya,itpynadt,ardgyssgyygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927214,MZ927213,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone F5 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F5 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgyvegmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqnihsylawyqqkpgkapklliydtsklqsgvpsrfsgsgsgtdftltisslqpedfanyychqyaaypwtfgggtkveik,gytfsnha,inpnigdt,ardgysgyvegmdv,qnihsy,dts,hqyaaypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927216,MZ927215,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone F7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F7 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysfstytihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgyessyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gysfstyt,inpytgdt,ardgysgyessyyyygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927218,MZ927217,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone G2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G2 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgytftanaihwvrqapgkglewmggigpgqgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardghcsggscpsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliygasiresgvpsrfsgsgsgtdftltisslqpedfanyycqqysafpwtfgggtkveik,gytftana,igpgqgdt,ardghcsggscpsgmdv,qdignh,gas,qqysafpwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927220,MZ927219,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone G4 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G4 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgytlsdhaihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgydfwsgsygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gytlsdha,inpytgdt,ardgydfwsgsygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927222,MZ927221,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone G5 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G5 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysygylsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdishhlawyqqkpgkapklliydaslratgipsrfsgsgsgtdftltisslqpedfanyychqyaaypwtfgggtkveik,gysftdhs,inpytgdt,ardgysygylsgmdv,qdishh,das,hqyaaypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927224,MZ927223,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone G6 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G6 immunoglobulin light chain variable region gene, partial cds",evqlvesgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgypgdysgldvwgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqpissylawyqqkpgkapklliyeasklqsgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gytfsnha,inpnigdt,ardgypgdysgldv,qpissy,eas,hqyatypwt,IGHJ5*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927226,MZ927225,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone G12 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G12 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgygdyrglygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gytfsnha,inpnigdt,ardgygdyrglygmdv,qdignh,ass,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927228,MZ927227,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone H2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone H2 immunoglobulin light chain variable region gene, partial cds",evqlvqsgaevkkpgasvkvsckvsgypftrstihwvrqapgkglewmgginagtgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyssgyygmdvwgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqgisdflawyqqkpgkapklliygasnratgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,gypftrst,inagtgdt,ardgyssgyygmdv,qgisdf,gas,hqyatypwt,IGHJ6*01 (human),IGHV1-24*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain; Science (2022) In press; 2021.",N/A,,,OL621229,OL621230,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone C1C-A3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone C1C-A3 immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvss,eivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleik,gftfssyg,iwydgtnt,ardlayrdyvwryfdl,qsvsty,das,qcrsnwppgit,IGHJ2*01 (human),IGHV3-33*01 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Krebs,S.J. et al.; Direct Submission; Submitted (16-AUG-2021) MHRP, HJF/WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA; 2021.",N/A,,,MZ825529,MZ825470,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens isolate WRAIR-2004 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate WRAIR-2196 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpssggtnyaqkfqgrvtmtrdtsistaymelsslrsddtavyycatdgddgenwfdpwgqgtlvivss,qpvltqpssvsvspgqtatitcsgdvlakkyarwfqqkpgqapmlviykdterpsgiperfsgsssgttvtltingaqvedeadyycysaaawvfgggtkltvl,gytftgyy,inpssggt,atdgddgenwfdp,vlakky,kdt,ysaaawv,IGHJ5*02 (human),IGHV1-2*06 (human),IGLJ3*02 (human),IGLV3-27*01 (human)
GenBank,,,"Altomare,C.G. et al.; Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses; Unpublished; 2021.",N/A,,,OK094317,OK094392,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Homo sapiens isolate ab007_VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate ab200_VL immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasphcsstsclyhyyyygmdvwgqgttvtvss,qseltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsayvvfgggtkltvl,ggtfssya,iipifgta,asphcsstsclyhyyyygmdv,ssnigagyd,gns,qsydsslsayvv,IGHJ6*01 (human),IGHV1-69*01 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",N/A,,,MZ751047,MZ751048,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Mus musculus clone 12C10 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus clone 12C10 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",evklqesggglvkpggslklscaasgftfsnysmswvrqtpekrlewvatisngggyiyyldsvkgrftisrdnakntlylqmsslrsedtamyycgrprpekefiststamdhwgqgttvt,evtmsckssqsllyssyqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypftfgsgtkleik,gftfsnys,isngggyi,grprpekefiststamdh,qsllyssyqkny,was,qqyysypft,IGHJ4*01 (mouse),IGHV5-9-1*01 (mouse),IGKJ4*01 (mouse),IGKV8-30*01 (mouse)
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,MT470197,MT470196,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CB6 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CB6 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvss,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleik,gftvssny,iysggst,arvlpmygdyldy,qsisry,aas,qqsystppeyt,IGHJ4*01 (human),IGHV3-66*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Xie,J. et al.; Direct Submission; Submitted (26-JUL-2021) The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, Anhui 230001, China; 2021.",N/A,,,MZ668598,MZ668599,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens isolate XG81 immunoglobulin heavy chain variable region gene, partial cds","Homo sapiens isolate XG81 immunoglobulin light chain variable region gene, partial cds",evqlvesggglvkpggslrlscaasgfsfsdawmswvrqapgkglewvgrikskvdggttdyaapvkgrftisrdeskdilylqmnslktedtavyfcatavvvvvtnglddafdiwgqgtmvtvss,diqmtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsfstlftfgpgtkvdlk,gfsfsdaw,ikskvdggtt,atavvvvvtnglddafdi,qsisss,aas,qqsfstlft,IGHJ3*02 (human),IGHV3-15*01 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Xie,J. et al.; Direct Submission; Submitted (26-JUL-2021) The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, Anhui 230001, China; 2021.",N/A,,,MZ668600,MZ668601,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens isolate XG83 immunoglobulin heavy chain variable region gene, partial cds","Homo sapiens isolate XG83 immunoglobulin light chain variable region gene, partial cds",qvqlvqsgaevkkpgssvkvsckasgdtfssytitwvrqapgqglewmgrvipilgtanyaqkfqgrvtitadkstrtaymelsslrsddsamyycarergysgngaayyfdywgqgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygdsnrpsgvpdrfsgsksgtsaslaitglqaedeadfycqsydsslstsifgggtkltvl,gdtfssyt,vipilgta,arergysgngaayyfdy,ssnigagyd,gds,qsydsslstsi,IGHJ4*01 (human),IGHV1-69*08 (human),IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,MZ883076,MZ883093,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens clone CV503_VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CV635_VL immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,ggtfg,iipilgta,ardgdsgsyyetlgfdy,alpkqy,kds,qsadssatyvv,IGHJ4*01 (human),IGHV1-69*08 (human),IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.",N/A,,,MZ514138,MZ514137,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone h11B11 humanized ACE2-targeting immunoglobulin heavy chain gene, partial cds","Synthetic construct clone h11B11 humanized ACE2-targeting immunoglobulin light chain gene, partial cds",evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleik,gftfidyy,irnkandytt,arhmyddgfdf,ssvry,dts,qqwsynplt,IGHJ5*01 (human),IGHV3-72*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665419,MT665032,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2072 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2072 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,gftftssa,ivvgsgnt,aaphcnrtscydafdl,qsvsssy,gas,qqygsspwt,IGHJ3*01 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665457,MT665070,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2489 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2489 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,ggsissttyy,iyysgst,arqwkwfgeawyfdl,qsvsssy,gas,qqygsspft,IGHJ2*01 (human),IGHV4-39*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665458,MT665071,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-3012 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-3012 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,gftfssyd,igtagdt,arvlydssgfynwfdp,qsissy,aas,qqsyeippwt,IGHJ5*02 (human),IGHV3-13*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665805,MT665418,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2183 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2183 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,gftfssya,isydgsnk,aradtmvrgtyfey,ssdvggyny,dvs,ssytssravl,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665427,MT665040,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2130 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2130 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,gftfrdvw,ikskidggtt,ttagsyyydtvgpglpegkfdy,qsvlyssnnkny,was,qqyystlt,IGHJ4*01 (human),IGHV3-15*01 (human),IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,MT665525,MT665138,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2838 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2838 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,gftfmssa,ivigsgnt,aapycssiscndgfdi,qsvsssy,gas,qhygssrgwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,MZ458523,MZ458524,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate A19-46.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A19-46.1 anti-SARS-CoV-2 immunoglobulin lambda light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,gftlssyg,isydgsnk,argwaywellpdyyygmdv,sgsvstayf,gtn,vlymgrgivv,IGHJ6*01 (human),IGHV3-30*03 (human),IGLJ2*01 (human),IGLV8-61*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,MZ458525,MZ458526,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate A19-61.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A19-61.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,gftfssya,isydgsnq,ardlaiavagtwhyyngmdv,qgissw,das,qqaksfpit,IGHJ6*01 (human),IGHV3-30*01 (human),IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,MZ458527,MZ458528,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate A23-58.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A23-58.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,gftftssa,ivvgsgnt,aapncsnvvcydgfdi,qsvsssy,sas,qqygtspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,MZ458529,MZ458530,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate B1-182.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate B1-182.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,gftftssa,ivvgsgnt,aapycsggscfdgfdi,qsvsssy,gas,qqygnspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,MW426536,MW426544,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate CC40.5-HC cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CC9.3-KLC cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,gftfsnyg,msydgsvt,akgqplddi,qtisyisnnkny,was,qqyfntpwt,IGHJ2*01 (human),IGHV3-30*18 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,MW532169,MW532198,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate CC10.1-HC cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CC40.7-LLC cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,ggsissgdyy,iyysgst,argksptvvtpwfdy,nigsks,ddg,qvwdssshwv,IGHJ4*01 (human),IGHV4-30-4*01 (human),IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv (2021) In press; 2021.",10.1126/sciadv.abf5632,,,MW881223,MW881224,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone 47D11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 47D11 immunoglobulin light chain variable region mRNA, partial cds",qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,ggsisshy,iyysgst,argvllwfgepifei,qsvsss,gas,qqynnwplt,IGHJ3*02 (human),IGHV4-59*11 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Voss,W.N. et al.; Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes; Science (2021) In press; 2021.",10.1126/science.abg5268,,,MZ049539,MZ049552,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Homo sapiens isolate CM17 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CM58 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevqkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfdpedgetfyaqkfqgrvtmtedsstdtaymelsslgsedtavyycataaavrgrgtidywgqgtlvtvss,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,gytlpels,fdpedget,ataaavrgrgtidy,ssdvggyny,dvs,ssytssstlvv,IGHJ4*01 (human),IGHV1-24*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.",N/A,,,MW454371,MW454370,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CA521 anti-SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone CA521 anti-SARS-CoV-2 immunoglobulin light chain mRNA, partial cds",evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,ggsfsgyy,vnhsgst,argntmvrgviipfey,qsvssy,das,qqrsnwplt,IGHJ4*01 (human),IGHV4-34*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MW681558,MW681586,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CV3-1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV3-1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,gftftssa,ivvgsgnt,aapscsggrcydgfdi,qsvsssy,gas,qqygtspwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MW681758,MW681759,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CV2-75 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV2-75 immunoglobulin lambda light chain variable region mRNA, partial cds",qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,ggsissyy,vyysgst,assqrpdgnlyyfdy,nigskt,dds,qvwdsssdhyv,IGHJ4*01 (human),IGHV4-59*01 (human),IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",N/A,,,MW579767,MW579768,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens strain H2L2 clone 1.6c7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 1.6c7 immunoglobulin light chain variable region mRNA, partial cds",qvqlqqsgpglvkpsqtlsltcaisgdsvssdsaawnwirqspsrglewlgrtyfrskwnnhyavsvksritinpdtsknqfslllnpvtpedtavyycaratlargaldywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnmnylawyqqkpgqppklliywastresgvpdrfsgsgpgtdftltisslqaedvavyycqqyystpwtfgqgtkleik,gdsvssdsaa,tyfrskwnn,aratlargaldy,qsvlyssnnmny,was,qqyystpwt,IGHJ4*01 (human),IGHV6-1*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",N/A,,,MW579769,MW579770,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens strain H2L2 clone 28d9 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 28d9 immunoglobulin light chain variable region mRNA, partial cds",qvqlqqsgpglvkpsqtlsltcaisgdnvfsnsaawnwirqspsrglewlgrtyyrskwnndyavsvkgritinpdtyknqfslqlnpvtpedtavyfcarvpmnrggmdvwgqgttvtvss,divmtqspdslavslgeratinckssqsvlassnnmnylawyqqkpgqppklliywasiresgvpdrfsgsgpgtdftltisslqtedvavyychqyysipntfgqgtkleik,gdnvfsnsaa,tyyrskwnn,arvpmnrggmdv,qsvlassnnmny,was,hqyysipnt,IGHJ6*01 (human),IGHV6-1*01 (human),IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",N/A,,,MW579771,MW579772,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens strain H2L2 clone 18h2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 18h2 immunoglobulin light chain variable region mRNA, partial cds",qvqlqqsgpglvkpsqtlsltcaisgdsvssnsvawnwirqsplrglewlgrtyyrskwnndyavsvksriiitpdtsknqfslqlnpvtpedtavyycarvglgkgafdiwgqgtmvtvss,divmtqspdslavslgeratinckssqsvlyrpnknnylgwyqqkpgqppkvliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysipwtfgqgtkvevk,gdsvssnsva,tyyrskwnn,arvglgkgafdi,qsvlyrpnknny,was,qqyysipwt,IGHJ3*02 (human),IGHV6-1*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Huang,K.-Y.A. et al.; Direct Submission; Submitted (28-AUG-2020) Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, No. 5, Fu-Shin street, Kweishan, Taoyuan 333, Taiwan; 2021.",N/A,,,MT943491,MT943518,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens clone FD 11A heavy chain variable region mRNA, partial cds","Homo sapiens clone FM 1A light chain variable region mRNA, partial cds",evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvss,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdqgvfgggtkltvl,gftfssyg,iwydgsnk,akgpdiltgyynyyyygmdv,nigsks,dds,qvwdsssdqgv,IGHJ6*01 (human),IGHV3-33*03 (human),IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,MT599861,MT599945,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate COVA2-15 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA2-15 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,gftfssya,isgsggst,akdtgycgddcyiklirggpdy,qslvysdgntf,qvs,mqgthwprt,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,MT599835,MT599919,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate COVA1-16 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA1-16 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,gytftsyy,inssggst,arpprnyydrsgyyqraeyfqh,qdisny,das,qqydnpplt,IGHJ1*01 (human),IGHV1-46*01 (human),IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,MT599837,MT599921,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate COVA1-18 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA1-18 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,gftvssny,iysggst,arvewaaagtfy,tgavtsghy,dts,llsysgvwv,IGHJ4*01 (human),IGHV3-66*01 (human),IGLJ3*02 (human),IGLV7-46*01 (human)
GenBank,,,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",N/A,,,MW271801,MW271802,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Mus musculus strain BALB/c clone 3C1 anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone 3C1 anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region mRNA, partial cds",evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvss,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleik,gdsitngy,isysgst,asdyhgskyyfdy,qdvgnd,was,qqynrypyt,IGHJ2*01 (mouse),IGHV3-8*02 (mouse),IGKJ2*01 (mouse),IGKV6-23*01 (mouse)
GenBank,,,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",N/A,,,MW271803,MW271804,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Mus musculus strain BALB/c clone 2H2 anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone 2H2 anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region mRNA, partial cds",qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvss,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleik,gfsltsyg,mwrggnt,aknggahamdf,esvdsygnsf,las,qqnnedpft,IGHJ4*01 (mouse),IGHV2-5-1*01 (mouse),IGKJ4*01 (mouse),IGKV3-10*01 (mouse)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,MW116210,MW116179,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone JS16 anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region gene, partial cds","Homo sapiens clone JS01 anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region gene, partial cds",qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,ggtfssya,iipifgta,araywgrgptifgvvsnttryygmdv,qsvsssy,gas,qqygssprgvt,IGHJ6*01 (human),IGHV1-69*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,Y. et al.; IgA MAb blocks SARS-CoV-2 spike-ACE2 interaction providing mucosal immunity; Nat Commun (2020) In press; 2020.",N/A,,,MT789771,MT789772,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens MAb362 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens MAb362 immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqlnslraedtaiyycareryfdwifdfwgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,gfsfssyg,iwydgsdk,areryfdwifdf,qsvsssy,gas,qqygsswt,IGHJ5*01 (human),IGHV3-33*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,MT712278,MT712315,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 4-8 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 2-17 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,ggtfssht,iipilgia,aslqtvdtaiekyygmdv,qsvssd,gas,qqynnwppft,IGHJ6*01 (human),IGHV1-69*02 (human),IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,,,MT763531,MT763532,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2196 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2196 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,gftfmssa,ivigsgnt,aapycssiscndgfdi,qsvsssy,gas,qhygssrgwt,IGHJ3*02 (human),IGHV1-58*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Ellebedy,A.H. et al.; Direct Submission; Submitted (14-APR-2020) Pathology, Washington University St. Louis, 425 South Euclid, St. Louis, MO 63110, USA; 2020.",N/A,,,MT341590,MT341641,not determined,Mus musculus (house mouse),2022-03-15,"Mus musculus isolate mCOV.2.1H10.G immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus isolate mCOV.2.1H06.K immunoglobulin light chain variable region mRNA, partial cds",qvqlkesgpglvapsqslsitctvsgfsltnyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarisyydyegvdywgqgttltvss,divltqspaslavslgqratiscrasesveyygtslmqwfqqkpgqppkllifaasnvesgvparfggsgsgtdfslnihpveeddiatyfcqqsrkvpwtfgggtkleik,gfsltnya,iwtgggt,arisyydyegvdy,esveyygtsl,aas,qqsrkvpwt,IGHJ2*01 (mouse),IGHV2-9-1*01 (mouse),IGKJ1*01 (mouse),IGKV3-1*01 (mouse)
GenBank,,,"Walker,L.M. et al.; Direct Submission; Submitted (03-JUN-2020) Antibody Sciences, ADIMAB LLC, 7 LUCENT DRIVE, Lebanon, NH 03766, United States; 2020.",N/A,,,MT565750,MT566149,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate ADI-55688_HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate ADI-56081_LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,gftfssyy,issdgynt,ardfsghtavagtgfey,qsvtsny,gas,qqygraplyt,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126644,MZ126659,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_1 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkdgssvkvsceasggtfsdyaiswvrqapgqglewmgriipilgitnyaqqfqtrvtitadkstsavymelsslrskdtaiyycarevnyysafddwgqgtqvtvss,eivmtqspdtlsvspgeratlscrasqnvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftlaisslqsedfavyycqqynfwwtfgqgtkvdik,ggtfsdya,iipilgit,arevnyysafdd,qnvssn,das,qqynfwwt,IGHJ5*01 (human),IGHV1-69*04 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126656,MZ126671,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_13 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_13 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvppggslglscaasgftfsefwmswvrqtpgkglewvanigqdgnskyyvdsvkgrftisrdnaksslnlqmnslraedtgvyycarvtivssftnrfdpwgqgvlvtvss,aiqltqspsslsasigdrvtftcrasqdisnflawyqqkpgeppklliysvstlqsgvpsrfsgsgsgtdftltisslqsedlatyycqhrvtfgpgtkvgik,gftfsefw,igqdgnsk,arvtivssftnrfdp,qdisnf,svs,qhrvt,IGHJ5*02 (human),IGHV3-7*01 (human),IGKJ3*01 (human),IGKV1-27*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126645,MZ126660,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_2 immunoglobulin light chain variable region mRNA, partial cds",evqlvqsgaevkkpgeslrisckgsgyrfitywiswvrqmpgrglewmgkidpsdsstnyspsfqghvaisvdksfntaylqwsrlntsdtamyycaagptgydlltgqyfpyfnywaqgtlvtvss,nfmltqphsvsespgktvsisctrssgsiaskfmqwyqqrpgsaptiliyednlrpsgvpdrfsgsidtssnsalltisglktedeadyycqsyhgsdvvfgggtkltvl,gyrfityw,idpsdsst,aagptgydlltgqyfpyfny,sgsiaskf,edn,qsyhgsdvv,IGHJ4*01 (human),IGHV5-10-1*01 (human),IGLJ2*01 (human),IGLV6-57*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126648,MZ126663,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_5 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_5 immunoglobulin light chain variable region mRNA, partial cds",qlrlqasgpglvrpsvtlsltcavsgasvksdksywgwfrqspgkglasiatiyyngnvyynpslksrvtlsldtstnqlslkmrsvtaadtaiyycarldyskqtwgqgilvtvss,divmtqsprslpvtpgepasiscrssqslvhtngynyldwylqkpgqspqlliylasnrasgvpgrfsgsgsgtdftlkisrveaddvgvyycmqalqtpltfgggtrleik,gasvksdksy,iyyngnv,arldyskqt,qslvhtngyny,las,mqalqtplt,IGHJ1*01 (human),IGHV4-39*01 (human),IGKJ5*01 (human),IGKV2-28*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126646,MZ126661,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_3 immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgftfsvypmhwvrqapgrglewvavisydgsnqyyadsvrgrftisrdnskntlylhmnslrpedtavfycardrsatyygpfdywgqgtlvtvss,sseltqdpavsvalgqtvritcqgdslrsysaswyqqkpsqapvlviyannnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdnsgnhpvifgggttltvl,gftfsvyp,isydgsnq,ardrsatyygpfdy,slrsys,ann,nsrdnsgnhpvi,IGHJ4*01 (human),IGHV3-30*01 (human),IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126652,MZ126667,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_9 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_9 immunoglobulin light chain variable region mRNA, partial cds",qvqlqesgpglvkpsetlsltciisggsvssgsyywswirqppgkgleyigyifysgntnynpslksrvtisvdtsknqfslrltsvtaadtavyhcaslptygsgrwgidswgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdisiwltwyqqrpgkapklliyaasalqrgvpsrfsgsgsgtdftltisslqpedfttyfcqqgnsfpltfgggtkveik,ggsvssgsyy,ifysgnt,aslptygsgrwgids,qdisiw,aas,qqgnsfplt,IGHJ5*01 (human),IGHV4-61*01 (human),IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126647,MZ126662,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_4 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_4 immunoglobulin light chain variable region mRNA, partial cds",evpllesggglvqpggslrlscvasgfpfssfalswvrqapgkglewvstintnggttyyldsvkgrftvsrdnskntlflqmsslraedtaiyycakdllshsgtysagstfdywgqgtlvivss,diqmtqspsslsasvgdrvtitcrasqsigvylnwyqqkpgkapkllihatsnlqsgvpsrfscsgsgteftltisslqpedfatyycqesystntfgqgtkleik,gfpfssfa,intnggtt,akdllshsgtysagstfdy,qsigvy,ats,qesystnt,IGHJ4*01 (human),IGHV3-23*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126658,MZ126673,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_15 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_15 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgselkkpgasvkvsckasgytftsyalnwvrqapgqglewmgwinintgkptyaqgftgrfvlsldtsvstaylqisslkaedtavyycardfdlvvpsatyppfyyhgmdvwgqgttvtvss,sseltqdpavsvalgqtvritcqgdslrtyyaswyqqkpgqapilviygknkrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgdqtfyvfgtgtqvtvl,gytftsya,inintgkp,ardfdlvvpsatyppfyyhgmdv,slrtyy,gkn,nsrdssgdqtfyv,IGHJ6*01 (human),IGHV7-4-1*02 (human),IGLJ1*01 (human),IGLV3-19*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126649,MZ126664,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_6 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_6 immunoglobulin light chain variable region mRNA, partial cds",qlqlqesgpglvkpsetlflfcsvsggsisisthywewirqppgkglewigsfyssgttyynpslkgrvtisadtsksqislkmssvtaadtavyycarrpqylllsmttgrrhhdfvmdvwgqgttvtvss,divmtqspdslavslgeratitckssqsvlfgsnnenylawyqkkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntprtfgqgtkvevk,ggsisisthy,fyssgtt,arrpqylllsmttgrrhhdfvmdv,qsvlfgsnneny,was,qqyyntprt,IGHJ6*01 (human),IGHV4-39*01 (human),IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126650,MZ126665,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_7 immunoglobulin light chain variable region mRNA, partial cds",gvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsginvngydtyyadsvkgrftisrdnskntlflqmisltaedtalyycvkedtplvfdswgqgtlvtvss,diqmtqspstlsasvgdrvtitcrasqfinswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltinslqpddfatyycqqydsystfgqgtkveik,gftfssya,invngydt,vkedtplvfds,qfinsw,aas,qqydsyst,IGHJ5*01 (human),IGHV3-64D*06 (human),IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126655,MZ126670,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_12 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_12 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevqkpgasvkvsckasgyrfdifdinwvrqasgqgpewmgwmnpnsgntgyahkfqgrvtmtrdsstntaymelssltfedtavyycardrvertgnvgfgyyamdvwgqgttvivss,diqmtqspsslsasvgdrvtitcrasqsitnylnwyqqrpgkaprlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfgtfycqqtysspsytfgqgtklemk,gyrfdifd,mnpnsgnt,ardrvertgnvgfgyyamdv,qsitny,aas,qqtysspsyt,IGHJ6*01 (human),IGHV1-8*01 (human),IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126654,MZ126669,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_11 immunoglobulin light chain variable region mRNA, partial cds",egqllesggglvqpggslrlsceasgftfsryamtwirqapgkglewvssitaipydrfyadslyadsvkgrftisrddsknmvylqanslrvedtavyycvkmrtavvgvtplwgqgtlvtvss,aiqvtqspsslsasvgdrititcrtsqgirddlgwyqqkpgkaptlliygatnlqsgvpsrfsgsesgtdftltisslqpedfatyyclqdynylfsfgpgtkvdik,gftfsrya,itaipydrfyads,vkmrtavvgvtpl,qgirdd,gat,lqdynylfs,IGHJ2*01 (human),IGHV3-23*01 (human),IGKJ3*01 (human),IGKV1-6*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126653,MZ126668,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_10 immunoglobulin light chain variable region mRNA, partial cds",evhlvesgggliqpggslklscaasgfavsgyymiwvrqapgkglewvsviftsgrtyyadsakgrftisrdsskntlylqmdslraedtavyycagflpvynngwsyfdswgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgsrpnignnkvnwyqqlpgtapkvliygnnqrpsgvpdrfsgsksatsaslaisglqsedeadyycavwddslngpvfgggtkltvl,gfavsgyy,iftsgrt,agflpvynngwsyfds,rpnignnk,gnn,avwddslngpv,IGHJ5*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126657,MZ126672,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_14 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_14 immunoglobulin light chain variable region mRNA, partial cds",evllvesgggviqpgaslrlscepsgttvssnfwtwvrqapgrrlehvaiiysgdatyyadsvkgrftifrdnsknmlflemnnlkvadsaiyfcvrgrtywgqgtlvsvss,eivmtqspatlslspgdtatlscrasqsvasnlawyqqkpgqaprllvsgastratgipprfsgsgsgteftltisslqsedfavyycqqynrwlwtfgqgtkveik,gttvssnf,iysgdat,vrgrty,qsvasn,gas,qqynrwlwt,IGHJ4*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,,,MZ126651,MZ126666,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 46472_8 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_8 immunoglobulin light chain variable region mRNA, partial cds",evqlvesgggfiqpggsvrlscsasgfnvydnyfswvrqapgrgpewvsviyrdgatryaesvqgrftmfrdnsrktlylqmnrlkagdtavyfcalgrkdygdyyrwgqgtlvtvss,eivltqspgtlslspgetatlscragqsvrsrflawyqqkpgqsprvliygasnrasgvpdrfsgsgsgtdftltitrlepedvavyycqqyapsppwyifgqgtkleik,gfnvydny,iyrdgat,algrkdygdyyr,qsvrsrf,gas,qqyapsppwyi,IGHJ1*01 (human),IGHV3-53*01 (human),IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,MT658806,MT658861,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CnC2t1p1_B10 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone MnC5t2p1_G1 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,ggtfssya,iipifgta,arvsgydssgywgdy,qsvsssy,gas,qqygsspwt,IGHJ4*01 (human),IGHV1-69*06 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530316,AY530323,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 27D anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 27D anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarnfgedfdywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdlgghnfvswyqqhpgkapklmiydvfnrpsgvssrfsgsksgntasltisglqaedeadyfcssytitnivvfgrgtkltvl,gftvssny,iysggst,arnfgedfdy,ssdlgghnf,dvf,ssytitnivv,IGHJ4*01 (human),IGHV3-53*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530314,AY530321,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 12E anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 12E anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgyygdyawgyyyygmdvwgqgtlvtvss,syeltqppsasgtpgqrvtiscsgssssigsetvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyyctawddtlngrvifgggtkltvl,gytftsyg,isayngnt,arvgyygdyawgyyyygmdv,sssigset,snn,tawddtlngrvi,IGHJ6*01 (human),IGHV1-18*01 (human),IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530313,AY530320,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 8C anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 8C anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",evqlvqsggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtgvyycardwgysfgdwgqgtlvtvss,iqmtqspsslsasvgdrvtitcratqsisthlnwyqqrggkapklliygastlesgvpsrfsgsgsgteftltisslqpedfatyyclqhrsypwtfgqgtnveik,gftfsdyy,isssgsti,ardwgysfgd,qsisth,gas,lqhrsypwt,IGHJ1*01 (human),IGHV3-11*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530317,AY530324,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 80R anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 80R anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,ttltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,gfafssya,isydgsnk,ardrsyyldy,qsvrsn,das,qqrsnwppt,IGHJ4*01 (human),IGHV3-30*01 (human),IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530318,AY530325,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 91M anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 91M anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsggglvqpggslrlscaasgftfssswmswvrqapgkglewvayikqdgsekyyvdsvkgrftisrdnaknslylqmdslraedtavyycardqgwgwdgteyysdywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyfcssytitdivvfgggtkltvl,gftfsssw,ikqdgsek,ardqgwgwdgteyysdy,ssdvggyny,dvs,ssytitdivv,IGHJ4*01 (human),IGHV3-7*01 (human),IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530315,AY530322,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 26H anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 26H anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",qvqlqesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarerwlqigedafdiwgqgttvtvss,qtvvtqepsfsvspggtitltcdlnsglvssshypswyqqtpgqaprtliyntnirssgvpdrfsgailgnkaaltitgaqaedesdyycvlymgsgisvfgggtkltvl,gftfsdyy,isssgsti,arerwlqigedafdi,sglvssshy,ntn,vlymgsgisv,IGHJ3*02 (human),IGHV3-11*01 (human),IGLJ2*01 (human),IGLV8-61*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530319,AY530326,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 92N anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 92N anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarddlsdygewlgpdywgqgtlvtvss,qpgltqppsasgtpgqrvtiscsgsrsniggntvnwyqhvpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycatwedslsgyvfgpgtkvtvl,gytfttyg,isayngnt,arddlsdygewlgpdy,rsniggnt,snn,atwedslsgyv,IGHJ4*01 (human),IGHV1-18*01 (human),IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554173,AY554181,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-001 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-001 anti-SARS-CoV immunoglobulin kappa light chain variable region mRNA, partial cds",evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisggstyyadsrkgrftisrdnskntlylqmnnlraedtavyycarhrfrhvfdywgqgtlvtvle,eltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkveik,gftfsgys,isggst,arhrfrhvfdy,qsissy,aas,qqsystppt,IGHJ4*01 (human),IGHV3-21*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554179,AY554183,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-015 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-015 anti-SARS-CoV immunoglobulin lambda light chain variable region mRNA, partial cds",evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtavyycarglslrpwgqgtlvtvsr,seltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhvvfgggtkltvl,gftfddyg,inwnggst,arglslrp,slrsyy,gkn,nsrdssgnhvv,IGHJ5*02 (human),IGHV3-20*04 (human),IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554175,AY554182,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-006 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-006 anti-SARS-CoV immunoglobulin kappa light chain variable region mRNA, partial cds",evqlvesggglvqpggslrlscaasgftfsgypmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsprtpsfdywgqgtlvtvle,diqmtqsphslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvgvyycqqrfrtpvtfgqgtkleik,gftfsgyp,isydgsnk,akdgsprtpsfdy,qgisny,aas,qqrfrtpvt,IGHJ4*01 (human),IGHV3-30*18 (human),IGKJ2*01 (human),IGKV1-27*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,MT462477,MT462570,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CV1 anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV48 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,gysissgyy,iyhsgst,artplslrlrynwyfdl,qslvysdgnty,kvs,mqgthwppt,IGHJ2*01 (human),IGHV4-38-2*02 (human),IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,MW802487,MW802274,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate P054_050 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate P003_001 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,gftfssyd,igtagdt,arasfdssgylnyfdy,qsvssny,aas,qqygssrnt,IGHJ4*01 (human),IGHV3-13*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"VanBlargan,L.A. et al.; Direct Submission; Submitted (03-AUG-2021) Internal Medicine, Washington University in St Louis, 425 S. Euclid Ave, St Louis, MO 63110, USA; 2021.",N/A,,,MZ703121,MZ703122,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus strain BALB/c clone SARS2-02 immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone SARS2-02 immunoglobulin kappa light chain variable region mRNA, partial cds",avqlqesgpdlvkpsqslsltctvtgfsitsaytwhwirqfpgnklewmgyihysgytyynpslksrisitrdtsknqfflqlnsvttedtatyycarrhdfysldcwgqgtsvtvss,dikmtqspssmyvslgervtitckasqdiysylnwfqrkpgkspktliyranslvdgvpsrfsgsgsgqdysltissleyedmgiyyclqydefpytfgggtkleik,gfsitsayt,ihysgyt,arrhdfysldc,qdiysy,ran,lqydefpyt,IGHJ4*01 (mouse),IGHV3-1*02 (mouse),IGKJ2*01 (mouse),IGKV14-111*01 (mouse)
GenBank,,,"VanBlargan,L.A. et al.; Direct Submission; Submitted (03-AUG-2021) Internal Medicine, Washington University in St Louis, 425 S. Euclid Ave, St Louis, MO 63110, USA; 2021.",N/A,,,MZ703123,MZ703124,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus strain BALB/c clone SARS2-38 immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone SARS2-38 immunoglobulin kappa light chain variable region mRNA, partial cds",qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttltvss,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklelk,gfsltryg,iwadgst,ardgrgyddy,stvsf,dts,qqwntyplt,IGHJ2*01 (mouse),IGHV2-9*02 (mouse),IGKJ5*01 (mouse),IGKV4-55*01 (mouse)
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605269,AY605278,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G18 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G18 immunoglobulin gamma light chain variable region mRNA, partial cds",lvqleesgtvlprpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtnynqkfkgratltavtststasmelssltnedsavyyctrdgygslyyyamdfwgqgtsvtvss,elvmtqspsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhagvpsrfsgsgsgtdysltisnleqediatyfcqqgytlpytfgggtkleik,gytftsyw,iypgnsdt,trdgygslyyyamdf,qdisny,yts,qqgytlpyt,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),IGKJ2*01 (mouse),IGKV10-96*01 (mouse)
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605267,AY605276,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G9 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G9 immunoglobulin gamma light chain variable region mRNA, partial cds",vqllesgtvlarpgasvkmsckasgysftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtsastaymelssltnedsavyyctrsvyygygyfdvwgagttvtvss,dilmtqshkcmstsvgdrvsitckasqdvstavvwyqqkpgqfpklliywastrhtgvpdrftgsgsgtdytltissvqaedlalyycqqhyttpytfgggtkleik,gysftsyw,iypgnsdt,trsvyygygyfdv,qdvsta,was,qqhyttpyt,IGHJ1*01 (mouse),IGHV1-5*01 (mouse),IGKJ2*01 (mouse),IGKV6-25*01 (mouse)
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605270,AY605279,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G19 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G19 immunoglobulin gamma light chain variable region mRNA, partial cds",evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,gytfttyr,iypgnsdt,tregipqllrtldy,qeisgy,aas,lqyvsypwt,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
GenBank,,,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",N/A,,,MZ555629,MZ555630,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate COV2-2164 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens isolate COV2-2164 immunoglobulin light chain mRNA, partial cds",qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkvei,ggtfssya,iipifgaa,artshydssgsyfey,qsvssy,das,hkrsnwppslt,IGHJ4*01 (human),IGHV1-69*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,,,MW002785,MW002803,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CV38-142 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone CV38-142 anti SARS-CoV-2 immunoglobulin kappa chain mRNA, partial cds",evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveik,gysftsyw,iypgesdt,arirgvyssgwiggdy,qsissy,aas,qqsystprqwt,IGHJ4*01 (human),IGHV5-51*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820103,MZ820112,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-11 immunoglobulin light chain variable region mRNA, partial cds",evqlvesgggliqpggslrlscaasgvnvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmislraddtavyycardlvyygmdvwgqgttvtvss,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvdsyspftfgpgtkvdik,gvnvssny,iysggst,ardlvyygmdv,qgissy,aas,qqvdsyspft,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820098,MZ820107,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-3 immunoglobulin light chain variable region mRNA, partial cds",evqlvesgggliqpggslrlscaasgftvsskymswvrqapgkglvcvsliyggdstyyadsvrgrftisrdsskntlylqmnslraedtavyycarvhfryyddsgyyeanpwffdlwgrgtpvtvss,qsvltqppsvsgapgqrvtiscagsssniganydvhwyqvlpgaapkllifrnnnrpsgvpdrfsgsksvtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,gftvssky,iyggdst,arvhfryyddsgyyeanpwffdl,ssniganyd,rnn,qsydsslsawv,IGHJ2*01 (human),IGHV3-53*01 (human),IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820105,MZ820114,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-15 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-15 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggglvqpgrslrlscaasgfifddyamhwvrqvpgkglewvsgvdwnsgtigyadsvkgrfiisrdnaknslylhmrslrvedtafyycakdrlktgpgyfdlwgrgtlvtvss,eivltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrsdwltfgggtnveik,gfifddya,vdwnsgti,akdrlktgpgyfdl,qsvsny,das,qqrsdwlt,IGHJ2*01 (human),IGHV3-9*01 (human),IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820100,MZ820109,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-5 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-5 immunoglobulin light chain variable region mRNA, partial cds",qvtlresgpalvkptqtltltctfsgfslsthgmsvswirqppgkalqwlaridwdddkfystslktrltiskdtsknqvvltmtnldpvdtatyycarvrlggfdyymdvwgkgttvtvss,qsvltqppsvsaapgqkvtiscsgtrsnignnyvswyqqlpgtapklliydntkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdnnlntgvfgggtkltvl,gfslsthgms,idwdddk,arvrlggfdyymdv,rsnignny,dnt,gtwdnnlntgv,IGHJ6*04 (human),IGHV2-70*17 (human),IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820099,MZ820108,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-4 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-4 immunoglobulin light chain variable region mRNA, partial cds",qitlkesgptlvkptqtltltctfsgfslstigvgvswirqppgkaldwlaliywdddkryspslksrltvtmdtsknqvvltltnmdpvdtatyfcahglfsssdwggldvwgqgttvtvss,dmqmtqspsslsasvgdrvtitcrasqsvftylnwyqqkpgkapklliyaasrlqsgvpsrfrgsgsgtdftltisslqpedfatyycqqshstpfifgpgtkvdik,gfslstigvg,iywdddk,ahglfsssdwggldv,qsvfty,aas,qqshstpfi,IGHJ6*01 (human),IGHV2-5*02 (human),IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820097,MZ820106,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-2 immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscaasgfafsnyamhwvrqapgkglewvavaphnrtdkyyadsvrgrftisrdtskntlyllmnsltvedtglyycakddgyclgrgcyyapgphwgqgtlvtvss,syeltqppsvsvspgqaaritcsgdalpekyaywyqqksgqapvlliyedfkrpseiperfsgsssgtvatltisgaqvddegdyycystdssgnqnyvfgtgtkvtvl,gfafsnya,aphnrtdk,akddgyclgrgcyyapgph,alpeky,edf,ystdssgnqnyv,IGHJ1*01 (human),IGHV3-30-3*02 (human),IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820101,MZ820110,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-7 immunoglobulin light chain variable region mRNA, partial cds",evqlvesggdlvqpgrslrlscaasgftfeyyamhwvrqppgkglewvsgigwnrgslgyadsvkgrftisrddaksslylqmnslrtedtafyycvrgfreflktsgpndywgqgtlvtvss,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliydnhsrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvyvfgsgtkvtvl,gftfeyya,igwnrgsl,vrgfreflktsgpndy,ssnignny,dnh,gtwdgslsvyv,IGHJ4*01 (human),IGHV3-9*01 (human),IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820102,MZ820111,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-10 immunoglobulin light chain variable region mRNA, partial cds",evqlvesgggliqpggslrlscaasglivsrnymtwvrqapgrglewvstiyaggsafyadsvkgrftisrdnskntlylqmnslraedtavyycardlnvrggldvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqginnylawyqqkpgkapkllifaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdpaltfgggtkveik,glivsrny,iyaggsa,ardlnvrggldv,qginny,aas,qqlnsdpalt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",N/A,,,MZ820104,MZ820113,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens isolate 54042-14 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-14 immunoglobulin light chain variable region mRNA, partial cds",qvqlvesgggvvqpgrslrlscsasgftfsnygmhwvrqapgkglewvaviwfdgnnkyyansvkgrftisrdnskntlylqmktlraedtavyycakdtwdvpaanppysfyymdvwgmgttvtvss,etvltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrstlitfgqgtrleik,gftfsnyg,iwfdgnnk,akdtwdvpaanppysfyymdv,qsvssy,das,qqrstlit,IGHJ6*01 (human),IGHV3-33*03 (human),IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Tong,P. et al.; Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike; Cell (2021) In press; 2021.",https://doi.org/10.1016/j.cell.2021.07.025,,,MW718328,MW718631,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Homo sapiens clone C81C10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone C81E12 immunoglobulin light chain variable region mRNA, partial cds",qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycavmeysgydslrpldywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgggtkltvl,gytftgyy,inpnsggt,avmeysgydslrpldy,alpkky,eds,ystdssgnhrv,IGHJ4*01 (human),IGHV1-2*06 (human),IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,OL741060,OL741311,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate R40-1A1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate R849-3H2 immunoglobulin kappa light chain variable region mRNA, partial cds",qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,gyafttfa,inpyngkt,arqypmprgphynymdv,qsissy,aas,qqsystwt,IGHJ6*04 (human),IGHV1-18*01 (human),IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.025,,,MW619742,MW619743,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone NT-193 immunoglogulin heavy chain variable region mRNA, partial cds","Homo sapiens clone NT-193 immunoglogulin light chain variable region mRNA, partial cds",evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvss,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleik,ggsfsgyy,inhsgst,argwdldyyygmdv,qgigny,aas,lqhgflpwt,IGHJ6*01 (human),IGHV4-34*01 (human),IGKJ1*01 (human),IGKV1-17*03 (human)
GenBank,,,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.025,,,MW619740,MW619741,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone NT-108 immunoglogulin heavy chain variable region mRNA, partial cds","Homo sapiens clone NT-108 immunoglogulin light chain variable region mRNA, partial cds",evqlqqsgpglvkpsqtlsltcsisgdsvssnsaawnwirqspsrglewlgrtyyrskwyndyagtvksriainpdtsknqfslhlnsvtpedtavyfcarvisvagyafdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprlliygasymatgipdrfsgsgsgtdftltisrlepedfavyycqqygssltfgggtkleik,gdsvssnsaa,tyyrskwyn,arvisvagyafdi,qsvsstf,gas,qqygsslt,IGHJ3*02 (human),IGHV6-1*01 (human),IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kaku,Y. et al.; Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19; Cell Rep 36 (2), 109385 (2021); 2021.",10.1016/j.celrep.2021.109385,,,MZ089617,MZ089626,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone 10-121 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone 9-105 anti SARS-CoV-2 immunoglobulin kappa light chain mRNA, partial cds",evqlvesgggliqpggslrlscaasgltvsrnymswvrqapgrglewvsliysggstyyadsvkgrftisrdsskntlylqmnslraedtavyycarpivgaragmdvwgqgttvtvss,divmtqspgtlslspgeratlscrasqsvpsiylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,gltvsrny,iysggst,arpivgaragmdv,qsvpsiy,gas,qqygsspgt,IGHJ6*01 (human),IGHV3-53*01 (human),IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Williams,W.B. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020) In press; 2020.",10.1101/2020.06.30.178921,,,MT470283,MT470354,not determined,Macaca mulatta (Rhesus monkey),2022-03-15,"Macaca mulatta clone DH715.1VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone DH1011VK immunoglobulin kappa light chain variable region mRNA, partial cds",qvklqesgpglvkpsetlsltcgvsggsisggydwswirqppgkglewigyvyyngghpyynpslnnrvtisidtskkyfsleltsvtaadtavyycarsyspdglylytsldlwgrgvlvtvss,divmtqtplsspvtlgqpasiscrssedlahsdgntylswlhqrpgqpprlliykiskrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqltqfprtfgqgtkveik,ggsisggyd,vyyngghp,arsyspdglylytsldl,edlahsdgnty,kis,mqltqfprt,IGHJ2*01 (human),IGHV4-30-4*07 (human),IGKJ1*01 (human),IGKV2-24*01 (human)
GenBank,,,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,,,7R98_F,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain F, Nanobody B6",N/A,evqlqasggglvqagdslrlscvavsgrtistfamgwfrqapgkerefvatinwsgssaryadpvegrftisrddakntvylemsslkpgdsavyycasgrylggitsysqgdfapwgqgtqvtvss,,grtistfa,inwsgssa,asgrylggitsysqgdfap,,,,IGHJ5*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,,,7N0I_L,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain L, Single-domain antibody E2",N/A,evqlqasggglvqaggslrlscaasgrtdstqhmawfrqapgkerefvtaiqwrgggtsytdsvkgrftisrdnakntvylemnslkpedtavyycatntrwtyfsptvpdrydywgqgtqvtvss,,grtdstqh,iqwrgggt,atntrwtyfsptvpdrydy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,,,7N0R_D,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain D, Single-domain antibody C2",N/A,evqlqasggglvrpggslrlscaasgftfssyammwvrqapgkglewvsainggggstsyadsvkgrftisrdnakntlylqmnslkpedtavyycakyqaavhqekedywgqgtqvtvss,,gftfssya,inggggst,akyqaavhqekedy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,,,6ZCZ_F,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain F, Nanobody",N/A,qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvss,,grtfstaa,irwsggsa,aqthyvsyllsdyatwpydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Li,L. et al.; Antibody engineering improves neutralization activity against K417 spike mutant variants of SARS-CoV-2; Unpublished; 2021.",N/A,,,7VMU_A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain A, scFv E4",N/A,qvqlvqsgggliqpggslrlscaasgvtvssnymswvrqapgrglewvsliypggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycardlsekggmdvwgqgttvtvss,,gvtvssny,iypggst,ardlsekggmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,T. et al.; Structural insight from a neutralizing human scFv in complex with RBD suggest a new site of vulnerability for SARS-CoV-2; Unpublished; 2021.",N/A,,,7CYV_H,N/A,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),2022-03-15,"Chain H, The heavy chain variable region of the scFv FD20,The light chain variable region of the scFv FD20",N/A,qvqlqqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmgriipilgianyaqkfqgrvtitadiststaymalsslrsedtavyycakvevnigmddyyyyygmdvwgqgttvtvss,,ggtfssya,iipilgia,akvevnigmddyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,,,7OLZ_B,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain B, Nanobody Re9F06",N/A,qvqlvesggglvqaggslrlscaasgrtfsndalgwfrqaprkerefvaainwnsgtyyadsvkgrftisrdnakntvylqmnslkpedtavyscaaasdyglpredflydywgqgtqvtvss,,grtfsnda,inwnsgt,aaasdyglpredflydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,,,7OLZ_C,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain C, Nanobody Re5D06",N/A,qvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvss,,gitldyya,irssdgst,aygpltkygsswywpyeydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAY_LLL,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain LLL, F2 nanobody",N/A,qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvss,,grtfhsyv,iswsstpt,aadrgesyyytrpteyef,,,,IGHJ1*01 (human),IGHV3-23*02 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAP_FFF,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain FFF, H3 nanobody",N/A,qvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvss,,grtfstys,mrwtgsst,aittivrayyteyteadfgs,,,,IGHJ5*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAP_AAA,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain AAA, C1 nanobody",N/A,qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvss,,gftndfys,lsvsdntp,aagrfagrdtwpssydy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAO_FFF,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain FFF, C5 nanobody",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7N9T_F,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain F, Nanobody Nb17",N/A,hvqlvesggglvqaggslrlscaasgsifssnamswyrqapgkqrelvasitsggnadyadsvkgrftisrdkntvypemsslkpadtavyychavgqeasayapraywgqgtqvtvss,,gsifssna,itsggna,havgqeasayapray,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7MEJ_B,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain B, Nanobody Nb36",N/A,vqlvesggglvqaggsltltcaasgrtfssetmdmgwfrqapgkerefvaadswndgstyyadsvkgrftisrdsakntlylqmnslkpedtavyycaaetysiyekddswgywgqgtqvtvs,,grtfssetmd,dswndgst,aaetysiyekddswgy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7MEJ_A,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain A, Nanobody Nb21",N/A,qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,,glgahr,iganggnt,aardietaeyty,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7ME7_B,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain B, Nanobody Nb105",N/A,vqlvesggglvqaggslrlscavsgrtfstygmawfrqapgkerdfvatitrsgettlyadsvkgrftisrdnakntvylqmnslkiedtavyycavrrdsswgysrdlfeydywgqgtqvtvs,,grtfstyg,itrsgett,avrrdsswgysrdlfeydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",N/A,,,7P7A_D,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain D, sybody#68",N/A,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,,gsissity,litvnght,aaaawgyawplhqddywy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",N/A,,,7P79_H,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain H, sybody#15",N/A,qvqlvesggglvqaggslrlscaasgfpvknfemewyrkapgkerewvaaiqsggvetyyadsvkgrftisrdnakntvylqmnslkpedtavyycfvyvgrsyigqgtqvtvs,,gfpvknfe,iqsggvet,fvyvgrsy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7N9E_D,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain D, Nb34 nanobody",N/A,dvqlvesggglvqaggslrlscaasgftfsnyvmywgrqapgkgrewvsgidsdgsdtayassvkgrftisrdnakntlylqmnnlkpedtalyycvkskdpygspwtrsefddywgqgtqvtvss,,gftfsnyv,idsdgsdt,vkskdpygspwtrsefddy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7N9C_E,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain E, Nanobody NB95",N/A,qvqlvesggglvqaggslrlscaasgrtfssysmgwfrqaqgkerefvatingngrdtyytnsvkgrftisrddatntvylqmnslkpedtaiyycaadkdvyygytsfpneyeywgqgtqvtvss,,grtfssys,ingngrdt,aadkdvyygytsfpneyey,,,,IGHJ4*01 (mouse),IGHV5-6-3*01 (mouse),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7N9B_F,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain F, NB21 Nanobody",N/A,qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,,glgahr,iganggnt,aardietaeyty,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,,,7MY3_D,N/A,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain D, Nanobody Nb12",N/A,qvkleesgggsvqaggslrlictapglthnncgldwyrrapgkerefvssisadgttsyadsvkgrftiskdkvedtvylqmnslkpedtaiyscktafpyfgnscvldywgqgtsvtvss,,glthnncg,isadgtt,ktafpyfgnscvldy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,,,7MY2_D,N/A,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain D, Nanobody Nb30",N/A,qvqlvesggglvqaggslrlscaasgltfskyamgwfrqapgkerkfvatiswsgdsafyadsvkgrftisrdnarntvylqmnslkpedtavyycaadrgmgygdfmdywgqgtsvtass,,gltfskya,iswsgdsa,aadrgmgygdfmdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,,,7N0H_Z,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain Z, Synthetic nanobody (Sb45)",N/A,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvsa,,gfpvyrdr,iysagqqt,nvkdvghhyeyydy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,,,7MFU_F,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain F, Synthetic nanobody #68 (Sb68)",N/A,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvsa,,gsissity,litvnght,aaaawgyawplhqddywy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,,,7MFU_E,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain E, Synthetic Nanobody #14 (Sb14)",N/A,qvqlvesggglvqaggslrlscaasgfpvqaremewyrqapgkerewvaaikstgtytayaysvkgrftisrdnakntvylqmnslkpedtavyycyvyvgssyigqgtqvtvsa,,gfpvqare,ikstgtyt,yvyvgssy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7B14_D,N/A,SARS-CoV-2,Camelus bactrianus (Bactrian camel),2022-03-15,"Chain D, Nanobody against SARS-CoV-2",N/A,qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,gvtldyya,igssdgrt,altvgtyysgnyhytcsddmdy,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
GenBank,,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,,,7DEU_B,N/A,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain B, antibody scFv",N/A,evqlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgkslewigginpnngdntynqklkgkatltvhkssstaymelrsltsedsavyycardgypyyyaldywgqgtsvtvss,,gytfteyt,inpnngdn,ardgypyyyaldy,,,,IGHJ4*01 (mouse),IGHV1-22*01 (mouse),,
GenBank,,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,,,7DET_D,N/A,SARS-CoV-2,Mus musculus (house mouse),2022-03-15,"Chain D, antibody scFv",N/A,qvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvss,,gysftsyw,ihpsdset,aradgyewyfdv,,,,IGHJ2*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,,,7DEO_C,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain C, antibody scFv",N/A,evqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvss,,gftfsyyg,iwydgsnr,atdppglrfrfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,,,7D30_A,N/A,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"Chain A, sybody fusion of MR17-SR31 with a GS linker",N/A,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvs,,gfpvevwr,iesyghgt,nvkddgqlayhydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7B17_B,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain B, SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama,SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama",N/A,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,gftfssya,iysdgst,ategslggwgrdfgs,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,,,7KLW_C,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain C, SB68, Synthetic nanobody",N/A,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,,gsissity,litvnght,aaaawgyawplhqddywy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,,,7KLW_B,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain B, SB45, Synthetic Nanobody",N/A,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvs,,gfpvyrdr,iysagqqt,nvkdvghhyeyydy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,,,7KGK_B,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain B, Sb16, Sybody-16, Synthetic Nanobody",N/A,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,,gfpvaykt,iesygikwt,ivwvgaqy,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7KSG_F,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain F, Nanobody against SARS-CoV-2 glycoprotein",N/A,qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,gvtldyya,igssdgrt,altvgtyysgnyhytcsddmdy,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
GenBank,,,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,,,7B27_DDD,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain DDD, neutralizing nanobody NM1230",N/A,qvqlvesggglvrpggslrlscvgsgftfsgyamnwyrqapgkalelvagisnagdlthyeepmkgrvaisrandkntvylqmddlkpedtavyrchapgvrvgtgerkdvwgqgaqvtvss,,gftfsgya,isnagdlt,hapgvrvgtgerkdv,,,,IGHJ6*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,,,7NKT_BBB,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain BBB, neutralizing nanobody NM1226",N/A,qvqlvesgggsvqpggslrlsclgsgsldyyaigwfrqapgkeregvsciassgdrtiyadsvkgrftisrdygkntvylqmnslkpedtamyycaalqgsyyytgfvaneydywgqgapvtvss,,gsldyya,iassgdrt,aalqgsyyytgfvaneydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7B18_I,N/A,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),2022-03-15,"Chain I, Nanobody against spike glycoprotein VHH V",N/A,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,gftfssya,iysdgst,ategslggwgrdfgs,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7B18_H,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain H, Nanobody against SARS-CoV-2 VHH E",N/A,qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,gvtldyya,igssdgrt,altvgtyysgnyhytcsddmdy,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
GenBank,,,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,,,6ZH9_FFF,N/A,"SARS-CoV-2, Spike protein RBD",Lama glama (llama),2022-03-15,"Chain FFF, Nanobody H11-H4",N/A,qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvss,,grtfstaa,irwsggsa,aqthyvsyllsdyatwpydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7KN7_B,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain B, VHH W",N/A,qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssgdsthyvdsvkgrftisrdnakntvylqmnslkpedtavyycaaqsgsyywcgsdwheydyrgqgtqvtvss,,gftldyya,isssgdst,aaqsgsyywcgsdwheydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7KN6_C,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain C, VHH V",N/A,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,gftfssya,iysdgst,ategslggwgrdfgs,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,,,7KN5_F,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain F, VHH U",N/A,qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,,gftldyya,isssggst,aaqsgsyywcgsdwheyey,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Xiang,Y. et al.; Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2; Science 370 (6523), 1479-1484 (2020); 2020.",10.1126/science.abe4747,,,7JVB_D,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain D, Nanobody Nb20",N/A,qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,,gagahr,igasggmt,aardietaeyiy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",N/A,,,7A25_F,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain F, Sybody 23",N/A,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,,gfpvesen,iystggwt,avqvgywy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,,,7KKL_F,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain F, Synthetic nanobody mNb6",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspaygdywgqgtqvtvss,,gyifgrna,itrrgsit,aadpaspaygdy,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,,,7KKK_F,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain F, Synthetic nanobody Nb6",N/A,qvqlvesggglvqaggslrlscaasgiifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspapgdywgqgtqvtvss,,giifgrna,itrrgsit,aadpaspapgdy,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",N/A,,,7A29_F,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain F, Neutralising sybody (Sb23)",N/A,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,,gfpvesen,iystggwt,avqvgywy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; BioRxiv (2020); 2020.",N/A,,,6ZXN_F,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain F, Nanobody Ty1",N/A,qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,,gftfssvy,ispnsgni,aiglnlssssv,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,,,6WAR_P,N/A,SARS-CoV,Lama glama (llama),2022-03-15,"Chain P, nanobody MERS VHH-55",N/A,qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvss,,gsifsina,itsggst,aaevggwgpprpdy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,,,7CAN_A,N/A,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"Chain A, sybody MR17-K99Y",N/A,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvyddgqlayhydywgqgtqvtvsa,,gfpvevwr,iesyghgt,nvyddgqlayhydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,,,7C8W_A,N/A,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"Chain A, Synthetic nanobody MR17",N/A,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsa,,gfpvevwr,iesyghgt,nvkddgqlayhydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,,,7C8V_A,N/A,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"Chain A, Synthetic nanobody SR4",N/A,qvqlvesggglvqaggslrlscaasgfpvyswnmwwyrqapgkerewvaaieshgdstryadsvkgrftisrdnakntvylqmnslkpedtavyycyvwvghtyygqgtqvtvsa,,gfpvyswn,ieshgdst,yvwvghty,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.",10.7554/eLife.64815,,,7KM5_D,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain D, nanobody",N/A,qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvss,,gftfknad,iysdgrt,magsksgheldh,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ge,S. et al.; Specific anti-SARS-CoV-2 S1 IgY-scFv is promising tools for COVID-19 diagnosis and treatment; Unpublished; 2021.",N/A,,,UGN74788,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 S1 scFv antibody, partial [synthetic construct]",N/A,sggglqtpggglglvckapgfsiggyimhwvrqtpgkgleyvagidagggvtwygaavkgratisrdngqstvrlqlndlraedtgiyycarstgsdyydwnyageigawghgtevivss,,gfsiggyi,idagggvt,arstgsdyydwnyageiga,,,,IGHJ2*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Hwang,W.C. et al.; Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R; J. Biol. Chem. 281 (45), 34610-34616 (2006); 2006.",10.1074/jbc.M603275200,,,2GHW_D,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Chain D, anti-sars scFv antibody, 80R",N/A,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gfafssya,isydgsnk,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,,,7MFV_B,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Chain B, Synthetic Nanobody #16 (Sb16)",N/A,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,,gfpvaykt,iesygikwt,ivwvgaqy,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,,,7ON5_A,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain A, Nanobody Re5D06",N/A,qvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvss,,gitldyya,irssdgst,aygpltkygsswywpyeydy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zhang,J. et al.; Recombinant expression of a SARS-CoV-2 neutralizing nanobody in Trichoderma reesei; Unpublished; 2021.",N/A,,,QZW25479,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 spike protein receptor-binding domain nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,,gagahr,igasggmt,aardietaeyiy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30720,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvss,,gyifgrna,itrggst,nadpyfwefdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30719,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvss,,gyifgrna,itrggst,ntdpapgnpllrypdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30718,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvss,,gyifgrna,itrggst,nadpylwefds,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30717,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gfifgrna,itrggst,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30716,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gyifgrna,itrggst,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30715,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvss,,ggifigna,irniggtt,ntdpapgnpllrypdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30714,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gfifgrna,inwggdnt,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,QYK30713,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvss,,gyifgrna,itrggst,aadpgdvgsdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,,,QYF06674,N/A,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),2022-03-15,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",N/A,qlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,,ertfsggv,irwngast,aravrtyassdyyfqertydy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,,,QYF06673,N/A,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),2022-03-15,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",N/A,qvqlvesggglvqpggtlrlscaasgftldyyaigwfrqapgkeregvscisgsggitnytdsvkgrftisrdnakntvylqmnslkpedtavyycapvshtvvagcafeawtdfgswgqgtqvtvss,,gftldyya,isgsggit,apvshtvvagcafeawtdfgs,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
GenBank,,,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,,,QYF06672,N/A,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),2022-03-15,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",N/A,qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvss,,grtyt,mrwsdt,aageawlarsthhydy,,,,IGHJ4*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,,,6WAQ_C,N/A,SARS-CoV,Lama glama (llama),2022-03-15,"Chain C, nanobody SARS VHH-72",N/A,qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvss,,grtfseya,iswsggst,aaaglgtvvsewdydydy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",N/A,,,QNA42481,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody sdAb-5F8, partial [synthetic construct]",N/A,qvqlvesggglvqpggslrlscaasgrqavvfgwfrqapgkgleavaaihvpaknryyadsvkgrftisrdnskntlylqmnslraedtavyycaahyefndfvwqgyssdywgqgtqvtvss,,grqavv,ihvpaknr,aahyefndfvwqgyssdy,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",N/A,,,QNA42480,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody sdAb-4D8, partial [synthetic construct]",N/A,qvqlvesggglvqpggslrlscaasgnidstryhgwfrqapgkgleavaaikgvwpedyyadsvkgrftisrdnskntlylqmnslraedtavyycaadqyewwvpgevgpylywgqgtqvtvss,,gnidstry,ikgvwped,aadqyewwvpgevgpyly,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",N/A,,,QNA42479,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody sdAb-3F11, partial [synthetic construct]",N/A,qvqlvesggglvqpggslrlscaasggnaaermagwfrqapgkgleavaaiyyakfgpyyadsvkgrftisrdnskntlylqmnslraedtavyycaaeafvqspysgshttkywgqgtqvtvss,,ggnaaerm,iyyakfgp,aaeafvqspysgshttky,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",N/A,,,QNA42478,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody sdAb-2F2, partial [synthetic construct]",N/A,qvqlvesggglvqpggslrlscaasglaqskwaygwfrqapgkgleavaaidvatgpwyyadsvkgrftisrdnskntlylqmnslraedtavyycaahhiptkhpafpdfrdywgqgtqvtvss,,glaqskwa,idvatgpw,aahhiptkhpafpdfrdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",N/A,,,QNA42477,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"anti-SARS-CoV-2 nanobody sdAb-1E2, partial [synthetic construct]",N/A,qvqlvesggglvqpggslrlscaasgadafviiggwfrqapgkgleavaaiawtdqheyyadsvkgrftisrdnskntlylqmnslraedtavyycaaqdsayikskgsrayeywgqgtqvtvss,,gadafvii,iawtdqhe,aaqdsayikskgsrayey,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133804,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KA1 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvss,,gyifgrna,itrggst,aadpgdvgsdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133811,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone K7.19 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvss,,gyifgrna,itrggst,nadpyfwefdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133805,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KC3 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gfifgrna,inwggdnt,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133806,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KC1 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvss,,ggifigna,irniggtt,ntdpapgnpllrypdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133807,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KA1.ep1 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gyifgrna,itrggst,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133809,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KC3.ep5 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvss,,gyifgrna,itrggst,nadpylwefds,,,,IGHJ5*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133810,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone K7.13 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvss,,gyifgrna,itrggst,ntdpapgnpllrypdfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Lamarre,A. et al.; A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice; Eur. J. Immunol. 27 (12), 3447-3455 (1997); 1996.",N/A,,,MMU73335,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus single chain Fv antibody fragment scFv 7-10A mRNA, partial cds",N/A,evklqqsgpdlvkpfqslsltctvtgysitsgyswhwirqfpgnklewmgyihysgsttynpslksrisitrdtsknqfflqlnsvttedtatyycvryyeyfdywgqgttvtvss,,gysitsgys,ihysgst,vryyeyfdy,,,,IGHJ2*01 (mouse),IGHV3-1*02 (mouse),,
GenBank,,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,,,MZ133808,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone KC3.ep3 anti-SARS-CoV-2 nanobody gene, partial cds",N/A,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvss,,gfifgrna,itrggst,nadpyfwefds,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91527,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardirdssgwanwfdpwgqgtlvtvss,,ggsissyy,iyysgst,ardirdssgwanwfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91525,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsmssyywswirqppgkglewigyiynsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarlegegqlvdyygmdvwgqgttvtvss,,ggsmssyy,iynsgst,arlegegqlvdyygmdv,,,,IGHJ6*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91523,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqsgrslrlscaasgftfssyamhwvrqapgkglewvavishdgsntyyedsvkgrftisrdnskntlhlqvnslrvedtavyycarakgevryfdwaeqggdywgqgtlvtvss,,gftfssya,ishdgsnt,arakgevryfdwaeqggdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91521,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfstyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymglsslrsedtavyycarwvtaygdyvpfdpwgqgtlvtvss,,gdtfstya,iipifgta,arwvtaygdyvpfdp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91519,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycardivgateidywgqgtlvtvss,,ggtfssya,iipifgia,ardivgateidy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91517,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsryaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymevsslrsedtavyycarktyyydssgypeafdiwgqgtmvtvss,,ggtfsrya,iipifgia,arktyyydssgypeafdi,,,,IGHJ3*02 (human),IGHV1-69*04 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91515,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslhlqmnslraedtalyycanlltpprrysgydlredyfeywgqgtlvtvss,,gftfddya,iswnsgsi,anlltpprrysgydlredyfey,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91513,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfspysmnwvrqapgkglewvssisvsniytyyadsvkgrftisrdnaknslylqmnslraedtaiyycardlkkggiqydafdiwgqgtvvtvss,,gftfspys,isvsniyt,ardlkkggiqydafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,UGO91511,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,,ggtfg,iipilgta,ardgdsgsyyetlgfdy,,,,IGHJ4*01 (human),IGHV1-69*08 (human),,
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91528,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,,,,alpkqy,kds,qsadssatyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91526,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvmviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qds,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91524,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdnsgdhgvfgggtkltvl,,,,alpkky,eds,ystdnsgdhgv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91522,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,,,,qsvsssy,gas,qqygssppwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91520,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,,,,qslvysdgnty,kvs,mqgthwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91518,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91516,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydrnnrpsgipdrfsgsssgntasltitgaqaedeadyychsrdssgnplhvvfgggtkltvl,,,,slrsyy,drn,hsrdssgnplhvv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91514,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvndylawyqqkpgqaprlliydasnratgfparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtrleik,,,,qsvndy,das,qqrsnwppt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,,,N/A,UGO91512,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,,,,ssdvggyny,evn,ssyagsnnlv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72511,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgesltisckasgyrftsnwitwvrqmpgkglewmgridpddpysnsspsfqghatlsldkaintaylhwsslkasdtamyycarvnrvgdgpdfwgqgtlvtvss,,gyrftsnw,idpddpys,arvnrvgdgpdf,,,,IGHJ5*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72510,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfndygvswvrqapgqglewmggiiaifgtanyaqkfqgrvaitadeststaymelsglrsedtavyfcaslggdsyisgthydrsgydpwgqgtlvivss,,ggtfndyg,iiaifgta,aslggdsyisgthydrsgydp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72509,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewltlisydginkyygdsvkgrftisrdnskntlyiqmnslrpedtavyycarayggnyyygmdvwghgttvtvss,,gftfstya,isydgink,arayggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72508,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvgsggglvqpggslrlscaasgftfstywmswvrqapgkglewvadikqdgsekyyvdsvkgrftisrdnaknslylqmnslrvedtalyycargglwgtfdywgqgtlvtvss,,gftfstyw,ikqdgsek,argglwgtfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72507,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsgasissssyywgwirqppgkglewigtmyyrgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycarrvpgdyycldvwgkgttvtvss,,gasissssyy,myyrgst,arrvpgdyycldv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72506,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssypitwvrqapgqgfewmgkiipilgiadyaqsfqgrvtitadkstttaymelsslrsedtavyycarekgysssssatyyldfwgqgtlvtvss,,ggtfssyp,iipilgia,arekgysssssatyyldf,,,,IGHJ5*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72505,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlrlwgagllkpsetlsltcavsggsfidyywtwirqppgkglewigeinhfggsgynpslksrvsisvdtsknqfslrlnsvtaadtaiyycarkpllhssvnpgafdiwgqgtmltvss,,ggsfidyy,inhfggs,arkpllhssvnpgafdi,,,,IGHJ3*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72504,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfssypmywvrqapgigleyvsgitdnggstyygdsvkgrftisrdnskntlnlqmnnlrtedtavyycvkgkiqlwlgadywgqgtlvtvss,,gftfssyp,itdnggst,vkgkiqlwlgady,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72503,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggtfssytiiwvrqapgqglewmgrvipvvhithyaqrfrgrvtisadkststaymelsslrsedtavyycarglwfgdsetvwfdpwgqgtlvtvss,,ggtfssyt,vipvvhit,arglwfgdsetvwfdp,,,,IGHJ5*02 (human),IGHV1-69*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72502,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfstsvvqwvrqprgqrlewiggivvgrgntkyaqnfqervtitrdmststaymelsnlrsedtavyycaadpfadywgqgtlvtvss,,gftfstsv,ivvgrgnt,aadpfady,,,,IGHJ4*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72490,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvefggglvqpgrslrlscatsgftfedfdmhwvrqapgkglewvsgstwnsgiigyadsvkgrfttsrdnaknslymqmnnlreedtalyycakdigrydhynifgrvggafdiwgqgtmvtvss,,gftfedfd,stwnsgii,akdigrydhynifgrvggafdi,,,,IGHJ3*02 (human),IGHV3-9*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72489,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdgdkryspslknrltitedtsknqvvltmtnmdpvdtatyycahhtvptiydywgqgtlvtvss,,gfslstsgvg,iywdgdk,ahhtvptiydy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72488,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglilpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarggwpsgdtfdiwgqgtmvtvss,,gvtvssny,iysggst,arggwpsgdtfdi,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72487,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsktqfslklssvtaadtavyycardrrgggwtasfdfwgqgtlvtvss,,ggsissssyy,iyysgst,ardrrgggwtasfdf,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72486,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftlssyamnwvrqapgkglewvsaisgsggstyyadsvkgrvtisrdnskntlylqmnslrvedtavyycakdafyygsgshfyyyyymdvwgkgttvtvss,,gftlssya,isgsggst,akdafyygsgshfyyyyymdv,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72485,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvsdnymswvrqapgkglqwvsviysggntyyadfvkgrfnitrddsknmlylqmnslrredtavyycvrdrrivgyyfgldvwgqgttvtvfs,,gftvsdny,iysggnt,vrdrrivgyyfgldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72484,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsctasggdftyyplswmrqapgrglewlggiipgyggahvarrfqdrvtitadestttvnmelrslrsddsavyycareegsgwwkhdywgqgtlvtvss,,ggdftyyp,iipgygga,areegsgwwkhdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72483,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitleesgptlvtptqtltltcsfsgfsldtigvavawirqppgkalewlgtvfwdydkryspplssrltvikdtsqqyvvlrltdvgpgdtatyycarlliehdafdiwgqgavvivss,,gfsldtigva,vfwdydk,arlliehdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72482,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evhlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggntyyadsvkgrftisrdnskntlylqmnslraedtavyycardrriigyyfgmdvwgrgttvtvss,,gftvssny,iysggnt,ardrriigyyfgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72481,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfnsysmnwvrqapgkglewvsyistssstmyyadsvkgrftisrdnaknslylqmnslraedtavyycareggwysvgwvdpwgqgtlvtvss,,gftfnsys,istssstm,areggwysvgwvdp,,,,IGHJ5*02 (human),IGHV3-48*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72480,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlsctasgitvstnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraddtavyyctrggwpsgdtfdiwglgtmvtvss,,gitvstny,iysggst,trggwpsgdtfdi,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72470,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgitfkdygmhwvrqapgrglewvafisydgsvqhygdsvkgrftisrddlkstlflqmnslrgddtavyycvkgatkidywgqgtlvtvss,,gitfkdyg,isydgsvq,vkgatkidy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72469,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansyiteyaasvkgrftisrddsknslylqmnslktedtavyycarvrggewvgdlgwyyyygmdvwgqgttvtvss,,gftfsdhy,trnkansyit,arvrggewvgdlgwyyyygmdv,,,,IGHJ6*01 (human),IGHV3-72*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72468,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscvdseftfityamswvrqapgkglewvstisgsgdstsyadsvkgrftisrdsskntlflqmhslraedtalyycaksativlmvsaiywgqgtlvtvss,,eftfitya,isgsgdst,aksativlmvsaiy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72467,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyswswirqspgtglewvgdiystgstnynpslksrltmsldtskshfslklssvaaadtavyycargageqrlvgglfgvshfyyymdvwgkgttvtvss,,ggsissys,iystgst,argageqrlvgglfgvshfyyymdv,,,,IGHJ6*04 (human),IGHV4-4*07 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72466,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqvsgpgllkpsetlsltcivsggsisshywswfrqppgkglewigyiyysgstnynpslksrvaisvdtsknhfslnltsvtaadtavyycargfdywgqgtlvtvss,,ggsisshy,iyysgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*11 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72465,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvtliwfdgsnqyyadsvkgrftisrdnskntlylqmnslrgedtavyycaregavgatsgldywgqgtlvtvss,,gfsfssyg,iwfdgsnq,aregavgatsgldy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72464,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggsfssyafswvrqapgqglewmggivgmfgttsysqkfqgrliitadeltstaymelsslrsedtavyfcarsggyrlwfgelwgpgtqvivss,,ggsfssya,ivgmfgtt,arsggyrlwfgel,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72463,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwisayngstnyaqklqgrvtmttdtststaymelrslrsddtavyycardpasyydlwsgyvdyyyygmdvwgqgttvtvss,,gytftsys,isayngst,ardpasyydlwsgyvdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,ULE72462,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,,gytftnyv,isayngst,ardpasyydfwsgyvdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72521,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,,,,qsllfgngyty,lgs,mqalqtpwt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72520,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgdratlscrasqsissflawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgggtkveik,,,,qsissf,das,qrrsnwppft,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72519,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtatitcsadklgkkyvcwyqqkpgqspvlviyqnnrrpsgiperfsgsnsgntatltisgtqpmdeadyycqawdsstasfvfgtgtkvtvl,,,,klgkky,qnn,qawdsstasfv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72518,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavywcqqfayslytfgqgtkleik,,,,qsvsssy,gas,qqfayslyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72517,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtvtcrasqsisdylnwyqqkpgkapklliyaasslqtgvpprfsgsgsgtdftltisslqpedfatyycqqsfsarvptfgggtkvesk,,,,qsisdy,aas,qqsfsarvpt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72516,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtaprlliyrnsnrpsgvpdrfsgsksgtaaslaisglqaedeadyycqsydssltalvfgggtkltvl,,,,nsnigagyd,rns,qsydssltalv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72515,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeraalscrasqsvagtylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyatsprtfgqgtqleir,,,,qsvagty,gas,qqyatsprt,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72514,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcranqtissylnwyqqkpgkapkvlifaassleggvpsrfsgsgsgtdftltisslqpedfatyscqqsyntpwtfgqgtkveik,,,,qtissy,aas,qqsyntpwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72513,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnityylnwyqqkpgkapnlliytasslqsgvpsrfigsgsgtdftltisslqpedfatyccqqsystpptfgqgtkveir,,,,qnityy,tas,qqsystppt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72512,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnignntvnwnhqvpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslnawvfgggtkltvl,,,,ssnignnt,nnn,atwddslnawv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72501,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtiscqtsqdisvslnwyqqkpgkppkvliydasnleagapsrfsgsgsgtdftftisslqpediatyycqhydnlprfgpgtkvdik,,,,qdisvs,das,qhydnlpr,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72500,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctatssdvgnynyvswyqhhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnplvfgggtkltvl,,,,ssdvgnyny,evs,ssyagsnplv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72499,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,,,,qgissy,aas,qqlnsypeit,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72497,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvtssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtrleik,,,,qsvtssy,gas,qqygsspt,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72496,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvrnynlvswyqqhpgkapklmifedskrpsgvsnrfsgsksgntasltiaglqpedeadyyccsyattwvfgggtkvtvl,,,,ssdvrnynl,eds,csyattwv,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72495,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisdylawyqekpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlsgypytfgqgtkleik,,,,qgisdy,aas,qqlsgypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72498,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlynsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhystpgytfgqgtkleik,,,,qsvlynsnnkny,was,qqhystpgyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72494,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvvtqspvslpatpgepasiscrasqsllhrngkhylhwylqrpgqspqlliylgsnrasgvpdrfsgsgsgtvfslkisrveaedvgiyycmqalhfpytfgqgtkldik,,,,qsllhrngkhy,lgs,mqalhfpyt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72493,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssyvgsfdlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccpyadtwvfgggtkltvl,,,,ssyvgsfdl,evs,cpyadtwv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72492,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqtvssnflawyqqkpgqaprlliygasiratgipdrfsgsgsatdftltisrlepedfavyycqqygssrtfgqgtkleik,,,,qtvssnf,gas,qqygssrt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72491,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,,,,qgissy,gas,qqlnsypeit,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72479,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsydhvswfqqhagkgpnvvifdvnsrpsgvsnrfsgsksgntasltisglqaedeadyycfsytsggtrvfgsgttvtvv,,,,ssdvgsydh,dvn,fsytsggtrv,,,IGLJ6*01 (human),IGLV2-14*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72478,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsnghnfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,,,,qsllhsnghnf,lgs,mqalqtprt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72477,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkaprlmiydvsdrpsgvsnrfsgsksgntasltisglrtedeadyycssytststlvfgggtkltvl,,,,ssdvggyny,dvs,ssytststlv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72476,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qtissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72475,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvgsiylawyqqkpgqaprllifgassraigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvgsiy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72474,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedtkrpsgiperfsgsssgtmatltisgaqvedeadyycysrdssgnplfgggtkltvl,,,,alpkky,edt,ysrdssgnpl,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72473,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratfscrasqsvnnnylawyqqkpgqaprlltsgtftratgipdrfsgsgsgtdftltisrvesedfavyycqqyggspatfgqgtrleik,,,,qsvnnny,gtf,qqyggspat,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72472,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygssrltfgpgtkvdik,,,,qsvsssy,gas,hhygssrlt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,ULE72471,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,elvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnsrltfgpgtkvdik,,,,qsvsssy,sas,qqygnsrlt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18853,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcivsddsinsyywswirqppgrglewigyiyysgstnydpslksratisldtsknqlslkltsvtaadtavyycarsgsygdrtfdhwgqgtlvtvss,,ddsinsyy,iyysgst,arsgsygdrtfdh,,,,IGHJ1*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18852,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgfntnyadsvkgrftisrdnskntlylqmnslraedtavyycakygwgllaaagdafdiwgqgtmvtvss,,gftfssya,isgsgfnt,akygwgllaaagdafdi,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18851,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkisckpsgytftnyliqwvrqapgqslewmgwinagdgysknslsfrgrvtftrdtsastasmelsslnsedtavyycarggfnyghgldywgqgtlvtvss,,gytftnyl,inagdgys,arggfnyghgldy,,,,IGHJ4*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18850,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasryafttyaihwvrqapgqglewmgwintntgdpmyahgftgrfvfslatsvstayleisslkaedtavyycaredtfyfdywgqgtlvtvss,,ryafttya,intntgdp,aredtfyfdy,,,,IGHJ4*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18849,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngdtkysqkfqgrvtitrdtsastaymelrslrsedtavyycarpprgyydrsgyynvllyfqhwgqgtlvtvss,,gytftsya,inagngdt,arpprgyydrsgyynvllyfqh,,,,IGHJ1*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18848,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftsydlhwvrqapgqrlewmgwinvgngntkysqkflgrvtftrdtsastvymelsslrsedtamyycarpprgyydrtgyynvvhyfqhwgqgtlvtvss,,gyiftsyd,invgngnt,arpprgyydrtgyynvvhyfqh,,,,IGHJ1*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18847,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsasywswirqppgkglewigeihhsgstnynpslesrvtisvdtsknqfslklssvtatdtavyycareysstvwdnwgqgtlvtvss,,ggsfsasy,ihhsgst,areysstvwdn,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18846,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqslsltcnvsggsissnnyywnwirqpagkglewigrgyssgstnynpslksrltisldtsknqfslklssvtaadtavyycarstyyydrsgystsdgmdvwgqgttvivss,,ggsissnnyy,gyssgst,arstyyydrsgystsdgmdv,,,,IGHJ6*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18845,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqllesgggvvqpgrslrlscavsgftfssygmhwvrqapgkglewvtfisydgsneyyadsvkgrftisrdsskntlylqmnslrpedtavyycakseysyaykvhfldywgqgtlvtvss,,gftfssyg,isydgsne,akseysyaykvhfldy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18844,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcsvsnysissgyywgwirqppgkglewigsifhsgstyynpslkgrvtisvdrsknqfslkltsvtaadtavylcakegargrgattsfyyyymdvwgkgttvtvss,,nysissgyy,ifhsgst,akegargrgattsfyyyymdv,,,,IGHJ6*04 (human),IGHV4-38-2*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18843,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvdsggglvqpggslrvscaasgftvssnhmswvrqapgkglewvsliygdgsthyadsvkgrftmsrdkskntlylqmnslraedtavyycardvthafdlwgqgtmvtvss,,gftvssnh,iygdgst,ardvthafdl,,,,IGHJ3*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18842,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evllvesggglvkpggslrlscaasgfsfssynmnwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycanmrtnydiftgyypdafdiwgqgtmvtvss,,gfsfssyn,issssnyi,anmrtnydiftgyypdafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,UKY18841,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,,ggsisstnyy,ifytgst,arytsyydrsgfrrveyfqh,,,,IGHJ1*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18866,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,,,,klgdky,hdt,qawgsstav,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18865,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvliqsplslpvtlgqpasiscrssqslvygdgdtylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkveik,,,,qslvygdgdty,kvs,mqgthwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18864,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvfwyqqhsgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagvtnnlifgggtkltvl,,,,ssdvggyny,evn,ssyagvtnnli,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18863,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,esvltqspgtlalspgeratlscrasqsvgsrylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspsfgqgtrleik,,,,qsvgsry,gas,qqygtsps,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18862,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqyvnlpltfgggtkveik,,,,qdisny,das,qqyvnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18861,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlsltfgggtkveik,,,,qdisny,das,qqydnlslt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18860,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgrhnyvswyqqypgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssayvvfgggtkltvl,,,,ssdvgrhny,dvs,ssytsssayvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18859,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgervtlscrasqsvsnslawyqqkpgqaprllidgassratgipdrfsgsgsetdftltisrlepedfavyycqqygsspltfgggtkveik,,,,qsvsns,gas,qqygssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18858,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnsvqwyqqrpgsapttviyednqrpswvpdrfsgsidsssnsasltisglkaedesdyycqsydssnhvlfgggtkltvl,,,,sgsiasns,edn,qsydssnhvl,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18857,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigaghdvhwyqqlpgtapklliygntnrpsgvpdrvsgsksgtsaslaisglqaedeadyycqsydislngwvlgggtkltvl,,,,ssnigaghd,gnt,qsydislngwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18856,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqiigmwlawyqqkpgkapklliykassleygvpsrfsgsgsgteftltisslqpddfatyycqqynsdlytfgqgtkleik,,,,qiigmw,kas,qqynsdlyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18855,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscsasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslesedfavyycqqyynwppwtfgqgtkveik,,,,qsvssn,gas,qqyynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",N/A,,,N/A,UKY18854,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapsllisgsssratdipdrfsgsgsgtdftltisrlepedfavyfcqqygsspytfgqgtkleik,,,,qsvsssy,gss,qqygsspyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89181,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatqggrfycsggscyryyfdywgqgtlvtvss,,ggtfssya,iipifgta,atqggrfycsggscyryyfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89180,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsdgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfvvvvaarshddyyfdywgqgtlvtvss,,gftfssya,isgsdgst,akdfvvvvaarshddyyfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89179,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwagadgmdvwgqgttvtvss,,gltvssny,iysggst,arwagadgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89178,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvrpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,,gftfssyd,igtagdt,arvrptmtkgfdwyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89177,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlsvaggmdvwgqgttvtvss,,gftvssny,iysggst,ardlsvaggmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89176,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardydyvwgsypsaccywgqgtlvtvss,,gytftsyg,isayngnt,ardydyvwgsypsaccy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89175,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmywvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaralygsgsystqagyyygmdvwgqgttvtvss,,gftfssyd,igtagdt,aralygsgsystqagyyygmdv,,,,IGHJ6*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89174,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarellllgycsggscypvgpdywgqgtlvtvss,,gftfsdyy,isssgsti,arellllgycsggscypvgpdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89173,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgysissayywgwirqppgkglewigsffhsgstyynpslksrvtitvdtskkqfslklssvtaadtavyycarddygdyavsywgqgtlvtvss,,gysissayy,ffhsgst,arddygdyavsy,,,,IGHJ4*01 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89172,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvsshymswvrqapgkglewvsvlysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlhssgpfdafdiwgqgtmvtvss,,gftvsshy,lysggst,ardlhssgpfdafdi,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89171,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhegstsplmvknyfdywgqgtlvtvss,,ggsissssyy,iyysgst,arhegstsplmvknyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89170,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgdsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyfcardyggnqnyfgywgqgtlvtvss,,gdsissggyy,iyysgst,ardyggnqnyfgy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89169,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivlmvyaiprgyygmdvwgqgttvtvss,,gftfgsyg,isydgskk,akdldivlmvyaiprgyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89168,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqksqervtitrdlstrtaymelsslrsedtavyycaapycsggscfdafdmwgqgtmvtvss,,gftftssa,ivvgsgnt,aapycsggscfdafdm,,,,IGHJ3*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89167,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlresgpglakpsgtlsltcavsggsitsiywwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyfcasapgtpwfdywgqgtlvtvss,,ggsitsiyw,iyhsgst,asapgtpwfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89166,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmsslraedtavyycardlavygmdvwgqgttvtvss,,gftvssny,iysggst,ardlavygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89165,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgysftshamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycartsgwsgpsygmdvwgqgttvtvss,,gysftsha,intntgnp,artsgwsgpsygmdv,,,,IGHJ6*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89164,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssyymnwvrqppgkglewvsviynggnayyadsvkgrftisrdnsrntlylqmnslraedtavyycargkwlrgafdiwgqgtmvtvss,,gftvssyy,iynggna,argkwlrgafdi,,,,IGHJ3*02 (human),IGHV3-53*03 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89163,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfpfsnygmhwvrqapgkglewvavisydgssqyyadsvkgrftisrdnskntlylqmnslrgddtavyycakdrsvgattsqynyyygmdvwgqgttvtvss,,gfpfsnyg,isydgssq,akdrsvgattsqynyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89162,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqsspklgddafdiwgqgtmvtvss,,ggsissssyy,iyysgst,arqsspklgddafdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89161,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgitftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggtchdgfdiwgqgtmvtvss,,gitftssa,ivvgsgnt,aapycsggtchdgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89160,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkssetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrlgprgpfdnhgnhfdywgqgtlvtvss,,ggsissssyy,iyysgst,arrlgprgpfdnhgnhfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89159,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgrirsktdggtpdyaaplkgrftisrddskntlylqmnslktedtavyycttdsldvgggsyvnfdywgqgtlvtvss,,gftfsnaw,irsktdggtp,ttdsldvgggsyvnfdy,,,,IGHJ4*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89158,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsihysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhagpyssswianwfdpwgqgtlvtvss,,ggsissssyy,ihysgst,arhagpyssswianwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89157,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaprpgdswfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arhaaprpgdswfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89156,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisddgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgstgttlgyygmdvwgqgttvtvss,,gftfgsyg,isddgsnk,akdfgstgttlgyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89155,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkarnyydssgyehdafdiwgqgtmvtvss,,gftfsnaw,iksktdggtt,ttdkarnyydssgyehdafdi,,,,IGHJ3*02 (human),IGHV3-15*07 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89154,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycardltqdwyfdlwgrgtlvtvss,,gftfssyd,igtagdt,ardltqdwyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89153,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgcirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhvgpysgydknnwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arhvgpysgydknnwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89152,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnilraedtavyycarsqstswhdywgqgtlvtvss,,gftfssyw,ikqdgsek,arsqstswhdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89151,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqlwlrsnfdswgqgtlvtvss,,ggsissssyy,fyysgst,atqlwlrsnfds,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89150,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsgdsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknlfslklssvtaadtavyycarrgwlrgyfdlwgrgtlvtvss,,gdsissssyy,fyysgst,arrgwlrgyfdl,,,,IGHJ2*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89149,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasrftfsnywmswvrqapgkglewvanikqdgsekycvdsvkgrftisrdnaknslylqmnslraedtavyycaralsmvrgviippyfdywgqgtlvtvss,,rftfsnyw,ikqdgsek,aralsmvrgviippyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89148,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargiaarpgdwhfdlwgrgtlvtvss,,ggsissssyy,iyysgst,argiaarpgdwhfdl,,,,IGHJ2*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89147,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriqsktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdpnqqpprgyyfyygldvwgqgttvtvss,,gftfsnaw,iqsktdggtt,ttdpnqqpprgyyfyygldv,,,,IGHJ6*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89146,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpsltsrvtisvdtsknqfslklssvtaadtavyycarqfwtrppsvwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arqfwtrppsvwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89145,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargtamaygmdvwgqgttvtvss,,gftvssny,iysggst,argtamaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89144,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvetgggliqpggslriscaasgltvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycardlitygmdvwgqgttvtvss,,gltvssny,iysggst,ardlitygmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89143,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscrasgytftsygitwvrqapgqglewmgwisvdngntkyaeklqgrvtmttdtststaymelrslgsddtavyycardggwtgimgainfdywgqgtlvtvss,,gytftsyg,isvdngnt,ardggwtgimgainfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89142,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftfsrsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstsaaymelsslrsedtavyycaapacsstrcydgfdiwgqgtmvtvss,,gftfsrsa,ivvgsgnt,aapacsstrcydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89141,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgahywswirqhpgkglewigyiyysggtyynpslkslvtisvdtsknhfslklssvtaadtavyycarttaprpgsswfdpwgqgtlvtvss,,ggsissgahy,iyysggt,arttaprpgsswfdp,,,,IGHJ5*02 (human),IGHV4-31*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89140,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasglivssnymswvrqapgkglewvsvlysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarwgrvgatglafdiwgqgtmvtvss,,glivssny,lysggtt,arwgrvgatglafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89139,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsrnaiswvrqapgqglewmggiipifgtahyaqkfqgrvtitadeststaymelsslrsedtavyycarreysstdwfdpwgqgtrvtvs,,ggtfsrna,iipifgta,arreysstdwfdp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89138,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycarggavipvwyfdlwgrgtlvtvss,,gftfssyd,igtagdt,arggavipvwyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89137,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvafisydgddkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakavysyayavlyfdywgqgtlvtvss,,gftfssyg,isydgddk,akavysyayavlyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89136,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglqwvaiisydesskyyadsvkgrftisrdnskntlylqmnslraedtamyycakdppqfavagtgyfdywgqgtlvtvss,,gftfsnyg,isydessk,akdppqfavagtgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89135,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysggtysnpslksrvtisvdtsknqlslklssvtaadtavyycarevapikqwlvsyfdywgqgtlvtvss,,ggsissssyy,iyysggt,arevapikqwlvsyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89134,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmkslraedtavyycardrfydysssgysldafdiwgqgtmvtvss,,gftfstyg,iwydgsnk,ardrfydysssgysldafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89133,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyytpslksrvtisvdtsknqfslklssvtaadtavyycarftrfaglyyfdywgqgtlvtvss,,ggsissssyy,iyysgst,arftrfaglyyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89132,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmsgthssgwyerwfdpwgqgtlvtvss,,gysftsyw,iypgdsdt,arhmsgthssgwyerwfdp,,,,IGHJ5*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89131,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqvawlprddyfdywgqgtlvtvss,,ggsisssryy,iyysgst,arqvawlprddyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89130,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,,gftvssny,iysggst,ardlavygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89129,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaraaydiltgyyrgmdvwgkgttvtvss,,gftfssyd,igtagdt,araaydiltgyyrgmdv,,,,IGHJ6*04 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89128,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmsslragdtavyycarghfygligymdvwgkgttvtvss,,gftfssyd,igtagdt,arghfygligymdv,,,,IGHJ6*04 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89127,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaignagdtyypasvkgrftisrenarnslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,,gftfssyd,ignagdt,arvrptmtkgfdwyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89126,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakdtyydifpdvfdiwgqgtmvtvss,,gftfssya,isgsggnt,akdtyydifpdvfdi,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89125,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgdtnytqkfqervtitrdmststaymelsslrsedtavyycaapycsgsscldgfdiwgqgtmvtvss,,gftftssa,ivvgsgdt,aapycsgsscldgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89124,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakapyaycsstscyadyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,akapyaycsstscyadyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89123,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycarggivpaatllfdpwgqgtlvtvss,,gytftsyy,inpsggst,arggivpaatllfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89122,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgshntnyaqkfqervtitrdmststaymelssltsedtavyycaaaiiasaapdywgqgtlvtvss,,gftfsssa,ivvgshnt,aaaiiasaapdy,,,,IGHJ4*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89121,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfnnyemnwvrqapgkglewvsyissggttmyyadsvkgrftisrdnaknslylemnslraedtalyycarvghpdtlfgveywgqgilvtvss,,gftfnnye,issggttm,arvghpdtlfgvey,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89120,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfifnnyemnwvrqapgkglewisyissggttvyyadsvkgrftisrdnaknslylqmsslraedtalyycvrvghpdtlfgvdywgqgtlvtvss,,gfifnnye,issggttv,vrvghpdtlfgvdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89119,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggwydykgyyfdywgqgtlvtvss,,gftfssyg,isydgsnk,akgggwydykgyyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89118,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgtqpipdygdffdpwgqgtlvtvss,,gftfssya,isgsggst,akgtqpipdygdffdp,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89117,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwaqqlvpsenlkpyyyyygmdvwgqgttvtvss,,gftvssny,iysggst,arwaqqlvpsenlkpyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89116,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarqpreyydfwsgyrrlfyfdywgqgtlvtvss,,gftfssye,isssgsti,arqpreyydfwsgyrrlfyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89115,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsggscydafdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapncsggscydafdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89114,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgtshyydssgyygadrnwfdpwgqgtlvtvss,,gytftsyg,isayngnt,ardgtshyydssgyygadrnwfdp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89113,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsihysgstyynpslksrvtisvdtsknqfslklssmtaadtavyycarhtgyydssgyyrleyfqhwgqgtlvtvss,,ggsissssyy,ihysgst,arhtgyydssgyyrleyfqh,,,,IGHJ1*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89112,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewiayiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgynyglglgwfdpwgqgtlvtvss,,ggsissyy,iyysgst,arsrgynyglglgwfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89111,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnglraedtavyycakvlgsycsggscyggsfdywgqgtlvtvss,,gftfssyg,isydgsnk,akvlgsycsggscyggsfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89110,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksgapaamrgyyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,aksgapaamrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89109,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdafgdpqglygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdafgdpqglygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89108,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgddygdlfyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,akgddygdlfyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89107,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkrpgssvkvsckasggtfsnygfswvrqapgqglewmggtsplfhtpnyvqkfqdrvtitadesttsvymelnsltsddtavyycacssgrwgvlgnyfdywgqgtlvtvss,,ggtfsnyg,tsplfhtp,acssgrwgvlgnyfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89106,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssygiswvrqapgqglewmggiipifgtayyaqkfqgrvtitadeststaymelsslrsedtavyycassspllryfdwpheaifdywgqgtlvtvss,,ggtfssyg,iipifgta,assspllryfdwpheaifdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89105,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddsknmlylqmnslktedtavyycttdpgytyspaywgqgtlvtvss,,gftfsnaw,iksktdggtt,ttdpgytyspay,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89104,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvssissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdvtvdtamvtifdnwgqgtlvtvss,,gftfssya,issnggst,vkdvtvdtamvtifdn,,,,IGHJ5*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89103,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtsgdtyypgsvkgrftisrenaknslylqmnslragdtavyycargggdgynlglwyfdlwgrgtlvtvss,,gftfssyd,igtsgdt,argggdgynlglwyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89102,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftfpssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcgggscydgfdiwgqgtmvtvss,,gftfpssa,ivvgsgnt,aaphcgggscydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,UKB89101,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,,gfpfstyg,isydgsnk,akdfqyvaathspyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89262,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,,,,qsvsssy,gas,qqygssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89261,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyknfpltfgggtkveik,,,,qsissw,kas,qqyknfplt,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89260,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssqytfgqgtkleik,,,,qsvssty,gas,qqygssqyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89259,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,,,,qsissf,aas,qqsyntlgt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89258,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssppitfgqgtrleik,,,,qsvsssy,gas,qqygssppit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89257,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsglsnrfsgsksgntasltisglqaedeadyycssytsstnwvfgggtkltvl,,,,ssdvggyny,evs,ssytsstnwv,,,IGLJ3*02 (human),IGLV2-14*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89256,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyraftfgpgtkvdik,,,,qsissy,aas,qqsyraft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89255,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhwvfgggtkltvl,,,,sgsiasny,edn,qsydssnhwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89254,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsalyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89253,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvaitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqydivgggtkveik,,,,qdisny,das,qqydi,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89252,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpitfgqgtrleik,,,,qgissw,aas,qqansfpit,,,IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89251,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqditnslnwyqqkpgkapklliydasnletgvpssfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qditns,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89250,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeaayycssytsssppvvfgggtkltvl,,,,ssdvggyny,evs,ssytsssppvv,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89249,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslftfgpgtkvdik,,,,qsvsssy,gas,qqygsslft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89248,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,,,,ssdvgryny,dvs,ssytssstlyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89247,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsfsssylawyqqipgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsslitfgqgtrleik,,,,qsfsssy,gas,qqydsslit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89246,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qavvtqepsltvspggtvtltcasstgavtsgyypnwfqqkpgqapraliysisnkhswtparfsgsllggkaaltlsgvqpedeaeyycllyfggaqyvfgtgtkvtvl,,,,tgavtsgyy,sis,llyfggaqyv,,,IGLJ1*01 (human),IGLV7-43*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89245,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapitviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdlwvfgggtkltvl,,,,sgsiasny,edn,qsydssdlwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89244,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqfpgtapklliydndkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwetslsaevfgggtrltvl,,,,ssnignny,dnd,gtwetslsaev,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89243,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsvvv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89242,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89241,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrviitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltvsslqpedfatyycqqlnsypwtfgqgtkveik,,,,qgissy,aas,qqlnsypwt,,,IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89240,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsvsvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89239,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteltltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89238,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqafsswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfptfgqgtrleik,,,,qafssw,aas,qqansfpt,,,IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89237,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgwvfgggtkltvl,,,,ssnigsny,rnn,aawddslsgwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89236,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlitfgqgtrleik,,,,qsissf,aas,qqsystlit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89235,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgthftlaisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89234,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,,,,qsvssy,das,qqrsnwplt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89233,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidtssnsasltisglktedeadyycqsydnnnhvvfgggtkltvl,,,,sgsiasny,edn,qsydnnnhvv,,,IGLJ2*01 (human),IGLV6-57*03 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89232,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwhqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnvvfgggtkltvl,,,,sgsiasny,edn,qsydsgnvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89231,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstnhvvfgggtkltvl,,,,sgsiasny,edn,qsydstnhvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89230,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidiysnsasltisglktedeadyycqsydssnhwvfgggtkltvl,,,,sgsiasny,edn,qsydssnhwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89229,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsrgvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsrgv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89228,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqapmtlicdtsnkhswtparfsgsllgdkaaltlsgaqpedeaeyycllsysgapvvfgggtkltvl,,,,tgavtsghy,dts,llsysgapvv,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89227,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignyyvswyqqlprtapklliydnnerpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignyy,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89226,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnniggqsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,,,,niggqs,dds,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89225,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyscqhlltfgggtkveik,,,,qginsy,aas,qhllt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89224,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywcqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslsgwvfgggtkltvl,,,,ssnigsny,rnn,atwddslsgwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89223,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapslliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89222,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdntlspgrgvfgggtkltvl,,,,ssnignny,dnn,gtwdntlspgrgv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89221,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtariscggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsdsnsgntatltisrveagdeadyycqvwdsssdhhyvfgtgtkvtvl,,,,nigsks,dds,qvwdsssdhhyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89220,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,,,,nigsks,dds,qvwdstsdhpgyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89219,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyshpgitfgpgtkvdik,,,,qsigsy,aas,qqsyshpgit,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89218,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsfasnsvqwyqqrpgsapttmiyednhrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydynnhvvfgggtkltvl,,,,sgsfasns,edn,qsydynnhvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89217,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnnigsknvhwyhqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,,,,nigskn,dds,qvwdsssdpwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89216,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvqwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsglvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsglv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89215,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvseaprqrvtiscsgsssnignnavnwfqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,,,,ssnignna,ydd,aawddslnawv,,,IGLJ3*02 (human),IGLV1-36*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89214,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglraddeadyycssyagtvlfgggtkltvl,,,,ssdvggyny,evs,ssyagtvl,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89213,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89212,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvgfynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnyvvfgggtkltvl,,,,ssdvgfyny,evs,ssyagsnnyvv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89211,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,,,,nigsns,dds,qvwdsssdhpvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89210,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgidftltisslqpedfatyycqqsyniastfgqgtkveik,,,,qnissy,aas,qqsyniast,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89209,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqklgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppltfgggtkveik,,,,qsissy,aas,qqsystpplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89208,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,,,,qsisty,aas,qqsyntlgt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89207,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitiscagtssdlggyyyvswyqhhpgkapklmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlpvfgtgtkvtvl,,,,ssdlggyyy,evs,ssytssstlpv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89206,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspdtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftlaisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvrssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89205,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssvvfgggtkltvl,,,,ssdvggyny,evs,ssytsssvv,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89204,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyscsfgqgtkleik,,,,qsissw,kas,qqynsyscs,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89203,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,,,,qsvssy,das,qqrsnwppyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89202,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscgasqsisstlawyqhkpgqaprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,,,,qsisst,gas,qqynnwprys,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89201,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqapslliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,,,,qsvssn,gas,qqynnwprys,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89200,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89199,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppctfgqgtkleik,,,,qsvsssy,gas,qqygssppct,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89198,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgytfgqgtkleik,,,,qsvsssy,gas,qqygsspgyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89197,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89196,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89195,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedgadyycqsydsslsgwvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89194,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylywyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89193,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyddvpftfgpgtkvdik,,,,qditny,das,qqyddvpft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89192,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydassleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlpsfgggtkveik,,,,qdisny,das,qqydnlps,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89191,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpedeadyycllsysgarevfgggtkltvl,,,,tgavtsghy,dts,llsysgarev,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89190,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfaqgtrleik,,,,qsitsy,aas,qqsystplt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89189,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrtltfgggtkveik,,,,qsllhsngyny,lgs,mqalqrtlt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89188,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqditdylnwyqqkpgqapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqyanllltfgggtkveik,,,,qditdy,das,qqyanlllt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89187,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwsgitfgqgtrleik,,,,qsvssy,das,qqrsnwsgit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89186,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcragqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlftfgpgtkvdik,,,,qsissy,aas,qqsystlft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89185,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,,,,qsissy,aas,qqsystpt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89184,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqrkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnppptfgpgtkvdik,,,,qsissy,aas,qqsysnpppt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89183,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,,,N/A,UKB89182,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylacyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgpgtkvdik,,,,qsvsssy,gas,qqygsspgvt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VNE_V,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain V, n3113.1",N/A,evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dssfydye,mypsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VNE_U,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain U, n3113.1",N/A,evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dssfydye,mypsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VNE_W,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain W, n3113.1",N/A,evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dssfydye,mypsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VND_D,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain D, n3113",N/A,evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dfsfydye,myhsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VND_V,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain V, n3113",N/A,evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dfsfydye,myhsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VNC_V,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain V, n3113",N/A,evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dfsfydye,myhsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,,,7VNB_A,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Chain A, n3113",N/A,evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,,dfsfydye,myhsgrt,vsnwasgstgdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAU_FFF,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain FFF, C5",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAU_BBB,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain BBB, C5",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAQ_FFF,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain FFF, H3",N/A,qvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvss,,grtfstys,mrwtgsst,aittivrayyteyteadfgs,,,,IGHJ5*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAQ_AAA,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain AAA, H3",N/A,qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvss,,gftndfys,lsvsdntp,aagrfagrdtwpssydy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAN_H,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain H, immunoglobulin mu heavy chain",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAN_G,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain G, immunoglobulin mu heavy chain",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",N/A,,,7OAN_F,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain F, immunoglobulin mu heavy chain",N/A,qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvss,,gvtlgrha,irtfdgit,algvtaacsdnpyf,,,,IGHJ1*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,,,7MDW_A,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"Chain A, nonobody Nb21",N/A,qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,,glgahr,iganggnt,aardietaeyty,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,,,7D2Z_A,N/A,"SARS-CoV-2, Spike protein RBD",synthetic construct,2022-03-15,"Chain A, SR31 against SARS-CoV-2 RBD, non neutralizing",N/A,qvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsa,,gfpvwqge,issmgykt,avmvgfwy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23909,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaiisydgsnkyyadsvkgrftisrdnsnntvylqinslrtedtavyycaksragsyyygmdvwgqgttvtvss,,gftfstya,isydgsnk,aksragsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23908,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisctgsgysfttywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtfsadksistaylqwsslkasdtaiyycarhgnryssgwyqptgvdvwgqgttvtvss,,gysfttyw,iypgdsdt,arhgnryssgwyqptgvdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23907,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgasigsyywswirqppgkgleyigyiyysgstdynpslksrvtisidtsknlfslnltsvtaadtavyycargfdswgqgtlvtvss,,gasigsyy,iyysgst,argfds,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23906,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggdvvqpgrslrlscaasgftfstyamhwvrqapgkglewvslisydginkyyagsvkgrfsisrdnskntlylqmnslrvedtavyycarslsggyyygmgvwgqgttvtvss,,gftfstya,isydgink,arslsggyyygmgv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23905,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwyhgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardretstnyvghyyngmdvwgqgttvtvss,,gftfssyg,iwyhgnnk,ardretstnyvghyyngmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23904,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwvnpnsgatncaqkfqgrvtmtrdtsittvymelsrlkfddtavyycargvdfsifgaaisddwgqgtlvtvss,,gyiftgyy,vnpnsgat,argvdfsifgaaisdd,,,,IGHJ5*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23903,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsenlsltcnvagdsisgyywswirqtpgkglefigymyyggstiynpslrtrvtisidtsknqfslnlnsvtaadtaiyycargfdlwgrgtlvtvss,,gdsisgyy,myyggst,argfdl,,,,IGHJ2*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23902,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsgyamhwvrqapgkglewvavisydgdnkyyadsvrgrftisrdnskntlylqmnslrvedtavyycarsssgsyfaafdiwgqgtmvtvss,,gftfsgya,isydgdnk,arsssgsyfaafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23901,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgdyfwtwirqppgkglewighifysgstyynpslksrvtisldtsknqfslklssvtaadtavyycarvvlaknyydrsgyfhgdwyfygmdvwgqgttvtvss,,ggsissgdyf,ifysgst,arvvlaknyydrsgyfhgdwyfygmdv,,,,IGHJ6*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23900,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvssvsgsgdrtyyadsvkghfiisrdnskntlylqmnslraedtavyycatdsyyhdrdgfvnyafdiwgqgtmvtvss,,gftfssya,vsgsgdrt,atdsyyhdrdgfvnyafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23899,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfnfnnvwmswvrqapgkglewvgliksksdggtkdyaapvrgrftisrddprnnlylqmnslktedtavyycstapyyydysaypqihfeywgrgtlvtvss,,gfnfnnvw,iksksdggtk,stapyyydysaypqihfey,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23898,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglecvsviygggptyyadsvkgrftisrdnskntlylqmnslraedtavyycardkripyyfygmdvwgqgttvtvss,,gftvssny,iygggpt,ardkripyyfygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23897,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasrfpfstygmhwarrapgkglewvslisddgknkyyadsvkgrftisrdnyentlylemnslrpedtavyycakailrgvkyylygvdiwgqgttvtvss,,rfpfstyg,isddgknk,akailrgvkyylygvdi,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23896,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpgvvkpsetlsltctvsgdsissyywswirqspgkglewigyiyssgstnynpslksrvamsvdtsknhfslkmtsvtaadtavyycargfdfwgqgtlvtvss,,gdsissyy,iyssgst,argfdf,,,,IGHJ5*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23895,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvsnrymswvrqtpgkglewvsiiysagstyyadsvkgrftisrdnskntlylqmnslrvedtavyycaragsplslrwrphidywgqgtlvtvss,,gftvsnry,iysagst,aragsplslrwrphidy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23894,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqvqqwgagllkpsetlsltcavyggsfsdyswtwirqspgkglewigeindsgitnydptlksriimsvdrsknqfslrltsvtaadtavyfcargstvlglsslryyssldvwgqgttvtvss,,ggsfsdys,indsgit,argstvlglsslryyssldv,,,,IGHJ6*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23893,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggevkkpgasvkvsckasgytftnyglswvrqapgqglewmgwisgnngntnyaqkfqgrvtmttdtststgymelrslrsddtavyycardqstvvtfgtfdywgqgtlltvss,,gytftnyg,isgnngnt,ardqstvvtfgtfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23892,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpggslrlscaasgftfssygmhwvrqapgkglewvafirydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaspsryydssgyylaeyfqhwgqgtlvtvss,,gftfssyg,irydgsnk,aspsryydssgyylaeyfqh,,,,IGHJ1*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23891,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpgpvkpsgtlsltcavsgdsitntnwwswvrqspggglewigeihhsgttnyksslksrviisidksknqfslkmrsvtaadtalyycargrynwnggyfdywgqgtlvtvss,,gdsitntnw,ihhsgtt,argrynwnggyfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23890,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvnvsckasggtfssyaiswvrqapgqglewmggifplygttkyaqqfqgrvtfsadestrtaymdlrslrsedtavyycarsadgdyvvgyyhymdvwgkgttvivss,,ggtfssya,ifplygtt,arsadgdyvvgyyhymdv,,,,IGHJ6*04 (human),IGHV1-69*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23889,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsggtfssytfswvrqapgqglewmgvfipifgttsyaqkfqgrvtitadestytsymelssltsedtamyycasrlgcpngachepdywgqgtlvtvss,,ggtfssyt,fipifgtt,asrlgcpngachepdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23888,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlsctasgftfntyaihwvrqapgkglesvalisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycargtggnyyygmdvwgqgttvtvss,,gftfntya,isydgink,argtggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23887,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmagimpifgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycasrhsgyryshfdywgqgtlvtvss,,ggtfssya,impifgrp,asrhsgyryshfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23886,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggwvqpggslrlscaasefsvstnymtwvrqapgkglewvsiiysdgrtfyadsvkgrftisrdnskntvylqmnnlrpedtavyfcararvtiivvvvdyffdywgqgtlvtvss,,efsvstny,iysdgrt,ararvtiivvvvdyffdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23885,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvkpggslrlscaasgftfynawmswvrqapgkglewvghikgntnggttdyaapvkgrftisrddskntlylqmnslrtedtgvyycttetllwfgespfdywgqgtlvtvss,,gftfynaw,ikgntnggtt,ttetllwfgespfdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23884,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgvtvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrddsmntlylqmsnvraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23883,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfnsyaftwvrqapgqglewmgaiipilgianheqkfqdratitadkststaymelrslrsddtavyycasgvvvpatdyyyamdvwgqgttvtvss,,ggtfnsya,iipilgia,asgvvvpatdyyyamdv,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23882,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgfifsssamswvrqapgkglewvsgisdsglrtyygdsvkgrftisrdnskntvsllmnslraedtavyycaygyspdywgqgtlvtvss,,gfifsssa,isdsglrt,aygyspdy,,,,IGHJ4*01 (human),IGHV3-23*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23881,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnnlrdedtamyycardlivygmdvwgqgtpvtvss,,gltvssny,iysggtt,ardlivygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23880,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasglivssnymswvrqapgkglewvsiiyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyyctrdlvyygmdvwgqgttvtvss,,glivssny,iyaggst,trdlvyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23879,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglaqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfysdsvkgrftisrdgpkntlylhmhslraedtavyycardlvhygmdvwgqgttvtvss,,gitvssny,myaggst,ardlvhygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23878,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwirqapgkglewvaviwsdginkyyvdsvkgrftisrdnskntlylqmnslraddtavyycarapqdpdsssyyyfyygldvwgqgttvtvss,,gftfsnyg,iwsdgink,arapqdpdsssyyyfyygldv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23877,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftayyihwvrqapgqglewmawinpmsgatnytqkfqgrvtmtrdtsittvymelsrlrsadtavyycarvspptifgvtvdhwgqgtlvtvss,,gyiftayy,inpmsgat,arvspptifgvtvdh,,,,IGHJ1*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23876,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymnwirqapgkglewvssisttgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddssgyyygsaldwgqgtlvtvss,,gftfsdyy,isttgsti,arddssgyyygsald,,,,IGHJ1*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23875,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfytdsvkgrftisrdnskntlylqmnslraedtavyycardlvvlygmdvwgqgttvtvss,,gitvssny,iysggst,ardlvvlygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23874,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaapgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardldyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23873,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfnnyainwvrqapgqglewmgriipmlgvvnhaqkfqgrvtitadkststaymelsslrsedtavyycatrvsvttmgvnfdgmdvwgqgttvtvss,,ggtfnnya,iipmlgvv,atrvsvttmgvnfdgmdv,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23872,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasglivssnymtwvrqapgkglewvsvlyaggssfyadsvkgrftisrdnskntlflqmnslraedtavyycardlvaygmdvwgqgttvsvss,,glivssny,lyaggss,ardlvaygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23871,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpessvkvsckvsggtfssygiswvrqapgqglewmgriipslgvvnyaqrfqgrvtftadkststaymdlsslksedtavyycakttvvtpglgkdafdvwgqgtmvtvss,,ggtfssyg,iipslgvv,akttvvtpglgkdafdv,,,,IGHJ3*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23870,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgyiftnfwiawvrqmpgkglewmgiiypddsdvrysppfqgqvtisadksintaylqwsslkasdtamyycarlsflpsgfshyyaldvwgqgttvtvss,,gyiftnfw,iypddsdv,arlsflpsgfshyyaldv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23869,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvalisydgsneyyadsvrgrftisrdnskntlylqmsslraedttmyycaranrgnyyygmdvwgpgttvtvss,,gftfstya,isydgsne,aranrgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*15 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23868,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqleqsgaevkkpgssvkvsckasgssfssyaitwvrqapgqglewmggiipifgtanyaqifqgrvtltaeestgaaymelsslrsedtalyyctiigmfdssgsythywgqgtlvtvss,,gssfssya,iipifgta,tiigmfdssgsythy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23867,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifntyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskstlylqmnslriedtavyycarsrsgsyfsafdiwgqgtkvtvsp,,gfifntya,isydgdnk,arsrsgsyfsafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23866,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvrpgrslrlscaasgftfssygmhwvrqapgkglewvalisydginkyypdsvkgrftisrdnsnntlylqmnslraedtavyycanaktgnyyygmdvwgqgttvtvss,,gftfssyg,isydgink,anaktgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23865,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsistyywswirqppgkrlewigyiyysgstnynpslksrvtisvdtsknqfslklnsvtaadtaiyycargfdywgqgtlvtvss,,ggsistyy,iyysgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23864,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgdkkyytdsvkgrftisrdnskntlflqmnslraedtavyycararegtyyygmdvwgqgttvtvss,,gftfssya,isydgdkk,araregtyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23863,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarlsfgyssssnyyyygmdvwgqgttvtvss,,gysftsyw,iypgdsdt,arlsfgyssssnyyyygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23862,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscavsgftfrsyamswvrqapgkglewvstisgsggrtdyadsvkgrftisrdnskntlyvqmsslraedtavyycalpylgwlrsfdywgqgtlvtvss,,gftfrsya,isgsggrt,alpylgwlrsfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23861,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqisgpglekpsgtlsltctvsggsvsrsdfywgwvrqppgkglewigsihysgstyynpslksrvtisvdtsenqlslrlssvtaadtavyycarsggysygravwfdnwgqgtlvtvss,,ggsvsrsdfy,ihysgst,arsggysygravwfdn,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23860,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsisaihwvrqapgkglewvavisydgfnkyyedsvkgrfiisrdnskntlylqmnslrvedtavyycakgggsyyhpfdnwgqgtlvsvss,,gftfsisa,isydgfnk,akgggsyyhpfdn,,,,IGHJ5*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23859,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptvvkptqtltltctfsgfslsisgegvgwirqppgkalewlaliywnderrytpslksrlsitkdtsknqvvltmtnmdpvdtatyycahtyyydsrgyafdnwgqgtlvpvss,,gfslsisgeg,iywnder,ahtyyydsrgyafdn,,,,IGHJ5*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23858,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavfggsfsayywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargsreqwlvrrawyfdlwgrgtlvtvss,,ggsfsayy,inhsgst,argsreqwlvrrawyfdl,,,,IGHJ2*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23857,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcavsggsisiyywswirqppgkglewigyishsgdtnynpslksrvtisvdtsknqfslrlssvtaadtalyycargdimwtqwltsggrfldywgqgalvtvss,,ggsisiyy,ishsgdt,argdimwtqwltsggrfldy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23856,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsisgyywswirqspgkglewmgylyysgsinynpslksrvtisidtsknqfslkmrsvtaadtavyycargfeswgqgtlvtvss,,ggsisgyy,lyysgsi,argfes,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23855,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgntfidsymhwvrqapgqglewmglidpsgknryypqnfqgrltltrdaststtymqlsslrsqdtavyycarmteagswdywgqgtlvtvss,,gntfidsy,idpsgknr,armteagswdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23854,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlslqlnslraedtavyycarmhsgsyigyfdywgqgtlvtvss,,gftfssya,isydgink,armhsgsyigyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23853,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfitysfhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarqksqwellfrgdafdiwgqgtmvtvss,,gftfitys,isydggnk,arqksqwellfrgdafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23852,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaliaydgdkkyyadsvrgrftlsrdnskntlylemnslraedtavyycarpysgsyygafeiwgqgtmvtvsa,,gftfstya,iaydgdkk,arpysgsyygafei,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23851,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnsnstlylqmnslraedtalyycarggyhyfrhfdywgqgtlvtvss,,gftfssyv,isydgsnk,arggyhyfrhfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23850,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,dvllvesggglvqpggslrlscsasgfpfitywmswvrqapgkglewvanikedgsekyyvdsvrgrftisrdnaenslslqmnslraddtavyycartggrgsldrgrfdywgqgtlvtvss,,gfpfityw,ikedgsek,artggrgsldrgrfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23849,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscvvsgftfntyamhwvrqapgkglewvavisydgnnhysadsvrgrfsvsrdnskktlflqmnslraedtavyycarsyggnylgyfdywgqgtlvtvss,,gftfntya,isydgnnh,arsyggnylgyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23848,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstnynpslksrvtisldtsknqfslkltsvtaadtavyycarrrrgysyghptyhafdmwgqgtmvtvsa,,ggsissssyy,myysgst,arrrrgysyghptyhafdm,,,,IGHJ3*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23847,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarhslrggtrggyyyyygmdvwgqgttvtvss,,gysftsyw,idpsdsyt,arhslrggtrggyyyyygmdv,,,,IGHJ6*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23846,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggavvqpgrslrlsceasgftfstyamhwvrqapgkglewvalvsydgsnkyyadsvkgrftisrdnskntlylqmdslraedsavyycaralsgsyyygmdvwgqgttvtvss,,gftfstya,vsydgsnk,aralsgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23845,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscavsgftfgsywmswvrqapgrglewvanirqdgsekyyvdsvkgrftisrdnaknsmylqmnslraedtavyycakenivavpaargydyyyymdvwgkgttvtvss,,gftfgsyw,irqdgsek,akenivavpaargydyyyymdv,,,,IGHJ6*04 (human),IGHV3-7*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23844,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlsceasgltfinawmswvrqapgkglewvgriksktdggttdfaapvkgrftisrddskntvflqmnslktedtavyycatdllfprdpgdnwgqgtlvtvss,,gltfinaw,iksktdggtt,atdllfprdpgdn,,,,IGHJ5*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23843,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevqkpgeslkiscrasgytftdqwigwvrqmpgkglewvgviypgdsdtryspsfqgqvtisvdksistaylqwsslkasdtamyycarqsafwtgylyyyafdvwgqgttvtvss,,gytftdqw,iypgdsdt,arqsafwtgylyyyafdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23842,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaaseftfstytmhwvrqapgkglewvalisydgshkyyadsvkgrftisrdnskntlslqmnslraddtavyycararggnyyygmdvwgqgttvtvss,,eftfstyt,isydgshk,ararggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23841,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggmvqpgrslrlscaasgftfstyaihwvrqapgkglewvavvsydglnkyyadsvrgrftisrdnskntlylqmnnlraedtalyycarsasggywselpywgqgtlvtvss,,gftfstya,vsydglnk,arsasggywselpy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23840,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsisrtnyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarlppwynsgwagldsltyqyymdvwgkgttvtvss,,ggsisrtnyy,iyysgst,arlppwynsgwagldsltyqyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23839,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlmesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglqwvavisydgnnkyyadsvkgrftisrdnskntlylqintlraedtavyycargyggnyhyfdywgqgtlvtvss,,gftfssya,isydgnnk,argyggnyhyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23838,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpseilsltctvsggsisshywswirqppgkglewigyisysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,,ggsisshy,isysgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*11 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23837,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaelkkpgeslrisckgsgysftsywiiwvrqmpgkglewmgridpsdsytkyspsfqghvtissdksistaylqwnslktsdtavyycarqfatlenvigpaaldwfdpwgqgtlvtvss,,gysftsyw,idpsdsyt,arqfatlenvigpaaldwfdp,,,,IGHJ5*02 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23836,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmhlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnygqkfqervtitrdlststvymelislrsedtavyfcaapyctggscfdafdiwgqgtmvtvss,,gftfsssa,ivvgsgnt,aapyctggscfdafdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23835,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewmavisydgsnkyyadsmkarfsisrdnskntlylhmnslrpedtavyycaraaggnyyygmdvwgqgttvtvss,,gfifstya,isydgsnk,araaggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23834,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvscraseyaftdyyihwvrqapgqtlewmgiinpsggsaryaqkfqgrvtmtrdtststvymevsslrfedtavyycardpsggssvttqnyfdswgqgtlvtvss,,eyaftdyy,inpsggsa,ardpsggssvttqnyfds,,,,IGHJ5*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23833,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasglivssnymnwvrqapgkglewvsvlysggstfyadsvkgrftisrdnskntlhlqmnslrvedtavyycardlvaygmdvwgqgttvtvss,,glivssny,lysggst,ardlvaygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23832,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnlgfswvrqapgqglewmggiipivalanyaekfqgrvtitadkststvymelsslrsedtavyycatkgdghnyfyyygvdvwgqgttvtvss,,ggtfsnlg,iipivala,atkgdghnyfyyygvdv,,,,IGHJ6*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23831,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasglivssnymnwvrqapgmglewvsviypggttyyadsvkgrftisrdnskntlflqmnslriddtalyycardlvyrgmdvwgqgttvtvss,,glivssny,iypggtt,ardlvyrgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23830,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsvifpggstfsadsvkgrftisrdnsnntlylqmnslraedtavyycargegwdlpfdywgqgilvtvss,,giivssny,ifpggst,argegwdlpfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23829,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscktsgytftsydinwvrqatgqglewmgwmnpnsgnrgyaqmfqgrvtmtsnpsigtaymeltslrsedtavyycargtkfgsnwfwfdhwgqgtlltvss,,gytftsyd,mnpnsgnr,argtkfgsnwfwfdh,,,,IGHJ1*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23828,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsiiypggstfyaesvkgrftisrdnskntlflqmnnlraedtaiyycardygdyyfdywgqgtlvtvss,,efivsrny,iypggst,ardygdyyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23827,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltcsvsgdsitnimsywgwirqspgkalewigsaynsgnsyynpslksrvtisvdtsknqfslklrsvtaadtsvyfcarhryyydgspgyffdywgqgtlvtvss,,gdsitnimsy,aynsgns,arhryyydgspgyffdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23826,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmggiipilhipnyaqkfqarltitadrststaymelsslksedtavyycagtaaehdylwgtyreiygldvwgqgttvtvss,,ggtfssya,iipilhip,agtaaehdylwgtyreiygldv,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23825,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyifisygiswlrqapgqglewmgwispynsntnyaqkfqgrvtmttdtststaymelrslrsddtavyycardgewggwfdpwgqgtlvtvss,,gyifisyg,ispynsnt,ardgewggwfdp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23824,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscvasgltvssnymtwvrqapgkglewvsvlyvggstfyadsvkgrftisrdkskntlylqmnnlraedtavyycardryvlgmdvwgqgttvtvss,,gltvssny,lyvggst,ardryvlgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23823,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfgsyainwvrqapgqglewmgrifpmldkatyaqnfqgrvtftadkstntasmelsslssedtafyycargivgptpfyfdywgqgtlvtvss,,ggtfgsya,ifpmldka,argivgptpfyfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23822,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssfvinwvrqapgqglewmggiipisatanyaqkfqgrvtitadestrtaymelsslrsedtavyycargsrkpfstdiyghvdyyyygmdvwgqgtavtvss,,ggtfssfv,iipisata,argsrkpfstdiyghvdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23821,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesaggvvqpgrslrlscaasgftfsdygmkwvrqapgkglewvaviwhdgsnkyyedsvkgrftisrdnsqntlylhmnslrvedtaiyfcargsgssdywgqgtlvtvss,,gftfsdyg,iwhdgsnk,argsgssdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23820,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsssamywvrqapgkglewvavisndgsnkyyadtvkgrftisrdiskntlyllmnslrvedtgiyycardslpgyngydapdywgqgtlvtvss,,gftfsssa,isndgsnk,ardslpgyngydapdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23819,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadkststasmelsslelsslrsedtavyycarthsydssgyyvdywgqgtlvtvss,,gdtfssya,iipifgtt,arthsydssgyyvdy,,,,IGHJ4*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23818,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvdsgggvvqpgrslrlscaasgfifssfamhwvrqtpgkglewvavisydginkyyadsvkgrftvsrdnskntlslqmnslrgedtavyycargqgayktafdswgqgtlvtvss,,gfifssfa,isydgink,argqgayktafds,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23817,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssyggyvgyfdywgqgtlvtvss,,gftfssyg,isydgsnk,akssyggyvgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23816,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgasissggyywswirqhpgkglewigyiyytgstyyspslkgrvtisvdtsknqfslklssltaadtavyycargsgpevvvirpyyldnwgpgtlvtvss,,gasissggyy,iyytgst,argsgpevvvirpyyldn,,,,IGHJ2*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23815,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfifskysmdwvrqapgkglewvsyidsggssryyadsvkgrftisrdnaknslylqmnslraedtavyycvrdardghsnndfdywgqgtlvtvss,,gfifskys,idsggssr,vrdardghsnndfdy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23814,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfnnyamhwvrqapgkglewvavisydgsnkhyvdsvrgrftisrdnskntlylqmislitedtavyycardwsakmatignfdywgqgslvtvss,,gftfnnya,isydgsnk,ardwsakmatignfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23813,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfdssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdvstntaymelrslgsedtavyfcaaphcnrttcydafdlwgqgtmvtvss,,gftfdssa,ivvgsgnt,aaphcnrttcydafdl,,,,IGHJ3*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23812,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsistgayywswirqhpgkgleligyiyysettyynpslksrvtmsvdtsenqfslklnsvtaadtavyycarvvhcsgggcsrhnyfdpwgqgtlvtvss,,ggsistgayy,iyysett,arvvhcsgggcsrhnyfdp,,,,IGHJ5*02 (human),IGHV4-31*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23811,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssfaihwvrqapgkglewvtvisfdgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglsgnyyyfdywgqgtlvtvss,,gftfssfa,isfdgnnk,arglsgnyyyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23810,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifssfaihwvrqapgkglewvavisydgsnkyyadsvkgrfsisrdnskntlylqmnslrsedtaiyycarplggnyggafdiwgqgalvtvss,,gfifssfa,isydgsnk,arplggnyggafdi,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23809,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqleesgpglvkpsetlsltcsvsadsisnyywswirqppgkglewigyiyysgstsynpslksrvtmsvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,,adsisnyy,iyysgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23808,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsiastyyywgwirqspgkglewianihyngstynkpslknrvtlsvdtsknqfslklssvtaadtavyycarygpyyydrsgsllsdpfdnwgqgtlvtvss,,ggsiastyyy,ihyngst,arygpyyydrsgsllsdpfdn,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23807,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqllesgpglvkpsetlslsctvsggsissyfwswlrqppgkglewigyisyigstnhnpslksrvtmsvdtskkqfslrlssvtdadtavyycarrfphhydstglssdafdiwgqgtmvtvss,,ggsissyf,isyigst,arrfphhydstglssdafdi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23806,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvnsgsyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycarvrfcsgsscrshnwfdpwgqgtlvtvss,,ggsvnsgsyy,iyytgst,arvrfcsgsscrshnwfdp,,,,IGHJ5*02 (human),IGHV4-61*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23805,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvhpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgnnkysadsvkgrftisrdnskntlylqmnslrpedsavyycarglggnyyaadywgqgslvtvss,,gftfstya,isydgnnk,arglggnyyaady,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23804,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgynkyyadsvkgrftisrdnskntlylqmnslrvedtamyycaralggnyyygmdvwgqgttvtvss,,gftfssya,isydgynk,aralggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23803,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvtvsckasgytftsyyihwvrqapgqglewmgiinpgagstsnaqkfqgrvtmtsdtststvymelsslrsedtavyycasgmdtlipaaqrafdiwgqgtvvtvss,,gytftsyy,inpgagst,asgmdtlipaaqrafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23802,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcsvsggsissgsvfwtwirqhpgkglewighiyyrgttnynpslksrisisvdtsknqfslnltsvtaadtaiyycarkaggcggdcyfdywgqgtlvtvss,,ggsissgsvf,iyyrgtt,arkaggcggdcyfdy,,,,IGHJ4*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23801,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqperslrlscaasgftfsrdgmhwvrrapgkglewvavisydgsnkvyaesvkgrftvsrdsskntvylqmnslraedtavyycakdgpqafgtyfdywgqgtlvivss,,gftfsrdg,isydgsnk,akdgpqafgtyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23800,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaeviqpgaslkvsckasgytftayylfwvrqapgrglewmgwinpnnggtnyaqnfqgrvtmtrdtsmstaymelsrlssddtavyfcarwmvavagmgdrgynyhyymdvwgkgttvtvss,,gytftayy,inpnnggt,arwmvavagmgdrgynyhyymdv,,,,IGHJ6*04 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23799,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqveesggglvkpggslrlscaasgfnfssygmnwvrqapgkglewvssisrssdfiyyadsvkgrftisrdnaknavflqmnrlrvedtavyycarnlkirssgdlfrgyyyhgmdvwgqgttvtvss,,gfnfssyg,isrssdfi,arnlkirssgdlfrgyyyhgmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23798,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvdsgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpgsgnylgyfdywgqgtlvtvss,,gftfssya,isydgdnk,arpgsgnylgyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23797,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvlsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwinpmsgatnfarkfqgrvtltrdtsittaymelsrlrsddtavyycarvppfyengahfdnwgqgslvtvss,,gyiftgyy,inpmsgat,arvppfyengahfdn,,,,IGHJ5*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23796,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargfwvpaaipgvwfdpwgqgtlvtvss,,gytftgyy,inpnsggt,argfwvpaaipgvwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23795,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsa,,gltvssny,iyaggst,ardlyvfgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23794,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgsslrlscaasgfsfisygmhwlrqapgeglewvaiiwfdgrnkyyadsvkgrftisrdnsksmlylqmnslraedtavyycardlpaqkrgdafdiwglgtmvtvss,,gfsfisyg,iwfdgrnk,ardlpaqkrgdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23793,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyythwvrqapgqglewmgwinpnsggtiyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycarwvpprgygmdvwgqgttvtvss,,gytftdyy,inpnsggt,arwvpprgygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23792,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsrygmnwvrqapgkglewvaviwydgnnkyyadsvkgrftisrdnskttlylqmkslraedtavyycaralqyydiltgdysvvrsdafdiwgqgtmvtvss,,gftfsryg,iwydgnnk,aralqyydiltgdysvvrsdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23791,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardrafgvvtvdfdywgqgtlvtvss,,gytftgyy,inpnsggt,ardrafgvvtvdfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23790,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggtlvkpggslrlscaasgftfsdyamswvrqapgrglewvsalsdsggstffadsvkgrftisrdnskntlylqmsslraedtakyycargevqpfllafdiwgqgtmvtvss,,gftfsdya,lsdsggst,argevqpfllafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23789,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgvtvsrnymswvrqapgkglewvsviyaggstfyadsvkgrftisrhnskntlylqmnslrvedtavyycvrdlvdygmdvwgqgttvtvss,,gvtvsrny,iyaggst,vrdlvdygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23788,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmsvnwirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdsvdtatyycarsvpttaldywgqgtlvivss,,gfslstsgms,idwdddk,arsvpttaldy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23787,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftdyymhwvrqapgqglewmgwinpksggtdfaqiflgrvtmtrdtsistaymelrglrsddtavyycargsyprdvvvvpaaapfnwldpwgqgtlvtvss,,gyiftdyy,inpksggt,argsyprdvvvvpaaapfnwldp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23786,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlshdgsesyyadsvkgrftisrdnsknslyvqmnslraedtavyycasacnsfncqlgdafdiwgqgtmvtvss,,gftfstya,lshdgses,asacnsfncqlgdafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23785,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggrvvqpggslrlscaasgftfhdyamhwvrqapgkglewvslingdgrgryyadsvkgrftisrdnsknslylqmnslrtedtalyycakdmesnwnesdfvdywgqgtlvtvss,,gftfhdya,ingdgrgr,akdmesnwnesdfvdy,,,,IGHJ4*01 (human),IGHV3-43*02 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,UIK23784,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,,gyafttfa,inpyngkt,arqypmprgphynymdv,,,,IGHJ6*04 (human),IGHV1-18*01 (human),,
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24035,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,,,,qsissy,aas,qqsystwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24034,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsniylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedsavfycqqygsspwtfgqgtkveik,,,,qsvsniy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24033,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpytfgpgtkvgik,,,,qsirsy,gas,qqsyttpyt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24032,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystrtitfgqgtrleik,,,,qsisty,aas,qqtystrtit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24031,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprllvyaassraigipdrfigsgsgtdftltinrlepedfavyfchqygsspwtfgqgtkvdik,,,,qsfsssy,aas,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24030,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntypwtfgqgtkveik,,,,qsissw,kas,qqyntypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24029,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrvsqsvssnylawfqqkpgqaprllifatssraigipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,,,,qsvssny,ats,qqygtspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24028,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dfqmtqspsslsasvgdrvtitcrasqtittylnwylqkpgkapdlliyaastlqsgvpsrfsgsgsgtdftltidslqpedfatyycqqsyttpytfgqgtkleik,,,,qtitty,aas,qqsyttpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24027,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqninrylnwyqqkpgqapklliyaasgvqsgvpsrfsgsvsgtdftltisslqpedfatyhrqqsyitpftfgpgtkvdik,,,,qninry,aas,qqsyitpft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24026,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,,,,qsvssy,das,qqrsnwplt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24025,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasrsvpsdylawyqqkpgqaprlliydtssratgipdrfsggasgtaftltisrlepedfavyychqygtslrtfgqgtkveik,,,,rsvpsdy,dts,hqygtslrt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24024,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqnianwlawyqqkpgkapklliytasnlesgvpsrfsasgsgteftltisslqpddfatyycqqynsysrlvtfgggtkvesk,,,,qnianw,tas,qqynsysrlvt,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24023,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtftcrasqgissylawyqlkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlssypftfgpgtkvdik,,,,qgissy,aas,qqlssypft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24022,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqsppflsasvgdrvtitcrasqgisrylawyqqkpgkapklliyaastlqsgvpprfsgtgsgteftltisslqpedfatyycqqlntyplafgggtkveik,,,,qgisry,aas,qqlntypla,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24021,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,airmtqspsslsastgdrvtitcrasqdissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqsedfatyhcqqyysyprtfgqrtkvevk,,,,qdissy,aas,qqyysyprt,,,IGKJ1*01 (human),IGKV1-8*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24020,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgignylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedlatyycqqvnsyppectfgqgtkleik,,,,qgigny,aas,qqvnsyppect,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24019,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkfgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwppytfgqgtkleik,,,,qsvssn,gas,qhynnwppyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24018,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdfftfgpgtkvdik,,,,qgisny,gas,qqlnsdfft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24017,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdritltcrasqgisnylawyqqkpgkapklliyaastlqggvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppdtfgqgtkleik,,,,qgisny,aas,qqlnsyppdt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24016,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspaflsasvgdrvritcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqltnyppdtfgqgtkleik,,,,qgissy,aas,qqltnyppdt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24015,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsispwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisglqpddfatyycqqyngysntfgqgtkveik,,,,qsispw,kas,qqyngysnt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24014,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppvfgpgtkvdik,,,,qgissy,aas,qqlnsyppv,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24013,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsyspltfgggtkveik,,,,qsissw,das,qqyhsysplt,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24012,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvggrvtitcrasqgissslawyqqkpgkapklliygastlrtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleik,,,,qgisss,gas,qqlnsdlyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24011,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapnlliydasnlesgvpsrfsgsgsgteftltisglqpddfatyycqqyhsyspltfgggtkvefk,,,,qsinsw,das,qqyhsysplt,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24010,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqtvrnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftitisrlepedfavyycqqygrahgafgpgtkveik,,,,qtvrnny,gas,qqygrahga,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24009,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqqpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysspftfgpgtkvdik,,,,qsinny,aas,qqtysspft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24008,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqnrrnwpplltfgggtkveik,,,,qsvsny,das,qnrrnwppllt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24007,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnslnwyqqrpgrapkllihaasslqsgvpsrfsgsgsgtdftltiaglqpedfatyycqqsfttpftsgqgtkleik,,,,qsisns,aas,qqsfttpft,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24006,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgteftltmsslqpedfatyycqqsysshtfgpgtkvdik,,,,qsigsy,aas,qqsyssht,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24005,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqtvssiylawfqqkpgqaprlliyaassraigipdrfsgsgsgtdftltisrlepedfavyyclqsgnspwtfgqgtkveik,,,,qtvssiy,aas,lqsgnspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24004,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgrapklliyaasslesgvpsrfsgsgsgtdftlsvsslqpedfatyycqqsyntpqtfgqgtrleik,,,,qsirny,aas,qqsyntpqt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24003,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllingassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssqgtfgqgtkveik,,,,qsvsssy,gas,qqygssqgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24002,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssyltwyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrtdwppevtfgqgtrleik,,,,qsvssy,das,qqrtdwppevt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24001,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqrpgqaprlliagtstratgipdrfsgsgsgtdftltisrlepedfavyycqqygasytfgqgtkleik,,,,qsvsssy,gts,qqygasyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK24000,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqsliswlawyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfpvtfgggtkveik,,,,qslisw,ats,qqtnsfpvt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23999,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynnypytfgqgtkleik,,,,qgisny,aas,qqynnypyt,,,IGKJ2*01 (human),IGKV1-16*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23998,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpvsisctssqsllhgggktslnwyhqkpgqppqlliygvsnrfsgvpdrfsgsgsgtdftlkisrvqaddvgvyycmqsislpwtfgqgtkveik,,,,qsllhgggkts,gvs,mqsislpwt,,,IGKJ1*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23997,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsslylawsqqkpgqaprllvfgassraigipdrfsgsgsgtdftliisrlepedfavyychqygsspwtfgqgtkvevk,,,,qsvssly,gas,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23996,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspdtlslspgeratlscrasqsigsrylawyqqkpgqaprllitaassratgipdrisgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleir,,,,qsigsry,aas,qqygssppryt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23995,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrlpvafgqgtkveik,,,,qsvsssy,gas,qqygrlpva,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23994,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlngyplfgggtkveik,,,,qgissy,aas,qqlngypl,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23993,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,ekvmtqspatlsmspgeratlscrasqsisnnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqynnwpftfgqgtklemk,,,,qsisnn,gas,qqynnwpft,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23992,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dfvmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,,,,qsllysngyny,lgs,mqalqtpft,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23991,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmsqspsslsasvgdrvtitcrasqdiayslnwyqqipgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdiays,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23990,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsinsylnwfqqkpgkapnlliyaasslqsgvpsrfsgggsgtdftltisrlqpedfatyycqqsystpltfgggtkveik,,,,qsinsy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23989,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dtvmtqsplslpvtpgepapiscrssqsllhsngynyldwylqksgqtpqlliylgshrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmealqtplftfgpgtkvhik,,,,qsllhsngyny,lgs,mealqtplft,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23988,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylvwyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsygytfgqgtkleik,,,,qgissy,aas,qqlnsygyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23987,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrtsqsvntklvwyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqhndwprsfgpgtkvdik,,,,qsvntk,gas,qqhndwprs,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23986,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsinsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqtyntphtfgqgtkldik,,,,qsinsy,aas,qqtyntpht,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23985,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyhcqqygtspwtfgqgtkveik,,,,qsvrssy,gas,qqygtspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23984,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscranqsvssylawyrqkpgqaprllihdasnratgiparisgsgsgtdftltisslepedfavyycqqrsnwpgftfgpgtkvdik,,,,qsvssy,das,qqrsnwpgft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23983,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwltfgggtkveik,,,,qsvsny,das,qqrsnwlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23982,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvnsiylawhqqkpgqaprlliygassraigipdrfsdsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvnsiy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23981,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,etvltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlviygpstratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvrssy,gps,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23980,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqdgvpsrfsgsgsgteftltisslqpedfatyycqqlnnypftfgpgtkvdik,,,,qgissy,aas,qqlnnypft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23979,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisshlawyqqkpgkapkllifaastlqsgvpsrfsgsgsgtefsltisslqpadfatyfcqhlemfgqgtkveik,,,,qgissh,aas,qhlem,,,IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23978,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divltqtplsspvtlgqpasiscrssqglvhsdgntylswlhqrpgqpprvliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqvtqfpfnfgpgtkvdik,,,,qglvhsdgnty,kvs,mqvtqfpfn,,,IGKJ3*01 (human),IGKV2-24*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23977,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,kiqmtqspsslsasvgdrviitcqasqdinkylhwyqqkpgeapklviydasnletgvpsrfsgsgsgtdftftisslqpedlaryycqqydnlpptfgggtkveik,,,,qdinky,das,qqydnlppt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23976,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,,,,qsvssn,gas,qqynnwprt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23975,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlqisrveaedvgvyycmqttqfpdtfgqgtkleik,,,,qslvhsdgnty,kis,mqttqfpdt,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23974,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtltcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqelnsypffgqgtrleik,,,,qgisny,aas,qelnsypf,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23973,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwltfgggtkveik,,,,qsvsss,gas,qqynnwlt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23972,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqvisnslnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgqgtkleik,,,,qvisns,das,qqydnlppt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23971,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistwlawyqqkpgkvpkllihkasnlhsgvpsrfsgsgsgteftltinslqpedfatyycqqynsystwtfgqgtkveik,,,,qsistw,kas,qqynsystwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23970,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23969,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsissy,aas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23968,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrashsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltitslqsediavyycqqynnwppltfgggtkveik,,,,hsvssn,gas,qqynnwpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23967,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynspwtfgqgtkveik,,,,qsissw,kas,qqynspwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23966,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,yiqmtqspsslsasvgdrvtitcrasqnidtylnwyqqtpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyscqqsysspltfgggtkveik,,,,qnidty,aas,qqsyssplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23965,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,nivltqspaalsfspgeratlscrasqsvsiflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpitfgqgtrleik,,,,qsvsif,das,qqrsnwpit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23964,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasglqsgvpsrfsgsgsgtdftltissllpedfatyycqqsyrtpfnfgpgtkvdik,,,,qsisry,aas,qqsyrtpfn,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23963,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygpssratgipdrfsgsgsgtdftltinrlepedfavyycqqydrspwtfgqgtkveik,,,,qsvrssy,gps,qqydrspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23962,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsasssylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyychqfgssfgggtkveik,,,,qsasssy,gas,hqfgss,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23961,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssrylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyychqygsspwtfgqgtkveik,,,,qsvssry,gas,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23960,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvgsnylawyqqkpgqsprlliyatssraigfpdrfigsgsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,,,,qsvgsny,ats,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23959,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,evvltqspgtlslspgeratlscrasqglsssslawyqqrpgqaprlliygasnratgisdrfsgsgsgtdftlsvsrlepedfavyycqqysnspltfgqgtkveik,,,,qglssss,gas,qqysnsplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23958,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtftcrasqaissklvwyqqkpgkapkvlisdasslqsgapsrfsgsgsgtdftltisslqpedfatyycqqakslpltfgggtkveik,,,,qaissk,das,qqakslplt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23957,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrstqsfagsylawyqqkagqaprllihgassrapgipdrfsgsgsgtdftltisrlepedfavyycqqyggsqwtfgqgtkveik,,,,qsfagsy,gas,qqyggsqwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23956,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqlygssprytfgqgtkleik,,,,qsvsssy,aas,qlygsspryt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23955,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratisckssqtvffisnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgpgtkveik,,,,qtvffisnnkny,was,qqyystppt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23954,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllmygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssvvtfgggttveik,,,,qsvsssy,gas,qqygssvvt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23953,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynnwppwtfgqgtkveik,,,,qsvssn,gas,hqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23952,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlcvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppltfgggtkveik,,,,qsvrsn,gas,qqynkwpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23951,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleik,,,,qgissy,aas,qqlnsdsst,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23950,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsvsvgdrvtitcrasqsisnylnwyqqkpgkapnllifaasslqrgvpsrfsgsgsgtdftltisslqpedfaayycqqsystpltfgqgtkvevn,,,,qsisny,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23949,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstflawyqqkagqaprlliygastrapgipdrfsgsgsgtdftltisrlepedfavyycqqfgssltfgggskveik,,,,qsvsstf,gas,qqfgsslt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23948,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsgtylawyqqkpgqaprlliygassrasgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,,,,qsvsgty,gas,qqygssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23947,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysrdtfgqgtkleik,,,,qginsy,gas,qqlnsysrdt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23946,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgtapklliysasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysiprtfgqgtkveik,,,,qsirsy,sas,qqsysiprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23945,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqtplslpvtpgepasfscrssqslldsddgntyldwylqkpgqspqlliysvsyrasgvpdrvsgsgsgtdftlkisrveaedvgvyycmqrtefpwtfgqgtkveik,,,,qslldsddgnty,svs,mqrtefpwt,,,IGKJ1*01 (human),IGKV2-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23944,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qtvviqepsfsvspggtvtltcglssgsvssnyyptwykqtpgqapstliyttntrssgvpdrfsgsilgnkaaltitgaqaddeceyhcalymgsgiwvfgggtkltvl,,,,sgsvssnyy,ttn,alymgsgiwv,,,IGLJ3*02 (human),IGLV8-61*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23943,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsespgqsitisctgtssdvgnynlvswyqhhpgkapklmiyevtkrpsgvsirfsgsksgntasltvsglqtedeadyyccsyagnstlvfgggtkltvl,,,,ssdvgnynl,evt,csyagnstlv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23942,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgspgqsvtisctgtssdigsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytsnntfvfgggtkltvl,,,,ssdigsynr,evs,ssytsnntfv,,,IGLJ2*01 (human),IGLV2-18*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23941,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvihedfkrpsgiperfsgsssgtmatltirraqaedeadyycystdnsgnrvfgggtkltvl,,,,alpkky,edf,ystdnsgnrv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23940,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,pyeltqppsvsvspgqtaritcsgdalprqfaywyqqkpgqapvlliykdterpsriperfsgsssgttftltisgvqaedeadyycqsaenggtypvfgggtkltvl,,,,alprqf,kdt,qsaenggtypv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23939,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgttsdvggynyvswyqqhpgkapkvmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlgvvfgggtkltvl,,,,tsdvggyny,evs,ssytssstlgvv,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23938,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasatpgqrvtiscsgsssnigsnpvnwyqqlpgtapklliynndqrpsrvpdrfsgsksgtsaslaisglqsedeadyycaawddslnglwvfgggtkmtvl,,,,ssnigsnp,nnd,aawddslnglwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23937,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgrnsdigsntvnwyqqfpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddrlhgwvfgggtklavl,,,,nsdigsnt,sdn,aawddrlhgwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23936,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,sfvltqppsvsvapgqtaritcggnniggktvhwyqqkpgqapvlvvhddsdrpsgiperfsgsnsgntatltisrvelgdeadyycqvwdssgghfyvfgagtkvtvl,,,,niggkt,dds,qvwdssgghfyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23935,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsmsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliynsnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycaawdsslsayvfgtgtkvtvl,,,,ssnignny,nsn,aawdsslsayv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23934,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnfvywyqqfpgtapkvliyrnslrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsarwvfgggtkltvl,,,,ssnigsnf,rns,aawddslsarwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23933,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagnnnfvfgtgtkvtvl,,,,ssdvggyny,evt,nsyagnnnfv,,,IGLJ1*01 (human),IGLV2-8*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23932,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnsvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgvvfgggtkltvl,,,,ssnigsns,rnn,aawddslsgvv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23931,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgnssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsal,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23930,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqaasvsgtpgqsitisctgtisnigsynyvswyqqhpgkapklliyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspwvfgggtkltvl,,,,isnigsyny,evs,ssytssspwv,,,IGLJ3*02 (human),IGLV2-14*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23929,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiyevsnwpsgvsnrfsgsksgntasltisglqaedeadyycssytssitlyvfgtgtkvtvl,,,,ssdvggyky,evs,ssytssitlyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23928,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrnyyanwyqqkpgqapvfvingknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpwvfgggtkltvl,,,,slrnyy,gkn,nsrdssgnhpwv,,,IGLJ3*02 (human),IGLV3-19*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23927,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapilviygqskrpsgipdrfsgstsgntasltitgaqaedeadyycssrdssgnhlvvfgggtkltvl,,,,slrsyy,gqs,ssrdssgnhlvv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23926,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgapgqrvtisctgsssnigagydvhwyqqlpgtppklliygndnrpsgvpdrfsgsksgtsaslaitglqvedeadyycqsydsslsgslfgggtkltvl,,,,ssnigagyd,gnd,qsydsslsgsl,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23925,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigigyavhwyqqlpgtapkllifgtsrrpsgvpdrfsgsrsgtsaslaitglqaedeavyycqsydnsqtdsvvfgggtkltvl,,,,ssnigigya,gts,qsydnsqtdsvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23924,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsasgppgqsvtisctgtssdvggyhyvswyqqhpgkapklmiygvtrrpsgvpdrfsgsksgntasltvsglqaddeadyycssyagsntvvfgggtkltvl,,,,ssdvggyhy,gvt,ssyagsntvv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23923,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsskdmifgggtkltvl,,,,ssdigsynl,evs,csyagsskdmi,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23922,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnpvswyqqlpgtapkllmydndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddtlnghfgggtkltvl,,,,ssnigsnp,dnd,aawddtlngh,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23921,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,,,,ssdvgsynl,evs,csyagsstwv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23920,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvlmqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydnslsdvlfgggtkltvl,,,,ssnigtgyd,gnn,qsydnslsdvl,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23919,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,,,,nsnigagyd,gnn,qsydssligsv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23918,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgiapklliygnnirpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,,,,ssnigagyd,gnn,qsydsslsvvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23917,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgapgqrvtisctgsssnigsgyvvhwyqhlpntapkllifgnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgvvfgggtkltvl,,,,ssnigsgyv,gnn,qsydsrlsgvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23916,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvgkrpsgvpdrfsgsksdntasltisglqaedeadyyccsyagspwvfgtgtkvtvl,,,,ssdvggyny,dvg,csyagspwv,,,IGLJ1*01 (human),IGLV2-11*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23915,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsittsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsnyvfgtgtkvtvl,,,,ssdvggyny,evs,ssytssstsnyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23914,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhhvvfgggtkltvl,,,,slrsyy,gkn,nsrdssgnhhvv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23913,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtstdvggydyvswyqqhpgkapkvmiygvsnrpsgvssrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,,,,stdvggydy,gvs,ssytsistwv,,,IGLJ3*02 (human),IGLV2-14*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23912,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagyvvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqsydsrlfvfgtgtkvtvl,,,,ssnigagyv,ans,qsydsrlfv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23911,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,sfeltqppsvsvspgqtarircsgnalprryaywyqqkpgqapvlviykdserpsgiperfssstsgttvtltisgvqaedeadyycqssdsngsymfgggtkltal,,,,alprry,kds,qssdsngsym,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,,,N/A,UIK23910,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvtnrppgvsnrfsgsksgntasltisglqaedeadyycssytststrvfgggtyltvl,,,,ssdvggynf,dvt,ssytststrv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",N/A,,,N/A,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,,,7MJI_E,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain E, VH ab8",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,,,7MJH_F,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain F, VH ab8",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,,,7MJH_E,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain E, VH ab8",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,,,7MJH_D,N/A,"SARS-CoV-2, Spike protein",synthetic construct,2022-03-15,"Chain D, VH ab8",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,,,7LX5_A,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain A, WNb 10",N/A,qvqlqesggglvqpggslrlscaasgftfrrylmgwarqvpgkglewvsgiysdgstyyadsvkgrftisrdnakntvylqmnslkpedtavyycakdrmdgstwperdfgswgqgtqvtvss,,gftfrryl,iysdgst,akdrmdgstwperdfgs,,,,IGHJ5*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,,,7LX5_C,N/A,SARS-CoV-2,Vicugna pacos (alpaca),2022-03-15,"Chain C, WNb 2",N/A,qvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssggntkyadsvkgrftasrdnakntfylqmnslkpedtavyycaaiaatyysgsyyfqcphdgmdywgkgtqvtvss,,gftldyya,isssggnt,aaiaatyysgsyyfqcphdgmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Bracken,C.J. et al.; Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike; bioRxiv (2020); 2020.",10.1101/2020.08.08.242511,,,7JWB_D,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"Chain D, autonomous human heavy chain variable domain",N/A,evqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvss,,gfriysyysy,iypssgyt,arwdfaspyypgssgldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.",N/A,,,QYU59153,N/A,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",N/A,vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,,gytftdya,isshngnr,aifdydfdy,,,,IGHJ2*01 (mouse),IGHV1-34*01 (mouse),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90084,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqlvqsgaevkkpgasvkvsckvsgyslievsvhwvrqapgkglewmggfdpenaetiyaqkfqgrvtmtedtstdtaymelsslkyedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,gyslievs,fdpenaet,atapavagpfyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90082,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvhlvqsgaevkkpgasvkvsckvsgytlvevsvhwvrqapgkgfewmggfdpenaatiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagplyyyyygmdvwgqgttvtvss,,gytlvevs,fdpenaat,atapavagplyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90080,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,gytltevs,fdpedaet,atapavagpfyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90078,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaktiyaqkfqgrvtmtedtstdtaymelsslssedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,gytltevs,fdpedakt,atapavagpfyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90076,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapekglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,gytltevs,fdpedaet,atapavagpfyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90074,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfynfyygidvwgqgttvtvss,,gytltevs,fdpedaet,atapavagpfynfyygidv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90072,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,,gftfssyg,iwydgsnk,vretvdgmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90070,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,,gftfssyg,iwydgsnk,vretvdgmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,QXI90068,N/A,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",N/A,qvqvvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgkglewvaviwydgsnqyyadsvkgrftisrdnskntlylqmnslrvedtavyhcvretvdgmdvwgqgttvtvss,,gftfsgyg,iwydgsnq,vretvdgmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90085,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90083,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90081,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90079,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90077,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprliiykvsnrfcgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90075,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,,,,qslvhsdgnty,kvs,tqatqfpht,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90073,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,niqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,,,,qdinny,aas,lqhnsypyt,,,IGKJ2*01 (human),IGKV1D-17*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90071,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,niqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,,,,qdinny,aas,lqhnsypyt,,,IGKJ2*01 (human),IGKV1D-17*01 (human)
GenBank,,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,,,N/A,QXI90069,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),2022-03-15,N/A,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",,niqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,,,,qdinny,aas,lqhnsypyt,,,IGKJ2*01 (human),IGKV1D-17*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 440 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87288,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 440 from patent US 11034762,N/A,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,,gygfityw,iypgdset,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 377 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87225,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 377 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywiswvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgiiqpmdvwgqgtlvtvss,,gggfityw,iypgdgea,aggsgiiqpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 376 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87224,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 376 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgstasyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,ggtfssya,iipifgsta,agewgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 375 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87223,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 375 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gggfityw,iypgdgea,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 374 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87222,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 374 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipvlhtvdyaqrlqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,ggtfssya,iipvlhtv,agewgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 373 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87221,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 373 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gggfityw,iypgdget,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 372 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87220,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 372 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgynftdyhiqwvrqapgqglewvgmiiprhggtayaqrfqgrvtitadeststaymelsslrsedtavyycaggsglttpmdvwgqgtlvtvss,,gynftdyh,iiprhggt,aggsglttpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 371 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87219,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 371 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtlssyaiswvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistprsvwgqgtlvtvss,,ggtlssya,iypgdset,aggsgistprsv,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 370 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87218,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 370 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggegistpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggegistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 369 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87217,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 369 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpysgntgyaqkfqgrvtitadeststaymelsslrsedtavyycavlsgistpmdvwgqgtlvtvss,,gytftnyg,mnpysgnt,avlsgistpmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 368 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87216,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 368 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfstywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gygfstyw,inpnsggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 367 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87215,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 367 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdstarysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistlydvwgqgtlvtvss,,ggtfssya,iypgdsta,aggsgistlydv,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 366 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87214,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 366 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgqinpsgdstryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,ggtfssya,inpsgdst,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 365 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87213,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 365 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfisyaiswvrqapgqglewmggiiptlgtynyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,,ggtfisya,iiptlgty,agswgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 364 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87212,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 364 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 363 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87211,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 363 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgilepmdvwgqgtlvtvss,,gygfisyw,iypgdset,aggsgilepmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 362 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87210,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 362 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,,gygfityw,iypgdset,agsdgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 361 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87209,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 361 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,,ggtfssya,intgggsv,aghwgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 360 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87208,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 360 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gygfityw,iypgdgea,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 359 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87207,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 359 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,ggtfityw,inpnsggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 358 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87206,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 358 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gggfityw,iypgdget,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 357 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87205,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 357 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsglltpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsglltpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 356 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87204,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 356 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnnglswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycrmgsgistpmdvwgqgtlvtvss,,ggtfsnng,iipifgta,rmgsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 355 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87203,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 355 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgwinpnsggtkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpidvwgqgtlvtvss,,gggfityw,inpnsggt,aggsgistpidv,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 354 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87202,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 354 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,ggtfssya,iypgdstt,ysgsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 353 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87201,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 353 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,,gygfisyw,iypgdget,agsdgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 352 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87200,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 352 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgypftnygiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycatlsgistpmdvwgqgtlvtvss,,gypftnyg,mnpnsgnt,atlsgistpmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 351 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87199,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 351 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetnysqkfqgrvtitadeststaymelsslrsedtavyycaggsglftpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsglftpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 350 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87198,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 350 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttnysqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,,ggtfssya,iypgdstt,aghwgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 349 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87197,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 349 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgiyvpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsgiyvpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 348 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87196,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 348 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 347 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87195,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 347 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgysfsdyyihwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gysfsdyy,idpnsggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 346 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87194,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 346 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgysftdyhihwvrqapgqglewmamivprggsttyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gysftdyh,ivprggst,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 345 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87193,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 345 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgyrftdyhlhwvrqapgqglewmggivpfsgttnfaqkfqgrvtitadeststaymelsslrsedtavyycaggsgettpmdvwgqgtlvtvss,,gyrftdyh,ivpfsgtt,aggsgettpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 344 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87192,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 344 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiiptlgtanyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,,ggtfssya,iiptlgta,agswgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 343 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87191,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 343 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfstywigwvrqapgqglewvgwinpnsgatkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gggfstyw,inpnsgat,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 342 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87190,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 342 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gggfityw,iypgdset,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 341 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87189,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 341 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgissdmdvwgqgtlvtvss,,gggfityw,iypgdset,aggsgissdmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 340 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87188,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 340 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgvltpmdvwgqgtlvtvss,,gggfityw,iypgdset,aggsgvltpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 339 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87187,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 339 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsglytpmdvwgqgtlvtvss,,gygfityw,iypgdset,aggsglytpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 338 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87186,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 338 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfstyafnwvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpgavwgqgtlvtvss,,ggtfstya,intgggsv,aggsgistpgav,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 337 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87185,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 337 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyyclpgsgistpmdvwgqgtlvtvss,,gytftsyg,iypgdgtt,lpgsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 336 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87184,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 336 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gygfityw,iypgdget,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 335 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87183,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 335 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftnyginwmrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gytftnyg,mnpnsgnt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 334 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87182,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 334 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgminpgggntnyaekfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,ggtfssya,inpgggnt,agewgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 333 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87181,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 333 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gytftghy,iypgdsea,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 332 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87180,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 332 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaavsgistpmdvwgqgtlvtvss,,gytftnyg,mnpnsgnt,aavsgistpmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 331 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87179,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 331 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytfstywigwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gytfstyw,idpnsggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 330 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87178,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 330 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgsvipvfgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,ggtfssya,vipvfgrp,agewgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 329 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87177,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 329 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnssinwvrqapgqglewmgrinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,ggtfsnss,inpnsggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*11 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 328 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87176,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 328 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfnshaiswvrqapgqglewmgwinpnsgatnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpvgvwgqgtlvtvss,,ggtfnsha,inpnsgat,aggsgistpvgv,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 327 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87175,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 327 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,,ggtfityw,iypgdgea,agsggistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 326 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87174,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 326 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgysfsdyhvhwvrqapgqglewvgmiiprhggtayaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gysfsdyh,iiprhggt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 325 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87173,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 325 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftdyyihwvrqapgqglewmgwmnpnsgntgyaqnfqgrvtitadeststaymelsslrsedtavyycaggsgistawdvwgqgtlvtvss,,gytftdyy,mnpnsgnt,aggsgistawdv,,,,IGHJ5*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 324 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87172,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 324 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfitywiywvrqapgqglewmgiiypgdgearysqkfygrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,,ggtfityw,iypgdgea,agsggistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 323 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87171,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 323 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,ggtfssya,iipifgtt,agewgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 322 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87170,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 322 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,gytftghy,iypgdsea,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 321 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87169,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 321 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnhaiswvrqaygqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,ggtfsnha,iypgdgtt,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 320 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87168,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 320 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,ggtfssya,iypgdstt,ysgsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 319 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87167,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 319 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiidpsggstsyaqqfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,ggtfssya,idpsggst,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 318 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYT87166,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 318 from patent US 11034762,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,ggtfssya,iypgdstt,ysgsgistpmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 441 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87289,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 441 from patent US 11034762,,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 437 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87285,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 437 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveik,,,,qsvlyssinkny,was,qqylstplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 436 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87284,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 436 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywsslresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytapftfgggtkveik,,,,qsvlyssinkny,wss,qqyytapft,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 435 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87283,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 435 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveik,,,,qsvlyssinkny,was,qqyhstpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 434 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87282,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 434 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveik,,,,qsvlyssinkny,was,qqylstplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 433 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87281,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 433 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygipytfgggtkveik,,,,qsvlyssinkny,was,qqyygipyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 432 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87280,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 432 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqhyyntpltfgggtkveik,,,,qsvlyssnnkny,was,qhyyntplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 431 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87279,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 431 from patent US 11034762,,divmtqspdslavslgeratinckssrilsyspdnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqsyitpytfgggtkveik,,,,rilsyspdnkny,was,qqsyitpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 430 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87278,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 430 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 429 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87277,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 429 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywatnresgvpdrfsgsgsgtdftltisslqaedvavyychqyyntpptfgggtkveik,,,,qsvlyssnnkny,wat,hqyyntppt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 428 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87276,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 428 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyrsnnlhylawyqqkpgqppklliywastrssgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyrsnnlhy,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 427 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87275,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 427 from patent US 11034762,,divmtqspdslavslgeratinctssqsvlhssnnlnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlhssnnlny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 426 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87274,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 426 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlhssnnlnyfawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlhssnnlny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 425 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87273,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 425 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveik,,,,qsvlyssinkny,was,qqyhstplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 424 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87272,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 424 from patent US 11034762,,divmtqspdslavslgeratinckstqsvlyssinknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 423 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87271,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 423 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstpytfgggtkveik,,,,qsvlyssinkny,was,qqysstpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 422 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87270,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 422 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 421 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87269,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 421 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygtpftfgggtkveik,,,,qsvlyssinkny,was,qqyygtpft,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 420 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87268,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 420 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveik,,,,qsvlyssinkny,was,qqyhstpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 419 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87267,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 419 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnnhny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 418 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87266,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 418 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 417 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87265,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 417 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 416 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87264,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 416 from patent US 11034762,,divmtqspdslavslgeratinckssqtisyssdnknylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qtisyssdnkny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 415 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87263,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 415 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliyrastrasgvpdrfsgsgsgtdftltisslqaedvavyycqqyystvitfgggtkveik,,,,qsvlyssnnkny,ras,qqyystvit,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 414 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87262,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 414 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssinkny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 413 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87261,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 413 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 412 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87260,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 412 from patent US 11034762,,divmtqspdslavslgeratincrssqsvlyssnnknyfawyqqkpgqppklliywasirgsgvpdrfsgsgsgtdftltisslqaedvavyychqyyttpptfgggtkveik,,,,qsvlyssnnkny,was,hqyyttppt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 411 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87259,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 411 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveik,,,,qsvlyssinkny,was,qqysttpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 410 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87258,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 410 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpwtfgggtkveik,,,,qsvlyssinkny,was,qqyhstpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 409 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87257,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 409 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveik,,,,qsvlyssinkny,was,qqyykipyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 408 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87256,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 408 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlhsainknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveik,,,,qsvlhsainkny,was,qqysttpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 407 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87255,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 407 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnnhny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 406 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87254,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 406 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpvtfgggtkveik,,,,qsvlyssnnkny,was,qqyystpvt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 405 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87253,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 405 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkveik,,,,qsvlyssinkny,was,qqyyslplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 404 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87252,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 404 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveik,,,,qsvlyssinkny,was,qqyhstplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 403 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87251,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 403 from patent US 11034762,,divmtqspdslavslgeratinckssqsvfhssnnknhlawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvfhssnnknh,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 402 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87250,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 402 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasmresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveik,,,,qsvlyssinkny,was,qqyyttpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 401 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87249,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 401 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrefgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveik,,,,qsvlyssinkny,was,qqyykipyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 400 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87248,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 400 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyatpytfgggtkveik,,,,qsvlyssinkny,was,qqyyatpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 399 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87247,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 399 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhtipytfgggtkveik,,,,qsvlyssinkny,was,qqyhtipyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 398 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87246,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 398 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastraagvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnniny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 397 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87245,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 397 from patent US 11034762,,divmtqspdslavslgeratinckssqrvlyssnnlnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qrvlyssnnlny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 396 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87244,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 396 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaytrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveik,,,,qsvlyssinkny,way,qqyystpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 395 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87243,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 395 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasnrepgvpdrfsgsgsgtdftltisslqaedvavyfchqyystpptfgggtkveik,,,,qsvlyssnnkny,was,hqyystppt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 394 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87242,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 394 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygfpltfgggtkveik,,,,qsvlyssinkny,was,qqyygfplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 393 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87241,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 393 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnlnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnnlny,wgs,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 392 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87240,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 392 from patent US 11034762,,divmtqspdslavslgeratincrssqtvlyrsnnynylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgggtkveik,,,,qtvlyrsnnyny,was,qqyystppt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 391 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87239,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 391 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnknnylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnknny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 390 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87238,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 390 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyyyapwtfgggtkveik,,,,qsvlyssinkny,was,qqyyyapwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 389 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87237,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 389 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastrasgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnniny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 388 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87236,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 388 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssinkny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 387 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87235,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 387 from patent US 11034762,,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveik,,,,qnvlyssinkny,was,qqyyttpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 386 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87234,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 386 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastrdfgvpdrfsgsgsgtdftltisslqaedvavyycqqyyalpltfgggtkveik,,,,qsvlyssnnkny,was,qqyyalplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 385 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87233,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 385 from patent US 11034762,,divmtqspdslavslgeratirctsslslqdrsnnknyltwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhysapltfgggtkveik,,,,lslqdrsnnkny,was,qqhysaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 384 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87232,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 384 from patent US 11034762,,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveik,,,,qnvlyssinkny,was,qqyyttpyt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 383 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87231,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 383 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaniresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,,,,qsvlyssinkny,wan,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 382 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87230,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 382 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlytsnnnny,wgs,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 381 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87229,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 381 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlytsnnnny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 380 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87228,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 380 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssinkny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 379 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87227,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 379 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssnny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 378 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYT87226,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 378 from patent US 11034762,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveik,,,,qsvlyssinkny,was,rqyystpwt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33726,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 208 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgiinprggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctreakpqllrtldywgqgtlvtvss,,gytftsyy,inprggst,treakpqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33717,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 199 from patent US 11028167,N/A,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,,gytfttyr,iypgnsdt,tregipqllrtldy,,,,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 168 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33686,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 168 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpngggtyyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,inpngggt,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 167 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33685,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 167 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,intsggyt,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 166 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33684,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 166 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregppqllrtldywgqgtlvtvss,,gytftene,inpsggst,tregppqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 165 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33683,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 165 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytfteyemhwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,,gytfteye,inpsggyt,tregipqvlrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 164 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33682,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 164 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgmvdpnsgntyyaqkfqgrftmtrdtststvymelsslrsedtavyyctregipqllgtldywgqgtlvtvss,,gytftsyd,vdpnsgnt,tregipqllgtldy,,,,IGHJ4*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 163 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33681,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 163 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytfsdyymhwvrqapgqglewmgiidpsggsasyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytfsdyy,idpsggsa,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 162 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33680,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 162 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgysftsyeihwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,,gysftsye,inpsggyt,tregipqvlrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 161 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33679,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 161 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvinpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrhldywgqgtlvtvss,,gytftene,inpsggyt,tregipqllrhldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 160 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33678,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 160 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,intsggyt,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 159 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33677,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 159 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgminpsggytnyaqefqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,inpsggyt,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 158 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33676,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 158 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpdggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,inpdggst,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 157 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33675,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 157 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgydfinyyihwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gydfinyy,idpsggst,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 156 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33674,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 156 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytfasydvnwvrqapgqglewmgiinprsgdanyaqkfqgrvtmtrdtststvymelsslrsedtavyyctrerhpqllmpldywgqgtlvtvss,,gytfasyd,inprsgda,trerhpqllmpldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 155 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33673,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 155 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsysmhwvrqapgqglewmgaiypgnsdttyaqkfqgrvtmtrdtststvymelsslrsedtavyyctldgipqllrtldywgqgtlvtvss,,gytftsys,iypgnsdt,tldgipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 154 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33672,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 154 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipwwlrtldywgqgtlvtvss,,gytftene,inpsggst,tregipwwlrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 153 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33671,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 153 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytfgnyainwvrqapgqglewmgaiypgnsdttynqkfqgrvtmtrdtststvymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gytfgnya,iypgnsdt,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 152 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33670,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 152 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgyrftsyevnwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllwaldywgqgtlvtvss,,gyrftsye,inpsggst,tregipqllwaldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 151 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33669,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 151 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,inpsggst,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 150 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33668,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 150 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gytftene,inpsagst,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 149 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33667,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 149 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgdiwrlhwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,gdiwr,mnpnsgnt,tregipqllrtldy,,,,IGHJ4*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 148 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33666,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 148 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgntftgyymhwvrqapgqglewmgaiypggsdtsynqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlawtldywgqgtlvtvss,,gntftgyy,iypggsdt,tregipqlawtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 147 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33665,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 147 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvvnpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrsqdywgqgtlvtvss,,gytftene,vnpsggyt,tregipqllrsqdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 146 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33664,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 146 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftshdinwvrqapgqglewmgminpsggytsyaqnfqgrvtmtrdtststvymelsslrsedtavyyctregipallrtldywgqgtlvtvss,,gytftshd,inpsggyt,tregipallrtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 145 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS33663,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 145 from patent US 11028167,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgvinpsgghtnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlagtldywgqgtlvtvss,,gytftsye,inpsgght,tregipqlagtldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33727,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 209 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqgidtylnwyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpediatyycqqydnlpltfgggtkveik,,,,qgidty,kas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33718,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 200 from patent US 11028167,,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,,,,qeisgy,aas,lqyvsypwt,,,IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33710,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 192 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysapytfgggtkveik,,,,qgirnd,aas,qqtysapyt,,,IGKJ4*01 (human),IGKV1-6*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 191 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33709,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 191 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnplhfgggtkveik,,,,qsissw,aas,qqsysnplh,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 190 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33708,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 190 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyhtsnletgvpsrfsgsgsgtdftltisslqpedfatyycqqsysfpattfgggtkveik,,,,qsissy,hts,qqsysfpatt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 189 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33707,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 189 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveik,,,,qsissw,aas,qqsysnpyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 188 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33706,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 188 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtk,,,,qsissy,aas,qqgyttprt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 187 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33705,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 187 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqvgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlavtfgggtkveik,,,,qsissy,aas,qqsystlavt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 186 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33704,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 186 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveik,,,,qsissw,aas,qqsysnpyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 185 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33703,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 185 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgswtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsisgy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 184 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33702,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 184 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveik,,,,qsissw,aas,qqsysnpyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 183 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33701,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 183 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsiyrwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsygnpytfgggtkveik,,,,qsiyrw,aas,qqsygnpyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 182 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33700,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 182 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqytfgggtkveik,,,,qsisry,aas,qqsystpqyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 181 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33699,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 181 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqdisdslawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysrlawtfgggtkveik,,,,qdisds,aas,qqsysrlawt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 180 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33698,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 180 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlesgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgggtkveik,,,,qsissy,aas,qqsystprt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 179 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33697,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 179 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygvsslhsgvpsrfsgsgsgtdftltisslqpedfatyyclqyvsypwtfgggtkveik,,,,qsissy,gvs,lqyvsypwt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 178 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33696,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 178 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpewtfgggtkveik,,,,qsissy,aas,qqsyttpewt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 177 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33695,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 177 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqeisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyvsypwtfgggtkveik,,,,qeisgy,aas,qqyvsypwt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 176 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33694,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 176 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 175 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33693,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 175 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsirtylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveik,,,,qsirty,aas,qqsystpsyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 174 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33692,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 174 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveik,,,,qsissy,aas,qqsystpsyt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 173 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33691,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 173 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqeissylswyqqkpgkapklliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqynsypltfgggtkveik,,,,qeissy,aas,qqynsyplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 172 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33690,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 172 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpediatyycqqfgsfgggtkveik,,,,qsmssy,aas,qqfgs,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 171 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33689,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 171 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 170 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33688,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 170 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyttpytfgggtkveik,,,,qgirnd,aas,qqtyttpyt,,,IGKJ4*01 (human),IGKV1-6*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 169 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS33687,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 169 from patent US 11028167,,diqmtqspsslsasvgdrvtitcrasqsisgylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkveik,,,,qsisgy,aas,qqgyttprt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 280 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31785,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 280 from patent US 11028150,N/A,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,,ggtfssyt,itpilgia,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*16 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 232 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31737,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 232 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggsfsrfpiswvrqapgqglewmggiipifgtanyaqrfqgrvtitadeststaymelsslrsedtavyycaletvmgglqvwgqgtlvtvss,,ggsfsrfp,iipifgta,aletvmgglqv,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 231 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31736,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 231 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftafyihwvrqapgqglewmggiipisgtanyaqkfqgratitadeststaymelsslrsedtavyycarevvmggmdvwgqgtlvtvss,,gytftafy,iipisgta,arevvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 230 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31735,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 230 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswmrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsnlrsedtavyycardtywggmdvwgqgtlvtvss,,ggtfssya,inpnsggt,ardtywggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 229 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31734,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 229 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssfaiiwvrqapgqglewmalinpssgttsyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,ggtfssfa,inpssgtt,aretvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 228 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31733,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 228 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgntfsmfainwvrqapgqglewvgvinpigstttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gntfsmfa,inpigstt,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 227 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31732,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 227 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gytfinyd,itpifgta,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 226 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31731,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 226 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggmqmwgqgtlvtvss,,gytftsyy,itpifgta,avetvmggmqm,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 225 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31730,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 225 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfssfyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,gytfssfy,iipifgea,ametvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 224 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31729,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 224 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfsdfylhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,gytfsdfy,itpifgta,ametvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 223 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31728,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 223 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsyyvhwvrqapgqglewmggilpilgtphyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmtawgqgtlvtvss,,gytftsyy,ilpilgtp,aletvmggmta,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 222 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31727,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 222 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggftvwgqgtlvtvss,,gytftsyg,inpnsggt,avetvmggftv,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 221 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31726,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 221 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgiinpsggstsyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmgvwgqgtlvtvss,,ggtfssyt,inpsggst,ardtvmggmgv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 220 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31725,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 220 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtakyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gytfinyd,itpifgta,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 219 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31724,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 219 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftgfymqwvrqapgqglewmggitpilgtanyaqkfqgrvtitadeststaymelsslrsedtavyycareivmggmdvwgqgtlvtvss,,gytftgfy,itpilgta,areivmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 218 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31723,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 218 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfinyeihwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gytfinye,itpifgta,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 217 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31722,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 217 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgysfnafyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,gysfnafy,iipifgta,aletvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 216 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31721,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 216 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfsdfdinwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycgmdtvmggmtswgqgtlvtvss,,gytfsdfd,iipifgta,gmdtvmggmts,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 215 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31720,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 215 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftdfhmhwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,gytftdfh,iipifgta,aletvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 214 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31719,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 214 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtffggmdvwgqgtlvtvss,,gytftsyd,inpnsggt,ardtffggmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 213 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31718,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 213 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gytfinyd,itpifgta,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 212 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31717,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 212 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgymftefymhwvrqapgqglewmggiipvsgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,gymftefy,iipvsgta,aretvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 211 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31716,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 211 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfssyyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,gytfssyy,iipifgea,ametvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 210 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31715,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 210 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgstfsmfainwvrqapgqglewvgvinprgssttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,gstfsmfa,inprgsst,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31714,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 209 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgyaftsyymhwvrqapgqglewmgvidpsegstsnarkfqgrvtitadeststaymelsslrsedtavyycvsdtvmggmdvwgqgtlvtvss,,gyaftsyy,idpsegst,vsdtvmggmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31713,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 208 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfgnypitwvrqapgqglewmgiiypgdsdaryrpsfqgrvtitadeststaymelsslrsedtavyycardfsmggmdvwgqgtlvtvss,,ggtfgnyp,iypgdsda,ardfsmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 207 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31712,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 207 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnfaltwvrqapgqglewmglinpsggstsyaqrfqgrvtitadeststaymelsslrsedtavyycardsvmggmdvwgqgtlvtvss,,ggtfsnfa,inpsggst,ardsvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 206 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31711,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 206 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgypfssyeinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycadetvmggmdvwgqgtlvtvss,,gypfssye,itpifgta,adetvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 205 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31710,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 205 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftdfyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,gytftdfy,iipifgta,aletvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 204 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31709,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 204 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnytitwvrqapgqglewlgwisayngntdyaqklqgrvtitadeststaymelsslrsedtavyycardalmggmdvwgqgtlvtvss,,ggtfsnyt,isayngnt,ardalmggmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 203 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31708,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 203 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsfdihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycayetvmggmdvwgqgtlvtvss,,gytftsfd,iipifgta,ayetvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 202 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31707,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 202 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnfaitwvrqapgqglewmgvinpgggsttyaqtfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,ggtfsnfa,inpgggst,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 201 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31706,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 201 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfsayymhwvrqapgqglewmggitplfgtpsyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggvgvwgqgtlvtvss,,gytfsayy,itplfgtp,aletvmggvgv,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31705,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 200 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgynfinyylhwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,gynfinyy,itpifgia,aretvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31704,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 199 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfnrfamtwvrqapgqglewmgtinpsggstiytqrfqgrvtitadeststaymelsslrsedtavyycghdtvmggmgewgqgtlvtvss,,gytfnrfa,inpsggst,ghdtvmggmge,,,,IGHJ1*01 (human),IGHV1-46*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 198 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31703,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 198 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgiidpiggttnyaqkfqgrvtitadeststaymelsslrsedtavyycardtvgfgmdvwgqgtlvtvss,,gytfttyd,idpiggtt,ardtvgfgmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 197 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31702,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 197 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasggtfsrydinwvrqapgqglewmgiinpsggsttyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmdvwgqgtlvtvss,,ggtfsryd,inpsggst,ahdtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 196 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31701,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 196 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfssfhinwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,gytfssfh,itpifgia,aletvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 195 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31700,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 195 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgysfnnydlhwvrqapgqglewmggiipifdtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmvkwgqgtlvtvss,,gysfnnyd,iipifdta,aletvmggmvk,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 194 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31699,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 194 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmglidpsggttsyaqkfqgrvtitadeststaymelsslrsedtavyycvwdtvmggmdvwgqgtlvtvss,,gytftsyy,idpsggtt,vwdtvmggmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 193 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31698,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 193 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtywggmdvwgqgtlvtvss,,gytfttyd,inpnsggt,ardtywggmdv,,,,IGHJ6*01 (human),IGHV1-8*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS31697,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 192 from patent US 11028150,N/A,qvqlvqsgaevkkpgssvkvsckasgctftrftmhwvrqapgqglewmggitpifgitnyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmeewgqgtlvtvss,,gctftrft,itpifgit,ahdtvmggmee,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 281 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31786,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 281 from patent US 11028150,,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,,,,nigsks,dds,qvwdsssdyv,,,IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 273 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31778,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 273 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 272 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31777,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 272 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdyvfgggtkltvl,,,,nigsks,yds,qvwdstsdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 271 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31776,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 271 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvl,,,,nigsks,yds,qvwdsssfyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 270 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31775,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 270 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvl,,,,nigsks,yds,qvwdssshyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 269 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31774,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 269 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwvsssdyvfgggtkltvl,,,,nigsks,yds,qvwvsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 268 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31773,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 268 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdshsdyvfgggtkltvl,,,,nigsks,yds,qvwdshsdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 267 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31772,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 267 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 266 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31771,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 266 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 265 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31770,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 265 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 264 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31769,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 264 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 263 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31768,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 263 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 262 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31767,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 262 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvl,,,,nigsks,yds,qvwdsssfyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 261 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31766,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 261 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 260 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31765,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 260 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdsssdyvfgggtkltvl,,,,nigsks,yds,qswdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 259 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31764,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 259 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 258 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31763,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 258 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdgssdyvfgggtkltvl,,,,nigsks,yds,qvwdgssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 257 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31762,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 257 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsshdyvfgggtkltvl,,,,nigsks,yds,qvwdsshdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 256 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31761,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 256 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 255 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31760,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 255 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvl,,,,nigsks,yds,qvwdsssyyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 254 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31759,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 254 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvl,,,,nigsks,yds,qvwdsrsdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 253 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31758,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 253 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 252 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31757,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 252 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 251 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31756,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 251 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdrssdyvfgggtkltvl,,,,nigsks,yds,qvwdrssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 250 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31755,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 250 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvl,,,,nigsks,dds,qvwdssslyv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 249 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31754,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 249 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwddssdyvfgggtkltvl,,,,nigsks,yds,qvwddssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 248 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31753,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 248 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssdyvfgggtkltvl,,,,nigsks,yds,qvwasssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 247 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31752,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 247 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvl,,,,nigsks,yds,qvwdssndyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 246 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31751,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 246 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvl,,,,nigsks,yds,qvwdssshyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 245 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31750,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 245 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvl,,,,nigsks,yds,qvwdsrsdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 244 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31749,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 244 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvl,,,,nigsks,yds,qvwdsssyyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 243 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31748,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 243 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 242 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31747,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 242 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveavdeadyycqvwdsssdyvfgggtkltvl,,,,nigsks,yds,qvwdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 241 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31746,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 241 from patent US 11028150,,syvltqppsvsvapgktaritcggnkigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdyvfgggtkltvl,,,,kigsks,yds,qvwdsgsdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 240 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31745,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 240 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqstdsssdyvfgggtkltvl,,,,nigsks,yds,qstdsssdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 239 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31744,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 239 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvl,,,,nigsks,dds,qvwdssslyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 238 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31743,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 238 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvl,,,,nigsks,yds,qvwdsssyyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 237 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31742,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 237 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdssgdyvfgggtkltvl,,,,nigsks,yds,qswdssgdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 236 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31741,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 236 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrieagdeadyycqvwdssgdyvfgggtkltvl,,,,nigsks,yds,qvwdssgdyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 235 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31740,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 235 from patent US 11028150,,syvltqppsvsvapgktaaritcggnnigsksvhwyqqkpgqapvlviykdgerpsgiperfsgsnsrntatltisrveagdeadyycqvwdssslyvfgggtkltvl,,,,nigsks,kdg,qvwdssslyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 234 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31739,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 234 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvl,,,,nigsks,dds,qvwdsssfyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 233 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS31738,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 233 from patent US 11028150,,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvl,,,,nigsks,yds,qvwdssndyv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 497 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20240,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 497 from patent US 11053304,N/A,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrnya,itsdgrnk,vtqrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 428 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20171,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 428 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgdrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 427 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20170,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 427 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrnya,vsssggsp,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 426 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20169,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 426 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsvisasggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isasggnt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 425 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20168,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 425 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfstya,vswngsrt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-35*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 424 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20167,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 424 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfafssyalhwvrqapgkglewvsaisgsggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfafssya,isgsggdt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 423 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20166,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 423 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfafsnyg,idgsggta,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 422 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20165,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 422 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isssgrnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 421 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20164,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 421 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isgsgdnt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 420 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20163,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 420 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,isydgsnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 419 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20162,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 419 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfpfslygmhwvrqapgkglewvavitsdgrskfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gfpfslyg,itsdgrsk,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 418 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20161,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 418 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgitfnnyamtwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycvtqrdnpvdyfphyfhdmdvwgqgtlvtvss,,gitfnnya,isgsggst,vtqrdnpvdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 417 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20160,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 417 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfrfddfgmhwyrqapgkglewvsatsgggsityyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfrfddfg,tsgggsit,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 416 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20159,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 416 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfkfntyamhwvrqapgkglewvsaisitggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfkfntya,isitggnt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 415 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20158,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 415 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,vsasgggp,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 414 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20157,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 414 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfsfrsygmhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnfdnsrdyfphyfhdmdvwgqgtlvtvss,,gfsfrsyg,issdgrnk,vtnfdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 413 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20156,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 413 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,isgsggtt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 412 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20155,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 412 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfifndygmhwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfifndyg,isgsggnt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 411 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20154,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 411 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgdrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 410 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20153,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 410 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsvitgdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,itgdgrnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 409 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20152,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 409 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisrsgdsayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isrsgdsa,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 408 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20151,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 408 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isgsggst,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 407 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20150,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 407 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfrfntyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfrfntya,isssgrnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 406 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20149,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 406 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgdrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 405 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20148,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 405 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgggp,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 404 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20147,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 404 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsgissggsgthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfsnya,issggsgt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 403 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20146,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 403 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfafsnyg,idgsggta,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 402 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20145,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 402 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfsfsrygmhwvrqapgkglewvsgisadggtayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfsfsryg,isadggta,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 401 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20144,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 401 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygvhwvrqapgkglewvavishdgkkkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnvdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,ishdgkkk,vtnvdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 400 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20143,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 400 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsgisgggagtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtyrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfsnsd,isgggagt,vtyrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 399 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20142,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 399 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsgisgsgdrtyyadsvkgrftisrdnskntlylqmnslraedtavyycsmqrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssys,isgsgdrt,smqrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 398 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20141,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 398 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfhdyamhwvrqapgkglewvavtsydgntkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfhdya,tsydgntk,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 397 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20140,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 397 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfgtsavswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfgtsa,isgsggst,vtqrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 396 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20139,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 396 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaysgsggytyfadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,ysgsggyt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 395 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20138,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 395 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavvsrsggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,vsrsggst,vtqrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 394 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20137,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 394 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvaaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,isgsggst,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 393 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20136,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 393 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisassagayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isassaga,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 392 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20135,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 392 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsringdgsttgyadsvkgrftisrdnskntlylqmnslraedtavyycvttgdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfsnsd,ingdgstt,vttgdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 391 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20134,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 391 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsshtiawvrqapgkglewlshisssgsttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdmsphyfhdmdvwgqgtlvtvss,,gftfssht,isssgstt,vtqrdnsrdmsphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 390 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20133,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 390 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvaaigasgestyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfplwfhdmdvwgqgtlvtvss,,gftfsdhy,igasgest,vtqrdnsrdyfplwfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 389 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20132,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 389 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfstygmhwvrqapgkglewvstisgngvstsyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfstyg,isgngvst,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 388 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20131,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 388 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgdrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 387 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20130,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 387 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftftsygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftftsyg,isgsggtt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 386 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20129,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 386 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfiftnyalhwvrqapgkglewvsaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gfiftnya,isgsggst,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 385 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20128,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 385 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvavisydgnyqyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfstya,isydgnyq,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 384 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20127,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 384 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfifssyamnwvrqapgkglewvsgisgsgggayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gfifssya,isgsggga,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 383 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20126,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 383 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfnnyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfnnya,vswngsrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-35*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 382 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20125,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 382 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrnya,vsssggsp,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 381 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20124,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 381 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,isssgrnk,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 380 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20123,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 380 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,vsasgdrt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 379 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20122,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 379 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrsya,issdgrnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 378 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20121,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 378 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,igagggt,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 377 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20120,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 377 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsavgdsgrstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssya,vgdsgrst,vtnldnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 376 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20119,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 376 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfssyg,isydgsnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 375 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20118,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 375 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfifssfgmhwvrqapgkglewvsaisdsgdatqyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfifssfg,isdsgdat,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 374 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20117,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 374 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsavsttggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfddya,vsttggst,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 373 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20116,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 373 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsaigtggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrnya,igtggdt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 372 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20115,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 372 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavishdasnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrsya,ishdasnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 371 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20114,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 371 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgfrfsdhpmhwvrqapgkglewvavitgsgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gfrfsdhp,itgsgrnk,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 370 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20113,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 370 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsvisgsgrntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfddya,isgsgrnt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 369 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20112,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 369 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfsnya,igagggt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 368 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYS20111,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 368 from patent US 11053304,N/A,evqlvesggglvqpggslrlscaasgftfsdyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfsdya,vswngsrt,vtnmdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-35*02 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 498 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20241,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 498 from patent US 11053304,,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,,,,qslvysdgdty,qvs,mqgshwppt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 490 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20233,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 490 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveik,,,,qsllhsngyny,lgs,mqalqtplg,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 489 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20232,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 489 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveik,,,,qslvhsdgdny,sgs,mqgthwplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 488 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20231,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 488 from patent US 11053304,,divmtqsplslpvtpgepasiscrssrsllhtnglnyidwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyctqalqtpisfgggtkveik,,,,rsllhtnglny,lgs,tqalqtpis,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 487 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20230,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 487 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalrtptfgggtkveik,,,,qsllysngyny,lgs,mqalrtpt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 486 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20229,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 486 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhrngynyvdwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlrisrveaedvgvyycmqarqtpltfgggtkveik,,,,qsllhrngyny,lgs,mqarqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 485 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20228,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 485 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrapgvpdrfsgsgsgtdftlkisrveaedvgvyycaqglqtpltfgggtkveik,,,,qsllhsngyny,lgs,aqglqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 484 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20227,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 484 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqllislgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtltfgggtkveik,,,,qsllhsngyny,lgs,mqalqtlt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 483 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20226,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 483 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveik,,,,qsllhsngyny,lgs,mqalqtplg,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 482 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20225,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 482 from patent US 11053304,,divmtqsplslpvtpgepasiscrssesllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyciqalqtpftfgggtkveik,,,,esllhsngyny,lgs,iqalqtpft,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 481 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20224,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 481 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylssnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqspytfgggtkveik,,,,qsllhsngyny,lss,mqglqspyt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 480 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20223,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 480 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqvpwtfgggtkveik,,,,qsllysdgdty,lgs,mqalqvpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 479 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20222,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 479 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveik,,,,qsllhsngyny,lgs,mqtlhtpgt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 478 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20221,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 478 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqaysfpwtfgggtkveik,,,,qsllhsngyny,lgs,qqaysfpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 477 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20220,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 477 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkitrveaedvgvyycmqalqtpltfgggtkveik,,,,qsllhsngyny,lgs,mqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 476 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20219,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 476 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveik,,,,qsllhsngyny,lgs,mqalqrplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 475 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20218,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 475 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsirasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsqqtpltfgggtkveik,,,,qsllhsngyny,lgs,mqsqqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 474 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20217,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 474 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpgtfgggtkveik,,,,qsllhsngyny,lgs,mqglqtpgt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 473 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20216,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 473 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveik,,,,qsllhsngyny,lgs,mqalqtplg,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 472 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20215,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 472 from patent US 11053304,,divmtqsplslpvtpgepasiscrssksllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaaqtpltfgggtkveik,,,,ksllhsngyny,lgs,mqaaqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 471 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20214,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 471 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyclqtlqtpltfgggtkveik,,,,qsllhsngyny,lgs,lqtlqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 470 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20213,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 470 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgtnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppkfgggtkveik,,,,qsllhsngyny,lgt,mqalqtppk,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 469 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20212,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 469 from patent US 11053304,,divmtqsplslpvtpgepasiscrsshsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqlphtfgggtkveik,,,,hsllhsngyny,lgs,mqalqlpht,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 468 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20211,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 468 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylaanrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveik,,,,qsllhsngyny,laa,mqglqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 467 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20210,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 467 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyfgsnrasgvpdrfsgsgsgtdftlkisrvetedvgvyycmqalqtpaltfgggtkveik,,,,qsllhsngyny,fgs,mqalqtpalt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 466 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20209,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 466 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyqgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,,,,qsllhsngyny,qgs,mqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 465 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20208,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 465 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaqqtpitfgggtkveik,,,,qsllhsngyny,lgs,mqaqqtpit,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 464 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20207,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 464 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllqsngdnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglhwpltfgggtkveik,,,,qsllqsngdny,lgs,mqglhwplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 463 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20206,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 463 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprfgggtkveik,,,,qsllhsngyny,lgs,mqalqtpr,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 462 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20205,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 462 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveik,,,,qslvhsngdty,lgs,qqsystpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 461 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20204,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 461 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsvqtpwtfgggtkveik,,,,qsllysdgdty,lgs,mqsvqtpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 460 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20203,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 460 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsvrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqgynmpltfgggtkveik,,,,qsllhsngyny,lgs,qqgynmplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 459 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20202,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 459 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgletpwtfgggtkveik,,,,qsllysdgdty,lgs,mqgletpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 458 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20201,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 458 from patent US 11053304,,divmtqsplslpvtpgepasisckssqsllhingfnyldwflqkpgqspqlliylgsnrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqslqnprtfgggtkveik,,,,qsllhingfny,lgs,qqslqnprt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 457 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20200,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 457 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveik,,,,qslvhsngdty,lgs,qqsystpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 456 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20199,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 456 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhingynyldwflqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnprtfgggtkveik,,,,qsllhingyny,lgs,mqalqnprt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 454 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20197,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 454 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngnnyldwylqkpgqspqlliyggsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsytppptfgggtkveik,,,,qsllhsngnny,ggs,qqsytpppt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 453 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20196,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 453 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyitpwtfgggtkveik,,,,qsllhsngdty,lgs,qqsyitpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 452 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20195,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 452 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslldsngfnyldwylqkpgqspqlliylgssrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyntpwtfgggtkveik,,,,qslldsngfny,lgs,qqsyntpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 451 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20194,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 451 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqtpwtfgggtkveik,,,,qsllysdgdty,lgs,mqsiqtpwt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 450 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20193,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 450 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvysdgytylnwylqkpgqspqlliyqvsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpaltfgggtkveik,,,,qslvysdgyty,qvs,mqalqtpalt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 449 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20192,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 449 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvhsdgytylnwylqkpgqspqlliyvgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqasqwpptfgggtkveik,,,,qslvhsdgyty,vgs,mqasqwppt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 448 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20191,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 448 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllqsngynyldwylqkpgqspqlliylgynrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqapltfgggtkveik,,,,qsllqsngyny,lgy,mqalqaplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 447 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20190,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 447 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrpsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtpfsfgggtkveik,,,,qsllhsngyny,lgs,mqvlqtpfs,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 446 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20189,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 446 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaiqnrrtfgggtkveik,,,,qsllhsngyny,lgs,mqaiqnrrt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 445 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20188,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 445 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllqsngynymdwylqkpgqspqlliyltsnraagvpdrfsgsgsgtdftlkisrveaedvgvyycqqsygppltfgggtkveik,,,,qsllqsngyny,lts,qqsygpplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 444 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20187,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 444 from patent US 11053304,,divmtqsplslpvtpgepasiscssrqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycvqalqtpltfgggtkveik,,,,qsllhsngyny,lgs,vqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 443 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20186,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 443 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveik,,,,qslvhsdgdny,sgs,mqgthwplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 442 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20185,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 442 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpptfgggtkveik,,,,qsllhsngyny,lgs,mqalqtppt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 441 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20184,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 441 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynrlawylqkpgqspqlliylgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpsfgggtkveik,,,,qsllhsngynr,lgs,mqalqtps,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 440 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20183,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 440 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngnnymdwylqkpgqspqlliylasqrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveik,,,,qsllhsngnny,las,mqalqrplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 439 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20182,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 439 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlqtprfgggtkveik,,,,qsllhsngyny,gas,mqtlqtpr,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 438 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20181,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 438 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqpptfgggtkveik,,,,qsllhsngyny,lgs,mqalqppt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 437 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20180,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 437 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngyndldwylqkpgqspqlliyggsngasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,,,,qsllhsngynd,ggs,mqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 436 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20179,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 436 from patent US 11053304,,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalhipytfgggtkveik,,,,qsllhsngyny,lgs,mqalhipyt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 435 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20178,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 435 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveik,,,,qsllhsngyny,lgs,mqtlhtpgt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 434 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20177,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 434 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngyiyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlrtpitfgggtkveik,,,,qsllhsngyiy,lgs,mqvlrtpit,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 433 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20176,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 433 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrmeaedvgvyycmqtlqmpltfgggtkveik,,,,qsllhsngyny,lgs,mqtlqmplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 432 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20175,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 432 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllhrngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyyctqslqtpltfgggtkveik,,,,qsllhrngyny,gas,tqslqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 431 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20174,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 431 from patent US 11053304,,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaahwpitfgggtkveik,,,,qsllhsngyny,lgs,mqaahwpit,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 430 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20173,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 430 from patent US 11053304,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,,,,qsllysdgdty,lgs,mqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 429 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYS20172,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 429 from patent US 11053304,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 436 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87209,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 436 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,,gyiftsyp,mnpnsgnt,ardrgsydtdafdi,,,,IGHJ3*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 427 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87201,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 427 from patent US 11021532,N/A,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,,gygfityw,iypgdset,aggsgistpmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 419 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87193,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 419 from patent US 11021532,N/A,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,gftfrnya,itsdgrnk,vtqrdnsrdyfphyfhdmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 411 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87185,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 411 from patent US 11021532,N/A,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,,gytfttyr,iypgnsdt,tregipqllrtldy,,,,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 403 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87177,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 403 from patent US 11021532,N/A,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gfafssya,isydgsnk,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 395 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87169,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 395 from patent US 11021532,N/A,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,,ggtfssyt,itpilgia,ardtvmggmdv,,,,IGHJ6*01 (human),IGHV1-69*16 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 364 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87138,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 364 from patent US 11021532,N/A,qvqlvqsgaevkkpgssvyvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvss,,gytftsyg,iipmfgtt,ardrgdtidy,,,,IGHJ4*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 363 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87137,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 363 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgiinpsdgsstyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgysydhdqiyyyygmdvwgqgttvtvss,,gytftsye,inpsdgss,ardrgysydhdqiyyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 362 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87136,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 362 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgwmnsnsgstgyaqkfqgrvtmtrdtststvymelsslrsedtavyycargwmaydafdiwgqgtmvtvss,,gytftsyd,mnsnsgst,argwmaydafdi,,,,IGHJ3*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 361 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87135,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 361 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycatvtpgygmdvwgqgttvtvss,,gytftsyd,idpsggst,atvtpgygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 360 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87134,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 360 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,,gytftryy,inpsggst,akgaphdyiwgsyrpdafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 359 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87133,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 359 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,,gytftryy,inpsggst,akgaphdyiwgsyrpdafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 358 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87132,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 358 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisarngntnyaqkfqgrvtmtrdtststvymelsslrsedtavyycttdpvlewfgysiwgqgtmvtvss,,gytftnyg,isarngnt,ttdpvlewfgysi,,,,IGHJ3*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 357 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87131,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 357 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftgsyaiswvrqapgqglewmgwinpktgdtnyaqefqgrvtmtrdtststvymelsslrsedtavyycargssgyyfgwgqgtlvtvss,,gytftgsya,inpktgdt,argssgyyfg,,,,IGHJ1*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 356 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87130,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 356 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftgnyihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycakdvqnyygsgssfdywgqgtlvtvss,,gytftgny,mnpnsgnt,akdvqnyygsgssfdy,,,,IGHJ4*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 355 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87129,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 355 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,,gytftene,inpsggst,ardsgvdtatlryyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 354 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87128,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 354 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,,gytftene,inpsggst,ardsgvdtatlryyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 353 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87127,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 353 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlmdivvvpwlggmdvwgqgttvtvss,,gytftene,inpsggst,ardlmdivvvpwlggmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 352 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87126,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 352 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaktryggnsrsryyyygmdvwgqgttvtvss,,gytftene,inpsggst,aktryggnsrsryyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 351 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87125,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 351 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyymqwvrqapgqglewmgwidphsgatnyahsfqgrvtmtrdtststvymelsslrsedtavyycarleggsywtgyfdlwgrgtlvtvss,,gytftdyy,idphsgat,arleggsywtgyfdl,,,,IGHJ2*01 (human),IGHV1-2*07 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 350 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87124,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 350 from patent US 11021532,N/A,qvqlvqsgaevkkpgssvkvsckasgytftdyyiqwvrqapgqglewmgwinpnsggpnyaqkfqgrvtitadeststaymelsslrsedtavyycarvdygdygrledywgqgtlvtvss,,gytftdyy,inpnsggp,arvdygdygrledy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 349 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87123,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 349 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyhmhwvrqapgqglewmgwmnpnsgntsyaqkfqgrvtmtrdtststvymelsslrsedtavyycagmgmgrdgynsrafdiwgqgtmvtvss,,gytftdyh,mnpnsgnt,agmgmgrdgynsrafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 348 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87122,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 348 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinydinwvrqapgqglewmgvinpsagstsyahkfqgrvtmtrdtststvymelsslrsedtavyycasahssswysdwfdpwgqgtlvtvss,,gytfinyd,inpsagst,asahssswysdwfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 347 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87121,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 347 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,,gyiftsyp,mnpnsgnt,ardrgsydtdafdi,,,,IGHJ3*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 346 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87120,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 346 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasggtftsyhmhwvrqapgqglewmgwmnpnsgntgyalkfqgrvtmtrdtststvymelsslrsedtavyycasferfgelvpetfdywgqgtlvtvss,,ggtftsyh,mnpnsgnt,asferfgelvpetfdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 345 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87119,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 345 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasggtfssyaiswvrqapgqglewmgivnpssgsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarvrgsaaiammdvwgqgttvtvss,,ggtfssya,vnpssgst,arvrgsaaiammdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 344 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87118,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 344 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasggtfrstaiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragyssssgyyyygmdvwgkgttvtvss,,ggtfrsta,mnpnsgnt,aragyssssgyyyygmdv,,,,IGHJ6*04 (human),IGHV1-8*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 343 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87117,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 343 from patent US 11021532,N/A,evqllesggglvqpggslrlscaasgftfsgsamhwvrqapgkgleyvsaisrnggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgtlitttldywgqgtlvtvss,,gftfsgsa,isrnggtt,akdgtlitttldy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 342 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87116,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 342 from patent US 11021532,N/A,evqllesggglvqpggslrlscaasgfsfsnydmhwvrqapgkglewvavisydggfklyadsvkgrftisrdnaknslylrmnslrsedtavyycargqvrgsgpqvvvmdvwgkgttvtvss,,gfsfsnyd,isydggfk,argqvrgsgpqvvvmdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 341 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR87115,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 341 from patent US 11021532,N/A,qvqlvqsgaevkkpgasvkvsckasgdtfsnygiswvrqapgqglewmgwmnpnsggtnyaqkfqgrvtmtrdtststvymelsslrsedtavyycaigttvvtpfgywgqgtlvnvss,,gdtfsnyg,mnpnsggt,aigttvvtpfgy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 437 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87210,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 437 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleik,,,,qdisny,aas,qqansfpst,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 428 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87202,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 428 from patent US 11021532,,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,,,,qsvlyssinkny,was,qqyystpyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 420 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87194,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 420 from patent US 11021532,,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,,,,qslvysdgdty,qvs,mqgshwppt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 412 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87186,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 412 from patent US 11021532,,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,,,,qeisgy,aas,lqyvsypwt,,,IGKJ1*01 (mouse),IGKV9-124*01 (mouse)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 404 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87178,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 404 from patent US 11021532,,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,,,,qsvrsn,das,qqrsnwppt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 396 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87170,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 396 from patent US 11021532,,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,,,,nigsks,dds,qvwdsssdyv,,,IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 388 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87162,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 388 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdik,,,,qgisnn,aas,qqgngfplt,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 387 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87161,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 387 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrvsqgissylnwyqqkpgkapklliyaasilqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpftfgpgtkvdik,,,,qgissy,aas,qqgystpft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 386 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87160,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 386 from patent US 11021532,,diqmtqspsslsasvgdrvtitcqasqsiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkveik,,,,qsiyny,das,qqaisfplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 385 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87159,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 385 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqtiysylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkleik,,,,qtiysy,das,qqaisfplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 384 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87158,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 384 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveik,,,,enidsw,eas,hqylsspet,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 383 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87157,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 383 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveik,,,,enidsw,eas,hqylsspet,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 382 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87156,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 382 from patent US 11021532,,divmtqspdslavslgeratinckssqsvfsssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,,,,qsvfsssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 381 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87155,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 381 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 380 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87154,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 380 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqgirnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppltfgqgtkveik,,,,qgirny,aas,qqsyspplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 379 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87153,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 379 from patent US 11021532,,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleik,,,,qdisky,gas,qqgystpys,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 378 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87152,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 378 from patent US 11021532,,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleik,,,,qdisky,gas,qqgystpys,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 377 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87151,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 377 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqaitnylawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyysypptfgqgtkleik,,,,qaitny,aas,qqyysyppt,,,IGKJ2*01 (human),IGKV1-16*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 376 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87150,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 376 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqhissylnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgygtpytfgqgtkveik,,,,qhissy,aas,qqgygtpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 375 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87149,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 375 from patent US 11021532,,eivmtqspatlsvspgeratlscrasqsvssnylawyqqkpgqaprlliyavssratgiparfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveik,,,,qsvssny,avs,qqygssplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 374 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87148,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 374 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqsiyswlawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypytfgqgtkveik,,,,qsiysw,das,qqlnsypyt,,,IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 373 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87147,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 373 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmpltfgqgtkveik,,,,qsisty,aas,qqsysmplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 372 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87146,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 372 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 371 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87145,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 371 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleik,,,,qdisny,aas,qqansfpst,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 370 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87144,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 370 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqgirndlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkleik,,,,qgirnd,aas,qqsystppt,,,IGKJ2*01 (human),IGKV1-6*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 369 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87143,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 369 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqdirnelgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleik,,,,qdirne,aas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 368 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87142,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 368 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqydtfpltfgqgtkveik,,,,qgisnn,aas,qqydtfplt,,,IGKJ4*01 (human),IGKV1-16*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 367 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87141,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 367 from patent US 11021532,,diqmtqspsslsasvgdrvtitcrasqsigyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpltfgggtkveik,,,,qsigyy,aas,qqsyttplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 366 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87140,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 366 from patent US 11021532,,diqmtqspsslsasvgdrvtitcqasqgirndlgwyqqkpgkapklliydasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyystppltfgqgtkveik,,,,qgirnd,das,qqyystpplt,,,IGKJ4*01 (human),IGKV1-6*01 (human)
GenBank,,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 365 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR87139,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 365 from patent US 11021532,,eivmtqspatlsvspgeratlscrasesvssrylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqgyknpptfgqgtkveik,,,,esvssry,gas,qqgyknppt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 102 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85030,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 102 from patent US 11021531,N/A,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gfafssya,isydgsnk,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 83 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85011,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 83 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,,gfsfssyg,mnrdgsyi,ardrsyyvgy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 82 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85010,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 82 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gftvssny,iypggst,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 81 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85009,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 81 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvaiiyeggsphyadsvkgrftisrdnskntlylqmnslraedtavyycardrsgyldywgqgtlvtvss,,gftfddya,iyeggsp,ardrsgyldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 80 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85008,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 80 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftfsdhymswvrqapgkglewvsaistsgdstfyadsvkgrftisrdnskntlylqmnnlraedtavyycardrsyyldywgqgtlvtvss,,gftfsdhy,istsgdst,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 79 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85007,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 79 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,,gfsfssyg,mnrdgsyi,ardrsyyvgy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 78 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85006,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 78 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsaisgtgdtteyadsvkgrftisrdnskntlylqmnslraedtavyycardrslmldywgqgtlvtvss,,gftfsnsd,isgtgdtt,ardrslmldy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 77 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85005,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 77 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftfsnhymswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gftfsnhy,isgsggst,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 76 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85004,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 76 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftftnyamtwvrqapgkglewvstmsniggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrrvyldywgqgtlvtvss,,gftftnya,msniggdt,ardrrvyldy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 75 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85003,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 75 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftfashamswvrqapgkglewvsgissdgsittyadsvkgrftisrdnskntlylqmnslraedtavyycardrgwyldywgqgtlvtvss,,gftfasha,issdgsit,ardrgwyldy,,,,IGHJ4*01 (human),IGHV3-23*03 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 74 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85002,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 74 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasglsvtsnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,glsvtsny,iypggst,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 73 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85001,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 73 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsvvypggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,gftvssny,vypggst,ardrsyyldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 72 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,QYR85000,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 72 from patent US 11021531,N/A,evqlvesggglvqpggslrlscaasgfrfsdaaihwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsygidywgqgtlvtvss,,gfrfsdaa,isgsggst,ardrsygidy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 103 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85031,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 103 from patent US 11021531,,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,,,,qsvrsn,das,qqrsnwppt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 95 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85023,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 95 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveik,,,,qsvssn,gas,qqrnnwppt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 94 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85022,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 94 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqasstpltfgggtkveik,,,,qsvsssy,gas,qqasstplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 93 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85021,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 93 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpptfgggtkveik,,,,qsvsnn,das,qqynnwppt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 92 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85020,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 92 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqfgtsppglsfgggtkveik,,,,qsvrsn,gas,qqfgtsppgls,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 91 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85019,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 91 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveik,,,,qsvrsn,gas,qqrnnwppt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 90 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85018,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 90 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveik,,,,qsvrsn,gas,qqrnnwppt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 89 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85017,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 89 from patent US 11021531,,eivmtqspatlsvspgeratlscrasqsigtylswyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqslslpvtfgggtkveik,,,,qsigty,gas,qqslslpvt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 88 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85016,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 88 from patent US 11021531,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveik,,,,qsissy,aas,qqygssplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 87 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85015,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 87 from patent US 11021531,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 86 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85014,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 86 from patent US 11021531,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 85 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85013,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 85 from patent US 11021531,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 84 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",N/A,,,N/A,QYR85012,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 84 from patent US 11021531,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98516,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgttvtvss,,gfpfkgty,iysggdt,ardremaiitertygldv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98515,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,gftfssyy,isedgyst,ardfsghtawagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98514,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsk,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98513,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvsdtpfywgwirqppgkglewigsmyytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpssifrgtvftpyyfdywgqgtlvtvss,,ggsvsdtpfy,myytgst,arhpssifrgtvftpyyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98512,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvnpggslrlscagsgftfsdyymgwirqapgkglevvsyisttgsyikdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgsfdywgqgtlvtvss,,gftfsdyy,isttgsyi,armgpygsgsfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98511,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglsqpggslrlscatsgfavrnncmnwvrqapgkglewvslicgdgityhsdsvkgrfiisrddsenalhlqmnslrvedtavyycvkasppggntgwpffhywgqgtlvtvss,,gfavrnnc,icgdgit,vkasppggntgwpffhy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98510,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewlsyishtastiyyadsvkgrftisrdnaknslflqmnsltaedtavyycardrgsgvidpwgqgtlvtvss,,gftfsdyy,ishtasti,ardrgsgvidp,,,,IGHJ5*02 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98509,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrepgssvklscktsggpfsthafswvrqapgqrpewmggimpvfgeskdtqkfkgrvtftadasttttymelrslksddtaiyycvrdsdpytatsshnhywyamdvwgqgttvtvss,,ggpfstha,impvfges,vrdsdpytatsshnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98508,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggiiplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,,ggtfstha,iiplfgts,vrdsdpytatsrnnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98507,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqwgagllkpsetlslrcavyggsfngfywtwirqapgqglewiaeinhsgttnynpslksrvtisidtskkqfslslksvtaadtamyfcargtispivgvptpvvprrgrswfdpwgqgtlvtvss,,ggsfngfy,inhsgtt,argtispivgvptpvvprrgrswfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98506,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgtslrlscaatgftfttypmhwvrqapgkglewvavisydgmnqyyadflkgrftisrdnskntlylqmnslraddtavyycarayggnyqnhfdhwgqgtlvtvss,,gftfttyp,isydgmnq,arayggnyqnhfdh,,,,IGHJ1*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98505,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgggvvqpggslrlscadsgnafianpmhwvrqapgkglewlalistdgnnrhyadsvkgrftfsrdnsknslylqmdslrpedtgvyycaresrssgragcfdswgqgtlvtvss,,gnafianp,istdgnnr,aresrssgragcfds,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98504,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfsryamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlflqmsnvrpedtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrya,inlngdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98503,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgpglvkpsetlsltctvsggsissnnlywgwirqppgkglewigsiyysgstyynpslksrviipvdtskdqfslrlssvtaadtavyycarhsqkdivlipaaqspifdywgqgtlvtvss,,ggsissnnly,iyysgst,arhsqkdivlipaaqspifdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98502,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggtfsshaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftvdestntaymeltslksedtaiyycvrdpdpytatvrhnhywhgmdvwgqgttvtvss,,ggtfssha,impifges,vrdpdpytatvrhnhywhgmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98501,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgpglvkpsetlsltctvsggsinsqywnwirqspgkglewigyvyysgstnynpslksrvtmsvdtsknhfslnlrsvtaadtavyycarglvvryfdgfpsgpiigafdiwnqgttvtvss,,ggsinsqy,vyysgst,arglvvryfdgfpsgpiigafdi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98500,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,,gdtfstna,ivplvgpa,ardsdpytatrrhnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98499,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcgvyggsfsgyfwswirqspgkglewigeinhsrsmsynpslksritmsvdtsknqfslnlnsvtaadtavyfcargkahrndfwsgyyphwfdpwgqgilvtvss,,ggsfsgyf,inhsrsm,argkahrndfwsgyyphwfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98498,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgfywtwirqppgkglewigeinhsgssnydlslksrvtmsvdtsknqfslklssvtaadtavyycargmispriprttrqrwfdtwgqgtlvtvss,,ggsfsgfy,inhsgss,argmispriprttrqrwfdt,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98497,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyvrkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdlwgqgttvtvss,,ggtfsnya,iipalsrv,ardpsflntgnhfwydfdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98496,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggilplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,,ggtfstha,ilplfgts,vrdsdpytatsrnnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98495,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkmpgssvkvsckvsggrfsdyaiswlrqapleglewmggivphlnrkgysqkfqdrltftaddststaymelsgltsedtavyycardptflntgnhfwyavdiwgqgttvtvss,,ggrfsdya,ivphlnrk,ardptflntgnhfwyavdi,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98494,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmlsdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,,ggmlsdya,impafgsp,ardpsilntgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98493,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaaseftfstyamhwvrqapgkglewvalisydginkyyadsvkgrfaisrdnskntlylqvnslraddtavyycvrpysgsytnwfdlwgqgtlvtvss,,eftfstya,isydgink,vrpysgsytnwfdl,,,,IGHJ2*01 (human),IGHV3-30*09 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98492,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscvasgftfsdfymswirqapgkglewvsyisgsgdtiyyadsvkgrftvsrdnaknslflqmsslgaedtamyycarematsfgyyfvldvwgqgttvtvss,,gftfsdfy,isgsgdti,arematsfgyyfvldv,,,,IGHJ6*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98491,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgtslrlscavsgfmfknyaihwvrqapgkglewvavisfdgsdisytesvqgrftisrdnsenmlylqmnslraedtamyycarepdgigaagisgywgqgtlvtvss,,gfmfknya,isfdgsdi,arepdgigaagisgy,,,,IGHJ4*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98490,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsehaqrfqarvkftadeststaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,ggtfstha,iiplfgts,vrdsdpytatsrnnhywygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98489,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98488,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggevkkpgasvkvsckasgytlssypiswvrqapghglewmgwintyngrtnyeqmlqgrvtmttdtststaymelrslrsddtavyycarvvfrhgqyddssgrlafdiwgqgtmvtvss,,gytlssyp,intyngrt,arvvfrhgqyddssgrlafdi,,,,IGHJ3*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98487,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvylqmnslrdedtavyfcareldsetyynynsldvwgqgttvtvss,,gfnfnsys,issrssti,areldsetyynynsldv,,,,IGHJ6*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98486,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkgpgasvkvsckvsgysfityditwvrqapgqglewmgwistksgdtryaqnvqgrvtmttdtstntaymelrnlksddtalyycarttprgweqwpvleywgqgtlvtvss,,gysfityd,istksgdt,arttprgweqwpvley,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98485,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgrglvkpsetlsltctvsggsitssryywgwirqppgrnlewigsihysgttsynpslwsrvaisvdtaqnqfslrlnsvtaadtavyycaapapsnheswsgtdwfdpwgqgilvtvss,,ggsitssryy,ihysgtt,aapapsnheswsgtdwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98484,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,ggrfsdya,iiprlnrk,ardptflnsgnhfwyavdi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98483,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrepgssvklscktsggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrsnhywyamdvwgqgttvtvss,,ggtfstha,impifges,vrdsdpytatvrsnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98482,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlsceasgftfadypmhwvrqapgkglewvavisshgrsqgyaasvkgrftfsrdnsqsslflqlnslrvedtavyfcareaqssgragcldawgqgtlvtvss,,gftfadyp,isshgrsq,areaqssgragclda,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98481,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscgasgftfsdyamswvrqapgkglewvstisgsgdktyyadslkgrftnsrdnskstlylqmtslraedtavyfcakdrycsggscfydafdiwgqgttvtvss,,gftfsdya,isgsgdkt,akdrycsggscfydafdi,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98480,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpfsgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98479,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkagssvkvsckasggpfssfaiswvrqapgqglewlggimtvfgpahyaqksrdrisitadeststsylelssltsddtavyycaaeersgtnhnyygldvwgqgttvtvss,,ggpfssfa,imtvfgpa,aaeersgtnhnyygldv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98478,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggdsvnpggslrlscagsgfsvrdvwmswvrqapgkglewigrikseadggssdyraslkdrfsiwrdaskntlylqvnglqtedtaiyfcswndvgwaftfwgqgtlvtvss,,gfsvrdvw,ikseadggss,swndvgwaftf,,,,IGHJ1*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98477,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgdkkyypdsvrgrftisrdnskntlhlqmnslrledtavyycarsyggsystvgywgqgalvtvss,,gftfssya,isydgdkk,arsyggsystvgy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98476,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavnggsfnnyywswirqppgkgpewigevvhsgsttynpslksrvtisidmsknqfalklnsvtaadtavyycargftftysdfltgqrtfeywgqgtlvtvss,,ggsfnnyy,vvhsgst,argftftysdfltgqrtfey,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98475,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscvasgfpfgryamhwvrqapgqglewltlisfdssnieysdsvqgrftisrdnsrntlflqmtslrpedtavyfcardlppldywgqgtlvtvss,,gfpfgrya,isfdssni,ardlppldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98474,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgptlvkptqtltltctfsgfslntrelgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltltnmdpgdtatyycahtselpprrpyaafdfwgqgtlvtvss,,gfslntrelg,iywdddk,ahtselpprrpyaafdf,,,,IGHJ5*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98473,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvkpggslrvscvgsgftfsdhymswirqapgkgleiisyistdgsyindadsvkgrfinsrdnaknsvylqlnslraedtavyycarmgpsgsgsldywgqgslvtvss,,gftfsdhy,istdgsyi,armgpsgsgsldy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98472,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,ggrfsdya,iiprlnrk,ardptflnsgnhfwyavdi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98471,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewmggiiplfgtsesaqrfqarvrftadeststaymelssltsedtavyycvrdsdpytatsrnnhywydmdvwgqgttvtvss,,ggtfstha,iiplfgts,vrdsdpytatsrnnhywydmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98470,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsggglvqpggslrlscaasgftfssysmswvrqapgkglewvsyitrssdniyyaesvkgrftisrdsaknslylhmnslrdedtavyycardpgleysgnyfsyyyyamdvwgqgttvtvss,,gftfssys,itrssdni,ardpgleysgnyfsyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98469,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvtdnymswvrqapgkglewvsvlysggstyyadavqgrfsisrdnsknalylqmnslraedtavyycargfgngwsyyfdywgqgtlvtvss,,gftvtdny,lysggst,argfgngwsyyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98468,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlsceasgftfsnynmnwvrqapgkglewvssisgsssyisyadsvkgrftisrdnaknslylqmnslrvedtavyycaradrdydfwsdpplidhwgqgtlvtvss,,gftfsnyn,isgsssyi,aradrdydfwsdpplidh,,,,IGHJ1*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98467,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkrpgasvkvsckasgyafsdyymhwvrqapgqgpewmgwinpnsgdtgypqkfrgwvtmtrdtsvstaymelkrlksddtavyycasgpnyfdywgqgtlvtvss,,gyafsdyy,inpnsgdt,asgpnyfdy,,,,IGHJ4*01 (human),IGHV1-2*04 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98466,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtlshyaiswvrqapgqglewmggimpvsgtvgyaqkfqgrvkftadeyastaymeltnlrsedsavyfcardpsivdsgphhwydldiwgqgtmvtvss,,ggtlshya,impvsgtv,ardpsivdsgphhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98465,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98464,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,,ggtfitha,ivplfgra,vrdsepytatrsqnhywydmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98463,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98462,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggilpafaasgspgyapifrgratfsadvststayleltnlkpedtavyycardpsilntgnhhwydldlwgqgtevtvss,,ggmftdya,ilpafaasgsp,ardpsilntgnhhwydldl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98461,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfskfamhwvrqapgkglewvaiisydgshknyadsvkgrftisrdnskntvylqvdslraedtavyycallygsgsyynfvffgwkdgsdawgpgttvtvss,,gftfskfa,isydgshk,allygsgsyynfvffgwkdgsda,,,,IGHJ2*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98460,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,,gfgfplya,vsydssni,ardnalqdgrpgyfds,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98459,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfifsdyymswirqapgkglewvsyitgsgrtihyadsvkgrftisrdnaknsvylqmnslraedtavyycarghrflefplnyfdpwgqgtlvtvss,,gfifsdyy,itgsgrti,arghrflefplnyfdp,,,,IGHJ5*02 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98458,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,,gfgfplya,vsydssni,ardnalqdgrpgyfds,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98457,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvkvsckasggtfynsafswlrhapgqgpewmggitpslgrvgyserflarltitadeststvymeltslasedtavyycardasivgtgnhlwygldfwghgttvtvss,,ggtfynsa,itpslgrv,ardasivgtgnhlwygldf,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98456,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqhfrgrlsitadesastaymeltglrsedtamyycardpsilntgnhhwydldlwgqgtmvtvss,,ggtladya,ikplhgaa,ardpsilntgnhhwydldl,,,,IGHJ3*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98455,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsaseftlrshamhwvrqapgkgleyvsgistdgsgrfyadsvkgrftisrdnsknklflqmsslrpedtavyycvrdwgssthydvfdlwgqgtmvtvss,,eftlrsha,istdgsgr,vrdwgssthydvfdl,,,,IGHJ3*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98454,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsgatyknsafswarqapgqgfqwmggiiplfgvphyvqmfqgrvtitadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,,gatyknsa,iiplfgvp,areeysgtvhnffgmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98453,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpifgspgyaeifqgrvtitadeskstvymeltslrsedtavyycardpsildtgnhhwydldiwgqgtmvtvss,,ggtlsdya,impifgsp,ardpsildtgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98452,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggglvqpggslrlscaasgfifsghwmswvrqapgkglewvanikqdgrekhyvdsvkgrftisrdnaknsvslqmnslraedtavyycvrqnvaiqyyyyamdvwgqgttvtvss,,gfifsghw,ikqdgrek,vrqnvaiqyyyyamdv,,,,IGHJ6*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98451,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfnsyalfwvrqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslktedtsvyycarprsgsyrqaidywglgtlvtvss,,gftfnsya,vsydgnnk,arprsgsyrqaidy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98450,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevknpgssvkisckssggtlgdyaiswvrqapglglewlggimplhgttgysqrfrprltitadesartaymeltalssedsaiyycardpsilntgnhhwydldlwgqgtevtvss,,ggtlgdya,implhgtt,ardpsilntgnhhwydldl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98449,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,,gfnfspyg,iisgsgti,arglldylhdafdi,,,,IGHJ3*02 (human),IGHV3-48*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98448,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlslactvsggsisnyywnwvrqppgkglewigniyysgsttfnpslksrvtisvdtsrnqfslklssvtaadtavyycarqssswynpyyfdqwgqgtlvtvss,,ggsisnyy,iyysgst,arqssswynpyyfdq,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98447,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgaevkkpgssvkvscktsggtfnsytiswvrqapgqglewmggiipildtphyaqkfrgrvtitadkststafmdlssltsedtavyycairrdysdyrdfdywgqgtlvtvss,,ggtfnsyt,iipildtp,airrdysdyrdfdy,,,,IGHJ4*01 (human),IGHV1-69*08 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98446,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqllesggglvqpgrslrlsctasgfrfgdytmtwfrqapgkglewvgfirsiayggttehaasvegrfiisrddsksiaylqmnslkaedtgvyfctrgsgmfygsssgmdvwgqgttvtvss,,gfrfgdyt,irsiayggtt,trgsgmfygsssgmdv,,,,IGHJ6*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98445,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlqesgpglvkpsetlsltcavsggsvssdtdywgwirqppgkglewigsihdsertyydpslksrvtisvdtsknqfslrlssvtaadtalyfcasrhldllpigsfdvwgrgtmvtvss,,ggsvssdtdy,ihdsert,asrhldllpigsfdv,,,,IGHJ3*01 (human),IGHV4-38-2*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98444,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,,gfnfspyg,iisgsgti,arglldylhdafdi,,,,IGHJ3*02 (human),IGHV3-48*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98443,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqvpgrglewvsgiswnsgtinyadsvmgrftisrdnaknslylqmnslraedtalyycakdgrycsgiscrtgmdvwgqgttvtvss,,gftfddya,iswnsgti,akdgrycsgiscrtgmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98442,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgpglvkpsqtlsltctvsngfissgeyywswirqspgkglewigyishsgstyynrslksrvtisldtsrnqfslnlssvtaadtavyycardlakwsygyyysgmdvwgqgttvtvss,,ngfissgeyy,ishsgst,ardlakwsygyyysgmdv,,,,IGHJ6*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98441,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgysstnygfswvrqapgqglewmgwisvhsgnanfaqkfqgritmttdtstttaymelrnlrsddtatyycatsassysryyfgldvwgqgttvtvss,,gysstnyg,isvhsgna,atsassysryyfgldv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98440,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfsnynmvwvrqapgkglewisyissssstiyyadsvkgrfiisrdnaknslhlqmnslrdedtavyycvrdycnsvscytyyyigmdvwgqgttvtvss,,gftfsnyn,isssssti,vrdycnsvscytyyyigmdv,,,,IGHJ6*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98439,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsggsftsyvlswvrqapgqglewmgrivpnlgvanyaqkfqdrvtitadkstttaylelrslrsedtavyycardlyydnggynyldywgpgtlvtvss,,ggsftsyv,ivpnlgva,ardlyydnggynyldy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98438,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevrkpgssvkvsckatggtfssygitwvrqapgqglewmgriiptlgrtnyaqkfqgrvtitadkststahmelsslrsedtavyycardlstlqpdaivnfdywgqgtlvtvss,,ggtfssyg,iiptlgrt,ardlstlqpdaivnfdy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98437,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,,gftfsdhy,isssgsfi,armgpygsgtfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98436,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgaevkkpgssvkvsckasggtfssdaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadestntaymelsslrsedtavyycardgpydsggyhlnhwgqgtlvtvss,,ggtfssda,iipifgtt,ardgpydsggyhlnh,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98435,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvilsckasgytvtnyyihwvrqapgqglewmgwidpdsgvtnfaekfqgrvtmtrdtsistaymelrwlesddtavyycakdlitvirglgggmdvwgqgttvtvss,,gytvtnyy,idpdsgvt,akdlitvirglgggmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98434,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelgslrsddtavyycarvlagsshewqlthdafdiwgqgttvtvss,,gytftsyy,ihpsggst,arvlagsshewqlthdafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98433,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagvlkpsetlsltcavyggsfrgffwswirqppgkglewigqithsgstnynsslksrltisvdtsknqfslnlssvtaadtaiyycargqggydlrrvgygltswfdpwgqgilvtvss,,ggsfrgff,ithsgst,argqggydlrrvgygltswfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98432,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,gasvssdhw,vyhsgst,atmwgglctasncygnpmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98431,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgggvvqpgkslrlscvasgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgvyycvkdqssgdrllylgyfdlwgpgtlvtvss,,gfsfgtyg,mwydgitq,vkdqssgdrllylgyfdl,,,,IGHJ2*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98430,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgkslrlscvpsgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgiyycvkdqssgdrllylgyfdlwgpgalvtvss,,gfsfgtyg,mwydgitq,vkdqssgdrllylgyfdl,,,,IGHJ2*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98429,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscktsgytftghyihwvrqapgqglewmgwinpasgdtnyaqkfqgrvtktrdtsittaymelnrlrsddtavyycarggplpwsdldivgtfdywgqgtlvtvss,,gytftghy,inpasgdt,arggplpwsdldivgtfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98428,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyyvhwvrqvpgqglewmgwispdsgdtiraqnfqgrvtmtrdtsmntaymevnrlrtddtaiyycardlisvirglgggmdvwgqgttvtvss,,gytftdyy,ispdsgdt,ardlisvirglgggmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98427,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfsnyamtwvrqapgkglkwvsginpsgdatfytdsvkgqftisrdnsknilylqmnrlraddtaiyycakglsfygsgsdafdvwgqgttvtvss,,gftfsnya,inpsgdat,akglsfygsgsdafdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98426,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssmkvsckasgvnfrsysfswvrqapgqglewmggvipyfptanyadkfrdrvtitadestgtvyldmsslrsedtavyfcaseyfdgrsyhsfcgldvwgqgttvtvss,,gvnfrsys,vipyfpta,aseyfdgrsyhsfcgldv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98425,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgeslkisckasgysftnywvgwvrqmpakglewmgiiwpddsdtryrpsfqgqvtisvdksistaylhwnslkasdngmyfcaraplascsggrcptynrfdlwgqgtlvtvss,,gysftnyw,iwpddsdt,araplascsggrcptynrfdl,,,,IGHJ2*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98424,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgpglvrpsgtlsvtcavsgdsissdywctwvrqspgkglewigkishsgslnynpslksrvtmsvdksknhfslklasvtaadtavyycarvrigashhnfwsgyytdafdiwgqgttvtvss,,gdsissdyw,ishsgsl,arvrigashhnfwsgyytdafdi,,,,IGHJ3*02 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98423,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsgrvywgqgtlvtvss,,gftfssyg,iwydgsnk,arvgsgrvy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98422,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvrvsckasggtfrksaiswvrqapgqgfewmggiiptldrrgfaqkfqdrltmtadeftstaymdlsdlrsddtavyycardasfpntgnhfwydfdlwgqgttvtvss,,ggtfrksa,iiptldrr,ardasfpntgnhfwydfdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98421,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscrvsggrfsdyafswlrqapvkglewmggiiprldrkgyshifqdrltftadeststtymelsgltsddtavyycardptflnsgnhfwydvdiwgqgttvtvss,,ggrfsdya,iiprldrk,ardptflnsgnhfwydvdi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98420,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvevsckvsggtfrdyaiswvrqapgqrlewmggimpglgspayaqifgdrvtisadtststaylqvtnlrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,ggtfrdya,impglgsp,ardpsilntgnhhwydldm,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98419,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,,gfdfrpya,ishdgvht,ardnalqnaqigyldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98418,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpgllkpsetlsltctvsnspissnywswirqpagkglewigriditgntnynpslksrvimsvdtsksqfslkmtsvtaadtavyycarsfisfdssghpyyyyamdvwgqgttvtvss,,nspissny,iditgnt,arsfisfdssghpyyyyamdv,,,,IGHJ6*01 (human),IGHV4-4*07 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98417,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlslicdvyggsfngfywswirqppgkglewigeishdgstnyspslksrvsisidtskkqfslklrsvtaadtamyycargmtspvvhlyssgrpsrwfdfwgqgtlvtvss,,ggsfngfy,ishdgst,argmtspvvhlyssgrpsrwfdf,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98416,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytfsnyamnwvrqapgqgpewmgwidtntgnptyaqgfigrfvfsldtsvntaylligsleaedtavyycareehydfssgyfrpaywgqgtlvtvss,,gytfsnya,idtntgnp,areehydfssgyfrpay,,,,IGHJ4*01 (human),IGHV7-4-1*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98415,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98414,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvklsckasggifsthaiswvrqapgqrpewmggiipifgeskdtrkfqgrvtftadestttaymelrslksddtaiyycvldsdpytatfshnhywyamdvwgqgttvtvss,,ggifstha,iipifges,vldsdpytatfshnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98413,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,,gfdfrpya,ishdgvht,ardnalqnaqigyldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98412,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,gasvssdhw,vyhsgst,atmwgglctasncygnpmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98411,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,,agltitrya,vshdgihi,vrddvlqhsrpsgpgyfvs,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98410,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmisdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvstntayleltslnpddtavyycardpsilntgnhhwydldmwgqgtmvtvss,,ggmisdya,impafgsp,ardpsilntgnhhwydldm,,,,IGHJ3*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98409,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesggglvqpggslrlscaasgftvnsygmswvrqapgkglewvsgfksrsdrpdyaesvkgrftisrdtskntvylemiglraedtatyycvrmdwmewmkyyfdswgqgalvtvss,,gftvnsyg,fksrsdrp,vrmdwmewmkyyfds,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98408,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrpewmggimpglgspayaqifrgratisadlststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,,ggmftdya,impglgsp,ardpsilntgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98407,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggimpglgspayaqifrdratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgttvtvss,,ggmftdya,impglgsp,ardpsilntgnhhwydldi,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98406,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,gdtfstha,iiplfgta,vrdsdpytatsrnnhywygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98405,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgpgllkpsetlsltctvsgdsvssgnfywswvrrppgkalewiayshytggtnsdpsfmgrvtmsidpsrnqfslrltsvaaadtavyycarttspltysghwplfdywgqgslvtvss,,gdsvssgnfy,shytggt,arttspltysghwplfdy,,,,IGHJ4*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98404,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgidggggssyyadsvrgrftvsrdnsknmlhlqmnslraddtavyfcakgdwiryfdwslpisffdywgqgalvtvss,,gftfssya,idggggss,akgdwiryfdwslpisffdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98403,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgadvkkpgasvkvsckasgytftsyymhwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelsslrsedtavyycarvlagsshewqlthdafdiwgqgttvtvss,,gytftsyy,ihpsggst,arvlagsshewqlthdafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98402,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,,gfifknep,irdngndv,vrdtdwafds,,,,IGHJ5*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98401,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,,gdtfstna,ivplvgpa,ardsdpytatrrhnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98400,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsmnhyywswirqppgkglegigytyysgstnynpslksrvtisvdasknqfslrlssvtaadtavyycargsqidlrgglgatffdywgqgtlvtvss,,ggsmnhyy,tyysgst,argsqidlrgglgatffdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98399,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,,agltitrya,vshdgihi,vrddvlqhsrpsgpgyfvs,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98398,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsitsrdwwswvrqppgkglewigevyhsgstsynpslksrvtisvdksknefslklssvtaadtavyycaragnivvmpaaqyyfdywgqgtlvtvss,,ggsitsrdw,vyhsgst,aragnivvmpaaqyyfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98397,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalskvgyagkfqarltfsadelkttvymdlssltsedtavyycardpsflnagnhfyydfdvwgqgtmvtvss,,ggtfsnya,iipalskv,ardpsflnagnhfyydfdv,,,,IGHJ3*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98396,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsafamhwvrqapgkglewvtiisydgsneyyadsvqgrfsisrdnskntlflqmsslrtedtaiyycaraggylsafdiwgqgttvtvss,,gftfsafa,isydgsne,araggylsafdi,,,,IGHJ3*02 (human),IGHV3-30*15 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98395,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsatlsltctvsggsinnyywtwvrqsagkglewigrintsgstnynaslksrvtmsidtsknefslrlssvtaadtavyycarefgvrfldrslfgamdvwghgatvtvss,,ggsinnyy,intsgst,arefgvrfldrslfgamdv,,,,IGHJ6*01 (human),IGHV4-4*07 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98394,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,,ggtfitha,ivplfgra,vrdsepytatrsqnhywydmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98393,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpvfgspgyaeifqgrltitadesrstaymeltslrsedtavyycardpsilntgphhwydldiwgpgttvtvss,,ggtlsdya,impvfgsp,ardpsilntgphhwydldi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98392,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgssvrvsckvsggpfssygvswarqapekglewmggvlpifgtvgyvhkfqgrvtitadeststvymalsslrsedtavyycvldttmshphnwygmdvwghgttvtvss,,ggpfssyg,vlpifgtv,vldttmshphnwygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98391,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftndgfvwvrqapgqvpewmgwisvhtgdtiyaqrfqgrvtmttdtstrtsymelmslrsddtavyycardygdgppdhwgqgtlvtvss,,gytftndg,isvhtgdt,ardygdgppdh,,,,IGHJ1*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98390,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggslrdyaiswvrqapgqgpewmggimpifgtagyaqkfqgrvkftadesattaymeltglrsedsavyfcardpsilntgnhhwydldiwgqgttvtvss,,ggslrdya,impifgta,ardpsilntgnhhwydldi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98389,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcgvygvsfsdyywswirqppgkglewigeinhsgitnynpslksrvtisvdtsknqfslklssvtaadtavyycarglisytlwlresyfdywgqgtlvtvss,,gvsfsdyy,inhsgit,arglisytlwlresyfdy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98388,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkisckasgyafrnnyinwirqapgqglewmgiinpsagtstyaqkfqgrvtmtrdtstntvymeitslrsedtatyfcarearrqvtqwfgefwgpynwfdpwgqgtlvtvss,,gyafrnny,inpsagts,arearrqvtqwfgefwgpynwfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98387,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvrpsetlsltctvsrgsisssywswirqppgkglewigfmyysgstnynpslksrvtisldtsknqfslklssvtaadtavyycakaqgiyyrgwsywfdpwgqgtlvtvss,,rgsisssy,myysgst,akaqgiyyrgwsywfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98386,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvflqmnslrdedtavyycareldsetyynynsldvwgqgttvtvss,,gfnfnsys,issrssti,areldsetyynynsldv,,,,IGHJ6*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98385,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggglvqpggslrlscsasgftfntytmhwvrqapgkgleyvsaissngvvtyyadsvkgrftisrdnskntlylqmsslraedtavyycvkalyssswcpfdywgqgalvtvss,,gftfntyt,issngvvt,vkalyssswcpfdy,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98384,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgfilddyavhwvrlapgkglewvsgitwnsgylgyadsvkgrftisrdnaknslylqmnslrpedtalyycaklgtdhpigvdvwgqgttvtvss,,gfilddya,itwnsgyl,aklgtdhpigvdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98383,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdtgrdtyyaasvkgrftisrdnskntvylqmnslraedtavyycantnfldywgqgtlvtvss,,gfpfstda,isdtgrdt,antnfldy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98382,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesggglvqpggslrlsceasgfsfsdfvmhwvrqvpgkglewvsrishdgsitsyvdsvkgrftvsrdngkktlylqmnsprtedtavyycardlawtffdywghgtlvtvss,,gfsfsdfv,ishdgsit,ardlawtffdy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98381,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,gasvssdhw,vyhsgst,atmwgglctasncygnpmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98380,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsgtlsltcavtgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,gasvssdhw,vyhsgst,atmwgglctasncygnpmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98379,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,gasvssdhw,vyhsgst,atmwgglctasncygnpmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98378,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvklscrasggtfhtytvnwvrqapgqglewlggiipifgtptyaqrfqgkvsitadsstntvfmeltsltsedtavyyctretgtdefdfwgqgalvtvss,,ggtfhtyt,iipifgtp,tretgtdefdf,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98377,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlqesgpgllkpsetlsltctvsgspiasnywswvrqpagkglewigridtspttdynpslksrvimsvdtstsqfslkmssvtaadtavyyctrsfisfdssghpyyyyamdvwgqgttvtvss,,gspiasny,idtsptt,trsfisfdssghpyyyyamdv,,,,IGHJ6*01 (human),IGHV4-4*07 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98376,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdsgrdtyyaasvrgrftisrdnskntvylqmnslrvedtavyycantnfldywgqgtlvtvss,,gfpfstda,isdsgrdt,antnfldy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98375,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgptlvkptqtltltctfsgfslttrrqgvgwlrrppgkalewlaliywdddkryspslksrltitkdtsknhvvlsltnvgpadtatyycahtselpprrpyaafdfwgqgtlvtvss,,gfslttrrqg,iywdddk,ahtselpprrpyaafdf,,,,IGHJ5*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98374,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,,gfifknep,irdngndv,vrdtdwafds,,,,IGHJ5*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98373,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaemkkpgeslkisckgsgysfpnywigwvrqmpgkglewmaimwpsdsdtryspsfqgqvtisadtststvylqwgslkasdtamyycvrqrycsggscflfedafeiwgqgtmvtvss,,gysfpnyw,mwpsdsdt,vrqrycsggscflfedafei,,,,IGHJ3*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98372,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggglvqpggslrlscsasgftfntyamhwvrqapgkrleyvssitrdgagkfyadsvkgrftisrdnskntlyqqmsslrpedtavyycvregqqwlglyfdhwgqgalvtvss,,gftfntya,itrdgagk,vregqqwlglyfdh,,,,IGHJ1*01 (human),IGHV3-64*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98371,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggnvvqpggslrlscvgsefsitffamqwvrrtpgkglewvalvshdgsnirysdsvkgrfiisrdnakntlylqldsltpedtgiyycardhalqngrpgyfdswgqgsqvtvss,,efsitffa,vshdgsni,ardhalqngrpgyfds,,,,IGHJ5*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98370,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,,gftfsdhy,isssgsfi,armgpygsgtfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98369,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfrgfywtwirqppgkglewigevshsgetnynpslksrvtisvdtsknqfslnlisvtaadtsvyycargytapiirevpitfrprwfdpwgqgtpvtvss,,ggsfrgfy,vshsget,argytapiirevpitfrprwfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98368,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmswvrqapgkglewvsghdggtthyadsvkgrftisrddsmntlslqmnslraedtavyycakerdlpgrggyfdhwgqgtlvtvss,,gftfssys,hdggtt,akerdlpgrggyfdh,,,,IGHJ1*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98367,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfsnyamywvrqapgkrpeyvsgissnggityyadsvegrftvsrdnskkslylqmsslrpedtavyycvkdlgatvtydvfdvwgqgtmvtvss,,gftfsnya,issnggit,vkdlgatvtydvfdv,,,,IGHJ3*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98366,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,,ggmfsdya,impglgsp,ardpsilntgnhhwydldm,,,,IGHJ3*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98365,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,gdtfstha,iiplfgta,vrdsdpytatsrnnhywygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98364,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscltsgfsfssywmiwvrqapgkglewvaniepdgneeyyvdsvkgrftisrdnaknslylqmnslraedtavyycargpirhfgldafdiwgqgttvtvss,,gfsfssyw,iepdgnee,argpirhfgldafdi,,,,IGHJ3*02 (human),IGHV3-7*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98363,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,ggmfsdya,impglgsp,ardpsilntgnhhwydldm,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98362,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,,ggmfsdya,impglgsp,ardpsilntgnhhwydldm,,,,IGHJ3*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98361,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsqhaqrfqarvkftadestntaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwghgttvtvss,,ggtfstha,iiplfgts,vrdsdpytatsrnnhywygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98360,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggmfrdyaiswlrqapgqrlewmggimpafgapgyaqifrgratisadvstttayleltslmpddtavyycardpsilntgnhhwydldlwgqgttvtvss,,ggmfrdya,impafgap,ardpsilntgnhhwydldl,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98359,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscvasgftlapygmqwvrqapgkglewvaflshdgshlgyvdsvkgrftisrdnskntlylemnslraedtatyycardnvvqqnadnvgyfdfwgqgslvtvss,,gftlapyg,lshdgshl,ardnvvqqnadnvgyfdf,,,,IGHJ5*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98358,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,ggmfsdya,impglgsp,ardpsilntgnhhwydldm,,,,IGHJ6*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98357,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsggglvqpggslrvscsasgftfssfamhwvrqapgkgleyvagisdnghttmyadsvkgrftisrdnskntlylqlsslrpedtavyfcvkdnvilpgaivrpqfdywgqgtlvtvss,,gftfssfa,isdnghtt,vkdnvilpgaivrpqfdy,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98356,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytttfshnhywyamdvwgqgttvtvss,,ggtfstha,iipifges,vrdsdpytttfshnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98355,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgtslrlscvasgftfstfamhwvrqapgkglewvalisfdstniryansvrgrftisrdnskntlylevdslriedtgvyycardlppldywgqgtlvtvss,,gftfstfa,isfdstni,ardlppldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98354,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvaviysdgrneyyadsvkgrftisrdnskntlhlqmnslgaadtavyycardpgpitffd,,gftfsryg,iysdgrne,ardpgpitffd,,,,IGHJ2*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98353,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggdlvkpgrslrlsctasgftigdyamtwfrqapgkglecvavirsrafggtteyaasvkgrfivsrddsnsvaflqmnslktedtavyycsrdlrrgyydsnghqqfdlwgqgtlvtvss,,gftigdya,irsrafggtt,srdlrrgyydsnghqqfdl,,,,IGHJ2*01 (human),IGHV3-49*05 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98352,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlqqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,,ggtsstha,iipifgtt,vrdgaydssgyystq,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98351,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyarkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdmwgqgttvtvss,,ggtfsnya,iipalsrv,ardpsflntgnhfwydfdm,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98350,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpglvrpsgtlsltcavsgdsisgdywctwvrqtpgkglewigkishsgsinynpslksritmsvdksknqfslklnsvtaadtamyycarvrvgashhnfwsgyytdafdiwgqgttvtvss,,gdsisgdyw,ishsgsi,arvrvgashhnfwsgyytdafdi,,,,IGHJ3*02 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98349,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpelkkpgssvrvsckasggsissyaiswvrqapgqrlewmggvlpmmgrespvqkfkdrvtiaadeststaymelrslsaedtavyycvvdttmadphnwygldvwgqgttvtvss,,ggsissya,vlpmmgre,vvdttmadphnwygldv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98348,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqlfrgrlsitadesastaymeltgltsddtamyycardpsilntgnhhwydldlwgqgttvtvss,,ggtladya,ikplhgaa,ardpsilntgnhhwydldl,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98347,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfslfhvhwvrqapgqglewmgwinphngdttfaerfqgrvaltrdtsintaymelsrltsddtavyfcardfgvryddsrqlmkycdswgqgtlvtvss,,gytfslfh,inphngdt,ardfgvryddsrqlmkycds,,,,IGHJ5*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98346,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvtvsckvsggrfsdyaiswlrqapveglewmggiiphlnkkgysqkfqdritftadeststaymelsgltsedtaiyycardptflntgnhfwyavdiwgqgttvtvss,,ggrfsdya,iiphlnkk,ardptflntgnhfwyavdi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98345,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,ggrfsdya,iiprlnrk,ardptflnsgnhfwyavdi,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98344,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,,ggtsstha,iipifgtt,vrdgaydssgyystq,,,,IGHJ1*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98343,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtqvtvss,,ggmfsdya,impglgsp,ardpsilntgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*10 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98342,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgggvvnpggslrlscvgsgftfsdyymgwirqapgkglevisyisstgsyirdadsvkgrftisrdnaensvylqmnslrgedtavyycarmgpygsgsfdywglgtlvtvss,,gftfsdyy,isstgsyi,armgpygsgsfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98341,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpelkkpgssvrvsckasggsfsnfavswvrqapgqrlewmggviprfgrseyvqkfqgrvtitvdeaastaymelsslrsedtaiyycvldttsanphnwygmdvwgqgttvtvss,,ggsfsnfa,viprfgrs,vldttsanphnwygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98340,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslrlrsvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,,ggsfsgfh,inhsgst,argslsreydfltapqngpwfds,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98339,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlqesgpglvkpsgtlsltcgvsgvsisssswwswvrqppgrglewigeispsgstsynpsfrsrltmsvdksrnqlslklssvtaadtavyycartqsndfwsgyytaafdlwgqgtmvtvss,,gvsissssw,ispsgst,artqsndfwsgyytaafdl,,,,IGHJ3*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98338,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssdwcswvrqppgkgpewiaeishsgstnynpslksrvtmsvdrsknqfslnlnsvtaadtavyycaarirgathydfwsgfwagpfdiwgqgttvtvss,,ggsisssdw,ishsgst,aarirgathydfwsgfwagpfdi,,,,IGHJ3*02 (human),IGHV4-4*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98337,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaemrkpgssvkvsckasggtfsrycfswvrqapgqrlewmggimsilgahyaqkfqgrvtftadestntaymelisltsedtavyycareepsgtyhnyygldvwgqgttvtvss,,ggtfsryc,imsilga,areepsgtyhnyygldv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98336,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglsqpggslrlscaasgftvrtycmnwvrqapgkglewvslvcgdnidyypdsvkgrfsisrddskntlllhmdslrvedtavyycaratppgggtgwpyfdfwgqgtlvtvss,,gftvrtyc,vcgdnid,aratppgggtgwpyfdf,,,,IGHJ5*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98335,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrnnhywyaldvwgpgtmvtvss,,ggtfstha,impifges,vrdsdpytatvrnnhywyaldv,,,,IGHJ3*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98334,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfstsamswvrqapgkglewvsrigggggrtkyadsvkgrftisrdnskntlylqmnslraddtavyycakcdlvryfdwlgeennwfdpwgqgtlvtvss,,gftfstsa,igggggrt,akcdlvryfdwlgeennwfdp,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98333,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsgasvtagssywgwirqppgkglewigymfssgntkynpslksrvtisadtsknqfslrlssvtaadtavyfcarvgwvryfdwskpyyyfdlwgrgtlvtvss,,gasvtagssy,mfssgnt,arvgwvryfdwskpyyyfdl,,,,IGHJ2*01 (human),IGHV4-59*02 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98332,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigevnhsgstkynpslksrvtvsvdtsknqfslrlssvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,,ggsfsgfh,vnhsgst,argslsreydfltapqngpwfds,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98331,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlslscavyggsfsgfywswirqppgkglewigeinhsgsanynpslmsrvtismdtskkqfslqlrsvtaadtavyycargqespivgvtgrwfdpwgqgtlvtvss,,ggsfsgfy,inhsgsa,argqespivgvtgrwfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98330,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98329,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevrtpgssvklsckasggtfsthafswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttvymelrslksddtaiyycvrdsdpytatyrnnhywyamdvwgqgttvtvss,,ggtfstha,iipifges,vrdsdpytatyrnnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98328,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,ggtltnya,impvshta,ardpsihytgnhhwydldi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98327,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsgypmhwvrqapgkglewvalisfdgdskyytdsvkarfaisrdnskntlflqmnslrvadtalyycarakggsysnafdywgqgtlvtvss,,gftfsgyp,isfdgdsk,arakggsysnafdy,,,,IGHJ4*01 (human),IGHV3-30*09 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98326,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckisggtfknsafswarqvpgqgfqwmggiipmfgvphsvqmfqgrvtltadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,,ggtfknsa,iipmfgvp,areeysgtvhnffgmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98325,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytatvtsnhywyamdvwgqgttvtvss,,ggtfstha,impifges,vrdsdpytatvtsnhywyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98324,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgggvvqpgrslklscvvsgfsfshygmnwvrqapgkglewvavmsydgsdkyyadsvkgrftisrdiskntlylemnslrtedtavyycakkgspycgvdcykgyfdywgqgtlvtvss,,gfsfshyg,msydgsdk,akkgspycgvdcykgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98323,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglsqpggslrlscaasgfvvknncmnwvrqapgkglewvalicadgityhsdsvtgrftiyrdesdntlhlqmdslriedtavyycvrasppggntgwpffedwgqgtlvtvss,,gfvvknnc,icadgit,vrasppggntgwpffed,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98322,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwmspntgdtgyahkfqgrvrmtsntsistaymelnsltsedtavyycarrgnnfgyyyyytvdvwgqgttvtvss,,gytfssyd,mspntgdt,arrgnnfgyyyyytvdv,,,,IGHJ6*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98321,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssmklsckasginfrsysfswvrqapgqglewmggvipyfptanyaekfrgrvtatadestgtvylemsslrsedtavyycaseyfdgrsyhsfcgldvwgqgtlvtvss,,ginfrsys,vipyfpta,aseyfdgrsyhsfcgldv,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98320,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglsrpggslrlscaasgfiasrncmqwvrqapgkglewvsiicgdeityirdsvkgrftisrddskntlhlemnslraddtavyycaratppggttgwpyidlwgqgtlvtvss,,gfiasrnc,icgdeit,aratppggttgwpyidl,,,,IGHJ2*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98319,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscrasgytfsgydinwvrqatgqglewmgwmnpnsgdtgyahkfqgrvtmtrnssistaymelssltsedtavyfcarekksfgpqyyygsgedwgqgtlvtvss,,gytfsgyd,mnpnsgdt,arekksfgpqyyygsged,,,,IGHJ1*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98318,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscsasgfsfgdyamswfrqapgkglqwvgliktraygaatdyaasvqgrfiisrddsksiaylqmnslktedtavyfcaregtslgyyyyyamdvwghgttvtvss,,gfsfgdya,iktraygaat,aregtslgyyyyyamdv,,,,IGHJ6*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98317,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssissssymyyadsmkgrftisrdnaqnslylqmsslraedtavyycardfpgdtavagtgfnywgqgtlvtvss,,gftfsdyy,issssym,ardfpgdtavagtgfny,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98316,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvrpsetlsltctvsgdsvsssdyhwgwirqppgkglewigsiyyggrshfnpslksrvaifvdtsnnqfslrlnsvtasdtavyfcagrhqellpmgsfdmwaqgttvtvss,,gdsvsssdyh,iyyggrs,agrhqellpmgsfdm,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98315,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,QXE98314,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,gftfssyy,issdgynt,ardfsghtavagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98313,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,,,,ssnigsns,sns,aawddslntfryv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98312,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,,,,ssnigagyd,gss,qsydsslsvlyt,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98311,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,,,,enilhy,das,qqranwpqn,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98310,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,,,,qsvtsny,gas,qqygraplyt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98309,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydssnratgtpdrfsasgsgteftltitrlepedsavyyclqyssattfgpgtkvdik,,,,qtvtrsq,dss,lqyssatt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98308,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspailsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydasnratgvparfsgsgfgteftltisslqsedfavyycqqynnwppltfgggtkvdik,,,,qsvrsn,das,qqynnwpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98307,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqsishylnwyqqkpgkapklliyaasnlqsgvpsrfsgngsgtdftltisslqpedfatyfcqqsystpltfgggtkvdik,,,,qsishy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98306,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqvlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkvdik,,,,qvlvhsdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98305,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,,,,qsvvhsdgnty,kvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98304,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnigndyvswyqqlpgtapklliyenykrpsgipdrfsgsksgtsatlditglqtgdeadyycgtwdsslsvdnyvfgtgtkltvl,,,,ssnigndy,eny,gtwdsslsvdnyv,,,IGLJ1*01 (human),IGLV1-51*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98303,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytmwtfgqgtkveik,,,,qsvlyssnnkny,was,qqyytmwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98302,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspsslsasvgdrvtitcrasqdisswlawyqqksgkapksliyaasslqngvpsrfsgsrsgtdftltisslqpedlgtyycqqydsypvtfgqgtrleik,,,,qdissw,aas,qqydsypvt,,,IGKJ5*01 (human),IGKV1D-16*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98301,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkvdik,,,,eniahy,das,qqrsnwpqn,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98300,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsatpgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsrlsavvfgggtkltvl,,,,ssnignny,dnn,gtwdsrlsavv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98299,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqaasiscrssqavvhsdgntylnwfqqrpgqpprrliykvsnrdsgvpdrfsgsgsgtvftlkisrveaedigvyycmqgtewprtfgqgtkveik,,,,qavvhsdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98298,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydafnratgvparfsgsgsgtdftltisslepedfavyycqqrtstltfgggtkvdik,,,,qsvssy,daf,qqrtstlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98297,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkveik,,,,qiamhsdgnty,kis,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98296,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqspgtlslspgervtlscrasqsissnylawyqqkpgqaprllisdassratgipdrfsgsgsgadftliisrlepedfavyfchqyggspttfgqgtkveik,,,,qsissny,das,hqyggsptt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98295,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpgltqpasvsgspgqsitisctgtsgdvgsdnlvswyqrhpgkapklmiyegskrpsgvshrfsgsnsgntasltisglqaeddadyyccsyagddtvvfgggtkltvl,,,,sgdvgsdnl,egs,csyagddtvv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98294,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasisctssqtvvhtdrntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgvyycmqgtewprtfgqgtkleik,,,,qtvvhtdrnty,kvs,mqgtewprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98293,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkveik,,,,qsvvhsdgnty,kvs,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98292,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslsvtlgqaasisctcsqsavhsdgttyfnwfhqrpgqsprrliykvsnrdsgvpdrfigsgsgthftlkisrveaedvgvyycmqttdwprtfgqgtkveik,,,,qsavhsdgtty,kvs,mqttdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98291,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,,,,qrvvhtdgnty,kvs,mqatewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98290,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlssspgeratlscrasqsvssrylawyqqkpgqaprlliygtsnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgpgtkleik,,,,qsvssry,gts,qqygssyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98289,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqtpsslsasvgdrvtitcrasqsisnyvnwyqqkpgrapnlliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqtystppegptfgpgtkveik,,,,qsisny,aas,qqtystppegpt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98288,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,givltqspdslavsvgeratinckssqtvlyssknkhylawyqqkpgqppklltsspstrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgqgtkvdik,,,,qtvlyssknkhy,sps,qqyyttpyt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98287,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,,,,qsvvhsdgnty,kvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98286,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,,,,qrivhtdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98285,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdsvtitcrasqsisnylnwyqdkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysdswtfgqgtkvdik,,,,qsisny,aas,qqsysdswt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98284,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlrpedsatyyckqynsypytfgqgtkleik,,,,qgistf,aas,kqynsypyt,,,IGKJ2*01 (human),IGKV1-16*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98283,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqvtqspatlsvspgervtlscrasqsisntlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynkwppitfgggtkveik,,,,qsisnt,gas,hqynkwppit,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98282,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspaslsasvgdrvtitcragqsistnlcwyqqrqgkapklliyaasslrsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvdik,,,,qsistn,aas,qqsystppt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98281,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkvdik,,,,qtavhsdgnty,kvs,mqttdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98280,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslavtlgqpasiscrsslglvhtngntylnwfqqrpgqsprrliyrvsnrdsgvpdrfsgsgsvtdftltisrveaedigvyycmqgtewprtfgqgtkveik,,,,lglvhtngnty,rvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98279,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspsslsasvgdrvtitcrasqaiagwlawyqqkpgrapksliyrasslqsgvpsrfsgsgsgtdfsltisnlqpedsatyycqhydsyptafgqgtrleik,,,,qaiagw,ras,qhydsypta,,,IGKJ5*01 (human),IGKV1D-16*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98278,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspsslsasvgdrvnitcrasqsistyltwyqqkpgkapklliygasslhsgvpsrftgvgsgteftlsisslqpedfatyycqqsyntfftfgggtkvdik,,,,qsisty,gas,qqsyntfft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98277,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,,,,ssnigsns,sns,aawddslntfryv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98276,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplflpvtlgqpasiscrssqrlvhtngntylnwfqqrpghsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgggtkleik,,,,qrlvhtngnty,qvs,mqgtewprt,,,IGKJ4*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98275,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgspgqsvsiscsgtssdfgnynriswyqqtpgtapkviiyevnsrpsgvpdrfsgsksgntasltitglqaedeadyyccsyrsdntyifgggtkvtvl,,,,ssdfgnynr,evn,csyrsdntyi,,,IGLJ1*01 (human),IGLV2-18*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98274,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaliqprsvsgspgqsvtisctgtssdvggsnyvswyqqhpgkapkllvydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagtyifgtgtkltvl,,,,ssdvggsny,dvt,csyagtyi,,,IGLJ1*01 (human),IGLV2-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98273,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaliqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssyisdiklvvfgggtkltvl,,,,ssdvgryny,dvs,ssyisdiklvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98272,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqspsslsasvgdrvtitcrasqgfgnkvawyqqkpgtapklliyetstlqsgvpsrfsgsgsgtefaftisslqpedgatyycqkynrapwtfgqgtkveik,,,,qgfgnk,ets,qkynrapwt,,,IGKJ1*01 (human),IGKV1-27*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98271,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsgaprqkvtiscsgssaniasngvnwyqqlpgkapklliyyddlvssgvsdrfsgsksgtsaslaisglqsedeadyycatwddilngpvfgggtkltvl,,,,saniasng,ydd,atwddilngpv,,,IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98270,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeraalscrasqivtrsqlawyqhkpgqpprlliydsssratgtpdrfsgsgsgtdftltisrlepedsavyychqysgsatfgpgtkveik,,,,qivtrsq,dss,hqysgsat,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98269,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkveik,,,,qtavhsdgnty,kvs,mqttdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98268,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqivvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,,,,qivvhsdgnty,kvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98267,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcrasqsisyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfiltisslqpediatyycqhsyssppltfgggtkveik,,,,qsisyy,aas,qhsysspplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98266,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqtpsslsasvgdrvtitcrasqtiatylswyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsysipwtfgqgtkvdik,,,,qtiaty,avs,qqsysipwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98265,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspatlslspgegatlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdytltisslepedfavyychqrsnwpytfgqgtkveik,,,,qsvsss,das,hqrsnwpyt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98264,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvspgqtaritcsadglpkqysywyqqkpgqapvmviykdterpsgiperfsgsssgttatltisgvqaedeadyycqsadsndsspvfgggtqltvl,,,,glpkqy,kdt,qsadsndsspv,,,IGLJ7*01 (human),IGLV3-25*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98263,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqsplslpvtlgqpasiscrssqfvvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqatewprtfgqgtkvdik,,,,qfvvhtdgnty,kvs,mqatewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98262,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,,,,qrivhtdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98261,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,,,,qtvvhsvdgnty,kvs,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98260,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,,,,qrivhtdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98259,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslpvglgqsasiscrssqwvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,,,,qwvvhtdgnty,kvs,mqatewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98258,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgttsdvggydyvswyqqrpgkapkliiydvinrpsgvsnrfsgsksgntasltisglqaddetdyycssytsggtlvfgtgtkltvl,,,,tsdvggydy,dvi,ssytsggtlv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98257,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkleik,,,,qsindy,das,qqrfswyn,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98256,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitiscavtssdvgsynlvswhqqhpgkapklmiyevnkrpsgvsnrfsgsksgntasltisglqaedeavyyccsyggrstsvvfgggtkltvl,,,,ssdvgsynl,evn,csyggrstsvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98255,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkveik,,,,qsindy,das,qqrfswyn,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98254,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplflpvtlgqpasisctssvhvvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtyftlkisrveaedvgvyycmqgtdwprtfgqgtkvdik,,,,vhvvhsdgnty,kvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98253,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslpvtlgqaasiscksshfivhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftleisgveaedvgvyycmqgtewprtfgqgtkvdik,,,,hfivhtdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98252,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsiniylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystplitfgqgtrleik,,,,qsiniy,aas,qqsystplit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98251,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvsrgqsasiscrsshsvvhsdgktyvnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgfdftlkisrveaedvgvyfcmqgtdwprsfgggtkvdik,,,,hsvvhsdgkty,qvs,mqgtdwprs,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98250,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvslgqpasiscrssqsvihtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,,,,qsvihtdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98249,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspgtlsvspgeratlscrasqsvisnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltiaslqsedfavyycqqyhhwppytfgqgtkvdik,,,,qsvisn,gas,qqyhhwppyt,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98248,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqspstlsasvgdrvtitcrasqtigswlawyqqkpgkapnlliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynslytfgqgtkleik,,,,qtigsw,kas,qqynslyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98247,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslsvtlgqaasiscrpnlglmhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfagsgsgthftleisgveaddvgvyycmqgtewprtfgqgtkleik,,,,lglmhtdgnty,kvs,mqgtewprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98246,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,,,,hsvssn,gas,qqynywpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98245,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiannyvqwlqqrpgsspttiiyednqrpsgvpdrfsgsidassnsasltisglktedeadyycqsydsssqvfgggtkvtvl,,,,sgsianny,edn,qsydsssqv,,,IGLJ1*01 (human),IGLV6-57*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98244,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqspsasaslggsvkltctltsghstyaiawhqqqpekgprflmklnsdgshnkgdgipdrfsgsssgaeryltisslqsedeadyychtwgtdiqvfgggtkltvl,,,,sghstya,lnsdgsh,htwgtdiqv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98243,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvgtylawyqqkhgqaprllisdvskratgiparfsgsgsgtdftltitslepedfavyycqqrtnwpgatfgpgtkvdik,,,,qsvgty,dvs,qqrtnwpgat,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98242,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqktgkapelliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyrfpitfgqgtrleik,,,,qsisty,vas,qqsyrfpit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98241,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,,,,hsvssn,gas,qqynywpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98240,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcrasrsissylnwyqqkpgkapnlliydastlqsgvpsrfsgsgsgtdfsltisslqpedfatyyclhtyttprtfgqgtkveik,,,,rsissy,das,lhtyttprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98239,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasgtpgqrvtiscsgsysnigtnpanwyqqlpgtapklliynndqrpsgvpdrfsgsksgtsaslaisglqsedetdyycatwddslngvvfgggtkltvl,,,,ysnigtnp,nnd,atwddslngvv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98238,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgvtfgggtkvdik,,,,qsllhsngyny,lgs,mqalqtpgvt,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98237,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsamsasvgdrvtitcrasqgindnlawfqqkpgkvpkrliyaasnlqngvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,,,,qgindn,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98236,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqsssasaslgssvkltctlrsghssyiiawhqqqpgkaprflmkvghsgsynkgsgvpdrfsgsrsgadhyltisnlqpddeadyyceawdnnnlgvfsggtkvtvl,,,,sghssyi,vghsgsy,eawdnnnlgv,,,IGLJ1*01 (human),IGLV4-60*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98235,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqsssasaslgssvkltctlssghssyilawhqqqpgkaprflmkfevggrynkgsgvpdrfsgsssgadryltisnlqsedeadyycetwdsnlkgvfgggtkvtvl,,,,sghssyi,fevggry,etwdsnlkgv,,,IGLJ1*01 (human),IGLV4-60*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98234,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtpgtlsvspgeratlscrasqiinrsqlgwyqhkpgqpprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkveik,,,,qiinrsq,dss,lqyslatt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98233,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspatlslspgeratlscranqsvsnflawyqqkpgqaprhliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,,,,qsvsnf,das,qqrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98232,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyyclqrsdwhpitfgqgtrleik,,,,qsvsty,das,lqrsdwhpit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98231,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,,,,qsvlyssnnkny,was,qqyystpyt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98230,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvliqpasvsgspgqsitisctgsssdvgsynlvswyqqhpgkapklmiyegykrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagssavvvvfgggtkltvl,,,,ssdvgsynl,egy,csyagssavvvv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98229,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtmatltisgaqvedeadyycystdstanykvfgggtkltvl,,,,alprry,edn,ystdstanykv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98228,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvifgpgtkveik,,,,qsvsiy,das,qqrakwpprvi,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98227,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvtfgpgtkvdik,,,,qsvsiy,das,qqrakwpprvt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98226,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqvtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkaptlliytasnlqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystpgfgpgtkvdik,,,,qsisss,tas,qqsystpg,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98225,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqvtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqqrsdwhpitfgqgtrleik,,,,qsvssy,das,qqrsdwhpit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98224,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykassletgvpsrfsgsgsgteftltisslqpddfatyycqqyksplsfgggtkveik,,,,qsissw,kas,qqykspls,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98223,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqglvhtngnlylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgiyycmqgtewprtfgqgtkveik,,,,qglvhtngnly,qvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98222,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsvsaapgqkvtiscsgsssniennyvswyqqlpgaapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdfslsagvfgggtkltvl,,,,ssnienny,dnn,gtwdfslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98221,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divvtqspgtlslspgeraalscrasqsvgnnylawyqqkpgqaprlliygatsratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,,,,qsvgnny,gat,qqygtspvyt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98220,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,,,,qsvlyssnnkny,was,qqyystpyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98219,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspvtlpvtlgqpasisctssrwlvhtngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlqisrveaedvgvyycmqgtewprtfgqgtkleik,,,,rwlvhtngnty,qvs,mqgtewprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98218,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkinrveaedvgiyycmqttdwprtfgqgtkveik,,,,qtavhsdgnty,kvs,mqttdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98217,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkleik,,,,qrvvhtngnty,kvs,mqatdwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98216,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,,,,qsvgrf,das,qrrgdgyn,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98215,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgdrvtlfcrasqniannhlawyqqkpgqaprvliygasttatdipdrfsgrvsgtdftltisrldpedfavyychqygsspwtfgqgtkleik,,,,qniannh,gas,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98214,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsstlscsgtssdvgsydlvswyqqhpgkapklmiyegtkrpsgvsdrfsgstsgntasltisglqaedeanyyccsyagsgtwifgggtkltvl,,,,ssdvgsydl,egt,csyagsgtwi,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98213,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcraghtistylnwyqqkpgkapkilisgasslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsystpytfgqgtkvdik,,,,htisty,gas,qqsystpyt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98212,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,,,,qrivhtdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98211,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqglvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,,,,qglvhsdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98210,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,,,,qsvgrf,das,qrrgdgyn,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98209,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedqadyycystdstanykvfgggtkltvl,,,,alprry,edn,ystdstanykv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98208,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,,,,qsvstf,das,qqrsdgyn,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98207,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqvtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,,,,qrvvhtdgnty,kvs,mqatewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98206,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspvtlsvspgeratlscrasqsvisnlawyqqkpgqaprllifgastratgvparfsgsgsgteftltisslqsedfavyycqqynnwpsltfgggtkleik,,,,qsvisn,gas,qqynnwpslt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98205,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqsplslpvglgqsasiscrssqrvvhtdgntylhwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqgtewprtfgqgtkleik,,,,qrvvhtdgnty,kvs,mqgtewprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98204,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqsplslpvglgqsasiscrssqrvvhtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqstdwprtfgqgtkleik,,,,qrvvhtdgnty,kvs,mqstdwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98203,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,,,,qtvvhtngnty,evs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98202,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspatlsvspgeratlscrasqsvtkhlawyqqkpgqaprlliygastratgvparfsgsgsdtefsltisslqsedfavyycqqyyswppltfgggtkleik,,,,qsvtkh,gas,qqyyswpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98201,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtnsdisnsysvswyqqypgkapklvifdvinrpsgvsnrfsgsksgntasltisglqaddeadyyccsytrtntpvlfgggtkltvl,,,,nsdisnsys,dvi,csytrtntpvl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98200,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,,,,qsvlyssnnkny,was,qqyystpyt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98199,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaliqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,,,,sstfgtdnh,avs,csspgtitwv,,,IGLJ3*02 (human),IGLV2-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98198,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqtplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkvdik,,,,qiamhsdgnty,kis,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-24*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98197,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapkltvydvrnrpsgvsnrfsgsksgntasltisglqaedeahyycssytstntvfgggtkltvl,,,,ssdvgayny,dvr,ssytstntv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98196,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,,,,qsvstf,das,qqrsdgyn,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98195,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcrasqdisnylawyqqkpgkapklliyaastlqsgvplrfsgsgsgtdftltisslqpedfatyyclqlhnyssfgggtkvdik,,,,qdisny,aas,lqlhnyss,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98194,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslpvtlgqpasisctssqdvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedagiyycmqgtdwprtfgqgtkvdik,,,,qdvvhtdgnty,kvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98193,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsgwtfgqgtkveik,,,,qsissw,kas,qqynsgwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98192,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgtssdvgsfnyvswyqqhpgkapklviydvynrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,,,,ssdvgsfny,dvy,ssytssstlyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98191,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,,,,qtvvhsvdgnty,kvs,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98190,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvslgqpasiscrssqsvvhtdgntylnwyqqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvavyycmqgtewprtfgqgtkvdik,,,,qsvvhtdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98189,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrsshslvhtngntylnwfqqrpgqpprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaddvgiyycmqgtdwprtfgqgtkvdik,,,,hslvhtngnty,qvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98188,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlfssnnknylawyqqkpglppklliywastrksgvsdrfsgsgsgtdftltisslqaedvavyycqqyyttplftfgpgtkvdik,,,,qsvlfssnnkny,was,qqyyttplft,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98187,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqtplslpvtlgqpasiscrssqfvshtdgntylnwfqqrpgqsprrliykvskrdsgvpdrfsgsgsgtdftltisrveaedvgvyycmqatewprtfgqgtkveyq,,,,qfvshtdgnty,kvs,mqatewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98186,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkigqppklliywasiresgvpdrftgsgsgtdftltisslqaedvavyycqqyystpptfgggtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98185,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqsplslsvtpgqpasiscrssqslqhtdgktylywylqkpgqspqlliyelfnrfsgvperfsgsgsgtdftlkisrveaedvgiyycmqsiqtpitfgqgtrleik,,,,qslqhtdgkty,elf,mqsiqtpit,,,IGKJ5*01 (human),IGKV2D-29*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98184,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvvtqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydsdkrpsgiperfsgsksatsatlgitglqtgdeadyycetwddslsavvfgggtkltvl,,,,ssnignny,dsd,etwddslsavv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98183,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlqpedsatyyckqynsypytfgqgtkleik,,,,qgistf,aas,kqynsypyt,,,IGKJ2*01 (human),IGKV1-16*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98182,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratniparfsgsgsgteftltisslqsedfavyycqqynlwpytfgqgtkvdik,,,,qsvssn,gas,qqynlwpyt,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98181,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplalsvtpgqpasisckssqsllhsdgktyfywylqkpgqsphlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqvpitfgggtkleik,,,,qsllhsdgkty,evs,mqsiqvpit,,,IGKJ5*01 (human),IGKV2D-29*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98180,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkvdik,,,,qglvhsdgniy,kvs,mqathwpra,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98179,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqpsslsaspgasasltctlhsgfnvgdhtinwyqqrpgsppryllkyksdsdkeqgsgvpirfsgskdasanagfllisglrsedeadyycmiwhdnavvfgggtkltvl,,,,sgfnvgdht,yksdsdk,miwhdnavv,,,IGLJ2*01 (human),IGLV5-45*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98178,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,,,,alprry,edn,ystdstanykv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98177,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,,,,alprry,edn,ystdstanykv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98176,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkvtvl,,,,alprry,edn,ystdstanykv,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98175,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliyeasnratgvparfsgsgsgtdftlaisslepedfavyycqhrsnwpprytfgqgtkveik,,,,qsvsss,eas,qhrsnwppryt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98174,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgervtlscratqsvsnnhlawyqqkpgqaprlliygasttatdipdrfsgrvagtdftltisrldpedfavyychqygsspwtfgqgtkveik,,,,qsvsnnh,gas,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98173,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkleik,,,,qglvhsdgniy,kvs,mqathwpra,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98172,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgvprqkvtiscsgstaniasngvnwyqlvpgkaprllisyddlvpsgvsarfsgsksgtsaslaisglqaedeadyycatwddilngpvfgggtkltvl,,,,taniasng,ydd,atwddilngpv,,,IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98171,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,,,,sstfgtdnh,avs,csspgtitwv,,,IGLJ3*02 (human),IGLV2-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98170,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspstlsasvgdrvtitcrasqnvnnwlawyqqkpgkapklliyeastlksgvpsrfsgsgsgteftltisslqpddfatyycqqynsqytfgqgtkvdik,,,,qnvnnw,eas,qqynsqyt,,,IGKJ3*01 (human),IGKV1-5*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98169,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqspsslsasvgdrvtitcrasqtinnylnwyqqkpgkapnlliyaastlqngvpsrfsgsgsgtdftltissvqpedfatyycqqtyitptwtfgqgtkveik,,,,qtinny,aas,qqtyitptwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98168,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspatlslspgeratlscraspsvftflawyqqrpgqpprllihdvsnrapgiparfsgsgsgtdftliisslepddsavyfcqqrsdgynfgpgtkvdik,,,,psvftf,dvs,qqrsdgyn,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98167,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlsvspgeratlscrasqiinrsqlgwyqhkpgqaprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkvdik,,,,qiinrsq,dss,lqyslatt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98166,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgtssdvgnynvvswyqqhpgkapqlfiyedtkrpsgvsdrfsgsksgitasltisrlqpedeadyyccsyavsgtvlfgggtkvtvl,,,,ssdvgnynv,edt,csyavsgtvl,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98165,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspdslalslgeratinckssqsvlfssnnnnylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyltpwtfgqgtkvdik,,,,qsvlfssnnnny,was,qqyyltpwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98164,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirvtqspsslsatvgdrvtitcrasqtitkylnwyqqkpgkapklllygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitpgtfgqgtrleik,,,,qtitky,gas,qqtyitpgt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98163,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslpvdlgqsasiscrssqtvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkvdik,,,,qtvvhtngnty,kvs,mqatdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98162,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,,,,qtvvhtngnty,evs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98161,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpgltqpasvsgspgqsitisctrtsgdvgdynsvswyvswyqqhpgrapklmlydvsnrpsgvsnrfsgsklgdtasltiselqaedeadyycstytststifgggtkltvl,,,,sgdvgdynsvswy,dvs,stytststi,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98160,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,,,,qrvvhtngnty,kvs,mqatdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98159,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvdlgqsasiscrssqtavhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrinrveaedvgvyycmqatdwprtfgqgtkleik,,,,qtavhtngnty,kvs,mqatdwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98158,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkleik,,,,qsvvhsdgnty,kvs,mqgtdwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98157,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,,,,qrvvhtdgnty,kvs,mqatewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98156,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,cirltqspatlslspgeratlscrasqsvtsylawyqqrpgqaprlliydtsnrvtgvpvrfsgsgygtdftltisslepedfavyycqqrgngytfgpgtkveik,,,,qsvtsy,dts,qqrgngyt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98155,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,,,,qrvvhtngnty,kvs,mqatdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98154,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspasvsasvgdrvtiscrasqgigrwlawyqqkpgrapkllifsasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaesfpftfgggtkveik,,,,qgigrw,sas,qqaesfpft,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98153,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrssqrlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,,,,qrlvhsdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98152,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqspfslsasvgdrvtitcrasqgfgnrlawyqqkpgrapklliydastlqsgvpsrfsgsgsetdfaltisslqpedvatyycqkhdrdpwtfgqgtkveik,,,,qgfgnr,das,qkhdrdpwt,,,IGKJ1*01 (human),IGKV1-27*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98151,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpgltqepsltvspggtvtltcgssagavtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeaeyfcflsyrgappvfgggthltvl,,,,agavtsghy,dtn,flsyrgappv,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98150,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspatlslspgeratlscrasqsigyylawfqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqhrtnwpytfgqgtkveik,,,,qsigyy,das,qhrtnwpyt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98149,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqtpatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkveik,,,,qsvsnf,das,qqrrnwppmyt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98148,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqsplslpvtlgqpasisctssqnvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgiyycmqgtdwprtfgqgtkveik,,,,qnvvhtdgnty,kvs,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98147,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspgtlslspgeratlscrasqsvgnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,,,,qsvgnny,gas,qqygtspvyt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98146,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqtplslpvtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliyqvshrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkvdik,,,,hglvhtngnty,qvs,mqgtdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98145,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqsplslpvtlgqaasiscrssqpiphtdgntylnwfhqrpgqsprrlihkvsnrdsgvpdrfsgsgsgldftleisgveaedvgiyycmqgtewprtfgqgtkveik,,,,qpiphtdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98144,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgkaviisctrssgniasnfvqwyqqrpgssptpviyedklrpsgvpdrfsgsidrssnsasltisglktedeadyycqsydsgnlvvfgggtkltvl,,,,sgniasnf,edk,qsydsgnlvv,,,IGLJ2*01 (human),IGLV6-57*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98143,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslsvtlgqaasisctcsqsavhsdgntyfnwfhqrpgqsprrliykvsnrdsgvperfsgsgsgthftliisrveaedvgvyycmqttdwprtfgqgtkvdik,,,,qsavhsdgnty,kvs,mqttdwprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98142,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkleik,,,,qtavhsdgnty,kvs,mqttdwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98141,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkleik,,,,qsvsnf,das,qqrrnwppmyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98140,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,,,,qrvvhtdgnty,kvs,mqatewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98139,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydsskratgspdrfsasgsgtdftltisglepedtgiyyclqysdattfgpgtkleik,,,,qtvtrsq,dss,lqysdatt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98138,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslavtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkveik,,,,hglvhtngnty,kis,mqgtdwprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98137,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsvsaapgqkvtiscsgsssnigdnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdtslsvvvfgggtkltvl,,,,ssnigdny,dnn,etwdtslsvvv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98136,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeraslscrasqsvsssylawyqhrpgqaprlliydassratgipdrfsgsgsgtdftltisrlesedfavyycqqygnsprtfgqgtkvdik,,,,qsvsssy,das,qqygnsprt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98135,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqspgtlslspgeratlscrasqsigssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsaplytfgqgtkveik,,,,qsigssy,gas,qqygsaplyt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98134,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslpvtlgqpasiscrssqslvhsngntylnwfqqrpgqsprrliyevsnrdsgvpdrftgsgsgtdftlkisrveaedvgvyycmqgthwprsfgggtkveik,,,,qslvhsngnty,evs,mqgthwprs,,,IGKJ4*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98133,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqvtqspatvsvspgegaslscrasqsvrsnlawfqqkpgqaprllisdastrasgvparftgsgfgteftltisslqsedfaiyycqqyntwppltfgggtkveik,,,,qsvrsn,das,qqyntwpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98132,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqsplslpvtlgqpasiscrssqhlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkveik,,,,qhlvhsdgnty,kvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98131,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpetapklliyangnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvlfgggtkltvl,,,,nsnigagyd,ang,qsydsslsgvl,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98130,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqlpgtapklliydnnnrpsgvpdrfsgsrsgtsaslaitglqaedegdyfcqsydsslsasfgggtkvtvl,,,,ssnigagyy,dnn,qsydsslsas,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98129,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnlgnnyvswyqqlpgtapklliydnhkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdsslsvvvfgggtkvtvl,,,,ssnlgnny,dnh,etwdsslsvvv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98128,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsvtisctgtssdvgsysdvgnyvswyqhhpgkapklmiyevrtrpswvstrfsgsksgttasltisglqaedeadyyccsyagaspfvvfgggtkltvl,,,,ssdvgsysdvgny,evr,csyagaspfvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98127,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,etgltqipfslpvtfgqpasiscrfsqrlvhtdgntnlnwflqrpgqfprgliykvfnrdsgvpdrfrgsgsgidftlkisrvevedvgiyygmqgtewlgtfgqgtkveik,,,,qrlvhtdgntn,kvf,mqgtewlgt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98126,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqsplslpvtlgqpasiscrsslrlvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,,,,lrlvhtdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98125,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,,,,qrivhtdgnty,kvs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98124,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqsvlyssnnenclawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqycstppytfgqgtkvdik,,,,qsvlyssnnenc,was,qqycstppyt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98123,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirmtqsplslpvtrgqpasiscrsshnvvhsdgktylnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgsdftltisrveaedvgvyycmqgtdwprsfgggtkveik,,,,hnvvhsdgkty,qvs,mqgtdwprs,,,IGKJ4*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98122,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqglvhsngntyvnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,,,,qglvhsngnty,evs,mqgtewprt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98121,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcqasqdirkclnwyqhipgkapkllihdasslesgvpsrfsgsgsgtdfsftinslhpediatyycqqfedlpitfgqgtrleik,,,,qdirkc,das,qqfedlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98120,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqtpatlsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydastratgvparftgsgsgtyftltisslqsedfavyycqqynswppltfgggtkleik,,,,qsvrsn,das,qqynswpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98119,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,dirltqspsslsasvgdrvtiacrasqsvsnylnwyqqkpgkapklliyaasslqngvpsrfggsgsgtdftltisslqpedfatyycqqcysypptfghgtkveik,,,,qsvsny,aas,qqcysyppt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98118,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,ettltqsplslpvtlgqpasiscrssqglahsngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,,,,qglahsngnty,qvs,mqgtewprt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98117,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgdgaslscrasqsvgsnlawyqqkpgqaprllisdasaratgvparftgsgsgtdftltisslqsedfavyychqyntwppltfgggtkleik,,,,qsvgsn,das,hqyntwpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98116,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcrasqsisnylywyqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpynfgqgtkvdik,,,,qsisny,vas,qqsystpyn,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98115,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqtpsslsasvgdrvtitcrasqtisyylnwyqqkvgkapqllvyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysvpltlgqgtkvdik,,,,qtisyy,aas,qqsysvplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98114,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqvpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsvlyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98113,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasigdrvtiscrasqnigsylnwyqqrpgkapnllifvasslqsgvpsrfsgsgsgtdftltisslqaedfatyycqqsyttpitfgqgtrleik,,,,qnigsy,vas,qqsyttpit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98112,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkveik,,,,eniahy,das,qqrsnwpqn,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,QXE98111,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,,,,ssnigagyd,gss,qsydsslsvlyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,QXE98038,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapycsggscfdgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,QXE98037,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapncsnvvcydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,QXE98036,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,,gftfssya,isydgsnq,ardlaiavagtwhyyngmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,QXE98035,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,,gftlssyg,isydgsnk,argwaywellpdyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,N/A,QXE98042,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,,,,qsvsssy,gas,qqygnspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,N/A,QXE98041,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,,,,qsvsssy,sas,qqygtspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,N/A,QXE98040,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,,,,qgissw,das,qqaksfpit,,,IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,,,N/A,QXE98039,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,,,,sgsvstayf,gtn,vlymgrgivv,,,IGLJ2*01 (human),IGLV8-61*01 (human)
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23469,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gfdfsrfa,inlhgdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23468,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlygdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23467,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlygdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23466,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23465,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmrsvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gfdfsrfa,inlwgdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23464,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlhgdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlhgdsk,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23463,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlygdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23462,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlygdsk,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23461,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23460,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23459,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsk,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23458,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23457,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,gftfssyy,isedgynt,ardfsghtavagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23456,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,gftfssyy,isedgynt,ardfsghtavagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23455,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggdlvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,,gftfssyy,isedgynt,ardfsghtasagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23454,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,gftfssyy,isedgyst,ardfsghtawagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23453,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslgaddtavyycardfsghtawagtgfeywgqgtlvtvss,,gftfssyy,isedgynt,ardfsghtawagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23452,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssisedgynpyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,gftfsdyy,isedgynp,ardfsghtawagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23451,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpflgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23450,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpflgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23449,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnnlrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpflgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23448,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlwgdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23447,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdsk,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23446,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyttyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,,gftfssyy,issdgytt,ardfsghtasagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23445,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsayymnwvrqapgkglewvssissdgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,gftfsayy,issdgyst,ardfsghtawagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23444,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgtmvtvss,,gfpfkgty,iysggdt,ardremaiitertygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23443,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfplrgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfplrgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23442,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysdgdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpflgty,iysdgdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23441,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpfkgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23440,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,gfpfsgty,iysggdt,ardremaiitersygldv,,,,IGHJ3*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23439,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gftfsrfa,inlngdst,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,QQP23438,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,gftfssyy,issdgynt,ardfsghtavagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 828 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47405,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 828 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 824 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47403,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 824 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 810 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47397,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 810 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 808 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47396,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 808 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 804 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47394,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 804 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 796 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47390,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 796 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 794 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47389,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 794 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 790 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47387,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 790 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 780 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47382,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 780 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 778 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47381,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 778 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 774 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47379,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 774 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 764 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47374,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 764 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 762 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47373,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 762 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 759 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47372,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 759 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 757 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47371,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 757 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 753 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47369,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 753 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 751 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47368,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 751 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 747 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47366,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 747 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 737 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47361,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 737 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 735 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47360,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 735 from patent US 10975139,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 731 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47358,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 731 from patent US 10975139,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 723 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47354,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 723 from patent US 10975139,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 721 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47353,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 721 from patent US 10975139,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 717 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47351,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 717 from patent US 10975139,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 708 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47347,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 708 from patent US 10975139,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 706 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47346,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 706 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 704 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47345,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 704 from patent US 10975139,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 702 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47344,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 702 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 700 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47343,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 700 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 698 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47342,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 698 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 696 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47341,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 696 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 692 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47339,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 692 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 678 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47332,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 678 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 674 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47330,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 674 from patent US 10975139,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 658 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47323,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 658 from patent US 10975139,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 654 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47321,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 654 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 640 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47315,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 640 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 636 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47313,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 636 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 624 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47308,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 624 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 620 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47306,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 620 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 608 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47300,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 608 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 604 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47298,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 604 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 594 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47293,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 594 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 592 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47292,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 592 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 588 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47290,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 588 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 574 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47284,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 574 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 572 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47283,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 572 from patent US 10975139,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 570 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47282,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 570 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 568 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47281,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 568 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 566 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47280,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 566 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 562 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47278,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 562 from patent US 10975139,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 548 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47271,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 548 from patent US 10975139,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 546 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47270,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 546 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 544 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47269,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 544 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 542 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47268,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 542 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 540 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47267,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 540 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 536 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47265,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 536 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 524 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47260,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 524 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 520 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47258,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 520 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 510 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47253,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 510 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 506 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47251,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 506 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 495 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47246,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 495 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 491 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47244,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 491 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 480 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47239,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 480 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 476 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47237,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 476 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 468 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47233,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 468 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 464 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47231,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 464 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 451 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47225,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 451 from patent US 10975139,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 447 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47223,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 447 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 432 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47216,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 432 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 430 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47215,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 430 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 428 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47214,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 428 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 426 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47213,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 426 from patent US 10975139,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 424 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47212,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 424 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 420 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47210,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 420 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 409 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47205,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 409 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 405 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47203,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 405 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 396 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47199,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 396 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 392 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47197,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 392 from patent US 10975139,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 381 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47192,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 381 from patent US 10975139,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 377 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47190,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 377 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 366 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47186,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 366 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 364 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47185,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 364 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 362 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47184,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 362 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 360 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47183,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 360 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 358 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47182,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 358 from patent US 10975139,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 356 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47181,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 356 from patent US 10975139,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 354 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47180,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 354 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 352 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47179,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 352 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 350 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47178,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 350 from patent US 10975139,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 348 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47177,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 348 from patent US 10975139,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 346 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47176,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 346 from patent US 10975139,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 342 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47174,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 342 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 333 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47170,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 333 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 329 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47168,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 329 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 316 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47162,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 316 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 312 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47160,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 312 from patent US 10975139,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 302 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47155,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 302 from patent US 10975139,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 298 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47153,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 298 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 284 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47147,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 284 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 280 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47145,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 280 from patent US 10975139,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 268 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47139,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 268 from patent US 10975139,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 264 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47137,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 264 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 252 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47131,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 252 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 248 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47129,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 248 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 238 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47124,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 238 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 234 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47122,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 234 from patent US 10975139,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 220 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47115,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 220 from patent US 10975139,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 216 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47113,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 216 from patent US 10975139,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 202 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47106,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 202 from patent US 10975139,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 198 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47104,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 198 from patent US 10975139,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 185 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47099,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 185 from patent US 10975139,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 183 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47098,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 183 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 179 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47096,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 179 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 167 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47090,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 167 from patent US 10975139,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 165 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47089,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 165 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 163 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47088,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 163 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 161 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47087,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 161 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 159 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47086,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 159 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 157 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47085,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 157 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 153 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47083,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 153 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 137 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47076,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 137 from patent US 10975139,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 133 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47074,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 133 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 119 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47067,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 119 from patent US 10975139,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 115 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47065,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 115 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 99 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47058,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 99 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 95 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47056,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 95 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 83 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47050,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 83 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 79 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47048,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 79 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 65 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47041,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 65 from patent US 10975139,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 63 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47040,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 63 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 59 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47038,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 59 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 44 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47032,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 44 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 42 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47031,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 42 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 38 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47029,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 38 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 22 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47022,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 22 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 18 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47020,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 18 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 2 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXD47013,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 2 from patent US 10975139,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 826 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47404,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 826 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 818 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47401,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 818 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 806 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47395,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 806 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 800 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47392,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 800 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 792 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47388,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 792 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 786 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47385,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 786 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 776 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47380,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 776 from patent US 10975139,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 770 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47377,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 770 from patent US 10975139,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 749 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47367,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 749 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 741 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47363,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 741 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 733 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47359,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 733 from patent US 10975139,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 727 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47356,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 727 from patent US 10975139,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 719 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47352,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 719 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 713 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47349,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 713 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 694 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47340,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 694 from patent US 10975139,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 686 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47336,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 686 from patent US 10975139,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 676 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47331,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 676 from patent US 10975139,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 666 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47327,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 666 from patent US 10975139,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 656 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47322,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 656 from patent US 10975139,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 646 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47318,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 646 from patent US 10975139,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 638 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47314,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 638 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 630 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47311,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 630 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 622 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47307,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 622 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 614 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47303,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 614 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 606 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47299,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 606 from patent US 10975139,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 600 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47296,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 600 from patent US 10975139,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 590 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47291,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 590 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 580 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47287,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 580 from patent US 10975139,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 564 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47279,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 564 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 556 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47275,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 556 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 538 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47266,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 538 from patent US 10975139,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 530 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47262,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 530 from patent US 10975139,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 522 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47259,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 522 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 514 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47255,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 514 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 508 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47252,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 508 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 503 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47250,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 503 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 493 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47245,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 493 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 487 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47242,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 487 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 478 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47238,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 478 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 472 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47235,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 472 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 466 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47232,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 466 from patent US 10975139,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 457 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47228,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 457 from patent US 10975139,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 449 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47224,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 449 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 440 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47220,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 440 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 422 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47211,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 422 from patent US 10975139,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 416 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47208,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 416 from patent US 10975139,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 407 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47204,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 407 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 401 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47201,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 401 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 394 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47198,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 394 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 387 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47195,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 387 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 379 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47191,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 379 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 372 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47188,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 372 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 344 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47175,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 344 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 338 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47172,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 338 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 331 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47169,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 331 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 323 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47165,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 323 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 314 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47161,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 314 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 306 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47157,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 306 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 300 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47154,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 300 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 290 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47150,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 290 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 282 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47146,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 282 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 276 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47143,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 276 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 266 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47138,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 266 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 260 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47135,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 260 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 250 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47130,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 250 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 242 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47126,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 242 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 236 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47123,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 236 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 228 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47119,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 228 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 218 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47114,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 218 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 210 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47110,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 210 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 200 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47105,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 200 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 191 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47102,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 191 from patent US 10975139,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 181 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47097,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 181 from patent US 10975139,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 175 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47094,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 175 from patent US 10975139,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 155 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47084,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 155 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 145 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47080,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 145 from patent US 10975139,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 135 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47075,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 135 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 127 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47071,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 127 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 117 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47066,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 117 from patent US 10975139,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 107 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47062,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 107 from patent US 10975139,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 97 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47057,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 97 from patent US 10975139,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 89 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47053,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 89 from patent US 10975139,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 81 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47049,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 81 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 73 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47045,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 73 from patent US 10975139,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 61 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47039,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 61 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 51 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47035,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 51 from patent US 10975139,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 40 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47030,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 40 from patent US 10975139,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 30 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47026,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 30 from patent US 10975139,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 20 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47021,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 20 from patent US 10975139,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 10 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXD47017,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 10 from patent US 10975139,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 828 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72641,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 828 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 824 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72639,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 824 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 810 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72633,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 810 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 808 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72632,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 808 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 804 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72630,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 804 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 796 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72626,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 796 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 794 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72625,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 794 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 790 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72623,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 790 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 780 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72618,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 780 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 778 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72617,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 778 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 774 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72615,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 774 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 764 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72610,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 764 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 762 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72609,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 762 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 759 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72608,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 759 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 757 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72607,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 757 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 753 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72605,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 753 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 751 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72604,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 751 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 747 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72602,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 747 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 737 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72597,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 737 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 735 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72596,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 735 from patent US 10954289,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 731 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72594,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 731 from patent US 10954289,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 723 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72590,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 723 from patent US 10954289,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 721 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72589,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 721 from patent US 10954289,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 717 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72587,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 717 from patent US 10954289,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 708 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72583,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 708 from patent US 10954289,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 706 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72582,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 706 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 704 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72581,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 704 from patent US 10954289,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 702 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72580,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 702 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 700 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72579,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 700 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 698 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72578,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 698 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 696 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72577,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 696 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 692 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72575,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 692 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 678 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72568,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 678 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 674 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72566,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 674 from patent US 10954289,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 658 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72559,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 658 from patent US 10954289,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 654 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72557,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 654 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 640 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72551,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 640 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 636 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72549,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 636 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 624 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72544,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 624 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 620 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72542,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 620 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 608 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72536,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 608 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 604 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72534,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 604 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 594 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72529,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 594 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 592 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72528,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 592 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 588 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72526,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 588 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 574 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72520,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 574 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 572 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72519,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 572 from patent US 10954289,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 570 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72518,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 570 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 568 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72517,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 568 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 566 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72516,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 566 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 562 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72514,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 562 from patent US 10954289,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 548 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72507,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 548 from patent US 10954289,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 546 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72506,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 546 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 544 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72505,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 544 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 542 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72504,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 542 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 540 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72503,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 540 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 536 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72501,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 536 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 524 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72496,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 524 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 520 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72494,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 520 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 510 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72489,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 510 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 506 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72487,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 506 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 495 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72482,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 495 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 491 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72480,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 491 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 480 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72475,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 480 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 476 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72473,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 476 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 468 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72469,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 468 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 464 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72467,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 464 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 451 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72461,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 451 from patent US 10954289,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 447 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72459,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 447 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 432 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72452,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 432 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 430 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72451,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 430 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 428 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72450,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 428 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 426 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72449,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 426 from patent US 10954289,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 424 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72448,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 424 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 420 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72446,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 420 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 409 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72441,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 409 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 405 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72439,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 405 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 396 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72435,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 396 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 392 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72433,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 392 from patent US 10954289,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 381 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72428,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 381 from patent US 10954289,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 377 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72426,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 377 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 366 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72422,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 366 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 364 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72421,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 364 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 362 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72420,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 362 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 360 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72419,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 360 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 358 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72418,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 358 from patent US 10954289,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 356 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72417,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 356 from patent US 10954289,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 354 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72416,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 354 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 352 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72415,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 352 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 350 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72414,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 350 from patent US 10954289,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 348 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72413,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 348 from patent US 10954289,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 346 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72412,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 346 from patent US 10954289,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 342 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72410,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 342 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 333 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72406,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 333 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 329 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72404,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 329 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 316 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72398,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 316 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 312 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72396,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 312 from patent US 10954289,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 302 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72391,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 302 from patent US 10954289,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 298 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72389,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 298 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 284 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72383,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 284 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 280 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72381,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 280 from patent US 10954289,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 268 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72375,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 268 from patent US 10954289,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 264 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72373,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 264 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 252 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72367,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 252 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 248 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72365,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 248 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 238 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72360,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 238 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 234 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72358,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 234 from patent US 10954289,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 220 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72351,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 220 from patent US 10954289,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 216 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72349,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 216 from patent US 10954289,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 202 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72342,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 202 from patent US 10954289,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 198 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72340,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 198 from patent US 10954289,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 185 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72335,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 185 from patent US 10954289,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 183 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72334,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 183 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 179 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72332,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 179 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 167 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72326,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 167 from patent US 10954289,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 165 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72325,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 165 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 163 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72324,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 163 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 161 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72323,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 161 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 159 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72322,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 159 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 157 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72321,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 157 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 153 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72319,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 153 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 137 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72312,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 137 from patent US 10954289,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 133 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72310,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 133 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 119 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72303,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 119 from patent US 10954289,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 115 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72301,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 115 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 99 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72294,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 99 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 95 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72292,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 95 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 83 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72286,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 83 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 79 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72284,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 79 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 65 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72277,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 65 from patent US 10954289,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 63 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72276,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 63 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 59 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72274,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 59 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 44 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72268,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 44 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 42 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72267,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 42 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 38 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72265,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 38 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 22 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72258,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 22 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 18 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72256,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 18 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 2 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,QXC72249,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 2 from patent US 10954289,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 828 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34286,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 828 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 824 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34284,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 824 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 810 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34278,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 810 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,gftfssyg,isydgsyk,aidggtvttifdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 808 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34277,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 808 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 804 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34275,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 804 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 796 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34271,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 796 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,gftvssny,iysggst,ardlaaagtdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 794 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34270,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 794 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 790 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34268,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 790 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 780 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34263,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 780 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,gfivsrny,iysggst,arelrgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 778 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34262,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 778 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 774 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34260,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 774 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 764 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34255,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 764 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,gftfsiyg,isydgsnk,akdreaaadafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 762 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34254,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 762 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 759 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34253,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 759 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 757 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34252,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 757 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 753 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34250,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 753 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,gftvssny,iysggst,aregygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 751 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34249,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 751 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 747 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34247,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 747 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 737 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34242,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 737 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,gftvssny,iysggst,ardgsaygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 735 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34241,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 735 from patent US 10787501,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 731 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34239,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 731 from patent US 10787501,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 723 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34235,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 723 from patent US 10787501,N/A,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,gltvssny,iysggst,ardrpitgttldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 721 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34234,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 721 from patent US 10787501,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 717 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34232,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 717 from patent US 10787501,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 708 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34228,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 708 from patent US 10787501,N/A,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,gftvssny,iysggst,ardgvsygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 706 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34227,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 706 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 704 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34226,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 704 from patent US 10787501,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 702 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34225,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 702 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 700 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34224,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 700 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 698 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34223,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 698 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 696 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34222,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 696 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 692 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34220,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 692 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 678 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34213,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 678 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,gyiftgyy,inpnsgga,argsrydwnqnnwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 674 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34211,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 674 from patent US 10787501,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 658 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34204,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 658 from patent US 10787501,N/A,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,gftfsnye,issrsgstl,arrgdgtsslihhyyymdv,,,,IGHJ6*04 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 654 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34202,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 654 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 640 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34196,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 640 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,gftfsnya,isydgsnk,asgsdygdyllvy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 636 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34194,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 636 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 624 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34189,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 624 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,eftvssny,iysggst,aralpygdlhfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 620 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34187,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 620 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 608 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34181,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 608 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,gftfddya,iswnrgsi,akdgerwdsvvvpsarngmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 604 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34179,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 604 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 594 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34174,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 594 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,gltvnrny,iysggst,argelgipygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 592 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34173,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 592 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 588 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34171,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 588 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 574 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34165,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 574 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,gltvssny,iysggtt,argeganyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 572 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34164,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 572 from patent US 10787501,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 570 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34163,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 570 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 568 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34162,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 568 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 566 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34161,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 566 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 562 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34159,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 562 from patent US 10787501,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 548 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34152,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 548 from patent US 10787501,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,ggtfssya,iipmfgia,artpfyydssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 546 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34151,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 546 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 544 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34150,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 544 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 542 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34149,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 542 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 540 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34148,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 540 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 536 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34146,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 536 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 524 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34141,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 524 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlyyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 520 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34139,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 520 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 510 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34134,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 510 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,gftvssny,iysggst,vrdpvgryyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 506 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34132,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 506 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 495 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34127,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 495 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,gftfssya,isydgsnk,ardgrtitmvrgviddafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 491 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34125,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 491 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 480 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34120,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 480 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,gftvssny,iypggst,ardqrdfa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 476 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34118,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 476 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 468 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34114,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 468 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,gltvssny,iysggst,aregriaatgygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 464 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34112,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 464 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 451 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34106,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 451 from patent US 10787501,N/A,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,vftvsyny,iysggst,aralpgwggsfeyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 447 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34104,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 447 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 432 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34097,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 432 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,ggsinnyy,iyhsgst,anmvrgvyeddy,,,,IGHJ4*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 430 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34096,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 430 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 428 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34095,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 428 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 426 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34094,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 426 from patent US 10787501,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 424 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34093,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 424 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 420 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34091,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 420 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 409 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34086,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 409 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgpygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 405 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34084,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 405 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 396 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34080,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 396 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,gltvssny,iysggst,ardlikygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 392 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34078,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 392 from patent US 10787501,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 381 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34073,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 381 from patent US 10787501,N/A,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,gftvsrny,iysggst,aryiprfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 377 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34071,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 377 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 366 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34067,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 366 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,gitvssny,iysggst,ardhgmaaagyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 364 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34066,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 364 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 362 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34065,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 362 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 360 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34064,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 360 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 358 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34063,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 358 from patent US 10787501,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 356 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34062,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 356 from patent US 10787501,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 354 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34061,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 354 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 352 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34060,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 352 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 350 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34059,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 350 from patent US 10787501,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 348 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34058,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 348 from patent US 10787501,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 346 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34057,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 346 from patent US 10787501,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 342 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34055,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 342 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 333 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34051,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 333 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,gitvssny,iysggst,vrdlevrggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 329 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34049,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 329 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 316 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34043,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 316 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,gltvssny,iysggsk,trdaqyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 312 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34041,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 312 from patent US 10787501,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 302 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34036,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 302 from patent US 10787501,N/A,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,gftvssny,iysggst,areggysydyny,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 298 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34034,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 298 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 284 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34028,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 284 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,gftfddya,vswnsgti,skdmgrldyysgldv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 280 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34026,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 280 from patent US 10787501,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 268 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34020,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 268 from patent US 10787501,N/A,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,gfslstnvvg,iywnddk,ahgptgdyfdy,,,,IGHJ4*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 264 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34018,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 264 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 252 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34012,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 252 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,gftfrnyg,iwydgsnr,ardppitgttggdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 248 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34010,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 248 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 238 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34005,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 238 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,gftvssny,iysggst,arvplgdyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 234 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY34003,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 234 from patent US 10787501,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 220 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33996,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 220 from patent US 10787501,N/A,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,gitfsnaw,iksktdggtt,ttarwdwyfdl,,,,IGHJ2*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 216 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33994,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 216 from patent US 10787501,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 202 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33987,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 202 from patent US 10787501,N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,gftfsdyy,itysgsti,ardrgttmvpfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 198 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33985,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 198 from patent US 10787501,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 185 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33980,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 185 from patent US 10787501,N/A,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,gltvssny,iysggst,arargdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 183 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33979,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 183 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 179 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33977,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 179 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 167 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33971,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 167 from patent US 10787501,N/A,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdkdwnsrgyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 165 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33970,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 165 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 163 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33969,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 163 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 161 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33968,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 161 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 159 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33967,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 159 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 157 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33966,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 157 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 153 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33964,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 153 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 137 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33957,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 137 from patent US 10787501,N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,ggsissyy,iyysgst,ardpllidy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 133 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33955,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 133 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 119 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33948,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 119 from patent US 10787501,N/A,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,gytfinyy,inpnsggt,aiitifgvvtwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 115 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33946,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 115 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 99 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33939,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 99 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,gftfsiye,itssgtti,asssssgyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 95 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33937,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 95 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 83 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33931,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 83 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,gitvssny,iysggst,arernfdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 79 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33929,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 79 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 65 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33922,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 65 from patent US 10787501,N/A,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,gftfsyyg,iwydgsnk,aaarpgyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 63 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33921,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 63 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 59 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33919,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 59 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 44 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33913,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 44 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,glivsrny,iysggst,ardlgtggmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 42 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33912,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 42 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 38 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33910,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 38 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 22 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33903,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 22 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,gftvssny,iysggst,ardlggyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 18 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33901,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 18 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 2 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,QPY33894,N/A,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,Sequence 2 from patent US 10787501,N/A,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,gftfrnye,itssgstm,ardgfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 826 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72640,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 826 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 818 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72637,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 818 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 806 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72631,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 806 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 800 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72628,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 800 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 792 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72624,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 792 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 786 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72621,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 786 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 776 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72616,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 776 from patent US 10954289,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 770 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72613,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 770 from patent US 10954289,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 749 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72603,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 749 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 741 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72599,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 741 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 733 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72595,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 733 from patent US 10954289,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 727 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72592,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 727 from patent US 10954289,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 719 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72588,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 719 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 713 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72585,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 713 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 694 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72576,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 694 from patent US 10954289,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 686 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72572,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 686 from patent US 10954289,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 676 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72567,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 676 from patent US 10954289,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 666 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72563,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 666 from patent US 10954289,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 656 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72558,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 656 from patent US 10954289,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 646 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72554,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 646 from patent US 10954289,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 638 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72550,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 638 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 630 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72547,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 630 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 622 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72543,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 622 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 614 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72539,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 614 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 606 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72535,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 606 from patent US 10954289,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 600 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72532,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 600 from patent US 10954289,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 590 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72527,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 590 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 580 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72523,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 580 from patent US 10954289,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 564 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72515,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 564 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 556 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72511,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 556 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 538 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72502,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 538 from patent US 10954289,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 530 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72498,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 530 from patent US 10954289,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 522 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72495,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 522 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 514 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72491,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 514 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 508 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72488,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 508 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 503 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72486,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 503 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 493 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72481,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 493 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 487 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72478,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 487 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 478 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72474,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 478 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 472 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72471,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 472 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 466 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72468,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 466 from patent US 10954289,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 457 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72464,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 457 from patent US 10954289,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 449 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72460,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 449 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 440 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72456,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 440 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 422 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72447,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 422 from patent US 10954289,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 416 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72444,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 416 from patent US 10954289,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 407 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72440,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 407 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 401 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72437,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 401 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 394 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72434,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 394 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 387 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72431,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 387 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 379 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72427,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 379 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 372 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72424,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 372 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 344 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72411,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 344 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 338 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72408,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 338 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 331 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72405,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 331 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 323 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72401,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 323 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 314 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72397,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 314 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 306 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72393,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 306 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 300 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72390,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 300 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 290 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72386,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 290 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 282 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72382,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 282 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 276 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72379,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 276 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 266 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72374,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 266 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 260 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72371,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 260 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 250 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72366,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 250 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 242 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72362,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 242 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 236 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72359,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 236 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 228 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72355,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 228 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 218 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72350,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 218 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 210 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72346,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 210 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 200 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72341,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 200 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 191 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72338,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 191 from patent US 10954289,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 181 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72333,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 181 from patent US 10954289,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 175 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72330,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 175 from patent US 10954289,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 155 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72320,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 155 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 145 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72316,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 145 from patent US 10954289,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 135 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72311,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 135 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 127 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72307,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 127 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 117 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72302,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 117 from patent US 10954289,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 107 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72298,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 107 from patent US 10954289,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 97 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72293,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 97 from patent US 10954289,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 89 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72289,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 89 from patent US 10954289,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 81 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72285,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 81 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 73 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72281,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 73 from patent US 10954289,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 61 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72275,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 61 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 51 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72271,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 51 from patent US 10954289,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 40 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72266,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 40 from patent US 10954289,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 30 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72262,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 30 from patent US 10954289,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 20 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72257,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 20 from patent US 10954289,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 10 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",N/A,,,N/A,QXC72253,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 10 from patent US 10954289,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 826 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34285,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 826 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 818 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34282,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 818 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,tas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 806 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34276,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 806 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 800 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34273,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 800 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,,,,qgissy,aas,qhlnsylyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 792 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34269,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 792 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 786 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34266,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 786 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,,,,qgissy,aas,qllnsypyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 776 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34261,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 776 from patent US 10787501,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 770 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34258,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 770 from patent US 10787501,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 749 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34248,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 749 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 741 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34244,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 741 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,,,,qsissf,aas,qqsyssppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 733 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34240,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 733 from patent US 10787501,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 727 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34237,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 727 from patent US 10787501,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,,,,qsissy,aas,qqtystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 719 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34233,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 719 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 713 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34230,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 713 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,aas,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 694 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34221,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 694 from patent US 10787501,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 686 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34217,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 686 from patent US 10787501,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,,,,ssdvgtyny,dvs,ssfttsstvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 676 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34212,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 676 from patent US 10787501,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 666 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34208,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 666 from patent US 10787501,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 656 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34203,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 656 from patent US 10787501,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 646 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34199,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 646 from patent US 10787501,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,,,,ssdvggyny,dvs,nsltsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 638 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34195,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 638 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 630 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34192,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 630 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,,,,ssnigtgyd,gnt,qsydsslsdsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 622 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34188,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 622 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 614 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34184,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 614 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgsyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 606 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34180,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 606 from patent US 10787501,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 600 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34177,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 600 from patent US 10787501,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 590 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34172,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 590 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 580 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34168,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 580 from patent US 10787501,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,,,,ssnigtgyd,gns,qsydsslsgyvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 564 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34160,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 564 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 556 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34156,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 556 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,,,,qsvssny,gas,qqyvrsprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 538 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34147,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 538 from patent US 10787501,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 530 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34143,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 530 from patent US 10787501,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,,,,qgisty,aas,qqldsypglt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 522 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34140,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 522 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 514 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34136,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 514 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,,,,qdinny,das,qqydnlprt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 508 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34133,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 508 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 503 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34131,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 503 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,,,,qdisny,das,qqydnlplt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 493 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34126,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 493 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 487 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34123,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 487 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,,,,qdisny,das,qqydnlppt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 478 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34119,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 478 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 472 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34116,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 472 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,,,,qdisny,das,hqydnlpqt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 466 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34113,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 466 from patent US 10787501,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 457 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34109,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 457 from patent US 10787501,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,,,,qsissw,kas,qqynsysvt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 449 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34105,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 449 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 440 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34101,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 440 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,,,,qsisny,aas,qqnyntplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 422 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34092,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 422 from patent US 10787501,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 416 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34089,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 416 from patent US 10787501,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,,,,qgissy,aas,qqlnsypgft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 407 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34085,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 407 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 401 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34082,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 401 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,,,,qdisny,das,qqydnlpph,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 394 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34079,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 394 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 387 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34076,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 387 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 379 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34072,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 379 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 372 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34069,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 372 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,,,,qdinky,das,qqydnlppa,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 344 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34056,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 344 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 338 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34053,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 338 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsfsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 331 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34050,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 331 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 323 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34046,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 323 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,,,,qsisty,aas,qqsystppei,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 314 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34042,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 314 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 306 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34038,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 306 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 300 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34035,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 300 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 290 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34031,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 290 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssd,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 282 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34027,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 282 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 276 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34024,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 276 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,,,,qsissy,aas,qqtystlmyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 266 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34019,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 266 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 260 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34016,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 260 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 250 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34011,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 250 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 242 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34007,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 242 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,,,,qdinky,das,qqsdnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 236 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34004,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 236 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 228 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY34000,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 228 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,,,,qdiwny,das,qqhddlppt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 218 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33995,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 218 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 210 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33991,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 210 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,,,,qditny,aas,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 200 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33986,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 200 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 191 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33983,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 191 from patent US 10787501,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,,,,qgisny,das,qqydnlrfft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 181 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33978,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 181 from patent US 10787501,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 175 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33975,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 175 from patent US 10787501,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,,,,qsissy,aas,qqsyitpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 155 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33965,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 155 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 145 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33961,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 145 from patent US 10787501,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsrsy,gvs,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 135 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33956,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 135 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 127 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33952,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 127 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 117 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33947,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 117 from patent US 10787501,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 107 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33943,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 107 from patent US 10787501,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 97 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33938,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 97 from patent US 10787501,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 89 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33934,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 89 from patent US 10787501,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,,,,qgissw,aas,qqansfplft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 81 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33930,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 81 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 73 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33926,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 73 from patent US 10787501,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,,,,qgisny,aas,qqynsyprt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 61 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33920,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 61 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 51 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33916,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 51 from patent US 10787501,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 40 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33911,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 40 from patent US 10787501,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 30 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33907,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 30 from patent US 10787501,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,,,,qsfssw,kas,qqynsyyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 20 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33902,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 20 from patent US 10787501,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 10 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",N/A,,,N/A,QPY33898,"SARS-CoV-2, Spike protein",Unknown.,2022-03-15,N/A,Sequence 10 from patent US 10787501,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsvgrv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33762,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,,ggtfssya,iipifgta,arvassgnrreidy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33761,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqdntamsyyyyygmdvwgqgttvtvss,,ggsissssyy,iyysgst,arqdntamsyyyyygmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33760,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,,ggsissssyy,iyysgst,arrtgtteyyyygmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33759,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,,ggsissssyy,iyysgst,arrtgtteyyyygmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33758,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,ecrllesggglvqpggslrlscaasgftfsiypmtwvrqapgkglewvsaitagggstyytdsvkgrftisrdnskntlylqmnslraedtaiyycakngdcdstscppdywgqgtlvtvss,,gftfsiyp,itagggst,akngdcdstscppdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33757,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,eaqllesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardivvatartagdyyyyygmdvwgqgttvtvss,,gftfssys,isssssyi,ardivvatartagdyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33756,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qcrlvesggglvkpggslrlscaasgftfsdfymswirqapgkglewisyisrsggtiyyadsvkgrftisrdnaknslylqmnslraedtavyycargvsgydygsrfdywgqgtlvtvss,,gftfsdfy,isrsggti,argvsgydygsrfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33755,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlqexgpglvkpsqtlsltctvxggsissgdxywswxrqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslkxssvtaadtavyycarvdcggdcypdywgqgtlvtvss,,ggsissgdxy,iyysgst,arvdcggdcypdy,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33754,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesggdlvkpggslrlscaasgfrfsntwmnwvrqapgrglewvgriktlgeggitdyaapvkgrftisrddskqtlylqmnslkiedtavyycttdlptafdsyygmaawgqgttvtvss,,gfrfsntw,iktlgeggit,ttdlptafdsyygmaa,,,,IGHJ6*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33753,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftftnarmtwvrqapgkglewvgriktktqggtidygapvrgrftisrddlkntldlqmnslktedtavyycaaiddgldhwgqgtlvtvss,,gftftnar,iktktqggti,aaiddgldh,,,,IGHJ1*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33752,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdfyanyspsfqghvtisadksistaylqwsslkasdtamyycarqtgycsstscyaggpfdpwgqgtlvtvss,,gysftsyw,idpsdfya,arqtgycsstscyaggpfdp,,,,IGHJ5*02 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33751,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqllesgsglvkpsqtlsltcavsggsissggyswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsknqfslklssvtaadtavyycarspydssgaidywgqgtlvtvss,,ggsissggys,iyhsgst,arspydssgaidy,,,,IGHJ4*01 (human),IGHV4-30-2*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33750,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqllesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhtdcsggscylggafdiwgqgtmvtvss,,ggsissyy,iyysgst,arhtdcsggscylggafdi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33749,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyyccffdywgqgtlvtvss,,ggtfssya,iipifgta,cffdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33748,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggetyvryyfdfwgqgglvtvss,,gftfssya,isgsggst,akgggetyvryyfdf,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33747,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdmtpyydilteaygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akdmtpyydilteaygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33746,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftftnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylemnslktedtavyycttrrycsstrcylgewsyfdcwgqgtlvtvss,,gftftnaw,iksktdggtt,ttrrycsstrcylgewsyfdc,,,,IGHJ5*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33745,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycasgwylswfdpwgqgtlvtvss,,gytftgyy,inpnsggt,asgwylswfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33744,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvsdyglfdywgqgtlvtvss,,gytftsyg,isayngnt,arvsdyglfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33743,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgpyydssgyfdafdiwgqgtmvtvss,,ggtfssya,iipifgta,arvgpyydssgyfdafdi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33742,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarggdlfgellgatgyygmdvwgqgttvtvss,,ggsissggyy,iyysgst,arggdlfgellgatgyygmdv,,,,IGHJ6*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33741,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycatcsggschpyyfdywgqgtlvtvss,,ggsissyy,iyysgst,atcsggschpyyfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33740,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardfsrggydspsgyyyyygmdvwgqgttvtvss,,gytftsyy,inpsggst,ardfsrggydspsgyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33739,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvefggglvqpgrslrlscaafgftfddyamhwvrqapgkglewvsgiswnsgsigyadfvkgrftisrdnaknslylqmnslraedtalyycaksriaaavfyyfdywgqgtlvtvss,,gftfddya,iswnsgsi,aksriaaavfyyfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33738,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssytmnwvrqapgkglewvsyitsdsstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarnkamddywgrgtlvtvss,,gftfssyt,itsdssti,arnkamddy,,,,IGHJ2*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33737,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscavsgftfssswmfwvrqapgkglvwvsrisadgytatyaesvegrftisrdnakntlylqmnslraedtalyycarglthdywgqgtmvtvss,,gftfsssw,isadgyta,arglthdy,,,,IGHJ4*01 (human),IGHV3-74*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33736,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaadlnyyyygmdvwgqgttvtvss,,gftfssys,isssssyi,ardldivvvpaadlnyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33735,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,,gftfsnaw,iksktdggtt,ttdlgrfrayyyygmdv,,,,IGHJ6*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33734,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,,gftfsnaw,iksktdggtt,ttdlgrfrayyyygmdv,,,,IGHJ6*01 (human),IGHV3-15*07 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33733,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaktmmgyyyyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,aktmmgyyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33732,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarangdydlpyfdywgqgtlvtvss,,gftfssya,isgsggtt,arangdydlpyfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33731,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycatdadniatgfwsgyyseyfdywgqgtlvtvss,,gftfssys,isssssti,atdadniatgfwsgyyseyfdy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33730,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycareardpfyyygmdvwgqgttvtvss,,ggsissggyy,iyysgst,areardpfyyygmdv,,,,IGHJ6*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33729,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsshwmhwvrqapgkglvwvsriigdgseityadsvkgrftisrdnvkntlyleinslraedtavyyclrghvsgstrhfdywgqgtlltvss,,gftfsshw,iigdgsei,lrghvsgstrhfdy,,,,IGHJ4*01 (human),IGHV3-74*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33728,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyycardlfpeyssswyrplyyyygmdvwgqgttvtvss,,gftfsdyy,isssssyt,ardlfpeyssswyrplyyyygmdv,,,,IGHJ6*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QUX33727,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,,gftfssya,isgsggst,akdrssswhyyfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96706,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssytiyyadsvkgrftisrdnaknslylqmnslrdedtavyycardpsdssswypiywyfdlwgrgtlvtvss,,gftfssys,issssyti,ardpsdssswypiywyfdl,,,,IGHJ2*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96705,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarspyydfwsgyhyyfdywgqgtlvavss,,gytftsyy,inpsggst,arspyydfwsgyhyyfdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96704,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,,ggsvssyy,fyysgst,aryivptspppyyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96703,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyymdvwgkgttvtvss,,ggsvssyy,fyysgst,aryivptspppyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96702,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaralssyyd,,gytftsyg,isayngnt,aralssyyd,,,,IGHJ2*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96701,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctasggsiasnsyywgwirqspgkgldwigsiyysgitysnsslksrvtisvdtsknqfslklssvtaadtavyhcaryssgwahddgfdiwgqgtmvtvss,,ggsiasnsyy,iyysgit,aryssgwahddgfdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96700,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevrkpgasvkvsckasgytfsnyaiiwvrqapgqglewmgwisayngktdyseklqdrvtmttdtstntaymelknlrsddtavyycardmffrewfgelihyygmdvwgqgttvtvss,,gytfsnya,isayngkt,ardmffrewfgelihyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96699,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsqtlsltctvsggsinngdyywswirqhpgkglewigyiyysgntyynpslksrvtisldtsknqfslklssvtaadtalyycargplgyyyyymdvwgkgttvtvss,,ggsinngdyy,iyysgnt,argplgyyyyymdv,,,,IGHJ6*04 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96698,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsnyaihwvrqapgkglewvafisydgsikyytdsvkgrftisrdsskntlflqmnnlrpedtavyyctrgavagnnafdvwgqgtmvtvss,,gftfsnya,isydgsik,trgavagnnafdv,,,,IGHJ3*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96697,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyyctagfmaqgliitsifdfwgqgtqvtvss,,gyrltels,fdpddget,tagfmaqgliitsifdf,,,,IGHJ5*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96696,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyycttgfmaqgliitsifdfwgqgtqvtvss,,gyrltels,fdpddget,ttgfmaqgliitsifdf,,,,IGHJ5*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96695,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyidnsgstyynpslksrvtisvdtsknqfslnlrsvtaadaavyycarerdlaaagidswgqgtlvtvss,,ggsissggyy,idnsgst,arerdlaaagids,,,,IGHJ5*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96694,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltctvsggsvnsdsyywswirqppgkglewigyiyysgstncnpslksrltisadtsknqfslklnsvtaadtavyycarveapeggsdywgqgtlvtvsp,,ggsvnsdsyy,iyysgst,arveapeggsdy,,,,IGHJ4*01 (human),IGHV4-59*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96693,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsdtlsltctvsggsissssyywgwirqppgkglewigsisysgstyynpslksrvtisgdtsknqlslklssvtaadtavyycarhtyyydssgylalapdiwgqgtmvtvss,,ggsissssyy,isysgst,arhtyyydssgylalapdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96692,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarsreskdwsygggfyyygmdvwgqgttvtvss,,gftfsdyy,isssgsti,arsreskdwsygggfyyygmdv,,,,IGHJ6*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96691,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggnlvqpggslrlscvvsgftfssysmnwvrqapgkglewvsvisgsgdttyyadsvkgrftisrdnskntlylqmnslraedtaiyycakdcdyeiltgyhsncfdpwgqgtlvtvss,,gftfssys,isgsgdtt,akdcdyeiltgyhsncfdp,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96690,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsrggsyhdafdiwgqgtmvtvss,,gftfssyg,isydgsnk,arsrggsyhdafdi,,,,IGHJ3*02 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96689,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggnyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,arsfggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96688,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcivsggsissssyywgwirqppgkglewigiiyfsgspyynpslksrvtisvdtsknqfslrlssvtaadtalyycarhnyltryyyyyyymdvwgkgttvtvss,,ggsissssyy,iyfsgsp,arhnyltryyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96687,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfdnyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdwggvyygsgtyytnwgqgtlvtvss,,gftfdnya,iswnsgsi,akdwggvyygsgtyytn,,,,IGHJ1*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96686,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqqsgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigslyysgstyynpslksrvsisvdtsknqfslklssvtaadtavyycatlyyvwgsyrglegnfdnwgqgtlvtvss,,ggsissstyy,lyysgst,atlyyvwgsyrglegnfdn,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96685,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpgvllwfgellspwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arhpgvllwfgellspwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96684,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarawgsyysafdywgqgtlvtvss,,gftfssyg,isydgsnk,arawgsyysafdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96683,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgvyydfwsgyyggdnggfwldywgqgtlvtvss,,gytftsyg,isayngnt,arvgvyydfwsgyyggdnggfwldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96682,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckisgytlielsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtgymelsslrsedtavyycvtgppysgsywfdpwgqgtlvtvss,,gytliels,fdpedget,vtgppysgsywfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96681,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlqesgpglvkpsqtlsltctvsgdsisrgsyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycaregsfwywfdywgqgtlvtvss,,gdsisrgsyy,iytsgst,aregsfwywfdy,,,,IGHJ4*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96680,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardysycsstscytsifdywgqgtlvtvss,,gftfssye,isssgsti,ardysycsstscytsifdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96679,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavsggsfsayywswirqspgkglewigeinhsgstnyspslksrvtisldtsknqlslkvtsvtaadtgvyfcardsrtsgwhkiyyyyamdvwgqgttvtvss,,ggsfsayy,inhsgst,ardsrtsgwhkiyyyyamdv,,,,IGHJ6*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96678,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltcavsgasisssgyywgwirqppgkglewignifyigsthynpslksrvtisldtsknqlslklrsvtaadtavyycarptndyggfyfdywgqgilvtvss,,gasisssgyy,ifyigst,arptndyggfyfdy,,,,IGHJ4*01 (human),IGHV4-38-2*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96677,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaaafsnyeyyfdywgqgtlvtvss,,gftfssyw,ikqdgsek,aaafsnyeyyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96676,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardskeyyyyyyymdvwgkgttvtvss,,gftfssya,isydgsnk,ardskeyyyyyyymdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96675,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscvvsgftfsnysmnwvrqapgkglewvssissvssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvlrryydfwsgyypdafdiwgqgtmvtvss,,gftfsnys,issvssyi,arvlrryydfwsgyypdafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96674,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyfsgatkynpslnrrvtmsvdtsknqfslklqsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,,ggsvssyy,fyfsgat,aryivptspppyyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96673,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesgpglvkpsetlsltctvsggsisssdyywgwirqppgkglewigsmyysgstyynpslnsrvtisvdtsknqfslnlnsvtaadtavyycarargycsivgcytslyyfdylgqgtlvtvss,,ggsisssdyy,myysgst,arargycsivgcytslyyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96672,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrfaisrdnaknslylqmnslraedtalyycardivpyssswlyyygmdvwgqgttvsvss,,gftfddya,iswnsgsi,ardivpyssswlyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96671,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsisnyywswirqppgkglewigyifysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwpdafdmwgqgtmvtvss,,ggsisnyy,ifysgst,ardrgyssgwpdafdm,,,,IGHJ3*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96670,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgdsisssywswirqtpgkglewigyidysgstnynpslksritmsvdtsknqfslklssvtaadtavyycarspnfdwllntggyygldvwgqgttvtvss,,gdsisssy,idysgst,arspnfdwllntggyygldv,,,,IGHJ6*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96669,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrsvrlscaasgftfsscamywvrqapgkglewvavisydvinkyyedsvkgrftisrdnskntlylqmnslraedtavyycasqppairafdiwgqgtmvtvss,,gftfssca,isydvink,asqppairafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96668,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvqsgggvvqpgrslrlscassgftfstyamhwvrqapgkglewvafisydgskkyyadslkgrftisrdnskntlylqtnslraedtavyycakvrrwlqfpetdafdiwgqgtmvtvss,,gftfstya,isydgskk,akvrrwlqfpetdafdi,,,,IGHJ3*02 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96667,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvrvsckasggpfsnyaifwvrqapgqglewmggiipvfgttnyaqkfqgrvtitadeststaymemsslrsedtavfycaglvastpwpdfwgqgtlvtvss,,ggpfsnya,iipvfgtt,aglvastpwpdf,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96666,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglelvsyisssgsiiyyadsvkgrftisrdnaknslslqmnslraedtavyycardaniwfgelrglstgymdvwgkgttvtvss,,gftfsdyy,isssgsii,ardaniwfgelrglstgymdv,,,,IGHJ6*04 (human),IGHV3-11*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96665,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardshiyrhdswetaitifgvviidafdiwgqgtmvtvss,,gytftsya,intntgnp,ardshiyrhdswetaitifgvviidafdi,,,,IGHJ3*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96664,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakrenrllwfgelllghdywgqgtlvtvss,,gftfssya,isgsggst,akrenrllwfgelllghdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96663,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrsltlscaasgftfssygvhwvrqapgkglewvslisyegsitqyadpvrgrftisrdnskntlylqmnslktedtavyycargavagndafdiwgqgtmvtvss,,gftfssyg,isyegsit,argavagndafdi,,,,IGHJ3*02 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96662,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisgnsgntkyaqkvqgrvtmttdtststaymelrslrsddtamyycardiiellwfgdyyygmdvwgqgttvtvss,,gytfttyg,isgnsgnt,ardiiellwfgdyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96661,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaakmglwfgelwwgqgtlvtvss,,gytftsyg,isayngnt,aakmglwfgelw,,,,IGHJ1*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QTI96660,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",N/A,evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,,gysftsyw,iypgdsdt,arqrfsgslyfyygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99137,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,,ggsissyy,vyysgst,assqrpdgnlyyfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99136,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaslqwsslkasdtamyycarqkrdgttwafdywgqgtlvtass,,gysftsyw,idpsdsyt,arqkrdgttwafdy,,,,IGHJ4*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99135,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnykyslksrvtisvdtsknqfslklssvtaadtavyycarekggtewefndafdiwgqgtmvtvss,,ggsvssgsyy,iyysgst,arekggtewefndafdi,,,,IGHJ3*02 (human),IGHV4-61*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99134,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvstnymswvrqapgkglewvsviysggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycastnsgsyshvfdiwgqgtmvtvss,,gftvstny,iysggst,astnsgsyshvfdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99133,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglgqpggslrlscaasgftfsnyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakagavgyydsngyyydvdyyygmdvwgqgttvtvss,,gftfsnya,isgsggst,akagavgyydsngyyydvdyyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99132,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrltitaddststaymelsslksedtavyycarfraydssgygpdywgqgtlvtvss,,ggtfssya,iipifgta,arfraydssgygpdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99131,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslklscaasgftfnsyamtwvrqapgkglewlstisgsggrtyyadsvkgrfaisrdnskntvflqmstlraedtavyfcardfyglesfypgidswgqgtlvtvss,,gftfnsya,isgsggrt,ardfyglesfypgids,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99130,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhiaglewlfraaavlnwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arhiaglewlfraaavlnwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99129,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycagtyydfwsgstnyygmdvwgqgttvtvss,,ggsissyy,iyysgst,agtyydfwsgstnyygmdv,,,,IGHJ6*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99128,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvhhcsggscygyyfdywgqgtlvtvss,,gftfgdya,irskayggtt,trvhhcsggscygyyfdy,,,,IGHJ4*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99127,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycaredsygsgstgafdiwgqgtmvtvss,,ggsissyy,iytsgst,aredsygsgstgafdi,,,,IGHJ3*02 (human),IGHV4-4*07 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99126,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlsgifgvviipgffdywgqgtlvtvss,,ggsissssyy,iyysgst,arlsgifgvviipgffdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99125,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardptavtgpfdywgqgtlvtvss,,gftfssya,isydgdnk,ardptavtgpfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99124,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvprppwddfwsgylyyfdywgqgtlvtvss,,gftfssye,isssgsti,arvprppwddfwsgylyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99123,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpseslslaffvyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargggysygaidywgqgtlvtvss,,ggsfsgyy,inhsgst,argggysygaidy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99122,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,gynfisyg,isayngnt,arvrifgvviivdtamvldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99121,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptvttvtnwfdpwgqgtlvtvss,,gytltels,fdpedget,atgptvttvtnwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99120,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilditnyaqkfqgrvtitadkststaymelsslrsedtavyycarglwrssiaglhvpygmdvwgqgttvtvss,,ggtfssya,iipildit,arglwrssiaglhvpygmdv,,,,IGHJ6*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99119,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,gynfisyg,isayngnt,arvrifgvviivdtamvldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99118,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgnslrlscvasgfkfsssamhwvrqapgkglewvaiiwfhgntkfygdfvkgrftvsrdnsnntlhlqmnslraedtavyhcarassdyggafdiwgqgtmvtvss,,gfkfsssa,iwfhgntk,arassdyggafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99117,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraltgnyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,araltgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99116,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggiipifgtanyaqnfqgrvtitadeststaymelsslrsedtavyycarvsyydssgyytdywgqgtlvtvss,,ggtfssyt,iipifgta,arvsyydssgyytdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99115,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtftsyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,,ggtftsya,iipifgta,arvgaydssgyyqdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99114,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadsvkgrftisrdsskntlylqmnslraedtavyycarggvgyqllfgndwfdpwgqgtlvtvss,,gftfssya,isydgink,arggvgyqllfgndwfdp,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99113,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptifgvvlqiprfdywgqgtlvtvss,,gftfssyg,isydgsnq,akdptifgvvlqiprfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99112,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpelvkpsetlsltcsvsggsissyywswirqppgkglewigyiyysgstnynpslsgstnynpslksrvtvsvdtsknqfslkvssvtaadtavyycargfdywgqgtlvtvss,,ggsissyy,iyysgstnynpslsgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99111,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigniyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarqlwgyydssgyyafdiwgqgtmvtvss,,ggsissssyy,iyysgit,arqlwgyydssgyyafdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99110,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymelsslrsedtavfycvsriaaaadfdywgqgtlvtvss,,ggtfsnya,iipifgta,vsriaaaadfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99109,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrlydyvwgsyrfghtwgqgtlvtvss,,gftfsnaw,iksktdggtt,ttdrlydyvwgsyrfght,,,,IGHJ1*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99108,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntldlqmnslraedtavyycarayggnyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arayggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99107,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfisygiswvrqapgqglewmgwisgyngntnyaqkfqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,gytfisyg,isgyngnt,arvrifgvviivdtamvldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99106,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraysydssgyspdywgqgtlvtvss,,ggtfssya,iipifgta,araysydssgyspdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99105,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardrrgsgwswdyyyygmdvwgqgttvtvss,,gytftsyg,isayngnt,ardrrgsgwswdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99104,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtstnqfslklssvtaadtavyycarrvhydiltgfyggalitrafdiwgqgtmvtvss,,ggsfsgyy,inhsgst,arrvhydiltgfyggalitrafdi,,,,IGHJ3*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99103,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissrssytnyadsvkgrftisrdnaknslylqmnslraedtavyycargydssgyhyslwgqgtlvtvss,,gftfsdyy,issrssyt,argydssgyhysl,,,,IGHJ2*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99102,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsgissnggstyyadsvkgritisrdnskktlylqmsslraedtavyycvksssrgyywgqgtlvtvss,,gftfssya,issnggst,vksssrgyy,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99101,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasarfitmvrgviniyyygmdvwgqgttvtvss,,ggtfssya,iipifgta,asarfitmvrgviniyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99100,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscrasgytftnfgiswvrqapglglewmgwistyngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarasgpyllglywgqgtlvtvss,,gytftnfg,istyngnt,arasgpyllgly,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99099,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycatnsnypywgqgtlvtvss,,gysftsyw,idpsdsyt,atnsnypy,,,,IGHJ4*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99098,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsncwmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarmgntawyfdlwgrgtlvtvss,,gftfsncw,ikqdgsek,armgntawyfdl,,,,IGHJ2*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99097,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasrftfstyamhwvrqapgkglewvtvisydgdnkyyadsvkgrftisrdnskntlylqmnslrtedtavyyctragsgsylsyfdywgqgtlvtvss,,rftfstya,isydgdnk,tragsgsylsyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99096,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarissydssgysmdvwgqgttvtvss,,ggtfssya,iipifgta,arissydssgysmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99095,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctmvwqqlhdafdiwgqgtmvtvss,,gftfgdya,irskayggtt,tmvwqqlhdafdi,,,,IGHJ3*02 (human),IGHV3-49*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99094,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadestntaymelssltsedtavyycakigdydssgyyfdywaqgtlvtvss,,ggtfssya,iipifgta,akigdydssgyyfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99093,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarayggsyfygmdvwgqgttvtvss,,gftfstya,isydgsnk,arayggsyfygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99092,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsvssnayywgwirqppgkglewigsvnyrgstyyiptlksritisvntsknqfslkltsvtaadtavyycarrgvalvtityfdfwgqgalvtvss,,ggsvssnayy,vnyrgst,arrgvalvtityfdf,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99091,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglefigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqevvlvrpynyngmdvwgqgttvtvss,,ggsissssyy,iyysgst,atqevvlvrpynyngmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99090,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaaagfifssyamnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlnlqmnslraedtavyycargngyiiidywgqgtlvtvss,,gfifssya,isydgsnk,argngyiiidy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99089,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgkidpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarqfggellgwfdpwgqgtlvtvss,,gysftsyw,idpsdsyt,arqfggellgwfdp,,,,IGHJ5*02 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99088,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisstsnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvspnydfwsgyypdafdiwgqgtmvtvss,,gftfssys,isstsnyi,arvspnydfwsgyypdafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99087,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfnsfamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsggyscfdywgqgtlvtvss,,gftfnsfa,isydgnnk,ardrsggyscfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99086,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycaseivsfigssedywgqgtlvtvss,,gftfssyg,isydgsnk,aseivsfigssedy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99085,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckafgytftknginwvrqapgqglewmgwispnngytnfaqkfqgratmtsdtststaymelrslrsddtavyycarvrvdydssgydayyyhldvwgqgttvtvss,,gytftkng,ispnngyt,arvrvdydssgydayyyhldv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99084,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmardtsistaymelsrlrsddtavyycardqvspycggdcpdafdiwgqgtmvtvss,,gytftgyy,inpnsggt,ardqvspycggdcpdafdi,,,,IGHJ3*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99083,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntlylqmnslrvedtavyycarpgggsyygpfdywgqgtlvtvss,,gftfssya,isydgink,arpgggsyygpfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99082,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,,ggtfssya,iipifgta,arvgaydssgyyqdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99081,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvstistnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvlgycsstscqhfdywgqgtlvtvss,,gftfssya,istnggst,vlgycsstscqhfdy,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99080,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssfafiwvrqapgqglewmggiipifgtakytqkfqgrvtitadeststaymelsslrsedtavyycarvsyydssgfytdywgqgtlvtvss,,ggtfssfa,iipifgta,arvsyydssgfytdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99079,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsggifssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasysgfddyghyrnywgqgtlvtvss,,ggifssya,iipifgta,asysgfddyghyrny,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99078,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssfalhwvrqapgkglewvavvsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarsmggnyadyfdywgqgtlvtvss,,gftfssfa,vsydgsnk,arsmggnyadyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99077,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylemnslraedtavyycastsdsgsyyihwyfdlwgrgtlvtvss,,gftfssye,isssgsti,astsdsgsyyihwyfdl,,,,IGHJ2*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99076,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylhmnslraedtavyycarpnsgsyhsyfdywgqgtlvtvss,,gftfssyg,isydgink,arpnsgsyhsyfdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99075,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssrsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycasnpaadpntyyyygmdvwgqgttvtvss,,gftfssys,isssrsyi,asnpaadpntyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99074,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsissstwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycarsasnyfgyyyygmdvwgqgttvtvss,,ggsissstw,iyhsgst,arsasnyfgyyyygmdv,,,,IGHJ6*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99073,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaagyydsinwgqgtlvtvps,,gftvssny,iysggst,aagyydsin,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99072,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscgasgfifssyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpysgtyfsafdiwgqgtmvtvss,,gfifssya,isydgnnk,arpysgtyfsafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99071,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgnsftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhrnydiltgyryyfdywgqgtlvtvss,,gnsftsyw,iypgdsdt,arhrnydiltgyryyfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99070,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlflqmnslrtedtavyycaramggnyfhafdiwgqgtmvtvss,,gftfsiya,isydgink,aramggnyfhafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99069,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnnaqkfqgrvtltadestsaaymelsslrsedtavyycariepyastgytfdywgqgtlvtvss,,ggtfssya,iipifgtt,ariepyastgytfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99068,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycvrvalydssgyspdywgqgtlvtvss,,ggtfssya,iipifgta,vrvalydssgyspdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99067,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigniyytgstyynpslksrvtisvdtsknhfslrlssvtaadtavyycarhnrfwsedtpfdpwgqgtlvtvss,,ggsissstyy,iyytgst,arhnrfwsedtpfdp,,,,IGHJ5*02 (human),IGHV4-39*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99066,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglaqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadslkgrftisrdnskstlylqmnslraedtavyycakgpmwqwlvrlslvgdywgqgtlvtvss,,gftfssya,isgsggnt,akgpmwqwlvrlslvgdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99065,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,,gftfssya,isydgsnk,arpysgsyyayfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99036,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssdnyywswirqppgkglewigyiyysgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargfvatyyyymdvwgkgttvtvss,,ggsvssdnyy,iyysgst,argfvatyyyymdv,,,,IGHJ6*04 (human),IGHV4-61*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99035,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfsvssnymnwvrqaprkglewvsviysggstyyadsvkgrftisrdnskntlylqmntlraedtavyycargygdsqrwgqgtlvtvss,,gfsvssny,iysggst,argygdsqr,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99034,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpgqvkpsetlsltctvsgysissgyfwgwvrqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycardhgsydfwsgysrdafdiwgqgtmvtfss,,gysissgyf,iyhsgst,ardhgsydfwsgysrdafdi,,,,IGHJ3*02 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99033,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvscktsgyiftdyfmhwvrqapgqglewmgwinpnsgganyaqkfqgrvtmtrdtsittvymelsrlriddtamyycareaslnrsryyssggtvyyyyyymdvwgkgttvtvss,,gyiftdyf,inpnsgga,areaslnrsryyssggtvyyyyyymdv,,,,IGHJ6*04 (human),IGHV1-2*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99032,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvglsswyfeywgqgtlvtvss,,gftfssyw,ikqdgsek,arvglsswyfey,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99031,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgpglvkpsetlsltctvsggsirsyshywgwirqppgkglewigtiyysgstyynpslksritisvdtsksqfslklssvtaadtavyfcastiptyddiltgyqfdywgqgtlvtvss,,ggsirsyshy,iyysgst,astiptyddiltgyqfdy,,,,IGHJ4*01 (human),IGHV4-59*11 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99030,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydgsnkyyadsvrgrftisrdnskntlylqmnslraedtavyycarggggyntffdywgqgtlvtvss,,gftfssya,isydgsnk,arggggyntffdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99029,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdgavatgpgyfyfymdvwgkgttvtvss,,gftfssya,isgsggst,akdgavatgpgyfyfymdv,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99028,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscaasgfpfrnyamhwvrqapgkglehisvissrgdttyyansvkgrftisrdnsqntlylqmdslraddmavyycarvqsgfsygygfdywgqgtlvtvss,,gfpfrnya,issrgdtt,arvqsgfsygygfdy,,,,IGHJ4*01 (human),IGHV3-64*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99027,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisadtsknqfslklssvtaadtavyycarapgatyssgwyyyyyymdvwgkgttvtvss,,ggsissyy,iyysgst,arapgatyssgwyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99026,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvss,,gytftryw,iypgdsdt,arlpqycsngvcqrwfdp,,,,IGHJ5*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99025,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydginkyyadsvkgrftssrdnskntlylqmnslraedtavyfcarmysgsylgyfdywgqgtlvtvss,,gftfssya,isydgink,armysgsylgyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99024,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsgpglvkpsetlsltctvsgdsissyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklssvtaadtavyycanlgynsgwyggyfeywgqgtlvtvss,,gdsissyy,iyytgst,anlgynsgwyggyfey,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99023,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfifsrysmnwvrqapgkglewvssissstsfiyyadsvrgrftisrdnaknslylqmnslraedtavyycarwiggdssgyypdafdiwgqgtmvtvss,,gfifsrys,issstsfi,arwiggdssgyypdafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99022,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgpglvkpsetlsltctvsgdsisnyywswirqppekglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtamyycardfslwgqgtlvtvss,,gdsisnyy,iyysgst,ardfsl,,,,IGHJ2*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99021,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscavsgftfsnygmhwvrqapgkglewvavilydgsnryyadsvkgrftvsrdnskntlylqmnslraedtavyycakgggpycgggscwahyfdywgqgtlvsvss,,gftfsnyg,ilydgsnr,akgggpycgggscwahyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99020,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsgpglvkpsqtlsltctvaggsissgtyywswirqpagkglewigriytsgsanynpslksrvtisvdtsknqfslrlssvtaedtavyycareysssyyyfyymdvwgkgttvtvss,,ggsissgtyy,iytsgsa,areysssyyyfyymdv,,,,IGHJ6*04 (human),IGHV4-61*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99019,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsqtlsltctvsggsissgnyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtalyycardayydflsgyiptynwfdpwgqgtlvtvss,,ggsissgnyy,iytsgst,ardayydflsgyiptynwfdp,,,,IGHJ5*02 (human),IGHV4-61*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99018,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpgrslrlsctasgftfgdyamiwfrqapgkglewvgfirskayggtteyaasmkgrftisrddsksiaylqmnslktedtavyyctrdldyydssgyyptyidywgqgtlvtvss,,gftfgdya,irskayggtt,trdldyydssgyyptyidy,,,,IGHJ4*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99017,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfsyyalswvrqapgkglewvsatygsgsntyyadsvkgrftisrdnskntlylqmsnlraddtavyycakdqrnaydsfdfwgqgtlvtvss,,gftfsyya,tygsgsnt,akdqrnaydsfdf,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99016,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgqglewvavisydgsnkyyadsvrgrftisrdnskntlylqmntlraedtavyycargptysymdvwgkgttvtvss,,gftfsiya,isydgsnk,argptysymdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99015,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdksknmvylqmnslraedtalyycakdleyytsgsyslfdywgqgtlvtvss,,gftfsryg,isydgsnk,akdleyytsgsyslfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99014,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcgfyggslnnyfwswirqppgkglewigdinhsgstnynpslksrvtvsvdtsknqfslnlnsvtaadtavyycarglflvyygsglggfdywgqgtlvtvss,,ggslnnyf,inhsgst,arglflvyygsglggfdy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99013,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssygmswvrqapgkglewvsginnhggstyygdsvkgrftisrdnskntlylqmnslraedtavyycaksdtamvpynwfdpwgqgtlvtvss,,gftfssyg,innhggst,aksdtamvpynwfdp,,,,IGHJ5*02 (human),IGHV3-23*02 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99012,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqgsgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhptfsgyeyyfdhwgqgtlitvss,,ggsissssyy,iyysgst,arhptfsgyeyyfdh,,,,IGHJ1*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99011,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlsceasgftfssyalswvrqapgkglewvsaisgsggsiyyadsvkgrftisrdnskstlylqmnslkaedtavyycakddstsayyyyyymdvwgkgttvtvss,,gftfssya,isgsggsi,akddstsayyyyyymdv,,,,IGHJ6*04 (human),IGHV3-23*04 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99010,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyigssgssihyadsvkgrftisrdnaknslylqmnslraedtavyycardgsygdyvrgywgqgalvivss,,gftfsdyy,igssgssi,ardgsygdyvrgy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,QSI99009,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapscsggrcydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33798,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qavvtqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,,,,klgdky,qds,qawdsstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33797,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,nfmltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvvfgggtkltvl,,,,klgdky,qds,qawdsstyvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33796,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigshpvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsgrvvfgggtkltvl,,,,ssnigshp,snn,aawddslsgrvv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33795,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsvltqepsltvspggtvtltcgsstgavtsghwpywfqqkpgqtprtliydtsnkqswtparfsgsllggkaaltlsgaqpedeaeyyclllysdgrvfgggtkltvq,,,,tgavtsghw,dts,lllysdgrv,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33794,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33793,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33792,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,,,,nigsks,dds,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33791,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33790,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvvfgggtkltvl,,,,alpkqy,kds,qsadssgtsvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33789,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsvltqepsltvspggtvtltcasstgvvtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeadyyclitysgrevfgggtkltvl,,,,tgvvtsghy,dtn,litysgrev,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33788,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyravvfgggtkltvl,,,,alpkqy,kds,qsadssgtyravv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33787,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33786,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",,qlvltqepslavspggtvtltcasstgtvtsgsypnwfqqkpgqppraliydtsnkhswtparfsgfllggkatlalsgaqpedeaeyycllynggvwvfgggtkltvl,,,,tgtvtsgsy,dts,llynggvwv,,,IGLJ3*02 (human),IGLV7-43*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33785,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvrtfgqgtkveik,,,,qsvssy,das,qqrsnwppvrt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33784,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppatfgqgtkleik,,,,qslvysdgnty,kvs,mqgthwppat,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33783,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvssnflawyqrkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,,,,qsvssnf,gts,qqygssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33782,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,,,,qsvssn,gas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33781,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,airmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpwtfgqgtkveik,,,,qsvssn,gas,qqynnwpwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33780,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqspstlsasvgdrvtitcrasqsvsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsywtfgqgtkveik,,,,qsvssw,kas,qqynsywt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33779,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystlaltfgggtkveik,,,,qsvlyssnnkny,was,qqyystlalt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33778,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvwtfgggtkveik,,,,qsvssy,das,qqrsnwppvwt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33777,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,,,,qsvlyssnnkny,was,qqyystpwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33776,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlfsfnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqynstpytfgqgtkleik,,,,qsvlfsfnnkny,was,qqynstpyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33775,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgqgtkveik,,,,qsvlyssnnkny,was,qqyystppt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33774,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgqgtrleik,,,,qsvssy,das,qqrsnwppkit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33773,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpftfgpgtkvdik,,,,qslvhsdgnty,kis,mqatqfpft,,,IGKJ3*01 (human),IGKV2-24*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33772,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpmtfgqgtkveik,,,,qsllhsngyny,lgs,mqalqtpmt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33771,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppntfgqgtkleik,,,,qsvsssy,gas,qqygssppnt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33770,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,diqmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrlmykvskrdsgvpdrfsgsgsgtdftlkisrveaedagiyycmqgthwppytfgqgtkleik,,,,qslvysdgnty,kvs,mqgthwppyt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33769,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfprtfgqgtkveik,,,,qgissw,aas,qqansfprt,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33768,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33767,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqtvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntpptfgqgtkleik,,,,qtvlyssnnkny,was,qqyyntppt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33766,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eilmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgrtfgpgtkvdik,,,,qsvssy,das,qqrsnwppgrt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33765,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,,,,qsvsssy,gas,qqygssprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33764,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,divmtqtpsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprytfgqgtkleik,,,,qsissy,aas,qqsystpryt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QUX33763,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltvsslepedfavyycqqrsnwppitfgqgtrleik,,,,qsvssy,das,qqrsnwppit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96751,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssspyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96750,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,nfmltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdsslsawvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsawv,,,IGLJ3*02 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96749,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssniesntvqwyqqlpgtapkliihnnskrpsgvpdrfsasksgtsaslaisglqsqddgdyycaawddslnawvfgggtkltvl,,,,ssniesnt,nns,aawddslnawv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96748,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsvsvapgktasiicggnnignknvhwyqqkpgqapvlvisydsgrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdlmvfgggtkltal,,,,nignkn,yds,qvwdsgsdlmv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96747,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrgvfgggtkltvl,,,,alpkky,eds,ystdssgnhrgv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96746,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,nfmltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsylsgyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsylsgyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96745,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,,,,ssnigsns,snn,aawddslngwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96744,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsvsvspgqtasitcsgdklgnryacwyqqkpgqspvlviyqnnkrpsgiperfsgsnsgnsatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgnry,qnn,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96743,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,,,,ssdvgsynl,egs,csyagsstlv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96742,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,nfmltqprsvsgspglsvtisctgsssdvggynyvswyqqhpgkapklmiydvsrrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytyvfgggtkltvl,,,,ssdvggyny,dvs,csyagsytyv,,,IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96741,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsvsvspgqtasitcsgdklgdkyaswyqqksgqspvlviyqdsrrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qds,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96740,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,,,,ssnigsnt,snn,aawddslnawv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96739,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsasatpgqrvtiscsgsssnigsnyvywyqqfpgtapklliygnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddspsvhwvfgggtkltvl,,,,ssnigsny,gnn,aawddspsvhwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96738,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsvsvapgktaritcggnnigtksvhwyqqkpgqapvlviyydtdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggakltvl,,,,nigtks,ydt,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96737,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96736,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsmsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydngkrpsgipdrfsasksgtsatlgitglqtgdeadyycgtwdsslstwvfgggtkltvl,,,,ssnignny,dng,gtwdsslstwv,,,IGLJ3*02 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96735,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,nfmltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycsssassttlhgvfgggtkltvl,,,,ssdvgsyny,dvs,sssassttlhgv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96734,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,nfmltqppsmsvspgqtasitcsgdklgnkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsestatltisgtlamdeadyycqawdsstegvvfgggtkltvl,,,,klgnky,qds,qawdsstegvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96733,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsvltqppsvsvspgqtasiicsgdklgdkyacwyqqkpgqspllviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyfcqawdsstavvfgggtkltvl,,,,klgdky,edt,qawdsstavv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96732,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfvvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgfvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96731,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtnsdvgaynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvvfgggtkltvl,,,,nsdvgayny,evs,ssyagsnnlvv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96730,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslesedfvvyycqqrsnwpytfgqgtkleik,,,,qsvssy,das,qqrsnwpyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96729,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqltqspssvsasvgdrvtitcrasqdisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfppptfgggtkveik,,,,qdissw,aas,qqaksfpppt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96728,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqtpgtlslspgeratlscrasqsvsnnylawyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnswtfgqgtkveik,,,,qsvsnny,gas,qqygnswt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96727,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqssstpsitfgqgtrleik,,,,qsinny,aas,qqssstpsit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96726,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpitfgqgtrleik,,,,qslvysdgnty,kvs,mqgthwpit,,,IGKJ5*01 (human),IGKV2-30*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96725,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpftfgggtkveik,,,,qsvssy,das,qqrsnwpft,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96724,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,airmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsasgagtdftlkisrveaedvgvyycmqatqfpytfgqgtkleik,,,,qslvhsdgnty,kis,mqatqfpyt,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96723,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,airmtqspsslsasvgdrviitcrasqsiagylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipytfgqgtkleik,,,,qsiagy,tas,qqsysipyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96722,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96721,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,,,,qsvsssy,gas,qqygsspmyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96720,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96719,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,,,,qsvsssy,gas,qqygsspmyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96718,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpqtfgqgtkveik,,,,qsvlyssnnkny,was,qqyystpqt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96717,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwytfgqgtkleik,,,,qsvssn,gas,qqynnwyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96716,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,,,,qsvssn,gas,qqyynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96715,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyycqqydnlpytfgqgtkleik,,,,qdisnf,das,qqydnlpyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96714,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqtpsslstsvgdrvtitcrtsqsigsflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystpytfgqgtkmeik,,,,qsigsf,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96713,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasiratgiparfsgsgsgtdftltisslepedfavyycqyrsnwpprltfgggtrveik,,,,qsvsnf,das,qyrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96712,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssnlawyqqkagqaprlliygastratgiparfsgsgsgteftltisslqsedfaiyycqqynnwpprtfgpgtkvdik,,,,qsvssn,gas,qqynnwpprt,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96711,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,,,,qsvsssy,gas,qqygssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96710,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,eivltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgpgtkvdik,,,,qgissy,aas,qqlnsyplt,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96709,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,airmtqsplslpvtlgqpasiscrssqslvysdgntyliwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlnisrveaedvgvyycmqgthwpltfgqgtrleik,,,,qslvysdgnty,kvs,mqgthwplt,,,IGKJ5*01 (human),IGKV2-30*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96708,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,,,,qgirnd,aas,lqhnsypyt,,,IGKJ2*01 (human),IGKV1-17*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QTI96707,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qsissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99210,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,,,,nigskt,dds,qvwdsssdhyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99209,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99208,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqpssvsvfpgqtaritcsgdvlekkyarwfqqkpgqapllviykdserpsgiperffgsssgttvtltisgaqvedeadyycysaadnnrgvfgggtkltvl,,,,vlekky,kds,ysaadnnrgv,,,IGLJ2*01 (human),IGLV3-27*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99207,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvfgtgtkvtvl,,,,alpkqy,kds,qsadssgtyv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99206,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqplsvsvalgqtaritcggnnigsknvhwyqqkpgqapvlviyrdsnrpsgiperfsgsnsgntatltisraqagdeadyfcqvwdsstvvfgggtkltvl,,,,nigskn,rds,qvwdsstvv,,,IGLJ2*01 (human),IGLV3-9*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99205,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigtnyvywyqqlpgtapklliyrntqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaswddshvvfgggtkltvl,,,,ssnigtny,rnt,aswddshvv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99204,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,enn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99203,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaevfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsaev,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99202,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapqlliydnnkrpsripdrfsgsksgtsatlgitglqtgdeavyycgtwdsslsavvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsavv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99201,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedesdyycssyttsstlyvfgtgtkvtvl,,,,ssdvggyny,evs,ssyttsstlyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99200,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeaayyccsyvgsstyvvfgggtkltvl,,,,ssdvgsynl,egs,csyvgsstyvv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99199,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeahyycgtwdsslsagvfgggtkltvl,,,,ssnignny,enn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99198,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytnsrtldvvfgggtkltvl,,,,ssdvggyny,evs,ssytnsrtldvv,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99197,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstllfgggtklrs,,,,ssdvggyny,evs,ssytssstll,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99196,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdvvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsdvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99195,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqatdeadyycqawdsstgvfgtgtkvtvl,,,,klgdky,qdn,qawdsstgv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99194,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyswvfgggtkltvl,,,,alpkqy,kds,qsadssgtyswv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99193,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtitctgsssnigsgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeahyycqsydssvvfgggtkltvl,,,,ssnigsgyd,gnt,qsydssvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99192,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitlsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistlvfgtgtkvtvl,,,,ssdvggyny,evs,ssytsistlv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99191,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmkfnsdgthskgdgipdrfsgsssgaersltisslqsedeadyycqtwgtggvfgggtkltvl,,,,sghssya,fnsdgth,qtwgtggv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99190,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyccystdssdnhrrvfgtgtkvtvl,,,,alpkky,eds,ystdssdnhrrv,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99189,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigrntvnwfqqlpgtapklliysnyqrpsgvpdrlsgsksgtsaslairglqsedeadyycaawddslhgwvfgggtkltvl,,,,ssnigrnt,sny,aawddslhgwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99188,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,,,,nigskg,dds,qvwdstsdhpgyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99187,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltlsglqaedeadyycssytssstlyvfgtgtkvtvl,,,,ssdvgsyny,evs,ssytssstlyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99186,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,,,,ssdvgayny,evs,ssytssstpyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99185,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyyccshagsstsyifgtgtkvtvl,,,,ssdvgsynl,dvs,cshagsstsyi,,,IGLJ1*01 (human),IGLV2-23*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99184,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvgvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfvgv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99183,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,,,,nigskg,dds,qvwdstsdhpgyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99182,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99181,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysaprtfgqgtkveik,,,,qsvlyssnnkny,was,qqyysaprt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99180,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgggtkveik,,,,qdisny,das,qqydnllt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99179,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,,,,qsvssy,das,qqrsnwppsit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99178,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgkratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqxygsspntfgqgtkleik,,,,qsvsssy,gas,qxygsspnt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99177,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,,,,qsllhsngyny,lgs,mqalqtprt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99176,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwvtfgggtkveik,,,,qsvssn,gas,qqynnwvt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99175,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyslltfgggtkveik,,,,qsissw,kas,qqynsysllt,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99174,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappgftfgpgtkvdik,,,,qgisny,aas,qkynsappgft,,,IGKJ3*01 (human),IGKV1-27*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99173,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,,,,qsvssy,das,qqrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99172,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvslgeratlscrasqsvtsslawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqynnwppwtfgqgtkvevt,,,,qsvtss,gas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99171,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkvdik,,,,qsissy,aas,qqsystpft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99170,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinslepedfavyycqqrsnwppeytfgqgtkleik,,,,qsvssf,das,qqrsnwppeyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99169,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,,,,qsvssy,das,qqrsnwppvit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99168,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkleik,,,,qsvssy,das,qqrsnwppt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99167,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvssiy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99166,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsissylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpplltfgggtkveik,,,,qsissy,das,qqrsnwppllt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99165,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprtfgqgtkveik,,,,qsvsssy,gas,qqygsspprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99164,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveik,,,,qgissa,das,qqfnnyplt,,,IGKJ4*01 (human),IGKV1-13*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99163,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkltfgggtkveik,,,,qsvssy,das,qqrsnwppklt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99162,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,,,,qslvysdgnty,kvs,mqgthwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99161,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlhtfgqgtkleik,,,,qsissy,aas,qqsystlht,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99160,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,,,,qsvlyssnnkny,was,qqyystpyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99159,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsyrpwtfgqgtkveik,,,,qgirnd,aas,lqhnsyrpwt,,,IGKJ1*01 (human),IGKV1-17*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99158,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygsspplftfgpgtkvdik,,,,qsvsssy,gas,hhygsspplft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99157,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgpgtkvdik,,,,qsvssy,das,qqrsnwpprvt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99156,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,,,,qsvssf,das,qqrsnwppsit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99155,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsfgggtkveik,,,,qsvsssy,gas,qqygs,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99154,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkvdik,,,,qgisny,aas,qkynsapft,,,IGKJ3*01 (human),IGKV1-27*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99153,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisslqsedfavyychqyynwppwtfgqgtkveik,,,,qsvssn,gas,hqyynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99152,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgeratlscrasqsvssklawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwwtfgqgtkveik,,,,qsvssk,gas,qqynnwwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99151,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,,,,qsvssy,das,qqrsnwppvit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99150,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppeytfgqgtkleik,,,,qsvssf,das,qqrsnwppeyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99149,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqtpatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrynwppeltfgggtkveik,,,,qsvsry,das,qqrynwppelt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99148,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvtnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpntfgqgtrleik,,,,qsvtny,das,qqrsnwpnt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99147,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlviydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtrleik,,,,qsvsssy,das,qqygsspqt,,,IGKJ5*01 (human),IGKV3D-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99146,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssqlawyqqkpgqaprllisdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkveik,,,,qsvssq,das,qqrsnwprt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99145,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyytyswtfgqgtkleik,,,,qsistw,kas,qqyytyswt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99144,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqlqpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiptfgqgtkveik,,,,qsvlyssnnkny,was,qqyysipt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99143,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppytfgqgtkleik,,,,qsvssn,gas,qqynnwppyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99142,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqrkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavfycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99141,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppritfgqgtrleik,,,,qsvssf,das,qqrsnwpprit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99140,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwppgitfgqgtrleik,,,,qsvsnf,das,qhrsnwppgit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99139,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99138,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwlaltfgggtkveik,,,,qsvssn,gas,qqynnwlalt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99064,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,,,,qsinny,aas,qqsyspyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99063,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,digmtqspstlsasvgdrvtitcrasqsisswlawyqhkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysftfgpgtkvdpk,,,,qsissw,kas,qqyntysft,,,IGKJ3*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99062,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqynsyprtfgqgtkveik,,,,qgirnd,aas,lqynsyprt,,,IGKJ1*01 (human),IGKV1-17*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99061,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletrvpsrfsgsgsgtdftftisslqpediatyycqhyttfgggtkveik,,,,qdisnf,das,qhytt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99060,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,airmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyfcqqyystpltfgggtkveik,,,,qsvlyssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99059,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqsplslpvtpgepasiscrssqsllhingynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkveik,,,,qsllhingyny,lgs,mqalqtpwt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99058,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,,,,qsllhsngyny,lgs,mqalqtpft,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99057,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleik,,,,qgissw,aas,qqgnsfpyt,,,IGKJ2*01 (human),IGKV1-12*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99056,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppitfgqgtrleik,,,,qsvssn,gas,qqynkwppit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99055,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdfiltirrlepedfavyycqqygsslytfgqgtkleik,,,,qsvssny,gas,qqygsslyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99054,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspvslsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,,,,qsvssn,gas,qqyynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99053,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliystssravgipdrfsgggsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,,,,qsvssiy,sts,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99052,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspsslstsvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpttfgqgtrleik,,,,qdisky,das,qqydnlptt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99051,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyvasnletgvpsrfsgsgfgtdftftisslqpediatyycqqfdnlpytfgqgtkleik,,,,qdisny,vas,qqfdnlpyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99050,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcqasqdisnylncyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqynnlpltfgggtkveik,,,,qdisny,das,qqynnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99049,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpaqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppltfgpgtkvdik,,,,qsvssty,gas,qqygsspplt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99048,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqdissalawyqqkpgktpkiliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveik,,,,qdissa,das,qqfnnyplt,,,IGKJ4*01 (human),IGKV1-13*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99047,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eixltqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgtparfsgsgsgteftltisslqsedfavyycqqynywppytfgqgtkleik,,,,qsvrsn,gas,qqynywppyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99046,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvnnylawyqqkpgqaprlliydashratdiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,,,,qsvnny,das,qqrsnwplt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99045,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyynsytfgqgtkleik,,,,qsvlyssnnkny,was,qqyynsyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99044,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qtissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99043,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,,,,qsvsssy,gas,qqygtspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99042,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgsssdvggydfvswyqqhpgkapkvviydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvl,,,,ssdvggydf,dvt,ssytssstrv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99041,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstgvfgggtkltvl,,,,klgdky,qdt,qawdsstgv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99040,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstsyvvfgggtkltvl,,,,ssdvgsynl,evs,csyagsstsyvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99039,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgapgqrvtisctgsgsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgpvvigggtkltvl,,,,gsnigagyd,gnn,qsydsslsgpvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99038,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qlvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvlfgggtkltvl,,,,ssnignny,dnn,gtwdsslsvvl,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,QSI99037,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynvvswyqqhpgkapqlmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstswvvfgggtkltvl,,,,ssdvgsynv,evs,csyagsstswvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15864,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,,gftfssyd,igtagdt,arasfdssgylnyfdy,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15863,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyycarhvqwlvlyyfdywgqgtlvtvss,,ggsissssyy,iyysgst,arhvqwlvlyyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15862,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartrggsyyygmdvwgqgttvtvss,,gftfssyg,isydggnk,artrggsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15861,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaemkepgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqdrvtitadeststaylelsslrsedtavyycaresttifgvviltsygmdvwgqgttitiss,,ggtfssya,iipifgta,aresttifgvviltsygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15860,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgggliqpggslrlscaasvfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrddskntlylqmnslraedtavyycarsrggpldywgqgtlvtvss,,vfivssny,iysggst,arsrggpldy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15859,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkepgasvkvsckasgytftsygiswvrqapgqglewmgwisaydgntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregsdyydssgfhdywgqgtlvtvss,,gytftsyg,isaydgnt,aregsdyydssgfhdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15858,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkgltwighisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycarqlwlrapfdywgqgalvtvss,,ggsissgdyy,isysgst,arqlwlrapfdy,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15857,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpgrslrltcaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrpedtalyycakddssswyfysraklgqyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akddssswyfysraklgqyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15856,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgsglvkpsqtlsltcavsggsidsggdswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsnnqfslklssvtaadtavyycarhsgydlggafdiwgqgtmvtiss,,ggsidsggds,iyhsgst,arhsgydlggafdi,,,,IGHJ3*02 (human),IGHV4-30-2*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15855,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewlggfdpedaetiyaqkfqgrvtmtedtstdtaymglssltsedtavyycatgvavagtqknysyyygldvwgqgttvtvss,,gytltels,fdpedaet,atgvavagtqknysyyygldv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15854,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvasgggvvqpgrslrlscaasgfiitsygmhwvrqapgkglewvaaiwydgsnkyyadsvkgrftisrdnskntlylqmnspraedtavyycarddptpdgdafdiwgqgtmvtvss,,gfiitsyg,iwydgsnk,arddptpdgdafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15853,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvkpggslrlscaasgftfstysmnwvrqapgkglewvssisssstdihyadsmkgrftisrdnaknslylqmnslraedtavyycardfhrgwydhsayifdfwgqgtlvtvss,,gftfstys,isssstdi,ardfhrgwydhsayifdf,,,,IGHJ5*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15852,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsviswhsgsidyadsvkgrftisrdnaknslylqmnslraedtalyhcakgtgysygyavdggfdywgqgtlvtiss,,gftfddya,iswhsgsi,akgtgysygyavdggfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15851,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyisssgstkyygdsvkgrftisrdnaknslylqlnslrdedtavyycartiysydssgyygteryfdywgqgtlvtvss,,gftfssys,isssgstk,artiysydssgyygteryfdy,,,,IGHJ4*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15850,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgeslkisckgsgysftnswiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdsamyycarlgswyvyyyyyaldvwgqgplvtvss,,gysftnsw,iypgdsdt,arlgswyvyyyyyaldv,,,,IGHJ5*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15849,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgfyihwvrqapgqglewmgwinpnsggsncaqkfqgrvtmtrdtsistaymevsrlrsddtavyycarysnyyyyygmdvwgqgttvtvss,,gytftgfy,inpnsggs,arysnyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15848,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavygesfsgyywswirqppgkglewigeiihsgstnynpplksrvtisvdtsksqfslklssvtaadtavyycaremsvavvdhwgqgtlvtvss,,gesfsgyy,iihsgst,aremsvavvdh,,,,IGHJ1*01 (human),IGHV4-34*12 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15847,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgtevkkpgasvkvsctasgytftvcyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvarhyydrsgnlhsadyfqhwgqgtlvtiss,,gytftvcy,inpnsggt,arvarhyydrsgnlhsadyfqh,,,,IGHJ1*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15846,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsggtdyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycaslsaagplndvfdiwgqgtmvtvss,,gytftdyy,inpnsggt,aslsaagplndvfdi,,,,IGHJ3*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15845,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitspgsaiyyadsvkgrftisrdnaknslylqmnslraedtalyyctrdgvipprfdywgqgtmvtvss,,gftfsdyy,itspgsai,trdgvipprfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15844,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasefivsrnymnwvrqapgkglewvsliysggttyyadavkgrftisrdnskntlylqmnslraedtavyycargfgdrrldywgqgtlvtvss,,efivsrny,iysggtt,argfgdrrldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15843,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydgstkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdrgtliegmdvwgkgttvtvss,,gftfssyg,isydgstk,akdrgtliegmdv,,,,IGHJ6*04 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15842,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpggslrlscaasglifshygmhwvrqapgkglewvafirndgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggyyyessgwfdywgqgtlvtvss,,glifshyg,irndgtnk,akdggyyyessgwfdy,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15841,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsshamnwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaksmfgydssgyfygedfdywgqgtlvtiss,,gftfssha,isgsggst,aksmfgydssgyfygedfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15840,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggstsssfhywgwirqppgkglewigniyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlgsgsyytadywgqgtrvtiss,,ggstsssfhy,iyysgst,arlgsgsyytady,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15839,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfisyamhwvrqapgkglewvavisydgnnkyysdsvkgrftisrdnskntlhlqmnslraedtavyycakdlsggysywdywgqgtlvtvss,,gftfisya,isydgnnk,akdlsggysywdy,,,,IGHJ4*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15838,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgdtftsydvnwvrqatgqglewmgwmdpnsgntgyaqnfqgrvtmtrstsigtaymelsslrsedtavyycarskergyynrtgyyypgdwfdpwgqgtlvtvss,,gdtftsyd,mdpnsgnt,arskergyynrtgyyypgdwfdp,,,,IGHJ5*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15837,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgdsisnnyaywgwirqppgkglewignlyysgstyynpslksrvtisvdtsenqfslrlssvtaadtavyycarlpygydyveafdiwgqgtlvtiss,,gdsisnnyay,lyysgst,arlpygydyveafdi,,,,IGHJ5*01 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15836,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvafisydgsnqystdpvkgrftfardnskdtlylqmnslrgddtavyycaksrggnyfdafdmwgqgtmvtvss,,gftfssna,isydgsnq,aksrggnyfdafdm,,,,IGHJ3*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15835,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvetgggliqpggslrlscaasgftvtanymswvrqapgkglewvstiysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycarergakafdpwgqgalvtvss,,gftvtany,iysggst,arergakafdp,,,,IGHJ5*02 (human),IGHV3-53*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15834,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgrglewvavisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakpysgsywsyfdywgqgtlvtvss,,gftfsgyg,isydgsnk,akpysgsywsyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15833,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissygkywswirqhpgkglewigyiyysgstqynpslksrvtisvdtsknqfslklnsvtaadtavyycardsaaghfdywgqgtlvtvss,,ggsissygky,iyysgst,ardsaaghfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15832,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgnthyaqkfqervtitrdmststaymelsslrsedtavyycaapyctttrchdgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapyctttrchdgfdi,,,,IGHJ3*02 (human),IGHV1-58*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15831,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrltifrdnskntlylqmnslraedtavyycaregadrsgwwgsfdywgqgtlvtvss,,gftfssyg,isydgsdk,aregadrsgwwgsfdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15830,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardrfgrindywgqgtlvtvss,,gitvnsny,iysggst,ardrfgrindy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15829,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckafgysftsfnlnwvrqapgqglewmgwisayngntsyaqkfqgrvtmttdtstttvymelrslrsddtavyycaralenyydrngnyyvgafdywgqgslvtvss,,gysftsfn,isayngnt,aralenyydrngnyyvgafdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15828,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsrtscqdgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapncsrtscqdgfdi,,,,IGHJ3*02 (human),IGHV1-58*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15827,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfsiywmhwvrqapgkglvwvsrinsdgsstsnadsvkgrftisrdnakntlylqmnslraedtavyycardhvvaatpgmdvwgqgttitvss,,gftfsiyw,insdgsst,ardhvvaatpgmdv,,,,IGHJ6*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15826,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfvaedgetiyaqkfqgrvsmtedtstdtaymelsslrsedtavyycatdrarldyfasgsyyghfdywgqgtlvtvss,,gytltels,fvaedget,atdrarldyfasgsyyghfdy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15825,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfmfssynmnwvrqapgkglewvssisssssyiyyedsvkgrftisrdnaknslylqmislsaedtavyycarmayfdssgyypnafdiwgqgtmvtvss,,gfmfssyn,isssssyi,armayfdssgyypnafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15824,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfifssydmhwvrqatgkglewvsgignagdthypgavkgrftisrenaknslylqmnslragdtavyycarahrgyydrsgyyhnpdafdiwgqgttvtiss,,gfifssyd,ignagdt,arahrgyydrsgyyhnpdafdi,,,,IGHJ3*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15823,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgysftsygiswvrqapgqglewmgwisafnnnanyvqkfqgrvtmttdtststaylelrslrsddaavyycardddnydttgyylywgqgtlvtiss,,gysftsyg,isafnnna,ardddnydttgyyly,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15822,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsgdtfrsysiswvrqapgqglewmgriipilgipnyaqkfqgrvtitadkstntaymelsslrsedtavyycarespycssttclsdywgqgtlvtiss,,gdtfrsys,iipilgip,arespycssttclsdy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15821,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglewigsmyysgntyynpplqsrvtisvdtsknqvslslssvtaadtalyycarhpdicdfwsgypgwfdpwgqgtlvtvss,,ggsisstsyy,myysgnt,arhpdicdfwsgypgwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15820,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgkslrlscaasgltfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegwgysygsyyfdywgqgtlvtvss,,gltfssyg,isydgsnk,akegwgysygsyyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15819,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycastprgdsygggaywgqgtlvtvss,,gftvssny,iysggst,astprgdsygggay,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15818,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggalvqpggslrlsceasefivsrnymnwvrqapgkglewvsviysggstfyadsvkgrfiisrdnskntlylqmnslraedtavyycarelvgyfdywgqgtlvtvss,,efivsrny,iysggst,arelvgyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15817,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyytdsvkgrftisrdnskntlylqmnslrpedravyycakdaadsritmfgvviishfdywgqgtlvtvss,,gftfssyg,isydgsnk,akdaadsritmfgvviishfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15816,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewassissnssciyyadsvkgrftisrdnaknslylqmnslraedtavyycasgehnyyyyygmdvwgqgttvtiss,,gftfssys,issnssci,asgehnyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15815,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqqsgaevkkpgasvkdsckasgytftsygiswvrqapgqglewvgwisayngntnyglklqgrvtmttdtststaymelrslrsddtavyycarahpfydsggysdywgqgslvtvss,,gytftsyg,isayngnt,arahpfydsggysdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15814,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrltcaasgfifssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyyctkadyydfwsgyqktyyyymdvwgkgttvtiss,,gfifssyg,isydgsyk,tkadyydfwsgyqktyyyymdv,,,,IGHJ6*04 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15813,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvetgggliqpggslrlscaasgltvsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycarniyddafdvwgqgtmvtvss,,gltvsany,iysggst,arniyddafdv,,,,IGHJ3*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15812,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtiss,,gfsfssys,issnsnyi,asnrspydssnyyfdy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15811,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnggiidyadsvkgrftisrdnaknslylhmrslraedtafyycakdigpfeaarpggnyyyyamdvwgqgttvtvss,,gftfddya,iswnggii,akdigpfeaarpggnyyyyamdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15810,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvtsnnyywgwirqppgeglewigsiyytgstfynpslksrvtisvdasknqfslklssvtaadtavyyctrqlvlvrgyfdywgqgtlvtiss,,ggsvtsnnyy,iyytgst,trqlvlvrgyfdy,,,,IGHJ4*01 (human),IGHV4-59*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15809,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgpglvkpsqtlsltctvsggsissgsyfwswirqpagkglewigriftsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargpdivvvpaadprnwfdpwgqgtlvtvss,,ggsissgsyf,iftsgst,argpdivvvpaadprnwfdp,,,,IGHJ5*02 (human),IGHV4-61*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15808,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvetgggliqpggslrlscatsgftvssnymtwvrqapgkglewvstiysggstyyadsvkgrfsisrdsskntlylqmnslraedtavyycargpyphfdywgqgtlvtvss,,gftvssny,iysggst,argpyphfdy,,,,IGHJ4*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15807,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyycakdiksfgifgvvtafdywgqgtlvtvss,,gftfddya,iswnsgsi,akdiksfgifgvvtafdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15806,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtvss,,gftfsnyg,isydgsne,akkgysygyfdyyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15805,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaresygmdvwgqgttitvss,,gitvssny,iysggst,aresygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15804,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgfifddyaihwvrqgpgkglewvsgiswnsgsigygdsvkgrftisrdnaknslylqmnslraedtafyycakggrraamllnyfdywgqgtlvtvsa,,gfifddya,iswnsgsi,akggrraamllnyfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15803,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvrgrftisrdnaknslflqmnslraedtalyycardpfsrwerpegwfdpwgqgtlvtiss,,gftfssys,isssssyi,ardpfsrwerpegwfdp,,,,IGHJ5*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15802,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgrifpilgianyaqkfqnrvtitadrststafmelsslrsedtavyycardqdsgyiwwfdpwgqgtlvtvss,,ggtfssyt,ifpilgia,ardqdsgyiwwfdp,,,,IGHJ5*02 (human),IGHV1-69*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15801,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtiss,,gftfsnyg,isydgsne,akkgysygyfdyyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15800,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytlteismhwvrqapgkglewmggfdpeegetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsevvvpgairhkaayyynymdvwgkgttvtiss,,gytlteis,fdpeeget,atsevvvpgairhkaayyynymdv,,,,IGHJ6*04 (human),IGHV1-24*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15799,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstnamhwvrqapgkglewvalisydgsnkyyavsakgrfiisrdnskntlhlqmsslraedtavyycvkglggnyyyfgfwgqgtlvtiss,,gftfstna,isydgsnk,vkglggnyyyfgf,,,,IGHJ1*01 (human),IGHV3-30*15 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15798,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmvgqycsggncylgyfdywgqgtlvtvss,,gftfstyg,isydgsnk,akmvgqycsggncylgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15797,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissttsytnyadsakgrftisrdnaknslylqmnslraedtavyycardvayyydsgsyyyfdywgqgtlvtvss,,gftfsdyy,issttsyt,ardvayyydsgsyyyfdy,,,,IGHJ4*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15796,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmmgqycsggdcysgyfdywgqgtlvtvss,,gftfssyg,isydgsnk,akmmgqycsggdcysgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15795,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsfiypggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycarsygdyyfdywgqgtlvtvss,,gftvssny,iypggst,arsygdyyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15794,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlslsctvsggsispyywswirqlpgkglewigyiyytgstnynpslkgrvtmsadmsknqfslnlssvtaadtamyycargydfwsrgtlvtvss,,ggsispyy,iyytgst,argydf,,,,IGHJ2*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15793,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgitwnsgtigyadsvkgrftiskdnaknslylqmnrlraedtafyycakdltgwgltfggvitnwgqgtlvtiss,,gftfddya,itwnsgti,akdltgwgltfggvitn,,,,IGHJ1*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15792,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslksedtavyycateehpfagraklhhldywgqgtlvtvss,,gftfsnaw,iksktdggtt,ateehpfagraklhhldy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15791,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftiyymhwvrqapgqglewmgiinpgggsrsyaqrfqgrvtmtrdtststvymelsslrsedtavyycargrycsssscyigldywgqgtlvtvss,,gytftiyy,inpgggsr,argrycsssscyigldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15790,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqprgslrlscaasgftfstywmtwvrqapgkglewvanigqdgseryfvdsvkgrftisrdnannslylqmnslraedsavyycardytddygdyggyfdlwgrgtlvtvss,,gftfstyw,igqdgser,ardytddygdyggyfdl,,,,IGHJ2*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15789,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsgdsissshwwswvrqppgkglewigeiyhsgstnynpslksrvtisveksknqfslklssvtaadtavyycarrrlgpssnnsgyfywgqgtlvtvss,,gdsissshw,iyhsgst,arrrlgpssnnsgyfy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15788,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfifsnyrmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardsvpryyyhyygmdvwgqgttvtvss,,gfifsnyr,isssssti,ardsvpryyyhyygmdv,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15787,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfniyvmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycakgrsgsyfnpldywgqgtlvtiss,,gftfniyv,isydgsne,akgrsgsyfnpldy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15786,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgtnkyyadsvngrftisrdnskntlylqmdslragdtavyycarpnsgsyssyldywgqgtlvtvss,,gftfssyg,isydgtnk,arpnsgsyssyldy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15785,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvhpggslrlscaasgftfssywmswvrqapgkglewvanikedgrekyyvdyvkgrftisrdnaknslylqmnslraedtavyycardsvhyyydssgyhysygmdvwgqgttvtiss,,gftfssyw,ikedgrek,ardsvhyyydssgyhysygmdv,,,,IGHJ6*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15784,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcaahggsfsgynwswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqlslklssvtaadtavyycarggtigttgiydiltgydpffdywgqgtlvtvss,,ggsfsgyn,inhsgst,arggtigttgiydiltgydpffdy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15783,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgnwndvlshyyyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akgnwndvlshyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15782,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctgsgftfgdyamswfrqapgkglewvgfirsedhggtteyaasvkgrftisrddsksiaylqmnslktedtavyycsrpltyyydssgyyypyyfdywgqgtlvtiss,,gftfgdya,irsedhggtt,srpltyyydssgyyypyyfdy,,,,IGHJ4*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15781,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgwggynthfdywgqgtlvtvss,,gftfssyg,isydgsnk,akgwggynthfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15780,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftiywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrtltttygmdvwgqgttvtvss,,gysftiyw,iypgdsdt,arrtltttygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15779,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakshsgsyfssgdywgqgtlvtvss,,gftfssyg,isydgsnk,akshsgsyfssgdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15778,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarenydfwsgyfngwfdpwgqgtlvtvss,,ggsissyy,iyysgst,arenydfwsgyfngwfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15777,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrhdskntlylqmnslktedtavyycttasnpdywgqgtrvtvss,,gftfsnaw,iksktdggtt,ttasnpdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15776,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardtrgrgghdafdiwgqgtmvtiss,,gytftsyg,isayngnt,ardtrgrgghdafdi,,,,IGHJ3*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15775,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygthwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpdsgsywgafdiwgqgtmvtvss,,gftfsnyg,isydgsnk,arpdsgsywgafdi,,,,IGHJ3*02 (human),IGHV3-30*03 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15774,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdladgetiyaqefqgrvtmtedtstdtaymalsslrsedtavyycatgpltiavagqwfdpwgqgtlvtiss,,gytltels,fdladget,atgpltiavagqwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15773,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftiprdnskntlylqmnslraedtavyycakggsgyryyfdywgqgtlvtvss,,gftfssyg,isydgsnk,akggsgyryyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15772,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksafgsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,aksafgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15771,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqvgatsgidywgqgtlvtvss,,gftfssyg,iwydgsnk,ardgqvgatsgidy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15770,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycashpyydssgyypnygmdawgqgttvtvss,,ggtfssya,iipifgta,ashpyydssgyypnygmda,,,,IGHJ6*01 (human),IGHV1-69*15 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15769,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnrlrdedtavyycardrcgdcygpyyygmdvwgqgttvtvss,,gftfssys,isssssti,ardrcgdcygpyyygmdv,,,,IGHJ6*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15768,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaarsyyyygmdvwgqgttvtvss,,gftfssys,isssssyi,ardldivvvpaarsyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15767,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptivvvavnptfdywgqgtlvtvss,,gftfstyg,isydgsnk,akdptivvvavnptfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15766,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyygdsvkgrftisrdnskntlylqmnslraedtavyycardfregafdiwgqgtmvtvss,,gftvssny,iysggst,ardfregafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15765,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfssywmhwvrqapgkglvwvsriniygsstsyadsvkgrftisrdnakntlylqmnslraedtavyycardlhydssgwdywgqgtlvtvss,,gftfssyw,iniygsst,ardlhydssgwdy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15764,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsgtlsltcavsggfisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrycsggscgyfdywgqgtlvtvss,,ggfisssnw,iyhsgst,asrycsggscgyfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15763,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycaraqyssgwylrfdywgqgtlvtvss,,gftfssyd,igtagdt,araqyssgwylrfdy,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15762,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargaasvlrflewlldywgqgalvtvss,,gytftgyy,inpnsggt,argaasvlrflewlldy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15761,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevknpgasvkvsctasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycalvgatdywgqgtlvtvss,,gytftsyg,isayngnt,alvgatdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15760,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycakafkgnyyygmdvwgqgttvtvss,,gftfssyg,isydgink,akafkgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15759,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardrppivvvttyyyygmdvwgqgttvtvss,,ggtfssya,iipifgta,ardrppivvvttyyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*15 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,QTX15758,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgpglvkssqtlpltctvsgasinsnnyywnwirqpagkglewigrihssgntnyspslrsrltisvdtsknqfsleltsvtaadtavyycarddwttaldcwgqgtlvtvss,,gasinsnnyy,ihssgnt,arddwttaldc,,,,IGHJ5*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15757,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipdwtfgpgtkveik,,,,qsirny,aas,qqsygipdwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15756,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynsvswyqhhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagrytlvfgggtkltvl,,,,ssdvggyns,dvs,csyagrytlv,,,IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15755,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftptisslqpedfatyycqqsystppytfgqgtkveik,,,,qsissy,aas,qqsystppyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15754,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsirswlawyqqkpgkapkvliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynyysvtfgqgtkveik,,,,qsirsw,das,qqynyysvt,,,IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15753,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipxwtfgpgtkleik,,,,qsirny,aas,qqsygipxwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15752,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyvtfgpgtkleik,,,,qsissw,kas,qqynsyvt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15751,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgisgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,,,,sgsiasny,edn,qsydsskyvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15750,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvnnylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedlavyycqqcsnwppsltfgggtkveik,,,,qsvnny,das,qqcsnwppslt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15749,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmisevskrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagsnnwvfgggtkltvl,,,,ssdvggyny,evs,nsyagsnnwv,,,IGLJ3*02 (human),IGLV2-8*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15748,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpitfgqgtrleik,,,,qslvhsdgnty,kis,mqatqfpit,,,IGKJ5*01 (human),IGKV2-24*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15747,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqppsvsvapgqtaritcggnsigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwhissdhlwvfgggtkltvl,,,,sigskt,dds,qvwhissdhlwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15746,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysftfgpgtkkdik,,,,qsissw,das,qqynsysft,,,IGKJ3*01 (human),IGKV1-5*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15745,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssnigsytvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngyvfgtgtkvtvl,,,,ssnigsyt,snn,aawddslngyv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15744,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspatlslspgeratlscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkleik,,,,qsvssy,das,qqrsnwpt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15743,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvsrnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynngrgtfgpgtkleik,,,,qsvsrn,gas,qqynngrgt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15742,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqtplslpvtpgepasiscrsgqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpwtfgqgtkleik,,,,qslldsddgnty,tls,mqriefpwt,,,IGKJ1*01 (human),IGKV2-40*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15741,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeatyycnsytssstyvlfgggtkltvl,,,,ssdiggyny,dvt,nsytssstyvl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15740,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnflnwyqekpgkapkllisdasnletgvpsrfsgsgsgtdftftitslqpediatyycqqydnllitfgqgtrleik,,,,qdisnf,das,qqydnllit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15739,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqpptvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperisgsssgtmatltisgaqvedgadyycysidssgnhyvfgtgtkvtvl,,,,alpkky,eds,ysidssgnhyv,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15738,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcqasqdiskylnwyqrkpgtaptlliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkveik,,,,qdisky,das,qqydnlpt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15737,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqfgewftfgqgtkleik,,,,qdinny,das,qqfgewft,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15736,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqppsvseaprqrvtiscsgsssnignnpvnwyqqlpgkapkpliyyddllpsgvsdrfsgsrsatsaslaisglqsedeadyyctawdgslngyvfgsgtkvtvl,,,,ssnignnp,ydd,tawdgslngyv,,,IGLJ1*01 (human),IGLV1-36*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15735,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqksgqaprlliygassratgipdrfsgsgsgtdftltisrlqpedfavyycqqygsspmytfgqgtkleik,,,,qsvsssy,gas,qqygsspmyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15734,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipptfgggtkvdik,,,,qsissy,aas,qqsysippt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15733,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgteftftitslqpediatyycqqydtlpptfgpgtkvdik,,,,qdisny,das,qqydtlppt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15732,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgggsgtdftltisslepedfavyycqqrsnwrtfgqgtkleik,,,,qsvssy,dts,qqrsnwrt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15731,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslgpedfavyycqqrsnwpptwtfgqgtkleik,,,,qsvsss,das,qqrsnwpptwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15730,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdgvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgggsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15729,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qsissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15728,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcqasqdirnylnwyqqtpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyychqydnlpqsfgggtkvdik,,,,qdirny,das,hqydnlpqs,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15727,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlhssnnknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyhcqqyystpltfgggtkveik,,,,qsvlhssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15726,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgagtyftftisslqpediatyycqqydnlpplftfgpgtkveik,,,,qdinny,das,qqydnlpplft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15725,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsllftfgpgtkleik,,,,qsvsrsy,gas,qqygsllft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15724,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspdslavslgeratinckssqsvlhnsknksylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyggrwtfgqgtkvdik,,,,qsvlhnsknksy,was,qqyyggrwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15723,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlpgtfgqgtkleik,,,,qdisny,das,qqydnlpgt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15722,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspgtlslspgeratlscrashnissthlvwyqqkpgqaprlliygasnratgipdrfsgggsgtdftltisrlepedfavyfcqqfgsspqtfgqgtkvdik,,,,hnissth,gas,qqfgsspqt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15721,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspgtlslspgeratlscrasqsvssshlawyqqksgqaprlfiygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,,,,qsvsssh,gas,qqygssppwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15720,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspeqtasitcsgdklgdkyacwyqqkagqspvlviyedgkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdrttavfgggtkltvl,,,,klgdky,edg,qawdrttav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15719,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgirsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlntyaltfgggtkleik,,,,qgirsy,aas,qqlntyalt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15718,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppwtfgqgtkleik,,,,qsvssn,gas,qhyynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15717,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqpasvsgspgqsitisctgtssdvgvydyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlyvfgtgtkvtvl,,,,ssdvgvydy,evs,ssytssstlvlyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15716,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspstlsasvgdrvtitcrasqsisrwlawyqqipgkapnlliyqtsslqsgvpsrfsgsgsgteftltisslqpddfatyycqqyysypltfgggtkveik,,,,qsisrw,qts,qqyysyplt,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15715,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqfpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssridvvfgggtkltvl,,,,nsnigagyd,dnt,qsydssridvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15714,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qavvtqppsvsgapgqrvtisctgsssnigagydihwyqqlpgtapklliynnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,,,,ssnigagyd,nns,qsydsslsgyv,,,IGLJ1*01 (human),IGLV1-40*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15713,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyhqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15712,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqspsasaslgasvkltctlssghssnaiawhqqqpekgprylmklnidgshrkgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgpnwvfgggtkltvl,,,,sghssna,lnidgsh,qtwgtgpnwv,,,IGLJ3*02 (human),IGLV4-69*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15711,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsflsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgygsgteftltisslqpedfatyycqhlnsyprytfgqgtkleik,,,,qgirnd,aas,qhlnsypryt,,,IGKJ2*01 (human),IGKV1-17*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15710,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsafvgdrvtiicrasqsisswlawyqqkpgkapklliykasslesgvpstfsgsgsgteftltisslqpddfatyfcqqynsypytfgqgtkveik,,,,qsissw,kas,qqynsypyt,,,IGKJ1*01 (human),IGKV1-5*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15709,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslavtpgepasiscrssqsllhsdgynyldwylqkpgqspqlltylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtsitfgqgtrleik,,,,qsllhsdgyny,lgs,mqalqtsit,,,IGKJ5*01 (human),IGKV2-28*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15708,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqqpgkapklllyaasrlasgvpsrfsgsgsgtdytltisslqpedfatyycqqyysapptfgqgtkveik,,,,qgitns,aas,qqyysappt,,,IGKJ1*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15707,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqitfgqgtrleik,,,,qsvsssy,gts,qqygsspqit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15706,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspsslsasvgdrvtitcrasqgvssylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppgtfgqgtkleik,,,,qgvssy,aas,qqlnsyppgt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15705,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveik,,,,qdisny,das,qhhdslplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15704,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qtvvtqapsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnvvvfgggtkltvl,,,,ssnigsnt,sdn,aawddslnvvv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15703,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qavvtqprsvsgspgqsvtisctgtssdvgaynfvswyqqhpgkapklmtydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsfyvfgtgtkvtvl,,,,ssdvgaynf,dvt,csyagsfyv,,,IGLJ1*01 (human),IGLV2-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15702,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgegatlscrasqsvgrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgggtkvdik,,,,qsvgry,das,qqrsnwppft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15701,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqsediatyycqqydnlpitfgqgtrleik,,,,qdirny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15700,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqpwrltfgggtkveik,,,,qsllhsdgkty,evs,mqsiqpwrlt,,,IGKJ4*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15699,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,,,,qsllhsdgkty,evs,mqsiqlpvt,,,IGKJ5*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15698,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsisstylawyqqkpgqaprllihgassratgisdrisgsgsgtdfiltisrlepedfavyycqqygsspgtfgqgtkveik,,,,qsissty,gas,qqygsspgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15697,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspatlsvslgeratlscrasqsvssnlawyqqkpgraprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppsitfgqgtrleik,,,,qsvssn,gas,qqynnwppsit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15696,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspssvsasvgdrvtitcrasqgissglawyrqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpytfgqgtkvdik,,,,qgissg,aas,qqansfpyt,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15695,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qtvvtqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,,,,ssnigagyd,gns,qsydssligsv,,,IGLJ1*01 (human),IGLV1-40*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15694,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,,,,qsllhsdgkty,evs,mqsiqlpvt,,,IGKJ5*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15693,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgqapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpadfatyycqqsysifrtsgqgtkveik,,,,qsissy,aas,qqsysifrt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15692,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgegatlscrasqsvssylawyqrkpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqersswppafgqgtrleik,,,,qsvssy,dss,qersswppa,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15691,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasegdrvtitcqasqdinnylnwyqqkpgkapklliydasnleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlppafgpgtkvdik,,,,qdinny,das,qqydnlppa,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15690,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwprtfgqgtkleik,,,,qsvssn,gas,qqynkwprt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15689,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsrtdftftisslqpddiatyycqqydkppvtfgqgtkvdik,,,,qdisny,das,qqydkppvt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15688,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlssspgeratlscrasqgvsssylawyqqklgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhsrtfgqgtkleik,,,,qgvsssy,gas,qhsrt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15687,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkleik,,,,qsvssiy,aas,qqygtspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15686,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnniggksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,,,,niggks,dds,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15685,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpedfatyfcqqyddlpytfgqgtkleik,,,,qdisny,das,qqyddlpyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15684,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftistlqpediatyycqqydnllsltfgggtkveik,,,,qdinny,das,qqydnllslt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15683,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsastgdrvtitcrasqgirtylvwyqqkpgqapnlliyaasslqsgvpsrfsgsgsgtdftltisglqsedfatyycqqyysypltfgggtkvevk,,,,qgirty,aas,qqyysyplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15682,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsissnlawhqqkpgqaprllisdastratgiparfsgsgsgteftltidslqsediavyycqqynnwpptitfgqgtrleik,,,,qsissn,das,qqynnwpptit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15681,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqgrlgpgqtaritcegnniggksvlwyqqkpgqapvlvvyddsdrpsgiperfsasnsgntatltisrveagdeadyycqvwdtssdhagvfgggtkltvl,,,,niggks,dds,qvwdtssdhagv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15680,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspstvsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisrlqpddfatyycqqynsylfgqgtkveik,,,,qsistw,kas,qqynsyl,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15679,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftlttsslqpddfatyycqqystyspltfgggtkvdik,,,,qsfssw,kas,qqystysplt,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15678,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylktfgqgtkleik,,,,qsfssw,kas,qqynsylkt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15677,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgapgqrvtisctgsssnigadydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssdsslsgsrvfgtgtkvtvl,,,,ssnigadyd,gns,qssdsslsgsrv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15676,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,,,,nigsks,dds,qvwdsssdhwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15675,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnryplytfgqgtkleik,,,,qgisny,aas,qqlnryplyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15674,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppptfgpgtkvdik,,,,qsvlyssnnkny,was,qqyyspppt,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15673,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapelpiyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkvdik,,,,qgissw,aas,qqansfpwt,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15672,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,nivmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystwtfgqgtkleik,,,,qsvlyssnnkny,was,qqyystwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15671,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,,,,qsvlyssnnkny,was,qqyystprt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15670,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkvdik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15669,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,,,,nigsks,dds,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15668,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssftfgpgtkvdik,,,,qsvsssy,gas,qqygssft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15667,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliymgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspynlgqgtkleik,,,,qsllhsngyny,mgs,mqalqspyn,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15666,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,,,,qsvsssy,gas,qqygssyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15665,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsaphtfgggtkveik,,,,qgisny,aas,qkynsapht,,,IGKJ4*01 (human),IGKV1-27*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15664,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedegdyycystdssgnkrvfgggtkltvl,,,,alpkky,eds,ystdssgnkrv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15663,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlarfgqgtkleik,,,,qsllhsdgkty,evs,mqsiqlar,,,IGKJ2*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15662,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,,,,qsisty,aas,qqsystpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15661,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyhvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyhvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15660,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytfgyvfgtgtkvtvl,,,,ssdvggyny,dvs,csyagsytfgyv,,,IGLJ1*01 (human),IGLV2-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15659,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsytltfgggtkvdik,,,,qgissy,aas,qqlnsytlt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15658,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleik,,,,qsissy,aas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15657,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,,,,ssdvgsynl,evs,csyagsstwv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15656,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssqytfgqgtkveik,,,,qsissy,aas,qqsyssqyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15655,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15654,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkveik,,,,qsvssy,das,qqrsnwpt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15653,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqsissylnwyqqepgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkleik,,,,qsissy,aas,qqsystpft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15652,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltissmqsedfavyycqqynnwppgdtfgqgtkveik,,,,qsvssn,gas,qqynnwppgdt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,,,N/A,QTX15651,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,,,,qsvssny,aas,qqygssrnt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26522,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgnnkyyadsvkgrftissdnskntlylqmnslraedtavyycakdlaawgpycsstncytggmdvwgqgttvtvss,,gftfsnyg,isydgnnk,akdlaawgpycsstncytggmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26521,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyyctteepgagslyyyyymdvwgkgttvtvss,,gftfsnaw,iksktdggtt,tteepgagslyyyyymdv,,,,IGHJ6*04 (human),IGHV3-15*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26520,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedggtiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatglqaarrdyyyygmdvwgqgttvtvss,,gytltels,fdpedggt,atglqaarrdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26519,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdpyypgsvkgrftisrenaknslylqmnslragdtavyycargggryydfwsgyygdyyhyymdvwgkgttvtvss,,gftfssyd,igtagdp,argggryydfwsgyygdyyhyymdv,,,,IGHJ6*04 (human),IGHV3-13*05 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26518,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifdttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvgdydssgyysdywgqgtlvtvss,,ggtfssya,iipifdtt,arvgdydssgyysdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26517,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitsssgyrnyadsvkgrftisrdnaknslylqmsslraedtavyycardsaldergyssgwhpphwgqgtlvtvss,,gftfsdyy,itsssgyr,ardsaldergyssgwhpph,,,,IGHJ1*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26516,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskttlylqmnslktedtavyycsrsillyyyastgyhheldywgqgtlvtvss,,gftfsnaw,iksktdggtt,srsillyyyastgyhheldy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26515,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftlssyamywvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlflqmnslraedtavyycarpysgsyreyfqhwgqgtlvtvss,,gftlssya,isydgtnk,arpysgsyreyfqh,,,,IGHJ1*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26514,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglggnyyavdywgqgtlvtvss,,gftfssya,isydgsnk,arglggnyyavdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26513,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmntlraedtavyycarsstyytgfdywgqgtlvtvss,,gftfssyw,ikqdgsek,arsstyytgfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26512,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsaissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdwavliqmpfdywgqgtlvtvss,,gftfssya,issnggst,vkdwavliqmpfdy,,,,IGHJ4*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26511,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlsctasgftlraydmiwvrqapgkglewvsysgrshsayyadsvkgrftisrddaenslylhmntlragdtalyycardrtycssgscyaydffygmdvwgqgttvtiss,,gftlrayd,sgrshsa,ardrtycssgscyaydffygmdv,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26510,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregivgattgfdywgqgtlvtvss,,gftfssyg,iwydgsnk,aregivgattgfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26509,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqsegygenymdvwgkgttvtvss,,gftfssyg,isydgsnk,akdqsegygenymdv,,,,IGHJ6*04 (human),IGHV3-30*18 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,QRG26508,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,,ggsissgdyy,iyysgst,argksptvvtpwfdy,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26537,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,,,,nigsks,ddg,qvwdssshwv,,,IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26536,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkvdik,,,,qsvssy,das,qqrsnwprt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26535,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllifdasiratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgqgtkleik,,,,qsvssy,das,qqrsnwplt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26534,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgihlqvgitfgpgtkveik,,,,qsllhsdgkty,evs,mqgihlqvgit,,,IGKJ3*01 (human),IGKV2-29*02 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26533,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppavtfgpgtkveik,,,,qsvssf,das,qqrsnwppavt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26532,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspstlsasvgdrvtiscrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsrsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qsissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26531,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytiistlgvfgggtkltvl,,,,ssdvggyny,evs,ssytiistlgv,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26530,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,,,,qsvlyssnnkny,was,qqyystpit,,,IGKJ5*01 (human),IGKV4-1*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26529,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqqgtfgqgtkleik,,,,qsvsssy,gas,qqqgt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26528,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydgsnhqvfgggtkltvl,,,,sgsiasny,edn,qsydgsnhqv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26527,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qavvtpepsltvspggtvtltcgssigavtgghfpywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpededeyycllsnsgarpvfgggtkltvl,,,,igavtgghf,dts,llsnsgarpv,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26526,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgrssnigdnyvswyqhlpgaapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtsdsslsaggvfgggtkltvl,,,,ssnigdny,enn,gtsdsslsaggv,,,IGLJ2*01 (human),IGLV1-51*02 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26525,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnpsfgtgtkvtvl,,,,alpkky,eds,ystdssgnps,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26524,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqaaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssdtwvfgggtkltvl,,,,alpkqy,kds,qsadssdtwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",N/A,,,N/A,QRG26523,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalwvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsalwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,QQY97159,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsirsdfwswirqfpgkglewigyiyysgstnynpslesrvtisvdtsknefslklnyvtaadtaiyycaretrwnwldswgqgtlvtvss,,ggsirsdf,iyysgst,aretrwnwlds,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,QQY97158,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscvapgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnslraddtavyfcvkgaslgdnwgqgtlvtvss,,gftlggyg,isydgsvq,vkgaslgdn,,,,IGHJ5*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,QQY97157,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvss,,gftfssyv,isgtgyt,aitmapvv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,QQY97156,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,,gftfsnyg,msydgsvt,akgqplddi,,,,IGHJ2*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,N/A,QQY97164,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,,,,qtisyisnnkny,was,qqyfntpwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,N/A,QQY97163,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdfgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,,,,qslvysdgdty,kvs,mqgthwpyt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,N/A,QQY97162,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,,,,qslvysdgdty,kvs,mqgthwpyt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,N/A,QQY97161,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvl,,,,alpkry,edk,ystdssgnhav,,,IGLJ7*01 (human),IGLV3-10*01 (human)
GenBank,,,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,,,N/A,QQY97160,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqsplslpvslgqsasiscrssqslvhtdgitylswfqqrpgqsprrllykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgtywpwtfgqgtkveik,,,,qslvhtdgity,kvs,lqgtywpwt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39016,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfsfssywmswvrqapgkglewvgnikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdpywgqgtlvtvss,,gfsfssyw,ikqdgsek,ardlgvlwfgdpy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39015,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsistaylqisslkaedtavyycarvgpssswpswgqgtlvtvss,,gytftsya,intntgnp,arvgpssswps,,,,IGHJ5*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39014,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggwysskwyyfdywgqgtlvtvss,,gftfssyg,iwydgsnk,akggwysskwyyfdy,,,,IGHJ4*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39013,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvhlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifdianyaqkfqgrvtmtadkstttaymeltslrsedtamyycarteysydsgssraysmdvwgkgttvtvss,,ggtfssya,iipifdia,arteysydsgssraysmdv,,,,IGHJ6*04 (human),IGHV1-69*04 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39012,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsavgtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycargfdtttgfyfdywgqgtlvtvss,,gftfssyd,vgtagdt,argfdtttgfyfdy,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39011,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakaagggysyiywggdywgqgtlvtsph,,gftfssyg,isydgsnk,akaagggysyiywggdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39010,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgrglewigsiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycariprhlgqdhyyyvmdvwgqgttvtvss,,ggsisssnyy,iyysgst,ariprhlgqdhyyyvmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39009,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkplewlaliywdddkryspslksrltitkdtsknqvvlrmtnmdpvdtatyycahspdhryfdvltgyfnserfyfdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahspdhryfdvltgyfnserfyfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39008,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsfstyywswirqppgkglewighisysgsthynpslkgrvtisldtsknqfslnlssvtaadtavyycarggyyygpprdfdywgqgtlvtvss,,ggsfstyy,isysgst,arggyyygpprdfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39007,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdllfssqgtlvtvss,,gftfssyw,ikqdgsek,ardlgvlwfgdllf,,,,IGHJ1*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39006,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwddakyystsletrltiskdtsnnqvvltltnmdpvdtatyycarevagavhldywgqgtlvtvss,,gfslstsgmc,idwddak,arevagavhldy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39005,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyfcardgsavagpmsyfdywgqgtpvtvss,,gftfsdyy,isssssyt,ardgsavagpmsyfdy,,,,IGHJ4*01 (human),IGHV3-11*05 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39004,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasghtftsylihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardppsgnydnidewtrsenhynygmdawgqgttvtvlt,,ghtftsyl,inpsggst,ardppsgnydnidewtrsenhynygmda,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39003,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,gytftsyd,mnpksvyt,arglwfgdltrtkynwfdp,,,,IGHJ5*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39002,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnynpsltsrvtlsvdtsknqfslklssvtaadtavyycareyfvslpaaqtlyyygidvwgqwttvtvss,,ggsvssgsyy,iyysgst,areyfvslpaaqtlyyygidv,,,,IGHJ6*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39001,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgisdsggspyyadsvkgrftisrdnskntlylqmnslrvedtavyycaesssltgnfnywgqgtlvtvss,,gftfssya,isdsggsp,aesssltgnfny,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW39000,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvrlvesgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvallsydgtnkyyadsvkgrftisrdnskstlflqmhslraedtavyfcakgggyisawstryyamdvwgqgttvtvss,,gftfssfg,lsydgtnk,akgggyisawstryyamdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38999,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyqsgstyynlslksrvtilvdtsknqlslklssvtaadtavyycarvgvatilgvdywgqgtlvtvss,,gysissgyy,iyqsgst,arvgvatilgvdy,,,,IGHJ4*01 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38998,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqhpgkglewigyifysgstyynpslksrviisvdtsknqfslklssvtaadtavyycarvsrytmvrgvifdywgqgtlvtvss,,ggsissgdyy,ifysgst,arvsrytmvrgvifdy,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38997,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlmesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgtnekyadsvkgrftisrdnskntlylqvnslraedtavyycakngysyayprqyfdywgqgtlvtvss,,gftfsnyg,iwydgtne,akngysyayprqyfdy,,,,IGHJ4*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38996,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaaseiivssnymswvrqapgmglewvsvvysggstfyadsvkgrftisrhnskntlylqmnslrtedtavyycareapnsrgsgtnfdywgqgtlvtvss,,eiivssny,vysggst,areapnsrgsgtnfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38995,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsrydmhwvrqttgkslewvsaigtagdtyypdsvkgrfiisrenansslylqmnslragdtavyycargsdtvttafdiwgqgtmvtvss,,gftfsryd,igtagdt,argsdtvttafdi,,,,IGHJ3*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38994,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasrgtfssyaiswvrqapgqglewmggiipifttpnyaqnfqgrvtitadkststaymelnsltsedtavyycavlplhssynwyyfdywgqgtlvtvss,,rgtfssya,iipifttp,avlplhssynwyyfdy,,,,IGHJ4*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38993,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfsifamswvrqapgkglewvsgingsgdntyyadsvkgrftisrdnsrntlylqmnslrpedtavyycakqtdygvgwfdpwgqgtlvtvss,,gftfsifa,ingsgdnt,akqtdygvgwfdp,,,,IGHJ5*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38992,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckrsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasqaaagyyyymdvwgkgttvtvss,,gysftsyw,iypgdsdt,asqaaagyyyymdv,,,,IGHJ6*04 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38991,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstyynpslksrvtisvdksknqfslklssvtaadtavyycarvqglidywgqgtlvtvss,,ggsisssnw,iyhsgst,arvqglidy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38990,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgplgmdvwgqgttvtvss,,gvtvssny,iysggst,ardlgplgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38989,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpgkslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgnigyadsvkgrftisrdnandslflqmnslraedtalyycakdirsgdyvgvfdywgqgalvtvss,,gftfddya,iswnsgni,akdirsgdyvgvfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38988,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrvscaasgfavsnnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmkslraedtavyycardlvvagidywgqgtlvtvss,,gfavsnny,iysggst,ardlvvagidy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38987,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggdlvqpggslrlscaasgitvssnymnwvrqapgkglewisviysggstyyadsvkgrftisrdnskntlflqmnslraedtavyycardldiagafdiwgqgtmvtvss,,gitvssny,iysggst,ardldiagafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38986,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaaagftfstydmhwvrqvtgkglewvsalgtsgdtyyadsvkgrftisrenaknslylqmnslragdtavyycvrgdhssgwygtyyyymdvwgkgttvtvss,,gftfstyd,lgtsgdt,vrgdhssgwygtyyyymdv,,,,IGHJ6*04 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38985,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygitwvrqapgqglewmgwisvyngnthyaqklqgrvtmttgtststaymelrslrsddtavyycavldycsggssssgyynygmdvwgqgttvtvss,,gytftsyg,isvyngnt,avldycsggssssgyynygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38984,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqnlqgrvtmttdtststaymelrslrsddtavyycaregagliiaydywgqgtlvtvss,,gytftsyg,isayngnt,aregagliiaydy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38983,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvtviwydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakggnygdylrgfdywgqgtlvtvss,,gftfstyg,iwydgsnk,akggnygdylrgfdy,,,,IGHJ4*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38982,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryrpsfqgqvtisadksistaylqwsslkasdtamyycalavgrgiptsyfdywgqgtlvtvss,,gysftsyw,iypgdsdt,alavgrgiptsyfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38981,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgasissyfwswirqppgkgldwigyiyyngstnynpslksrvtisvdtsknqfslklssvtaadtavyfcastywdssgyyygvdywghgtlvtvss,,gasissyf,iyyngst,astywdssgyyygvdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38980,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarekirsiaaagtvyyygmdvwgqgttvtvss,,ggsissggyy,iyysgst,arekirsiaaagtvyyygmdv,,,,IGHJ6*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38979,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaglfwyggyfdywgqgtlvtvss,,gftfssyw,ikqdasek,aglfwyggyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38978,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgsstyyadsvkgrftisrdtskntlylqmnslraedtavyycarglqyyydtsgyykdsyyygvdvwgqgttvtvss,,gftfssya,isgsgsst,arglqyyydtsgyykdsyyygvdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38977,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgasvkvsckasgytftsyyvhwvrqapghglewmaiinpdagstsfaqrfqgrltmttdtststvymglnslrsedtavyycargglvpavmpaldywgqgalvtvss,,gytftsyy,inpdagst,argglvpavmpaldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38976,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqliqsgaevkkpgasvkvscttsgytftsyflhwvrqapgqglewmgiinpsdgtttyaqkfqgrvtmtrdtstgtvsmelsslryedtavyycardgalysnsptefdywgqgtlvtvss,,gytftsyf,inpsdgtt,ardgalysnsptefdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38975,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsintaymelsrltsddtavyycardslfsrvdwyfdlwgrgtlvtvss,,gyiftgyy,inpnsggt,ardslfsrvdwyfdl,,,,IGHJ2*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38974,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvllqesgpglvkpsqtlsltctvsggsisngsyywswirqhpgkglewigyiyysgstyynpslrsrvtisldtsmnqfslklssvtaadtavyycariyrgtmvvvfsdlhwyfdlwgrgtlvtvss,,ggsisngsyy,iyysgst,ariyrgtmvvvfsdlhwyfdl,,,,IGHJ2*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38973,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpeansttyaqkfqgrvtmtsdtststvyldlsslrsedtavyycartgflipskgggmdvwgqgttvtvss,,gytftsyy,inpeanst,artgflipskgggmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38972,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgselkkpgasvkvsckasgysftdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqistlkaedtavyycastvgrgsgtyyygnyysysmdvwgqgttvtvss,,gysftdya,intntgnp,astvgrgsgtyyygnyysysmdv,,,,IGHJ6*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38971,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckasgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksittaylqwsslkasdtaiyycarlpphfgsgsyygnafdiwglgtmvtvss,,gysfttyw,iypgdsdt,arlpphfgsgsyygnafdi,,,,IGHJ3*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38970,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdpvdtatyycariqrgiaadywgqgilvtvss,,gfslstsgmc,idwdddk,ariqrgiaady,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38969,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaaskftfsnyamnwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakgellwfgellenwfdpwgqgtrvtvss,,kftfsnya,isgsggnt,akgellwfgellenwfdp,,,,IGHJ5*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38968,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,,gdtfssya,iipilgia,atgrytygygyyfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38967,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddddryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslpskysysygsfdywgqgtlvtvss,,gfslstsgvg,iywdddd,ahslpskysysygsfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38966,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsiifsggttyyadsvkgrftisrdnsrntlylqmsslraedtavyycaetgwdgmdvwgqgttvtvss,,gftvssny,ifsggtt,aetgwdgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38965,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkgldwigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardyggnsnyfhywgqgtlvtvsp,,ggsissggyy,iyysgst,ardyggnsnyfhy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38964,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvatisydgsdkfyadsvkgrftisrdnsrntlyvqmnslrpedtalyycakggwygdirvdywgqgtlvtvss,,gftfstyg,isydgsdk,akggwygdirvdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38963,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,dvqlvesggglvqpggslrlscaasefivssnymswvrqapgrglewisviysggstfyadsvkgrftisrdsskntlylqmnslraedtavyycardlplhgdyfdywgqgtlvtvss,,efivssny,iysggst,ardlplhgdyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38962,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkgldwvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarelgpvggtdqwgqgtlvsvss,,gltvssny,iysggst,arelgpvggtdq,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38961,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qlqlqesgpglvkasetlsltctvsggsissssyywgwirqppgkglewigsihdsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaryygpgtyydafdiwgqgtmvtvss,,ggsissssyy,ihdsgst,aryygpgtyydafdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38960,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsfysihwvrqapgkglewvavisydgsykfyadsvkgrftisrdnskdtvylqmnslraedtavyycardwvhygsgsyppdywgqgtlvtvss,,gftfsfys,isydgsyk,ardwvhygsgsyppdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38959,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgdsfpsywiewvrqmpgkglewmgliypgdsdtryspsfqgqvtisadksistaylqlsslkasdtamyfcarhpvlrgnidywgqgtlvivss,,gdsfpsyw,iypgdsdt,arhpvlrgnidy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38958,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasglivsrnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlenggldvwgqgttvtvfs,,glivsrny,iysggst,ardlenggldv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38957,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesgggflqpggslrlscaasgftfssddmhwvrqvtgkglewvsaigtsgdtyysgsvkgrftisrenaknslylqmnslrvgdtavyycargslrggilsgyafdiwgqgtmvtvss,,gftfssdd,igtsgdt,argslrggilsgyafdi,,,,IGHJ3*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38956,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewvsyisssgatiyyadsvkgrftisrdnaknslylqmtslraedtavyycaspllshnygsgsyynvywyfelwgrgtlvsvss,,gftfsdyy,isssgati,aspllshnygsgsyynvywyfel,,,,IGHJ2*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38955,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsiityywswirqppgkglewigyidysgstnynpslksrvtisvdtsknqfslelssvtaadtavyycartlgayydiltgfrtpggwfapwgqgtlvtvss,,ggsiityy,idysgst,artlgayydiltgfrtpggwfap,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38954,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisasgdstyyadfvkgrftisrdnskntvylqmnslraedtaiyycakepsfglwfgelsgwgqgtlvtvss,,gftfssya,isasgdst,akepsfglwfgelsg,,,,IGHJ1*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38953,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,gytftsyd,mnpksvyt,arglwfgdltrtkynwfdp,,,,IGHJ5*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38952,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,,tytftnfg,isayngnt,arvqefwldp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38951,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaviywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahttwyyygsgwfdpwgqgtlvtvss,,gfslstsgvg,iywdddk,ahttwyyygsgwfdp,,,,IGHJ5*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38950,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,,gysfstyw,iypydsdt,arqesgwsfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38949,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycaritphlvydywsqgtlvtvss,,gfslstsgmc,idwdddk,aritphlvydy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38948,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqivqsgaevkkpgasvkvsckasgytftsyaihwvrqapgqrlewmgwintgngntkysqnfqdrvtitrdtsattaymelssltpedtavyycaragwelnywgqgtlvtvss,,gytftsya,intgngnt,aragwelny,,,,IGHJ4*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38947,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasrftfsnyamtwvrqapgkglewvsaisgsagsiyyadsvkgrftisrdnskntlylqmnslraddtavyfcakgqrgspdffdywgqgtlvtvss,,rftfsnya,isgsagsi,akgqrgspdffdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38946,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,gytftsyd,mnpksvyt,arglwfgdltrtkynwfdp,,,,IGHJ5*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38945,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftrywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarieyyndssgyyqfwgqgtlvtvss,,gysftryw,iypgdsdt,arieyyndssgyyqf,,,,IGHJ1*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38944,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgfsfsnawmswvrqapgkglewvgrikfttdggtsdyaapvrgrftisrddskntlylqmnslrtedtavyycsttndygdysanywgqgtlvtvss,,gfsfsnaw,ikfttdggts,sttndygdysany,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38943,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,,gfsfstya,isydesnk,agggvlvtsdpdafdi,,,,IGHJ3*02 (human),IGHV3-30*10 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38942,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissfywswirqpagkglewigrmsasgstnynpslksrvtmsvdtsenqislklgsvtaadtavyycageqhivttiidywgqgtlvtvss,,ggsissfy,msasgst,ageqhivttiidy,,,,IGHJ4*01 (human),IGHV4-4*07 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38941,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesggdvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycakdptslycsggscynnwfdpwgqgtlvtvss,,gftfssyg,isydgsnk,akdptslycsggscynnwfdp,,,,IGHJ5*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38940,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggdlvqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstfyadsvkgrftisrlsskntlylqmnslrvedtavyycargpypssswawgqgtlvtvss,,gftvssny,iysggst,argpypssswa,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38939,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasmtvsckasgytfstyyihwvrqapgqglewmgiinpsagstsyaqkfqgrvtmttdtststvymelsslrsedtavyycardysritmirgagdywgqgtlvtvss,,gytfstyy,inpsagst,ardysritmirgagdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38938,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsskyyadsvkgrstisrdnskntlylqmnslraedtavyycakrggtycsggicyggyfdywgqgmlvtvss,,gftfssyv,isydgssk,akrggtycsggicyggyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38937,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,,gfsfstya,isydesnk,agggvlvtsdpdafdi,,,,IGHJ3*02 (human),IGHV3-30*10 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38936,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycareeaagtkldywgqgtlvtvss,,gfslstsgmc,idwdddk,areeaagtkldy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38935,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslntsgmcvswirqppgkalewlaridwddekyystslqtrltiskdtsknqvvltmtnmdpvdtatyycarmipipaldywgqgtlvtvss,,gfslntsgmc,idwddek,armipipaldy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38934,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslntsgmsvswirqppgkalewlaridwdddkyystslktrlsiskdtsknqvvltmtnvdpvdtatyyctrtatvvkdywgqgtlvtvss,,gfslntsgms,idwdddk,trtatvvkdy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38933,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssfamswvrqapgkglewvsvisssgdytsyadsvkgrftisrdnskntlylqmnslraedtavyycakdvgsrliydvfdywgqgtlvtvss,,gftfssfa,isssgdyt,akdvgsrliydvfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38932,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evkkpgssvkvscktsggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasfgslwdlrdywgqgtlvtvss,,ggtfssya,iipifgta,asfgslwdlrdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38931,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlslictvsggsitsyywtwirqppgkglewigyiyyngssnynpslesrvtisvdasknqfslklssvtaadtavyycatdyydssgyrygmdvwgqgttvtvss,,ggsitsyy,iyyngss,atdyydssgyrygmdv,,,,IGHJ6*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38930,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfnsygiswvrqapgqglewmgwissyngntnyaqklqgrvtmttdtststaymelrsltsddtavyycatddpdivlvpaamsldywgqgtlvtvss,,gytfnsyg,issyngnt,atddpdivlvpaamsldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38929,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,,gftvssny,iysggst,ardygdyyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38928,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycakdgsgsyynsgaldywgqgtlvtvss,,gftfssyg,iwydgsnk,akdgsgsyynsgaldy,,,,IGHJ4*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38927,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscagsgftfshygmhwvrqapgkglewvavilydgsnnyyadsvkgrftvsrdnskntlylqmnslrtedtavyycgkgagpycgggscyptkvdywgqgtlvtvss,,gftfshyg,ilydgsnn,gkgagpycgggscyptkvdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38926,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggalvqpggslrlscaasgftfssydmhwvrqatakglewvstigtagdtyypgsvkgrftisrenaknslylqmnnlragdtavyycarvgydssgyywyldlwgrgtlvtvss,,gftfssyd,igtagdt,arvgydssgyywyldl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38925,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvnwirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycartrlgitafdiwgqgtmvtvss,,gfslstsgmc,idwdddk,artrlgitafdi,,,,IGHJ3*02 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38924,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviyngvttyyadsvkgrftisrdiskntvylqmnslraedtavyycaragwlrgrfdpwgqgtlvivss,,gitvnsny,iyngvtt,aragwlrgrfdp,,,,IGHJ5*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38923,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslqisckgsgysfisnwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylrwsslkasdtamyycarigdwigfdywgqgtlvtvss,,gysfisnw,iypgdsdt,arigdwigfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38922,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardleergamdvwgqgttvtvss,,gltvssny,iysggst,ardleergamdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38921,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,,gysfstyw,iypydsdt,arqesgwsfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38920,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslriscaasgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmntlrvedtavyycardavgsyyygmevwgqgttvtvss,,gftvssny,iysggst,ardavgsyyygmev,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38919,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvrptqtltltctfagfslrthgmcvswirqppgkalewlaridwdgdkyystslktrltiskdtskdqvvltmtnmdpvdtatyycarflvggfkawfdpwgqgtlvtvss,,gfslrthgmc,idwdgdk,arflvggfkawfdp,,,,IGHJ5*02 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38918,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycakmlwlrgwfdpwgqgtlvtvss,,gftvssny,iysgdnt,akmlwlrgwfdp,,,,IGHJ5*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38917,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckasgdtfsshyihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvylelsslrsedtavyycardqafivatlgpdywgqgilvtvss,,gdtfsshy,inpsggst,ardqafivatlgpdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38916,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscaasgftfddyamnwvrqapgkglewvslisgdgdspsysgsvkgrftisrdnsknslylqmislrtedtalyycarespkltgyfdywgqgtlvtvss,,gftfddya,isgdgdsp,arespkltgyfdy,,,,IGHJ4*01 (human),IGHV3-43*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38915,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaaagftfsnydmhwvrqatgkglewvsvigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarayydtsgyynyfdhwgqgtlvtvss,,gftfsnyd,igtagdt,arayydtsgyynyfdh,,,,IGHJ1*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38914,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymnwvrqapgkglewvsviysgdnthyadsvkgrftisrdnskntlylqmnslraedtavyycargygsgsygwfdpwgqgtlvtvss,,gftvssny,iysgdnt,argygsgsygwfdp,,,,IGHJ5*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38913,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqmsslgvedtavyycakggfgyasgwyyldywgqgtlvtvss,,gftfstya,iwydgsdk,akggfgyasgwyyldy,,,,IGHJ4*01 (human),IGHV3-30*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38912,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglvgttltfdywgqgslvtvss,,giivssny,iysggst,areglvgttltfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38911,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasagtfssyavswvrqapgqglewmgriipivsitkyaqkfqgrvtmtadkststaymelsslrsedtavyycargrytygtegyfdnwgqgtlvtvss,,agtfssya,iipivsit,argrytygtegyfdn,,,,IGHJ5*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38910,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglgmdvwgqgttvtvss,,gitvssny,iysggst,areglgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38909,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardpmrpgmdvwgqgttvtvss,,gftvssny,iysggst,ardpmrpgmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38908,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssytlhwvrqapgkglewvavissdgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppgnmgsmaqhlvllvvfdiwgqgtmvtvss,,gftfssyt,issdgssk,ardpppgnmgsmaqhlvllvvfdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38907,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtftsyafswvrqapgqglewmggiipifgtsnyaqkfqgrvtisadessstaymelsslrsedtavyycargpayvsgtyywnafdiwgqgtmvtvss,,ggtftsya,iipifgts,argpayvsgtyywnafdi,,,,IGHJ3*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38906,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,emqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyissstnsiyyagsvqgrftisrgnaknslylqmnslraedtavyycargrddygdyrggdfdywgqgtlvtvss,,gftfstye,issstnsi,argrddygdyrggdfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38905,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkiscegsgysfisywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsistaylqwsslkasdtamyycvrsdgdyvighdywgqgtlvtvss,,gysfisyw,iypgdsdt,vrsdgdyvighdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38904,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatdggggsyyyahyyygmdvwgqgttvtvss,,ggtfssya,iipifgta,atdggggsyyyahyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38903,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdlssgwdlfdywgqgtlvtvss,,gftfddya,iswnsdsi,akdlssgwdlfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38902,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvisnymswvrqapgkglewvsviyrggstyfadsvkgrftisrdnskntlylqmnslraedtavyycarlasdgsgsyldyfdywgqgtlvtvss,,gftvisny,iyrggst,arlasdgsgsyldyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38901,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckasgyrftnywtvwvrqmpgkglewmgiiypgdseirysppfqgqvtisadksistaylqwsslkasdtamyycarhpsnfydsggdyyamdvwgqgtpvtvss,,gyrftnyw,iypgdsei,arhpsnfydsggdyyamdv,,,,IGHJ6*01 (human),IGHV5-51*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38900,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswssgsivyadsvkgrftvsrdnaknslylqmnslrvedtafyycakdmvagphyygmdvwgqgttvtvss,,gftfddya,iswssgsi,akdmvagphyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38899,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslrtrltiskdtsknlvvltmtnmdpvdtatyycalgragtmdywgqgtlvtvss,,gfslstsgmc,idwdddk,algragtmdy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38898,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsnydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtalyycarvgyygsgsyplywyfdlwgrgtlvtvss,,gftfsnyd,igtagdt,arvgyygsgsyplywyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38897,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,,gdtfssya,iipilgia,atgrytygygyyfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38896,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywitwvrqmpgkglecmgridpsdsyskyspsfqghvtisadksistaflqwsslkasdtamyycarlpfcdsascgrahyyygmdvwgqgttvtvss,,gysftsyw,idpsdsys,arlpfcdsascgrahyyygmdv,,,,IGHJ6*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38895,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftlsrywmswvrqapgkglewvanikqdgsekkyvdsvkgrftisrdntknslylqmnslraedtavyycarlmyyygnfdywgqgtlvtvss,,gftlsryw,ikqdgsek,arlmyyygnfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38894,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasglivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlniaggfdiwgqgtmvtvss,,glivsrny,iysggst,ardlniaggfdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38893,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsavgvgwirqppgkalewlaliywnddkryspslknrltitkdpsknqvvltmtnmdpvdtatyycahrlapdydfltgyyngddafdvwgpgtmvtiss,,gfslstsavg,iywnddk,ahrlapdydfltgyyngddafdv,,,,IGHJ3*01 (human),IGHV2-5*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38892,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvsvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahsmvrgvlfgadfdywgqgtlvavss,,gfslstsgvs,iywdddk,ahsmvrgvlfgadfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38891,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssysiswvrqapgqglewmgriipilgvaddaqkfqgrvtitadkststaymelsslrsedtavyycareagttdwyfdlwgrgtlvtvss,,ggtfssys,iipilgva,areagttdwyfdl,,,,IGHJ2*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38890,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,rilltqsgaevkkpgasakvsckvsgyslsespmhwvrqapgkglewmggfdpedgeiinvqkfkgrvtmtedtssdtaymeltsltsedtavyfcaitslarglkgyfdswgqgtllivss,,gyslsesp,fdpedgei,aitslarglkgyfds,,,,IGHJ5*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38889,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrwdgvgfdiwgqgtmvtvss,,gysftsyw,iypgdsdt,arrwdgvgfdi,,,,IGHJ3*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38888,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfnnywmtwvrqapgkglewvanikldgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycarsphyyggfdywgqgtlvtvss,,gftfnnyw,ikldgsek,arsphyyggfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38887,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywtwirqapgkglewigyiynsgstnynpslrgrvtisvdtsknqfslnlssvtaadtavyycardqgyssgwndafdiwgqgtmvtvss,,ggsissyy,iynsgst,ardqgyssgwndafdi,,,,IGHJ3*02 (human),IGHV4-4*08 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38886,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggfissyywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycarrsmgycsggncysgfdpwgqgtlvtvss,,ggfissyy,iyysgtt,arrsmgycsggncysgfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38885,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,,gytfttyg,vsayngnt,ardygwfgelstegqfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38884,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsryglhwvrqapgkglewvgvilydgsdehyadsvkgrftisrdnskntldlqmnslrpedtavyycakqaspycsggscysgnfdywgqgtlvtvss,,gftfsryg,ilydgsde,akqaspycsggscysgnfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38883,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissntfywgwirqppgkglewigsihytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarfitdgyssgsdswgqgtlvtvss,,ggsissntfy,ihytgst,arfitdgyssgsds,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38882,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgiyywswirqppgkglewigyvfysgstnynpslksrvtisvdtsknqfslklrsvtaadtavyycamtyydyiwgrvdpqfdpwgqgtlvtvss,,ggsvssgiyy,vfysgst,amtyydyiwgrvdpqfdp,,,,IGHJ5*02 (human),IGHV4-61*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38881,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsisstshywgwirqppgkglewigsihysgstyynpslksrvtisvdtskkqfslklrsvtaadtavyycarfitdgyssgsdswgqgtlvtvss,,ggsisstshy,ihysgst,arfitdgyssgsds,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38880,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,,gysfinyg,isayngnt,arvqwlrldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38879,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsdntnyaqkfqervtitrdmstrtaymelsslrsedtavyycaadrmrivggkgyyygmdvwgqgttvtvss,,gftfttsa,ivvgsdnt,aadrmrivggkgyyygmdv,,,,IGHJ6*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38878,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalqwlaridwdddkyystslktrltiskdtsknqvvltvtnvdpvdtgtyycarvqvaaagspydywgqgtlvtvss,,gfslstsgmc,idwdddk,arvqvaaagspydy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38877,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsgkhyadsvkgqftisrdnskntlylqmnslraedtavyycardgvdfgmvtlfdywgqgtlvtvss,,gftfssyg,iwydgsgk,ardgvdfgmvtlfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38876,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,,gytfttyg,vsayngnt,ardygwfgelstegqfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38875,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamnwvrqapgkglewvsgiswnsgsfgyadsvkgrftisrdnaknslylqmnslrpedtalyycakdigcsstscsyyhyygmdvwglgttvtvss,,gftfddya,iswnsgsf,akdigcsstscsyyhyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38874,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evmlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycarfrygdypdywgqgtlvtvss,,gfivssny,iysggst,arfrygdypdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38873,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvgsggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlflqmnslrpedtavyycardgravagtdwgqgtlvtvss,,gftvssny,iysggst,ardgravagtd,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38872,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycgvpycsssscyryygmdvwgqgttvtvss,,ggsfsgyywy,inhsgst,gvpycsssscyryygmdv,,,,IGHJ6*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38871,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahrpagfwsahfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38870,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavygrsfsgnswswirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycargwtvpplwvlnwfdpwgqgtlvtvss,,grsfsgns,idhsgst,argwtvpplwvlnwfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38869,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipilgvanyaqkfqgrvtitadkststaymelsslrsedtavyycaregttiteyfqqwgqgtlvtvss,,ggtfssys,iipilgva,aregttiteyfqq,,,,IGHJ1*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38868,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddnkryspslksrltitkdtsknqvvltmttmdpvdtatyycahrplfsgpfdywgqgtlvtvss,,gfslstsgvg,iywddnk,ahrplfsgpfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38867,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qlqlqesgpglvrpsetlsltctvsggsissssyfwgwirqppgkglewigsiyysgtthynpslksritisvdtsknqfslkltsvtaadtavyycatlewlrapfdnwgqgtlvtvss,,ggsissssyf,iyysgtt,atlewlrapfdn,,,,IGHJ5*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38866,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsggtnfvqkfqgrvtmtrdtsistaymelsrlksddtavyycargtppdsvvvpaaihpynwfdpwgqgtlvtvss,,gytftgyy,inpnsggt,argtppdsvvvpaaihpynwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38865,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasevtvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardglvgatlafdfwgqgtlvtvss,,evtvssny,iysggst,ardglvgatlafdf,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38864,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,,tytftnfg,isayngnt,arvqefwldp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38863,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycak,,gftfddya,iswnsgsi,ak,,,,IGHJ2*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38862,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,,gysfinyg,isayngnt,arvqwlrldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38861,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,vqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsgiysggstyyadsvkgrftisrdkskntlylqmnslraedtavyycardggysaytlfysdfafdiwgqgtmvtvss,,gftvssny,iysggst,ardggysaytlfysdfafdi,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38860,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgifnpgagttnypqkfqgrvtmtrdtststvymelsslrsedtavyycardgspwgndydiygmdvwgqgttvtvss,,gytftsyy,fnpgagtt,ardgspwgndydiygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38859,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftlsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkgplffwsgyytdywgqgtlvtvss,,gftlsnaw,iksktdggtt,ttdkgplffwsgyytdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38858,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahrpagfwsahfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38857,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggfiryyywtwirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslnlssvtaadtavyycarrgkygsgspddafdvwgqgtmvtvss,,ggfiryyy,iyysgst,arrgkygsgspddafdv,,,,IGHJ3*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,QRW38856,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfnsyaihwvrqtpgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycardgrifylsfyfdywgqgtlvtvss,,gftfnsya,isydgsnk,ardgrifylsfyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39177,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdgvtitcrasqgisnslawyqqkpgkapklllyaastvesgvpsrfsgrgsgtdytltissllpedfatyycqqyysaprtfgqgtkveik,,,,qgisns,aas,qqyysaprt,,,IGKJ1*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39176,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsisty,vas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39175,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqspvslpvtpgepasmscrssqsllhsngyiyldwyvqkpgqspqllfylgsnrapgvpvrfsasgsgtdftlkisrveaedvgvyycmqalqmgtfgqgtkveik,,,,qsllhsngyiy,lgs,mqalqmgt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39174,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqtisnylnwyqqkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqthstprtfgqgtkveik,,,,qtisny,aas,qqthstprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39173,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqkpgkapklllyaasrlqsgvpsrfsgsgsgtdytltisslqpedfavyycqqdynfpwtfgqgtkveik,,,,qgitns,aas,qqdynfpwt,,,IGKJ1*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39172,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvl,,,,sgsiasny,edn,qsydssnlwv,,,IGLJ3*02 (human),IGLV6-57*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39171,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyagifvfgtgtkvtvl,,,,ssdvgsynl,egs,csyagifv,,,IGLJ1*01 (human),IGLV2-23*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39170,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,rsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapkvliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39169,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqgvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspqytfgqgtkleir,,,,qgvssny,gas,qhygsspqyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39168,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqkpgtapklllyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqyysdpprtfgqgtkveik,,,,qgisns,aas,qqyysdpprt,,,IGKJ1*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39167,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslpasvgdrvtitcrasqsirryinwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedsaiyycqqsfstprtfgqgtkveik,,,,qsirry,vas,qqsfstprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39166,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqppsslsasvgdrvtitcrasqdisnslawyqqkpgkapklllyaasrlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyysiprtfgqgtkveik,,,,qdisns,aas,qqyysiprt,,,IGKJ1*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39165,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvrsflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpyltfgggtkveik,,,,qsvrsf,das,qqrsnwpylt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39164,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeraalscrasqgvtstylawyqqkpgqaprlliygvstratgipdrfsgsgsgtdftltisrlepedfavyychqydsspltfgggtkveik,,,,qgvtsty,gvs,hqydssplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39163,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspvtlsvspgeratlscrasqsvssnlawyqqkpgqgprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqyknwppwtfgqgtkveik,,,,qsvssn,gas,qqyknwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39162,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdtawvfgggtkltvl,,,,nigsks,dds,qvwdtawv,,,IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39161,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgnapklmiydvnnrpsgvsdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,,,,ssdvggyny,dvn,ssytssstwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39160,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,nfmltqphsvsespgktviisctrssgsiasnyvqwyqqrpgsapttviyedslrpsgvphrfsgsidsssnsasltisglmtedeadyycqsydsswvfgggtkltvl,,,,sgsiasny,eds,qsydsswv,,,IGLJ3*02 (human),IGLV6-57*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39159,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitlsctgtssdvgsydlvswyqhhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyycclyaghstyvvfgggtkltvl,,,,ssdvgsydl,evt,clyaghstyvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39158,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisndlnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqhydnlkvtfgqgtkleik,,,,qdisnd,das,qhydnlkvt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39157,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqsystppytfgqgtkleik,,,,qsinny,aas,qqsystppyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39156,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpgltfgggtkveik,,,,qsissf,aas,qqsyttpglt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39155,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissleaedfavyycqqrsnwppgmytfgqgtkleik,,,,qsvssy,das,qqrsnwppgmyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39154,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnfsltfgggtkveik,,,,qdirny,das,qqydnfslt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39153,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsynilwtfgqgtkveik,,,,qsissy,aas,qqsynilwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39152,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgignslawyqqkpgkapklllyaastlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyystpprtfgqgtkleik,,,,qgigns,aas,qqyystpprt,,,IGKJ2*01 (human),IGKV1-NL1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39151,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divltqspgtlslspgeratlscrasqsvsssslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygssplfgqgtrleik,,,,qsvssss,gas,qqygsspl,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39150,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgipasfsgsgsgteftltisslqsedfavyycqqyndwppmytfgqgtkleir,,,,qsvssn,gas,qqyndwppmyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39149,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqllnsdsptfgqgtkleik,,,,qgisny,aas,qllnsdspt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39148,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsfpitfgqgtrleik,,,,qgissy,aas,qllnsfpit,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39147,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpediatyycqqsyssppwtfgqgakveik,,,,qsirsy,gas,qqsyssppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39146,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgerttlscrasqsvrgsylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspytfgqgtkleik,,,,qsvrgsy,gas,qqygrspyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39145,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspdfqsvtpkekvtitcrasqsiasslhwyqqkpdqspkllikyasqsfsgvpsrfsgsgsgtdftltinslepedaatyychqssslpytfgqgtkleik,,,,qsiass,yas,hqssslpyt,,,IGKJ2*01 (human),IGKV6-21*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39144,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftfaisslqpediatyycqqyhnvppafgggtkveik,,,,qdisny,das,qqyhnvppa,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39143,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatfycqqyhnlpitfgpgtkvdik,,,,qdisny,das,qqyhnlpit,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39142,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgthftltisslqpedfatyycqqansfrltfgggtkveik,,,,qgissw,aas,qqansfrlt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39141,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtefthtisslqsedfavyycqqynnwppwtfgqgtkveik,,,,qsvssn,gas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39140,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,vltqppsvsgapgqrvtisctgsssnigagagydvhwyqqfpgtapklliygnnnrpsgvpdrfsgsksgtsasltitglqaedeadyycqsydrslsvlyvfgtgtkvtvl,,,,ssnigagagyd,gnn,qsydrslsvlyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39139,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,,,,ssnigsny,rnn,aawddslsgpv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39138,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,,,,ssnigsny,rnn,aawddslsgpv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39137,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycttwdasrggwvfgggtkltvl,,,,nsnigsny,rnn,ttwdasrggwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39136,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgntvvfgggtkltvl,,,,ssnigagyd,dnt,nsrdssgntvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39135,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvvtqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvmyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssadhyvfgtgtkvtvl,,,,nigsks,yds,qvwdssadhyv,,,IGLJ1*01 (human),IGLV3-21*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39134,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspeqsitisctgtssdvgvynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssslqifgggtkltvl,,,,ssdvgvyny,dvs,ssytsssslqi,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39133,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadfyctsytgsstsvvfgggtkltvl,,,,ssdvgtyny,dvs,tsytgsstsvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39132,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrsnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddsltgpvfgggtkltvl,,,,ssnigsny,rsn,atwddsltgpv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39131,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqtissylnwfqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleik,,,,qtissy,vas,qqsystprt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39130,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqadsfpwtfgqgtrveik,,,,qgissw,aas,qqadsfpwt,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39129,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,,,,qsvsssy,gas,qqygssrt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39128,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsinyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysapytfgqgtkleik,,,,qsinyy,aas,qqsysapyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39127,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpgtfgqgtkveik,,,,qsvssy,das,qqrsnwpgt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39126,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdiskylswyqqkpgkapklliydasnletgvpsrfsgsgsgadftftisslqpediatyycqqydtlpltfgggtkveik,,,,qdisky,das,qqydtlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39125,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgttftftisslqpadiatyycqhynnlpltfgggtkveik,,,,qdisny,das,qhynnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39124,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsvvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39123,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkqgkapnlliyaasslqsgvpsrfsgsgsgtdftltitslqvedfatyycqqshstpytfgqgtkveik,,,,qsissy,aas,qqshstpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39122,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasmsgspgqsitisctgttsdvgaynyvswyqqhpgkapklmisnvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,,,,tsdvgayny,nvs,ssytssstwv,,,IGLJ3*02 (human),IGLV2-14*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39121,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqppsvsgspgqsvtiscagtssdvgsynrvswyqqppgtaprlmiyevgnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,,,,ssdvgsynr,evg,ssytssstwv,,,IGLJ3*02 (human),IGLV2-18*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39120,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctasssnigadydvhwyqqlpgtvpklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslrgsvfgggtkltvl,,,,ssnigadyd,gnt,qsydsslrgsv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39119,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgiskwvawyqqkpgkapkiliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgggtkveik,,,,qgiskw,aas,qqtnsfpt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39118,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdtvtitcrasqiinsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppwtfgqgtkveik,,,,qiinsy,aas,qqsyssppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39117,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqqlgtfgqgtkleik,,,,qsvssy,das,qqlgt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39116,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscragqsvsssylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39115,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqslsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslpytfgqgtkleik,,,,qslsssy,gas,qqygsslpyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39114,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,,,,ssnigsnt,nnn,aawddslngwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39113,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgktasitcggnnigsksvhwyqqrpgqapvlviyydtdrpsgiperfsgsnsvntatltisrveagdeadyycqvwdsssdhplfgggtkltvl,,,,nigsks,ydt,qvwdsssdhpl,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39112,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnnvnwyqqlpgtapkvliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnghvfgggtkltvl,,,,ssnigsnn,snn,aawddslnghv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39111,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyscnsrdssgnhwvfgggtkltvl,,,,slrsyy,gkn,nsrdssgnhwv,,,IGLJ3*02 (human),IGLV3-19*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39110,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapksliyvasslqsgvpsrfsgsgsgtnftltisslqpedfatyycqqsysiprtfgqgtkleik,,,,qsisry,vas,qqsysiprt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39109,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysfwafgqgtkveik,,,,qsvlyssnnkny,was,qqyysfwa,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39108,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydssslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyspltfgggtkveik,,,,qsissw,dss,qqynsysplt,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39107,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfngsgsgtdftltisslqpedfatyycqqfnnflltfgggtkveik,,,,qgissa,das,qqfnnfllt,,,IGKJ4*01 (human),IGKV1-13*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39106,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,,,,qsvsssy,gas,qqygsswt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39105,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsisry,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39104,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqksgkapklliydasnletgvpsrfsgsgsgadftftisslqpedigtyycqqsdnvpvtfgpgtkvdik,,,,qdisny,das,qqsdnvpvt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39103,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqplsasgtpgqrvtiscsgkssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,,,,ssnigsnt,snn,atwddslngrv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39102,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,,,,qsisry,aaa,qqtystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39101,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvterpsgvsnrfsgsksgntasltisglqaedeadyycssftssstpyvfgtgtkvtvl,,,,ssdvggyny,dvt,ssftssstpyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39100,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaqvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsaqv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39099,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtvsctgsssnigagydvqwyqhlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdwgvfgggtkltvl,,,,ssnigagyd,gnt,qsydsslsdwgv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39098,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapkffmysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,,,,ssnigsns,snn,aawddslngwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39097,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrtsqsirvylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsirvy,aas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39096,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslstsvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtnftltisslqpedfatfycqqsystphtfgqgtkleik,,,,qsisry,tas,qqsystpht,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39095,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqtisrylnwyqqrpgkapklliyiasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qtisry,ias,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39094,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkllmyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystppysfgqgtkleik,,,,qsirsy,aas,qqsystppys,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39093,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,esvltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsrtfgggtkveik,,,,qsvssny,gas,qqygtsrt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39092,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspssvsaslgdrvtitcrasqgisgwlawyqqkpgkapmlliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqansfpltfgggtkveik,,,,qgisgw,aas,qqansfplt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39091,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqhedfatyycqqsyntlalsfgggtkveik,,,,qsisiy,aas,qqsyntlals,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39090,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,,,,qsvssty,gas,qqygssprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39089,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqktgkapkpliydasileagvpsrfsgsgsgtdftftitslqpediatyycqqydnlppytfgqgtnleik,,,,qdisns,das,qqydnlppyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39088,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnclnwyqqkpgkaptlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllwtfgpgtkmeik,,,,qdisnc,das,qqydnllwt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39087,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcraslsigrylnwyqqkpgkapkllisaastlqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsyttplftfgpgtkvdik,,,,lsigry,aas,qqsyttplft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39086,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqniktylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttprtfgqgtkveik,,,,qnikty,aas,qqsyttprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39085,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdeadyycqvwdsttdlphwvfgggtkltvl,,,,nigskn,dds,qvwdsttdlphwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39084,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdesdyycqvwdsttdlphwvfgggtkltvl,,,,nigskn,dds,qvwdsttdlphwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39083,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsslwtfgqgtkveik,,,,qsvssty,gas,qqygsslwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39082,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqninkylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qninky,vas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39081,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,,,,qsvssn,gas,qhynnwplyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39080,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgiapelliydnnkrpsgipgrfsgsrsgtsatlditglqtgdeadyycgtwdtslnvwvfgggtkltvl,,,,ssnignny,dnn,gtwdtslnvwv,,,IGLJ3*02 (human),IGLV1-51*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39079,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssdsasltisglktedeadyycqsydtsnhwvfgggtkltvl,,,,sgsiasny,edn,qsydtsnhwv,,,IGLJ3*02 (human),IGLV6-57*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39078,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qtvvtqepsfsvspggtvtltcglssgsvstsyyaswyqqtpgqaprtliystntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgiwvfgggtkltvl,,,,sgsvstsyy,stn,vlymgsgiwv,,,IGLJ3*02 (human),IGLV8-61*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39077,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgqtagitcggddigsknvhwyqqkpgqapvlvvyddhdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpyvfgtgtkvtvl,,,,digskn,ddh,qvwdsssdpyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39076,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,,,,qsvssn,gas,qhynnwplyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39075,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,,,,qsvssn,gas,qhynnwplyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39074,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqkpgkapklliydasdletgvpsrfsgsgsgtdftftisslqpediatyycqqygnlppiafgqgtrleik,,,,qdisns,das,qqygnlppia,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39073,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgdsylnwfqqrpgqsprrliykvsnwdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppgtfgqgtkleik,,,,qslvysdgdsy,kvs,mqgthwppgt,,,IGKJ2*01 (human),IGKV2D-30*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39072,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyhcqqynnlytfgqgtkleik,,,,qsistw,das,qqynnlyt,,,IGKJ2*01 (human),IGKV1-5*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39071,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,,,,qsvssn,gas,qhynnwplyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39070,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfiftisslqpediatyycqqydnlprtfgqgtkveik,,,,qdisny,das,qqydnlprt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39069,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttlaltfgggtkveik,,,,qsissy,aat,qqsyttlalt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39068,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,,,,qsvssn,gas,qhynnwplyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39067,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qivltqspatlslspgeratlscrasqsvttylawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgpgtkveik,,,,qsvtty,das,qqrsnwppit,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39066,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssniggntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,,,,ssniggnt,nnn,atwddslngrv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39065,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qtvvtqepsfsvspggtvtltcglssgsvptsyfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgivvfgggtkltvl,,,,sgsvptsyf,gtn,vlymgsgivv,,,IGLJ2*01 (human),IGLV8-61*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39064,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatlsisrveagdeagyycqvwdtsgdplvfgggtkltvl,,,,nigsks,yds,qvwdtsgdplv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39063,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigadydvhwyqqfpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgswvfgggtkltvl,,,,ssnigadyd,gns,qsydsslsgswv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39062,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssnvgnydlvswyqqhpgkapklmiyevnkrpsgvsdrfsgsksgntasltisglqaedeadfyccsyagssswvfgggtkvtvl,,,,ssnvgnydl,evn,csyagssswv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39061,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,,,,ssnigsnt,nnn,aawddslngwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39060,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpgdfatyycqqsysppytfgqgtkleik,,,,qsirsy,aas,qqsysppyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39059,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtpspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgteftltisslqpedfatyfcqqsysappwtfgqgtrveir,,,,qsisiy,aas,qqsysappwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39058,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,,,,qsvsssy,gas,qqygssrt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39057,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpetfgqgtkleik,,,,qsvssn,aas,qqynnwpet,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39056,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,airitqspsslsastgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisrlhsedfatyycqqyygyptfgqgtkleik,,,,qgissy,aas,qqyygypt,,,IGKJ2*01 (human),IGKV1-8*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39055,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnidpitfgqgtrleik,,,,qgissy,aas,qhlnidpit,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39054,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqpedfatyycqqsyntlalsfgggtkveik,,,,qsisiy,aas,qqsyntlals,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39053,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvseaprqrvtiscsgsssnighnavnwyqqipgkapklliyyddlvpsgvsdrfsgsksgtsaslaisglqsedeaeyycaawddslngpvfgggtkltvl,,,,ssnighna,ydd,aawddslngpv,,,IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39052,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,,,,ssnigagyd,dnt,qsydsslsvvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39051,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsasgtpgqrvniscsgsssnlgnnfvywyqqlpgtapkllsyldsrrpsgvpdrfsgsksgtsasldisglrsedeadyycaawddslsgvifgggtkltvl,,,,ssnlgnnf,lds,aawddslsgvi,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39050,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydknnrpsdipdrfsgsssgntasltitgaqaedeadyycnsrdssinhyvfgtgtkvtvl,,,,slrsyy,dkn,nsrdssinhyv,,,IGLJ1*01 (human),IGLV3-19*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39049,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsvasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsyhnsvwvfgggtkltvl,,,,sgsvasny,edn,qsyhnsvwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39048,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyhccsyagsrfwvfgggtkltvl,,,,ssdvgsynl,egs,csyagsrfwv,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39047,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapelliyaasslqsgvpsrfsgsesgtdftltisslqpedfatyycqqsystpltfgggtkveik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39046,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyychqyassprtfgqgtkveik,,,,qsvsssy,aas,hqyassprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39045,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqanqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdnvpltfgggtkveik,,,,qdisny,das,qqhdnvplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39044,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,dvvmtqspvslpvtlgqpasiscrssqslvhsdgntylnwfqqrpgqsprrliykvsyrhsgvpdrfsgsgsgtdftleisrveaedvgvyycmqgthwpmytfgqgtkveik,,,,qslvhsdgnty,kvs,mqgthwpmyt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39043,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvggvyycmqgthwpptfgqgtkveik,,,,qslvysdgnty,kvs,mqgthwppt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39042,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsvssylnwyqqnpgkapklliyaastlqsgvpsrfsgsgsgtdftltistlqpedfatyfcqqsystprltfgggtkveik,,,,qsvssy,aas,qqsystprlt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39041,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqhisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqakgfpltfgggtkveik,,,,qhissw,das,qqakgfplt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39040,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsitswlawyqqkpgkapklliykastlergvpsrfsgsgsgpeftltisslqpddfatyycqqynsyspgdtfgqgtkleik,,,,qsitsw,kas,qqynsyspgdt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39039,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,,,,qsisry,aaa,qqtystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39038,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntppwtfgqgtkveik,,,,qsitsy,aas,qqsyntppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39037,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrrdftfgpgtrvdik,,,,qsvsry,das,qqrrdft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39036,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtptfgqgtkleik,,,,qsllhsngyny,lgs,mqalqtpt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39035,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisiylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediaiyycqqydnlpsftfgpgtkvdik,,,,qdisiy,das,qqydnlpsft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39034,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpvdiatyychqydnlprtfgqgtkveik,,,,qdinny,das,hqydnlprt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39033,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypqatfgqgtrleik,,,,qgissy,aas,qqlnsypqat,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39032,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpawtfgqgtkveik,,,,qsissy,aas,qqsystpawt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39031,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlviylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgggtkveik,,,,qsllhsngyny,lgs,mqalqtprt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39030,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssltgsvfgggtkvtvl,,,,nsnigagyd,gns,qsydssltgsv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39029,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,sfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttliyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsstiifgggtkltvl,,,,sgsiasny,edn,qsydsstii,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39028,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnvvfgggtkltvl,,,,sgsiasny,edn,qsydssnvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39027,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtlsctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgnfvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgnfv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39026,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,,,,qsissy,aas,qqsystppyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39025,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39024,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtnftltisslqpedfathycqqsystpytfgqgtkleik,,,,qsisny,ats,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39023,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqtplslsvtpgqpasiscksrqsllhsdgktylywylqkpgqspqlliydvssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgihlptfgqgtrldik,,,,qsllhsdgkty,dvs,mqgihlpt,,,IGKJ5*01 (human),IGKV2-29*02 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39022,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcragqnissylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspprtfgqgtkveik,,,,qnissy,ats,qqsysspprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39021,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftlnisslqaedvavyycqqyystpytfgqgtkleik,,,,qsvlyssnnkny,was,qqyystpyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39020,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssprtfgqgtkleik,,,,qsvsssy,gas,qhygssprt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39019,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsigynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspytfgqgtkleik,,,,qsllhsigyny,lgs,mqalqspyt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39018,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleir,,,,qsisty,aas,qqsystprt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",N/A,,,N/A,QRW39017,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvnsnyltwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqsdnspftfgpgtkvdik,,,,qsvnsny,gas,qqsdnspft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77621,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgglipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycanfigdgynyeedymdvwgkgttvtvss,,ggtfssya,lipifgta,anfigdgynyeedymdv,,,,IGHJ6*04 (human),IGHV1-69*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77620,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasakvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqrfqgrvtmtedastdtaymelsslrsedtavyycttvgfpdyydssvylrhfdywgqgtlvtvss,,gytltels,fdpedget,ttvgfpdyydssvylrhfdy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77619,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgftftnyyihwvrqapgqglewmgiinpsggstiyaqkfqgrvtmtrdtstrtvymelsslrsedtavyycadllldywgqgtlvtvss,,gftftnyy,inpsggst,adllldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77618,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgkslrlscadsgftfssyamhwvrqapgkglewvavisfdgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwlnwafdywgqgtlvtvss,,gftfssya,isfdgskk,aregqwlnwafdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77617,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkdrftisrdnskntlylqmnslraedtavyycvrdlysygmdvwgqgttvtvss,,gltvssny,iysggst,vrdlysygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77616,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgyslielsmhwvrqapgkglewmggfdpedvetiyaqnlqgrvtmtedtstdtaymelsslrsedtavyycatffavrgalnwfdswgqgtlvtvss,,gysliels,fdpedvet,atffavrgalnwfds,,,,IGHJ5*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77615,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggitpifhtanyaqkfqgrvtitadeststvymelsslssedtavyycaretgdqgvtapfdlwgrgtlvtvss,,ggtfssya,itpifhta,aretgdqgvtapfdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77614,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlfcaasgftfsdyymswfrqapgkglewvsyisssgsniyyadsvkgrftvsrdnaknslylqmnslraedtavyfcargrlwgwfdpwgqgtlvtvss,,gftfsdyy,isssgsni,argrlwgwfdp,,,,IGHJ5*02 (human),IGHV3-11*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77613,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqtpgkglewmggfdpadaetiyaqklqgrvtmtedtstdtaymelsslrsedtavyycatalpitmvrgvqyyyygmdvwgpgttvtvss,,gytltels,fdpadaet,atalpitmvrgvqyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77612,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslraadtavyycatgtydfwsdnhyldywgqgtlvtvss,,gftfssyg,isydgsnk,atgtydfwsdnhyldy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77611,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgpsvkvsckasggtfssytinwvrqapgqglewmgriipmlgiakyaqkfqgrvtitadkststaymelsslrsedtavyycargivgatpgyfdywgqgtlvtvss,,ggtfssyt,iipmlgia,argivgatpgyfdy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77610,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvsinymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaapllwadsyymdvwgkgttvtvss,,gftvsiny,iysggst,aapllwadsyymdv,,,,IGHJ6*04 (human),IGHV3-66*01 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77609,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntdyvqkfqgrvtitrdmststaymelsslrsedtavyycaapycssttchdgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapycssttchdgfdi,,,,IGHJ3*02 (human),IGHV1-58*02 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,QRN77608,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvss,,ggtfssyt,iipildrv,arraidsdtyveqshfdy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77635,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgpgtkvdik,,,,qsvssf,das,qqrsnwppft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77634,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyprtfgqgtkleik,,,,qgissy,aas,qqlnsyprt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77633,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleik,,,,qginny,aas,qqynsypft,,,IGKJ5*01 (human),IGKV1-16*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77632,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsslsasvgdrvtitcragqsissylnwyqqkpgkapklliylastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptwtfgqgtkveik,,,,qsissy,las,qqsystptwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77631,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleik,,,,qgissy,aas,qqvnsypt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77630,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleik,,,,qsvssn,gas,qqynnwpplt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77629,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqlrgnwppwtfgqgtkveik,,,,qsvssy,das,qlrgnwppwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77628,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleik,,,,qdisny,das,qqydhllit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77627,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgiyycmqvtqfpytfgqgtkleik,,,,qslvhsdgnty,kis,mqvtqfpyt,,,IGKJ2*01 (human),IGKV2-24*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77626,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypsttfgggtkveik,,,,qgisss,aas,qqlnsypstt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77625,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspaalsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgswsgteftltisslqsedlavyycqqynnwltfgggtkveik,,,,qsvssn,gas,qqynnwlt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77624,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqrgvpsrfsgsgsgteftltisslqpedfatyyclqhnsylwtfgqgtkveik,,,,qdirnn,aas,lqhnsylwt,,,IGKJ1*01 (human),IGKV1-17*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77623,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveik,,,,qsvsssy,gas,qqygrspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",N/A,,,N/A,QRN77622,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveik,,,,qsvssy,das,qqplt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 71 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72470,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 71 from patent US 10851155,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavy,,gytftsya,inagngnt,,,,,IGHJ2*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 70 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72469,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 70 from patent US 10851155,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavy,,gftfssyg,isydgsnk,,,,,IGHJ2*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 69 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72468,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 69 from patent US 10851155,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavy,,ggtfssya,iipilgia,,,,,IGHJ2*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 68 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72467,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 68 from patent US 10851155,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavy,,ggtfssya,iipifgta,,,,,IGHJ2*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 26 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72432,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 26 from patent US 10851155,N/A,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,,ggtfssya,iipifgia,assnyygsgsyyprsafdi,,,,IGHJ3*02 (human),IGHV1-69*17 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 22 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72430,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 22 from patent US 10851155,N/A,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,,gytfnvya,iipilgia,ardyygsgargfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 18 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72428,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 18 from patent US 10851155,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,,ggtfssya,iipifgta,arasycsttscasgafdi,,,,IGHJ5*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 14 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72426,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 14 from patent US 10851155,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,,ggtfssya,iipifgta,arvgycsstschigafdi,,,,IGHJ3*02 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 10 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72424,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 10 from patent US 10851155,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,,ggtfssya,iipifgka,ardqgisanfkdafdi,,,,IGHJ3*02 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 6 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72422,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 6 from patent US 10851155,N/A,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,,ggtfgsya,idaangnt,ardrwmttrafdi,,,,IGHJ3*02 (human),IGHV1-3*01 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 2 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,QRL72420,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 2 from patent US 10851155,N/A,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,,eftfntyg,isydgtkk,arsgdsdafdi,,,,IGHJ3*02 (human),IGHV3-30*03 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 71 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34220,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 71 from patent US 10131704,N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavy,,gytftsya,inagngnt,,,,,IGHJ2*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 70 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34219,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 70 from patent US 10131704,N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavy,,gftfssyg,isydgsnk,,,,,IGHJ2*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 69 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34218,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 69 from patent US 10131704,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavy,,ggtfssya,iipilgia,,,,,IGHJ2*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 68 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34217,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 68 from patent US 10131704,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavy,,ggtfssya,iipifgta,,,,,IGHJ2*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 26 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34182,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 26 from patent US 10131704,N/A,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,,ggtfssya,iipifgia,assnyygsgsyyprsafdi,,,,IGHJ3*02 (human),IGHV1-69*17 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 22 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34180,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 22 from patent US 10131704,N/A,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,,gytfnvya,iipilgia,ardyygsgargfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 18 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34178,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 18 from patent US 10131704,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,,ggtfssya,iipifgta,arasycsttscasgafdi,,,,IGHJ5*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 14 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34176,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 14 from patent US 10131704,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,,ggtfssya,iipifgta,arvgycsstschigafdi,,,,IGHJ3*02 (human),IGHV1-69*06 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 10 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34174,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 10 from patent US 10131704,N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,,ggtfssya,iipifgka,ardqgisanfkdafdi,,,,IGHJ3*02 (human),IGHV1-69*04 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 6 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34172,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 6 from patent US 10131704,N/A,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,,ggtfgsya,idaangnt,ardrwmttrafdi,,,,IGHJ3*02 (human),IGHV1-3*01 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 2 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,AZK34170,N/A,SARS-CoV,Unknown.,2022-03-15,Sequence 2 from patent US 10131704,N/A,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,,eftfntyg,isydgtkk,arsgdsdafdi,,,,IGHJ3*02 (human),IGHV3-30*03 (human),,
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 77 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72476,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 77 from patent US 10851155,,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeady,,,,snnvgnqg,rnn,,,,IGLJ1*01 (human),IGLV10-54*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 76 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72475,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 76 from patent US 10851155,,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavy,,,,qsvsssy,gas,,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 75 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72474,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 75 from patent US 10851155,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavy,,,,qsvlyssnnkny,was,,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 74 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72473,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 74 from patent US 10851155,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavy,,,,qsvssn,gas,,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 73 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72472,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 73 from patent US 10851155,,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeady,,,,ssnigsny,rnn,,,,IGLJ1*01 (human),IGLV1-47*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 72 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72471,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 72 from patent US 10851155,,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeady,,,,klgdky,qds,,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 28 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72433,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 28 from patent US 10851155,,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,,,,qsisnd,gas,qqygvsplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 24 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72431,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 24 from patent US 10851155,,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,,,,snnvgnqg,tnn,aswdsslsvwv,,,IGLJ3*02 (human),IGLV10-54*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 20 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72429,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 20 from patent US 10851155,,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,,,,qsvlyssnnkny,was,qqyysvpft,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 16 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72427,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 16 from patent US 10851155,,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,,,,qsvsss,dss,qqyssspyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 12 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72425,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 12 from patent US 10851155,,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,,,,esvgsn,gas,qqynnwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 8 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72423,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 8 from patent US 10851155,,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,,,,ssnigsny,rnn,aawddslrgpv,,,IGLJ1*01 (human),IGLV1-47*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 4 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",N/A,,,N/A,QRL72421,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 4 from patent US 10851155,,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,,,,elgdkf,qds,qawdsnsyv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 77 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34226,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 77 from patent US 10131704,,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeady,,,,snnvgnqg,rnn,,,,IGLJ1*01 (human),IGLV10-54*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 76 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34225,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 76 from patent US 10131704,,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavy,,,,qsvsssy,gas,,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 75 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34224,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 75 from patent US 10131704,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavy,,,,qsvlyssnnkny,was,,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 74 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34223,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 74 from patent US 10131704,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavy,,,,qsvssn,gas,,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 73 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34222,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 73 from patent US 10131704,,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeady,,,,ssnigsny,rnn,,,,IGLJ1*01 (human),IGLV1-47*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 72 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34221,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 72 from patent US 10131704,,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeady,,,,klgdky,qds,,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 28 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34183,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 28 from patent US 10131704,,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,,,,qsisnd,gas,qqygvsplt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 24 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34181,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 24 from patent US 10131704,,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,,,,snnvgnqg,tnn,aswdsslsvwv,,,IGLJ3*02 (human),IGLV10-54*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 20 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34179,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 20 from patent US 10131704,,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,,,,qsvlyssnnkny,was,qqyysvpft,,,IGKJ3*01 (human),IGKV4-1*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 16 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34177,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 16 from patent US 10131704,,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,,,,qsvsss,dss,qqyssspyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 12 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34175,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 12 from patent US 10131704,,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,,,,esvgsn,gas,qqynnwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 8 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34173,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 8 from patent US 10131704,,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,,,,ssnigsny,rnn,aawddslrgpv,,,IGLJ1*01 (human),IGLV1-47*01 (human)
GenBank,,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 4 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",N/A,,,N/A,AZK34171,SARS-CoV,Unknown.,2022-03-15,N/A,Sequence 4 from patent US 10131704,,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,,,,elgdkf,qds,qawdsnsyv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 96 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",N/A,,,QRJ89103,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 96 from patent US 10822379,N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 8 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",N/A,,,QRJ89017,N/A,SARS-CoV-2,Unknown.,2022-03-15,Sequence 8 from patent US 10822379,N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvss,,gftvssny,iysggst,argygdyyfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 16 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",N/A,,,N/A,QRJ89025,SARS-CoV-2,Unknown.,2022-03-15,N/A,Sequence 16 from patent US 10822379,,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveik,,,,qsvssy,was,qqygssplt,,,IGKJ4*01 (human),IGKV3D-7*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23548,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,,ggtfssya,iipifgta,araywgrgptifgvvsnttryygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23547,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrhssgwdnwyfdlwgrgtlvtvss,,ggtfssya,iipifgta,arggwrhssgwdnwyfdl,,,,IGHJ2*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23546,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,,gftfssyg,iwydgsnk,ardgsgsyywgsldy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23545,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,,ggtfssya,iipifgta,arggwvicsstscytkysyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23544,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,,gftfssyg,iwydgsnk,ardgsgsyywgsldy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23543,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvgplmvrgviipwgqgtlvtvss,,gftfssyg,iwydgsnk,vgplmvrgviip,,,,IGHJ5*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23542,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgspsggwytldywgqgtlvtvss,,gftfssyg,iwydgsnk,ardgspsggwytldy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23541,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdvwgqgttvtvss,,gftfsfya,isydgsnk,arewfgetwegmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23540,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpglvkpsetlsltctvsggsissyywswirqppgkglewigniyysgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycareqfsggdyegfdfwgqgtlvtvss,,ggsissyy,iyysgst,areqfsggdyegfdf,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23539,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelgslrsedtavyycaragwsvsplkynwfdpwgqgtlvtvss,,ggtfsnya,iipifgta,aragwsvsplkynwfdp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23538,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraaygpyygmdvwgqgttvtvss,,gftfssyg,iwydgsnk,araaygpyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23537,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlrgptgwtfdywgqgtlvtvss,,gfifssyg,iwydgsnk,ardlrgptgwtfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23536,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttegamvrrviygmdvwgqgttvtvss,,gftfsnaw,iksktdggtt,ttegamvrrviygmdv,,,,IGHJ6*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23535,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,,ggtfssya,iipifgta,arggwvicsstscytkysyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23534,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdawgqgttvtvss,,gftfsfya,isydgsnk,arewfgetwegmda,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,QQX23533,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrssgyhdysyygmdvwgqgttvtvss,,ggtfssya,iipifgta,arggwrssgyhdysyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23532,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygngnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvfgggtkltvl,,,,ssnigagyd,gng,qsydsslsvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23531,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdssliarlfgggtkltvl,,,,ssnignny,dnn,gtwdssliarl,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23530,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslnvvfgggtkltvl,,,,ssnigagyd,gns,qsydsslnvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23529,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23528,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvsiscsgstssigrntvswfqqlpgtapklliyrdnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycsawhdtlngvvfgggtkltvl,,,,tssigrnt,rdn,sawhdtlngvv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23527,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsisnigsahvswyqqvpgtapklliydnserpsgiparfsafkygtsatlditglqtgdeadyycaswdislsagifgggtkltvl,,,,isnigsah,dns,aswdislsagi,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23526,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystllgtfgpgtkvdik,,,,qsissy,aas,qqsystllgt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23525,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspatlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkvdik,,,,qsvsssy,gas,qqygssplft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23524,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpwtfgqgtkvei,,,,qsvssy,gas,qqrsnwpwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23523,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrwtfgqgtkveik,,,,qsvsssy,gas,qqygssrwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23522,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnpitfgqgtrleik,,,,qsvssy,das,qqrsnpit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23521,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspiftfgpgtkvdik,,,,qsvsssy,gas,qqygsspift,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23520,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwkitfgqgtrleik,,,,qsvsny,dss,qhrsnwkit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23519,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspgtlslspgeratlscrarqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleik,,,,qsvsssy,gas,qqygsspit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23518,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplltfgggtkveik,,,,qsvssy,das,qqrsnwpllt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,,,N/A,QQX23517,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,,,,qsvsssy,gas,qqygssprgvt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74752,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,,gftfsnyv,isgsggst,akdltrdyydssgyqtgafdi,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74751,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,,gftfsnyv,iggsgdst,akgaapyyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74750,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,,gftvrsny,iysggst,ardlavygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74749,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,,gytftgyy,inpnsggt,argwatyydiltgyslfdy,,,,IGHJ4*01 (human),IGHV1-2*04 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74748,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,,gftfssya,isgsggrt,akdldivvvitgdafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74747,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,,gytftnyf,inpsvgst,arthvaqlweiwyfdi,,,,IGHJ2*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74746,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,,ggairsgsyy,ifhigna,vrpnnehggfffdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74745,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,,gftfssfa,isgsggrt,akdmdivvvitgdafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,QQO74744,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,,gytftsys,istyngnt,areeplycsggscyefqh,,,,IGHJ1*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74743,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,,,,nigsks,dds,qvwggv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74742,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,,,,ssdvggydy,evs,ssytsssalyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74741,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,,,,qgissy,gas,qqlnnyppvt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74740,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,,,,ssdvgsynl,evs,csyagsstphvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74739,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,,,,alprhy,kds,qsadssgtyrv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74738,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,,,,tsnigsna,sdn,aawddslkgv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74737,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,,,,nigsrs,ydt,qvwvstfdhvv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74736,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,,,,alpkqy,kds,qsadssgtyrv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,QQO74735,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,,,,qsvssd,das,qqrinwppift,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17516,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtlvtvss,,gltldyya,isssdgst,aavpstyysgtyyytchpggmdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17515,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtqvtvss,,gltldyya,isssdgst,aavpstyysgtyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17514,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesgggsveaggslrlscaasgvtldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtadyycaavpstyysgtyyynchpgamhywgkgtqvtvss,,gvtldyya,isssdgst,aavpstyysgtyyynchpgamhy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17513,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftisrdnakntvylqmnslkpddtavyycaaalseggytidgsswcyhsvygmdywgkgtqvtvss,,gftldyya,isssdgst,aaalseggytidgsswcyhsvygmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17512,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscitnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycasfpstyysgsyyytchpggmdywgkgtqvtvss,,gftldyya,itnsdgst,asfpstyysgsyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17511,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsggstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,gftldyya,isnsggst,aavpstyysgsyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17510,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtlvtvss,,gftldyya,isnsdgst,aavpstyysgsyyytchpggmdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17509,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,gftldyya,isnsdgst,aavpstyysgsyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17508,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,gftldyya,isnsdgst,aavpstyysgsyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17507,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvacisssdgttyyadsvkgrftisrdnakntvylqmnslkpedtavyycatrpltyysgsyyttcsdygmdywgkgtlvtvss,,gftldyya,isssdgtt,atrpltyysgsyyttcsdygmdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17506,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscaasgltldyytigwfrqapgkeregvscisssddstyyadsvkgrftisrdnakntvylqmnslkpedtavyycatapgtyykgsyypmchyygmdywgkgtqvtvss,,gltldyyt,isssddst,atapgtyykgsyypmchyygmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17505,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyysgtyyynchpggmdywgkgtqvtvss,,gftldyya,isssdgst,aavpstyysgtyyynchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",N/A,,,QNS17504,N/A,SARS-CoV-2,Lama glama (llama),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",N/A,dvqlqesggdlvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyyngsyyytchpggmdywgkgtqvtvss,,gftldyya,isssdgst,aavpstyyngsyyytchpggmdy,,,,IGHJ6*04 (human),IGHV3-23*01 (human),,
GenBank,,,"Li,W. et al.; High potency of a bivalent human VH domain in SARS-CoV-2 animal models; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.007,,,QNN25877,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region VHab8, partial [synthetic construct]",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; Nat Commun 11 (1) (2020) In press; 2020.",10.1038/s41467-020-18174-5,,,QLR06781,N/A,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),2022-03-15,"SARS-CoV-2 RBD-specific neutralizing immunoglobulin heavy chain, partial [Vicugna pacos]",N/A,qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,,gftfssvy,ispnsgni,aiglnlssssv,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58173,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvss,,gltfssyv,iwydgskk,ardprdyydfwsgydyyygldv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58172,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvss,,gftfssyg,isydgsnk,akdsgynygyswfdp,,,,IGHJ5*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58171,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvaaisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsilygggmdvwgqgttvtvss,,gftfssyt,isydgnnk,arsilygggmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58170,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyyctragwelrldafdiwgqgtmvtvss,,gftfssys,isssssyi,tragwelrldafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58169,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvss,,gftfsdhy,trnkansytt,arvhrwaycingvcfgaysdy,,,,IGHJ4*01 (human),IGHV3-72*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58168,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfyygmdvwgqgttvtvss,,gltvssny,iysggst,ardlfyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58167,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahhkierifdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58166,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,,ggsvsssnyy,myysgst,arevyyydrsgyyasdgfdi,,,,IGHJ3*02 (human),IGHV4-59*02 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58165,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsisnyywswirqspgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsakhwlappgdyyyymdvwgkgttvtvss,,ggsisnyy,iyysgst,arsakhwlappgdyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58164,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvss,,gytliels,fdpedvet,atgwaykstwyfgy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58163,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvss,,gytliels,fdpedaet,atgiavigpppstyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58162,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgwavagssdvwyyyygmdvwgqgttvtvss,,gytliels,fdpedaet,atgwavagssdvwyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58161,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqllqsgaevkkpgasvkvsckasgysftsyymhwvrqapgqglewmgiinpsgggttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpgggsyqefdywgqgtlvtvss,,gysftsyy,inpsgggt,arpgggsyqefdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58160,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvss,,gytftsyy,inpsggst,ardrephsdssgywdslkyyyyyaldv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58159,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,,gytftgyy,inpnsggt,ardrswavvyyymdv,,,,IGHJ6*04 (human),IGHV1-2*02 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58158,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvss,,gytftgyy,inpisdgt,arggsrcsggncygwaydafdi,,,,IGHJ3*02 (human),IGHV1-2*04 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58157,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,,gytftgyy,inpnsggt,arglgvgcsggncyldyyymdv,,,,IGHJ6*04 (human),IGHV1-2*02 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58156,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvss,,ggtfssya,nipifgta,argvgyrgviplnwfdp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,QMI58155,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,,ggtfssht,iipilgia,aslqtvdtaiekyygmdv,,,,IGHJ6*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58192,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,,,,qsvssd,gas,qqynnwppft,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58191,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlqvtfgggtkveik,,,,qsissy,aas,qqsyntlqvt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58190,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvl,,,,alakqy,kds,qstdnsgtypnwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58189,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrssyaswyqqkpgqapilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgilfgggtkltvl,,,,slrssy,dkn,nsrdssgil,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58188,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,,,,klgdky,qdn,qawdsstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58187,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleik,,,,qsvsssy,gas,qqygsspst,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58186,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveik,,,,qsvsssy,gas,qqygssgalt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58185,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,,,,qsvsssy,gas,qqygsspqt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58184,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgqapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58183,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypcfgpgtkvdik,,,,qgissy,aas,qqlnsypc,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58182,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyltfgggtkveik,,,,qgissy,aas,qqlnsylt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58181,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdik,,,,qgissy,aas,qqlntypft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58180,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvl,,,,ssdvggyny,evs,ssyagsrmg,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58179,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,,,,ssdvggyny,evs,ssyagsnnlv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58178,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsalaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,,,,ssdvgayny,dvs,ssyttsstv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58177,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssstyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58176,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,,,,ssdvgsynr,evs,ssytssstyv,,,IGLJ1*01 (human),IGLV2-18*02 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58175,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,,,,ssdvggynf,dvs,ssytssstfv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,,,N/A,QMI58174,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62517,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,,ggtfsssa,iipildit,alrnqwdllvy,,,,IGHJ4*01 (human),IGHV1-69*10 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62516,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiafagsvkgrftisrdnaknslylqmnslraedtalyycakdqgysygnyfdywgqgtlvtvss,,gftfddya,iswnsgsi,akdqgysygnyfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62515,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvscmasgytftsyymhwvrqapgqglewmgiispsgggtsyaqkfqgrvtltrdtststvymelsslrsedtavyycarwydstgsidywgqgtlvtvss,,gytftsyy,ispsgggt,arwydstgsidy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62514,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,,ggtfsiya,iipiigta,ardfrycsstrcyfwfdp,,,,IGHJ5*02 (human),IGHV1-69*06 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62513,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytfatyalnwvrqapgqglewmgwvntntgsptyaqgftgrfvfsfdtsvstaylqirtlkaedtavyycavyyydsgspgwfdpwgqgtlvtvss,,gytfatya,vntntgsp,avyyydsgspgwfdp,,,,IGHJ5*02 (human),IGHV7-4-1*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62512,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfsnyamtwvrqapgkglewvsaissgsgstyyadsvkgrftisrdnskntvylqmnslraedtaiyycakankysssefdfwgqgtlvtiss,,gftfsnya,issgsgst,akankysssefdf,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62511,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfigyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistvymelsrlrsddtavyycarempaamgyyyygmdvwgqgttvtvss,,gytfigyy,inpnsggt,arempaamgyyyygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62510,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtvsadksistaylqwsslkasdtamyycarvnyydssgypsfhfdywgqgtlvtvs,,gysftsyw,iypgdsdt,arvnyydssgypsfhfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62509,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,,gftfssya,isgsgdst,akdryyefwsgysnwfdp,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62508,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscsasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrtgnyyygmdvwgqgttvtvss,,gftfsiyg,isydgsnk,akdrtgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62507,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqgdcsttscaydywgqgtlvtvss,,ggsissssyy,iyysgst,arqgdcsttscaydy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62506,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgfaqnmvlltpywgqgtlvtvss,,gytltels,fdpedaet,atgfaqnmvlltpy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62505,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymdlsslrsedtavyycatafsifgvvppdywgqgtlvtvs,,gytltels,fdpedget,atafsifgvvppdy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62504,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslrgedtavyycakdqayydiltgylnppknyyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,akdqayydiltgylnppknyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62503,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgsgsgsypnyyyyygmdvwgqgttvtvss,,gftfssya,isgsggst,akgsgsgsypnyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62502,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarlhcggdcyldywgqgtlvtvss,,gytftsyy,inpsggst,arlhcggdcyldy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62501,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglegvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssgsyyyyyygmdvwgqgttvtvss,,gftfrnyg,isydgsnk,akssgsyyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62500,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnknyadsvkgrftisrdnskntldlqmnslraedtavyycardpfpgavagtgylqywgqgtlvtvss,,gftfssyg,iwydgsnk,ardpfpgavagtgylqy,,,,IGHJ1*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62499,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmsslraedtaiyycardrrrryctngvcyrpeeidywgqgtlvtvss,,gftfstye,isssgsti,ardrrrryctngvcyrpeeidy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62498,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfnyysmnwvrqapgkglewissistsssfvyyadsvkgrftisrdnaktslylqmnslraedtavyfcarggycsdgscyvqdrliyyysgldvwgqgttvtvss,,gftfnyys,istsssfv,arggycsdgscyvqdrliyyysgldv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62497,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardpygyssiwdgqgghwgqgtlvtvss,,gftvssny,iysggst,ardpygyssiwdgqggh,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62496,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtavyycargprysgtyfdywgqgtlvtvss,,gyiysgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62495,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,gyifsgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62494,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiysgyfmhwvrqapgqglewmgwispdsgganyaqtfqgrvtmtrdtstttahmelsrlrsddtavyycargprysgthfdywgqgtlvtvss,,gyiysgyf,ispdsgga,argprysgthfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62493,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqnfqgrvtmtrdtsistgymelsrlrsddtamyycargprysgtyfdywgqgvlvtvss,,gyifsgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62492,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,gyifsgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62491,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvtcktsgyifsgyymhwvrqvpgqglewmgwispdsgatnyaqkfqgrvtmtrdtsittsyveltwlksddtavyycargprysgtyfdfwgqgtlvtvss,,gyifsgyy,ispdsgat,argprysgtyfdf,,,,IGHJ5*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62490,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittgymelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,gyifsgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62489,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtamyycargprysgtyfdywgqgtlvtvss,,gyiysgyy,ispdsggt,argprysgtyfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62488,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispnsggtnyaqkfqgwvtmtrdtsvstaymelsrlrfddtavyycateswvygsgsyssgafdiwgqgtmvtvss,,gytftgyy,ispnsggt,ateswvygsgsyssgafdi,,,,IGHJ3*02 (human),IGHV1-2*04 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62487,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,,gftvssny,iysggst,ardfgdfyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62486,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsvfysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdlyfdywgqgtlvtvss,,gftvssny,fysggst,ardygdlyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,QLI62485,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,,gltvssny,iysggst,ardldvygldv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62550,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,,,,qsvsssy,gas,qhygsslwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62549,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qlvltqppsvsvapgktaritcggnnigsksvywyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpyvfgsgtkvtvl,,,,nigsks,dds,qvwdsssdhpyv,,,IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62548,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypiltfgggtkleik,,,,qgirnd,aas,lqhnsypilt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62547,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqeagkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,,,,qnissy,aas,qqsystprt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62546,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqtassylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpptfgqgtkvdik,,,,qtassy,aas,qqsystppt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62545,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgaapklliyrndqrpsgvpdrfsgsksgtsvslaisglrsedeadyycaawddslsgwvfgggtkltvl,,,,ssnigsny,rnd,aawddslsgwv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62544,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstfvfvfgtgtkvivl,,,,ssdvgsynl,egs,ysyagsstfvfv,,,IGLJ1*01 (human),IGLV2-23*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62543,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcvsstgavtsgyypnwfqqkpgqapraliystskkhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggaqrwvfgggtkltvl,,,,tgavtsgyy,sts,llyyggaqrwv,,,IGLJ3*02 (human),IGLV7-43*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62542,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snd,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62541,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,,,,qsissy,aas,qqsystpwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62540,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssgtylvvfgggtklavl,,,,alpkqy,kds,qsadssgtylvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62539,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,,,,qsvssn,gas,qqynnwppit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62538,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qavvtqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62537,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsvltqppsasstpgqrvtiscsgsssnigsnyvywyqqlpgtapklliytnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgrvvfgggtkltvl,,,,ssnigsny,tnn,aawddslsgrvv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62536,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,syeltqspsvsvapgqtaritcggnnigsksvhwyqrkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdnnsdhlvfgggtkltvl,,,,nigsks,dds,qvwdnnsdhlv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62535,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiannyvkwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnheeiwvfgggtklivl,,,,sgsianny,edn,qsydssnheeiwv,,,IGLJ3*02 (human),IGLV6-57*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62534,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddtdrpsgiperfsgsssgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,,,,nigsks,ddt,qvwdsssdhpvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62533,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,,,,nigsks,dds,qvwdsssdpwv,,,IGLJ3*02 (human),IGLV3-21*02 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62532,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qavltqppsvsgapgqrvtisctgsssnieagydvhwyqqlpgtapklliyvnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvvfgggtklivl,,,,ssnieagyd,vns,qsydsslsgvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62531,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvfycmqgthwpptfgqgtkvdik,,,,qslvysdgnty,kvs,mqgthwppt,,,IGKJ3*01 (human),IGKV2-30*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62530,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,dvvmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnfatgvpsrfsgtgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62529,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsgstqvfgggtkltvl,,,,ssdvggyny,dvs,ssytsgstqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62528,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,,,,ssdvggyny,dvs,ssytsssaql,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62527,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsltisctgtssdvggynyvswyqqhpdkapklmiydvnnrpsgvsnrfsgsksgstasltisglqaedeadyycssyagsstqvfgggtkltvl,,,,ssdvggyny,dvn,ssyagsstqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62526,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqvfgggtkltvl,,,,ssdvggyny,dvs,ssytsssaqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62525,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynhvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,,,,ssdvggynh,dvs,ssytsssaql,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62524,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsltisctgtssdiggfnyvswyqqhpgkapklmifdvskrpsgvpnrfsgsksgntasltisglqaedegdyycssytissaqvfgggtkltvl,,,,ssdiggfny,dvs,ssytissaqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62523,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsaltqptsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytvsstqvfgggtkltvl,,,,ssdvggyny,dvs,ssytvsstqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62522,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssytssstqvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstqv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62521,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,qsvltqppsasgspgqsvtisctgtssdvggydyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvpglqaedeadyyctsyagsnnfvfgggtklivl,,,,ssdvggydy,evs,tsyagsnnfv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62520,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,,,,qsvssy,gas,qqygssprt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62519,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsetdftltisrlepeefavyycqqygssprtfgqgtkleik,,,,qsvsssy,gvs,qqygssprt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,QLI62518,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveik,,,,qgissy,aas,qqlnsyppkft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,,,QLI33947,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,,,QLI33945,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,gytftsyy,inpgggst,argaippnsraeidy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,,,N/A,QLI33948,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,,,,qsvsssy,gas,qhygssrgwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,,,N/A,QLI33946,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,,,,qsvssn,gas,qqyynwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76702,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqkfqervtitrdvststaymelsslrsedtavyycaaprcsggscydgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aaprcsggscydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76701,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkisckasgyifinyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtslstaylqissleaedtavyycakigsrnslgvwgqgtlvtvsa,,gyifinya,intntgnp,akigsrnslgv,,,,IGHJ1*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76700,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,gasissnhyf,mhysgst,argvnyydrngyyrndgfdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76699,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggilgyadsvkgrftisrdnaknslylqmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,,gftfddya,iswnggil,akdlrrqdyyadwyfdl,,,,IGHJ2*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76698,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,gasissnhyf,mhysgst,argvnyydrngyyrndgfdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76697,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggildyadsvkgrftisrdnaknslylhmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,,gftfddya,iswnggil,akdlrrqdyyadwyfdl,,,,IGHJ2*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76696,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssntryytdsvmgrftisrdnaknslflqmnslraedtavyycasskgfcsggscsdywgqgtlvtvss,,gftfssys,issssntr,asskgfcsggscsdy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76695,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,gasissnhyf,mhysgst,argvnyydrngyyrndgfdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76694,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfsrytiiwvrqapgqglewmgriipildianyaqkfqgrvtitadkststaymelsslrsedtavyycareggldyfgsrnsgwtytwfdpwgqgtlvtvss,,ggtfsryt,iipildia,areggldyfgsrnsgwtytwfdp,,,,IGHJ5*02 (human),IGHV1-69*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76693,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycatgarfgespfdywgqgtlvtvss,,gftvssny,iysggst,atgarfgespfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76692,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgrglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycatgarfgespfdywgqgtlvtvss,,gftvssny,iysggst,atgarfgespfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76691,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfrnyamtwvrqapgkglewvsgisdsgdrtynadsvkgrfsisrdnskntlhlqmnslraedtavyycalasgsyfgganywgqgtlvtvss,,gftfrnya,isdsgdrt,alasgsyfggany,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76690,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtglyycakdinydsggyhknyfdywgqgtlvtvss,,gftfddya,iswnsgsi,akdinydsggyhknyfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76689,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqgrvtitrdmstrtaymelsslrsedtamyycaapycsstrcydafdiwgqgtmvtvss,,gftfsssa,ivvgsgnt,aapycsstrcydafdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76688,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyffdywgqgtlvtvss,,gfivssny,iysggst,ardygdyffdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76687,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardfgdfffdywgqgtlvtvss,,gftvssny,iysggst,ardfgdfffdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76686,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaatgftfrrygmhwvrqapgkglewvagilfdgsnkyyvdsvkgrftisrdssrntlylqlnslrredtavyycakggdyewelleswgqgtlvtvss,,gftfrryg,ilfdgsnk,akggdyewelles,,,,IGHJ5*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76685,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcssticydgfdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aaphcssticydgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76684,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgrnkyyvdsvkgrftisrdnskntlylqisslraedtavyycaraarrpvvtdtmayymdvwgkgttvtvss,,gftfssyg,iwydgrnk,araarrpvvtdtmayymdv,,,,IGHJ6*04 (human),IGHV3-33*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76683,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,,gytflrfa,idtntgtp,arslrganlvp,,,,IGHJ5*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76682,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,,gytflrfa,idtntgtp,arslrganlvp,,,,IGHJ5*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76681,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarattdcsstscwsldfwsgyytggrekifdywgqgtlvtvss,,gytftsyd,mnpnsgnt,arattdcsstscwsldfwsgyytggrekifdy,,,,IGHJ4*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76680,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdapirtaymelsglgsddtavyycarasvatitdfdywgqgtlvavss,,gyiftnyy,ihslsggt,arasvatitdfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76679,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevknpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdasirtaymelsrlgsddtalyycarasvstitdfdywgqgtlvavss,,gyiftnyy,ihslsggt,arasvstitdfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76678,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksivylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,,gftfgdya,irskayggtt,trvrrlwfgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76677,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,,gftfgdya,irskayggtt,trvrrlwfgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-49*03 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76676,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvss,,gytftsyg,isayngnt,ardgellgwfdp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,QKY76675,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,,ggtfssya,iipifgta,arvsgydssgywgdy,,,,IGHJ4*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76730,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76729,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrashsvdrsylawyqqkpglaprlliygassratgipdrfsgsgsgtdftltisrlepedfalyycqhfgtssvtfgrgtrleik,,,,hsvdrsy,gas,qhfgtssvt,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76728,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,,,,qgirnd,aas,lqhntypft,,,IGKJ3*01 (human),IGKV1-17*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76727,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtkvdv,,,,qgissw,aas,qqgnsfpft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76726,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,,,,qgirnd,aas,lqhntypft,,,IGKJ3*01 (human),IGKV1-17*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76725,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmiqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtivdv,,,,qgissw,aas,qqgnsfpft,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76724,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfvvyychqygsspwtfgqgtkveik,,,,qsvsssy,gvs,hqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76723,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,,,,qgirnd,aas,lqhntypft,,,IGKJ3*01 (human),IGKV1-17*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76722,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapnlliyaasslqsgvpprfsgsgsgtdftltisslqpedfatyycqqsystlysfgqgtkleik,,,,qnissy,aas,qqsystlys,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76721,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,,,,qgissw,aas,qqansfpgt,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76720,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,,,,qgissw,aas,qqansfpgt,,,IGKJ1*01 (human),IGKV1-12*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76719,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qavvtqepsltvspggtvtltcgsstgpvtsdhypywfqqkpgqapttliydtnnkhswtparfsgsllggkaaltlsgaqpedeaeyycllsytgarvfgggtkltvl,,,,tgpvtsdhy,dtn,llsytgarv,,,IGLJ2*01 (human),IGLV7-46*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76718,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdratitcrasqsissylnwyqekpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpltfgggtkveik,,,,qsissy,aas,qqsysnplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76717,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkvei,,,,qsvsssy,gas,qqygrspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76716,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllisgassraagipdrfsgsgsgtdftltinrlepedfavyycqqygssprtfgqgtkleik,,,,qsvssy,gas,qqygssprt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76715,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,,,,qsvssy,gvs,qqygssprt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76714,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstvsasvgdrvtitcrasqsidnwlawyqekpgkapkvliykasslesgvpsrfsgrgsgteftltisslqpgdfatyycqhyhsfpltfgggtkvdik,,,,qsidnw,kas,qhyhsfplt,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76713,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76712,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscraslslssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptwtfgqgtkaeik,,,,lslssy,das,qqrsnwpptwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76711,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdvsny,daf,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76710,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdvsny,daf,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76709,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,,,,qsvsssy,gas,qqygsspgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76708,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtsgdigsynlvswyqqypgkapkliiyeaskrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,,,,sgdigsynl,eas,csyagvrtvv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76707,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtsgdvgsynlvswyqqhpgkapklviyeatkrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,,,,sgdvgsynl,eat,csyagvrtvv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76706,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,,,,qsllhsngyny,lgs,mqalqtpgt,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76705,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,,,,qsllhsngyny,lgs,mqalqtpgt,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76704,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,,,,ssdvgsynl,egs,csyagsstwv,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,,,N/A,QKY76703,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppaltfgggtkveik,,,,qsvssy,das,qqrsnwppalt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76674,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,,gftfssya,isydgsnk,aradtmvrgtyfey,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76673,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,gftfsfyw,ikqdggek,arlsgsswdfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76672,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,ggtfssya,iipifgaa,artshydssgsyfey,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76671,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,ggtfssya,iipifgaa,artshydssgsyfey,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76670,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,,gftfssya,isydgnnk,arpytgsyksymdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76669,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,ggtfssya,iipifgtt,arighfdssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76668,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,,gftfstyg,isydgsnk,akdgsiaaady,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76667,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,ggtfssya,iipifgtt,arighfdssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76666,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arstsgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76665,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfstywmtwvrqapgkglewvanikqdgsekyyvdsvkyrftisrdnaknslylqmnslraedtavyycarvgssswyfdywgqgtlvtvss,,gftfstyw,ikqdgsek,arvgssswyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76664,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arstsgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76663,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,,gftfssyg,iwydgskk,ardqsqgayiltgyrgygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76662,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydmnwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarggiyylvrgfiigyygmdvwgqgttvtvss,,gytftsyd,mnpnsgnt,arggiyylvrgfiigyygmdv,,,,IGHJ6*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76661,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,gftfsfyw,ikqdggek,arlsgsswdfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76660,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,,gftfssya,isydgsnk,aradtmvrgtyfey,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76659,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,,gftfssyg,iwydgskk,ardqsqgayiltgyrgygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76658,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdnigyadsvkgrftisrdiaknslylqmnslraedtalyycakgiyydifmplldwgrgtlvtvss,,gftfddya,iswnsdni,akgiyydifmplld,,,,IGHJ2*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76657,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,,gftfsyypmh,tsydgtnk,arggatnfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76656,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaityyydssgywwddwgqgtlvtvss,,ggtfssya,iipifgta,aityyydssgywwdd,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76655,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,,gytfknyg,isaytgnt,arvqrrrldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76654,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,ggtfssya,iipifgaa,artshydssgsyfey,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76653,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,,gftfnnya,iggsggst,arvegdwllggpyyhyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76652,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscatsgftfssfalhwvrqapgkglewvtvisddgnnkyyvdsvkgrftisrdnskntlflqmnslrvedtaiyycarasynsnwsigeyfrdwgqgtlvtvss,,gftfssfa,isddgnnk,arasynsnwsigeyfrd,,,,IGHJ1*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76651,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtvisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksyngnyydafdiwgqgtmvtvss,,gftfstya,isydgsnk,aksyngnyydafdi,,,,IGHJ3*02 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76650,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigrvyiyssgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargaasfdywgqgtlvtvss,,ggsissgsyy,vyiyssgst,argaasfdy,,,,IGHJ4*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76649,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgdsissgsyywswirqpagkglewigriytsgsttynpslksrvtisvntsknqfslnlssvtaadtavyycarvggispyyyyyymdvwgkgttvtvss,,gdsissgsyy,iytsgst,arvggispyyyyyymdv,,,,IGHJ6*04 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76648,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwvnpnsghtgyaqkfqgrvtmtrntsvstaymelsslrsedtavfycargrvgyvgsgsrgyyyyydmdvwgqgttvtvss,,gytfssyd,vnpnsght,argrvgyvgsgsrgyyyyydmdv,,,,IGHJ6*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76647,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiylsgttnynpsltsrvtisvdksknqfslklnsvtaadtaiyycarptagaggafdiwgqgtvvtvss,,ggsisssn,iylsgtt,arptagaggafdi,,,,IGHJ3*02 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76646,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfgsyviswvrqapgqglqwmggiipifgkpnyaqkfqgrvtitadeststaymelsslrsedtavyycargwfgellkgtywfdpwgqgtlvtvss,,ggtfgsyv,iipifgkp,argwfgellkgtywfdp,,,,IGHJ5*02 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76645,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgssyyspslksrvtisadtsknqfslnlrsvtaadtavyycasgppymatfsyyfdywgqgtlvtvss,,ggsissssyy,iyysgss,asgppymatfsyyfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76644,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,gfsvstsgeg,iywdddk,ahrlwfrdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76643,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggdlvqpggslrltcaasgftfsshwmtwvrqapgkglewvanikedgrekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarvvvevatnkgihgvdyyyyyymdvwgkgttvtvss,,gftfsshw,ikedgrek,arvvvevatnkgihgvdyyyyyymdv,,,,IGHJ6*04 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76642,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgynkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,,gftfssya,isydgynk,araqggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76641,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,ggtfssya,iipifgtt,arighfdssgyyldy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76640,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscadsaftfssfwmswvrqapgkglewvanikqdgsekfyldsvkgrftisrdnaknslylqmnslraedtavyycarlgrsswnfdywgqgtlvtvss,,aftfssfw,ikqdgsek,arlgrsswnfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76639,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylemnslraedtavyycarprggsyqtcfdywgqgtlvtvss,,gfifstya,isydgdnk,arprggsyqtcfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76638,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtlisydggnkyyadsvkgrftisrdnskntlylqmnslraedaavyfcarghtgnyyygmdvwgqgttvtvss,,gftfstya,isydggnk,arghtgnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76637,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqleesgpglvkpsetlsltctvsggsisshywswirqppgkglewigyiqdsgstnynpslksrvtisvdtsknqfslrlssvttadtavyycvrgamawfdpwgqgtlvtvss,,ggsisshy,iqdsgst,vrgamawfdp,,,,IGHJ5*02 (human),IGHV4-59*11 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76636,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgfsfrnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,gfsfrnyg,isgdennk,akggdssgwawdgdnpptdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76635,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigriftsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarggllwfggagnymdvwgkgttvtvss,,ggsissgsyy,iftsgst,arggllwfggagnymdv,,,,IGHJ6*04 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76634,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,,gftfstyg,isydgsnk,akdgsiaaady,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76633,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,,gfivssny,iysggst,arestq,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76632,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlylqmnslraedtavyycarprsgsyyayfdywgqgtlvtvss,,gftfssya,isydgink,arprsgsyyayfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76631,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarelmsvgwgqgtlvtvss,,gftfssfa,isydgsnk,arelmsvg,,,,IGHJ1*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76630,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygmhwvrqapgqrlewmgwinvgngntkysqrfqgrvtitrdtsastaymelsslrsedtavyycamgpsafswldpwgqgtlvtvss,,gytftsyg,invgngnt,amgpsafswldp,,,,IGHJ5*02 (human),IGHV1-3*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76629,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmtwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslslqmnslrvedtavyycvrlgvsswyfdywgqgtlvtvss,,gftfssyw,ikqdgsek,vrlgvsswyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76628,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,,gftfsnyg,isndefnk,akggdgsgwawdgdnpptdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76627,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltcavsgasissgsyywswirqpagkglewigriytsgntnynpslksrvtisvdtsknqfslklssvtaadtavyycatgyigtyyyymdvwgkgttvtvss,,gasissgsyy,iytsgnt,atgyigtyyyymdv,,,,IGHJ6*04 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76626,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiyhsgttnynpslrsrvtisvdksknqlslklnsvtaadtaiyycarptagaggafdtwgqgtmvtvsa,,ggsisssn,iyhsgtt,arptagaggafdt,,,,IGHJ3*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76625,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,gfsvstsgeg,iywdddk,ahrlwfrdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76624,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,gftfsfyw,ikqdggek,arlsgsswdfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76623,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,,ggtfssya,iipvfgta,arigsypeyfqh,,,,IGHJ1*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76622,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfilsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,,gfilsdhy,trnkansytt,asvitfggvivrsy,,,,IGHJ4*01 (human),IGHV3-72*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76621,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnpkntlylqmnslraedtavyycardtatyvllwsgdfnldywgqgtlvtvss,,gftfstya,isydgsnk,ardtatyvllwsgdfnldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76620,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsrhamhwvrqapgkglewvavisydgsnkyyadsvkgrfaisrdnskntlylqmnslrpedtavyycardpsplvlitsidywgqgtlvtvss,,gftfsrha,isydgsnk,ardpsplvlitsidy,,,,IGHJ4*01 (human),IGHV3-30*09 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76619,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsiywmswvrqapgkglqwvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlggsswhfdywgqgtlvtvss,,gftfsiyw,ikqdasek,arlggsswhfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76618,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsyyailwfrqapgkglewvaiisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycarpqsggyyapldywgqgtlvtvss,,gftfsyya,isydgsnk,arpqsggyyapldy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76617,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,,gytfknyg,isaytgnt,arvqrrrldy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76616,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardvggysgydlgfdyyyymdvwgkgttvtvss,,gftfssyw,ikedgsek,ardvggysgydlgfdyyyymdv,,,,IGHJ6*04 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76615,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvelvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,,gfifssya,isydggnk,araqggnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76614,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,gftfstya,isydgynk,argsagnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76613,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvnsgsyysyfdywgqgtlvtvss,,gftfssya,isydgink,arvnsgsyysyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76612,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgsalkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycargrsyglslgywgqgtlvtvss,,gytftsya,intntgnp,argrsyglslgy,,,,IGHJ4*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76611,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtsvstaylqisslkaedtavyycarglvgridpwgqgtlvtvss,,gytfttya,intntgnp,arglvgridp,,,,IGHJ5*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76610,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,gfsvstsgeg,iywdddk,ahrlwfrdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76609,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtskkqfslklssvtaadtavyycageevrgvklyyyyamdvwgqgttvtvss,,ggsissssyy,iyysgst,ageevrgvklyyyyamdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76608,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arstsgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76607,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgttnyaqklqgrvtisadeststaymevsslrsedtavyycarvsgygdygaysdywgqgtlvtvss,,ggtfssya,iipvfgtt,arvsgygdygaysdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76606,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,gftfsnyg,isgdennk,akggdssgwawdgdnpptdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76605,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslraedtavfycargdgdvynfllvrnwfdpwgqgtlvtvss,,gftfssya,isydgsnk,argdgdvynfllvrnwfdp,,,,IGHJ5*02 (human),IGHV3-30*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76604,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,,ggtfssya,iipvfgta,arigsypeyfqh,,,,IGHJ1*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76603,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsfisgtgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqarvqdyiwgsyrsygmdvwglgttvtvss,,gftfssya,isgtgdst,akdqarvqdyiwgsyrsygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76602,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,,gftfsyypmh,tsydgtnk,arggatnfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76601,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkgldwvavisydgsnryyaasvkgrftisrdnskntlylqmnslrtedtavyfcargdgyrsqfdpwgqgtlvtvss,,gftfsnya,isydgsnr,argdgyrsqfdp,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76600,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngnsnygkkfqgrvtmtadtststaymelrslrsddtavyycardlpikvvvpaadynwfdpwgqgtlvtvss,,gytfttyg,isayngns,ardlpikvvvpaadynwfdp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76599,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,,gftfssya,isydgnnk,arpytgsyksymdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76598,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,,gftfddsa,iswnsgnv,tkasrycssticywnwfdp,,,,IGHJ5*02 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76597,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,,gftfddsa,iswnsgnv,tkasrycssticywnwfdp,,,,IGHJ5*02 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76596,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaylqisslkaedtavyycararllgycsstscytigwgafdiwgqgtmvtvss,,gytftsya,intntgnp,ararllgycsstscytigwgafdi,,,,IGHJ3*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76595,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,gftfstya,isydgynk,argsagnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76594,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,gftfsnyg,isgdennk,akggdssgwawdgdnpptdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76593,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyfvdsvkgrftisrdnaknslylqmnslraedaavyycarlvttvttanglyyysyyymdvwgkgttvtvss,,gftfssyw,ikqdgsek,arlvttvttanglyyysyyymdv,,,,IGHJ6*04 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76592,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,,gfivssny,iysggst,arestq,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76591,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfafsnyaihwvrqapgkglewvavisydgnnkdyadsvkgrftisrdnskntlylqmnslraedtavyycarvpvmvrgvyfdywgqgtlvtvss,,gfafsnya,isydgnnk,arvpvmvrgvyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76590,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdltivvipaapnfdywgqgtlvtvss,,gftfssyg,isydgsnk,akdltivvipaapnfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76589,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlsctasgfifgdyamgwvrqapgkglewvgfirgkaydgtteyaasvkgrftisrddskyiahlqmnslktedtavyycirdydfwggyyyhplrafdiwgrgtmvtvss,,gfifgdya,irgkaydgtt,irdydfwggyyyhplrafdi,,,,IGHJ3*02 (human),IGHV3-49*04 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76588,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavissdgsnkyyagsvkgrftisrdnskntlylqmnslraedtavyycakdmveplfshyyyygmdvwgqgttvtvss,,gftfssyg,issdgsnk,akdmveplfshyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76587,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgtyywswirqpagkglewigrfytsgstnynpslksrvtisvdasknqfslklssvtaadtavyycararpdyyyyyamdvwgqgttvtvss,,ggsissgtyy,fytsgst,ararpdyyyyyamdv,,,,IGHJ6*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76586,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvqvsceasgytfttyymhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymdlsslrsedtavyycardrlgdgsylgggyygmdvwgqgttvtvss,,gytfttyy,inpsggst,ardrlgdgsylgggyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76585,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,,gysftsyw,iypgdsdt,arpdyssgwfsywyfdl,,,,IGHJ2*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76584,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggavqpgrslrlscaasgftfstyamywvrqapgkglewvavisydgsnryyadsvkgrftisrdnskntlylqmnslrpedtavyycardrsgnyrdafdiwgqgtmvtvss,,gftfstya,isydgsnr,ardrsgnyrdafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76583,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsvyyigstyynpslksrvtmsvdtsknqfslklssvtaadtavyycarapfqlldkyyffyymdvwgkgttvtvss,,ggsissssyy,vyyigst,arapfqlldkyyffyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76582,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,,gysftshw,iypgdsdt,asalrergvqlwsv,,,,IGHJ1*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76581,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydeinkyyadsvkgrftisrdnskttldlqmnslraedtavyycaragggsyrgpfdywgqgtlvtvss,,gftfssya,isydeink,aragggsyrgpfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76580,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraddtavyycakgrgnyltffdswgqgtlvtvss,,gftfsnyg,isydgtnk,akgrgnyltffds,,,,IGHJ5*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76579,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsfyaihwvrqapgqglewaaaissdgtykyyadsvkgrftisrdnskntsylqmnslraedtavyycaralnkgfdpwgqgtlltvss,,gftfsfya,issdgtyk,aralnkgfdp,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76578,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvsp,,ggsfsgyy,inhsgst,arcrqmgnfyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76577,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,gfsvstsgeg,iywdddk,ahrlwfrdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76576,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggrlvlpggslrlscaasgftfsvyemnwvrqapgkglewlsyigtsgspiyyadsvkgrftvsrdnaknslylqmnslrvedtalyycardrgwnygldywgqgtlvtvss,,gftfsvye,igtsgspi,ardrgwnygldy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76575,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,,gysftsyw,iypgdsdt,arrgeaagiwyfdl,,,,IGHJ2*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76574,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,,gysftsyw,iypgdsdt,arpdyssgwfsywyfdl,,,,IGHJ2*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76573,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,,gysftnsw,iypgdsdt,athrcsggfcylay,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76572,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvsgnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnspraedtavyycardpsayydiltgysgdvwgkgttvtvss,,gftvsgny,iysggst,ardpsayydiltgysgdv,,,,IGHJ6*04 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76571,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysagstyyadsvkgrfsisrdkskntlylqmnslraedtavyycakeggsgslryyyygmdvwgqgttvtvss,,gftvssny,iysagst,akeggsgslryyyygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76570,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,,gysftshw,iypgdsdt,asalrergvqlwsv,,,,IGHJ1*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76569,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgpplvepkqtltltctfsgfslttsgeavgwirqppgkalewlaliywdddkhyspslrnrltitrdtsknqvvltltnvdpadtgtyycahravilnfdhwgqgflvtvss,,gfslttsgea,iywdddk,ahravilnfdh,,,,IGHJ1*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76568,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrvscaasgftfsshgmhwvrqapgkglewvsviwydgsnkyyadsvkgrftisrdnskntlslqmnslraedtavyycaresadissrldywgrgtlvtvss,,gftfsshg,iwydgsnk,aresadissrldy,,,,IGHJ2*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76567,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsppasyynpstgyfdywgqgtlvtvss,,gfifssya,isydgsnk,arsppasyynpstgyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76566,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytftrhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycvreygsghplpiwgqgtlvtvss,,gytftrha,intntgnp,vreygsghplpi,,,,IGHJ1*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76565,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysfsdywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarltfggsgsyyfyyngmdvwgqgttvtvss,,gysfsdyw,iypgdsdt,arltfggsgsyyfyyngmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76564,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyviswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardqgptyyygsgsphygmdvwgqgttvtvss,,gytftsyv,isayngnt,ardqgptyyygsgsphygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76563,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,gftfssyg,isydgsnk,argsagnyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76562,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmsslraedtavyycakegewelrgnaldiwgqgtmvtvss,,gftfssyg,isydgrnk,akegewelrgnaldi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76561,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctvsgfslstsgvgvgcirqppgkalewlaliywdddkryspslksrltitrdtsknqvvltmtnmdpvdtgtyfcvhrhvsgafdywgqgtlvtvss,,gfslstsgvg,iywdddk,vhrhvsgafdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76560,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfifstygmhwvrqapgkglewvavisydgsnkynadsvkgrftisrdnskntlylqmnslrvedtavyycaiygyyyygldvwgqgttvtvss,,gfifstyg,isydgsnk,aiygyyyygldv,,,,IGHJ6*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76559,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvss,,ggsfsgyy,inhsgst,arcrqmgnfyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76558,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qgqlvqsggdvvqpgkslrlscaasgftftnyamhwvrqapgkglewvavisndgsnekyvdsvkgrfslsrdnskntvyldmhslrpedtaiyycardrsnlerlvmtfggiiagafdiwgqgarvtvss,,gftftnya,isndgsne,ardrsnlerlvmtfggiiagafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76557,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,gfsvstsgeg,iywdddk,ahrlwfrdafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76556,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytfsdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarglislfrgaifhyyygmdvwgqgttvtvss,,gytfsdya,intntgnp,arglislfrgaifhyyygmdv,,,,IGHJ6*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76555,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgrikgktdggttdyaapvkgrftiskddskntlylqmsslntedtavywcttltyyydssaylndafdiwgqgtmvtvss,,gftfsnaw,ikgktdggtt,ttltyyydssaylndafdi,,,,IGHJ3*02 (human),IGHV3-15*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76554,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgkglewigtihysgisyynpslksrvtisvdtsnnkfslelssvtaadtavyfcarrtyydlwsaysstayycmdvwgkgttvtvss,,ggsisssnyy,ihysgis,arrtyydlwsaysstayycmdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76553,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisndgrnkyyadsvkgrltisrdnskntlylqmnslraedtavyycarpsnwyfdlwgrgtlvtvss,,gftfssya,isndgrnk,arpsnwyfdl,,,,IGHJ2*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76552,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycardggnayssgwyryyyhmdvwgkgttvtvss,,ggsissyy,iyysgst,ardggnayssgwyryyyhmdv,,,,IGHJ6*04 (human),IGHV4-59*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76551,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfhnyaiswvrqapgqglewmggfipilgttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvegegvdsyyygmdvwgqgttvtvss,,ggtfhnya,fipilgtt,arvegegvdsyyygmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76550,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqiqqwgagvlkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslklssvtaadtavyycargppvttffvfsllfdpwgqgtlvtvss,,ggsfsghy,inhsgst,argppvttffvfsllfdp,,,,IGHJ5*02 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76549,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgkslrlscaasgftfssygmhwvrqapgkglewvaviwydgnnkfyvdsvkgrftisrdnskntlymemnslraedtavyycarkgplwrfdywgqgtlvtvss,,gftfssyg,iwydgnnk,arkgplwrfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76548,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapdkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwpnqafdiwgqgtmvtvss,,gftfssyg,iwydgsnk,aregqwpnqafdi,,,,IGHJ3*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76547,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,,gysftsyw,iypgdsdt,arrgeaagiwyfdl,,,,IGHJ2*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76546,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckaseytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpgkaaafdywgqgtlvtvss,,eytftsya,intntgnp,arpgkaaafdy,,,,IGHJ4*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76545,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqgtyldywgqgtlvtvss,,gftfssyg,iwydgsnk,aregqgtyldy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76544,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavvsydgsnkyytdsvkgrftisrdnskntlflqmiglreedtavyycaqgrggyyspfddwgqgtlvtvss,,gftfssyg,vsydgsnk,aqgrggyyspfdd,,,,IGHJ5*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76543,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslntngvavgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrgiltedafdiwgqgtmvtvss,,gfslntngva,iywdddk,ahrrgiltedafdi,,,,IGHJ3*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76542,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgnkkycadsvkgrctisrdnskntlylqmnslraedtavyycaregpfgdreasgafdvwgqgtmvtvss,,gftfstyg,iwydgnkk,aregpfgdreasgafdv,,,,IGHJ3*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76541,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisgdnskntlylqmnslrvddtavyycardpgsrysggwydyyyamdvwgqgttvtvss,,gltvssny,iysggst,ardpgsrysggwydyyyamdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76540,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssnywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardprvvvtarmynwfdpwgqgtlvtvss,,ggsissssny,iyysgst,ardprvvvtarmynwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76539,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwtwvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrwgdyfdssgaydswgqgtlvtvss,,ggsisssnw,iyhsgst,asrwgdyfdssgayds,,,,IGHJ5*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76538,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssylmhwvrqapgkglewvaviwangnryyadsvkgrftisrdiskntlylqmnslraedtamyycardycngvtcnsnywgqgtlvtvss,,gftfssyl,iwangnr,ardycngvtcnsny,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76537,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttatvss,,gfslstsglc,idwdddk,arattffygmdv,,,,IGHJ6*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76536,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsgsyygwfdpwgqgtlvtvss,,gftfsiyg,isfdgsnk,akdgsgsyygwfdp,,,,IGHJ5*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76535,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlacaasgftfssygmhwvrqapgkglewvavisydgnnkyyadslkgrftisrddskntlylqmnslraedtavyycakdrtavflffglgdafdiwgqgtmvtvss,,gftfssyg,isydgnnk,akdrtavflffglgdafdi,,,,IGHJ3*02 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76534,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwfdgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycaregdfwsgyytgwfdpwgqgtlvtvss,,gftfssyg,iwfdgsnk,aregdfwsgyytgwfdp,,,,IGHJ5*02 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76533,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,gftfstya,isydggnk,aknlgpycsggtcyslvgdy,,,,IGHJ4*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76532,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,,gysftnsw,iypgdsdt,athrcsggfcylay,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76531,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,gdtfssyt,iipilgip,argrgysnygasyymdv,,,,IGHJ6*04 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76530,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaradpyqllgqhyyygmdvwgqgttvtvss,,gftfssyd,igtagdt,aradpyqllgqhyyygmdv,,,,IGHJ6*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76529,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtalyycarearyfdwifegsdyyyygmdvwgqgttvtvss,,gytftsyd,mnpnsgnt,arearyfdwifegsdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76528,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,gftfddyg,inwnggst,arrrsssryssgwymyyyymdv,,,,IGHJ6*04 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76527,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklnsvtaadtavyycasrwgdyfdssgaydswgqgtlltvss,,ggsisssnw,iyhsgst,asrwgdyfdssgayds,,,,IGHJ5*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76526,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvadisydgsekyyadsvkgrftiyrdnskntlylqmnslraedtavyycakdfggdntamveyffdfwgqgtlvtvss,,gftfssya,isydgsek,akdfggdntamveyffdf,,,,IGHJ5*01 (human),IGHV3-30-3*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76525,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,gftfddyg,inwnggst,arrrsssryssgwymyyyymdv,,,,IGHJ6*04 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76524,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyfcakvgwelsidafdlwgqgtmvtvss,,gftfddya,iswnsgsi,akvgwelsidafdl,,,,IGHJ3*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76523,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviyydgsnkyyadsvkgrftisrdnskntlylqihslraedtavyycaregqmaattgidywgqgtlvtvss,,gftfsnyg,iyydgsnk,aregqmaattgidy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76522,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,,gftfsnyg,isndefnk,akggdgsgwawdgdnpptdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76521,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evalvesggglvkpggslrlscaasgfifsnawmtwvrqapgkglewvgrikskseggtpeyaapvkgrfiisrddstnslhlqmnylriedtavyycttggyssyaasdywgqgtlvtvss,,gfifsnaw,ikskseggtp,ttggyssyaasdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76520,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arstsgsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76519,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,gftfddyg,inwnggst,arrrsssryssgwymyyyymdv,,,,IGHJ6*04 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76518,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahnrfqycssttcytllpfdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahnrfqycssttcytllpfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76517,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvrdlalfevviqqgvwgqgtlvtvss,,gftfsnyg,iwydgsnk,vrdlalfevviqqgv,,,,IGHJ1*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76516,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrrggigieygmdvwgqgttvtvss,,gysfttyw,iypgdsdt,arrrggigieygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76515,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscavsgftfssywmhwvrqapgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylqmnslraedtavyycareveqlahmvdywgqgtlvtvss,,gftfssyw,insdgsst,areveqlahmvdy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76514,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycardlagvpaalgcwfdpwgqgtlvtvss,,gytftshy,inpsggst,ardlagvpaalgcwfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76513,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,,ggsissttyy,iyysgst,arqwkwfgeawyfdl,,,,IGHJ2*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76512,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysfptywigwvrqmpgkglewmgiiypgdsdtrygpsfqgqvtisadksistaylqwsslkasdtamyycarrdtdfdywgqgtlvtvss,,gysfptyw,iypgdsdt,arrdtdfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76511,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evrllesggglvqpggslrlscaasgftfsdyamnwvrqapgkglewvsaisatggstfyadsvkgrfsisrdnsknslvlqmnslraedtavyycakpygmdvwgqgttvtvss,,gftfsdya,isatggst,akpygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76510,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgqglewvagiwydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycagssgegglyyyygmdvwgqgttvtvss,,gftfsnyg,iwydgsnk,agssgegglyyyygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76509,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfdsygvhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlyvqmnslrtedtavyycardsggnygdsyfdywgqgtlvtvss,,gftfdsyg,isydgsnk,ardsggnygdsyfdy,,,,IGHJ4*01 (human),IGHV3-30*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76508,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaflhigslkaedtavyycardqdsgyptyyyyymdvwgkgttvtvss,,gytfttya,intntgnp,ardqdsgyptyyyyymdv,,,,IGHJ6*04 (human),IGHV7-4-1*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76507,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftftsyamswvrqapgkglewvsgisisggstyyaasvkgrftisrdnskntlylqmnslraedtavyycakdsrsgiagvdafdiwgqgtmvtvss,,gftftsya,isisggst,akdsrsgiagvdafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76506,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,,ggsissyy,iyysgst,araprerlqwgeyyfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76505,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,,gftfstya,isydgsnk,ardwaptyydmpsafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76504,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,,gfslsnakmg,ifsndek,arivlgasgtypspgfdp,,,,IGHJ5*02 (human),IGHV2-26*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76503,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycargwyfdywgqgtlvtvsa,,ggsisssnw,iyhsgst,argwyfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76502,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggslssyywswirqppgkglewigyiydsggasrstnynpslksrvtisvdtsrnqlslklssvtaadtavyycardqrqfqllgrfgwfdpwgqgtlvtvss,,ggslssyy,iydsggasrst,ardqrqfqllgrfgwfdp,,,,IGHJ5*02 (human),IGHV4-4*08 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76501,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgssnynpslksrvtisvdtsknqfslklssvtaadtavyycargwgwgavagraeyyfdywgqgtlvtvss,,ggsfsgyy,inhsgss,argwgwgavagraeyyfdy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76500,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,,gftfssya,isydgsnk,ardqewfrelflfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76499,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycareandsgsfyngpfdywgqgtlvtvss,,ggsissggyy,iyysgst,areandsgsfyngpfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76498,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,,gytltels,fdpedaet,atgfavfgraavpy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76497,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evrllesggglvqpggslrlscaasgftftsyamswvrqapgkglqwvstisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdpasgivgpthfdywgqgtlvtvss,,gftftsya,isvsggst,akdpasgivgpthfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76496,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaavkkpgssvkvsckasggtfssyaiswvrqapgqglewmggivpifgtanyaqkfqgrvtitadestttaymelnslrsedtavyycaredyygsgslvdpyyyyrmdvwgqgttvtvss,,ggtfssya,ivpifgta,aredyygsgslvdpyyyyrmdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76495,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvss,,gftfssyw,inqdggek,ardpydlygdyggtfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76494,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,,gftfssys,isnsnsfi,arvngnsnwnfgsyyyyymdv,,,,IGHJ6*04 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76493,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissgtyycgwirqppgkglewigstyyggstlynpslrgrvtisvdtsknqfslklssvtaadtavyycarrgnyydsknwfdpwgqgtlvtvss,,ggsissgtyy,tyyggst,arrgnyydsknwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76492,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,,gftfssye,isssgsai,arearsryfdwlpsyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76491,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftftsyamnwvrqapgkglewvsaisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgsgivgatgfdfwgqgtlvtvss,,gftftsya,isvsggst,akdfgsgivgatgfdf,,,,IGHJ5*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76490,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftftsygmswvrqapgkglewvsaisisggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakllgsgitldndafdiwgqgtmvtvss,,gftftsyg,isisggst,akllgsgitldndafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76489,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyscaslwfgdlysfdywgqgtlvtvss,,ggsissssyy,fyysgst,aslwfgdlysfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76488,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,,gftfsgys,isssssyi,arwlqlrsdyyyfgmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76487,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifsgdeksystslksrltiskdtsksqvvltmtnmdpldtatyycarttwgtwiqawyfdiwgrgtlvtvss,,gfslsnarmg,ifsgdek,arttwgtwiqawyfdi,,,,IGHJ2*01 (human),IGHV2-26*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76486,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,,ggsfsghy,inhsgst,arppqaarihyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76485,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggpisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklnsvtaadtavyycarhdgsgemdtitwgpiyyymdvwgkgttvtvss,,ggpisssryy,iyysgst,arhdgsgemdtitwgpiyyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76484,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlsctasgftfssyamhwvrqapgkglewvalisydgnnkyyadsakgrftisrdnskntlylqmnslrsedtavyycardlgrgldpwgqgtlvtvss,,gftfssya,isydgnnk,ardlgrgldp,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76483,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsirsssyywgwirqppgkglewiasiyysgstyynsslksrvtisvdtsknqfslkvnsmtaadtavyycailwrgsswadrhyyyysmdvwgqgttvtvss,,ggsirsssyy,iyysgst,ailwrgsswadrhyyyysmdv,,,,IGHJ6*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76482,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllqsggglvqpggslrlscaasgftfrnyamswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakneritmlvvvtlfdywgqgtlvtvss,,gftfrnya,isgsggtt,akneritmlvvvtlfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76481,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,,gftfssse,isssgsii,arrsyrsswyyyygmdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76480,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvhpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnrlraedtavyycaqmgplgstssaadywgqgtlvtvss,,gftfssya,isgsggst,aqmgplgstssaady,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76479,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgdsinsgnyywswirqpagkglewigrmftsgstnynpsltsrvtmsidtsknqfslnlnsvtaadtamyycarghvaawescyywgqgilvtvss,,gdsinsgnyy,mftsgst,arghvaawescyy,,,,IGHJ4*01 (human),IGHV4-61*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76478,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,,gfslsnakmg,ifsndek,arivlgasgtypspgfdp,,,,IGHJ5*02 (human),IGHV2-26*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76477,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,,ggsfsghy,inhsgst,arppqaarihyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76476,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,,ggsissyy,iyysgst,araprerlqwgeyyfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76475,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,,gftfsgys,isssssyi,arwlqlrsdyyyfgmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76474,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,,gftfssys,isnsnsfi,arvngnsnwnfgsyyyyymdv,,,,IGHJ6*04 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76473,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,,gftfssya,isydgsnk,ardqewfrelflfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76472,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,,gytltels,fdpedaet,atgfavfgraavpy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76471,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,,gftfssye,isssgsai,arearsryfdwlpsyyfdy,,,,IGHJ4*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76470,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,,gftfstya,isydgsnk,ardwaptyydmpsafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76469,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,,gftfssse,isssgsii,arrsyrsswyyyygmdv,,,,IGHJ6*01 (human),IGHV3-48*03 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76468,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedgetvyaqkfqgrvtmtedtssdtaymelsslrsedtavyycatsfpirgdpsyyyyyygmdvwgqgttvtvss,,gytltels,fdpedget,atsfpirgdpsyyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76467,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytlielsihwvrqapgkglewmggfdpedvetiyaqkfqgrvtmtedtstdtaymelssltsedravyycatqpaaiggtppyywgqgtlvtvss,,gytliels,fdpedvet,atqpaaiggtppyy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76466,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqnfqgrvtmtedtstdtaymelsslrsedtalyycaaapavmtagwfdpwgqgtlvsvss,,gytltels,fdpedaet,aaapavmtagwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76465,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,,ggsissggyf,iyysgst,arggsgsyslfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76464,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,gftfddya,iswnsdsi,akgrgagytsymdv,,,,IGHJ6*04 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76463,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arilviftlnwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76462,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrlptpqllpsfenwfdpwgqgtlvtvss,,gfslstsgvg,iywdddk,ahrlptpqllpsfenwfdp,,,,IGHJ5*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76461,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgseltkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintdtgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardpsycsstrcytvgwfdpwgqgtlvtvss,,gytftsya,intdtgnp,ardpsycsstrcytvgwfdp,,,,IGHJ5*02 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76460,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslntsgvgvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahrppsyhgwcyfdywgqgnlvtvss,,gfslntsgvg,iywdddk,ahrppsyhgwcyfdy,,,,IGHJ4*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76459,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavilydgsnryyadsvkgrftisrdnskntlylqmnslraedtavyycakqgglycsgtncwggyldywgqgtlvtvss,,gftfstyg,ilydgsnr,akqgglycsgtncwggyldy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76458,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvgiisydasdktyaesvkgrftisrdnskntlylqmnslraedtavyycakvsatyyyyyygmdvwgqgttvtvss,,gftfsryg,isydasdk,akvsatyyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76457,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywvgwvrqmpgkglewmgiiypgdsdtrdspsfqgqvtisadksistaylqwsslkasdtamyycarlgseskidyyyygmdvwgqgttvtvss,,gysftsyw,iypgdsdt,arlgseskidyyyygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76456,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglecvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpirdgvwglnendywgqgtlvtvss,,gftfsdyy,isssgsti,ardpirdgvwglnendy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76455,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvymelsslrsedtamyycardvfwvpaassfdywgqgtlvtvss,,gytftshy,inpsggst,ardvfwvpaassfdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76454,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstkrvgvgwirqppgkalewlaliywdddqryspslksrltitkdtsknqvvltmtnmdpvdtatyycahsgppdlspvlsqgwfdpwgqgtlvtvss,,gfslstkrvg,iywdddq,ahsgppdlspvlsqgwfdp,,,,IGHJ5*02 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76453,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgitiyyadsvkgrftisrdnaknslylqmnslraedtavyyctgvvaapaeyfqhwgqgtlvtvss,,gftfsdyy,isssgiti,tgvvaapaeyfqh,,,,IGHJ1*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76452,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,,ggsissggyf,iyysgst,arggsgsyslfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76451,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywnwlrqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvggyyyyymdvwgkgttvtvss,,ggsfsgyy,inhsgst,arvggyyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76450,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevktpgasvkvsckasgytftsydinwvrqatgqgpewmgwmnpnsgntgyahkfqgrvtmtrntsistaymelsslrsedtavyycargpsiltgfynpldywgqgtlvtvss,,gytftsyd,mnpnsgnt,argpsiltgfynpldy,,,,IGHJ4*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76449,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,,gfifddyd,inwnggst,avimspiprysgydwagdafdi,,,,IGHJ3*02 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76448,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytftsydinwvrqatgqglewmgwmnpnsghtgyaqkfqgrvtmtrntsistaymelsslryedtavyycargygltyymdvwgkgttvtvss,,gytftsyd,mnpnsght,argygltyymdv,,,,IGHJ6*04 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76447,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgtlvtvss,,gftfrryg,isydgtdk,akkggpycgggncyagyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76446,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgdtfssyylhwvrqapgqglqwmgisnpsggsttyaqkfqgrvtmtgdtststvymelsslrsedtavyycargglvpaarnafdiwgqgtmvtvss,,gdtfssyy,snpsggst,argglvpaarnafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76445,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiqpgdsdtryspsfqgqvtmsadkststaylqwsslkasdtamyycardliiestiaarpgyygmdvwgqgttvtvss,,gysftsyw,iqpgdsdt,ardliiestiaarpgyygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76444,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtagdtyypdsvkgrftisrenaknslflqmnslragdtavyycarvdfdiltgyysnwgqgtlvtvss,,gftfssyd,igtagdt,arvdfdiltgyysn,,,,IGHJ1*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76443,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvrlvqsgaevkkpgssvkvsckasggtfsdyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeftitaymelsslrsedtavyycarlsgsgwlgyamdvwgqgttvtvss,,ggtfsdya,iipifgta,arlsgsgwlgyamdv,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76442,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,,gfifddyd,iswnggnt,avimspiprysgydwaggafdi,,,,IGHJ3*02 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76441,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvalisydgrneyyadsvkgrftisrdnskntlylqmnslragdsavyycardlayhpyrdygdddyyyyygmdvwgqgttvtvss,,gftfsrya,isydgrne,ardlayhpyrdygdddyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76440,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,,gftfddya,isgdggnt,akdemayppshhyyyyymdv,,,,IGHJ6*04 (human),IGHV3-43*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76439,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyfadsvkgrftisrdnskntlylqmnslraedtavyycardqgtvvthfdywgqgtlvtvss,,gftfssya,isydgsyk,ardqgtvvthfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76438,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhggstdynpslksrvtisvdksknqfslkltsvtaadtavyycarvdhvnvrdywgpgtlvtvss,,ggsisssnw,iyhggst,arvdhvnvrdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76437,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavfycakdlppyasgwyeggfdywgrgtqvtvss,,gftfssyg,isfdgsnk,akdlppyasgwyeggfdy,,,,IGHJ2*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76436,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,,gftfsdya,isfdgsnk,ardlsttwylemwgpdafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76435,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,gftfsnyg,msydgsnk,aknlgpycsggtcyslvgdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76434,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,,ggsfsayy,inhsgst,arvgysqgyyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76433,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,eaqlvesggglvqpggslrlsceasgfifssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvndgrpnpleyyfdywgqgtlvtvss,,gfifssyw,ikqdgsek,arvndgrpnpleyyfdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76432,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqsggslrlscaasgftfstygmhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntvylqmnslrtedtamyycakgdgsylmdyfdywgqgtlvtvss,,gftfstyg,isydgink,akgdgsylmdyfdy,,,,IGHJ4*01 (human),IGHV3-30*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76431,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargltgssaykdeiyfdywgqgtlvtvss,,ggtfssya,iipifgta,argltgssaykdeiyfdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76430,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,,gftfnnya,iggsggst,arvegdwllggpyyhyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76429,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifwndensystslktrltiskdtsksqvvlnmtnmdpvdtatyycartewllsdnwfdswgqgtlvtvss,,gfslsnarmg,ifwnden,artewllsdnwfds,,,,IGHJ5*01 (human),IGHV2-26*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76428,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgilvtvss,,gftfrryg,isydgtdk,akkggpycgggncyagyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76427,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarggdsgydlgawyfdlwgrgtlvtvss,,gftfssyd,igtagdt,arggdsgydlgawyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76426,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,gftfddya,iswnsdsi,akgrgagytsymdv,,,,IGHJ6*04 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76425,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,,ggsissssyy,iyysgst,arilviftlnwfdp,,,,IGHJ5*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76424,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfrsydmhwvrqvtgkglewvstigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvfetkvirggryyyyyymdvwgkgttvtvss,,gftfrsyd,igtagdt,arvfetkvirggryyyyyymdv,,,,IGHJ6*04 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76423,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapgqglewmgilnpgagstsyaqkfqgrvtmtsdtstntvymqlsslksedtavyycardqqivphadgfdiwgqgtmvtvss,,gytftnyy,lnpgagst,ardqqivphadgfdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76422,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,gftfddya,iswnsdsi,akgrgagytsymdv,,,,IGHJ6*04 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76421,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvssitsllgyyfdswgqgtlvtvss,,gftfddya,iswnsgsi,akvssitsllgyyfds,,,,IGHJ5*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76420,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,gftfsnyg,msydgsnk,aknlgpycsggtcyslvgdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76419,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsssdlhwvrqatgkglewvsaigtagdtyylgsvkgrftisrengknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,gftfsssd,igtagdt,arvlydssgfynwfdp,,,,IGHJ5*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76418,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,,gftfddya,isgdggnt,akdemayppshhyyyyymdv,,,,IGHJ6*04 (human),IGHV3-43*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76417,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyylhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtstsavymelrslrsedtavyycarendygdyveprdyyygmdvwgqgttvtvss,,gytftsyy,inpsggst,arendygdyveprdyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76416,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76415,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycardlgdgynlrvpayfdlwgrgtlvtvss,,ggsissggyy,isysgst,ardlgdgynlrvpayfdl,,,,IGHJ2*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76414,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,,gftfsrhw,ikqdgsek,arlgfyyggady,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76413,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggdlvkpgrslrlscsasgftfgdytmswfrqapgkglewvafirskayggtteyaasvigrftisrddsksiaylqmnslksedtavyycsrvrgsfygsvgknygmdvwgqgttvtvss,,gftfgdyt,irskayggtt,srvrgsfygsvgknygmdv,,,,IGHJ6*01 (human),IGHV3-49*05 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76412,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,gfsfssyv,isydgssk,ardidsgydptpvfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76411,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktaggtsssyaiswvrqapgqglewmgriipilgvaiyaqkfqgrvtitadkststaymelnslrsedtavyyctttqggdygdnlyyldywgqgtlvtvss,,ggtsssya,iipilgva,tttqggdygdnlyyldy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76410,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,,ggsvssgsyy,iyysgss,agspvpptivgasy,,,,IGHJ4*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76409,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgilvtvss,,gdtfttyy,inpsggsr,argygfvpnvlyyfdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76408,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,gftfssyd,igtagdt,arvlydssgfynwfdp,,,,IGHJ5*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76407,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqvvesggglvqpgrslrlscaasgftfedyamhwvrqapgkglewvsgvswnsgiigyadsvkgrftisrdnaknslylqmnslraedtalyycakldvggydfvsghyyafdiwgqgtmvtvss,,gftfedya,vswnsgii,akldvggydfvsghyyafdi,,,,IGHJ3*02 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76406,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,gftfsnyg,msydgsnk,aknlgpycsggtcyslvgdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76405,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,,gftfsdya,isfdgsnk,ardlsttwylemwgpdafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76404,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmhwvrqvpgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylemnslraqdtavyycagspwlrgdidywgqgtlvtvss,,gftfssyw,insdgsst,agspwlrgdidy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76403,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvhlvqsgaevkkpgasvklsckasgytftnyllhwvrqapgqglewmgnvnpsrgtatypqklddrvtmtsdksastiymelsglrsedtaiyycarersgtyffdywgqgtlltvss,,gytftnyl,vnpsrgta,arersgtyffdy,,,,IGHJ4*01 (human),IGHV1-46*04 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76402,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkrpgasmnisckasgynfnnnyiywvrqapgqglewmgvvnptgggtayaqgfqdrvtitsdtprntvylgvtglhsedtavyfcarggewrivpggrdyfdywgqgtlvtvsa,,gynfnnny,vnptgggt,arggewrivpggrdyfdy,,,,IGHJ4*01 (human),IGHV1-46*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76401,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,gytftsyy,inpgggst,argaippnsraeidy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76400,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,gftfssyd,igtagdt,arvlydssgfynwfdp,,,,IGHJ5*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76399,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,,gytfttyy,inpsagst,argfhvpaalrnwfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76398,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,,gvtvssny,iysggst,argpepdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76397,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,gftftssa,ivvgsgnt,aaphcnrtscydafdl,,,,IGHJ3*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76396,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,gfsfssyv,isydgssk,ardidsgydptpvfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76395,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissrsstikyadsvkgrftisrdnaknslylqmnslrdedtavyycarvdyygsgsvywyfdlwgrgtlvtvss,,gftfssys,issrssti,arvdyygsgsvywyfdl,,,,IGHJ2*01 (human),IGHV3-48*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76394,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76393,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyaesvkgrftisrdnskntlylqmnslraedtavyycardlhqdwvvvvaanvygmdvwgqgttvtvss,,gftfssyg,iwydgsnk,ardlhqdwvvvvaanvygmdv,,,,IGHJ6*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76392,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,gftfddya,iswnsgti,akdiirqgedgmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76391,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargtlipahrgafdiwgqgtmvtvss,,gytftsyy,inpsagst,argtlipahrgafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76390,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrsltlscaasgftfddytmhwvrqapgkglewvsgidwnggtigyadsvkgrftisrdnaknslylqmnslraedtalyycakagyyayvwgsyrfeyfdnwgqgtlvtvss,,gftfddyt,idwnggti,akagyyayvwgsyrfeyfdn,,,,IGHJ5*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76389,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,gytftdyy,inpnsrgt,arvvvlgygrpnnyydgrnvwdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76388,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttvtvss,,gfslstsglc,idwdddk,arattffygmdv,,,,IGHJ6*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76387,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqvvesggglvqpgrslrlscvssgfifddyvmhwvrqrpgkglewvagitynggilgygdsvkgrfiiardnvrgflslqmgdlrtedtalyycardycssttcpaetyyymdvwgkgtavtvss,,gfifddyv,itynggil,ardycssttcpaetyyymdv,,,,IGHJ6*04 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76386,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggdliqpggslrlscaasgltvssnymswvrqapgkglewvsiiysggstyyadsvkgrfsisrdnsnntlylqmnslraedtavyfcarhipawgykwgqgtlvtvss,,gltvssny,iysggst,arhipawgyk,,,,IGHJ1*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76385,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarddnspqgsgwyfyyyyamdvwgqgttvtvss,,gftfssya,isydgsnk,arddnspqgsgwyfyyyyamdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76384,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqvvqsgpglvkpsetlsltctvsgdpvintnyywgwirqppgkglewigtlsysggthynpslssrvtiavdsskkrfsltlrsvtaadtaiyycarhpvdgynygysdlwgqgtlvtvss,,gdpvintnyy,lsysggt,arhpvdgynygysdl,,,,IGHJ2*01 (human),IGHV4-59*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76383,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,,ggsvssgsyy,iyysgss,agspvpptivgasy,,,,IGHJ4*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76382,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,gltvrsny,iysggst,ardlvtygldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76381,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtdss,,ggsvssgsyy,iyysgss,agspvpptivgasy,,,,IGHJ4*01 (human),IGHV4-61*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76380,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqagaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargaavpaagefdywgqgtlvtvss,,gytftsyy,inpsggst,argaavpaagefdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76379,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytftgyvvhwvrqapgqdlewmgwintgygntkysqkfqgrvtiswdtsattaymelsnlksedkavyycasmtrmseqtyygmdvwgqgttvtvss,,gytftgyv,intgygnt,asmtrmseqtyygmdv,,,,IGHJ6*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76378,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,gftvssny,iypggsa,arsydiltgyrdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76377,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76376,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgdsissgryywswirqhpgkglewigfvyysgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaretysayemppyfdywgqgtlvtvss,,gdsissgryy,vyysgst,aretysayemppyfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76375,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgtlvtvst,,gdtfttyy,inpsggsr,argygfvpnvlyyfdy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76374,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkrpgssvkvsckasggtfssytiswvrqapgqglewmgriipilavanyaqkfqgrvtitadkststaymelsslrsedtavyycardhsgyydstslmspffdywgqgtlvtvss,,ggtfssyt,iipilava,ardhsgyydstslmspffdy,,,,IGHJ4*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76373,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlpltctvsggsissssyywgwirqppgkglqwigniyysgstyynsslksrvtisvdtsknqfslklssvtaadtavyycarqsrgysyawsfdywgqgtlvtvss,,ggsissssyy,iyysgst,arqsrgysyawsfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76372,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,gftfddya,iswnsgti,akdiirqgedgmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76371,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmspnsgntgyaqkfqgrvtmtrdtsistaymelnslrsedtavyycarmrsgwpthgrpddhwgqgtlvtvss,,gytftsyd,mspnsgnt,armrsgwpthgrpddh,,,,IGHJ1*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76370,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgeslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrfiisrhnskntlylqmnslraedtavyycardlnehgldvwgqgttvsvss,,gitvssny,iysggst,ardlnehgldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76369,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcsvsggsirsyfwnwvrqppgkglewigyiyysgstnykpsfksrvtisldtsknqislklssvtaadtavyycaratwlrdafgiwgqgtmvtvss,,ggsirsyf,iyysgst,aratwlrdafgi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76368,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscvaseftfssywmswfrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,,eftfssyw,inwnggst,asvitfggvivrsy,,,,IGHJ4*01 (human),IGHV3-20*04 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76367,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqvslklssvtaadtavyycarfrrsygsgsyynisfdywgqgtlvtvss,,ggsissgdyy,iyysgst,arfrrsygsgsyynisfdy,,,,IGHJ4*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76366,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,gltvrsny,iysggst,ardlvtygldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76365,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarhqrycsssschvwdywgqgtlvtvss,,ggsissssyy,iyysgit,arhqrycsssschvwdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76364,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvscqasgytftsydinwvrqatgqglewmgwmksnsgntgyaqkfqgrvtmtrntsistaymeltslrsedtavyycarmrsgwpthgrpddlwgrgtlvtvss,,gytftsyd,mksnsgnt,armrsgwpthgrpddl,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76363,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,,ggtfssys,iipvlgia,arvgvsgfksgsnwyfdl,,,,IGHJ2*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76362,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycariqyqlngmdvwgqgttvtvss,,gfslstsgmc,idwdddk,ariqyqlngmdv,,,,IGHJ6*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76361,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,gdtfssyt,iipilgip,argrgysnygasyymdv,,,,IGHJ6*04 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76360,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,gftfddya,iswnsgti,akdiirqgedgmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76359,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,eaqllesggalvqpggslrlscaasgftfsccamgwvrqapgrglewvssihddgvgtfyavsvkgrfsisrdnskntvylqmnglraedtgvyycakwagpivmkyylqywgqgalvtvss,,gftfscca,ihddgvgt,akwagpivmkyylqy,,,,IGHJ1*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76358,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgfsvstnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardyrdwiwgqgtlvtvss,,gfsvstny,iysggst,ardyrdwi,,,,IGHJ1*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76357,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycasaklvatisyfdywgqgtlvtvss,,ggsissggyy,iyysgst,asaklvatisyfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76356,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgnagygqkfqgrvtmtrntsistaymelsslrsedtavyycarmrsgwpthgrpddywgrgtlvtvss,,gytftsyd,mnpnsgna,armrsgwpthgrpddy,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76355,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvgytisrqwlvgefdywgqgtlvtvss,,gftfddya,iswnsgsi,akvgytisrqwlvgefdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76354,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartptlynwfhpwgqgtpvtvss,,gysftnyw,iypgdsdt,artptlynwfhp,,,,IGHJ5*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76353,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,,gfslgtsgmc,idwdddk,argvvtydy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76352,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,,gytfttyy,inpsagst,argfhvpaalrnwfdp,,,,IGHJ5*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76351,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,gftfddya,iswnsgti,akdiirqgedgmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76350,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,gftftssa,ivvgsgnt,aaphcnrtscydafdl,,,,IGHJ3*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76349,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,,gytftsyd,mnsnsgna,armrtgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76348,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnpnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrsgwpthgrpddfwgrgtlvtvss,,gytftsyd,mnpnsgna,armrsgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76347,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,gytftsyy,inpgggst,argaippnsraeidy,,,,IGHJ4*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76346,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,gftvssny,iypggsa,arsydiltgyrdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76345,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,,gytfgsfd,mnsnsgnt,armrsgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76344,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvkvsckasgytftshtmnwvrqapgqglewmgwintntgnpmyaqgftgrfvfsldtsgstaylqisslkaedtavyycarwgpdygdyasndywgqgtlvtvss,,gytftsht,intntgnp,arwgpdygdyasndy,,,,IGHJ4*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76343,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,gytftdyy,inpnsrgt,arvvvlgygrpnnyydgrnvwdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76342,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalissdggnkfyadsvkgrftisrdnskntlylqmnslraedtavyycardvpttvtaftvftywgqgtlvtvss,,gftfssya,issdggnk,ardvpttvtaftvfty,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76341,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycararggynwnfdywgqgtlvtvss,,gftfssyd,igtagdt,ararggynwnfdy,,,,IGHJ4*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76340,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,,gfslgtsgmc,idwdddk,argvvtydy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76339,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdttynpsfqgqvtisadkslttaflhwsslkasdtaiyycarrfygpssfdywgqgtlvivss,,gysftsyw,iypgdsdt,arrfygpssfdy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76338,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,gfsfssyv,isydgssk,ardidsgydptpvfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76337,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,,ggtfssys,iipvlgia,arvgvsgfksgsnwyfdl,,,,IGHJ2*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76336,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvscisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpvwvdgellsggipfdywgqgtlvtvss,,gftfssys,isssssfi,ardpvwvdgellsggipfdy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76335,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,gdtfssyt,iipilgip,argrgysnygasyymdv,,,,IGHJ6*04 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76334,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,nvqlvesggglvqpggslrlscaasgftfhhyamhwvrqapgkglewvsgisgssdyrayadslkgrftisrdyaknslwlqmnsltsedtafyycakgvdyggklayfdswgqgtlvtvss,,gftfhhya,isgssdyr,akgvdyggklayfds,,,,IGHJ5*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76333,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlresgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavfycarmsrgynyaytfdiwgqgtmvtvss,,ggsissssyy,iyysgst,armsrgynyaytfdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76332,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,evtvssny,iysggtt,ardflrwhdl,,,,IGHJ2*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76331,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,,ggsfsayy,inhsgst,arvgysqgyyyyymdv,,,,IGHJ6*04 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76330,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,gftvssny,iypggsa,arsydiltgyrdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76329,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiaytdsvkgrftisrdnaknslylqmnslraedtalyycakahstghqyyygmdvwgqgttvtvss,,gftfddya,iswnsgsi,akahstghqyyygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76328,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76327,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,gftfssyd,igtagdt,arvlydssgfynwfdp,,,,IGHJ5*02 (human),IGHV3-13*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76326,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,,ggsissttyy,iyysgst,arqwkwfgeawyfdl,,,,IGHJ2*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76325,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymevsslrsedtavyycarscgdcysadldfwgqgtlvtvss,,ggtfssya,iipifgta,arscgdcysadldf,,,,IGHJ5*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76324,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgfgynftnywigwvrqmpgkglewmgiiypgdsetrnspsfqgqvtisadksmstaylqwsslkasdtamyycarlgvskycsggrclsggsnwfdpwgqgtlvtvss,,gynftnyw,iypgdset,arlgvskycsggrclsggsnwfdp,,,,IGHJ5*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76323,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfrdysmnwvrqapgkglewvssissggsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarggsilwwlidywgqgtlvtvss,,gftfrdys,issggsyi,arggsilwwlidy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76322,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,,gftfsrhw,ikqdgsek,arlgfyyggady,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76321,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarllwlrghfdywgqgtlvtvss,,ggsissssyy,myysgst,arllwlrghfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76320,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evhlvgsgggliqpggslrlscaasgftvssnfmswvrqapgkglewvsiihnggdsyytdsvkgrftisrdnskntlylqmnnlraedtavyycassswlrgafdiwgqgtmvtvss,,gftvssnf,ihnggds,assswlrgafdi,,,,IGHJ3*02 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76319,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslstsgmclswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtgtyycartmatinafdiwgqgtmvtvss,,gfslstsgmc,idwdddk,artmatinafdi,,,,IGHJ3*02 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76318,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewighiyytgssyynpslksrvtisldtsknqfslklnsvtaadtavyycarlrwlrggidfwgqgtlvivss,,ggsissyy,iyytgss,arlrwlrggidf,,,,IGHJ5*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76317,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,evtvssny,iysggtt,ardflrwhdl,,,,IGHJ2*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76316,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiistsggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,,gftfsnya,iistsggat,vkglfdwfpl,,,,IGHJ3*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76315,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,,gitvssny,iyaggst,ardalyyngpgrdgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76314,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgftlddyglswvrhapgkglewvsginwnggrtayadsvkgrftisrdnaknslylqmnslraedtalyhcarargpseqyydlltgyydafdiwgqgtmvtvss,,gftlddyg,inwnggrt,arargpseqyydlltgyydafdi,,,,IGHJ3*02 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76313,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvtlresgpalvkptqtltltctfsgfslttsgmcvswirqppgkalewlaridwdddkyystslqtrltiskdtsknqvvltmtnmdpvdtatyycaretpvtaidywgqgtlvtvss,,gfslttsgmc,idwdddk,aretpvtaidy,,,,IGHJ4*01 (human),IGHV2-70*15 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76312,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrtedtalyycamgpfgellpyyfdywgqgtlvtvss,,gftfddya,iswnsgsi,amgpfgellpyyfdy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76311,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,,gitvssny,iyaggst,ardalyyngpgrdgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76310,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,gftvssny,iypggsa,arsydiltgyrdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76309,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsrtcavygasfsnyywswirqppgkglewigeinhsentnynpslksrvtisvdtsknqfslrlssvtaadtavyycarlrysssgghifdywgqgtlvtvss,,gasfsnyy,inhsent,arlrysssgghifdy,,,,IGHJ4*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76308,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiisssggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,,gftfsnya,iisssggat,vkglfdwfpl,,,,IGHJ3*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76307,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltmtnmdpvdtgtyycarhqivvlfdmwgqgtrvtvss,,gfslstsgvg,iywdddk,arhqivvlfdm,,,,IGHJ5*01 (human),IGHV2-5*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76306,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,,gvtvssny,iysggst,argpepdafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76305,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,evtvssny,iysggtt,ardflrwhdl,,,,IGHJ2*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76304,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,,gytftsyd,mnsnsgna,armrtgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76303,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,gltvrsny,iysggst,ardlvtygldv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76302,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlaqsgaevkkpgasvkvsckaggytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrtgwpthgrpddfwgrgtlvtvss,,gytftsyd,mnsnsgna,armrtgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76301,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,,gfifddyd,iswnggnt,avimspiprysgydwaggafdi,,,,IGHJ3*02 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76300,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvgsnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqlnslraedtavyycarevvgyfdcwgqgtlvtvss,,gltvgsny,iysggst,arevvgyfdc,,,,IGHJ5*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76299,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,,gfifddyd,inwnggst,avimspiprysgydwagdafdi,,,,IGHJ3*02 (human),IGHV3-20*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76298,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfvtsgihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggpnkevlyfgelldygmdvwgqgttvtvss,,gftfvtsg,isydgsnk,akggpnkevlyfgelldygmdv,,,,IGHJ6*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76297,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsgdsissagyywswirqhpgkglewigyiyysgrtyynpslksrvtmsvdtsknqfslrlrsvtaadtavyycarvvptrgpvawfdpwgqgtlvtvss,,gdsissagyy,iyysgrt,arvvptrgpvawfdp,,,,IGHJ5*02 (human),IGHV4-31*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76296,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,,gftfrdvw,ikskidggtt,ttagsyyydtvgpglpegkfdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76295,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,gytftdyy,inpnsrgt,arvvvlgygrpnnyydgrnvwdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76294,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglecvsviyaggntyyadsvkgrftisrdnskntlylqmnslraedtavyycargdggyyspfdywgqgtlvtvss,,gltvssny,iyaggnt,argdggyyspfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76293,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,,gytfgsfd,mnsnsgnt,armrsgwpthgrpddf,,,,IGHJ2*01 (human),IGHV1-8*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76292,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvscktsgdtsssytvgwvrqapgqglewmgriipilgiaysaqkfqgrltitadkststsymelsslrsedtavyycargvvaatpgwfdpwgqgtlvtvss,,gdtsssyt,iipilgia,argvvaatpgwfdp,,,,IGHJ5*02 (human),IGHV1-69*02 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76291,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwiavgsgntnyaqkfqervsitrdmststaymelsslrsedtavyycaapycsrtschdafdiwgqgtkvtvss,,gftftssa,iavgsgnt,aapycsrtschdafdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76290,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,gftfmssa,ivigsgnt,aapycssiscndgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76289,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsvssrsyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhtvdcggdcfpndafdiwgqgtmvtvss,,ggsvssrsyy,iyysgst,arhtvdcggdcfpndafdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,QKY76288,N/A,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,gftftssa,ivvgsgnt,aaphcnrtscydafdl,,,,IGHJ3*01 (human),IGHV1-58*01 (human),,
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76287,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,,,,ssdvggyny,dvs,ssytssravl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76286,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,,,,klgdky,qds,qawdsstgv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76285,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,,,,qsvssy,das,hkrsnwppslt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76284,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,,,,qsvssy,das,hkrsnwppslt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76283,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,,,,qsvlyssnnkns,was,qqyysiswt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76282,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,,,,qsvssf,das,qhrtnwpplft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76281,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,,,,qsvlhssnnkds,was,qqyystpwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76280,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,,,,qsvssf,das,qhrtnwpplft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76279,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,,,,ssdvgdyny,dvs,ssytssstllyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76278,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvvviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,,,,klgdky,qds,qawdsstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76277,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,,,,ssdvgdyny,dvs,ssytssstllyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76276,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,,,,qsllhsngyny,lgs,mqalqtpft,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76275,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,,,,qsvlyssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76274,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,,,,klgdky,qds,qawdsstgv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76273,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,,,,ssdvggyny,dvs,ssytssravl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76272,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,,,,qsllhsngyny,lgs,mqalqtpft,,,IGKJ3*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76271,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprllifgassratgipdrfsgsgsgtdftltisrlepedfavyychqygtspytfgqgtkleik,,,,qsvsstf,gas,hqygtspyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76270,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,,,,nigrks,dds,qvwdsssdhpewv,,,IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76269,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsytfgqgtkleik,,,,qsvssf,das,qqrsnwppsyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76268,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,,,,etllhsdgkty,evs,mqsiqla,,,IGKJ5*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76267,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,,,,qsvssy,das,hkrsnwppslt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76266,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,,,,ssnigsny,rnn,lvwddslnglv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76265,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsllytsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppwtfgqgtkveik,,,,qsllytsnnkny,was,qqyysppwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76264,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscragqtvsssylawyqhkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,,,,qtvsssy,gas,qqygssyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76263,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsdgytyldwylqkpgqspqlliylgskrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,,,,qsllhsdgyty,lgs,mqalqtplt,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76262,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapkllmyaastlqsgvpsrfsgsgsgteftltintlqpedfatyycqqlnsypitfgqgtrleik,,,,qgissy,aas,qqlnsypit,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76261,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkprqapvliisgnnnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlrvfgggtkltvl,,,,slrsyy,gnn,nsrdssgnhlrv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76260,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrffgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfv,,,,nskigsys,rnn,svwddslngpl,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76259,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpgfgqgtkleik,,,,qsvlyssnnkny,was,qqyystpg,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76258,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswfqhhpdkaprlmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpfvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssstpfv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76257,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,,,,qsisny,aas,qqsystpt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76256,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvvviygknnrpsgipdrfsgsssgnkasltitgaqagdeadyycnsrdnsgnlnwvfgggtkltvl,,,,slrsyy,gkn,nsrdnsgnlnwv,,,IGLJ3*02 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76255,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigtkgvhwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,,,,nigtkg,dds,qvwdsssdhhvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76254,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,,,,qsvssf,das,qhrtnwpplft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76253,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkfvcwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsstgvfgggtkltvl,,,,klgdkf,qdn,qawdsstgv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76252,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,,,,qsvssn,gas,qqynnwpgt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76251,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,itcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfggsasgtdftltisslqpedfatyycqqsystftfgpgtkvdik,,,,qsissy,aas,qqsystft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76250,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagynvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsfdsslsgsdvfgtgtkvsvl,,,,ssnigagyn,gnn,qsfdsslsgsdv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76249,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,,,,qsvlhtpknkny,was,qqyytaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76248,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystppytfgqgtkveik,,,,qsvlyssnnkny,was,qqyystppyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76247,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,,,,qsvlhssnnkds,was,qqyystpwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76246,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,,,,hsissw,kas,qqyntysqt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76245,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedvatyycqqynshpptfgggtkveik,,,,qgisny,aas,qqynshppt,,,IGKJ4*01 (human),IGKV1-16*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76244,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigarydvhwyqqlpgtapkllmygnnnrpsgvpdrfsgsksgtsvslaitglqaedeadyycqsydsslsgwvfgggtkltvl,,,,ssnigaryd,gnn,qsydsslsgwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76243,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwsvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgwsv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76242,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgssrgvfgggtkltvl,,,,klgdky,qdt,qawgssrgv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76241,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,,,,qsvlytpknkny,was,qqyytaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76240,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystltfgggtkveik,,,,qsisty,aas,qqsystlt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76239,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfl,,,,nskigsys,rnn,svwddslngpl,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76238,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,,,,qsisny,aas,qqtystfwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76237,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,,,,klgdky,qds,qawdsstgv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76236,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,,,,qsvssf,das,hyrsnwppvlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76235,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqyygsspfgfgpgtkvdik,,,,qsvsssy,gas,qyygsspfg,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76234,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtsgdvgaynyvswyqqhpvkapklmiydvskrpsgvsnrfsgsksgntasltisglqtedeadyycssytssstlwvfgggtkltvl,,,,sgdvgayny,dvs,ssytssstlwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76233,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalprqytywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadtigtywvfgggtkltvl,,,,alprqy,kds,qsadtigtywv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76232,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkysswyqqkpgqspvlviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawssstavfgggtkltvl,,,,klgdky,edt,qawssstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76231,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76230,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,,,,etllhsdgkty,evs,mqsiqla,,,IGKJ5*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76229,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyanwyqqkpgqapvvvifgknnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdssgyiwgwmfgggtkltvl,,,,slrsyy,gkn,nsrdssgyiwgwm,,,IGLJ3*02 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76228,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvkvvyhdgdrpsgiperfsgsnsgntatltinrveagdeadyscqvwdsssdhhvvfgggtkltvl,,,,nigskn,hdg,qvwdsssdhhvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76227,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qtitny,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76226,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgqgtkveik,,,,qsvlyssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76225,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllqftfgpgtkvdik,,,,qdisny,aas,qqydnllqft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76224,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnslswyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlllftfgpgtkvdik,,,,qdisns,das,qqydnlllft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76223,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,,,,qsisny,aas,qqsystpgt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76222,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,,,,ssdiggyny,dvs,ssytsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76221,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,,,,ssdvgdyny,dvs,ssytssstllyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76220,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvsrflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,,,,qsvsrf,das,qqrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76219,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,,,,qsvlhtpknkny,was,qqyytaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76218,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvgnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,,,,ssdvggyny,dvg,ssytssstlyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76217,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,,,,qsvssf,das,hyrsnwppvlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76216,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqsphlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkveik,,,,qsllhsngyny,lgs,mqalqtprt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76215,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,,,,nigrks,dds,qvwdsssdhpewv,,,IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76214,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,,,,qsvsssy,gas,qqygssyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76213,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvqik,,,,qsissy,aas,qqsystppt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76212,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,,,,qsvlyssnnkns,was,qqyysiswt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76211,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,,,,qsissy,gas,qqsystpt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76210,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,,,,qsissy,gas,qqsystpt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76209,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasldiskylnwyqhkpgkapnlliydafnlergvpsrfsgsgsgtdftftisslqpediatyycqqydnlppgvsttfgqgtrleik,,,,ldisky,daf,qqydnlppgvstt,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76208,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qtitny,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76207,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,,,,qsvlhtpknkny,was,qqyytaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76206,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsyasslsahvvfgggtkltvl,,,,ssnigagyd,gnt,qsyasslsahvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76205,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,,,,hsissw,kas,qqyntysqt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76204,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvvgynyvswyqqhpgkapklmiydvrnrpsgvsnrfsgsksgntasltisglqaedeadyfcisytssrtlvfgggtkltvl,,,,ssdvvgyny,dvr,isytssrtlv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76203,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgntasltisglqaedeadyycssytssstpvvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstpvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76202,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvtkrpsgvperfsgsksgntasltisglqaedeadysccsyagsytyvfgtgtkvtvl,,,,ssdvggyny,dvt,csyagsytyv,,,IGLJ1*01 (human),IGLV2-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76201,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaisglqaedeadyscqsydsslsgyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydsslsgyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76200,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsystwtfgqgtkveik,,,,qsisnw,kas,qqynsystwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76199,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkrgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkveik,,,,qsvsssy,gas,qqygssprlt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76198,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,,,,qsvssnf,gas,qqygrspit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76197,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnenylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyssytfgqgtkveik,,,,qsvlyssnneny,was,qqyyssyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76196,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgvtfgqgtrleik,,,,qsvssy,das,qqrsnwppgvt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76195,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,,,,ssnigagyd,ins,qsydsslgal,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76194,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,,,,ssdvggyny,dvs,sayagsnnlv,,,IGLJ2*01 (human),IGLV2-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76193,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,,,,qsvssn,gas,qqynnwpgt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76192,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysspytfgqgtkleik,,,,qsvlyssnnkny,was,qqyysspyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76191,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsfdigrggwifgggtkltvl,,,,ssnigagfd,gnn,qsfdigrggwi,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76190,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvsageratlscrasqsissnlawyhqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynsysltfgggtkveik,,,,qsissn,gas,qqynsyslt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76189,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqpssvsvspgqtaritcsgdalpkryaywyrqksgqapvlvihedskrpsgiperfsgstsgtmatltitgaqledeadyycfsmdssgdlrvfgggtkltvl,,,,alpkry,eds,fsmdssgdlrv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76188,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfeyvv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76187,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,,,,qsvssnf,gas,qqygrspit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76186,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfvfvv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76185,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqysiyswtfgqgtkveik,,,,qsinsw,kas,qqysiyswt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76184,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvvtqppsasgtpgqrvtiscsgsssnigynivnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslsisglqsedeadyycaawddslngyvfgtgtkvtvl,,,,ssnigyni,snn,aawddslngyv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76183,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,,,,ssnigagyd,ins,qsydsslgal,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76182,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,fyeltqppsvsvspgqtagitcsgdklghkyaywyqqkpgqspilliyqddkrpsgiperfsgsnsgtiatltisgtqpvdeadyycqawdndagvvfgggtkltvl,,,,klghky,qdd,qawdndagvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76181,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalptkyaywyqqksgqapvlviyddskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnvfgtgtkvtvl,,,,alptky,dds,ystdssgnv,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76180,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatfycqqsystpmhtfgqgtkleik,,,,qsissy,aas,qqsystpmht,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76179,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsadalskqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssshwvfgggtkltvl,,,,alskqy,kds,qsadssshwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76178,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrssgtfgqgtkveik,,,,qsvsssy,gas,qqygrssgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76177,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmaqtplslpvtpgepasiscrssqslldsddgntyfdwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkinrveaedvgvyycmqriefpwtfgqgtkleik,,,,qslldsddgnty,tls,mqriefpwt,,,IGKJ1*01 (human),IGKV2-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76176,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgtfgqgtrleik,,,,qsissy,aas,qqsystpgt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76175,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsadalpkhyaywyqqrpgqapvlviykdierpsgiperfsgsssgttvtltitgaqaedeadyycqsvdgsgssvvfgggtklavl,,,,alpkhy,kdi,qsvdgsgssvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76174,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgetyvswyqqkpgqspvlviyedskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstggvfgtgtkvtvl,,,,klgety,eds,qawdsstggv,,,IGLJ1*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76173,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyfwvfgggtkltvl,,,,alpkqy,kds,qsadssgtyfwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76172,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvassylawyqqkpgqaprlliygasgratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,,,,qsvassy,gas,qqygssppryt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76171,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlsvspgeratlscrasqslsshlawyqqkpgqaprlliygvstratgiparfsgsgsgteftlaisslqsedsavyycqqyhvwppitfgqgtrleik,,,,qslssh,gvs,qqyhvwppit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76170,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,,,,qsisny,aas,qqtystfwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76169,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggytyvswyqqhpgkapklmiydvnkrpsgvpdrfsgsksgitasltisglqaedeadyyccsyagrytwvfgggttltvl,,,,ssdvggyty,dvn,csyagrytwv,,,IGLJ3*02 (human),IGLV2-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76168,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvisedskrpsgiperfsgsssgtvatltisgaqvedeadyycystdssgnhrvfgggtkltvl,,,,alpkky,eds,ystdssgnhrv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76167,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76166,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyasssivvfgggtkltvl,,,,ssdvgsynl,evs,csyasssivv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76165,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratviparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,,,,qsvssn,gas,qqynnwpyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76164,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsadalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdssgsyvvfgggtkltvl,,,,alpkqy,kds,qstdssgsyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76163,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyssnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgwvfgggtkltvl,,,,ssnigsny,ssn,aawdaslsgwv,,,IGLJ3*02 (human),IGLV1-47*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76162,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqipgtapkllfygnnnrpsgvpdrfsdsksgtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,,,,ssnigagyd,gnn,qsydsslsawv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76161,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvihqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdssthvvfgggtkltvl,,,,klgdky,qds,qawdssthvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76160,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfeyvv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76159,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrvqaedvgvyycmqalqtpwtfgqgtkveik,,,,qsllhsngynf,lgs,mqalqtpwt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76158,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyahwyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyyccstdssgnqrvfgggtkltvl,,,,alpkky,eds,cstdssgnqrv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76157,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlsvspgeratlscrasqtlssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyhcqqynnwplafgqgtkveik,,,,qtlssn,gas,qqynnwpla,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76156,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgygtdftltisslqpedfatyycqqsyntprtfgqgtkveik,,,,qsissy,aas,qqsyntprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76155,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkytywyqqksgqapvvviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgkgvfgggtkltvl,,,,alpkky,eds,ystdssgkgv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76154,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppytfgqgtkleik,,,,qsvsssy,gas,qqygssppyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76153,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspgtlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,,,,qsvssn,gas,qqynnwppmyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76152,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqrgvpsrfsgsgsgtdftltisslqpedfatyycqqanslpltfgggtkvevk,,,,qgissw,aas,qqanslplt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76151,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,dfvmtqspgslavslgeratincrssqsvldnssnknhlawhqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysshwtfgqgtkveik,,,,qsvldnssnknh,was,qqyysshwt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76150,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyrvfgggtkltvl,,,,alpney,kds,qsvdssgtyrv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76149,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspdfqsvtpkekvtitcrasqnigsslhwyqqkpdqspkviikyasqsfsgvpsrfsgsgsgtdftltinsleaedaatyychqssslpptfgggtkveik,,,,qnigss,yas,hqssslppt,,,IGKJ4*01 (human),IGKV6-21*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76148,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvvvvyddsdrpsglperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,,,,nigsks,dds,qvwdsssdhwv,,,IGLJ3*02 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76147,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgnrvein,,,,qsvssn,gas,qqynnwprt,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76146,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,,,,ssnigagfd,gnn,qsydsslsgyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76145,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfvfvv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76144,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinhylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftitslqpedvatyycqqsdnlpmytfgqgtkleik,,,,qdinhy,das,qqsdnlpmyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76143,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplitfgqgtrleik,,,,qsvsssy,gas,qqygssplit,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76142,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssslrvfgggtkltvl,,,,ssdvgsynr,evs,ssytssslrv,,,IGLJ2*01 (human),IGLV2-18*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76141,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,,,,qsvstw,eas,qqyntysgt,,,IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76140,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqgnsfpltfgggtkveik,,,,qgissw,aas,qqgnsfplt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76139,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysptfgqgtkveik,,,,qsissw,kas,qqynsyspt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76138,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,,,,qsvstw,eas,qqyntysgt,,,IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76137,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylgwyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrstfgqgtkleik,,,,qsvsssy,gas,qhygssrst,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76136,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvsprqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdtsgnhwvfgggtkltvl,,,,alpkky,eds,ystdtsgnhwv,,,IGLJ3*02 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76135,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,,,,qsvlytpknkny,was,qqyytaplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76134,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqlitifcngsisdvggwnyvswyqqhpdkapkmmiydvrhrpsgvssrfsgsksgntasltisglqaedegdyycssftsrgalvlfgggtkltvl,,,,isdvggwny,dvr,ssftsrgalvl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76133,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,,,,ssdvgdyny,dvs,ssytssstllyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76132,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,,,,qsvstw,eas,qqyntysgt,,,IGKJ1*01 (human),IGKV1-5*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76131,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvrdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypftfgpgtkvdik,,,,qgissy,aas,qqlnsypft,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76130,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhwvfgggtkltvl,,,,alpkky,eds,ystdssgnhwv,,,IGLJ3*02 (human),IGLV3-10*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76129,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sneltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqstassgtyvvfgggtkltvl,,,,alpkqy,kdt,qstassgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76128,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtswvfgggtkltvl,,,,alpnqy,kds,qsadssgtswv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76127,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaykrdtgiparfsgsgsgtdftltisslepedfavyycqqrsnwpliftfgpgtkvdik,,,,qsvssy,day,qqrsnwplift,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76126,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvvtqspsasaslgasvkltctldsghrsyaiawhqqrpekgprflmrittdgrhtkgdgipdrfsgsgsgteryltisslqsedeadyycqtwgtfgggtrltvl,,,,sghrsya,ittdgrh,qtwgt,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76125,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqppsasaslgasvtltctlssgysnykvdwfqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvyvvfgggtkltvl,,,,sgysnyk,vgtggivg,gadhgsgsnfvyvv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76124,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynfvswhqqhpgkapknmiydvskrpsgvsnrfsgsksgntasltisglhtedeadyycssytststpwvfgggtkltvl,,,,ssdvggynf,dvs,ssytststpwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76123,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqttritcsgdalpkqygywyqqkagqapilviykdserpsgiperfsgsssgttvtltisgvqaedeahyycqsgdssgtyvvfgggtkltvl,,,,alpkqy,kds,qsgdssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76122,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalskqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdrsgtyfnwvfgggtkltvl,,,,alskqy,kds,qsvdrsgtyfnwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76121,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqppltfgggtkveik,,,,qsllhsdgkty,evs,mqsiqpplt,,,IGKJ4*01 (human),IGKV2D-29*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76120,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgrtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgskfgntatliisrveagdeadyscqvwdsgsdhvvfgggtkvtvl,,,,nigsks,dds,qvwdsgsdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76119,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,,,,ssdvgsynl,evi,csyavsttyvi,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76118,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,,,,nignkg,dds,qvwdsssdhpgv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76117,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,,,,agavtsgyy,sta,llyyggawv,,,IGLJ3*02 (human),IGLV7-43*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76116,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstwvfgggtkltvl,,,,ssdvgsynl,evs,ysyagsstwv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76115,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,,,,qsvssn,gas,qqynnwprt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76114,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwgfgtgtkvtvl,,,,ssdvgsynl,evs,csyagsstwg,,,IGLJ1*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76113,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,,,,qgissw,das,qqansfppt,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76112,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystrtfgqgtkleik,,,,qsvlyssnnkny,was,qqyystrt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76111,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qga,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76110,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qlvltqspsasaslgasvkltctlssghttyaiawhqqqpekgprylmklnsdgshtrgdgipdrfsgsssgaeryltisslqsedeadyycqswdtgigvfgggtkltvl,,,,sghttya,lnsdgsh,qswdtgigv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76109,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkvein,,,,qsvssn,gas,qqynnwwrt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76108,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkprkapklliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysltfgggtkveik,,,,qsissw,kas,qqynsyslt,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76107,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,,,,qsvssy,dts,qqrgnwwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76106,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatvsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsasgsgteftltisslqsedfavyycqqynnwppmytfgqgtkveik,,,,qsvssn,gas,qqynnwppmyt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76105,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,,,,ssdiggyny,dvs,ssytsssthvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76104,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlvmckdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpnqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76103,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystplytfgqgtkleik,,,,qsissy,aat,qqtystplyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76102,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtftcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgigsgtdftltisslqpedvatyycqkynsapwtfgqgtkveik,,,,qgisny,aas,qkynsapwt,,,IGKJ1*01 (human),IGKV1-27*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76101,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,,,,qsvsnn,gas,qqcynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76100,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqypgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyaggntfvvfgggtkltvl,,,,ssdigsynl,evs,csyaggntfvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76099,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,,,,qsvssn,gas,qqynywpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76098,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyyvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsstlnvlfgggtkltvl,,,,ssdvggyny,yvs,ssytsstlnvl,,,IGLJ2*01 (human),IGLV2-14*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76097,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqspsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,,,,klgdky,qds,qawdsstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76096,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgstsnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgpsaslaisglqsvdeadyycaawddslngwvfgggtkltvl,,,,tsnigsnt,snn,aawddslngwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76095,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyiswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsavv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76094,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,,,,qgissy,aas,qqlnsypvt,,,IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76093,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdkmgdkyacwyqqkpgqspvvviyednkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsslvvfgggtkltvl,,,,kmgdky,edn,qawdsslvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76092,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nivmtqsplslpvtpgepasiscrssqsllnsngltyldwylqkpgqspqlliyfvsnrasgvsdrfsgsgsgadftltisrveaedvgvyycmqalqtpqtfgqgtkveik,,,,qsllnsnglty,fvs,mqalqtpqt,,,IGKJ1*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76091,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtlarfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,,,,agavtsgyy,sta,llyyggawv,,,IGLJ3*02 (human),IGLV7-43*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76090,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,,,,qsvssn,gas,qqynywpplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76089,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,,,,ssdvgsynl,evi,csyavsttyvi,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76088,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,,,,qsvsnn,gas,qqcynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76087,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,,,,qsvssy,dts,qqrgnwwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76086,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,,,,qgissw,das,qqansfppt,,,IGKJ3*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76085,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qga,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76084,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,,,,ssdiggyny,dvs,ssytsssthvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76083,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,,,,nignkg,dds,qvwdsssdhpgv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76082,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,,,,qgissy,aas,qqlnsypvt,,,IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76081,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgitnylawfqqkpgkapksliyavsslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypwtfgqgtkveik,,,,qgitny,avs,qqynsypwt,,,IGKJ1*01 (human),IGKV1-16*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76080,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsghvvfgggtkltvl,,,,ssnigsny,rnn,aawdaslsghvv,,,IGLJ2*01 (human),IGLV1-47*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76079,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggyhyvswyqhhpgkapkliiydvikrpsgvsnrfsgsksgntasltisglqaedeayyycssytssttwvfgggtrltvl,,,,ssdvggyhy,dvi,ssytssttwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76078,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,,,,qditny,das,qqydnlysvh,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76077,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,,,,nigsks,dds,qvwdsssdhhvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76076,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,,,,sgsiasny,edn,qsydsgnpi,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76075,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvseaprqrvtiscsggssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaswddsligpvfgggtkltvl,,,,ssnignna,ydd,aswddsligpv,,,IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76074,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvvvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpvvfgggtkltvl,,,,nigskn,dds,qvwdsssdpvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76073,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkleik,,,,qsisiy,aas,qqsysthmst,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76072,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylhwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyhnlppitfgqgtrleik,,,,qdisny,das,qqyhnlppit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76071,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllftfgpgtkvdvk,,,,qdisty,das,qqydnllft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76070,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrpsqsittylnwyqqkpgkaprlliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtrleik,,,,qsitty,avs,qqsystppt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76069,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qpvltqsssasaslgssvkltctlssghssyiiawhqqqpgkaprylmklegsgsynkgsgvpdrfsgsssgadcyltisnlqsedeadyycetwdsntrvfaggtkltvl,,,,sghssyi,legsgsy,etwdsntrv,,,IGLJ2*01 (human),IGLV4-60*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76068,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsylgtfgqgtkveik,,,,qgissy,aas,qqlnsylgt,,,IGKJ1*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76067,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviyrdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadstgwvfgggtkltvl,,,,alpkqy,rds,qsadstgwv,,,IGLJ3*02 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76066,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpfyvfgtgtkvtvl,,,,nigsks,dds,qvwdsssdpfyv,,,IGLJ1*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76065,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,,,,qditny,das,qqydnlysvh,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76064,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyttlltfgggtkveik,,,,qsitsy,aas,qqsyttllt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76063,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsiisylnwyhqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsiisy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76062,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,,,,slrsyy,dkn,nsrdssgnavv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76061,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssyyhpvvfgggtkltvl,,,,nigskn,dds,qvwdssyyhpvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76060,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasigdrvtitcrasqnirsylnwyqhkpgkapklliyaastlqsgvpsrfsgsesgtdftltisslqpedfatyycqqsssspitfgqgtkleik,,,,qnirsy,aas,qqsssspit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76059,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyswtfgqgtkveik,,,,qsissw,kas,qqynsyswt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76058,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdafpkqygywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsrgavfgsgtkvtvl,,,,afpkqy,kds,qsadsrgav,,,IGLJ6*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76057,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,dfqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnllifaasslhsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyssewtfgqgtkveik,,,,qsisty,aas,qqsyssewt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76056,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyyctsytssstlnvvfgggtkltvl,,,,ssdvggynf,dvs,tsytssstlnvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76055,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,,,,slrsyy,dkn,nsrdssgnavv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76054,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcfgdalpkqyaywyqqkpgqgpvlviykdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,,,,alpkqy,kds,qsadssgtyrv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76053,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,,,,alpney,kds,qsvdssgtyphvi,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76052,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslstsvgdrvtitcrasqsirsylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsirsy,vas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76051,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssipyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytsssipyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76050,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qtvvtqepsltvspggtvtltcasstgavtsgyfpnwfqqkpgqapralifstnnrhswtparfsgsllgdkaaltlsgvqpedeaeyycllyyggpwvfgggtkltvl,,,,tgavtsgyf,stn,llyyggpwv,,,IGLJ3*02 (human),IGLV7-43*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76049,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,,,,qsissw,kas,qqynsypyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76048,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,,,,qdisny,das,qqyanlpft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76047,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,,,,qsisny,aas,qqsyttllt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76046,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyhqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvlfgggtkltvl,,,,alpkqy,kds,qsadssgtsvl,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76045,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqyddwppevtfgggtkveik,,,,qsvsnn,gas,qqyddwppevt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76044,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgsrfgggtkltvl,,,,alpkqy,kdt,qsadssgsr,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76043,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsswvfgggtkltvl,,,,ssnigsny,rnn,aawddslsswv,,,IGLJ3*02 (human),IGLV1-47*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76042,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdawpnqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyfcqssdssgvvfgggtkltvl,,,,awpnqy,kdt,qssdssgvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76041,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkagkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdvk,,,,qdisny,das,qqydnlpla,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76040,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsvsiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltvsslqpedfatyycqqsysmppitfgqgtrleik,,,,qsvsiy,aas,qqsysmppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76039,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,,,,nigsks,dds,qvwdsssdhhvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76038,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,,,,sgsiasny,edn,qsydsgnpi,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76037,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,,,,qsissy,aas,qqsysnpsyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76036,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprtwtfgqgtkveik,,,,qsvssy,das,qqrsnwpprtwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76035,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,,,,nigsks,dds,qvwdsssdhhvv,,,IGLJ2*01 (human),IGLV3-21*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76034,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwpprltfgggtkveik,,,,qsvssy,das,qhrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76033,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,,,,qdisny,das,qqyanlpft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76032,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslksgvpsrfggsgsgtdftltisslqpedfatyycqqsyemppwtfgqgtkveie,,,,qsissy,aas,qqsyemppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76031,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,,,,alpney,kds,qsvdssgtyphvi,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76030,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssaayvvfgggtkltvl,,,,alpkqy,kds,qsadssaayvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76029,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdik,,,,qsisny,das,qqydnlpla,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76028,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpnqyaywyhqkpgqapvvviykdserpsgipqrfsgsssgttvtltisgvqaedeadyycqsadssgyvfgtgtkvtvl,,,,alpnqy,kds,qsadssgyv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76027,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,,,,sgsiasny,edn,qsydginrawv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76026,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplytfgqgtkleik,,,,qsllhsngyny,lgs,mqalqtplyt,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76025,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,,,,qsissy,aas,qqsysslsit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76024,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syvltqppsvsvapgktasitcegnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrlyvfgtgtkvtvl,,,,nigsks,yds,qvwdsssdrlyv,,,IGLJ1*01 (human),IGLV3-21*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76023,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,,,,sgsiasny,edn,qsydginrwlv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76022,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctrssgsiassyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdvvfgggtkltvl,,,,sgsiassy,edn,qsydssdvv,,,IGLJ2*01 (human),IGLV6-57*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76021,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,,,,qsissy,aas,qqsyeippwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76020,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvssrdsgvpdrfsgsgsgtaftlkisrveaedvgvyycmqgthwpytfgqgtkleik,,,,qslvysdgnty,kvs,mqgthwpyt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76019,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,,,,qdisny,das,qqyanlpft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76018,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,,,,qsissw,kas,qqynsypyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76017,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglmtedeadyycqsydgsnhavvfgggtkltvl,,,,sgsiasny,edn,qsydgsnhavv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76016,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqsvtiscsgsssnignnkvnwyqqlpgtapkvliynsnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslhsyvfgtetkvtvl,,,,ssnignnk,nsn,avwddslhsyv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76015,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,dmevtqfpsslsasigdrvtitcratqsistylnwyqqkpgkapnlliysashlqrgvparfsgsgsgteftltittlqpedvgtyychqsygvpitfgggtkvdik,,,,qsisty,sas,hqsygvpit,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76014,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,,,,qsvssn,gas,qqyynwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76013,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,,,,qsissy,aas,qqsyeippwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76012,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycatwddslngpvfgggtkltvl,,,,ssnigsnt,nnn,atwddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76011,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,,,,qgissy,aas,qqsysnpsyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76010,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76009,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,,,,qsissy,aas,qqsysslsit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76008,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagiwvfgggtkltvl,,,,ssdvggyny,dvs,csyagiwv,,,IGLJ3*02 (human),IGLV2-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76007,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,,,,qsvsssy,gas,qhygssrgwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76006,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrryyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnprwfgggtkltvl,,,,slrryy,gkn,nsrdssgnprw,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76005,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltva,,,,slrsyy,dkn,nsrdssgnavv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76004,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssflawyqqkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspqfgpgtkvdik,,,,qsvsssf,gas,qqygnspq,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76003,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklllyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,,,,qsissy,aas,qqsystppwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76002,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqekpgqaprllmysassratgipdrfsgsgsatdftltinrlepedfavyycqqyveppftfgqgtkleik,,,,qsvsssy,sas,qqyveppft,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76001,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsrynigsnyvywyqqlpgtaprlliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsglifgggtkltvq,,,,rynigsny,snn,aawddslsgli,,,IGLJ2*01 (human),IGLV1-47*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY76000,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syelaqppsvsvapgetatifcratyigrknvqwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgdtatltisrieagdeaayycqvwdgindrvvfgggtkltvl,,,,yigrkn,dds,qvwdgindrvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75999,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapelliydasnletgvpsrfsgsgsgtdfiftisslqpediatyychqydylpytfgqgtkldik,,,,qdirny,das,hqydylpyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75998,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnerpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsayvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsayv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75997,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlalsvgeratlscvasqrvssdyiawyqkkpglaprllvyhgsawatgssarfsgsgsgtaftltisslepedfavyycqqygnspftfgpgtkvefk,,,,qrvssdy,hgs,qqygnspft,,,IGKJ3*01 (human),IGKV3D-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75996,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,,,,sgsiasny,edn,qsydginrwlv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75995,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,,,,qgisny,aas,qllnshplt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75994,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,,,,sgsiasny,edn,qsydginrwlv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75993,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysytfgqgtkleik,,,,qsissw,kas,qqynsysyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75992,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,,,,qsisny,aas,qqsyttllt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75991,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,,,,ssnigsgsd,gnt,qsydsrlsgfvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75990,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,,,,qsvsssy,gas,qqygssppryt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75989,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyarsstrvfgggtkltvl,,,,ssdvgsynl,egs,csyarsstrv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75988,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgitasltisglqaedeadyyccsyagsstwlfgggtkltvl,,,,ssdvgsynl,egs,csyagsstwl,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75987,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgntnrpsgvpdrfsgsksgtstslaitglqaedeadyycqsydsslngdvfgggtkltvl,,,,ssnigagyd,gnt,qsydsslngdv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75986,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgshgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgstsgntasltisglqaedeadyyccsyagivlfgggtkvtvl,,,,ssdvgsynl,evs,csyagivl,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75985,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,,,,qniasy,aas,qqsystpwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75984,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapkllifgnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggakltvl,,,,nsnigsyt,gnn,vawddsrnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75983,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgqgtrleir,,,,qgissw,aas,qqtnsfpt,,,IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75982,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgnsgsiasnyvqwyqqrpgsapttviyedsqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsfdsgnvvfgggtkltvl,,,,sgsiasny,eds,qsfdsgnvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75981,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedennyycavwddslngvvfgggtkltvl,,,,ssnigsnt,snn,avwddslngvv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75980,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyvgsstyvvfgggtkltvl,,,,ssdvgsynl,evs,csyvgsstyvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75979,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,,,,qgisny,aas,qllnshplt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75978,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwlfgggtkltvl,,,,ssdvgsynl,egs,csyagsstwl,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75977,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapklliydnnqrtsgvpdrlsgsksgtsaslaisglqsedeanyycavwddslnglvfgggtkltvl,,,,nsnigsyt,dnn,avwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75976,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,,,,nsnigagyd,gns,qsydsslsdsv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75975,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissy,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75974,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,,,,ssnigagyd,ans,qsydsslsgsv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75973,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyychqsyftpqtfgqgtkleik,,,,qniasy,aas,hqsyftpqt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75972,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qslltqppsvsgapgqrvtlscagatsnigagsdvhwyqqlpgtapklliyyntnrpsgvpdrfsgsksatsaslvitglqtedeadyycqsydislggwvfgggtkltvl,,,,tsnigagsd,ynt,qsydislggwv,,,IGLJ3*02 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75971,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyhnlprtfgqgtkveik,,,,qdisky,das,qqyhnlprt,,,IGKJ1*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75970,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvseaprqrvtiscsgsssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,,,,ssnignna,ydd,aawddslngvv,,,IGLJ2*01 (human),IGLV1-36*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75969,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtfscsgsnsnigsytvnwyqqlpgtapklliydnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslnglvfgggtkltvl,,,,nsnigsyt,dnn,avwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75968,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdvgtynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,,,,ssdvgtyny,evs,sayagsnnlv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75967,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsnslnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngswvfgggtkltvl,,,,ssnigsns,snn,aawddslngswv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75966,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,,,,qsiagy,gtt,qqsystpgt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75965,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggtkltvl,,,,ssnigsnt,nnn,vawddsrnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75964,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,,,,qniasy,aas,qqsystpwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75963,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfalyycqqynnwwrtfgqgtkveik,,,,qsvsssy,gas,qqynnwwrt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75962,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,,,,nsnigsyt,dnn,lvwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75961,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,,,,nsnigsyt,dnn,lvwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75960,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,,,,qsvssn,gas,qqyynwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75959,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaisglqseaeadyycvawddsrnglvfgggakltvl,,,,ssnigagyd,ans,vawddsrnglv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75958,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,,,,nsnigsyt,gnd,avwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75957,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,syeltqpssvsvspgqtaritcsgdvlaknyarwfqqkpgqapvlviykdserpsgipkrfsgsssgttvtltisgaqvedeadyycysaadnnrvfgggtkltvl,,,,vlakny,kds,ysaadnnrv,,,IGLJ2*01 (human),IGLV3-27*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75956,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,,,,ssnigsnt,snn,aawddslnalv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75955,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgltfgggtkveik,,,,qsisty,aas,qqsystpglt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75954,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,,,,qsissy,das,qqsystppit,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75953,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,,,,qsiagy,gtt,qqsystpgt,,,IGKJ5*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75952,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvtitcqgdslrshyaswykvkpgqapllviygrnnrpsgipdrfsgsrsgntasltitgaqvddeadyycssgdsstdhhvvfaggtklavv,,,,slrshy,grn,ssgdsstdhhvv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75951,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,,,,qsissy,aas,qqsystpwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75950,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,,,,nsnigagyd,gns,qsydsslsdsv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75949,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssniesnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,,,,ssniesns,snn,aawddslngvv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75948,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,,,,ssnigagyd,ans,qsydsslsgsv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75947,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtpgepasiscrssqsllhslgynslswylqkpgqsphlliylgsnrasgvpdrfsgsgsatdftlkisrleaedvgvyycmqalqtpltfgqgtrleik,,,,qsllhslgyns,lgs,mqalqtplt,,,IGKJ5*01 (human),IGKV2-28*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75946,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklkiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvlfgggtkltvl,,,,ssdvgsynl,egs,csyagsvl,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75945,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,,,,qdinny,das,qqydnlppv,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75944,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,,,,qsisny,aas,qqsyttllt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75943,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycvawddsrnglvfgggakltvl,,,,ssnigsgsd,gnt,vawddsrnglv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75942,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaafnlqsgvpsrfsgsgsgtdftltisslqsedfatyycqqsyntpytfgqgtkleik,,,,qsissf,aaf,qqsyntpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75941,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,etvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,,,,qsvsssy,gas,qhygssrgwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75940,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,,,,qsissy,aas,qqsyeippwt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75939,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,,,,qsvsssy,gas,qqygsspft,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75938,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsissflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgpgtkvdik,,,,qsissf,das,qrrsnwppft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75937,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,,,,qsvssn,gas,qqynnwppmyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75936,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstsrvvfgggtkltvl,,,,sgsiasny,edn,qsydstsrvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75935,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,,,,sgsiasny,edn,qsydginrawv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75934,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnywvfgggtkltvl,,,,sgsiasny,edn,qsydssnywv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75933,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,,,,sgsiasny,edn,qsydsskyvv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75932,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasagdrvtitcrasqsiryylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsfstprtfgqgtkleik,,,,qsiryy,aas,qqsfstprt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75931,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,nlmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsnnqvfgggtkltvl,,,,sgsiasny,edn,qsydsnnqv,,,IGLJ2*01 (human),IGLV6-57*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75930,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdfiftisslqpediatyycqqydnlppvfgggtkveik,,,,qdinny,das,qqydnlppv,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75929,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,,,,qsvrsn,gas,hqynnwpqt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75928,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,,,,qdinky,das,qqyanlpft,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75927,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscgasqsisssylawyqqkpgqaprlliygassraagipdrfsgsgsgtdftltisrlepedfavyfcqqyggsltfgggtkveik,,,,qsisssy,gas,qqyggslt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75926,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsisry,tas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75925,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,,,,qsvssy,dts,qqrsnwppyt,,,IGKJ2*01 (human),IGKV3-11*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75924,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgqgtkleik,,,,qdinky,das,qqydnlprt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75923,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,,,,ssnigsgsd,gnt,qsydsrlsgfvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75922,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqksgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqydnlpytfgqgtkleik,,,,qdinny,das,qqydnlpyt,,,IGKJ2*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75921,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,,,,qsvrsn,gas,hqynnwpqt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75920,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtgsdvggsnyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlfgggtklsvl,,,,gsdvggsny,dvs,ssytssstlvl,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75919,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfetfgpgtkvaik,,,,qgissy,aas,qqlnsysfet,,,IGKJ3*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75918,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,,,,qdinny,das,qqydnlppv,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75917,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,,,,nsnigsyt,dnn,lvwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75916,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,,,,qgisny,aas,qllnshplt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75915,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeasyyclawddslnglvfgggtkltvl,,,,nsnigsyt,dnn,lawddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75914,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,,,,slrsyy,dkn,nsrdssgnavv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75913,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypgytfgqgtkleik,,,,qgisty,aas,qqlnsypgyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75912,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,,,,slrsyy,dkn,nsrdssgnavv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75911,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasfsckssqsllhsdgktylywylqkpgqspqlliyavsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpytfgqgtkleik,,,,qsllhsdgkty,avs,mqsiqlpyt,,,IGKJ2*01 (human),IGKV2D-29*02 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75910,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltistlqpedfatyycqqsystllytfgqgtkleik,,,,qsissy,aas,qqsystllyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75909,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,,,,qsvlyssnnkny,was,qqyystlt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75908,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,,,,ssnigsnt,snn,aawddslnalv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75907,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaastmqsgvpsrfrgsgsgtdftltisslqledfatyycqqsystpqtfgqgtkveik,,,,qsissy,aas,qqsystpqt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75906,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,,,,nsnigsyt,gnd,avwddslnglv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75905,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgggsgteftltisslqsedfavyycqqynnfltfgggtkveik,,,,qsvssn,gas,qqynnflt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75904,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,evvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyhcqhfgsssqwtfgqgtkveik,,,,qsvsssy,gas,qhfgsssqwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75903,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,,,,qsvsssy,gas,qhygssrgwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75902,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapllviygknnrpsgipdrfsgsssgntpsltitgaqaedeadyycnfrdssghhpvfgegtkltvl,,,,slrsyy,gkn,nfrdssghhpv,,,IGLJ2*01 (human),IGLV3-19*01 (human)
GenBank,,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,,,N/A,QKY75901,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,,,,qsvsssy,gas,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15231,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesraemkkpgeslkisckgsgytftnhwiawvrqmpgkglewmgiiypgdsdtryspsfegqvtisadksistaylqwsslkasdtamyycarrgytygadfygldvwgqgtrvtvss,,gytftnhw,iypgdsdt,arrgytygadfygldv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15230,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakmgpdpahdygrkndafdiwgqgtmvtvss,,gftfddya,iswnsgsi,akmgpdpahdygrkndafdi,,,,IGHJ3*02 (human),IGHV3-9*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15229,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslrlscaasgfiftnywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarerylttdgwfdpwgqgtlvtvss,,gfiftnyw,ikqdgsek,arerylttdgwfdp,,,,IGHJ5*02 (human),IGHV3-7*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15228,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakaepevggydyymdvwgkgtmvtvss,,gftfddya,iswnsgsi,akaepevggydyymdv,,,,IGHJ6*04 (human),IGHV3-9*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15227,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesraevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgitnyaqkfqgrvtitadkststaymelsslrsedtavyycardapdyydssgptyfdywgqgtlvtvss,,ggtfssya,iipilgit,ardapdyydssgptyfdy,,,,IGHJ4*01 (human),IGHV1-69*04 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15226,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycataysvdtamvrgvgywgqgtlvtvss,,gytltels,fdpedget,ataysvdtamvrgvgy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15225,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsvkstagydfwsgdpfdywgqgtlvtvss,,gftfssyg,iwydgsnk,arvgsvkstagydfwsgdpfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15224,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakeiavagcfdywgqgtlvtvss,,gftfssya,isgsggnt,akeiavagcfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15223,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardweeqwlvafdywgqgtlvtvss,,gftfssyw,ikqdgsek,ardweeqwlvafdy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15222,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargpaatyyyymdvwgkgtrvtvss,,ggsissyy,iyysgst,argpaatyyyymdv,,,,IGHJ6*04 (human),IGHV4-59*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15221,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdsaknslylqmnslraedtalyycakvatyyydrsgyyyggaldywgqgtlvtvss,,gftfddya,iswnsgsi,akvatyyydrsgyyyggaldy,,,,IGHJ4*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15220,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctasggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpsglyqllnwgqgtlvtvss,,ggsissssyy,iyysgst,arhpsglyqlln,,,,IGHJ1*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15219,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgaevkkpgasvkisckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargdgdyydssgyyrptlynwldpwgqgtrvtvss,,gytftgyy,inpnsggt,argdgdyydssgyyrptlynwldp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15218,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnsltaedtavyycaregsrqwlviyfdywgqgtlvtvss,,gftfssya,isydgsyk,aregsrqwlviyfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15217,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqpgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngdtnyaqklqgrvtmttdtststaymelrslksddtavyycarfdygypysswsvlsidywgqgtlvtvss,,gytftsyg,isayngdt,arfdygypysswsvlsidy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15216,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsgpglvkpsqtlsltctvsgasitsggyywtwirqhpgkglewigyiyysgssfynpslmsrvsisvdtskkqfslklrsvtaadtavyycakegsgggsqnwfdlwgqgtlvtvss,,gasitsggyy,iyysgss,akegsgggsqnwfdl,,,,IGHJ2*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15215,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscsasgftfsnynmdwvrqapgkglewvssisssssyiyladsvkgrftisrdnaknslylqmnslraedtavyycarvqkdivvvpvaladyyyygmdvwgqgttvtvss,,gftfsnyn,isssssyi,arvqkdivvvpvaladyyyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15214,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgssnynpslksrvtisvdksknqfslklnsvtaadtavyycagrycsggrcgwfdpwgqgtlvtvss,,ggsisssnw,iyhsgss,agrycsggrcgwfdp,,,,IGHJ5*02 (human),IGHV4-4*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15213,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvss,,gftvssny,iytggtt,arahvdtamvesgafdi,,,,IGHJ3*02 (human),IGHV3-53*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15212,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqsgpglvkpsetlpltctvsggsissssyywgwirqppgkglewigsvfysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycarqvrqwleddafdiwgqgtmvtvss,,ggsissssyy,vfysgst,arqvrqwleddafdi,,,,IGHJ3*02 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15211,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkgldwmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatspavmsvgwvdpwgqgtlvtvss,,gytlpels,fdpedget,atspavmsvgwvdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15210,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgifypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhnpdyydssgpldywgqgtlvtvss,,gysftsyw,fypgdsdt,arhnpdyydssgpldy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15209,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnsknmvylqmnslraddtavyycardgsnescsggfcsdswgqgtlvtvss,,gftfsiyg,iwydgsnk,ardgsnescsggfcsds,,,,IGHJ5*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15208,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafdywgqgtlvtvss,,gftfssya,isydgsnk,arsasgsyygafdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15207,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgeslrisckgsgysftshwiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarlkvitifgvvrddygmdvwgqgttvtvss,,gysftshw,idpsdsyt,arlkvitifgvvrddygmdv,,,,IGHJ6*01 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15206,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgratittdeststaymelsslgsedtavyycarthsydnsgqyfdywgqgtmvtvss,,ggtfssya,iipifgta,arthsydnsgqyfdy,,,,IGHJ4*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15205,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgvevkkpgasvkvsckafgytftgqdmhwvrqapgqglewmgwinpssagtnyaqkfqgrvtmtrdtsistaymelsrlrsddtsvyycrkmltifgkvnqtmlliswgqgtmvtvss,,gytftgqd,inpssagt,rkmltifgkvnqtmllis,,,,IGHJ5*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15204,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargvedpvvpaaipwcwfdpwgqgtrvtvss,,ggsissgdyy,iyysgst,argvedpvvpaaipwcwfdp,,,,IGHJ5*02 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15203,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaslpvvpaaigplpafdiwgqgtmvtvss,,gftfssyt,isydgsnk,aslpvvpaaigplpafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15202,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmdslraedtamyycakdkappcssgwyyfdywgqgtlvtvss,,gftfssyg,iwydgsnk,akdkappcssgwyyfdy,,,,IGHJ4*01 (human),IGHV3-33*03 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15201,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarvvgsswypvdafdiwgqgtrvtvss,,gytftsyd,mnpnsgnt,arvvgsswypvdafdi,,,,IGHJ3*02 (human),IGHV1-8*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15200,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrgdsygyyycmdvwgkgtrvtvss,,gftfsnaw,iksktdggtt,ttdrgdsygyyycmdv,,,,IGHJ6*04 (human),IGHV3-15*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15199,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqtpgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptiaaaatnwfdpggqgtlvtvss,,gytlpels,fdpedget,atgptiaaaatnwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15198,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarpnpaggydssgwvdafdiwgqgtrvtvss,,gysftsyw,idpsdsyt,arpnpaggydssgwvdafdi,,,,IGHJ3*02 (human),IGHV5-10-1*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15197,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprycsstscyagvyfdywgqgtrvtvss,,ggtfssya,iipifgta,argprycsstscyagvyfdy,,,,IGHJ4*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15196,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycarwkyndrfdywgqgtrvtvss,,ggsissyy,iytsgst,arwkyndrfdy,,,,IGHJ4*01 (human),IGHV4-4*07 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15195,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslipssvtaadtavyycarggelphynwfdpwgqgtlvtvss,,ggsissyy,iyysgst,arggelphynwfdp,,,,IGHJ5*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15194,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaspllltppdyyyymdvwgkgtmvtvss,,gftvssny,iysggst,aspllltppdyyyymdv,,,,IGHJ6*04 (human),IGHV3-53*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15193,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsysiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasvvggriaaagclgywgqgtrvtvss,,gytftsys,isayngnt,asvvggriaaagclgy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15192,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtittdeststaymelsslrsedtavyycarvysydssgyyleywgqgtrvtvss,,ggtfssya,iipifgtt,arvysydssgyyley,,,,IGHJ4*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15191,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtfssyginwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycasfgddsgdegvrwgqgtlvtvss,,ggtfssyg,iipifgta,asfgddsgdegvr,,,,IGHJ1*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15190,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycassdssgfvgsrgfdywgqgtrvtvss,,gytftdyy,vdpedget,assdssgfvgsrgfdy,,,,IGHJ4*01 (human),IGHV1-69-2*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15189,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,,gftfssya,isgsggst,akdtgycgddcyiklirggpdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15188,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycarvryydssgyyedywgqgtlvtvss,,ggtfssya,iipifgta,arvryydssgyyedy,,,,IGHJ4*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15187,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldtmggmdvwgqgtrvtvss,,gftvssny,iysggst,ardldtmggmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15186,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfgsysmswvrqapgkglewvssisrsssyiynadsvrgrltisrdnaknslylqmnslrvedtavyycardqplpdiltgyytgpldywgqgtlvtvss,,gftfgsys,isrsssyi,ardqplpdiltgyytgpldy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15185,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,gaevkkpgpsvkvscqagrapsssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprgcsstscygsyfdywgqgtlvtvss,,grapsssya,iipifgta,argprgcsstscygsyfdy,,,,IGHJ4*01 (human),IGHV1-69*05 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15184,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesggglvqpggslklscaasgftfssyamswvrqapgkglewvsaisgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycakglrgqqlvipteyfqhwgqgtlvtvss,,gftfssya,isgsgsnt,akglrgqqlvipteyfqh,,,,IGHJ1*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15183,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqqwgagllkpsetlsltcavsggsfsnyywtwirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslwlssvtaadtavyycargrnyvlqfsewphprahfdnwgqgtlvtiss,,ggsfsnyy,idhsgst,argrnyvlqfsewphprahfdn,,,,IGHJ5*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15182,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarviggnyfgafdiwgqgtrvtvss,,gftfsrya,isydgsnk,arviggnyfgafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15181,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvetgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycareaygmdvwgqgtmvtvss,,gltvssny,iysggst,areaygmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15180,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlpltctvsggsissfywswirqppgkglewigyihnngntnynpslksrvtmsidtsknqfslklssvtaadaavyycarggwsldswgqgtlvtvss,,ggsissfy,ihnngnt,arggwslds,,,,IGHJ5*01 (human),IGHV4-4*08 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15179,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqllesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmrpsiaarpgyqyymdvwgkgtrvtvss,,gysftsyw,iypgdsdt,arhmrpsiaarpgyqyymdv,,,,IGHJ6*04 (human),IGHV5-51*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15178,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvss,,gftvssny,iysggst,ardleraggmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15177,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycareansdfwsgylgyfdywgqgtlvtvss,,gftfssys,isssssti,areansdfwsgylgyfdy,,,,IGHJ4*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15176,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,vqlqqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrstsrwgyyymdvwgkgtrvtvss,,ggsissssyy,iyysgst,arrstsrwgyyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15175,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglqwvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarggdrypvgyfdlwgrgtlvtvss,,gftfssyd,igtagdt,arggdrypvgyfdl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15174,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtpvyycarhnraeewepgfdiwgqgttvtvss,,gytftsya,inagngnt,arhnraeewepgfdi,,,,IGHJ3*02 (human),IGHV1-3*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15173,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsqtlsltctvsggsissggyywswirqlpgkglewigyiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycarqqldyydssgcfdywgqgtlvtvss,,ggsissggyy,iyysgst,arqqldyydssgcfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15172,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlnydfwsgyysyalyymdvwgkgtmvtvss,,ggsisstsyy,iyysgst,arlnydfwsgyysyalyymdv,,,,IGHJ6*04 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15171,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgeslkisckgsgyrfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwssltasdtaiyycaryyydsrgytsidfwgqgtlvtvss,,gyrfttyw,iypgdsdt,aryyydsrgytsidf,,,,IGHJ5*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15170,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppddssgwtmgyfdywgqgtlvtvss,,gftfssyg,iwydgsnk,ardpppddssgwtmgyfdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15169,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngytnsaqklqgrvtmttdtststaymelrslrsddtavyycardlvdtamvqtlddygmdvwgqgtmvtvss,,gytftsyg,isayngyt,ardlvdtamvqtlddygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15168,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdntkntlylqmnslraedtavyycardseyydiltgylapthyyyyymdvwgkgttvtvss,,gftfssya,isydgsnk,ardseyydiltgylapthyyyyymdv,,,,IGHJ6*04 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15167,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrddaknslflqmnslraedtavyycagdqnlycsgdscyyhyygmdvwgqgtvvtvss,,gftfssys,isssssyi,agdqnlycsgdscyyhyygmdv,,,,IGHJ6*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15166,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwksdyydssgyypaafdiwgqgtmvtvss,,gftfssys,isssssfi,arwksdyydssgyypaafdi,,,,IGHJ3*02 (human),IGHV3-21*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15165,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,,gftvssny,iysggst,arvewaaagtfy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15164,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgttnyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycareavaarpgnfdywgqgtlvtvss,,gytftgyy,inpnsgtt,areavaarpgnfdy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15163,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,,gytftsyy,inssggst,arpprnyydrsgyyqraeyfqh,,,,IGHJ1*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15162,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycarprggnylagfdpwgqgtrvtvss,,gftfssna,isydgsnk,arprggnylagfdp,,,,IGHJ5*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15161,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsggsmnlyywiwirqppgkglewigyvyytgstnynpslksrvtmsvdtsksqfslkmsavtaadtavyycarrgevngyrgafdiwgqgarvtvss,,ggsmnlyy,vyytgst,arrgevngyrgafdi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15160,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnrlraedtavyycaretptstyssgwynyyyymdvwgkgttvtvss,,gftfssyw,ikqdgsek,aretptstyssgwynyyyymdv,,,,IGHJ6*04 (human),IGHV3-7*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15159,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgtevkkpgasvkvsckasgytfpgyyihwvrqapgqglewmgwinpnsgvaksaqkfqgrvtmtrdssistvyldvtsddtavyycardlvwatvsgtmdvwgqgttvtvss,,gytfpgyy,inpnsgva,ardlvwatvsgtmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15158,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafgywgqrtlvtvss,,gftfssya,isydgsnk,arsasgsyygafgy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15157,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvtstymtwvrrapgkglewvsiiynddttyyadsvkdrvtvsrddskntlylqmnslraedtaiyycarggyyydpsgyysrsfsfdywgqgtlvtvss,,gftvtsty,iynddtt,arggyyydpsgyysrsfsfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15156,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qlqlvesgpglvkpsetlsltctvsggsissyfwswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhsqgwlqqavafdiwgqgtmvtvss,,ggsissyf,iyysgst,arhsqgwlqqavafdi,,,,IGHJ3*02 (human),IGHV4-59*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15155,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpggslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaredyydssgsfdywgqgtlvtvss,,gftfssya,isydgsnk,aredyydssgsfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15154,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtlssyaitwvrqapgqglewvggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgysndywgqgtlvtvss,,ggtlssya,iipifgta,arvgaydssgysndy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15153,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsggglvqpgrslrlscaasgftfgeyamhwvrqapgkglewvsgiswnsgsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdmgeavagthygmdvwgqgtmvtass,,gftfgeya,iswnsgsi,akdmgeavagthygmdv,,,,IGHJ6*01 (human),IGHV3-9*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15152,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsrvrgvsnwfdpwgqgtpitiss,,gytltels,fdpedget,atsrvrgvsnwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15151,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaripgydssgyyrgdywgqgtlvtvss,,ggtfssya,iipifgta,aripgydssgyyrgdy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15150,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgqyyd,,gftfssyg,isydgsnk,akdgqyyd,,,,IGHJ2*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15149,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggvvqpgrslrlscaasgftfsiyamhwvrqapgkglewvavisydgsnqyyadsvrgrftisrgnskntlylqmnslrpedtavyycararggsyndafdiwgqgtmvtvss,,gftfsiya,isydgsnq,ararggsyndafdi,,,,IGHJ3*02 (human),IGHV3-30*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,QKQ15148,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",N/A,hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgt,,ggftisscyk,syyssst,arvssgyyftpfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15315,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,,,,qsvlyssnnkny,was,qqyystpit,,,IGKJ5*01 (human),IGKV4-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15314,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgpgtkleik,,,,qsvsssy,gas,qqygsspft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15313,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkleik,,,,qsmssy,aas,qqsystlt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15312,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgpgtkleik,,,,qsissy,aas,qqsystplt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15311,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkvdik,,,,qsvlyssnnkny,was,qqyystplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15310,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,nfmltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngphwvfgggtkltvl,,,,ssnigsnt,snn,aawddslngphwv,,,IGLJ3*02 (human),IGLV1-44*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15309,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,,,,nigsks,dds,qvwdsssdhyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15308,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qtvvtqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,,,,alpkqy,kds,qsadssgtyrv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15307,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qds,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15306,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkveik,,,,qsmssy,aas,qqsystlt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15305,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgthftltisslqaedvavyycqqyystppltfgggtkvdik,,,,qsvlyssnnkny,was,qqyystpplt,,,IGKJ4*01 (human),IGKV4-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15304,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllsltfgggtkveik,,,,qdisny,das,qqydnllslt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15303,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,,,,qsvsssy,gas,qqygsspyt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15302,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttfiytfgqgtkleik,,,,qsissy,aas,qqsyttfiyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15301,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15300,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvtsnlawyqqkrgqaprlliydasnratgiparfsgsgsgtdftltisglepedfavyycqqrsnwptfgqgtrleik,,,,qsvtsn,das,qqrsnwpt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15299,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqpedfavyycqqcynwppwtfgqgtrvefk,,,,qsvssn,gas,qqcynwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15298,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyeaskrpsgisnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkptvl,,,,ssdvgsynl,eas,csyagsstwv,,,IGLJ3*02 (human),IGLV2-23*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15297,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,,,,ssdvgsynl,evt,csyagsstwv,,,IGLJ3*02 (human),IGLV2-23*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15296,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15295,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliydnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,,,,ssnigagyd,dnn,qsydsslsgsv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15294,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylwtfgqgtkleik,,,,qsissw,kas,qqynsylwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15293,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qpvltqppsvsvapgqtaritcggdnigskdvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsstdhvvfgggtkltvl,,,,nigskd,dds,qvwdsstdhvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15292,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlglyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssstlglyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15291,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydsskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvfgggtkltvl,,,,ssdvgsynl,dss,csyagsv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15290,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkvdik,,,,qsvssf,das,qqrsnwpprlt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15289,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqtplslsvtpgqpasiscksgqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpptfgqgtkveik,,,,qsllhsdgkty,evs,mqsiqlppt,,,IGKJ1*01 (human),IGKV2D-29*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15288,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssvvfgggtkltvl,,,,nigsks,dds,qvwasssvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15287,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsissy,aas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15286,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywplitfgqgtrleik,,,,qsvssn,gas,qqynywplit,,,IGKJ5*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15285,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstlvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15284,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qlvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavvfgggtkltvl,,,,klgdky,qds,qawdsstavv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15283,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgdtasltisglqaedeadyycssytssstwvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15282,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqtfgqgtkleik,,,,qsissy,aas,qqsystpqt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15281,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgggtkleik,,,,qsvsssy,gas,qqygsspgvt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15280,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,,,,qdisny,das,qqydnlpit,,,IGKJ5*01 (human),IGKV1-33*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15279,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysrtfgqgtkleik,,,,qsissw,kas,qqyntysrt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15278,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,dvvmtqspsslsvsvgnivtitcrasqgirndlggisrnqgkplsaiygasslqsgvpsrfrgrgwgteftlpisslqledfaiyyciqhnsylwtfgqgpkveik,,,,qgirnd,gas,iqhnsylwt,,,IGKJ1*01 (human),IGKV1-17*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15277,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspgtclclqgkshplcrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspntfgqgtkvdik,,,,qsvsssy,gas,qqygsspnt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15276,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,,,,qsvssy,das,qqrsnwppsit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15275,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkveik,,,,qsvssy,das,qqrsnwppyt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15274,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypplfgqgtkveik,,,,qgirnd,aas,lqhnsyppl,,,IGKJ1*01 (human),IGKV1-17*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15273,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,,,,qslvysdgntf,qvs,mqgthwprt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15272,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppmytfgqgtkveik,,,,qsvssy,das,qqrsnwppmyt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15271,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,,,,qsvsssy,gas,qqygsspgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15270,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkleik,,,,qsvsss,aas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15269,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkvdik,,,,qsvsssy,gas,qqygssprlt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15268,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslltfgggtkveik,,,,qsvsssy,gas,qqygssllt,,,IGKJ4*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15267,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqsvlfstnsknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,,,,qsvlfstnskny,was,qqyystpyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15266,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfalyycqqydnwplftfgpgtkvdik,,,,qsvssn,gas,qqydnwplft,,,IGKJ3*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15265,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgswsgtdftltisrlepedfavyycqqygsspgtfgqgtkvdik,,,,qsvsssy,gas,qqygsspgt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15264,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivltqspgtlplspgeratlscrasqsvtnnylawyqqkpgqaprllihatstratgipdrfsgsgsgtdftltisrlepedfavyycqqyggplpytfgqgtkleik,,,,qsvtnny,ats,qqyggplpyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15263,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkleik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15262,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdik,,,,qsvsssy,gas,qqygslyt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15261,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpqvtfgqgtrleik,,,,qsvssy,das,qqrsnwpqvt,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15260,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklllyaasdlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkvdik,,,,qsisny,aas,qqsysthmst,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15259,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppvtfgggtkveik,,,,qsissy,aas,qqsystppvt,,,IGKJ4*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15258,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,dvvmtqspgtlslspgeratlscrasqnvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkveik,,,,qnvsssy,gas,qqygssplft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15257,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlhsypltfgggtkvdik,,,,qgissy,aas,qqlhsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15256,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysitfgpgtkvdik,,,,qsissw,kas,qqynsysit,,,IGKJ3*01 (human),IGKV1-5*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15255,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,syeltqppsvsaapgqkvtiscsgsssnignnfvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvwvfgggtkltvl,,,,ssnignnf,dnn,gtwdgslsvwv,,,IGLJ3*02 (human),IGLV1-51*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15254,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtysvvfgggtkltvl,,,,alpkqy,kds,qsadssgtysvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15253,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvtyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,,,,klgdky,qdn,qawdsstav,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15252,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlsyrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppgtfgqgtkleik,,,,qsvssn,gas,qqynnwppgt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15251,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,nfmltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,,,,nigsks,yds,qvwdsssdhwv,,,IGLJ3*02 (human),IGLV3-21*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15250,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,,,,qsvssn,gas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15249,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,,,,tgavtsghy,dts,llsysgvwv,,,IGLJ3*02 (human),IGLV7-46*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15248,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,,,,tgavtsghy,dts,llsysgvwv,,,IGLJ3*02 (human),IGLV7-46*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15247,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,,,,qdisny,das,qqydnpplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15246,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,dvvmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllidgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkvdik,,,,qsvsssy,gas,qqygsspqt,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15245,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15244,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,airmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,,,,qsissw,kas,qqynsypwt,,,IGKJ1*01 (human),IGKV1-5*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15243,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqppsasgspgqsvtisctgtssdigtynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaddegdyycssyvgnnnwvfgggtkltvl,,,,ssdigtyny,evt,ssyvgnnnwv,,,IGLJ3*02 (human),IGLV2-8*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15242,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,,,,klgdky,qds,qawdsstvv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15241,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,nfmltqpasvsgspgqsitisctgsssdiapytfvswyqqhsgtapkliiydvrnrpsgisdrfsgsrsgntaslsisglqaedeadyycsaytttstswvfgggtkltvl,,,,ssdiapytf,dvr,saytttstswv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15240,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvrdrvtitcrasqsitsslnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,,,,qsitss,aas,qqsystpyt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15239,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrhwvfgggtkltvl,,,,ssdvggyny,dvs,ssytssstrhwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15238,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,diqltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgggtkveik,,,,qsvssy,das,qqrsnwpprvt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15237,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqppsvsvspgqtasipcsgdklgdiyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsttakvfgggtkltvp,,,,klgdiy,qdt,qawgsttakv,,,IGLJ2*01 (human),IGLV3-1*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15236,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccscagsstyvfgtgtkvtvl,,,,ssdvgsynl,evs,cscagsstyv,,,IGLJ1*01 (human),IGLV2-23*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15235,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlpiydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprftfgpgtkvdik,,,,qsvssy,das,qqrsnwpprft,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15234,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappafgqgtkvdik,,,,qgisny,aas,qkynsappa,,,IGKJ3*01 (human),IGKV1-27*01 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15233,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,nfmltqpasvsgspgqsitisctgassdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpvvfgggteltvl,,,,ssdvggyny,dvs,ssytssstpvv,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,QKQ15232,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspppftfgpgtkvdik,,,,qsvsssy,gas,qqygsspppft,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,QJU69682,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvss,,gftvssny,iysggst,arvlpmygdyldy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,QJU69680,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregycsggscysgyyyyygmdvwgqgttvtvss,,gytftsyg,isayngnt,aregycsggscysgyyyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,N/A,QJU69681,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleik,,,,qsisry,aas,qqsystppeyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,N/A,QJU69679,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdik,,,,qsvssy,das,qqrrnwgt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69735,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardimfgddwlqkqpdywgqgtlvtvss,,gftfssyg,iwydgsnk,ardimfgddwlqkqpdy,,,,IGHJ4*01 (human),IGHV3-33*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69734,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssytinwvrqapgqglewmgriipilgiadyaqkfqgrvtitadkststaymelsslrsedtavyycardlvedtamvtgaaagtwgqgtlvtvss,,ggtfssyt,iipilgia,ardlvedtamvtgaaagt,,,,IGHJ1*01 (human),IGHV1-69*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69733,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisaysgntnyaqklqgrvtmttdtststaymevrslrsddtavyycarvglwwlghpdvfdiwgqgtmvtvss,,gytftsyg,isaysgnt,arvglwwlghpdvfdi,,,,IGHJ3*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69732,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsikyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,,gfnlsnya,isydgsik,vrggvsgpnsfdm,,,,IGHJ5*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69731,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvtveaifgvvilplknwfdpwgqgtlvtvss,,gytftsyg,isayngnt,arvtveaifgvvilplknwfdp,,,,IGHJ5*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69730,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardltstssspysyyygmdvwgqgttvtvss,,gytftsyy,inpsggst,ardltstssspysyyygmdv,,,,IGHJ6*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69729,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvtvvhfdywgqgtlvtvss,,gftfssya,isydgsnk,arvtvvhfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69728,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqkvqgrvtmttdtststaymelrslrsddtavyycardrgyaatfgvfdywgqgtlvtvss,,gytftsyg,isayngnt,ardrgyaatfgvfdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69727,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartkggsyfapfdywgqgtlvtvss,,gftfssya,isydgsnk,artkggsyfapfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69726,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfssygiswvrqdpgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvglwwlghpdafdiwgqgtmvtvss,,gytfssyg,isayngnt,arvglwwlghpdafdi,,,,IGHJ3*02 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69725,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrsmrlscaasgfnlssyamhwvrqasgkglewvslisydgsikyyadsvkgrftvsgdnskntlflqmsslraddsalyycvrggvsgpnafdiwgqgttvtvss,,gfnlssya,isydgsik,vrggvsgpnafdi,,,,IGHJ3*02 (human),IGHV3-30*15 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69724,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqtahysssfdywgqgtlvtvss,,gftfssya,isydgsnk,araqtahysssfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69723,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycararvaydyiwgsyrykafdywgqgtlvtvss,,gytftsyg,isayngnt,ararvaydyiwgsyrykafdy,,,,IGHJ4*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69722,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelnrlrsddtavyfcardltttagtdyyygmdvwgqgttvtvss,,gytftgyy,inpnsggt,ardltttagtdyyygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69721,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,,gysissgyy,iyhsgst,artplslrlrynwyfdl,,,,IGHJ2*01 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69720,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsyggsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arsyggsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69719,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsydiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardsvagiyyyygmdvwgqgttvtvss,,gytftsyd,isayngnt,ardsvagiyyyygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69718,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsdvtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareardyygsgsldywgqgtlvtvss,,gytftgyy,inpnsdvt,areardyygsgsldy,,,,IGHJ4*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69717,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,,gytltels,fdpedget,atappysppsswfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69716,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvss,,gvivssny,iysggst,ardldvsggmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69713,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggsyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,arsfggsyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69712,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardeayydiltgyinapknyyyygmdvwgqgttvtvss,,gftfssya,isydgsnk,ardeayydiltgyinapknyyyygmdv,,,,IGHJ6*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69711,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardhhydfwsgyssyyyygmdvwgqgttvtvss,,ggsissgdyy,iyysgst,ardhhydfwsgyssyyyygmdv,,,,IGHJ6*01 (human),IGHV4-30-4*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69710,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,,gytltels,fdpedget,atappysppsswfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69709,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycarvwgycsggscyvdafdiwgqgtmvtvss,,gytftsya,inagngnt,arvwgycsggscyvdafdi,,,,IGHJ3*02 (human),IGHV1-3*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69708,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardresydiltgysmegcfdywgqgtlvtvss,,gftfssys,isssssyi,ardresydiltgysmegcfdy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69707,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrvydyiwgsyryldywgqgtlvtvss,,gftfsnaw,iksktdggtt,ttdrvydyiwgsyryldy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69706,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareyyydssvypyyyyamdvwgqgttvtvss,,gytftgyy,inpnsggt,areyyydssvypyyyyamdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69705,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycattspivgaitwfdpwgqgtlvtvss,,gytltels,fdpedget,attspivgaitwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69704,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvdygsgsygwgwfdpwgqgtlvtvss,,gytftgyy,inpnsggt,arvdygsgsygwgwfdp,,,,IGHJ5*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69703,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarqssfyssgwysygmdvwgqgttvtvss,,gysftsyw,iypgdsdt,arqssfyssgwysygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69702,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardfnsyqllwyyyygmdvwgqgttvtvss,,gftfssyw,ikqdgsek,ardfnsyqllwyyyygmdv,,,,IGHJ6*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69701,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,,gysftnha,intntgnp,arasarpgvatnldf,,,,IGHJ5*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69700,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsvkyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,,gfnlsnya,isydgsvk,vrggvsgpnsfdm,,,,IGHJ5*01 (human),IGHV3-30*10 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69699,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarettghfdywgqgtlvtvss,,ggsissggyy,iyysgst,arettghfdy,,,,IGHJ4*01 (human),IGHV4-31*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69698,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltcnvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,,ggsissyy,iyysgst,argfdy,,,,IGHJ4*01 (human),IGHV4-59*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69697,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycathivvvtatpnwyfdlwgrgtlvtvss,,ggsissssyy,iyysgst,athivvvtatpnwyfdl,,,,IGHJ2*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69696,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarlvptwasyydfwsgypggygmdvwgqgttvtvss,,gytftsyg,isayngnt,arlvptwasyydfwsgypggygmdv,,,,IGHJ6*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69695,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,,gftfssya,isydgsnk,arsisgsylgafdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69694,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgppycsstscehwfdpwgqgtlvtvss,,gytltels,fdpedget,atgppycsstscehwfdp,,,,IGHJ5*02 (human),IGHV1-24*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69693,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgaevkkpgasvkvtckasgytftsyylhwvrqapgqglewmgiinpsggttsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragrrysssddgafdiwgqgtmvtvss,,gytftsyy,inpsggtt,aragrrysssddgafdi,,,,IGHJ3*02 (human),IGHV1-46*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69692,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,,gftfssya,isydgsnk,arsisgsylgafdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69691,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,,gysftnha,intntgnp,arasarpgvatnldf,,,,IGHJ5*01 (human),IGHV7-4-1*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69690,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvrgsyylfdywgqgtlvtvss,,gftfssya,isydgsnk,arvrgsyylfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,QJU69689,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,,gysissgyy,iyhsgst,artplslrlrynwyfdl,,,,IGHJ2*01 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69782,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,,,,qslvysdgnty,kvs,mqgthwppt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69781,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69780,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,,,,qslvysdgnty,qvs,mqgthwpvt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69779,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitaftfgpgtkvdik,,,,qsissy,aas,qqtyitaft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69778,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,,,,qsvssn,gas,qqynnwplt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69777,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,,,,qgirnd,aas,lqhnsyplt,,,IGKJ4*01 (human),IGKV1-17*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69776,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,,,,qslvysdgnty,kvs,mqgthwpvt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69775,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgqgtrleik,,,,qsvssy,das,qqrsnwppit,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69774,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprfgpgtkvdik,,,,qdisny,das,qqydnlpr,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69773,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,,,,qsvsssy,gas,qqygsspqt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69771,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypftfgpgtkvdik,,,,qgirnd,aas,lqhnsypft,,,IGKJ3*01 (human),IGKV1-17*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69770,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,,,,qsvssn,gas,qqynnwpyt,,,IGKJ2*01 (human),IGKV3-15*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69769,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,,,,qsvssy,das,qqrsnwplt,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69768,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppkytfgqgtkleik,,,,qsvsssy,gas,qqygssppkyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69767,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrgtfgqgtkveik,,,,qsvsssy,gas,qqygssrgt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69766,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,,,,qnidny,aas,qqsysnplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69765,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,dvvmtqsplslpvtlgqpatiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,,,,qslvysdgnty,qvs,mqgthwpvt,,,IGKJ1*01 (human),IGKV2-30*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69764,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppiftfgpgtkvdik,,,,qsvssy,das,qqrsnwppift,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69763,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagspwtfgqgtkveik,,,,qsvssiy,gas,qqyagspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69762,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtrleik,,,,qsvsssy,gas,qqygsspgt,,,IGKJ5*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69761,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,,,,qsissw,kas,qqynsyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69760,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsssytfgqgtkleik,,,,qsvsssy,gas,qqygsssyt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69759,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,divmtqspdslavslgeratinckssqnvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyitpytfgqgtkleik,,,,qnvlyssnnkny,was,qqyyitpyt,,,IGKJ2*01 (human),IGKV4-1*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69758,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,,,,qsissw,kas,qqynsyt,,,IGKJ2*01 (human),IGKV1-5*03 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69757,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,,,,qnidny,aas,qqsysnplt,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69756,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppsltfgggtkveik,,,,qsvssn,gas,qqynnwppslt,,,IGKJ4*01 (human),IGKV3-15*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69755,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnlyvfgtgtkvtvl,,,,alpkky,eds,ystdssgnlyv,,,IGLJ1*01 (human),IGLV3-10*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69754,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssltlyvfgtgtkvtvl,,,,ssnigagyd,gns,qsydssltlyv,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69753,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69752,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnwvfgggtkltvl,,,,sgsiasny,edn,qsydssnwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69751,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtymifgtgtkvtvl,,,,alpkqy,kdt,qsadssgtymi,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69750,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69749,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqphsvsvataqmaritcggnnigskavhwyqqkpgqdpvlviysdsnrpsgiperfsgsnpgntatltisrieagdeadyycqvwdsssdhvvfgggtkltvl,,,,nigska,sds,qvwdsssdhvv,,,IGLJ2*01 (human),IGLV3-12*02 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69748,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpvvfgggtkltvl,,,,ssnigagyd,gns,qsydsslsgpvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69747,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsavv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69746,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsasyv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69744,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssstpyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69743,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,,,,ssnignny,dnn,gtwdsslsasyv,,,IGLJ1*01 (human),IGLV1-51*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69742,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,,,,alpkqy,kds,qsadssgtyvv,,,IGLJ2*01 (human),IGLV3-25*02 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69741,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklnsdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgirvfgggtkltvl,,,,sghssya,lnsdgsh,qtwgtgirv,,,IGLJ2*01 (human),IGLV4-69*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69740,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagpvfgggtkltvl,,,,ssnignny,dnn,gtwdsslsagpv,,,IGLJ2*01 (human),IGLV1-51*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69739,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstyvfgtgtkvtvl,,,,ssdvgsynl,egs,csyagsstyv,,,IGLJ1*01 (human),IGLV2-23*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69738,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytwvfgggtkltvl,,,,ssdvggyny,dvs,csyagsytwv,,,IGLJ3*02 (human),IGLV2-11*01 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69737,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkltvl,,,,ssdvggyny,dvs,ssytsistwv,,,IGLJ3*02 (human),IGLV2-14*03 (human)
GenBank,,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,,,N/A,QJU69736,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snn,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28229,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,qqlkesggrlvtpgtpltltctasgfslssyyvswvrqapgkglewigiipgtgptycaswakgrftisktsttvdlkitspttedtatyfcarvyagfstwlyfdlwgpgtlvtvss,,gfslssyy,ipgtgpt,arvyagfstwlyfdl,,,,IGHJ2*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28228,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,svkesggrlvtpgtpltltctvsgfslssyamswvrqapgkglewigiisksgstyyaswakgrftisktsttvdlkitspttedtatyfcarddilytsssgyyygmdlwgpgtlvtvss,,gfslssya,isksgst,arddilytsssgyyygmdl,,,,IGHJ2*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28227,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,svkesggrlvtpgtpltltctvsgfslssydmiwvrqapgeglewigiidtaggayyaswakgrftisrtsttvdlkitspttedtatyfcarafygsgwgftrldlwgqgtlvtvss,,gfslssyd,idtagga,arafygsgwgftrldl,,,,IGHJ2*01 (human),IGHV3-13*01 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28226,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,eqlkesggrlvtpgtpltltctvsgfdlsscsmgwvrqapgkgleyigiisssgstyyaswpkgrftisktsttvdlkitspttedtatyfcargfwyfnlwgqgtlvtvss,,gfdlsscs,isssgst,argfwyfnl,,,,IGHJ2*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28225,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,svkesggrlvtpgtpltltctasgfslssyymswvrqapgkglewigiiyassstnyaswatgrftisktsttvdlkitspttedtatyfcarvyssgwgdafdlwgpgtlvtvss,,gfslssyy,iyassst,arvyssgwgdafdl,,,,IGHJ2*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,QIQ28224,N/A,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",N/A,svkesggrlvtpgtpltltctvsgfslssywmswvrqapgkglewigiiftggstyyaswakgrftisktsttvdlkitspttedtatyfcartsyydvsgwgvgrldlwgqgtlvtvss,,gfslssyw,iftggst,artsyydvsgwgvgrldl,,,,IGHJ2*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28235,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,dpmltqtaspvsaavggtvtincqasqsisssnwlswyqqkpgqppklliykastlasgvpsrfkgsgsgtqftltisgvqcddaatyyclgyysftsadnafgggtevvvk,,,,qsisssnw,kas,lgyysftsadna,,,IGKJ4*01 (human),IGKV1-5*03 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28234,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,alvmtqtpasvsaavggtvtincqasediysnlawyqqkpgqppklliygastlasgvpsrfkgsgsgteytltisgvqcddaatyycqctydsssytfgggteleik,,,,ediysn,gas,qctydsssyt,,,IGKJ2*01 (human),IGKV1-8*01 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28233,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,dpvltqtpssasepvggtvnikcqasqsigtrlawyqqkpgqppklliyyastlasgvpsrfkgsgsgteytltisgvqcddaatyyclgehsyssgdgrtafgggtevvvk,,,,qsigtr,yas,lgehsyssgdgrta,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28232,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,alvmtqtpssvsepvggtvtincqasediysnlawyqqkpgqppklliydasnlasgvpsrfsgsgsgteytltisgvqcadaatyycqtyystvtrafgagtkveik,,,,ediysn,das,qtyystvtra,,,IGKJ4*01 (human),IGKV1-5*01 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28231,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,apvltqtpspvsaavggtvtincqaseniysflawyqqkpgqppklliytasklasgvpsrfkgsgsgtqftltisdvqcddaatyycqqtdtysnvdnafgggtevvve,,,,eniysf,tas,qqtdtysnvdna,,,IGKJ4*01 (human),IGKV1-13*02 (human)
GenBank,,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",N/A,,,N/A,QIQ28230,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),2022-03-15,N/A,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",,dpmltqtassvsaavggtvtiscqssqsvydnnwlgwyqqkpgqppklliysastlasgvpsrfkgsgsgtqftltisdlecddaatyycaggysgnifafgggteleil,,,,qsvydnnw,sas,aggysgnifa,,,IGKJ5*01 (human),IGKV1-12*01 (human)
GenBank,,,"Kang,X. et al.; Human neutralizing SARS-CoV specific Fab molecules generated by phage display; Unpublished; 2006.",N/A,,,N/A,ABG79005,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"anti-SARS-CoV S protein immunoglobulin kappa light chain, partial [Homo sapiens]",,eltqspatlslspgeratlscrtsqnigtwlawfqqkpgqtprlliydaskraagiparfsgsgsgtdftltinsleaedfavyycqqrlqwatentfgrgtrldik,,,,qnigtw,das,qqrlqwatent,,,IGKJ5*01 (human),IGKV3-11*01 (human)
GenBank,,,"Lindner,J.M. et al.; Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC Polyomaviruses; Immunity (2019) In press; 2019.",10.1016/j.immuni.2019.02.003,,,QBK47409,N/A,not determined,Homo sapiens (human),2022-03-15,immunoglobulin heavy chain [Homo sapiens],N/A,qvqlvqsgaevkkpgasvkvsckasgytftayymhwvrqapgqglewmgwinpntgvtnfaqkfqgrvtmtrdtsigtayielswlrsddtavyycardrdasmasyyyygmdvwgqgttvtvss,,gytftayy,inpntgvt,ardrdasmasyyyygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Lewis,A.P. et al.; Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody; J. Immunol. 151 (5), 2829-2838 (1993); 1993.",N/A,,,AAA02914,N/A,not determined,Homo sapiens (human),2022-03-15,IgG [Homo sapiens],N/A,qmqvvqsgaevkkpgssvtvsckasggtfsnyaiswvrqapgqglewmggiiplfgtptysqnfqgrvtitadkststahmelislrsedtavyycatdryrqanfdrarvgwfdpwgqgtlvtvss,,ggtfsnya,iiplfgtp,atdryrqanfdrarvgwfdp,,,,IGHJ5*02 (human),IGHV1-69*06 (human),,
GenBank,,,"Lundquist,R. et al.; Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties; Infect. Immun. 74 (6), 3222-3231 (2006); 2006.",10.1128/IAI.00928-05,,,AAX82494,N/A,not determined,Homo sapiens (human),2022-03-15,"anti-Plasmodium falciparum merozoite surface protein 3 immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,qvqlqesggglvkpggslklscaasgftfssygmswvrqtpdkrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyycarlyygyryyfdywgqgtmvtvss,,gftfssyg,issggsyt,arlyygyryyfdy,,,,IGHJ2*02 (mouse),IGHV5-6*01 (mouse),,
GenBank,,,"Jin,H. et al.; Direct Submission; Submitted (09-JUL-2012) Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka 565-0871, Japan; 2012.",N/A,,,AFR78282,N/A,not determined,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain, partial [Homo sapiens]",N/A,vqlvqsggglvkpggslrlscaasgftfssysvtwvrqapgkglewvssisssssyisyadsvkgrftisrdnaknslylqmnslraedtavyfcardplrvavagevmdywgqgtlvtvss,,gftfssys,isssssyi,ardplrvavagevmdy,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Morbach,H. et al.; Clonally Expanded CD27+ and CD27- Memory B Cells Might Function as Antigen Presenting Cells in the Joints of Children with Juvenile Idiopathic Arthritis; Unpublished; 2009.",N/A,,,ACT68971,N/A,not determined,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,vsgysisggyywgwirqppgkglewigslfysgsphynpslksrvtisldtsknqfslnlssvtaadtavyfcasgrlgycctnscnyngld,,gysisggyy,lfysgsp,asgrlgycctnscnyngld,,,,IGHJ6*01 (human),IGHV4-38-2*01 (human),,
GenBank,,,"Hansen,T.O. et al.; Sterile DJH rearrangements reveal that distance between gene segments on the human Ig H chain locus influences their ability to rearrange; J. Immunol. 194 (3), 973-982 (2015); 2015.",10.4049/jimmunol.1401443,,,CEF94348,N/A,not determined,Homo sapiens (human),2022-03-15,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",N/A,gaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarvfigycsstscytggfcnwfdpwgqgtl,,gysftsyw,iypgdsdt,arvfigycsstscytggfcnwfdp,,,,IGHJ5*02 (human),IGHV5-51*01 (human),,
GenBank,,,"Beernink,P.T. et al.; Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein; MBio 6 (3), e00842-15 (2015); 2015.",10.1128/mBio.00842-15,,,N/A,AKL91145,not determined,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain, partial [Homo sapiens]",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkagqaprlliygassratgiperfsgsgsgtdftltisrlepedfaiyycqqygssrfifgpgtkvdik,,,,qsvsssy,gas,qqygssrfi,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Haines,B.B. et al.; Germline diversity of the expressed BALB/c VhJ558 gene family; Mol. Immunol. 38 (1), 9-18 (2001); 2000.",N/A,,,AAG39162,N/A,not determined,Mus musculus (house mouse),2022-03-15,"immunoglobulin heavy chain variable region, partial [Mus musculus]",N/A,evqlqqsgtvlagpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtststaymelssltnedsavyyctr,,gytftsyw,iypgnsdt,tr,,,,IGHJ1*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Flamar,A.L. et al.; Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells; AIDS 27 (13), 2041-2051 (2013); 2015.",10.1097/QAD.0b013e3283624305,,,AJD85777,N/A,not determined,synthetic construct,2022-03-15,anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],N/A,evklvesggglvqpggslklscatsgftfsdyymywvrqtpekrlewvayinsgggstyypdtvkgrftisrdnakntlylqmsrlksedtamyycarrglpfhamdywgqgtsvtvss,,gftfsdyy,insgggst,arrglpfhamdy,,,,IGHJ4*01 (mouse),IGHV5-12*02 (mouse),,
GenBank,,,"Goossens,T. et al.; Receptor revision plays no major role in shaping the receptor repertoire of human memory B cells after the onset of somatic hypermutation; Eur. J. Immunol. In press; 2001.",N/A,,,N/A,CAC94292,not determined,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin lambda chain variable region, partial [Homo sapiens]",,qsitisctgtsghvgnynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsgtxvfgg,,,,sghvgnynl,egs,csyagsgtxv,,,IGLJ2*01 (human),IGLV2-23*01 (human)
GenBank,,,"Takashi,T. et al.; Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof; EP1158004-A2 28-NOV-2001 Japan Tobacco Inc. (JP); 2001.",N/A,,,CAD19025,N/A,not determined,Homo sapiens (human),2022-03-15,unnamed protein product [Homo sapiens],N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinphsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycartyyydssgyyhdafdiwgqgtmvtvss,,gytftgyy,inphsggt,artyyydssgyyhdafdi,,,,IGHJ3*02 (human),IGHV1-2*02 (human),,
GenBank,,,"Akahori,Y. et al.; Construction and characterization of antibody libraries: isolation of therapeutic human antibodies and application to functional genomics; Unpublished; 2002.",N/A,,,N/A,BAC01727,not determined,Homo sapiens (human),2022-03-15,N/A,"immunoglobulin kappa light chain VLJ region, partial [Homo sapiens]",,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,,,,qsissy,aas,qqsystprt,,,IGKJ1*01 (human),IGKV1-39*01 (human)
GenBank,,,"Chouchane,L. et al.; Molecular characterization of a human anti-Rh(D) antibody with a DH segment encoded by a germ-line sequence; Eur. J. Biochem. 207 (3), 1115-1121 (1992); 1993.",N/A,,,S42399,N/A,not determined,Homo sapiens (human),2022-03-15,"IgVH Rh D [human, mRNA Partial, 296 nt]",N/A,qvqlvqsgaevkkpgasvkvsckasgytfamyaihwvrqapgqslewmgwisvadgktkysqkfqdrvtitrdtsattaymevrglrsedtavyycar,,gytfamya,isvadgkt,ar,,,,IGHJ2*01 (human),IGHV1-3*01 (human),,
GenBank,,,"Serizawa,N. et al.; DNA CODING VARIABLE REGION OF MONOCLONAL ANTIBODY, AND RECOMBINED ANTIBODY; JP1997322796-A 1 16-DEC-1997 SANKYO CO LTD; 1999.",N/A,,,E14571,N/A,not determined,Mus musculus (house mouse),2022-03-15,Mouse mRNA for immunoglobulin heavy chain of anti-human Fas mouse monoclonal antibody CH11,N/A,evqlqqsgpelvkpgasvkisckasgytftdynmhwvkqshgkslewigyiypynggtgynqkfkskatltvdnssstaymelrsltsedsavyycarsyyamdywgqgtsvtvss,,gytftdyn,iypynggt,arsyyamdy,,,,IGHJ4*01 (mouse),IGHV1S29*02 (mouse),,
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,MZ927184,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct clone 41 immunoglobulin heavy chain variable region gene, partial cds",N/A,qvqlvqsgaevkkpgasvkvsckvsgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdsyyydssgsglgggfdywgqgtlvtvss,,gytspat,ispykgdt,akdsyyydssgsglgggfdy,,,,IGHJ4*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",N/A,,,N/A,MZ927183,SARS-CoV-2,synthetic construct,2022-03-15,N/A,"Synthetic construct clone 41 immunoglobulin light chain variable region gene, partial cds",,diqmtqspssvsasvgdrvtitcrasrdissylawyqqkpgkapklliygastrasgvpsrfsgsgsgtdftltisslqpedfanyyclqysiypwtfgggtkveik,,,,rdissy,gas,lqysiypwt,,,IGKJ4*01 (human),IGKV1-12*01 (human)
GenBank,,,"Sasso,E.H. et al.; A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles; J. Clin. Invest. 91 (6), 2358-2367 (1993); 1992.",10.1172/JCI116468,,,Z14302,N/A,not determined,Homo sapiens (human),2022-03-15,H.sapiens gene for immunoglobulin heavy chain variable region (VH1),N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycar,,ggtfssya,iipifgta,ar,,,,IGHJ2*01 (human),IGHV1-69*06 (human),,
GenBank,,,"Suzuki,O. et al.; NEDO human cDNA sequencing project; Unpublished; 2003.",N/A,,,AK123800,N/A,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens cDNA FLJ41806 fis, clone NOVAR2001108, highly similar to Human (hybridoma H210) anti-hepatitis A IgG variable region, constant region, complementarity-determining regions mRNA, complete cds",N/A,llqlvqsgaevkkpgssvtvsceasgdssptytiswvrqapgqglewmgditpvfgtkemsqkfqdrvsitadsvsvtadtrrtvylevrrltsddsavyycaksetdhsfyyyielwgqgttvtvss,,gdssptyt,itpvfgtk,aksetdhsfyyyiel,,,,IGHJ6*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Kiyono,K. et al.; THERAPEUTIC AGENT FOR HEPATITIS; JP1997124509-A 8 13-MAY-1997 SUMITOMO ELECTRIC IND LTD; 1998.",N/A,,,E13088,N/A,not determined,Mus sp.,2022-03-15,cDNA encoding variable region of H chain of anti-human Fas ligand antibody which hybridoma NOK5 produces,N/A,vqlqesgaepakpgasvkmsckasgytfttywmhwvkqrpgqglewigyinpssgyteynqkfkdkatltadkssstaymqlisltsedsavyycarrgnyyyfdywgqgttvtvss,,gytfttyw,inpssgyt,arrgnyyyfdy,,,,IGHJ2*01 (mouse),IGHV1-4*01 (mouse),,
GenBank,,,"Murakami,H. et al.; ANTIBODY AND ANTIBODY CDNA; JP1996280386-A 1 29-OCT-1996 MORINAGA & CO LTD; 1998.",N/A,,,E12189,N/A,not determined,Homo sapiens (human),2022-03-15,DNA encoding variable region of heavy chain of human anti-human pulmonary carcinoma antibody,N/A,qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisadtsknqfslkvnsvtaadtavyycarrnydfwsggdgpfdywgqgtlvtvss,,ggsisssnw,iyhsgst,arrnydfwsggdgpfdy,,,,IGHJ4*01 (human),IGHV4-4*02 (human),,
GenBank,,,"Masuda,S. et al.; ANTIBODY-FIREFLY LUCIFERASE FUSION PROTEIN, GENE OBTAINED THEREFROM, NOVEL RECOMBINANT DNA AND PRODUCTION OF ANTIBODY-FIREFLY LUCIFERASE FUSION PROTEIN; JP1997187281-A 3 22-JUL-1997 KIKKOMAN CORP; 1998.",N/A,,,E13412,N/A,not determined,unidentified,2022-03-15,cDNA encoding fused protein consisted of antibody and firefly luciferase,N/A,kvklqesgaelvrpgssvkisckasgyvfssywmnwvkqrpgqglewigqinpgdgdtnyngkfkgkvtltadkssstahmqlssltsedsavyfctrmgvrrdywgqgttvtvss,,gyvfssyw,inpgdgdt,trmgvrrdy,,,,IGHJ2*01 (mouse),IGHV1-80*01 (mouse),,
GenBank,,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.",N/A,,,MZ751046,N/A,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Mus musculus clone 15G9 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds",N/A,vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,,gytftdya,isshngnr,aifdydfdy,,,,IGHJ2*01 (mouse),IGHV1-34*01 (mouse),,
GenBank,,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",N/A,,,MZ751049,N/A,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,"Mus musculus clone 10D2 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds",N/A,vqlqqsgpelkkpgetvkisckasgytftkyrmhwvkqapgkglkwmgwintntgestyaddfkgrfafsletsastaylqinnlknedtatyfcassmdywgqgttvtvss,,gytftkyr,intntges,assmdy,,,,IGHJ4*01 (mouse),IGHV9-2-1*01 (mouse),,
GenBank,,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",N/A,,,N/A,MZ751050,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),2022-03-15,N/A,"Mus musculus clone 15G9/10D2 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",,divltqspaslavslgqratisyrasksvstsgysymhwnqqkpgqpprlliylvsnlesgvparfsgsgsgtdftlnihpveeedaatyycqhir,,,,ksvstsgysy,lvs,qhir,,,IGKJ5*01 (mouse),IGKV3-12*01 (mouse)
GenBank,,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",N/A,,,N/A,MT470194,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone CA1 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdik,,,,qsvssy,das,qqrrnwgt,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Nakatani,T. et al.; HUMAN ANTIBODY, ANTIBODY GENE AND CORRESPONDING RECOMBINANT; JP1988267295-A 6 04-NOV-1988 SUMITOMO CHEM CO LTD, SUMITOMO PHARMACEUT CO LTD; 1997.",N/A,,,N/A,E01737,not determined,Homo sapiens (human),2022-03-15,N/A,Genomic DNA encoding V region of L-chain of monoclonal antibody against pseudomonas aeruginosa exotoxin,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkprqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,,,,qsvlyssnnkny,was,qqyystprt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,MZ151910,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P5A-1D2HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvss,,gfivssny,iysggst,aralqvgatsdyfdy,,,,IGHJ4*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,MZ151912,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P5A-3C8HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvss,,gftvssny,iysggst,ardlqehgmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,MZ151914,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P22A-1D1HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvss,,gftvssny,iysggst,ardrdyygmdv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,MW259136,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P2B-2F6HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvss,,gysissgyy,iyhsgst,aravvgivvvpaagrrafdi,,,,IGHJ3*02 (human),IGHV4-38-2*02 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,MW259138,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P2C-1F11HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvss,,gitvssny,iysggst,ardlvvygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,MW259140,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate P2C-1A3HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvss,,gftfsdyy,isssgsti,ardfshqqlvps,,,,IGHJ5*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,N/A,MZ151911,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P5A-1D2LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvl,,,,ssnigagyd,gns,qscdsslsvvv,,,IGLJ2*01 (human),IGLV1-40*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,N/A,MZ151913,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P5A-3C8KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleik,,,,qgissy,aas,qhlnsyppgyt,,,IGKJ2*01 (human),IGKV1-9*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",N/A,,,N/A,MZ151915,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P22A-1D1KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveik,,,,qgissy,aas,lhlnsyrt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,N/A,MW259137,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P2B-2F6LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,,,,ssdvggyny,evs,ssyagsnnlv,,,IGLJ2*01 (human),IGLV2-8*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,N/A,MW259139,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P2C-1F11KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleik,,,,qsvsssy,gas,qqygsspt,,,IGKJ2*01 (human),IGKV3-20*01 (human)
GenBank,,,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",N/A,,,N/A,MW259141,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate P2C-1A3KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,,,,qgissy,aas,qqlnsyplt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Hozumi,T. et al.; DNA CODING H-CHAIN OF ANTIPYOCYANIC HUMAN-TYPE ANTIBODY; JP1988152983-A 1 25-JUN-1988 WAKUNAGA PHARMACEUT CO LTD; 1997.",N/A,,,E01610,N/A,not determined,Homo sapiens (human),2022-03-15,DNA encoding variable region H chain of anti pseudomonas aeruginosa (F4 type) antibody,N/A,evqllesggglvqpggslrlsctasgftfstyamswvrqtpgkglhwvsaisgsdtgtyhaesvrgrltisrdnskntlylqmnnlrvedtalyfcak,,gftfstya,isgsdtgt,ak,,,,IGHJ2*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926396,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.1A11.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesggglvkpggslrlscaasgftfsyawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlflqmnslktedtavyfcttgwftgtygdyfdywgqgtlvtvss,,gftfsyaw,iksktdggtt,ttgwftgtygdyfdy,,,,IGHJ4*01 (human),IGHV3-15*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926407,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.20.28.GC.3C08.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaregtyyydssayynggldywgqgtlvtvss,,gftfssyw,ikedgsek,aregtyyydssayynggldy,,,,IGHJ4*01 (human),IGHV3-7*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926409,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.1B08.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvqsgaeakkpgasvniscrtsgytfsnyyihwvrqapgqglewmgifnpsgggtsyaqnfqgrltmtsdtststvfmelsslgsedtavyycardprvpavtnvndafdlwgqgtmvtvss,,gytfsnyy,fnpsgggt,ardprvpavtnvndafdl,,,,IGHJ3*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MZ292481,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.GC.28.1A12.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesggglvqpgrslrlsctasgftfgdyamnwvrqapgkglewvgfirskpyggttqyaasvkgrftisrddsksiaylqmnslktedtavyyctrvkycsggscygyhfdhwgqgtlvtvss,,gftfgdya,irskpyggtt,trvkycsggscygyhfdh,,,,IGHJ1*01 (human),IGHV3-49*04 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926397,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.1H09.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmsslraedtavyycardfregafdiwgqgtmvtvss,,giivssny,iysggst,ardfregafdi,,,,IGHJ3*02 (human),IGHV3-66*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926418,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.3A11.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewlgeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvwvrwwyfdlwgrgtlvtvss,,ggsfsgyy,inhsgst,arvwvrwwyfdl,,,,IGHJ2*01 (human),IGHV4-34*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926401,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.3D07.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesgggvvqpgrslrlscaasgftfsrytmhwvrqapgkglewvafisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvlwlrgmfdywgqgtlvtvss,,gftfsryt,isydgsnk,arvlwlrgmfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926403,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.4B05.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargrldsysgsyyswfdpwgqgtlvtvss,,ggtfssya,iipilgia,argrldsysgsyyswfdp,,,,IGHJ5*02 (human),IGHV1-69*04 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926399,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.2A10.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,qvqlqesgpglakpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarypvwgafdiwgqgtmvtvss,,ggsissggyy,iyysgst,arypvwgafdi,,,,IGHJ3*02 (human),IGHV4-31*02 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926412,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.1E11.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlflqmsslraedtavyycakmggvycsagncysgrleywglgtlvtvss,,gftfssyg,isydgsnk,akmggvycsagncysgrley,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926400,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.2C08.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstntaymelsslrsedtavyycaaaycsggscsdgfdiwgqgtmvtvss,,gftfsssa,ivvgsgnt,aaaycsggscsdgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926410,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.1B12.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvetgggliqpggslrlscavseftvssnymswvrqapgeglewvsviylggstdyadsvkgrftisrdnskntlylqmnslraedtavyycarshlevrgvfdnwgqgtlvtvss,,eftvssny,iylggst,arshlevrgvfdn,,,,IGHJ5*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926415,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.2B06.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvetgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqlygmdvwgqgttvtvss,,gftvssny,iysggst,ardlqlygmdv,,,,IGHJ6*01 (human),IGHV3-53*02 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MZ292499,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.GC.28.1B04.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesggvvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrftisrdnskntlylqmnslraedtavyycakqgggtycgggscyrgyfdywgqgtlvtvss,,gftfssyg,isydgsdk,akqgggtycgggscyrgyfdy,,,,IGHJ4*01 (human),IGHV3-30*18 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926402,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.07.28.GC.4A07.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvesgggvvqpgrslrlscaasgftfssyamfwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycargdyygsgsypgktfdywgqgtlvtvss,,gftfssya,isydgsne,argdyygsgsypgktfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,MW926414,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate 368.22.28.GC.2A06.HC immunoglobulin variable region heavy chain mRNA, partial cds",N/A,evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgrglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrewggslghidywgqgtlvtvss,,gysftsyw,iypgdsdt,arrewggslghidy,,,,IGHJ4*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926430,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.20.28.GC.3C08.LC immunoglobulin variable region light chain mRNA, partial cds",,syeltqppsvsmspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdsggnpqgvfgggtkltvl,,,,alpkky,eds,ystdsggnpqgv,,,IGLJ2*01 (human),IGLV3-10*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926432,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.1B08.LC immunoglobulin variable region light chain mRNA, partial cds",,eivltqspatlslspgeratlscrasqsvssylawyqhkpgqaprliiynasnratgiparfsgsrsgtdftltisslepedfavyycqqrsnrpprwtfgqgtkveik,,,,qsvssy,nas,qqrsnrpprwt,,,IGKJ1*01 (human),IGKV3-11*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926441,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.3A11.LC immunoglobulin variable region light chain mRNA, partial cds",,syeltqppsvsvapgqtaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltlsrveagdeadyycqvwdnssdqpnyvfgtgtkvtvl,,,,nigrks,dds,qvwdnssdqpnyv,,,IGLJ1*01 (human),IGLV3-21*02 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MZ292510,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.GC.28.3F08.LC immunoglobulin variable region light chain mRNA, partial cds",,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyhavfgggtqltvl,,,,nigsks,dds,qvwdsssyhav,,,IGLJ7*01 (human),IGLV3-21*02 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926437,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.2A06.LC immunoglobulin variable region light chain mRNA, partial cds",,nfmltqphsvsespgktvtisctrsrgsiagnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeaeyycqsfdssnvvfgggtkvtvl,,,,rgsiagny,edn,qsfdssnvv,,,IGLJ2*01 (human),IGLV6-57*03 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926423,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.2C08.LC immunoglobulin variable region light chain mRNA, partial cds",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllicatssratgipdrfsgsgsgtdftltirrlepedfalyycqqygsspwtfgqgtkveik,,,,qsvsssy,ats,qqygsspwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926424,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.3D07.LC immunoglobulin variable region light chain mRNA, partial cds",,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydisnhwvfgggtkltvl,,,,sgsiasny,edn,qsydisnhwv,,,IGLJ3*02 (human),IGLV6-57*02 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926425,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.4A07.LC immunoglobulin variable region light chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qditny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926438,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.2B06.LC immunoglobulin variable region light chain mRNA, partial cds",,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyhcqvwdsssdpvvfgggtkltvl,,,,nigsns,dds,qvwdsssdpvv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926435,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.1E11.LC immunoglobulin variable region light chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgpgtkvdik,,,,qdisny,das,qqydnllt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926426,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.4B05.LC immunoglobulin variable region light chain mRNA, partial cds",,divmtqspdslavslgeratinckssqsvlyssnnkdylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,,,,qsvlyssnnkdy,was,qqyystpyt,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926433,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.28.GC.1B12.LC immunoglobulin variable region light chain mRNA, partial cds",,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpcsfgqgtkveik,,,,qsvlyssnnkny,was,qqyystpcs,,,IGKJ1*01 (human),IGKV4-1*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926419,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.1A11.LC immunoglobulin variable region light chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgggtkveik,,,,qdisny,das,qqydnlppt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926420,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.1H09.LC immunoglobulin variable region light chain mRNA, partial cds",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypptfgggtkveik,,,,qgissy,aas,qqlnsyppt,,,IGKJ4*01 (human),IGKV1-9*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MW926422,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.07.28.GC.2A10.LC immunoglobulin variable region light chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqhydnlpptfgpgtkvdik,,,,qdisny,das,qhydnlppt,,,IGKJ3*01 (human),IGKV1-33*01 (human)
GenBank,,,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,,,N/A,MZ292500,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate 368.22.GC.28.1B04.LC immunoglobulin variable region light chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,,,,qdisny,das,qqydnlplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Prosniak,M. et al.; Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies; J. Infect. Dis. 188 (1), 53-56 (2003); 2003.",10.1086/375247,,,N/A,AY172962,not determined,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens anti-rabies SOJB immunoglobulin lambda light chain mRNA, complete cds",,syvltqppsvsvapgktarincggnnieyrsvhwyqqksgqapvaviydnsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdissdvvfgggtkltvl,,,,nieyrs,dns,qvwdissdvv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Hirayasu,K. et al.; Direct Submission; Submitted (27-MAR-2012) Department of Immunochemistry, Immunology Frontier Research Center, Osaka University, Yamadaoka 3-1, Suita, Osaka 565-0871, Japan; 2012.",N/A,,,N/A,JQ837832,not determined,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens immunoglobulin kappa light chain mRNA, complete cds",,diqmtqspsslsacvgdrvtitcraghnitnflswyqqkpgkaptlliyavsnlqrgvpsrfsgsgsgaeftltisslqpedfatyycqqnynfsftfgggtkvdnk,,,,hnitnf,avs,qqnynfsft,,,IGKJ3*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MW681614,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CV2-1 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,,gftfssya,isydgsnk,arpysgsyyayfdy,,,,IGHJ4*01 (human),IGHV3-30*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MZ151260,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CN2-39 anti-SARS-CoV-2 immunoglobulin gamma heavy chain gene, partial cds",N/A,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,,ggtfssya,iipifgta,arvassgnrreidy,,,,IGHJ4*01 (human),IGHV1-69*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MW806097,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate PCV1-1 anti-SARS-CoV-2 immunoglobulin gamma gene, partial cds",N/A,evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,,gysftsyw,iypgdsdt,arqrfsgslyfyygmdv,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,MZ151189,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CN1-1 anti-SARS-CoV-2 immunoglobulin gamma heavy chain gene, partial cds",N/A,evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,,gftfssya,isgsggst,akdrssswhyyfdy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,MW681613,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate CV3-48 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,,,,qsinny,aas,qqsyspyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",N/A,,,N/A,MW806188,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate PCV1-66L anti-SARS-CoV-2 immunoglobulin lambda gene, partial cds",,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,,,,ssdvggyny,dvs,ssytssspyv,,,IGLJ1*01 (human),IGLV2-14*03 (human)
GenBank,,,"Osada,N. et al.; Collection of Macaca fascicularis cDNAs derived from bone marrow, kidney, liver, pancreas, spleen, and thymus; BMC Res Notes 2, 199 (2009); 2008.",N/A,,,N/A,DK580821,not determined,Macaca fascicularis (crab-eating macaque),2022-03-15,N/A,"DK580821 macaque thymus cDNA library QthA Macaca fascicularis cDNA clone QthA-17029 5', mRNA sequence",,divmtqtplslpvtpgepasiscrssqslldsedgstfldwylqkpgqspqlliyevsnrasgvpdrfsgsgsdtdftlkisrveaedvgvyycmqalefpltfgggtkveik,,,,qslldsedgstf,evs,mqalefplt,,,IGKJ4*01 (human),IGKV2-40*01 (human)
GenBank,,,"Sakharkar,M. et al.; Prolonged evolution of the human B cell response to SARS-CoV-2 infection; Sci Immunol 6 (56) (2021); 2021.",10.1126/sciimmunol.abg6916,,,MW457639,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone ADI-56674_HC immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryrsslksrltitkdtsknqvvltmtnmdpvdtatyycahynplyvfdywgqgtlvtvss,,gfslstsgvg,iywdddk,ahynplyvfdy,,,,IGHJ4*01 (human),IGHV2-5*09 (human),,
GenBank,,,"Sakharkar,M. et al.; Prolonged evolution of the human B cell response to SARS-CoV-2 infection; Sci Immunol 6 (56) (2021); 2021.",10.1126/sciimmunol.abg6916,,,MW458926,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone ADI-63420_HC immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgaevkkpgeslkisckgfgysftnywiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtmsadkssttaylqwsslkasdtamyycarqrrgvsapgthyyygtevwgqgttvtvss,,gysftnyw,iypgdsdt,arqrrgvsapgthyyygtev,,,,IGHJ6*01 (human),IGHV5-51*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367317,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-1109_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,,gytftsys,istyngnt,areeplycsggscyefqh,,,,IGHJ1*01 (human),IGHV1-18*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367319,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2189_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,,gftfssfa,isgsggrt,akdmdivvvitgdafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367321,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-1145_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,,ggairsgsyy,ifhigna,vrpnnehggfffdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367323,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2220_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,,gytftnyf,inpsvgst,arthvaqlweiwyfdi,,,,IGHJ2*01 (human),IGHV1-46*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367325,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2230_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,,gftfssya,isgsggrt,akdldivvvitgdafdi,,,,IGHJ3*02 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367327,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2212_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,,gytftgyy,inpnsggt,argwatyydiltgyslfdy,,,,IGHJ4*01 (human),IGHV1-2*04 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367329,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2303_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,,gftvrsny,iysggst,ardlavygmdv,,,,IGHJ6*01 (human),IGHV3-66*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367331,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-2310_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,,gftfsnyv,iggsgdst,akgaapyyyyyygmdv,,,,IGHJ6*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,MW367333,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone TAU-1115_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,,gftfsnyv,isgsggst,akdltrdyydssgyqtgafdi,,,,IGHJ3*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367318,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-1109_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region mRNA, partial cds",,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,,,,qsvssd,das,qqrinwppift,,,IGKJ3*01 (human),IGKV3-11*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367320,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2189_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,,,,alpkqy,kds,qsadssgtyrv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367322,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-1145_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,,,,nigsrs,ydt,qvwvstfdhvv,,,IGLJ2*01 (human),IGLV3-21*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367324,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2220_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,,,,tsnigsna,sdn,aawddslkgv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367326,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2230_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,,,,alprhy,kds,qsadssgtyrv,,,IGLJ1*01 (human),IGLV3-25*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367328,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2212_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,,,,ssdvgsynl,evs,csyagsstphvv,,,IGLJ2*01 (human),IGLV2-23*02 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367330,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2303_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region mRNA, partial cds",,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,,,,qgissy,gas,qqlnnyppvt,,,IGKJ5*01 (human),IGKV1-9*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367332,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-2310_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,,,,ssdvggydy,evs,ssytsssalyv,,,IGLJ1*01 (human),IGLV2-14*01 (human)
GenBank,,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",N/A,,,N/A,MW367334,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone TAU-1115_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,,,,nigsks,dds,qvwggv,,,IGLJ2*01 (human),IGLV3-21*02 (human)
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,MT599820,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate COVA1-01 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds",N/A,hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgt,,ggftisscyk,syyssst,arvssgyyftpfdy,,,,IGHJ4*01 (human),IGHV4-39*01 (human),,
GenBank,,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",N/A,,,N/A,MT599987,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate COVA3-10 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,,,,qsvlyssnnkny,was,qqyystpit,,,IGKJ5*01 (human),IGKV4-1*01 (human)
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,MW417369,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate ADI-55688 immunoglobulin heavy chain variable region gene, partial cds",N/A,evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,gftfssyy,issdgynt,ardfsghtavagtgfey,,,,IGHJ4*01 (human),IGHV3-21*01 (human),,
GenBank,,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,,,MW417400,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens isolate ADI-57993 immunoglobulin heavy chain variable region gene, partial cds",N/A,qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,gfdfsrfa,inlhgdsr,vkdggyydssgpgh,,,,IGHJ1*01 (human),IGHV3-64D*06 (human),,
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,MZ439265,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate ADG-1 immunoglobulin light chain variable region gene, partial cds",,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,,,,enilhy,das,qqranwpqn,,,IGKJ4*01 (human),IGKV3-11*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,MZ439267,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate ADG-2 immunoglobulin light chain variable region gene, partial cds",,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,,,,ssnigagyd,gss,qsydsslsvlyt,,,IGLJ1*01 (human),IGLV1-40*01 (human)
GenBank,,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,,,N/A,MZ439269,SARS-CoV,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate ADG-3 immunoglobulin light chain variable region gene, partial cds",,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,,,,ssnigsns,sns,aawddslntfryv,,,IGLJ1*01 (human),IGLV1-44*01 (human)
GenBank,,,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; Nat Commun 11 (1) (2020) In press; 2020.",10.1038/s41467-020-18174-5,,,MT784731,N/A,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),2022-03-15,"Vicugna pacos SARS-CoV-2 RBD-specific neutralizing immunoglobulin heavy chain mRNA, partial cds",N/A,qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,,gftfssvy,ispnsgni,aiglnlssssv,,,,IGHJ6*01 (human),IGHV3-48*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,MT594038,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CC12.1-HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,,gltvssny,iysggst,ardldvygldv,,,,IGHJ6*01 (human),IGHV3-53*01 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,MT594062,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens isolate CC12.25-HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,,gftfssya,isgsgdst,akdryyefwsgysnwfdp,,,,IGHJ5*02 (human),IGHV3-23*04 (human),,
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,MT594103,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate CC6.33-KC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,,,,qsvsssy,gas,qhygsslwt,,,IGKJ1*01 (human),IGKV3-20*01 (human)
GenBank,,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,,,N/A,MT594095,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate CC12.25-LC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,,,,ssnigsnt,snd,aawddslngpv,,,IGLJ2*01 (human),IGLV1-44*01 (human)
GenBank,,,"Bizen,F. et al.; GENE CODING HUMAN ANTIBODY CONTAINING B TYPE PSEUDOMONAS AERUGINOS AS ANTIGEN; JP1995327677-A 2 19-DEC-1995 MITSUI TOATSU CHEM INC; 1997.",N/A,,,N/A,E10414,not determined,Homo sapiens (human),2022-03-15,N/A,cDNA encoding the variable region of lambda chain of human anti-Lipopolysaccharide of Pseudomonas sp,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdtapklliydvsnrpsgvstrfsgsksgntasltisglqaedeaeyycsshaitstlifgggtkltvl,,,,ssdvggyny,dvs,sshaitstli,,,IGLJ2*01 (human),IGLV2-14*03 (human)
GenBank,,,"Perez,C.J. et al.; Direct Submission; Submitted (10-JAN-2001) Immunology Unit, School of Veterinary Sciences, University of Buenos Aires, Chorroarin 280, Capital Federal, Buenos Aires 1427, Argentina; 2002.",N/A,,,N/A,AF334738,not determined,Sus scrofa (pig),2022-03-15,N/A,"Sus scrofa clone 1-1 immunoglobulin kappa light chain VJ region mRNA, partial cds",,aivltqsplslsvspgepasiscrsshsleiygsnllswyqqkpgqsprlliyfatnkasgvpdrfsgsgsgtdftlkisrveaedagvyycqqhkeslvfgsgtkleik,,,,hsleiygsnl,fat,qqhkeslv,,,IGKJ4*01 (human),IGKV2-28*01 (human)
GenBank,,,"Perez,C.J. et al.; Direct Submission; Submitted (10-JAN-2001) Immunology Unit, School of Veterinary Sciences, University of Buenos Aires, Chorroarin 280, Capital Federal, Buenos Aires 1427, Argentina; 2002.",N/A,,,N/A,AF334742,not determined,Sus scrofa (pig),2022-03-15,N/A,"Sus scrofa clone G502 immunoglobulin kappa light chain VJ region mRNA, partial cds",,aivltqtplslsvspgepasiscrssqsllhttgknylnwylqkpgqspqrliyqatnrdtgvpdrftgsgsgtdftlkisrveaedagvyyclqfkesppgfgagtklelk,,,,qsllhttgkny,qat,lqfkesppg,,,IGKJ2*01 (human),IGKV2-28*01 (human)
GenBank,,,"Stalin Raj,V. et al.; Rapid identification of nanobodies by direct cloning from a bone marrow cDNA library; Unpublished; 2020.",N/A,,,KX278382,N/A,MERS-CoV,Camelus dromedarius (Arabian camel),2022-03-15,"Camelus dromedarius clone nb21 anti-MERS-CoV immunoglobulin heavy chain VHDJ region (IgVH) mRNA, partial cds",N/A,qvqlqesgggsvqtggslrlscaasgsvycmgwirqapgkeregvarinsdgsvtyygssakgrfsisrdsakntvtllmnslkpedtaiytctagtrkcmdlgswidfdyrgqgtqvtvss,,gsvyc,insdgsvt,tagtrkcmdlgswidfdy,,,,IGHJ4*01 (human),IGHV3-74*01 (human),,
GenBank,,,"Stalin Raj,V. et al.; Rapid identification of nanobodies by direct cloning from a bone marrow cDNA library; Unpublished; 2020.",N/A,,,KX278416,N/A,MERS-CoV,Camelus dromedarius (Arabian camel),2022-03-15,"Camelus dromedarius clone nbp2E6 anti-MERS-CoV immunoglobulin heavy chain VHDJ region (IgVH) mRNA, partial cds",N/A,qvqlqesgggsvqaggslrlscaaswhtyssnclgwfrqapgkerdlvaalyinggstyyadsvkgrfaisqdsarnsvylqmnslkpedtamyycaaddpalddlssggycsraygyhywgqgtqvtvss,,whtyssnc,lyinggst,aaddpalddlssggycsraygyhy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Ekiert,D.C. et al.; A highly conserved neutralizing epitope on group 2 influenza A viruses; Science 333 (6044), 843-850 (2011); 2011.",10.1126/science.1204839,,,N/A,JN093123,not determined,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens immunoglobulin light chain variable region mRNA, complete cds",,eivltqspgtlslspgeratlscrasqsvsmnylawfqqkpgqaprlliygasrratgipdrisgsgsgtdftltisrlepadfavyycqqyg,,,,qsvsmny,gas,qqyg,,,IGKJ3*01 (human),IGKV3-20*01 (human)
GenBank,,,"Chen,W. et al.; Direct Submission; Submitted (12-JUN-2020) Vaccine and Antibody, Beijing Insititute of Biotechonology, Dongdajie Street, Beijing, MB 100071, China; 2020.",N/A,,,MT622682,N/A,not determined,Homo sapiens (human),2022-03-15,"Homo sapiens clone 4A8 immunoglobulin heavy chain variable region gene, partial cds",N/A,evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvss,,gytltels,fdpedget,atstavagtpdlfdyyygmdv,,,,IGHJ6*01 (human),IGHV1-24*01 (human),,
GenBank,,,"Mallender,W.D. et al.; Primary structures of three Armenian hamster monoclonal antibodies specific for idiotopes and metatopes of the monoclonal anti-fluorescein antibody 4-4-20; Mol. Immunol. 32 (14-15), 1093-1103 (1995); 1997.",N/A,,,N/A,S80615,not determined,Cricetulus migratorius (Armenian hamster),2022-03-15,N/A,"Ig=idiotopes and metatopes of anti-fluorescein antibody 4-4-20-specific antibody {clone 1F4} [Cricetulus migratorius=Armenian hamster, mRNA Partial, 642 nt]",,diqmtqcpsslpaslgdrvtincqasqdignylswyqqkpgkapqlliyyinkladgvpsrfsgsgsgrdysftisslesedigsyycqqysnfpltfgdgtkleik,,,,qdigny,yin,qqysnfplt,,,IGKJ4*01 (human),IGKV1-33*01 (human)
GenBank,,,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",N/A,,,AY530312,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 6A anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlvqsgggvvqpgrslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdygegfdywgqgtlvtvss,,gftvssny,iysggst,akdygegfdy,,,,IGHJ4*01 (human),IGHV3-66*01 (human),,
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554177,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-013 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycakgltplyfdywgqgtlvtvss,,gftfsdhy,trnkansytt,akgltplyfdy,,,,IGHJ4*01 (human),IGHV3-72*01 (human),,
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554174,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-002 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvkpggslrlscaasgftfsgysmswvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycaryysrslkafdywgqgtlvtvle,,gftfsgys,trnkansytt,aryysrslkafdy,,,,IGHJ4*01 (human),IGHV3-72*01 (human),,
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554176,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-009 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesgggvvqpgrslrlscaasgftfsdypmnwvrqapgkglewvssisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakglfmvttyafdywgqgtlvtvle,,gftfsdyp,isgsggst,akglfmvttyafdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554180,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-018 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakfnpftsfdywgqgtlvtvss,,gftfssya,isgsggst,akfnpftsfdy,,,,IGHJ4*01 (human),IGHV3-23*04 (human),,
GenBank,,,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,,,AY554178,N/A,SARS-CoV,Homo sapiens (human),2022-03-15,"Homo sapiens clone 03-014 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvss,,gftfsdhy,trnkansytt,argispfyfdy,,,,IGHJ4*01 (human),IGHV3-72*01 (human),,
GenBank,,,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies; Cell (2020) In press; 2020.",N/A,,,MT350284,N/A,SARS-CoV,Lama glama (llama),2022-03-15,"Lama glama immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvss,,grtfseya,iswsggst,aaaglgtvvsewdydydy,,,,IGHJ4*01 (human),IGHV3-23*01 (human),,
GenBank,,,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies; Cell (2020) In press; 2020.",N/A,,,MT350283,N/A,SARS-CoV,Lama glama (llama),2022-03-15,"Lama glama immunoglobulin heavy chain variable region mRNA, partial cds",N/A,qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvss,,gsifsina,itsggst,aaevggwgpprpdy,,,,IGHJ4*01 (human),IGHV3-64*04 (human),,
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605273,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G8 immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,vqllesgaelvkpgasvkvsckasgytftsywihwvkqrpgqglewigeinpsngrtnyngnfeskatltvdkssntaymhlssltyedsavyhctrldywgqgttltvss,,gytftsyw,inpsngrt,trldy,,,,IGHJ2*01 (mouse),IGHV1-53*01 (mouse),,
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605265,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G3 immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evrlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgknlewigginpnnggttynqkfkgkatltvdkssntaymelrsltsedsavyycsrgdygtsygyfdvwgagttvtvss,,gytfteyt,inpnnggt,srgdygtsygyfdv,,,,IGHJ1*01 (mouse),IGHV1-26*01 (mouse),,
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605272,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G6 immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,qvqlqqpgaelvkpgasvkvsckasgytftnywihwvkqrpgqglewigeinpgngrtnyngnfmnkatltvdkssntaymqlssltsedsavyhcarldywgqgttltvss,,gytftnyw,inpgngrt,arldy,,,,IGHJ2*01 (mouse),IGHV1-53*01 (mouse),,
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605268,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G10 immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,evqleesgtvlarpgasvkmsckasgysftsywmhwvkqrpgqgldwigaiypensdtsynqkfkgkakltavtsastaymehssltnedsavyyctrsvyygygyfdvwgagttvtvss,,gysftsyw,iypensdt,trsvyygygyfdv,,,,IGHJ1*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,,,AY605266,N/A,SARS-CoV,Mus musculus (house mouse),2022-03-15,"Mus musculus clone F26G7 immunoglobulin gamma heavy chain variable region mRNA, partial cds",N/A,vellesgtvlarpgasvkmsceasgytfttywmhwikqrpgqglewigaiypgnsdttynqkfkgkakltavtststaymelssltnedsavyyctregipqllrtmdywgqgtsvtvss,,gytfttyw,iypgnsdt,tregipqllrtmdy,,,,IGHJ4*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",N/A,,,N/A,MZ555491,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate COV2-vax-69 immunoglobulin light chain mRNA, partial cds",,dvvmtqsplslpvtlgqaasiscrssqslvysdentylnwfqqrpgqsprrliykvsnrdagvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtqwpytfgqgtkleik,,,,qslvysdenty,kvs,mqgtqwpyt,,,IGKJ2*01 (human),IGKV2-30*01 (human)
GenBank,,,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",N/A,,,N/A,MZ555628,"SARS-CoV-2, Spike protein",Homo sapiens (human),2022-03-15,N/A,"Homo sapiens isolate COV2-vax-13 immunoglobulin light chain mRNA, partial cds",,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,,,,qsvssn,gas,qqynnwppwt,,,IGKJ1*01 (human),IGKV3-15*01 (human)
GenBank,,,"Maeda,H. et al.; GENE FRAGMENT TO CODE ANTI-HIV ANTIBODY VARIABLE RANGE, ANTI-HIV CHIMERA ANTIBODY MANIFESTED BY USING THE SAME FRAGMENT AND; JP1990002352-A 1 08-JAN-1990 CHEMO SERO THERAPEUT RES INST; 1997.",N/A,,,E02168,N/A,not determined,Mus musculus (house mouse),2022-03-15,DNA encoding variable region of H chain of anti-HIV antibody,N/A,qvqlqqsgaelvkpgasvkmsckafgytfttypiewmkqnhgkslewignfhpysddtnynekfkgkakltvekssstvylefsrltsddsavyycaihygsayamdywgqgtsvtvss,,gytfttyp,fhpysddt,aihygsayamdy,,,,IGHJ4*01 (mouse),IGHV1-47*01 (mouse),,
GenBank,,,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,,,MW002770,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone CV07-209 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds",N/A,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssvstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardgvipprfdywgqgtlvtvss,,gftfsdyy,isssvsti,ardgvipprfdy,,,,IGHJ4*01 (human),IGHV3-11*01 (human),,
GenBank,,,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,,,N/A,MW002805,SARS-CoV-2,Homo sapiens (human),2022-03-15,N/A,"Homo sapiens clone CV-X2-106 anti SARS-CoV-2 immunoglobulin kappa chain mRNA, partial cds",,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpytfgqgtkleik,,,,qsissf,aas,qqsystpyt,,,IGKJ2*01 (human),IGKV1-39*01 (human)
GenBank,,,"Schmitz,A.J. et al.; A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.013,,,MZ615309,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone 368-28_b30 immunoglobulin heavy chain mRNA, partial cds",N/A,qmqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsstscydafdiwgqgtmvtvss,,gftftssa,ivvgsgnt,aapncsstscydafdi,,,,IGHJ3*02 (human),IGHV1-58*02 (human),,
GenBank,,,"Schmitz,A.J. et al.; A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.013,,,MZ615310,N/A,SARS-CoV-2,Homo sapiens (human),2022-03-15,"Homo sapiens clone 368-07_b7 immunoglobulin heavy chain mRNA, partial cds",N/A,qmqllqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymnlsslrsedtavcycaapycsggtcsdgfdiwgqgtmvtvss,,gftfsssa,ivvgsgnt,aapycsggtcsdgfdi,,,,IGHJ3*02 (human),IGHV1-58*01 (human),,
GenBank,,,"Tsuchiya,M. et al.; DNA CAPABLE OF CODING VARIABLE REGION OF MURINE MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR; JP1993236966-A 28 17-SEP-1993 CHUGAI PHARMACEUT CO LTD; 1997.",N/A,,,N/A,E05421,not determined,Mus musculus (house mouse),2022-03-15,N/A,cDNA sequence encoding mouse monoclonal antibody kappa type L chain variable region against human IL-6 receptor,,divliqspaslavslgqratiscrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsrtdftltinpveaddvatyycqqsnedpptfgagtklelk,,,,esvdsygnsf,ras,qqsnedppt,,,IGKJ5*01 (mouse),IGKV3-5*01 (mouse)
GenBank,,,"Hagiwara,H. et al.; AMINO ACID SEQUENCE OF ANTICANCER HUMAN MONOCLONAL ANTIBODY AND DNA BASE SEQUENCE CODING FOR THE SAME; JP1997100300-A 1 15-APR-1997 HAGIWARA YOSHIHIDE; 1998.",N/A,,,E12917,N/A,not determined,Homo sapiens (human),2022-03-15,"Human mRNA for variable region of heavy chain of anti-carcinoma monoclonal antibody CLN''1-IgM,complete cds",N/A,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargpkgycsstscyfdyyyygmdvwgqgttv,,gytftgyy,inpnsggt,argpkgycsstscyfdyyyygmdv,,,,IGHJ6*01 (human),IGHV1-2*02 (human),,
GenBank,,,"Ishizuka,M. et al.; DNA BASE SEQUENCE AND AMINO ACID SEQUENCE IN VARIABLE REGION OF ANTIHUMAN LIPOPROTEIN (A) MONOCLONAL ANTIBODY; JP1997173063-A 1 08-JUL-1997 COSMO SOGO KENKYUSHO:KK, COSMO OIL CO LTD; 1998.",N/A,,,E13306,N/A,not determined,Mus sp.,2022-03-15,"DNA encoding V region of anti human lipoprotein antibody,KOS-A heavy chain",N/A,qesgqesgpdlvkpsqslsltctvtgysitsgyswhwirqlrnnslewvasrhiqenqkfkgkakltavtftyyrdredyygglqmfdswaedtpqlncvttedtsqslsdtwgqgttvts,,gysitsgys,rhiqenq,vttedtsqslsdt,,,,IGHJ1*01 (mouse),IGHV3-1*02 (mouse),,
GenBank,,,"Hagiwara,H. et al.; AMINO ACID SEQUENCE OF ANTI-IDIOTYPE ANTIBODY TO ANTI-CANCER HUMAN MONOCLONAL ANTIBODY AND DNA BASE SEQUENCE CODING FOR THE SAME; JP1995101999-A 6 18-APR-1995 HAGIWARA YOSHIHIDE; 1997.",N/A,,,N/A,E09034,not determined,Mus musculus (house mouse),2022-03-15,N/A,cDNA encoding light chain variable region of mouse antiidiotype antibody named Idio3 against CLN-IgG idiotype,,divltqspaslavsplgqratisyrasksvqlhlaivymhwnqqkpgqpprlliylvsnlesgvparfsgsgsgtdftlnihpveeedaatyycqhirvaytfgggtkleik,,,,ksvqlhlaivy,lvs,qhirvayt,,,IGKJ2*01 (mouse),IGKV3-12*01 (mouse)
GenBank,,,"Jin,N. et al.; Complete Genome Sequence of Lactobacillus plantarum subsp. plantarum CGMCC 1.557; Unpublished; 2017.",N/A,,,N/A,N/A,not determined,Lactiplantibacillus plantarum subsp. plantarum,2022-03-15,N/A,N/A,,,,,,,,,,,,
GenBank,,,"Haines,B.B. et al.; Germline diversity of the expressed BALB/c VhJ558 gene family; Mol. Immunol. 38 (1), 9-18 (2001); 2000.",N/A,,,AF303881,N/A,not determined,Mus musculus (house mouse),2022-03-15,"Mus musculus clone J558.50 immunoglobulin heavy chain variable region mRNA, partial cds",N/A,evqlqqsgtvlagpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtststaymelssltnedsavyyctr,,gytftsyw,iypgnsdt,tr,,,,IGHJ1*01 (mouse),IGHV1-5*01 (mouse),,
GenBank,,,"Li,W. et al.; High potency of a bivalent human VH domain in SARS-CoV-2 animal models; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.007,,,MT943599,N/A,SARS-CoV-2,synthetic construct,2022-03-15,"Synthetic construct anti-SARS-CoV-2 immunoglobulin heavy chain variable region VHab8 gene, partial cds",N/A,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,gftfddya,mynngrt,ardnlgyrpsenlygmdv,,,,IGHJ6*01 (human),IGHV3-23*04 (human),,
